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Both genetic and environmental factors can play a role in an individual’s cancer susceptibility, and 
lifestyle-related factors have been a primary focus of our prevention efforts for several decades. 
However, advances in our understanding of cancer causation have resulted in additional concerns being 
raised about exposures to chronic, low-level exposures to combinations of chemicals.  In this project, a 
large multinational task force comprised of twelve teams was organized to review 11 hallmark 
phenotypes of cancer and identify priority target sites for disruption in each area. Prototypical chemical 
disruptors for all targets were then identified, and dose-response information was gathered.  Evidence 
of low-dose effects for each chemical was noted and cross-hallmark effects for all targets and chemicals 
were documented. In total, 85 examples of chemicals were reviewed for actions on key 
pathways/mechanisms related to carcinogenesis. Only 15% (13/85) were found to have evidence of a 
dose-response threshold, whereas 59% (50/85) exerted low-dose effects. No dose-response information 
was found for the remaining 26% (22/85). This analysis reveals that every day exposures to individual 
(non-carcinogenic) chemicals that act on a range of mechanisms, pathways, and systems could conspire 
to instigate environmental carcinogenesis. Additional research on carcinogenesis is needed and the 
carcinogenic potential of low-dose exposures to mixtures of chemical that act selectively to enable these 
hallmark phenotypes also needs to be explored.  Current models of risk assessment will also need to be 








Chapter 1: General Introduction 
 
1.1 Background 
Cancer is the single leading cause of death in the world, responsible for approximately 8.2 
million deaths in 2012, and there were 14.1 million new cases of cancer in 2012.   Moreover, 
the incidence of cancer cases worldwide is predicted to rise by 75% to reach 25 million in the 
next two decades  (Forman & Ferlay, 2014).   Although the incidence rates of cancer is much 
higher in western nations, the number of deaths due to cancer is disproportionally higher in 
lesser developed countries (see Figure 1), and by 2025 it is predicted that almost 80% of the 
increase in cancer deaths will occur in lesser developed countries (Forman & Ferlay, 2014). 
 
Both genetic and environmental factors can play a role in an individual’s cancer susceptibility 
(Malhotra, 2014; McGuinn et al., 2012).  In terms of non-heritable influences, in lesser 
developed countries, infections play a major role in disease causation (i.e., 23.4% of all 
cancers). Whereas infections are only estimated to be a risk factor in 7.5% of all cancers in 
western nations.  The most common infections are Helicobacter pylori in gastric cancers, 
Hepatitis B and C in liver cancers, and Human papilloma viruses in cervical/uterine cancers 
(de Martel et al., 2012).  For other major cancers, influences related to “lifestyle” include 
exogenous hormones (e.g. birth control pills), smoking, obesity, lack of exercise, dietary 
patterns (e.g., consumption of red and processed meat, lack of fiber), alcohol consumption, 
excessive sunlight exposure, and certain occupational exposures, all of which are believed to 
have a significant role to play in cancer incidence (Cogliano et al., 2011; Sankpal et al., 2012).   
At the same time there has also been an emphasis placed on the identification of exposures to 
chemical carcinogens (e.g., agricultural, occupational, etc.) which are believed to account for 
7%-19% of all cancers (Mathers, Stevens, & Mascarenhas, 2009; Straif, 2008)”.  Finally, 
advances in our understanding of cancer causation have resulted in additional concerns being 
raised about in utero chemical exposures and exposures to chronic, low-level exposures to 







Figure 1 – Cancer Incidence and Disease by Country in 2102 





Although the incidence of various cancer types can vary considerably by country, migration 
studies of immigrants moving from one country to another have helped affirm that 
environmental influences are likely underpinning the high incidence of cancer seen in many 
westernized countries (Boysen et al., 2008; John, Phipps, Davis, & Koo, 2005; McCredie, 
1998; Parkin & Khlat, 1996).   
 
However, despite many decades of research related to disease causation, Parkin et al. recently 
estimated that only 43% of cancers can now be attributed to lifestyle and known environmental 
factors. In other words, the underlying causes of 57% of all cancers are still unexplained 
(Parkin, Boyd, & Walker, 2011).  This suggests that our understanding of disease causation is 
by no means complete and we must therefore redouble our efforts to identify other potential 
sources of cancer causation.   
 
Environmental chemical exposures are one area where additional research is definitely needed.  
Scientists who have raised concerns about the great number of chemical exposures that are 
faced by the general population in westernized countries have called for research to support the 
“exposome”.  The exposome is a conceptual model that is intended to complement the human 
genome by capturing the totality of all environmental exposures of an individual over his or 
her lifetime (Wild, 2005).  Although there are significant challenges associated with the 
implementation of this idea (Vrijheid, 2014), epidemiologists are hopeful that the exposome 
will help them pinpoint the causes of environmentally induced diseases such as cancer (Wild, 
2012; Wild, Scalbert, & Herceg, 2013). 
 
In terms of the current approach to the chemical exposures that we do face, the 2008-2009 
President’s Cancer Panel Annual Report in the United States (Reuben, LaSalle, & Kripke, 
2010) called for a critical review of the role that chemical exposures play in cancer causation, 
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noting that the “true burden of environmentally induced cancer has been grossly 
underestimated” (Clapp, 2011).  Christiani also called on the National Institutes of Health 
(NIH) to expand their investigation of environmental causes of cancer pointing to “massive 
gaps” in toxicologic data, and noting that only about 50% of the high volume chemicals in use 
in the United States have undergone even minimal testing for carcinogenicity (Christiani, 
2011).   
 
Additionally, there have been serious critiques of the way in which environmental chemicals 
are currently assessed for carcinogenicity (Trosko & Upham, 2005).  The development of the 
Ames test as a quick and easy way to determine whether or not a chemical causes mutations in 
the DNA was a landmark event (Ames, 1971).  Early research by Ames and his colleagues 
showed that there was a high correlation between carcinogenicity and mutagenicity (McCann 
& Ames, 1976) and that set in motion a longstanding quest for individual mutagenic chemicals 
as (complete) “carcinogens”.   This was an important beginning, but it spawned a widely held 
hypothesis that suggested that environmental chemical mutagens were inducing a substantial 
percentage of the cancers in the population.  In the decades that followed, direct measurements 
of mutations in human tissues did not support a clear relationship with exposure to 
environmental agents (except for excessive exposures to sunlight and skin-related cancers) 
(Thilly, 2003).  So Trosko and Upham reviewed the multistage and multi-mechanistic process 
of cancer and pointed out that it involves both genotoxic and epigenetic events.  They 
highlighted the importance of stem and progenitor cells in the development of cancer, and then 
argued that all of the relevant aspects of cancer biology needed to be considered in chemical 
risk assessment, not just mutagenicity (Trosko & Upham, 2005).  Although this cogent critique 
was made nearly a decade ago, their insights remain relevant since the ‘mutagen as carcinogen’ 




An additional complication has emerged from the endocrine disruption research that has been 
undertaken over the past two decades.  The endocrine system is made up of approximately 30 
different glands which tightly regulate a diverse range of physiological processes. What makes 
these sub-systems unique is their inherent sensitivity to hormonal signaling, which has been 
found to be vulnerable to perturbations resulting from low dose exogenous chemical exposures 
(Marty, Carney, & Rowlands, 2011).  Notably, in a recent and somewhat comprehensive 
review of the field, Vandenberg et al. identified several hundred examples of non-monotonic 
dose-response relationships (i.e., examples where the relationship between dose and 
response/effect is complex and the slope of the curve changes sign - from positive to negative 
or vice versa - somewhere within the range of doses examined) (Vandenberg et al., 2012). 
Since many cancers are hormone-related, these low-dose effects and complex dose-response 
relationships must be considered as well.    
 
Unfortunately, in traditional chemical risk assessments, these non-linear dose-response 
relationships and low dose effects are generally not considered.  Toxicity studies are typically 
conducted with individual chemicals in animal models using a series of higher doses aimed at 
identifying a point of departure, which is also known as the no-observed-adverse-effect level 
(NOAEL) or the lowest-observed–adverse-effect level (LOAEL).  This point of departure is 
used to determine the quantity of substance above which adverse effects can be expected in 
humans, and the NOAEL, combined with uncertainty factors (which acknowledge gaps in the 
available data), are then used to establish safety criteria for human exposure (Wignall et al., 
2014).  However, the determination of a safe level of exposure often relies on a linear 
extrapolation (using a series of data points gathered from dose-response data gathered at higher 
dose levels).  So this assumption of linearity ignores the possibility of non-monotonic dose 
response curve and therefore may not always be an accurate prediction nor always provide a 




The World Health Organization International Programme on Chemical Safety (WHO IPCS) 
offers guidance on risk assessment for many countries that involves the use of a “Mode of 
Action” framework (Boobis et al., 2006; Dellarco & Fenner-Crisp, 2012; Meek et al., 2003; 
"OECD Guidance Document 116 On The Conduct And Design Of Chronic Toxicity And 
Carcinogenicity Studies, Supporting Test Guidelines 451, 452 And 453," 2012).  In this 
guidance “mode of action” is defined as a sequence of key events and processes, starting with 
interaction of an agent with a cell, proceeding through operational and anatomical changes, and 
resulting in an adverse outcome, in this case, cancer formation.  Regulators are only to consider 
chemical mixture effects when individual chemicals are: 
 
(1) known to act via a common sequence of key events and processes;  
(2) known to act on a common target/tissue; and  
(3) known to produce a common adverse outcome (e.g., cancer) 
 
But in light of Trosko and Upham’s pointed critique (Trosko & Upham, 2005), these criteria 
now appear to be outdated and inappropriately restrictive. In cancer it seems that mixtures of 
chemicals that produce relevant, but dissimilar, key cancer-related events could produce pro-
carcinogenic synergies of concern, and the individual chemicals wouldn’t even need to be 
carcinogenic themselves (i.e., not known to produce a common adverse outcome).  Yet, we are 
all exposed to a great number of chemicals on an ongoing basis and chemicals are still primarily 
tested one at a time on this basis (Carpenter, Arcaro, & Spink, 2002; Claus Henn, Coull, & 
Wright, 2014).  
 
So there is good reason to believe that environmental factors are driving the high incidence of 
cancer that we are seeing in Westernized countries, and chemical exposures are known to be 
an important influence in disease causation.  But many individual chemicals remain untested, 
and the current approach to regulatory testing doesn’t consider the nuanced nature of biological 
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effects that can occur in response to certain low dose chemical exposures.  Instead, the testing 
focuses too narrowly on mutagens and does not account for the complexity of cancer’s biology 
(i.e., the effects of exposures to mixtures of chemicals in the environment are largely ignored). 
This has resulted in significant gaps in our understanding of the role that low-dose chemical 
exposures might play in the development of human cancer and it is therefore the focus of this 
thesis.  
 
1.2 First principles 
 
To develop an integrated understanding of low-dose chemical exposures in the development of 
human cancer, a return to first principles is important.  Our understanding of cancer has 
advanced considerably in the past two decades, so it is useful to first review what is now known 
about the disease.     
 
Some of the earliest work on the two-stage model of carcinogenesis (initiation and promotion) 
was conducted by Mottram (Mottram, 1944),  Friedewald and Rous (Friedewald & Rous, 
1944), and Berenblum and Shubik (Berenblum & Shubik, 1949).  This need for an initiating 
exposure was shown to be applicable to humans by Roger Case in his studies of dye industry 
workers (Case, 1953a, 1953b). Armitage and Doll are then credited with the first description 
of a multi-stage theory of the disease in 1954 (Armitage & Doll, 1954).  Miller and Miller 
looked specifically at chemical carcinogenesis in 1981 noting that initiation “occurs rapidly 
and appears to be irreversible” and noted that it typically results from one or more mutations 
of cellular DNA.  While the second stage, “promotion”, was understood to be complex and 
something that takes place over a longer period of time. “Complete carcinogens” were therefore 
understood to have both initiating and promoting activities (E. C. Miller & Miller, 1981).  But 
by 1990 our understanding of the disease had advanced considerably to encompass the 
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influence of "free radicals", proto-oncogenes, oncogenes, epigenetic mechanisms and other 
synergistic or antagonistic factors (Truhaut, 1990).    
 
As the exploration of cancer advanced, Hanahan and Weinberg authored two landmark papers 
(Hanahan & Weinberg, 2000, 2011) that helped us organize the great number of cancer cell 
genotypes that were being investigated into a series of categories of cellular phenotypes that 
are seen in immortalized cells and malignant growth.  These phenotypes are referred to as the 
‘Hallmarks of Cancer’ and they can be briefly described as follows:   
 
Cancer cells exhibit inherent instability, which accounts for the destabilization of many normal 
processes and their self-mutating nature (Genomic instability).   Immortalized cancer cells also 
have an acquired capacity to sustain their ability to grow, replicate and proliferate (Self-
sufficiency in growth signals); they are not responsive to tumor suppressor signaling or anti-
growth signaling (Insensitivity to anti-growth signals); they are resistant to signaling that would 
normally initiate programmed cell death (Evading Apoptosis); and they bypass senescence 
which would normally prevent cells from proliferating endlessly (Limitless replicative 
potential).   
 
Additionally, cancer cells produce signals that evoke the production of new blood vessels that 
allow the cells within a tumor to sustain growth (Sustained angiogenesis); they have 
Dysregulated metabolism, which allows the cells within a tumor to survive in a hypoxic 
environment; they expand beyond the constraints of the tumor microenvironment by invading 
nearby tissues and infiltrating the bloodstream which allows them to metastasize (Tissue 
invasion and metastasis); and they avoid immune surveillance, which also accounts for other 
ways in which the immune system might fail to recognize and/or attack cancer cells (Avoiding 
Immune Destruction) and produce a self-reinforcing pro-inflammatory milieu  which instigates 
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a number of other hallmarks (e.g., angiogenesis, metastasis, and the subversion of adaptive 
immunity) (Colotta, Allavena, Sica, Garlanda, & Mantovani, 2009).  Additionally, Hanahan 
and Weinberg added that there are several aspects of the tumor microenvironment that warrant 
special consideration (e.g., stem cells, inflammation, immunoevasion etc) (Hanahan & 
Weinberg, 2011).  The entirety of this framework is illustrated in Figure 2 below.   
 
The two enabling factors (i.e., Genomic instability, and Tumor-promoting inflammation), the 
other hallmark phenotypes named above, and the tumor microenvironment are depicted in 















Figure 3 – Acquired Hallmark Phenotypes in Carcinogenesis**  
(Goodson et al., 2015) 
 
**Note - Some of the acquired hallmark phenotypes are known to be involved in many stages of 
disease development, but the precise sequencing of the acquisition of these hallmarks and the degree 
of involvement that each has in carcinogenesis are factors that have not yet been fully 






1.3 Aims and objectives  
In this dissertation, my aim is to determine whether or not we now have enough evidence to 
illustrate that low dose exposures to complex chemical mixtures in the environment may be an 
important underlying factor for environmental carcinogenesis.  One of my key objectives was 
to also look at the hallmarks of cancer framework as a heuristic that might have utility for this 
purpose.  
 
In a recent study the US EPA used data from in vitro high-throughput screening (HTS) assays 
to assess the utility of the hallmarks of cancer framework for individual chemical screening. 
The assays were selected based on their relevance to the various hallmarks.  Data from 292 
chemicals tested in 672 assays was gathered and chemicals were then assessed for activity 
across the hallmarks, and classified as (1) "possible"/"probable"/"likely" carcinogens, (2) "not 
likely" to be carcinogens, or (3) "evidence of non-carcinogenicity" (i.e., based on the extent to 
which each chemical appeared to activate various hallmark processes). These predictions were 
then compared to existing in-vivo rodent carcinogenicity data found in the EPA’s Toxicity 
Reference Database (ToxRefDB) and the approach appeared to have good predictive power 
(Kleinstreuer et al., 2013).  In other words, individual chemicals that act disruptively in a 
manner that supports a good number of hallmark processes are more likely to be carcinogenic 
in vivo, which supports the idea that this framework may have utility for mixtures research as 
well.  
 
So the objective in this research was to look carefully at an approach that used this framework 
as a way to identify priority mixtures (i.e., those with substantive carcinogenic potential).  In 
the absence of such a tool, an important gap in capability exists in the field of toxicology and 
risk assessment. So an exploration of this sort of an approach appears to be an important step 




Unfortunately, the very straight forward nature of the cellular phenotypes encompassed by the 
Hallmarks of Cancer framework belies the complex nature of the biology involved with each 
of these areas, which makes it quite difficult to discern which disrupted mechanisms are most 
important.   Indeed, the depth of research underpinning the biology encompassed in each of 
these areas is substantial, making it nearly impossible for any single researcher to have a 
comprehensive understanding of cancer biology.   
 
For example, the Cancer Genome Project began in 2006 and the massive effort profiled 10,000 
tumors and discovered nearly 10 million cancer-related mutations (Ledford, 2015).  Although, 
this appears overwhelming at first, Jones et al. authored one of the earliest studies that 
organized these mutations in a 2008 article titled “Core Signaling Pathways in Human 
Pancreatic Cancers Revealed by Global Genomic Analyses” (S. Jones et al., 2008).  The 
authors performed a comprehensive genetic analysis of 24 pancreatic cancers and found that 
most contained an average of 63 genetic alterations, the majority of which were point 
mutations. Then they organized the alterations and defined a core set of 12 cellular signaling 
pathways and processes that were each genetically altered in 67 to 100% of the tumors (see 
Figure 4).   Vogelstein, who was part of this first study, later refined this work by looking at a 
much greater number of cancer types.  He  reported that a small number (~140) of “driver” 
genes (i.e., those that promoted tumorigenesis) were found to be altered in a high percentage 
of tumors in most cancer types and he also classified them into 12 signaling pathways that 
regulate three core cellular processes: cell fate, cell survival, and genome maintenance 








Figure 4. - The 12 pathways and processes whose component genes were genetically 






Figure 5. Cancer cell signaling pathways and the cellular processes they regulate 





1.4 The Approach 
 
 
Given the scale of this problem and the breadth of expertise in the various facets of cancer 
biology that was going to be needed, it was decided that a large task force should be organized 
to approach this problem.  So in 2011, I co-founded a Canadian non-profit organization called 
“Getting to Know Cancer” (www.gettingtoknowcancer.org) with the assistance of Michael 
Gilbertson, PhD, who was an expert in the field of low dose, endocrine disruption. A strategic 
plan was crafted and approximately twenty senior scientists (cancer biologists, toxicologists 
and endocrine disruption scientists) were recruited to form an initial advisory board.         
 
In 2012, an initiative called “The Halifax Project” was launched to assess the carcinogenic 
potential of chemical mixtures in the environment using the ‘Hallmarks of Cancer’ framework. 
The plan was to establish teams that could produce a series of reviews on each of the cancer 
hallmarks to assess what is currently known about biologically disruptive chemicals in each of 
the hallmark areas.  Accordingly, a “request for quotation” was sent to the top twenty peer-
reviewed cancer journal (ranked by impact factor) for a special issue that would be focused on 
assessing the carcinogenicity of low dose exposures to chemical mixtures in the environment 
(see Appendix 1).  Responses were then evaluated and Oxford University Publishing's 
"Carcinogenesis" (Impact factor: 5.334) was selected as the journal of choice for the special 
issue. 
 
A website registration page was then created and a single unsolicited email was sent to 
approximately 40,000 cancer scientists in July 2012.  Respondents were able to download an 
“Invitation to Authors” document describing The Halifax Project and the role that the 
environmental mixtures task force would play (see Appendix 2).  Those who were interested 
in the project were then asked to submit personal details, select areas of expertise that aligned 
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with their own interest, and provide details related to their own publishing track records.  In 
total, 703 scientists responded to the email and from that group, 11 team leaders were selected 
to lead reviews for each of the hallmark area (i.e., ten hallmarks plus an eleventh team to 
consider the tumor microenvironment).   And one additional team leader was also recruited to 
lead a cross-validation team (explained below).   
 
In early correspondence, each team leader was provided with a set of project guidelines that 
included details on the background of the project, the planned approach, the scope and format of 
each of the planned reviews, the details of the intended makeup of each of the teams, a 
description of the all-author capstone paper that was planned to bring the work of the individual 
teams together into an important synthesis paper, and the project timelines (see Appendix 3) 
 
Team leaders were then asked to form individual teams by drawing from the pool of researchers 
who had expressed interest in the project, and from their own labs and preferred collaborators.  
Ultimately, each team was asked to include cancer biology specialists, environmental health 
specialists (e.g. toxicologists, endocrine disruption experts etc.), and they were also encouraged 
to engage junior researchers as well.  Where expertise was missing, additional researchers were 
identified and contacted by email and/or phone until all teams had been fully formed.  Team 
members were also provided with a set of project participation guidelines (see Appendix 4). 
Ultimately 174 scientists from 28 countries chose be part of the environmental mixtures task 
force within the Halifax Project.  
 
Once the project got underway, each of the 11 writing teams was specifically tasked to describe 
the hallmark, its systemic and cellular dysfunctions, and its relationships to other hallmarks.  A 
priority list of relevant (i.e., prototypical) target sites for disruption was to be developed by the 
team and a list of corresponding chemicals in the environment that have been shown to have 
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the potential to act on those targets was to be created, along with a discussion of related issues 
and future research needed (in the context of project goals).  
 
In August of 2013, a workshop was held in Halifax, Nova Scotia to bring the teams together 
and to hear from several experts outside the taskforce and discuss key project related issues.  
Rick Woychik, PhD, the Deputy Director of the United States National Institutes of Health, 
National Institute of Environmental Health Sciences (NIEHS) was recruited to give the keynote 
address.  Danielle Carlin, PhD, DABT discussed NIEHS priorities, and Nicole Kleinstrauer, 
PhD offered insights into the EPAs research on in vitro perturbations of targets in cancer 
hallmark processes (i.e., to predict rodent chemical carcinogenesis).  Laura N. Vandenberg, 
PhD of Tufts University provided a briefing on low-doses and non-monotonic dose-response 
relationships, Cynthia Rider, PhD, DABT (Division of National Toxicology Program/NIEHS) 
provided a talk on systems biology (for assessing the toxicity of mixtures), and finally, Linda 
K. Teuschler and Glenn E. Rice (United States Environmental Protection Agency Office of 
Research and Development, National Center for Environmental Assessment) talked about 
chemical mixtures in cancer risk assessment.  All of the 11 team leaders were given timeslots 
to provide team progress updates as well.  Finally, breakout sessions at the workshop involved 
discussions on the use of Toxcast Data, selectively disruptive chemicals, chemical mixtures, 
toxicological approaches, molecular epidemiology, risk assessment practices, regulatory 
decision making, strategic issues, and a discussion of important barriers (see Appendix 5).   
 
In the discussions that resulted, the teams settled on the following criteria for “prototypical” 
chemicals in the environment that had demonstrated an ability to act on the selected targets.  It 
was determined that chemicals should be (1) ubiquitous in the environment; (2) known to 
selectively disrupt individual targets such as specific receptors, specific pathways or specific 
mechanisms; (3) not deemed to be “lifestyle” related (e.g., tobacco, poor diet choices, alcohol 
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etc.), and (4) not carcinogenic to humans (i.e. not IARC Group 1, Carcinogens).  This set of 
criteria was specifically intended to ensure that the focus would be on common chemicals that 
might be relevant to carcinogenesis but overlooked in the current approach to risk assessment.  
 
In total, the teams selected 85 examples of chemicals that had been shown to act disruptively on key 
mechanisms/pathways in each of these hallmark areas (see Table 1).  To assess the quality and 
relevance of data that was gathered by each of the teams for these reviews, each team was later 
asked to further identify any relevant low-dose research that might exist for each chemical 
selected and each mechanism identified, as well as any studies containing dose-response 
characterizations.   The term “Low Dose” was defined using the European Food Safety 
Authority definition (i.e., responses that occur at doses well below the traditional lowest dose 
of 1 mg/kg that are used in toxicology tests) and the definition for “Low Dose Effects” (LDE) 
was based on the US EPA definition (National Toxicology Program's report of the endocrine 
disruptors low dose peer review, 2001) - as follows: 
 
Any biological changes occurring:  
a)      in the range of typical human exposures or  
b)      at doses lower than those typically used in standard testing protocols, i.e. doses 
below those tested in traditional toxicology assessments (Melnick et al., 2002), 
or 
c)      at a dose below the lowest dose for a specific chemical that has been measured 
in the past, i.e. any dose below the lowest observed effect level (LOEL) or 
lowest observed adverse effect level (LOAEL) (Welshons, Nagel, & vom Saal, 
2006) 
d)     occurring at a dose administered to an animal that produces blood concentrations 
of that chemical in the range of what has been measured in the general human 
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population (i.e. not exposed occupationally, and often referred to as an 
environmentally relevant dose because it creates an internal dose relevant to 
concentrations of the chemical measured in humans) (Brucker-Davis, Thayer, 
& Colborn, 2001; Vandenberg, Hauser, Marcus, Olea, & Welshons, 2007). 
 
Additionally, after feedback from the initial peer-review, each team was further asked to 
categorize each chemical by using one of five possible categories (to determine the relevance 
and relative strength of the underlying evidence for each of the chemicals being considered).  
The categories were as follows: (1) Low Dose Effects (i.e., levels that are deemed relevant 
given the background levels of exposure that exist in the environment); (2) Linear Dose-
Response with Low Dose Effects;  (3) Non-linear Dose-Response with Low Dose Effects; (4) 
Threshold (i.e., this action on this mechanism/pathway does not occur at low dose levels); (5) 
Unknown.  Finally, the reported results for these details were reviewed by three trained 
toxicologists and these findings are also shown in Table 1 below.   
 
In recognition of the degree of overlap that exists between many cellular signaling pathways 
and the various hallmarks, another team was created and tasked to create a more complete 
mapping of the actions that might be anticipated as the result of an action on the target sites 
identified, or by the disruptive effects of the chemicals selected.  That “cross-validation” team 
conducted an additional literature review of submitted targets and chemicals from each writing 
team, searching for evidence to identify cross-hallmark activity.  Each potential target-hallmark 
or approach-hallmark interaction was assessed to determine whether the inhibition or activation 
of each target and the corresponding biological activity of each chemical might reasonably be 
expected to have either a pro-carcinogenic or anti-carcinogenic effect on key 
pathways/processes in the various hallmark areas (see Figure 6).  These results were to be 






Figure  6 - The role of the cross-validation team 
 
All of the teams focused on hallmarks will have the support of a cross-functional group of 
scientists on the “cross-validation team”. This team will assess the prioritized targets and 
disruptive chemicals that are selected by each team by conducting a background literature 
research to identify instances where a particular target or chemical that is of interest to one 
of the teams also has relevance for the topics being studied by other teams.  
 
For example, if the team reviewing sustained proliferative signaling selected HER-2 (the 
EGFR receptor) as a prioritized disruption site, then this team will then review the literature 
to determine whether or not disruptive action at that particular target site would be expected 
to produce complementary (pro-carcinogenic) contributions in any of the other hallmark 
areas under review.  This same process will be repeated for all of prioritized disruption sites 
that are selected by each of the teams. Similarly, all of the disruptive chemicals that are 






These 11 teams published articles for each of the hallmark areas as planned (Brooks Robey et 
al., 2015; Carnero et al., 2015; Casey et al., 2015; Engstrom et al., 2015; Z. Hu et al., 2015; 
Kravchenko et al., 2015; Langie et al., 2015; Nahta et al., 2015; Narayanan et al., 2015; 
Ochieng et al., 2015; Thompson et al., 2015).  Then a final capstone paper was created as a 
synthesis that addressed the objectives of this dissertation (Goodson et al., 2015).  As the 
architect of this initiative and the project manager, several teams relied on my ongoing 
direction, feedback, and scholarly inputs on their papers, so I earned authorship recognition in 
several of the team’s reviews.  My contributions in this regard are shown in Chapter 2 (Z. Hu 
et al., 2015), Chapter 3 (Thompson et al., 2015), Chapter 4 (Kravchenko et al., 2015), Chapter 
5 (Narayanan et al., 2015), and Chapter 6 (Brooks Robey et al., 2015) of this dissertation.  
Additionally, I played a prominent and central role on the core writing team that authored the 
capstone paper.  My contribution in this regard earned me a co-corresponding authorship on 
the paper and this is detailed in Chapter 7 (Goodson et al., 2015).  
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Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 
Low Dose Effect   (LDE, LLDE, NLDE, Threshold, Unknown) 
Angiogenesis 
 
Diniconazole Vascular Cell Adhesion Molecule and 
Cytokine Signaling 
Threshold (H-PC)(EPA) 
Ziram Vascular Cell Adhesion Molecule and 
Cytokine Signaling 
Threshold (H-PC)(EPA; Taylor & Whalen, 2011) 
Chlorothalonil Thrombomodulin, Vascular Proliferation 
and Cytokine Signaling 
Unknown (H-PC)(EPA)  
NLDE (A-in vivo)(McMahon et al., 2011) 
Biphenyl Angiogenic Cytokine Signaling Unknown (H-PC)(EPA) 





Plasminogen Activating System and 
Cytokine Signaling 
Unknown (H-PC)(EPA) 
HPTE Vascular Cell Adhesion Molecule and 
Cytokine Signaling 
Unknown (H-PC)(EPA)  
Threshold (A-I*)(Goldman, Murr, Buckalew, Schmid, & Abbott, 2004) 
LDE (A-I*)(Chapin et al., 1997) 
*Extrapolated from in vivo data on the parent compound, Methoxychlor 
PFOS Angiogenic Cytokine Signaling Threshold (H-PC)(EPA)  
LDE (H-CL)(Qian et al., 2010) 
Bisphenol AF Matrix Metalloproteinase Expression and 
Estrogen Receptor Signaling 
Unknown (H-PC)(EPA) 






Cypermethrin AR and ER expression, Reduction of ATP 
and Mitochondrial Enzymes, 
Mitochondrial Membrane Potential 
LLDE (A-I)(J. X. Hu et al., 2013) 
NLDE (A-I)(J. X. Hu et al., 2013) 
NLDE (H-CL)(EPA; Jin, Li, Xu, Wen, & Zhao, 2010; Kakko, Toimela, & Tahti, 2004) 
Acrolein p53 Activation, DNA Repair Inhibition, 
PERK Phosphorylation, Mitochondrial 
Dysfunction, Cell Survival 
LLDE (A-I, A-CL, H-PC, H-CL)(Feng, Hu, Hu, & Tang, 2006; Günther, Wagner, & Ogris, 
2008; Luo et al., 2013; Roy, Pallepati, Bettaieb, & Averill-Bates, 2010; Tanel, 
Pallepati, Bettaieb, Morin, & Averill-Bates, 2014; Tang et al., 2011) 
NLDE(Tanel et al., 2014)  






Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 




Rotenone Cell Cycle, DNA Damage Response, 
Proliferation, Differentiation, 
Mitochondria 
LLDE (H-CL)(Cabeza-Arvelaiz & Schiestl, 2012; Deng, Huang, & Lin, 2010; Goncalves 
et al., 2011) 
NLDE (H-CL)(Cabeza-Arvelaiz & Schiestl, 2012; Goncalves et al., 2011)  
Unknown (H-CL,H-PC)(EPA) 
Copper p53 Activation, p21 Upregulation, Cell 
Viability 
LLDE (H-CL)(Y. Li et al., 2013; Ostrakhovitch & Cherian, 2005; Parr-Sturgess et al., 
2012) 
Nickel Neutrophil Apoptosis, E-Cadherin 
Regulation, MMP Production 
LLDE (H-CL)(Freitas, Barcellos-de-Souza, Barja-Fidalgo, & Fernandes, 2013)  
NLDE (H-CL)(Wu, Tang, Wang, Lee, & Ko, 2012)  
Threshold (H-CL)(Wu et al., 2012) 
Cadmium p53-dependent Apoptosis, Cell 
Proliferation 
LLDE (H-CL)(Aimola et al., 2012), 
Threshold (H-CL)(Yuan et al., 2013) 
Diazinon AChE Activity, Neuronal Cytotoxicity Unknown (A-PC)(Aluigi, Guida, & Falugi, 2010)  
LLDE (H-CL)(Giordano et al., 2007)  
Threshold (H-CL)(EPA) 
Iron KRAS Mutations LLDE (A-I)(Gilsing et al., 2013) 





Bisphenol A MMP-2 and MMP-9 Expression, Increased 
Migration, Invasion, EMT, Oxidative 
Stress, ER Signaling 
LDE (H-CL)(Chen et al., 2014; Zhu et al., 2010),  
Threshold (H-CL, H-PC)(EPA) 
Hexacholorobenzene Activation of c-Src, HER1, STAT5b and 
ERK1/2 signaling 
LLDE (H-CL, A-I)(Pontillo et al., 2013) 
Sulfur dioxide MMP-9 Expression Unknown (A-PC)(O'Brien et al., 2004) 
Phthalates MMP-2 and MMP-9 Expression LDE (H-CL)(Zhu et al., 2010),  
Unknown (H-CL, H-PC)(EPA) 
Iron ROI Generation, NFkB Activation, uPA 
Expression 
Unknown (H-CL)(Ornstein & Zacharski, 2007) 






Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 




Bisphenol A (BPA) Inhibition of GJIC, Activation of mTOR 
pathway, downregulation of p53, p21 and 
BAX, binding to ER-alpha, weakly binds to 
TH receptor and AR,  activation of ERK1/2 
and p38 
NLDE(H-CL, A-CL)(Bouskine, Nebout, Brucker-Davis, Benahmed, & Fenichel, 2009; 
Hernandez, van Benthem, & Johnson, 2013; Wetherill, Petre, Monk, Puga, & 
Knudsen, 2002) 
Threshold (H-CL, H-PC)(EPA) 
Dibutyl phthalate (DBP) Activation of PPAR-alpha, inhibition of 
GJIC, expression of cyclin D and cdk-4, 
activation of AhR/HDAC6/c-Myc pathway 
NLDE (H-CL)(S. H. Park et al., 2009)  
Unknown (H-CL, H-PC)(EPA) 
Chlorothalonil Upregulation of ErbB-2 tyrosine kinase 
and MAP kinase, aromatase inhibitor 
Threshold-based (i.e. non-linear) (A-I)(Wilkinson & Killeen, 1996) Unknown (H-
PC)(EPA)  
Threshold (H-CL)(EPA) 
Lindane Induction of MAPK/ERK pathways Threshold-based (i.e. non-linear) (A-I)(Vesselinovitch & Carlborg, 1983) Threshold 
(H-CL)(EPA) 
Dichlorvos Expression of p16, Bcl-2 and c-myc LLDE (A-I)(Q. L. Wang et al., 2013)  
Threshold (H-CL)(EPA) 
Methoxychlor Binding to ER-alpha receptor, 
upregulation of cyclin D1, downregulation 
of p21 
LLDE (H-CL, A-CL)(Lee et al., 2012; S. H. Park et al., 2009)  
Unknown (H-PC)(EPA)  
Threshold (H-CL)(EPA) 
Oxyfluorfen Expression of Cyp2b10 and Cyp4a10 
transcripts (markers of PPAR-alpha 
activation) 
Threshold (A-I)(Stagg, LeBaron, Eisenbrandt, Gollapudi, & Klaunig, 2012),  
Unknown (H-CL, H-PC)(EPA) 
Diethylhexyl phthalate 
(DEHP) 
Activation of PPAR-alpha, inhibition of 
GJIC 
Threshold-based (i.e. non-linear) (A-I)(Doull et al., 1999) 





compounds, (e.g. Nickel 
chloride) 
Epigenetic silencing of p16  LLDE (H-CL, A-PC) (Yasaei et al., 2013) 
Diethylstilbestrol Allelic loss and point mutation in ETRG-1 
gene  
LLDE (A-I) (Singh & Roy, 2008) 







Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 




Phenobarbital Reduces expression of the CDKN1A 
product p21, CAR Activation  
LLDE (A-I) (Geter, Bhat, Gollapudi, Sura, & Hester, 2014; Martens, Lennartsson, 
Hogberg, & Stenius, 1996) 
Acetaminophen Cellular energy loss, mitochondrial 
damage, Telomerase activation 
LDE (H-CL, A-I, A-CL)(Bader, Petters, Keller, & Pavlica, 2011; Bode-Boger, Martens-
Lobenhoffer, Tager, Schroder, & Scalera, 2005; Heinloth et al., 2004; Nguyen et al., 
2005; Tsuruga et al., 2008) 
Cotinine Telomerase activation LLDE (H-PC) (Jacob, Clouden, Hingorani, & Ascher, 2009) 
Nitric oxide p53 inactivation  LLDE (H-PC, H-CL, A-CL, A-I) (Brune, von Knethen, & Sandau, 2001) 
Na-selenite p53 promoter methylation  LLDE (A-CL, A-I) (Arner & Holmgren, 2006; Davis, Uthus, & Finley, 2000) 





Bisphenol A Estrogen receptor activation, Cell 
cycle/senescence 
LLDE (A-I, H-CL, H-E) (Vandenberg et al., 2012; vom Saal et al., 2007) 
NLDE (A-I)(Peluso, Munnia, & Ceppi, 2014; X. Y. Qin et al., 2012)  
Threshold (H-CL)(EPA) 
Cyprodinil Increased proliferation signaling, Aryl 
hydrocarbon receptor activation 
Unknown (H-PC, H-CL)(Bharadwaj & Yu, 2004; EPA; Fang et al., 2013)  
Threshold (H-CL)(EPA) 
Imazalil AR signaling   NLDE (A-I)(Orton, Rosivatz, Scholze, & Kortenkamp, 2011; Tanaka, Ogata, Inomata, 
& Nakae, 2013)  
Threshold (H-CL, H-PC)(EPA) 
Maneb Nitric Oxide Signaling Unknown (A-CL, H-CL, H-PC) (Ahmad, Kumar, Shukla, Prasad Pandey, & Singh, 2008; 
EPA; "Integrated Risk Information System - Maneb (CASRN 12427-38-2)," 1988) 
Methoxyclor ER signaling  Threshold (H-CL)(EPA)  
LDE (A-I)(X. Du et al., 2014; K. P. Miller, Gupta, & Flaws, 2006) 
NLDE (A-I)(Palanza, Parmigiani, & vom Saal, 2001) 
PFOS Nuclear hormone receptors Threshold (H-CL)(EPA)  
LLDE (A-I) (G. Du et al., 2013; Kim et al., 2011) 
Phthalates CAR, ER signaling Unknown (H-CL)(EPA)  
LDE (A-I)(Eveillard et al., 2009; Grande, Andrade, Talsness, Grote, & Chahoud, 2006; 
Nakai et al., 1999) 
Phosalone Increased proliferation, PXR signaling Unknown (H-PC, H-CL) (EPA; Kojima, Sata, Takeuchi, Sueyoshi, & Nagai, 2011; 
"Phosalone Reregistration Eligibility Decision (RED)," 2006) 
Polybrominated 
diphenylethers (PBDEs) 
ER signaling LDE (A-I)(Berger et al., 2014; X. Li, Gao, Guo, & Jiang, 2013) 
 
Prochloraz ER signaling LDE (A-I)(Hofmeister & Bonefeld-Jorgensen, 2004; Jacobsen et al., 2012) 
Trenbolone acetate Insulin-like growth hormone-1 and AR 
signaling 
Unknown,  





Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 





Bisphenol A immune cell proliferation, pro-
inflammatory cytokine induction 
Threshold (H-PC)(EPA)  
LDE (A-I, H-CL, H-E)(Erden et al., 2014; Kharrazian, 2014; Liu et al., 2014; Rogers, 
Metz, & Yong, 2013; Yan, Takamoto, & Sugane, 2008) 
 
Phthalates Immunomodulation of macrophages, 
lymphocytes, eosinophils, and neutrophils 
Unknown (H-PC, H-CL, H-E)(Deutschle et al., 2008; EPA) 
PBDEs Induction of pro-inflammatory cytokines 
(IL6, IL8 and CRP), Inhibition of anti-
inflammatory cytokines (IL10) 
Threshold (H-PC, H-CL)(Koike, Yanagisawa, Takigami, & Takano, 2014; H. R. Park, 
Kamau, & Loch-Caruso, 2014; H. R. Park & Loch-Caruso, 2014; Peltier et al., 2012) 
Atrazine Immunomodulation of T cell and B cells, 
Pro-inflammatory cytokines 
Unknown (H-PC, A-I)(EPA; Rowe, Brundage, Schafer, & Barnett, 2006; Zhao et al., 
2013) 
Vinclozolin Pro-inflammatory cytokine induction, 
NFkB activation 
Unknown (H-PC, A-I)(Anway & Skinner, 2008; Cowin et al., 2008; EPA; Skinner & 
Anway, 2007) 
4-Nonylphenol Pro-inflammatory cytokine induction, 
NFkB activation, iNOS induction 





Pyridaben Chemokine signaling, TGF-b, FAK, HIF-1a, 
IL-1a pathways 
Unknown (H-CL, H-PC, A-CL)(EPA; Gollamudi et al., 2012; Morgan et al., 2010) 
Threshold (A-I)(Pyridaben (Sanmite) Pesticide Tolerance Petition 3/97, [PF-721; FRL-
5592-7], 1997) 
Triclosan Chemokine signaling, TGF-b, FAK, IL-1a 
pathways 
Threshold (H-CL, H-PC, A-I)(Barros et al., 2010; Bhargava & Leonard, 1996; EPA; 
Wallet et al., 2013)  
LDE (A-I, H-CL)(Stoker, Gibson, & Zorrilla, 2010; Winitthana, Lawanprasert, & 
Chanvorachote, 2014) 
Pyraclostrobin Chemokine signaling, TGF-b, IL-1a 
pathways 
Unknown (H-CL, H-PC)(EPA) 
Fluoxastrobin Chemokine signaling, EGR, HIF-1a, IL-1a 
pathways 






Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 





Bisphenol A Chemokine signaling, TGF-b pathway Threshold (H-PC)(EPA)  
LDE (A-I)(Vandenberg et al., 2012) 
NLDE (H-CL)(Shioda et al., 2006)  
NLDE (A-CL),(Alyea & Watson, 2009; Jeng & Watson, 2011; Welshons, Nagel, Thayer, 
Judy, & Vom Saal, 1999; Wozniak, Bulayeva, & Watson, 2005)  
NLDE (A-I)(Cabaton et al., 2011; B. A. Jones, Shimell, & Watson, 2011; Lemos et al., 
2010; Markey, Michaelson, Veson, Sonnenschein, & Soto, 2001) 
Maneb PI3K/Akt signaling, Chemokine signaling, 
TGF-b, FAK, IGF-1, IL-6, IL-1a pathways 
Unknown (H-CL, H-PC)(EPA; Filipov, Seegal, & Lawrence, 2005; Knudsen & 
Kleinstreuer, 2011; R. Qin et al., 2011)  
LDE (A-I)(Manfo, Chao, Moundipa, Pugeat, & Wang, 2011)   
Threshold (A-I)(Gollamudi et al., 2012; Matsushita, Arimatsu, & Nomura, 1976) 





DDT Induces MDM2, cyclin D1, E2F1 
expression, disrupts gap junctions   
NLDE (A-I, H-CL, A-CL)(Kazantseva, Yarushkin, & Pustylnyak, 2013; Lin, Kavanagh, 
Trosko, & Chang, 1986; Ruch, Klaunig, & Pereira, 1987) 
 
chlorpyrifos Increases proliferation LDE (H-CL, H-PC)(Mense et al., 2006; Ventura et al., 2012) 
folpet Disrupts G1-S checkpoint kinases, 
downregulates p53, promotes 
proliferation 
LDE(A-C)(Santucci et al., 2003) 
atrazine Induces estrogen production and 
proliferation 
LDE(H-CL, A-I)(Albanito et al., 2008; Tsuda et al., 2005; Wetzel et al., 1994) 
Bisphenol A Reduced p53, reduced connexin 43 
expression, increased proliferation  
NLDE (H-CL, A-I)(Andersson & Brittebo, 2012; Andrysik et al., 2013; Betancourt et 




Nickel reactive oxygen species and cellular stress NLDE (A-I)(Haber et al., 2000) 
BPA IL-6 expression, improper dendritic cell 
maturation and polarization, ROS 
production 
LLDE (A-I)(LN et al., 2013)  
NLDE (A-I)(LN et al., 2013) 
 
Butyltins (such as TBT) Natural Killer cell inhibition LDE (A-I)(Tryphonas et al., 2004) 
 
methylmercury Chronic oxidative stress LDE (H-PC, H-CL)(Petroni, Tsai, Agrawal, Mondal, & George, 2012; Watanabe et al., 
2013) 






Selected Chemicals Disruptive Action on Key 
Mechanism/Pathway 




Lead Dysfunctional DNA repair, defect in 
telomere maintenance 
Unknown (A-CL)(Asmuss, Mullenders, Eker, & Hartwig, 2000; Hartwig et al., 2002; 
McNeill, Narayana, Wong, & Wilson, 2004),  
Threshold (H-CL, H-E)(Pottier et al., 2013; Zhang, Lin, Funk, & Hou, 2013) 
Acrylamide Inactivation of DNA repair 
proteins/enzymes  
Unknown (A-CL, A-I, H-CL)(Exon, 2006; Sickles, Sperry, Testino, & Friedman, 2007)   
Quinones Affect free cysteine residues in catalytic 
center of DNA methyltransferases (DNMT) 
Unknown (A-CL)(X. Wang & Wang, 2013)  
Nickel Affect enzymes that modulate post-
translational histone modification 
LDE (H-E)(Arita et al., 2012; Cantone et al., 2011) 
LDE (A-CL, H-CL)(Chervona, Arita, & Costa, 2012)   
Bisphenol A Epigenetic changes via interactions with 
miRN 




Disruption of DNA damage/redox 
signaling involving Nrf, NFKB, Egr, etc. 
 LDE (A-I)(Roedel, Cafasso, Lee, & Pierce, 2012)  
Titanium dioxide NPs   Decreased NADH levels and impaired 
mitochondrial membrane potential and 
mitochondrial respiration, ROS generation 
Unknown (A-PC)(Freyre-Fonseca et al., 2011)  
Benomyl Spindle defects leading to formation of 
micronuclei 
Threshold (H-CL)(Elhajouji, Lukamowicz, Cammerer, & Kirsch-Volders, 2011) 
Threshold (A-CL) (Ermler, Scholze, & Kortenkamp, 2013) 
Carbon nanotubes Spindle defects leading to formation of 
micronuclei 
LLDE (A-CL)(Muller et al., 2008; Sargent et al., 2012)  




1.5 Authors Note  
 
It should be noted that The Halifax Project involved two cancer-related initiatives and both 
were similar in scale and in complexity.  I was the architect of both projects and both projects 
ran in parallel.  I did lead the effort that was undertaken by the environmental task which was 
focused on chemical mixtures in the environment force (described above), but I also led an 
additional “therapeutic” task force that was focused on a novel “broad-spectrum” approach to 
cancer prevention and therapy.  This second initiative was intended to address the longstanding 
challenge that we have faced with refractory cancers and disease relapse.   
 
In the appendices, I have included all related documentation to support my contributions to that 
effort as well.  Appendix 6 is a similar “Request for Quotation” that was sent to top cancer 
journals for a separate special issue on a novel integrative design for cancer prevention and 
therapy.  Elsevier’s Seminars in Cancer Biology (Impact Factor: 9.330) was the journal that 
was selected for this part of the project.    This task force was recruited by the same means and 
Appendix 7 shows a copy of the invitation to authors that was used for The Halifax Project 
therapeutic design task force, while Appendix 8 and Appendix 9 contain the project guidelines 
for lead authors and other team members.  In total the Halifax Project involved more than 350 
scientists in 31 countries. 
 
The workshop for the therapeutic group was also held in Halifax, Nova Scotia in August of 
2013 (it was scheduled to run back-to-back with the workshop for the environmental mixtures 
taskforce).  Again, the objective was to bring the teams together and to hear from several 
experts outside the taskforce and discuss key project related issues (see Appendix 5).  Notable 
keynote speakers included Jeffrey D. White, M.D., Director, Office of Cancer Complementary 
and Alternative Medicine, Division of Cancer Treatment and Diagnosis, National Cancer 
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Institute (NIH) who spoke about integrative oncology research (mechanistic understandings 
and clinical research) and Bert Vogelstein, MD from Johns Hopkins University who talked 
about the cancer genome landscape (intratumoral heterogeneity, therapeutic implications and 
implications for prevention).  
 
As well, all of the 11 team leaders were given timeslots to provide team progress updates as 
well.  Breakout sessions at the workshop involved discussions that included a review on 
phytochemicals, a discussion on the cancer genome (heterogeneity and the implications for 
target selections), clinical issues (personalizing protocols and alternate modalities to reach 
targeted pathways), safety issues, target selections, strategic needs, barriers, and other issues 
related to follow-on testing (see Appendix 5).   
 
As that task force got underway, I was invited to co-author an editorial on this topic in the 
Journal of Gastrointestinal & Digestive System.  This article is shown as Collaborative Project 
7 in Appendix 10 (i.e., Amin, A, Lowe L. (2012), Plant-Based Anticancer Drug Development: 
Advancements and Hurdles, Journal of Gastrointestinal & Digestive System, 2(5)).   
 
Again, as the project manager and architect of the project, several teams relied on my ongoing 
direction, feedback, and scholarly inputs on their papers, so I earned an authorship in one of 
those reviews as well (see Appendix 11 - Collaborative Project 8 - Broad targeting of resistance 
to apoptosis in cancer).  After one of the original team leaders failed to meet several important 
deadlines, I had to step in as provisional team leader for one of the reviews (see Appendix 12 
- Collaborative Project 9 - A multi-targeted approach to suppress tumor promoting 




Finally, I also served as co-corresponding author on the capstone paper for that special issue.  
The capstone paper was an all-author synthesis from the task force and it can be found in 
Appendix 13 (Collaborative Project 10 - A Broad-spectrum integrative design for cancer 
prevention and therapy).  This should also be a landmark paper because it provides the basis 
for an entirely new approach to prevention and therapy that should help us tackle the 
longstanding problem of refractory cancers and disease relapse, and at a cost that should be 
affordable in many countries that have been unable to afford the latest therapies (Lopes Gde, 
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Abstract
One of the important ‘hallmarks’ of cancer is angiogenesis, which is the process of formation of new blood vessels that 
are necessary for tumor expansion, invasion and metastasis. Under normal physiological conditions, angiogenesis is well 
balanced and controlled by endogenous proangiogenic factors and antiangiogenic factors. However, factors produced 
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Review
by cancer cells, cancer stem cells and other cell types in the tumor stroma can disrupt the balance so that the tumor 
microenvironment favors tumor angiogenesis. These factors include vascular endothelial growth factor, endothelial tissue 
factor and other membrane bound receptors that mediate multiple intracellular signaling pathways that contribute to 
tumor angiogenesis. Though environmental exposures to certain chemicals have been found to initiate and promote 
tumor development, the role of these exposures (particularly to low doses of multiple substances), is largely unknown in 
relation to tumor angiogenesis. This review summarizes the evidence of the role of environmental chemical bioactivity 
and exposure in tumor angiogenesis and carcinogenesis. We identify a number of ubiquitous (prototypical) chemicals 
with disruptive potential that may warrant further investigation given their selectivity for high-throughput screening 
assay targets associated with proangiogenic pathways. We also consider the cross-hallmark relationships of a number of 
important angiogenic pathway targets with other cancer hallmarks and we make recommendations for future research. 
Understanding of the role of low-dose exposure of chemicals with disruptive potential could help us refine our approach 
to cancer risk assessment, and may ultimately aid in preventing cancer by reducing or eliminating exposures to synergistic 
mixtures of chemicals with carcinogenic potential.
Introduction
Angiogenesis, the formation of new blood vessels from existing 
blood vessels, was identified as one of the ‘hallmarks of cancer’ by 
Hanahan and Weinberg (1,2) due to the recognition that this pro-
cess is of crucial importance during the transition from benign 
hyperplastic nodules to malignant lesions (3). This review article 
focused on angiogenesis constitutes an integral component of 
the 2013 Halifax Project on ‘Assessing the Carcinogenic Potential 
of Low-Dose Exposures to Chemical Mixtures in the Environment’ 
(see Capstone Article for details). Tumor expansion is dependent 
on the ability of the tumor to induce the growth of new blood ves-
sels, which provide nutrients and oxygen to the growing tumor 
mass and simultaneously serve as a conduit for tumor cells to 
metastasize to distant organs (4,5). Tumor angiogenesis is inte-
gral not only in solid tumor progression but also in leukemia 
(6). Recent cancer treatments target tumor angiogenesis using 
antiangiogenesis inhibitors (7,8), which prevent new vessel for-
mation, or by using vascular-disrupting/damaging agents (9–11) 
and neovascular-targeting immunoconjugates (12–14). However, 
angiogenesis is also necessary for normal organ function, tissue 
growth and regeneration (e.g. wound healing, female menstrua-
tion, ovulation and pregnancy), necessitating a fine balance to 
avoid complications due to antiangiogenic therapy (15–17).
Though human exposures to environmental chemicals, 
which often occur due to the leaching of plastics into food and 
water (18), have been found to promote tumorigenesis of mul-
tiple cancers through various mechanisms (19–24), less atten-
tion has been focused on their role in tumor angiogenesis. With 
increases in our knowledge of endocrine disruptors (25), new 
concerns have arisen about potential exposures to low doses of 
environmental chemicals that are generally regarded as non-car-
cinogens, but may be acting as proangiogenic agents. Here, we 
consider the possibility that certain chemical disruptors, which 
are prevalent in the environment (e.g. as pesticides and indus-
trial surfactants) (26), may have a role to play in environmental 
carcinogenesis by stimulating proangiogenic pathways, provid-
ing an environment conducive to tumor growth and metastasis.
In this review, we discuss emerging data on specific environ-
mental chemicals that may act as proangiogenic agents, and 
identify key angiogenesis pathways and corresponding molecu-
lar components as prioritized targets for future study. We briefly 
summarize in vitro and in vivo angiogenesis model systems with 
an emphasis on high-throughput screening (HTS) assays. We 
also consider the cross-hallmark relationships that a number 
of important angiogenic pathway targets have with other hall-
marks of the disease and we make recommendations for future 
research. 
Identifying VEGFR- and TF-mediated signaling 
as two key tumor angiogenesis pathways and 
corresponding molecular components as prioritized 
targets for assessing the carcinogenic potential of 
low-dose exposures to chemical mixtures in the 
environment
Tumor growth and metastasis require angiogenesis to provide a 
circuit for increased blood supply and dissemination of tumor 
cells (27). Angiogenesis is tightly controlled by diverse subsets of 
ligands and receptors. Enrichment of ligands, including growth 
factors, chemokines and cytokines or a decrease in the produc-
tion of endogenous angiogenesis inhibitors, has been exten-
sively observed in tumors during vascularization. The biology 
and mechanisms of tumor angiogenesis have been elegantly 
summarized elsewhere (4,28–33). Here, we will only briefly 
review some of the key angiogenic pathways [vascular endothe-
lial growth receptor (VEGFR) and tissue factor (TF)-mediated 
signaling] (Figure 1A) and pathway-associated molecular com-
ponents (Figure 1B) to provide a framework for our review and 
discussion of potential chemical disruptors (Figure 1B).
The vascular endothelial growth factor (VEGF) pathway is 
crucial for cancer angiogenesis. As a tumor enlarges, the tis-
sue becomes hypoxic and deprived of nutrients leading to 
Abbreviations 
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CXCL9 and 10 C-X-C motif chemokine ligands 9 and 10 
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increased expression of factors involved in both fighting against 
and adapting to these stressful conditions (34). Such factors will 
activate the growth of new blood vessels to increase the oxy-
gen and nutrients supply but also lower the oxygen-dependent 
metabolism by causing a shift to glycolytic metabolism in the 
tumor cells (35). A  well-studied example of hypoxia-induced 
tumor angiogenesis is the stabilization of hypoxia-inducible fac-
tor 1 alpha (HIF-1α) in hypoxic tumor tissues which lead to pro-
duction of VEGF-A and nitric oxide synthase (NOS) that act as 
drivers of neovascularization and dilation of the existing blood 
vessels, respectively (36). In addition to VEGF-A, other growth 
factors including angiopoeitin-2 (Ang-2), fibroblast growth fac-
tors (FGFs), platelet-derived growth factors, insulin-like growth 
factor and transforming growth factor-beta (TGF-β) are also pro-
duced at high levels by hypoxic tumor or tumor stromal cells and 
lead to disruption of the tumor vessels (37). The tumor milieu, 
which has been compared to that of a healing wound (38), also 
leads to massive recruitment and activation of inflammatory 
cells types, including macrophages, neutrophils and lympho-
cytes, which are producing proangiogenic cytokines including 
tumor necrosis factor-alpha, interleukin 1 beta (IL-1β) and inter-
leukin 6 (IL-6). In addition, carcinoma-associated fibroblasts are 
also rich sources of a wide range of angiogenic factors, further 
complicating the proangiogenic phenotype of solid tumors 
(39,40). In addition to angiogenic factors, deregulated vessel 
sprouting and path finding through disruptions in, for instance 
Notch-activation by delta-like ligand 4 (Dll4) and Jagged1 ligands 
(41), are involved in disrupting the tumor vascular functions fur-
ther contributing to the pathological phenotypes of the tumor 
blood vessels. Activated endothelial cells and tumor-associ-
ated macrophages produce matrix metalloproteinases (MMPs) 
including a disintegrin and metalloproteases, MMP-2 and MMP-
9, which cleave extracellular matrix (ECM) to release more ECM-
bound angiogenic factors and further reduce the integrity of 
the vasculature, leading to a vicious circle driving pathologic 
progression in cancer (42,43). In addition to expressed proteins, 
angiogenesis-modulating miRNAs, so called angiomiRs, directly 
repress gene expression of several angiogenic or antiangiogenic 
factors by binding to the 3′-untranslated regions (3′-UTR) of tar-
get mRNAs (44). For instance, miR-21 promotes cancer progres-
sion and angiogenesis through Akt and ERK pathways (45).
As a consequence of such untamed and exaggerated angi-
ogenic signaling by the broad palette of proangiogenic factors 
existing at high levels in the tumor, the vasculature become 
highly chaotic, immature and of very low quality (in terms of 
the stability and barrier function of the vascular wall) and func-
tionality (in terms of supporting efficient perfusion through 
the tumor) (46). As such, tumor blood vessels exhibit excessive 
leakage, causing highly elevated interstitial fluid pressure and 
inhibited delivery of blood, paradoxically further contributing to 
tumor hypoxia and decreasing delivery of drugs injected to the 
blood stream. At the same time, such deregulated tumor blood 
vessels pose little opposition against tumor-cell intravasation 
and metastatic dissemination. As such the pathological vascu-
lature can be considered a main cause of resistance to therapy 
and progression of the cancer to metastatic disease (47).
While tumor angiogenic vascular endothelial cells (VECs) 
may express VEGFR at higher levels (48), VEGFRs are not spe-
cific for angiogenic endothelial cells, but are constitutively 
expressed also in the quiescent vasculature in normal organs 
(49,50). In contrast, TF may be a promising target, which is 
specifically expressed by angiogenic vessels, making it more 
specific for the tumor vasculature than VEGF receptors. Under 
physiological conditions, TF is only expressed on some cells 
outside of vessels, but is not expressed by quiescent endothe-
lial cells of blood vessels in normal organs (51). Accumulating 
evidence suggests that TF also contribute directly and indirectly 
to tumor angiogenesis (52–56). TF is a transmembrane protein 
receptor (57–60), which is composed of 263 amino acid (aa) resi-
dues with an extracellular domain (1–219 aa), a transmembrane 
domain (220–242 aa) and a short cytoplasmic domain (243–263 
aa). As a type I membrane bound receptor, TF forms an excep-
tionally strong and specific complex with its natural ligand 
coagulation factor VII (61,62), the initial step of the coagulation 
Figure 1. VEGF and TF-signaling pathways as prioritized tumor angiogenic pathways (A) and proposed angiogenic molecular targets and their corresponding chemical 
disruptors (B). (A) The diagram shows VEGF produced by tumor cells binds to VEGFR on vascular endothelial cells to activate VEGF signaling pathways in tumor angio-
genesis. In addition, VEGF binding to endothelial cells can induce TF expression, an angiogenic endothelial receptor in pathological neovasculature. After its ligand 
fVII binds, TF could contribute to tumor angiogenesis via proteolysis-dependent pathways through PARs or proteolysis-independent pathway through its cytoplasmic 
domain. (B) Proposed list of specific angiogenesis molecular targets and corresponding chemical disruptors. 
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pathway (63). In tumor angiogenesis, it is found that TF expres-
sion is only detected on angiogenic tumor VECs (13,64–66), a 
downstream product induced by VEGF that can be secreted by 
cancer cells (67,68) and cancer stem cells (69). More importantly, 
TF is selectively expressed in vivo in the tumor neovasculature 
(12,13,64,65,70) and in vitro by VEGF-stimulated VECs, thus the 
latter could serve as an in vitro model of angiogenic endothe-
lial cells (71–73). Other angiogenic factors and inflammatory 
chemokines (such as bFGF, IL-1β, tumor necrosis factor-alpha, 
bacterial lipopolysaccharide (LPS)) can also induce TF expres-
sion on VECs under pathological conditions (54). Thus TF can 
be regarded as an angiogenic-specific endothelial receptor 
(65,72,73). We believe that this unique feature makes TF a prom-
ising therapeutic target for neovascular-targeted therapy (73) 
and an interesting angiogenic receptor for discussion in this 
review and for future studies of chemical angiogenesis. 
After induction by VEGF and other factors, vascular endothe-
lial TF contributes to tumor angiogenesis via proteolysis-
dependent and -independent signaling pathways (Figure  1A). 
More details on TF signaling in tumor angiogenesis were pre-
viously described and reviewed (52,74–77). Briefly, coagulation 
factor VII/TF complex can initiate the proteolysis-dependent 
pathway by activating protease-activated receptors (PARs), 
which is modulated by thrombomodulin (THBD), the endothe-
lial-specific type I  membrane receptor that binds thrombin to 
reduce thrombin generation, and ultimately results in the tran-
scription of genes such as early growth response-1, adhesion 
molecules [intercellular adhesion molecule 1 (ICAM1), vascular 
cell-adhesion molecule 1 (VCAM1), P- and E-selectin], growth 
factors and cytokines (IL-6, IL-8, chemokines), whereas the cyto-
plasmic serine residues can be phosphorylated and ultimately 
influences endothelial cell migration. Note that many of these 
angiogenic components involved in VEGFR- and TF-mediated 
signaling are chosen as potential angiogenic targets for selected 
chemical disruptors (Figure 1B).
To review the role of low-dose exposures to environmental 
chemical disruptors in tumor angiogenesis, our angiogenesis 
team as part of the Halifax Project was asked to identify 10 
angiogenesis molecular targets and 10 corresponding potential 
chemical disruptors for these angiogenic targets. We choose 
the following angiogenic components involved in VEGFR- and 
TF-signaling pathways as prioritized VCAM1, C-X-C motif 
chemokine ligands 9 and 10 (CXCL9 and CXCL10), THBD, mono-
cyte-like chemoattractant protein (CCL2), ICAM1, urokinase-
type plasminogen activator receptor (uPAR), collagen III, MMP1 
and aryl-hydrocarbon receptor (AHR). These targets were cho-
sen based on their relevance to the signaling pathways reviewed 
above, and, importantly, based on previous work that examined 
a large database of animal toxicity studies (ToxRefDB; http://
actor.epa.gov/toxrefdb/) and the concordance between tumor 
incidence in vivo and chemical activity profiles in vitro. The 10 
molecular targets in Figure 1B were angiogenic signaling mol-
ecules that showed statistically significant associations with 
mammalian carcinogenicity (78).
This list of target sites was not intended to be compre-
hensive. Other targets exist, including well-known molecules 
such as collagen IV, CXCL4, thrombospondin, MMP9, etc., But 
we selected these targets because each of them are actively 
involved in tumor angiogenesis and all of them have been 
shown to be of considerable importance. For example, sup-
pression of the angiostatic molecules CXCL9 and CXCL10 and 
upregulation of the proangiogenic chemokine CCL2 would pro-
vide a local environment of proliferative and migratory signals 
to endothelial cells forming new vessels to feed a tumor (79,80). 
Decreased THBD expression was highly correlated with tumor 
invasiveness, metastasis and lower survival rates (81,82). CCL2 
is complementary to angiogenesis, through p53 regulation 
of CCL2 gene expression (83,84). ICAM1 is also complemen-
tary to angiogenesis through NF-κB-independent role for p53 
in ICAM1 regulation that may link p53 to ICAM1 function in 
various physiological and pathological settings (85). CXCL10 is 
complementary to angiogenesis through activation of p53 and 
p53-responsive genes. Over expression of IP10 upregulated p53 
and resulted in altered expression of p53-responsive genes such 
as the p21Cip1, p27kip1, NF-κB, Bax and PUMA genes and the 
mitochondrial translocation of Bax (86). The AHR is complemen-
tary to angiogenesis through its role in cell cycle regulation. AHR 
modulates angiogenesis through a mechanism requiring VEGF 
activation in the endothelium and TGF-β inactivation in the 
stroma. Activation of AHR by its various ligands disrupts contact 
inhibition and induces cell proliferation depending on the tis-
sue and cell type involved (87–93). THBD is contrary to angiogen-
esis due to over expression of p53 suppressed THBD expression 
(94,95). It is also complementary to genetic instability (96,97) and 
resistance to cell death (98). uPAR is contrary to angiogenesis 
(wild type p53 downregulates uPAR expression). P53 acts as an 
uPAR mRNA binding protein that downregulates uPAR mRNA 
stability and decreases cellular uPAR expression. Codepletion of 
Cathepsin B and uPAR reduced the expression of cyclin D1, cyc-
lin D2, p-Rb and cyclin E while the expression of Cdk2 was unaf-
fected. The MMP1 is contrary when cross validated with evasion 
of antigrowth signaling hallmark (99–102). Inactivation of Rb 
leads to increased expression of MMP1 and dysfunction of p53. 
p53 inhibits basal and UV-induced MMP-1 expression in human 
dermal fibroblasts and p53 dysfunction caused by XPC defects 
in lung cancers may enhance tumor metastasis via increased 
MMP1 expression (99–101,103).
To examine the role of these angiogenic pathways and pri-
oritized targets in chemical angiogenesis, we also identify 10 
corresponding chemical disruptors (Figure 1B) as novel environ-
mental chemicals in tumor angiogenesis, which are discussed 
below in the Sections of ‘Environmental Carcinogens Affecting 
Angiogenic Pathways’ and ‘Identifying Novel Environmental 
Chemical Disruptors’.
Environmental carcinogens affecting 
angiogenic pathways
Here, we review the evidence for proangiogenic actions of ciga-
rette smoke, nicotine and arsenic as case study compounds that 
provide supporting evidence for the subsequent selection of 
environmental chemicals that disrupt angiogenic signaling tar-
gets and potentially contribute to cancer.
Cigarette smoke
Cigarette smoke is one of the oldest environmental exposures 
linked to cancer (104) and contains numerous carcinogenic 
compounds, such as nicotine and its derivatives, described else-
where (105,106). Cigarette and second hand smoke have both 
been shown to induce or be associated with angiogenesis by a 
variety of mechanisms, although separating angiogenic effects 
from other carcinogenic activities is a challenge. Mouse models 
of chronic colitis were found to have dose-dependent increases 
in blood vessel formation and VEGF protein expression fol-
lowing exposure to CS (107). Tumor growth, capillary density, 
plasma VEGF levels and circulating endothelial progenitor cells 
were significantly increased in mice subcutaneously injected 
with Lewis lung cancer cells after a 17-day exposure to second 
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hand smoke compared to mice exposed to clean room air. These 
results were attenuated with mecamylamine, an inhibitor of 
nicotine cholinergic receptors (108).
A hospital-based case-control study consisting of 730 urothe-
lial carcinoma cases, 470 bladder cancers, 260 upper urinary 
tract urothelial carcinomas and 850 age-matched controls found 
significant correlations between bladder and upper urinary tract 
urothelial carcinomas (UUTUC) and both cigarette smoking and 
arsenic exposure (109). The risk for both bladder cancer (6.6; 95% 
CI, 3.1–13.9) and UUTUC (9.9; 95% CI, 4–24.5) were increased with 
the presence of VEGF polymorphisms associated with increased 
cancer risk.
Nicotine
Nicotine, one of the main carcinogenic components of ciga-
rettes, has been found to influence angiogenesis. Several in vitro 
studies have linked nicotine to proangiogenic effects in cancer. 
The ERK/COX-2 pathway was suggested to play a role in nico-
tine-induced VEGF expression in gastric cancer cells after VEGF 
levels were decreased by inhibitors of MEK (U0126) and COX-2 
(SC-236) (110). Nicotine was further shown to influence angio-
genesis in lung cancer (111). Nicotine significantly stimulated 
HIF-1α protein and VEGF expression in human non-small cell 
lung cancer (NSCLC) cells. Increased capillary and tubule for-
mation was shown in human umbilical VECs (HUVECs) follow-
ing treatment with conditioned medium containing nicotine. 
The possible mechanism of nicotine-induced VEGF expression 
was investigated with human dermal microvascular endothe-
lial cells, which showed that the nicotine acetylcholine receptor 
was needed for pro-migratory effects of VEGF and bFGF in cul-
ture (111). In addition, cultured HUVECs were observed to have 
increased cell proliferation, migration and tube formation fol-
lowing exposure to nicotine at concentrations similar to those 
found in smokers (112).
Although in vitro studies provide some evidence that nico-
tine has proangiogenic properties, animal studies further bol-
ster nicotine as a promoter of neovascularization, as well as 
provide possible biological mechanisms. An increase in lesion 
growth and lesion vascularity was seen in lung cancer and ath-
erosclerosis mouse models following nicotine exposure (113). In 
addition, in a mouse model of hind-limb ischemia systemically 
administered nicotine (100 μg/ml in drinking water) resulted in 
an increase of capillary density in the hind limb from 0.38 to 
0.71 (95% CI 0.55–1.01) capillaries/myocyte compared to control. 
Later it was shown that nude mice injected subcutaneously 
with HT-29 cells, a colon cancer cell line, exhibited significant 
increases in both blood vessels and microvessel densities after 
drinking water containing 200 μg/ml nicotine for 25 days. VEGF 
expression correlated with microvessel density. B1 and b2-selec-
tive antagonists reversed nicotine-induced tumor growth; sug-
gesting b-adrenoceptors may be involved in nicotine-induced 
angiogenesis in colon cancer (114). The growth rate of breast, 
colon and lung cancer tumor cells implanted in a chorioallan-
toic membrane model exhibited significant increases following 
1 week of exposure to nicotine (115). This study further showed 
that nicotinic receptor antagonists and integrin avb3 antago-
nists abrogated nicotine-mediated angiogenesis, suggesting 
molecular and cellular mechanisms of nicotine-mediated angi-
ogenesis (116).
Arsenic
Another carcinogen that shows angiogenic properties is arsenic, 
an environmental contaminant that humans may be exposed 
to via environmental, medical and occupational sources (117). 
An in vitro study using HUVECs revealed that low concentrations 
(≤ 1 μM) of sodium arsenite increased cell growth and vascular 
tubular formation compared to higher concentrations (> 5 μM) 
that induced cytotoxicity and inhibited angiogenesis (117). Low 
concentrations of arsenic also induced transcript expression of 
VEGF and von Willebrand Factor, an early detector of endothelial 
activation, in tumor metastasis. Several subsequent in vitro stud-
ies focused on the proangiogenic properties of arsenic in human 
microvascular endothelial (HMVEC) cells. Klei et al. (118) investi-
gated signaling interactions between arsenic and alcohols using 
non-cytotoxic concentrations of arsenite (1–5 mM) with or with-
out the presence of 0.1% ethanol. Data in this study showed that 
both agents together, but not ethanol alone, increased phos-
phorylation of the regulator of vascular integrin signaling PYK2 
and VEGF gene expression as well as endothelial tube formation 
(118). Another study revealed that the sphingsine-1-phosphate 
type 1 receptor is important for arsenic-stimulated signaling for 
angiogenic effects (119) and that heme oxygenase-1 plays a role 
in arsenic-induced angiogenesis (120). Moreover, environmen-
tally relevant levels of arsenic were shown to promote angio-
genesis, neovascularization and inflammatory cell infiltration 
in Matrigel plugs implanted in C57BL/6 mice following 5 weeks 
exposures (drinking water) to concentrations ranging from 5 to 
500 ppb (121).
These examples from the literature on known carcinogens 
indicate that environmental exposures to cigarette smoke, nico-
tine and arsenic can result in the increase of angiogenic activ-
ity through several pathways. There is a diversity of techniques 
available for investigating angiogenic activity, though there are 
challenges to separating effects that are specific to angiogenic 
pathways from other hallmark pathways.
Other environmental chemicals with proangiogenic 
properties
In addition to cigarette smoke, nicotine and arsenic, other poten-
tially carcinogenic compounds have been identified that induce 
proangiogenic effects. Whole diesel exhaust has been shown to 
enhance angiogenesis in mice with either subcutaneous scaf-
fold implantation or hindlimb ischemia (122). Increased CD31 
expression, vessel volume and VEGF and HIF-1 gene expression 
was observed in these models. Bisphenol A has been intensively 
studied over the past few years due to its detrimental effects 
on developmental processes and metabolic effects and has 
recently been shown to influence angiogenesis (123). Increased 
gene expression of VEGFR-2, VEGF-A, eNOS and Cx43 and pro-
duction of nitric oxide was found after HUVECs were exposed to 
1 M bisphenol A for 6 h (123). Furthermore, manganese induced 
hypoxia-associated transcript expression of proangiogenic 
genes in mice (124) and both dioxin (125) and trimethyltin chlo-
ride (109) were found to influence angiogenesis and vasculariza-
tion during early development in rat and zebra fish models.
Identifying novel environmental chemical disruptors
As discussed above, tumor angiogenesis is critical for carcino-
genesis, and despite the evidence that several known carcino-
gens are targeting proangiogenic pathways the role of most 
environmental chemicals in tumor angiogenesis is largely 
unknown. In this project, we were tasked to identify ‘prototypi-
cal’ environmental chemicals with disruptive potential that met 
the following criteria: chemicals that are ubiquitous in the envi-
ronment; chemicals that have been shown to disrupt specific 
mechanisms/pathways for angiogenesis; and chemical expo-
sures that are not related to ‘lifestyle’ choices (i.e. chemicals that 
are not already known or designated to be human carcinogens). 
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Our intent was to explore the possible synergies of disruptive 
environmental chemicals with proangiogenic capabilities that 
could potentially contribute to carcinogenesis (especially when 
combined, or when acting with other chemicals that are known 
to perturb other cancer hallmark pathways).
Thousands of untested chemicals in the environment lack 
hazard characterization of their carcinogenic potential. The 
Tox21 partnership of regulatory and scientific federal agencies, 
including USA. EPA, the National Toxicology Program (NTP), the 
National Center for Advancing Translational Science (NCATS) 
and USA. FDA, are addressing this data gap using in vitro HTS 
and computational modeling to predict hazard and prioritize 
compounds for targeted testing (126,127). The EPA’s ToxCast 
research project (127), part of Tox21, has tested over a thousand 
chemicals with known and unknown toxicities in hundreds of 
assays for human gene and protein targets in pathways linked 
to cancer disease processes (128). This effort is concurrent with 
the creation of the Toxicity Reference Database (ToxRefDB) con-
taining >40 years’ worth of in vivo animal toxicity data, such as 
2-year chronic cancer studies, broken down into a computable 
and searchable ontology structure (129). A model was recently 
published that used the ToxCast Phase I HTS data to predict in 
vivo rodent carcinogenicity endpoints from ToxRefDB (78). This 
work employed an unsupervised statistical approach to iden-
tify significant correlations between in vitro assay activity and 
preneoplastic and neoplastic lesions in a variety of tissue types, 
across a training set of 232 compounds with both in vitro and in 
vivo data. The model was able to accurately predict carcinogenic-
ity classifications from the EPA’s Office of Pesticide Programs for 
an external test set of compounds, based solely on their in vitro 
HTS data. Interestingly, the majority of HTS assays that were 
strongly associated with particular types of rodent cancers were 
linked to genes, pathways and hallmark processes documented 
to be involved in tumor biology and cancer progression, includ-
ing stimulation of angiogenesis.
Most of the chemical carcinogens in the model training set 
were food-use pesticides, meaning they are non-genotoxic and 
instead act as tumor promoters (130). In addition to broad activ-
ity across assays that were mapped to other hallmark processes 
(i.e. apoptosis, proliferative signaling, evading growth sup-
pression, enabling replicative immortality, metastasis, avoid-
ing immune destruction, tumor-promoting inflammation and 
deregulating cellular energetics) some of these compounds were 
linked to targets in angiogenic pathways (1,2). Thus, a subset of 
these chemicals may have the potential to act as tumor promot-
ers primarily via induction of angiogenesis, based on specific 
patterns of bioactivity against in vitro targets associated with 
vascular development. Many of these targets were from enzyme-
linked immunosorbent assay-based chemokine expression 
assays in human primary cell cocultures. Statistically significant 
associations were observed between pesticide exposures caus-
ing rodent liver, thyroid, spleen and kidney tumors and differen-
tial regulation of inflammatory chemokines as well as cellular 
adhesion molecules, and elements of the plasminogen activat-
ing system. Many of these targets, shown in Figure 1, belong to 
signaling pathways reviewed above. Therefore, the results from 
the in vitro screens of these mammalian carcinogens were in all 
cases consistent with a proangiogenic and thus a protumori-
genic program.
Analysis of bioactivity patterns of over a thousand chemicals 
across hundreds of in vitro assays revealed that other carcino-
gens were preferentially affecting targets in chemokine signal-
ing, vascular cellular adhesion molecules and ECM interactions 
controlling vascular growth factor release (78). These results 
strongly support the concept that at some point in cancer pro-
gression, the angiogenic switch is turned ‘ON’, facilitating tumor 
growth, and that carcinogenic environmental chemicals may 
participate in this process by regulating cellular signaling in a 
proangiogenic fashion.
A number of environmental chemicals tested in the ToxCast 
program were identified as potential tumor promoters through 
their ability to interact with the angiogenic signaling molecules in 
vitro that had been shown to be significantly associated with in vivo 
tumorigenesis. Many of these compounds had associated in vivo 
data and evidence in the literature confirming their carcinogenic 
effects (78), while others are candidates for further study. In the 
ToxCast Phase I study, there were 27 chemicals tested in the in vitro 
assays for which there was no corresponding in vivo guideline data 
or EPA carcinogenicity classification (examples shown in Table 1). 
As shown in Figure 1B, we identify several of these Phase I com-
pounds that may be acting via proangiogenic mechanisms, their 
cancer hallmark score and the specific angiogenic targets affected. 
All of these compounds are present in the environment, are pre-
dicted to be selectively disruptive, are not ‘lifestyle’-related, and 
not known to be ‘Carcinogen to Humans’ (i.e. IARC Group 1). The 
Toxicological Priority Index (130) (ToxPi, key shown in Figure 2) dis-
plays the activity of each chemical against the angiogenic in vitro 
assay targets that were previously identified as significantly asso-
ciated with tumor endpoints in vivo. The size of the slice is deter-
mined by the potency of the compound in the assay, based on the 
half-maximal activity concentration (AC50). The chosen angiogenic 
prototypical disruptors are Bisphenol AF, Methoxychlor, perfluo-
rooctane sulfonate (PFOS), Diniconazole, Ziram, Chlorothalonil, 
Biphenyl, Tributyltin Chloride, 2,2-bis-(p-hydroxyphenyl)-1,1,1-
trichloroethane (HPTE) and C.I. Solvent Yellow 14 (Figure 1B). For 
several of these compounds, there is literature evidence that sup-
ports their potential angiogenic activity. For example, Bisphenol 
AF may induce angiogenesis via inactivation of the p53 axis and 
underlying deregulation of proliferation kinetics and cell death in 
human epithelial cells, as well as through its effect on Estrogen 
Receptor (ERα) (131). Bisphenol AF also affected a number of 
vascular targets in the ToxCast assay portfolio, including uPAR, 
THBD and ICAM1, as well as downregulating the antiangiogenic 
chemokines CXCL9 and CXCL10. Methoxychlor (the parent com-
pound to HPTE) was shown to induce increases in histological 
expression of angiogenic factors such as VEGF, VEGFR2 and ANG1 
in rat pituitary and uterus (132). The angiogenic HTS targets of 
HPTE include CXCL10, CXCL9, MMP1, uPAR, THBD, ICAM1 and 
VCAM1. Exposure to PFOS induced actin filament remodeling 
and endothelial permeability changes as well as ROS production 
in human microvascular endothelial cells (133). PFOS could also 
overwhelm homeostasis of antioxidative systems, boost ROS gen-
eration, impact the mitochondria and affect protein expression of 
apoptotic regulators in endothelial cells (134). Diniconazole (a pes-
ticide) is predicted to be carcinogenic and shown to target certain 
angiogenic molecules CXCL10, uPAR and VCAM1 in vitro. Ziram 
may induce angiogenesis through activation of mitogen-activated 
protein kinases (MAPK) and decreases cytolytic protein levels in 
human natural killer cells (135,136).
Phase II of the ToxCast program expanded the chemi-
cal library beyond pesticides to over a thousand compounds, 
many of which lack cancer data but appear to be targeting 
angiogenic signaling and may also be candidates for future 
examination. A  number of organotin compounds, including 
tributyltin chloride, tributyltin methacrylate and triphenyltin 
hydroxide, caused a decrease in expression of THBD in vascu-
lar smooth muscle cells as well as other proangiogenic activ-
ity in the ToxCast assays. As in the case of dioxin, AHR ligands 
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may be potential tumor promoters via angiogenic pathways, 
and it has been hypothesized that AHR signaling may suppress 
VEGF-A expression by competing with HIF-1α for their common 
dimerization partner ARNT (137). Compounds such as C.I. sol-
vent yellow 14, Benzo(b) fluoranthene and 7,12 dimethyl(benz)
anthracene are active in the AHR assay in addition to multiple 
Table 1. Examples of  ToxCast Phase I chemicals predicted to be carcinogens and shown to target certain angiogenic molecules in vitro, but lack-
ing in vivo data or EPA carcinogenicity classifications
Chemical name Chemical use class
Cancer hazard model score 
(#cancer hallmark assays hit) Angiogenic targets Proangiogenic ToxPi
Diniconazole Pesticide 18 CXCL10, uPAR, VCAM1
HPTE Pesticide metabolite 17 CXCL10, CXCL9, MMP1, uPAR, 
ICAM1, THBD, VCAM1
Methylene bis(thiocyanate) Pesticide 16 CXCL10, CXCL9, MMP1, uPAR, 
ICAM1, THBD, VCAM1
PFOS Industrial surfactant 7 CXCL10, MMP1, uPAR, VCAM1
These compounds were identified in an analysis linking rodent chemical carcinogenesis to HTS assay targets in cancer hallmark pathways (78). All of these com-
pounds are ubiquitous in the environment, are predicted to be selectively disruptive, are not ‘lifestyle’ related and not known to be ‘Carcinogen to Humans’ (i.e. IARC 
Group 1). The Toxicological Priority Index (ToxPi) key mapping assays to slices is shown in Figure 2. CXCL9 and 10, C-X-C motif chemokine ligands 9 and 10.
Figure 2. The ToxPi key for proangiogenic in vitro assay targets that were previously identified as being statistically significantly associated with tumor endpoints in 
vitro. The number of components represents the number of ToxCast assays for that target. Results for certain ToxCast Phase I test chemicals are shown in Figure 1B. 
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other angiogenic targets, however their downstream effects 
on VEGF expression and angiogenesis will be dependent on 
their agonist vs. antagonist activity and are not yet known. 
Other chemicals exhibited specific activity on cytokine sign-
aling, such as acrylamide and biphenyl, both of which caused 
increased expression of the proangiogenic chemokine CCL2 in 
vascular smooth muscle cells. The release of the full ToxCast 
Phase II dataset in late 2013 (http://www.epa.gov/ncct) is assist-
ing in further identification of key assay targets and prioritiza-
tion of potential chemical modulators of tumor angiogenesis. 
There are also a number of compounds that emerged from this 
analysis that have been tested in animals and assigned positive 
carcinogenicity classifications, but whose effects have not been 
well characterized histologically. If some of these were studied 
in more depth, they could also potentially serve as proangio-
genic reference compounds.
In vitro and in vivo angiogenesis assays including 
HTS assay for assessing the effects of environmental 
chemicals in tumor angiogenesis
To screen the effects of environmental chemicals in tumor 
angiogenesis, there are many well developed in vitro and in vivo 
angiogenesis model systems that can be used or adapted (138–
151). Each model has distinct advantages and disadvantages. 
Microvascular endothelial cells or well-characterized immortal-
ized microvascular endothelial cell lines are generally considered 
superior to HUVEC in tumor angiogenesis studies, since tumor 
blood vessels are presumably microvessels. In vitro assays are usu-
ally designed to examine endothelial cell proliferation, migration 
and ability to form tube-like structures in coculture, matrigel or 
other matrix-containing environments. In vivo assays include, but 
are not limited to, the chorioallantoic membrane assay (chicken 
embryos), mesenteric window assay (small gut of rats and mice), 
corneal angiogenesis assay (rabbit, rat or mouse eyes), matrigel 
plug assay (mice and rats), sponge implant assay (rats) and alter-
nate animal models such as hamster and zebrafish.
With technological advancement and the development 
of HTS, several in vitro angiogenesis assays have been used to 
screen and profile large numbers of chemical compounds that 
can be assayed in 96-well to 1536-well microplates. Because can-
cer cells can survive through compensation pathways, a battery 
of angiogenesis assays in HTS formats are needed to rapidly pro-
file thousands of environmental chemicals and to build better 
predictive toxicology models. These assays are grouped into bio-
chemical and cell-based categories and summarized in Table 2.
Biochemical HTS assays directly measure the effects of test 
chemicals on target protein or peptide samples. These methods are 
particularly useful for well-validated angiogenic signaling compo-
nents. Several biochemical assays have been implemented in large 
scale screens for VEGFR (166), TF (171), TGF-β (175), HIF (176) and 
integrins (177). Particularly, Yauch et al. (171) described a HUVEC-
based HTS assay for the VEGF signaling pathway followed by quan-
titative real-time PCR for measuring downstream gene products TF 
Table 2. HTS assays for assessing the role of environmental chemicals in tumor angiogenesis
Assay technology Target Assay principle HTS format Reference
Biochemical HTS assays
 Fluorescence intensity Integrin Binding to dye-labeled fibronectin Microarray (163)
 FP VEGF, Competitive binding of dye-labeled 
proteins or ligands
384 well, microfluidics (164)
 TRF HIF-1α Protein–ligand binding interactions 96 well (176)
 AlphaScreen VEGFR Protein–ligand binding interactions 1536 well (165)
 TR-FRET TGF, VEGFR Product formation catalyzed by ac-
tive enzymes
96 well, 384 well (175,166)
Cell-based HTS assays
 Phenotype Tube formation Total tube length measured by ds-
Tomato fluorescent protein, nuclear 
stains or cell permeable dyes




Wound closures Scratch assays or stopper assays, 
with some measured by cell perme-
able dyes
96 well, 384 well, microfluidics (173,174, 357, 
358,359)
Chemifluorescence IL-1α/β, IL-6, IL-10 Detection of endogenous target 
proteins
96 well (360)
 β-lactamase reporter IL-6, HIF-1α, NFκB, Target-driven β-lactamase reporter 
gene system and β-lactamase- 
cleavable FRET substrates
384 well, 1536 well (181,182,361,184)
 GFP reporter NFκB, VEGF, IL-8 Target-driven GFP reporter gene 
system
96 well, 384 well (362–364)
 Luciferase reporter NFκB, HIF-1/2, VEGFR, 
IL-8, TGF- β
Target-driven luciferase reporter 
gene system
96 well, 384 well, 1536 well (184,365,366,180, 
185)
HIF-1α Degradation of a luciferase-fused 
HIF-1α reporter
384 well (183)
 TRF E-selectin, ICAM-1, 
VCAM-1
Detection of endogenous targets 96 well (367)
 RT-PCR VEGFR mRNA levels of ICAM-1 and tissue 
factor
96 well (171)
FP, fluorescence polarization; GFP, green fluorescent protein; HIF-1, HIF-2, HIF-1α, hypoxia-inducible factor 1, 2 and 1 alpha; ICAM-1, intracellular cell adhesion mole-
cule 1; IL-1α, IL-1β, IL-6, IL-8 and IL-10, Interleukin 1 alpha, 1 beta, 6, 8 and 10; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; RT-PCR, real-time 
polymerase chain reaction; TRF, time-resolved fluorescence; TR-FRET, time resolved fluorescence resonance energy transfer. 
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and ICAM1 as transcriptional readouts. This HTS/real-time qPCR 
assay could be improved, e.g. using microvascular endothelial cells 
as discussed above, for future study of assessing chemical disrup-
tors in tumor angiogenesis, as we propose in this review.
Cell-based HTS assays can be used to assess phenotypic 
changes or specific pathway activation/inhibition caused by 
exposure to test chemicals in cells or tissues. Active compounds 
identified from biochemical screens do not always exhibit similar 
activities in physiological conditions, thus cell-based assays, espe-
cially human primary cells, are useful to identify chemicals that 
exert adverse effects in the natural environment. Angiogenesis-
associated phenotypic changes such as proliferation, apoptosis, 
motility and tube formation are routinely quantified in endothe-
lial cells by a wide selection of commercially available assay kits 
and instruments (178,179). Chemicals that alter gene expression 
or protein–protein interaction can be detected by immunofluo-
rescence or intracellular reporter gene assays. A battery of such 
assays have been applied to screen and identify chemicals tar-
geting cellular signal pathways including HIFs (180,182,183,361), 
NF-κB (184), IL-6 (181), IL-8 (185) and TGFs (186,187).
The environmental chemicals can be assessed and profiled 
using the aforementioned assays in a quantitative HTS platform 
in which each test chemical is assayed at multiple concentrations 
covering at least four-log concentrations (188). The quantitative 
HTS-generated concentration response curves greatly reduce 
rates of false positives and false negatives, facilitating chemical 
prioritization for follow-up in-depth studies. For example, a cell-
based hypoxia-response element-β-lactamase reporter assay has 
been optimized and miniaturized into a 1536-well format, and 
utilized to identify inhibitors and activators of the HIF-1 signaling 
pathway from 73 000 compounds from the Molecular Libraries 
Screening Centers Networks (MLSCN) (361) and 1408 environ-
mental chemicals from the collection of the National Toxicology 
Program (182). Three environmental chemicals—iodochloro-
hydroxyquinoline, cobalt sulfate and O-phenanthroline were 
identified as chemical inducers of hypoxia signaling pathway. 
These quantitative HTS assays combined with a robotic system 
will greatly increase screening throughput for future assessment 
of environmental chemicals that may be affecting angiogenesis 
and other cancer hallmarks (189).
Discussion
When tumor vasculature was first successfully targeted in 
cancer to prevent growth and dispersion of malignant cells, it 
appeared that not only the blood vessels but the entire microen-
vironment within the tumor was participating in tumor growth, 
progression and resistance to treatment (152). A  new concept 
providing additional relevant factors in this already complex 
multifaceted pathology was emerging to explain why current 
therapies are not fully or only transiently efficient (153). It is not 
only that ‘normal cells’ could turn into ‘conscripted or subverted 
cells’ to establish a cancer but some other normal cells would 
be triggered by the mutant cancer cells to help them proliferate 
and survive. These include normal host cells such as endothelial 
cells, fibroblasts, monocytes/macrophages, mesenchymal cells 
and cells of hematopoietic origin, at sites distant from and local 
to the site at which malignant transformation occurs (154). In 
addition, host and cancer cell interactions are occurring within 
a network that governs and influences both cancer and host cell 
properties. This ECM is now recognized as a crucial regulator of 
cancer evolution (152). Thus, several cell types in a complex and 
dynamic non-cellular environment collaborate to stimulate angi-
ogenesis. One would therefore predict that chemical mixtures 
potentially modifying the tumor environment would therefore 
affect angiogenesis for the benefit of the cancer cells. On the 
other hand, tumor angiogenesis is also closely tied to hypoxia 
and thus deregulated metabolism, tumor-promoting inflamma-
tion, accelerated tumor growth, invasion and metastasis.
The carcinogenicity of low-dose exposures to chemical 
mixtures in any given tissue will probably depend upon simul-
taneous activation of several important tumor promotion 
mechanisms and the disruption of several important defense 
mechanisms. The potential synergies of combinations of chemi-
cals will ultimately be involved in several mechanisms of dis-
ruptive actions that are known to be relevant in cancer biology. 
We undertook a thorough cross validation activity to illustrate 
the importance of the prioritized target sites for disruption (i.e. 
across multiple aspects of cancer’s biology) and to illustrate the 
extent to which the prototypical chemical disruptors that were 
identified disrupt other mechanisms that are also relevant to 
carcinogenesis. Since tumor angiogenesis is not only an early 
and central event in the development of a tumor, but also criti-
cal and essential for tumor growth, invasion and metastasis. In 
addition, it is closely tied to hypoxia and deregulated metabo-
lism. Therefore, we cross validate their potential participation of 
these angiogenic targets in other cancer hallmarks (Table 3) and 
their potential effects of chemical disruptors of angiogenesis in 
other cancer hallmarks (Table 4).
When studying the role of chemical disruptors in tumor 
angiogenesis, it is also important to keep in mind that inflam-
mation and angiogenesis are closely linked (126,155–157). Many 
of the angiogenic molecule targets that are selected as impor-
tant targets in this review are also involved in inflammation 
pathways. However, the critical role of VEGFR and TF pathways 
in chemical angiogenesis can be examined in vitro with HTS 
systems where individual chemical disruptors can be added to 
the assay wells to explore their role in angiogenesis, followed 
by a variety of assay techniques as reviewed and summarized 
above and in Table 2 for measuring the changes of these angio-
genic priority targets (CCL2, ICAM1, CXCL9, CXCL10, AHR, THBD, 
uPAR, MMP1, VCAM1 and collagen III) that we choose as poten-
tial targets for chemical disruptors (Bisphenol AF, Methoxychlor, 
PFOS, Diniconazole, Ziram, Chlorothalonil, Biphenyl, Tributyltin 
Chloride, HPTE and C.I. Solvent Yellow 14).
It is worth noting that many common drugs and some die-
tary compounds can prevent cancer by inhibiting tumor angi-
ogenesis. For example, aspirin and metformin are two cases 
where epidemiological evidence indicates cancer prevention 
(158,159), and experimental evidence suggested that inhibition 
of angiogenesis plays a part in this role (160,161). As well, there 
is substantial experimental evidence for phytochemicals, in par-
ticular dietary phytochemicals, preventing angiogenesis (162). 
So simultaneous exposures to both antiangiogenic and proan-
giogenic substances may represent two competing forces that 
could influence the process of environmental carcinogenesis. 
However, it is beyond the scope of this review to simultaneously 
consider these antiangiogenic exposures as well. Primarily, we 
believe that proangiogenic environmental exposures have not 
been considered in detail elsewhere, so they are the focus of 
this review. However, we do recognize that the combined effects 
of these constituents with other chemicals warrant careful 
consideration.
Conclusions
In conclusion, we propose to study the role of environmental 
chemicals on angiogenesis, particularly at low doses of selective 
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chemical disruptors. We believe there is a great need for future 
research that explores the potentially carcinogenic synergies 
produced by low-dose exposures to a wide range of chemicals 
with disruptive potential. Those with proangiogenic potential 
may be non-carcinogenic, but combinations of those chemicals 
may warrant further research and how they might combine 
with other chemicals that act on other hallmarks may help us 
better understand whether or not these types of combination 
exposures have a role to play in environmental carcinogenesis. 
In this regard, we identify prioritized vascular signaling targets, 
identify various environmental chemicals as novel, potential 
selectively disruptive agents in tumor angiogenesis, consider 
the cross-hallmark relationships within tumor angiogenesis 
pathways and targets as well as with other cancer hallmarks 
and make suggestions for assessing environmental chemicals 
in tumor angiogenesis for future studies. Understanding of the 
role of low-dose exposure of chemicals with disruptive poten-
tial could help us to refine our approach to cancer risk assess-
ment, and may ultimately aid in preventing cancer by reducing 
or eliminating exposures to synergistic mixtures of chemicals 
with carcinogenic potential.
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Abstract
An emerging area in environmental toxicology is the role that chemicals and chemical mixtures have on the cells of the 
human immune system. This is an important area of research that has been most widely pursued in relation to autoimmune 
diseases and allergy/asthma as opposed to cancer causation. This is despite the well-recognized role that innate and adaptive 
immunity play as essential factors in tumorigenesis. Here, we review the role that the innate immune cells of inflammatory 
responses play in tumorigenesis. Focus is placed on the molecules and pathways that have been mechanistically linked with 
tumor-associated inflammation. Within the context of chemically induced disturbances in immune function as co-factors in 
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carcinogenesis, the evidence linking environmental toxicant exposures with perturbation in the balance between pro- and 
anti-inflammatory responses is reviewed. Reported effects of bisphenol A, atrazine, phthalates and other common toxicants 
on molecular and cellular targets involved in tumor-associated inflammation (e.g. cyclooxygenase/prostaglandin E2, nuclear 
factor kappa B, nitric oxide synthesis, cytokines and chemokines) are presented as example chemically mediated target 
molecule perturbations relevant to cancer. Commentary on areas of additional research including the need for innovation and 
integration of systems biology approaches to the study of environmental exposures and cancer causation are presented.
Introduction
The assessment of the cancer potential of chemicals has histori-
cally relied on in vitro genotoxicity assays and evaluation of tumor 
formation in rodents. This approach emphasizes the ‘tumor ini-
tiation’ properties of individual compounds and a one-at-a-time 
testing paradigm. This strategy, while experimentally robust, 
is highly reductionist and does not consider the complex and 
permutable pathogenesis of tumorigenesis. The complex patho-
genesis of cancer has been synthesized into discrete aspects or 
hallmark features by Hanahan et al. (1) as the ‘cancer hallmarks’. 
These cancer hallmarks are the features of carcinogenesis that 
encompass the multiple perturbations of the host and tissue 
anti-tumor defense mechanisms. Integrating this complex etiol-
ogy into environmental cancer causation studies is an imposing 
challenge to the field. Over the past few decades, there has been 
a rapid expansion of chemicals in the human environment with 
ever-increasing exposure of humans to low-dose, mixtures of 
man-made chemicals. This is occurring in the absence of much 
needed attention and resources to innovate within the field of 
chemical carcinogenesis including expanding beyond genotoxic-
ity and single agent research to the study of mixtures in biologi-
cal systems as targets of chemicals in carcinogenesis.
As reviewed in refs. (2–4), effective tumor immunity is pro-
vided through the pleiotropy or duality (polarity) of the immune 
system via the self-terminating and protective properties of acute 
inflammation or maintenance of balance in tumoricidal (yin) and 
tumorigenic (yang) properties of immune surveillance (Figure 1). 
Tissue exposure to foreign elements induces specific and non-
specific local and/or systemic signals as a host defense response 
to protect the host. These immune ‘perturbagens’ are numer-
ous and include pathogens, biological, chemical or environmen-
tal hazards (e.g. pollen, dust, prescription and over-the-counter 
drugs, asbestos, paints, detergents, hair sprays, cosmetics, food 
additives, pesticides), oxidized metabolites of chemical mixtures, 
as well as defective cells (e.g. senescent and cancerous cells). 
Whereas humans have evolved controlled responses to foreign 
pathogens, altered self and other naturally occurring plant expo-
sures, it is less understood how man-made environmental chem-
icals impact the immune system. Emerging evidence suggests 
that chronic and mixed exposures to specific chemicals may act 
to disrupt or perturb the balance of highly evolved regulatory 
mechanisms of the immune system to deal with xenobiotics, 
altered-self and other exposures. While increasingly recognized 
as potentially important in disorders of the immune and nervous 
system, little attention has been given to the role of environmen-
tal chemicals as carcinogens that act through indirect effects on 
inflammatory response and resolution mechanisms.
Overview of inflammation and cancer
Inflammation enables tumor development
Inflammation is mediated by immune cells as an immediate 
defense in response to infection or injury by noxious stimuli. 
Innate immune cells such as neutrophils, mast cells, and mac-
rophages possess receptors that signal the activation and pro-
duction of an array of biologically active proteins and defense 
molecules in response to foreign substances as well as to dam-
aged or altered self-molecules (2). The infiltration of immune 
cells into sites of solid tumors, observed first by Rudolf Virchow 
in 1863, has for many years been pursued as a failed effort of the 
immune system to resist tumor development. Though this latter 
is true and the basis of tumor escape from immune surveillance, 
Virchow’s idea that the immune cells associated with tumors 
reflected a role for these cells in the origination of cancer was the 
first to suggest that the immune cells ‘themselves’ were active 
participants in tumor development.
It is now well recognized that the presence of inflammatory 
cells commonly precedes tumor development (5). Demonstration 
that inflammation plays a causal role in tobacco-related carcino-
genesis, viral carcinogenesis and asbestos-associated carcinogen-
esis, highlights the significance of inflammation in tumorigenesis. 
Substantial evidence from both experimental models and human 
studies have demonstrated that inflammation fosters the devel-
opment of tumors by acting on or with the cancer hallmarks 
identified by Hanahan et al. (1). This includes effects on evasion 
of apoptosis, uncontrolled growth and dissemination, as well as 
altering/deregulating tumor immune surveillance. In fact, Colotta 
et al. (5) suggested that inflammation be considered a separate 
cancer hallmark, an idea supported in the update to the cancer 
hallmarks, where because of the broad acting role of inflamma-
tory cells in tumor development, Hanahan et al. (6) conceptual-
ized the role of inflammation as one of ‘enabling’ tumorigenesis.
As discussed by Khatami (3), some of the earliest evidence 
for a direct association between inflammation and tumorigen-
esis were obtained in experimental models of acute and chronic 
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inflammatory ocular diseases. Analyses of a series of these 
studies led to one of the first reports on time-course kinetics of 
inflammation-induced ‘phases’ of immune dysfunction. These 
and the studies of others have led to the identification of at 
least three distinct inflammation response phases. During the 
acute phase, there is an initial response to an irritant or infec-
tious organism that mimics the healing response to a wound or 
during an infectious process. This phase is often followed by an 
intermediate response phase that, in a healthy state, serves to 
down-regulate or dampen the acute response to resolve inflam-
mation. Finally, there is a chronic response phase that, if unre-
solved, can have potent pathologic properties. As a consequence 
of persistence, a ‘pro-inflammatory’ state sustains the release of 
cytokines and chemokines with the capability of causing pro-
gressive alterations in the cellular and molecular composition 
of the microenvironment. This leads to elevated levels of pro-
mutagenic reactive oxygen (ROS) and reactive nitrogen species 
(RNS), alterations in the vasculature (e.g. vascular hyperperme-
ability, neovascularization, and angiogenesis), disturbances in 
mitochondrial function, and, importantly, the disruption of nor-
mal cell-cell signaling/cross-talk such as recruitment of mac-
rophages with suppressive function to disable T cell-mediated 
tumor immunity. It is this chronically inflamed state or ‘failed 
wound healing’ response or localized ‘system’ response that has 
been identified as a common feature in tumor development and 
metastasis.
Figure 1. Graphic representation of ‘yin’ and ‘yang’ arms of acute inflammation. The scheme depicts two, tightly controlled and biologically opposing arms of self-
terminating acute inflammatory responses. Stimuli induce activation of innate and/or adaptive immune cells by expression of appropriate ‘death factors’ in yin (apop-
tosis, growth-arrest) processes to destroy foreign elements and injured tissue; while yang simultaneously produces ‘growth factors’ (wound healing, growth-promote) 
to terminate and resolve inflammation. Yin and yang processes are intimately facilitated by activation of a vasculature response and expression of apoptotic and 
wound-healing mediators. Reproduced with permission (3) [Exp. Opin. Biol. Ther. 2008, All Rights Reserved.]
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Acute versus chronic inflammation and 
carcinogenesis
Acute inflammation possesses two balanced and biologically 
opposing effector arms represented in a ‘yin’ (pro-apoptotic 
or tumoricidal) and ‘yang’ (wound healing or pro-tumorigenic) 
relationship model, where immune cells participate with the 
non-immune cells in the local environment (e.g. epithelial, vas-
culature and neuronal) (3). Local or systemic adaptive immune 
responses (cell-mediated and humoral immunity) are mobilized 
by selective signaling between the activated innate immune 
effector cells (e.g. macrophages and mast cells) and their coun-
terparts in the adaptive immune system (e.g. T and B lympho-
cytes). In acute inflammation, immune cells possess shared 
and specialized properties that function in the recognition and 
elimination of intrinsic or extrinsic foreign elements and that 
injure or damage host tissue (acute phase/’yin’ response]. In the 
intermediate or resolution (‘yang’) phase response, the immune 
cells function to resolve inflammation and repair the damaged 
tissue.
Unresolved and persistent inflammation has been 
described as the loss of or deregulation in the balance between 
the ‘yin’ and ‘yang’ responses. The role of persistent inflamma-
tion as a contributing factor in tumorigenesis is well accepted 
and, in many cancers, thought to be a necessary component. 
Examples include a causal relationship between inflamma-
tion and infectious agent-associated cancers [e.g. hepatitis B 
and C virus (liver), human papilloma virus (e.g. cervix, anal) 
and the bacterium Helicobacter pylori (stomach)]. The relation-
ship between cancer and inflammation is also supported by 
the elevated risk of cancer in chronic inflammatory conditions, 
such as colitis-associated colorectal cancer. Importantly, the 
cause-effect relationship between inflammation and cancer is 
a challenging concept as it implies that inflammation precedes 
the processes. However, current evidence widely suggests that 
in the case of cancer, which is a multi-step and complex pro-
cess, inflammation is an integral component of the overall 
pathogenesis of disease at the microenvironment level that 
not only contributes in a causal way but also supports a per-
missive state for tumors to grow (6). As such, it is important 
to recognize that tumor-associated inflammation (TAI) in solid 
tumors is itself a complex pathologic process, with contribu-
tions from classic immune cells as well as poorly character-
ized, cancer-associated fibroblasts and the epithelial tumor cell 
compartment.
Cellular mechanisms of inflammation and 
tumorigenesis
Over the past two decades, our understanding of inflammation 
in tumorigenesis has led to the identification of a number of 
molecules that are strongly linked to the development of human 
cancers (5,7,8). Like tumorigenesis, tumor-promoting inflam-
mation and TAI are the phenotypic product of a complex set of 
cellular and molecular interactions that result in an imbalance 
in local microenvironment cross-talk that is most analogous to 
an unresolved ‘wound-healing’ response (8). The cellular and 
molecular composition of TAI has been the subject of a number 
of extensive recent reviews (5,8) including work from co-author 
Khatami (2–4), which are abbreviated below and illustrated in 
Figure 1.
A number of the cellular and molecular mechanisms 
involved in inflammation-induced tumor initiation, promotion, 
and progression are now well described (see examples in Box 1). 
Essential to these inflammation-induced changes at the cellular 
and tissue level is the diverse array of immune cell-derived 
effector molecules (Figure 1). Among the best characterized are 
the pro-inflammatory ROS and RNS, cytokines, chemokines and 
lipid-derived products of the inducible COX-2 in arachidonic 
acid metabolism, including the highly potent PGE2 molecule.
Nitric oxide and ROS
At physiological levels, both ROS and RNS are important cell 
signaling molecules (9). However, at high levels or with aber-
rant production, ROS and RNS are capable of causing consider-
able cellular damage resulting in cell injury, DNA damage and 
prompting an inflammatory response (10,11). During tumori-
genesis, ROS and RNS have been characterized for their abil-
ity to induce a plethora of effects on cells and on the local 
environment that include DNA damage, adduct of cellular pro-
tein and lipids, and, in the absence of apoptosis at high levels, 
promotion of abnormal cell proliferation and transformation 
(8). Considerable levels of ROS and RNS are produced by the 
innate immune system in response to tissue injury or dam-
age. Thus, ROS and RNS produced in response to cell-damage 
by inflammatory cells, that unresolved have the potential to 
set up a vicious cycle leading to chronic and aberrantly high 
levels of ROS and RNS. These high levels and chronic exposure 
of cells to reactive species in tissue microenvironments from 
macrophages and mast cells are linked to a range of tissue 
pathologies, including neurodegenerative and autoimmune 
diseases, along with the propagation of mast cells that are 
thought to promote myeloid-suppressor cell expansion that 
inhibit tumor immunosurveillance as well as acting to enable 
the ‘maintenance’ of a tumor promoting microenvironment 
(8,12,13). As such, uncontrolled or deregulated ROS or RNS 
production have been, and continue to be, investigated as bio-
logical indicators of exogenous and endogenous insults with 
cancer-causing potential, independent of their DNA-damaging 
potential.
Mitochondria are the primary source of intracellular ROS 
(8,10). A number of known carcinogens (e.g. benzene, halocar-
bons, nitrosamines, etc.) exert adverse human health effects by 
Box 1: Examples of molecular, cellular and tissue 
alterations observed with chronic inflammation and 
tumor promoting consequence
•	 Genomic instability, chromosome remodeling, 
epigenetic changes and altered gene and miRNA 
expression
•	 Altered post-translational modification, activity and 
localization of cell proteins
•	 Altered cell metabolism
•	 Induction of cell growth and anti-apoptotic sig-
nals→ uncontrolled cell growth and retention of 
cells with damaged genomes
•	 Vasodilation, leakage of the vasculature and infiltra-
tion of leukocytes → disrupted tissue integrity and 
altered microenvironment and immuno-suppres-
sion and recruitment of myeloid suppressor cells
•	 Altered cell polarity → disturbance in stroma/epithe-
lial tissue matrix and loss of differentiation signals
•	 Tissue necrosis → neovascularization and hypoxia
•	 Induction of matrix metalloproteinases → invasive-
ness and spread
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promoting inflammatory states as a consequence of ROS pro-
duction (14). Individuals exposed to chemicals that promote 
ROS, including asbestos, coal, arsenic, vinyl chloride, mustard 
gas, auto fumes, diesel soot, crystalline silica, inorganic dust and 
agricultural dusts, have a higher risk of lung and other cancers 
(15,16). A number of these chemicals are International Agency 
for Research on Cancer (IARC) group 1 carcinogens, primar-
ily associated with their DNA-damaging or genotoxic effects. 
However, it is clear that DNA damage alone is not sufficient for 
the development of metastatic cancers (1,6) and that environ-
mental chemicals do not exist in isolation. As such, it is increas-
ingly clear that, in addition to or independent of their genotoxic 
effects, the activity of a chemical or complex mixture to perturb 
ROS or RNS balance, should be considered when evaluating its 
carcinogenic capacity.
A well-studied example of chemical mixtures in the envi-
ronment that are capable of acting as ROS inducers is vehicle 
exhaust. It is through work on diesel exhaust particulates, a 
mixture of polycyclic aromatic hydrocarbons and metals, in ani-
mal model and cell culture that we have a reasonable mechanis-
tic understanding of the relationship between ROS production 
and inflammation following exposure to diesel exhaust par-
ticulates (17–20). Interesting and important work by Zhao et al. 
(21), aimed at teasing apart mitochondrial and cytosolic nitric 
oxide stress responses with diesel exhaust particulates expo-
sure, led to the observation that alveolar macrophages activate 
ROS and nitric oxide (NO) in response to diesel exhaust particu-
lates, but the two have distinct effects. Using an inducible nitric 
oxide synthase (iNOS) mutant and wildtype mouse model sys-
tem, this group demonstrated that intracellular ROS production 
and related mitochondrial dysfunction occurred independently 
from NO production. In this model, NO production was asso-
ciated with a pro-inflammatory response and was required to 
maintain an inflamed state. This pro-inflammatory response 
was hypothesized by the authors as a counterbalance to a 
ROS-induced adaptive stress response that promotes an anti-
inflammatory response that increases sensitivity to bacterial 
infections in individuals exposed to diesel exhaust particulates 
(21). Importantly, knockout of iNOS resulted in a dramatic reduc-
tion in lung tumor multiplicity (80% reduction) compared with 
wild-type animals demonstrating the important role of the NO 
induced pro-inflammatory response in tumor development (22). 
The Zhao study is highlighted here to emphasize a few recur-
rent themes that are relevant across exposures: (i) the dynamic 
interplay among cells of the immune response and the local 
microenvironment in determining the ultimate fate of local sys-
tems response following toxic exposure and (ii) the importance 
of developing a better systems level mechanistic understanding 
of the tissue level response to a toxicant in developing biological 
indicators of a chemical’s potential to promote a pro-tumor or 
tumor favorable environment.
Cyclooxygenase, prostaglandins and their receptors
The cyclooxygenase (COX) enzymes were among the first identi-
fied molecular targets of interest in TAI. Before the identification 
of COX-2 as a major enzyme mediator of TAI, a handful of epi-
demiological studies had reported lower cancer rates in regu-
lar users of aspirin and other non-steroidal anti-inflammatory 
agents that are now explained by the inhibitory activity of these 
drugs on the pro-inflammatory/pro-tumorigenic effects of PGE2 
(23,24). There are three COX isoforms: COX-1 or prostaglandin 
G/H synthase 1 (PTGS1), which is constitutively expressed; COX-2 
(PTGS2), the inducible form of the COX enzymes; and COX-3, an 
alternative splice variant of COX-1. COX enzymes catalyze the 
formation of lipid mediators, including prostanoids, prostacyc-
lins and thromboxanes. Of the three, COX-2 is over-expressed in 
acute and chronic inflammation as well as in tumors. Extensive 
research efforts over the past three decades have established a 
strong link between COX-2 expression, inflammation, and can-
cer, including demonstration that COX-2 suppression prevents 
neoplasia in numerous rodent models of cancer as well as in 
human clinical trials (6). COX-2 can be induced by a number of 
factors including cytokines, chemokines, ROS and environmen-
tal chemicals (see later). Induction of COX-2 activates mPGES-
1, the inducible enzyme that catalyzes the COX-2-derived lipid 
intermediate PGH2 to PGE2, the biological mediator of the tumor-
igenic effects of COX-2. PGE2 is the most abundant prostaglandin 
(PG) in solid tumors and has been shown to influence tumor cell 
growth, migration and invasiveness. The tumorigenic actions of 
PGE2 are numerous and include the induction of angiogenesis, 
transactivation of the epidermal growth factor receptor, inhibi-
tion of apoptosis and immunosuppression (25).
The physiological and pathological effects of PGE2 are medi-
ated through interactions with specific PG receptor subtypes 
present on an array of cell types, including most immune cells 
and epithelial cells. PGE2 shows the highest affinity for the EP 
receptor subtypes 1–4 (PTGER1-4 or EP1-4). Through the recent 
use of receptor subtype specific inhibitors, antibodies and engi-
neered mouse models, the multiple PGE2/EP signaling pathways 
associated with human health and disease have become clearer. 
All four of the EP receptors are present on the majority of cells 
involved in immune responses (26,27). Under normal physiolog-
ical conditions, PGE2 attenuates the activity of macrophages and 
dendritic cells by inhibiting the production of tumor necrosis 
factor (TNF)-α and interleukin (IL)-10. The EP2 and EP4 receptors 
mediate these activities as well as regulate the proliferation and 
differentiation of T and B cells. And while it is clear that the bio-
logically diverse activity of PGE2 is determined by the nature and 
distribution of the EP receptors, very little is known about the 
EP receptor subtype/PGE2 interactions, interaction with environ-
mental chemicals and potential contribution of toxicants in the 
evolution and progression of TAI. This represents an important 
area for active research in environmental toxicology.
Within the intent of this review, it is important to recognize 
that COX-2 expression is regulated by a number of transcription 
factors that themselves can become deregulated leading to the 
sustained induction of COX-2 as a co-factor in TAI. These include 
the hypoxia inducible factors (HIF-1α and HIF-2α), NF-κB, CREB 
and members of the signal transducer and activator of tran-
scription family (STAT) (28,29).
STAT family proteins regulate cytokine-dependent inflam-
mation and immunity. STAT protein family members, including 
STAT 1–6, are overexpressed in a number of human cancers. The 
role the STATs in TAI has recently been well characterized in 
prostate cancer where chronic inflammation is believed to play 
a major role in tumor development (30). STAT3 has been mecha-
nistically linked to the induction and maintenance of an inflam-
matory microenvironment in the prostate and to the malignant 
transformation and progression due to the maintenance of a 
pro-inflammatory state. The pro-inflammatory cytokine IL-6 is a 
potent inducer STAT3 where binding to the IL6R induces activa-
tion of the Janus tyrosine family kinase (JAK)-signal transducer 
leading to a phosphorylation dependent activation STAT3. This 
promotes the dimerization of STAT3 monomers via their SH2 
domain and promotes their active transport to the nucleus 
where the active dimer binds to cytokine-inducible promoter 
regions of genes containing gamma-activated site motif (31). 
In normal tissues, this robust response is countered by a SHP 
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phosphatase and the suppressor of cytokine signaling molecule 
(SOCS3). This negative feedback loop insures resolution of the 
signaling and restoration to homeostasis. In prostate and other 
cancers such as breast, STAT3 becomes constitutively activated; 
a phenotype thought to reflect the influence of the local micro-
environment and in particular TAI. Because STAT3 activation 
induces a number of transcriptional factors that include onco-
genes involved in cell survival, proliferation, inflammation and 
angiogenic factors (32), its constitutive activation is associated 
with a number of the cancer hallmarks and nicely illustrates the 
molecular aspects of TAI that enable tumorigenesis (31).
STATs, like other transcription factors, have a dual and 
self-perpetuating role in inflammation and, like other similar 
molecules, is considered to be both a friend and a foe in tumo-
rigenesis (33). They can be induced by inflammation and can, 
in turn, induce inflammation by activating NFκB and IL-6 path-
ways. If unchecked this leads to an uncontrolled pro-inflam-
matory/pro-tumorigenesis state (Figure  2). For example in the 
liver the resident myeloid cells or Kupffer cells, in response to 
an environmental or endogenous stimuli produce pro-inflam-
matory cytokines as a result of activation of the IKKβ/NFκB 
complex. The activation of IKKβ/NFκB is potent stimuli for IL-6 
and thus activation of the STAT3 protein. Inflammation is an 
established risk factor for hepatocellular cancer (HCC) from 
viral infection and other environmental or drug insults. STAT3 
is overexpressed in the majority of HCC in human with high lev-
els correlated with IL-6 levels in the local tumor environment 
(34); findings that support a role of IL-6 and STAT3 as a TAI phe-
nomenon in HCC in humans. Given the role of STATs in inflam-
mation and evidence as an important signaling molecule in 
TAI, the STAT transcription factors represent an important and 
unexplored family of molecules as putative mediators of TAI in 
the presence of environmental chemicals and other toxicants.
Cytokines as immune effector molecules
Cytokines are a large group of small proteins (5–20 kD) that 
act as pleiotropic paracrine and autocrine messengers with a 
wide spectrum of biological functions across numerous tissue 
and cell types. Collectively, the cytokines include chemokines, 
interferons, interleukins, lymphokines and TNF. Cytokines are 
produced by cells of the immune system (e.g. B and T lympho-
cytes, macrophages and mast cells), stromal cells (endothelial 
cells and fibroblasts) as well as tumor cells. Cytokines exhibit 
paracrine, and autocrine effects on a wide range of tissues and 
cells. The cytokine most consistently associated with tumor cell 
killing is TNFα. Upon engagement of TNFα with its receptor, a 
subsequent chain of cellular events leads to the activation of the 
transcription factor nuclear factor (NF)κB and subsequent pro-
duction of IL-1β, IL-6, IL-8 and IL-17. In the simplest mechanistic 
model, these pro-inflammatory molecules are coupled to each 
other via TNFα binding to its receptor (TNFR), which activates the 
NFκB pathway in the acute phase response. This results in the 
upregulation of a group of pro-inflammatory cytokines as a pro-
grammed response to wounding or infection. It is this response 
that is triggered in the initial response to injury or infection (35) 
that, when unresolved or chronic, is widely believed to promote 
tumorigenesis and contribute or enable tumor progression.
Under homeostatic conditions, two membrane receptors, 
TNFR1 and TNFR2, mediate the actions of the TNF family of mol-
ecules (36). While initially described as an anti-tumor molecule, 
the role of TNFα as pro-tumorigenic is now well characterized. 
Tumor and inflammatory cells within the tumor microenviron-
ment constitutively produce TNFα, supporting tumorigenesis 
and metastasis by promoting: genomic instability through the 
production of ROS and RNS, cell survival by deregulating apop-
totic pathways, promoting invasion through induction of matrix 
metalloproteinases (MMPs), and angiogenesis via the induction 
of pro-angiogenic factors. Part of this response may be due to the 
presence of TNFR1 on tumor, stromal and immune cells, thereby 
allowing TNFα to exert its activity both directly on the tumor and 
indirectly within the tumor microenvironment to sustain local 
inflammation and recruitment of cells with inhibitory effects 
(i.e. myeloid suppressor cells) on tumor immunity. The effects of 
TNFα as a pro-tumor molecule have been clearly demonstrated 
in TNFR1-deficient mice, which are resistant to tumorigenesis. 
The best-characterized mechanism of the tumor-promoting 
effects of TNFα are those related to the tumor cell itself and 
molecular alterations (i.e. mutation, deletion and amplification) 
in key regulatory genes that lead to the constitutive activation 
and deregulated activation of NFκB. More recently, the role of 
non-genetic factors in the localized overproduction of TNFα is 
recognized. These include previously underappreciated effects 
of the local microenvironment and the cancer-associated fibro-
blasts and immune cells that fail to produce or recognize the 
wound resolving cues. In the presence of active NFκB signaling, 
TNFα and NFκB interact to induce cytokines (e.g. IL-1, IL-6), COX-
2, adhesion proteins and MMPs. In turn, high levels of inflam-
matory cytokines trigger uncontrolled NFκB expression and 
activation, ultimately preventing the resolution of the response 
(5,7). Failed resolution of TAI resulting in a localized mileau of 
chronic cytokine activation is believed to shift the balance away 
from cell death toward survival and tumor cell invasion (5–7,36). 
Thus, independent of direct genotoxicity, this adaptation to the 
local microenvironment stressors is thought to place a selective 
pressure on tumor cells that promotes angiogenesis and ulti-
mately escape of tumor cells from the toxic environment; two 
critical cancer hallmarks of metastasis.
Along with TNF-α, IL-6 is among the most commonly over-
expressed cytokine in human tumors (37). Similar to other 
aspects of inflammation, IL-6 can act as a double-edged sword. 
Induced in response to injury or infection, IL-6 can induce 
COX-2 expression and PGE2 synthesis as well as function in 
the resolution phase of an acute response by inhibiting TNFα 
and IL-1 and by inducing other anti-inflammatory or resolution 
Figure 2. The activation of NFκB is a potent stimuli for IL-6 and IL-6 activates the STAT3 protein. Cancer cells and surrounding inflammatory immune cells have been 
shown to produce excessive and continuous amounts of IL-6 and other cytokines promoting chronic stimulation of STAT3. If unchecked, this leads to an uncontrolled 
pro-inflammatory/pro-tumorigenesis state mediated by the effects of STAT3 on gene transcription that promote proliferation, resistance to apoptosis, angiogenesis, 
immune evasion, invasion and metastasis; all hallmarks of cancer.
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cytokines such as IL-10. Thus, IL-6 exhibits both anti- and pro-
inflammatory actions at the site of a wound. In the tumor 
microenvironment, IL-6 has been shown to negatively regulate 
apoptotic processes, making cells more resistant to cell death 
in an inflamed, highly reactive microenvironment. Two types 
of receptors, membrane-bound and soluble, bind IL-6 (38). The 
membrane bound IL-6 receptor is predominantly expressed in 
hepatocytes, lymphocytes, neutrophils, monocyte/macrophages 
and epithelial cells. After binding to IL-6, the receptor associ-
ates with the signal-transducing protein gp130 to initiate its 
signaling cascade. The interaction with gp130 promotes a nega-
tive feedback loop responsible for the anti-inflammatory effect 
of IL-6. The soluble IL6 receptor (IL-6R) is present in body flu-
ids and is linked to the inflammatory action of IL-6 in cells not 
expressing IL-6R. In this case, the IL-6/IL-6R complex can bind 
to gp130, which is expressed in all cell types, thus explaining 
the broad spectrum and systemic action associated with IL-6 in 
inflammation.
The diverse functions of IL-6 are mechanistically linked to 
interactions across distinct signaling pathways, including the 
MAP/STAT pathway and the AKT/PI3K signaling cascade, which 
negatively regulates apoptosis and promotes cellular prolifera-
tion. Recently, IL-6 has been shown to play a key role in main-
taining the balance between the regulatory subclass of T cells 
(Treg) and Th17, an effector T cells that produces IL-17, IL-6, TNFα 
and other pro-inflammatory chemokines (39). This function, 
of pivotal importance in immunity and immune pathology, is 
linked to inflammation which, when chronically maintained, 
promotes the onset of malignancies in different organs and that 
acts to suppress tumor immune surveillance and tumor killing 
through the recruitment of immunosuppressive myeloid sup-
pressor cells (40).
Along with IL-6, a number of other cytokines that participate 
in inflammation and present in TAI, have been mechanistically 
implicated in tumor metastasis. In the case of IL-8 and IL-17 
(41), these two pro-inflammatory cytokines have received con-
siderable attention for their ability to induce neovascularization 
and to enhance the activity of the matrix-degrading enzymes 
MMP-2 and MMP-9 (42). IL-8, which is also known as CXCL8, has 
received considerable attention as a potential therapeutic target 
for a number of inflammatory diseases given its critical role in 
innate immune responses and as a chemoattractant for neutro-
phils. The activity of IL-8 is mediated by binding of monomeric 
or dimeric forms of CXCL8 to one of its two receptors CXCR1 
and CXCR2. Expressed normally on the surface of leukocytes, 
these receptors have also been shown to be upregulated on both 
tumor and tumor-associated stromal cells in a variety of cancers 
including lung, prostate and colorectal. Via CXCR1/2, IL-8 acti-
vates several important signaling pathways that are overactive 
in tumors (MAPK, PI3K, PKC, FAK and Src) and which function 
in tumor cell proliferation and migration. IL-8 pathway signal-
ing is induced by a number of factors including inflammatory 
cytokines (e.g. TNF-α, IL-1), ROS, and steroid hormones. There 
is now convincing evidence that IL-8 and CXCR1/2 signaling are 
major drivers in conditions of chronic inflammation including 
TAI. As such, the IL-8/CRCR receptor interactions receptors are 
the focus of intensive drug development for use in cancer and 
other inflammatory disease states (42).
Like IL-8, the IL-17 molecule is a recently recognized potent, 
pro-inflammatory cytokine that is produced by the Th17 sub-
population of T lymphocytes and is thought to be involved in 
tumorigenesis (41). After binding to its receptor, IL-17RA, IL-17A 
then activate the MAPKs ERK1/2 and p38, PI3K/Akt and NFκB 
pathways, leading to the production and secretion of IL-1β, IL-6, 
TNFα and IL-8, as well as CXCL1 and CXCL6, which attract neu-
trophils. Although reported in some other cancers, IL-17 has 
been strongly linked with tumor development in the colorec-
tum in animal models (43). Here, leakage of bacterial products 
with tumor development and endotoxin exposure appears to 
mobilize cells producing IL-17. The presence of IL-17-producing 
macrophages in these models has been linked directly to sup-
pressive effects on both local and systemic anti-tumor T cell 
responses. The importance of IL-17 in tumor development is 
supported by observations that inhibition of IL-17 in animal 
models of colorectal carcinogenesis prevents tumor formation, 
an effect that both prevents the pro-inflammatory response 
and the ‘poisoning’ effect of the pro-inflammatory response on 
tumor specific immunity.
Lipoxygenases and lipoxins
The lipoxygenases/lipoxin products of polyunsaturated fatty 
acid metabolism represent a more recently recognized set of 
bioactive metabolites in inflammation both in its induction and 
resolution for which there has been little work with regard to 
environmental exposures and modulation. These are briefly 
mentioned here. For example 5-lipoxygenase (5-LOX) has been 
implicated in inflammation-related neoplasia. 5-LOX is a non-
heme iron dioxygenase that synthesizes leukotrienes, lipoxins, 
resolvins, and protectins from different substrates belonging to 
the polyunsaturated fatty acids (44). The 5-LOX is located in the 
cytoplasm or nucleus and is activated in the nuclear envelope, 
where it translocates to interact with 5-lipoxygenase activat-
ing protein to mediate the transfer of arachidonic acid from the 
membrane to 5-LOX. Besides its well-known role in inflamma-
tion, the over-expression of 5-LOX occurs in a number of tumor 
tissues and cell lines (45). Consistent with overexpression, the 
end products of 5-LOX, such as 5-hydroxyeicosatetraenoic acid 
and leukotrienes A4 and B4 (LTA4 and LTB4) contribute to cell 
survival and growth. The inhibition of 5-LOX enzymatic activity 
or the silencing of 5-LOX and leukotriene receptor expression 
attenuates the metastatic phenotype in colon cancer cells (46). 
As with the COXs, there are anti-proliferative effects with 5-LOX 
inhibitors such as AA-861, zileuton, nordihydroguaiaretic acid 
and 5-lipoxygenase activating protein inhibitors such as MK 
886, MK 591. These molecules induce apoptosis in breast (47), 
leukemia (48) and pancreatic (49) cell lines. As such, much like 
the interest in COX2 and PGE2, the LOX pathway is emerging as 
an important mediator of tumorigenesis with direct effects on 
tumor-associated and tumor-promoting inflammation.
Environmental chemicals as selective 
disruptors of inflammation and prioritized 
targets of activity
Human studies on environmental chemicals, 
inflammation and cancer
Given the importance of inflammation as an enabling factor in 
carcinogenesis, we consider the paucity of research on chemi-
cals as pro-inflammatory molecules and carcinogenesis signifi-
cant. Our ability to study chemically associated cancer-specific 
outcomes in humans has largely been limited to comparing can-
cer burden among exposed and unexposed individuals in obser-
vational epidemiologic studies. This approach is important and 
has successfully linked cancer etiology in humans to a number 
of important carcinogens (e.g. tobacco exposure, asbestos and 
tumor viruses). However, in the absence of strong and reliable 
estimates of an exposure (e.g. viral antigens, asbestos fibers or 
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numbers of cigarettes smoked), the protracted and multi-facto-
rial nature of tumor development makes it incredibly difficult to 
causally link chemical exposures in the environment to cancer 
risk. This is particularly true when the carcinogenic potential of 
an exposure is dependent on often unmeasured factors such as 
the dose/duration of the exposure, timing of the exposure (i.e. 
when in life), biomarker of adverse effect after exposure and 
presence in the population of heterogeneity with regard to sen-
sitivity (genetic or other such as sex or diet). And while there are 
some large-scale, bio-banked cohort studies (particularly in the 
in the absence of testable hypotheses to relate exposures with 
cancer outcomes. As a result, there is a need to integrate the 
knowledge that has been gained about the etiopathogenesis of 
cancer in the study of environmental chemical effects including 
effects on specific cellular and molecular processes important 
in carcinogenesis.
To example a strategy for inflammation and cancer, we 
focused on chemicals thought to act on immune cells and molec-
ular targets mechanistically linked to TAI. Thus, we undertook 
a process to identify candidate chemicals in the environment 
[i.e. Bisphenol A  (BPA), polybrominated diphenyl ether (PBDE), 
vinclozolin, nonylphenol (NP), phthalates and atrazine] shown 
to on specific target molecules (i.e. ER, iNOS, NFκB, IL-6, COX-2 
and TNFα, respectively) that have been identified in the cancer 
biology field as relevant in TAI. The chemicals that we focused 
on were prioritized for their ubiquitous nature in the environ-
ment and the relative level of evidence that their disruption may 
promote disturbances in immune and non-immune cells favor-
ing inflammation (Summarized in Table 1). These chemicals are 
not currently classified as carcinogens and themselves are not 
considered genotoxic. While a number of these are recognized 
as toxicants, our goal is to highlight the potential role of these 
chemicals from the perspective of their ability to disrupt immu-
nomodulatory molecules related to inflammation and to chal-
lenge thinking on how these chemicals, alone or in combination 
with other exposures, influence cancer risk in humans.
Bisphenol A
Perhaps the most abundant (>3 million tons/year produced) 
and best studied environmental endrocrine disruptor is the 
synthetic xenoestrogen BPA. While the role of BPA as an endo-
crine disruptor with ligand activity for the estrogen and aryl 
hydrocarbon receptors (AhRs) has been extensively reviewed 
elsewhere, the impact of BPA on the immune system and as an 
immune disruptor is less recognized (75). BPA is present in the 
environment as a result of its widespread use in the synthesis 
of polycarbonates, epoxy resins and thermal paper (76), result-
ing in everyday exposures from food packaging, plastic bottles, 
water-pipes, electronic equipment, paper and toys (77,78). The 
physio-chemical properties of BPA, reproductive organ toxic-
ity, activity on the hormone and AhRs, and toxic effects, along 
with levels and sources of exposure in humans, have recently 
been reviewed by Michałowicz (75). Notably, this review high-
lights the evidence for both immune-activating and immune-
inhibiting consequences of exposure to BPA and suggests that 
the inconsistency in reported effects reflect a more generalized 
disruption in innate immune balance as opposed to more easily 
defined and specific effects on antigen-driven immune or adap-
tive immune responses. Most relevant to carcinogenesis are the 
findings from rodent studies linking BPA exposure to histologi-
cal changes in the prostate gland. In rats, the Prins laboratory 
(79) have shown that early life exposure to BPA mimics estro-
gen-induced prostate intraepithelial neoplasia (a prostate can-
cer precursor lesion), which includes BPA-dependent epigenetic 
reprogramming of DNA along with the development of lateral 
prostate inflammation in the adult animal, reported earlier to 
reflect BPA effects on prolactin levels (80). Because inflamma-
tion of the prostate is ‘insufficient’ for the development of pros-
tate cancer in animal models and since the role of inflammation 
in human prostate cancer unclear, it has been argued that the 
effects of BPA in rodents may not be relevant to humans. An 
alternative explanation is that in the presence of genotoxic or 
other co-factors, the immune deregulating effects of BPA on 
the prostate act to enhance or accelerate tumor development 
in the rat and while not sufficient are necessary exposures for 
carcinogenesis.
In addition to the work in prostate, evidence for an effect 
of BPA on the immune system is present from studies of BPA 
effects on immune cell components, particularly the T cell com-
partment. BPA appears to largely act on the immune system by 
promoting ‘immune’ cell proliferation (81), though the exact 
nature of the effect on specific cells of the immune system and, 
thus, the consequences are complex and poorly delineated. An 
example is the effect of BPA on T lymphocytes. CD4+ T lympho-
cytes, for example comprise the Th1 and Th17 helper T cells that 
produce pro-inflammatory cytokines whereas the Th2 or Treg 
cells produce anti-inflammatory or regulatory cytokines. A num-
ber of studies have been conducted on BPA effects on CD4+ T cell 
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cytokines (IL-6, IL-8, 
IL-17, TNFα)
BPA (synthesis of poly-
carbonates, epoxy 
resins…)
+ ↓ (50) + (51) ↑ (52) ↑ (53) ↑ (54) and ↓
PBDEs (flame retardants) + (55) − + (56) + ? (57) ↑ (56,57)
Vinclozolin (fungicide) + (58) − + (59) − − + (59)
4-NP (degradation of 
surfactant in house-
hold products)
+ ↓ (50) and ↑ (60) ↓(61) and ↑(62) ↑(62,63) +(64) +
Phthalates (plastics) + (65–67) ↑ (68) ↑ (69) ↑ (70) and ↓ ? ↑ (67) and ↓
Atrazine (herbicide) + (71, 72) ↑ No effect(73) and ↑(72) ↑IL-4 (74) ↑ (72) ↓
‘+’ indicates evidence that the chemical is probably acting through pathway; ‘−’ indicates no evidence the chemical is acting through this pathway; “?” unclear; ↑ 
indicates induces; ↓ indicates inhibits.
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polarization toward one or the other subtype with highly mixed 
results. There are results indicating BPA activation of Th1 and 
Th2, often with dominance of one type over the other, effects 
which vary depending on the dose, duration and timing (adult 
or early life) of the exposure, and no reported effects on Th17 cell 
differentiation. Interesting work from Yan et al. (82), found that 
prenatal BPA exposure had a much more dramatic inhibitory 
effect on the anti-inflammatory, Treg cells than that seen in the 
rodent prostate studies, but the exact mechanisms and a role of 
BPA in susceptibility to TAI has not been investigated. Currently, 
it is unclear why BPA-exposed CD4+ cells polarize to either a 
pro- or anti-inflammatory state, but there is sufficient evidence 
to support an effect of BPA on CD4+ T cells at exposure levels 
comparable to those in humans. Much like the BPA-exposed T 
cells, results from studies on macrophages and B cells are also 
conflicting (81).
As noted from the prostate studies in rodents, the immu-
nomodulatory effect of BPA on cells has been linked with BPA 
activity as a ligand for ER (83). CD4+ T cells in humans express 
ERα and, to a lesser extent, ERβ. Though studied under differ-
ent model conditions, low estradiol levels have been associated 
with Th1 T cell development, whereas high estradiol during preg-
nancy, for example has been shown to promote Th2 polarization; 
results that may explain the immune effects of BPA through its 
recognized endocrine disrupting function.
In addition to putative immune effects of BPA mediated 
through ER, the ability of BPA to bind to the AhR and the reports 
of BPA activity on the peroxisome proliferator-activated receptor 
(PPAR), a family of nuclear receptors implicated in inflammatory 
disease states (84), should be considered. For example the endo-
crine disrupting potential of BPA has been partially correlated 
to weak AhR modulation (85). BPA in this study was shown to 
weakly suppress AhR activation in mouse cells whereas more 
recent studies proved that BPA toxicity is only partially regulated 
by AhR pathways suggesting that further studies are needed to 
clarify the nature of the BPA/AhR interaction. In breast cancer 
cells ARNT2, a heterodimeric partner for the activated AhR, 
decreases with BPA exposure in an ERα-dependent fashion (86). 
This finding contrasts with 2,3,7,8-tetrachlorobenzo-p-dioxin 
(TCDD), a wide-spread anthropogenic chemical and prototype 
agonist of the AhR, which acts as an immunosuppressive com-
pound across model systems (87–89). To date, there is no evi-
dence of direct binding of BPA to the AhR PASB domain (the 
domain TCDD binds to).
In addition to the AhR, there is growing interest on the 
effects of BPA and BPA analogs on members of the PPAR nuclear 
receptor family members α, β/δ and γ. Various studies implicate 
a role for PPARs in the pathogenesis of inflammatory diseases. 
For example, haploinsufficieny for PPARγ resulted in exacer-
bated experimental arthritis in mice compared with wildtypes 
(90). PPARγ is present on macrophages (91), dendritic cells (92), 
T cells (93) and B cells (90). For BPA exposure, the PPARγ isoform 
is of particular interest given the findings (94) that bisphenol-A 
diglycigyl ether, an analog of BPA present in some food contain-
ers (95) and in waste waters (81), antagonizes PPARγ. In addition, 
the role of PPARs as BPA targets is further suggested by obser-
vations that other BPA analogs (e.g. tetrabromobisphenol A, a 
brominated BPA found in flame retardants) antagonize PPARs 
in direct relation to the bulkiness of the brominated BPA ana-
logs. Bulkier brominated BPA analogs were found to have greater 
activity as partial agonists of PPARγ and weaker estrogenic activ-
ity that could potentially disrupt or deregulate PPAR-dependent 
anti-inflammatory effects (96).
Polybrominated diphenyl ethers
As flame retardants, PBDEs are ubiquitous in the environment 
in a number of consumer products from textiles to electronic 
components. Leaching of PBDEs from treated products results 
in air, food, water and soil contamination, where exposure 
through ingestion and inhalation is associated with an esti-
mated half-life of the common congeners in human adipose 
tissues of 1–3 years (97). Body burdens of PBDE have increased 
over the past few decades raising concerns on long-term 
health effects. The need to understand the bioactivity and/
or toxicity of PBDEs is made more relevant by the demonstra-
tion of increased concentrations of PBDEs in breast milk (98), 
placenta (99), amniotic fluid and umbilical cord blood (100), 
with additional evidence that PBDEs cross the placental bar-
rier, accumulating in the cotyledons (100). For women living 
near electronic waste sites, the placental burden of PBDEs 
is nearly 20-fold higher than for women residing in a refer-
ent site (101). These results support very early life exposures 
for which the long term health effects are unknown, includ-
ing risk of cancer. There is currently little experimental evi-
dence that the PBDEs act as direct mutagens. The activity 
and chemical structure of PBDEs are similar to TCDD. While 
limited to a handful of studies, recent work on PBDE effects 
on inflammatory cytokines in placental explant models is 
notable for its potential implications for other health out-
comes, including cancers, where microbes are implicated. 
Pro- and anti-inflammatory factors play a critical role in 
the placenta during fetal development and at parturition, 
wherein the pro-inflammatory cytokines induce PGs that pro-
mote uterine contraction and cervical ripening. Thus, during 
pregnancy, potent anti-inflammatory cytokines, in particular 
IL-10, are elevated as a defense against preterm birth induced 
by bacterial infections. Peltier et  al. recently found that pla-
cental explants treated with a mixture of the cogeners BDE-
47, BDE-99 and BDE-100 and then exposed to Escherichia coli 
were ‘reprogrammed’ toward a pro-inflammatory response 
(increased IL-1β and TNFα) and away from the expected anti-
inflammatory response (decreased IL-10) compared with 
untreated placenta. The switch from an anti- to pro-inflam-
matory response was not detectable in the absence of the 
E.coli stimuli. Interestingly, basal PGE2 levels were increased 
in the absence of E.coli, suggesting an effect of PBDE on the 
basal PG pathway that predisposed the treated cells toward 
a pro-inflammatory response when exposed to E.coli, com-
pared with the untreated cells that exhibited a potent IL-10 
induction. An important conclusion drawn by these authors is 
that chronic PBDE exposure may ‘lower the threshold for bac-
teria to stimulate a pro-inflammatory response’. The poten-
tial relevance of this conclusion to other health outcomes is 
intriguing. This study is noted here given the established link 
between bacteria and cancers, such as H.pylori and gastric 
cancer, where tumor development is dependent on inflamma-
tion. Emerging evidence also shows that many other human 
cancers may have a bacterial component, with cancers of the 
gastrointestinal tract (esophagus, liver, stomach, pancreas, 
colon and rectum) strongly believed to involve a disturbance 
in the interaction between normal flora and the immune sys-
tem that promotes chronic, low-grade inflammation (i.e. dys-
biosis). To our knowledge, there has been no consideration of 
the role of environmental immune disruptors, such as PBDEs, 
as contributors to these cancers, where incidence rates have 
increased in parallel to industrialization.
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Vinclozolin
Introduced in the mid-1970s in Germany, the non-systemic, 
dicarboximide fungicide vinclozolin is classified by the World 
Health Organization (WHO) as ‘unlikely to present acute haz-
ard in normal use’ due to its extremely low toxicity in rats. This 
opinion contrasts with a review by the EPA concluding that vin-
clozolin or a breakdown product of the compound, 3,5-dichloro-
aniline moiety, induces testicular tumors in rats and tumors of 
the kidneys and prostate glands in dogs, with species sensitiv-
ity identified as a factor for tumor development. As a result, the 
EPA has classified vinclozolin as a possible human carcinogen, 
although vinclozolin is not listed as a carcinogen by IARC or the 
United States NTP Carcinogens program.
More convincing than potential effects on cancer risk is 
the evidence demonstrating endocrine-disrupting activity of 
Vinclozolin, anti-androgenic effects on lipid metabolism and 
storage, deleterious effects on sperm count, reduced prostate 
weight and delayed puberty in animals (102). Despite toxicity 
concerns and declining use, vinclozolin remains a common fun-
gicide for use on specific crops in the USA and Europe. There 
have been efforts to minimize exposure using safe handling 
practices (protective equipment and clothing), different applica-
tion methods (to reduce exposure through inhalation or absorp-
tion) and reductions in recommended uses (i.e. specific crops to 
minimize ingestion such as fruit with inedible, thick peel).
Vinclozolin is of particular interest as an environmental 
chemical, where transient early-life exposures in utero have 
been linked to both adult-onset disease and transgenerational 
disease that involves inflammation (103,104). For example, tran-
sient vinclozolin exposure in utero has been shown to promote 
inflammation in the prostate (prostatitis) of postpubertal rats 
coupled with a down-regulation of the androgen receptor (AR) 
and increase in nuclear NFκB. The late or delayed effect of expo-
sure is hypothesized to reflect a mechanism whereby vincoz-
olin exposure during a critical development window imprints 
an irreversible alteration in DNA methyltransferase activity, 
leading to reprogramming of the AR gene(s), which manifest as 
inflammation in early adult life with adverse effects on sper-
matid number. Evidence for early life exposure leading to epig-
enome alterations that manifest later as disease in the adult is 
supported by the work of others and raised as a concern in can-
cer risk (103). Transient vinclozolin exposure during gestation in 
the F0 generation manifests as adult onset spermatogenic cell 
defects in the F3 generation, suggesting that, at least in some 
cases, changes to the methylation status of specific genes are 
heritable and that the exposure effect acts transgenerationally.
This work on viclozolin is noted for the reader as it demon-
strates the inflammation-related changes in the prostate with in 
utero exposure and raises intriguing possibilities about environ-
mental causes of cancer, where single-generation experimental 
models may be inadequate to fully detect carcinogenic activity 
of a given chemical. This is a grossly understudied molecular 
mechanism by which environmental chemicals may impact 
human health, including risk of cancer, and represents an 
important area for future studies.
4-Nonylphenol
A ubiquitous environmental chemical implicated recently in 
inflammation is 4-nonylphenol (4-NP). Human exposure to 
4-NP occurs through ingestion of contaminated food and water 
from liquid detergents, cosmetics, paints, pesticides and other 
common products, where NP ethoxylates are used as nonionic 
surfactants (105). Of special note, 4-NP is present at higher 
concentrations in treated waste water than at the inlet source 
as a result of microbial biodegradation of the parent compound 
NP ethoxylate (106). As an endocrine disruptor, 4-NP is recog-
nized for its potent reproductive effects. More recently, how-
ever, 4-NP has been shown to increase progenitor white adipose 
levels, body weight and overall body size in rodents exposed 
prenatally. Like viclozolin, 4-NP effects on adipogenesis in the 
perinatal period confer transgenerational inheritance of the 
obesogenic effects observable in F2 offspring, consistent with 
genome reprogramming through an epigenetic process (107). 
The proadipogenic effect of 4-NP in these studies was associ-
ated with a decrease in ERα in adipose tissue, consistent with 
its weak endocrine disrupting activity and to the induction of 
genes related to fatty acid metabolism and lipogenesis (e.g. 
Ppar-γ, Srebp-1, Lpl and Fas). With the recognized overlap in 
signaling molecules between the endocrine and the immune 
system, Han et al. recently reported that 4-NP may be acting as 
an immune disruptor. In their studies, 4-NP induced COX-2 pro-
tein and gene expression in the murine macrophage cell line 
RAW264.7 and significantly increased PGE2 production. 4-NP was 
further shown to activate the Akt/MAP kinases/CRE signaling 
response elements involved in the activation of COX-2 expres-
sion (108,109). This observation is the first insight on a potential 
mechanism for the observed lung inflammation and asthma 
in mice exposed to 4-NP. And while limited, the recent find-
ings from the Cadet laboratory suggesting an effect of 4-NP on 
pro-inflammatory cytokines in a model of inflammatory bowel 
disease raise important concerns about 4-NP as a common 
environmental chemical that mimic an inflammatory state. As 
such, given the iniquitousness of 4-NP and evidence favoring 
transgenerational transmission of exposure effects, there is suf-
ficient evidence to recommend the investigation of cancer risks 
associated with 4-NP exposures.
Atrazine
The triazine herbicide atrazine is widely used in agricultural to 
control the unwanted growth of grasses and broadleaf weeds. 
Being one of the most commonly used pesticides in the world 
(110), atrazine is widespread in the environment and a fre-
quently detected contaminant in waterways. Like BPA and other 
chemicals, there are scientific indications that atrazine has 
endocrine-disrupting potential (110,111), causing mammary 
gland tumors in rodents (112) and altering male reproduction 
(113). The mechanism(s) of action associated with reproductive/
endocrine disruption do not seem to be receptor-mediated, as 
there is no detectable interaction with AhR or ER (112,114,115), 
although there may be with AR (115). In a recent study by Jin 
et al., both atrazine and its major metabolite diaminochlorotria-
zine (116,117) induced changes in the anti-oxidant capacity of 
the liver and decreased the transcription of genes involved in 
testosterone production (111), supporting that oxidative stress 
may contribute to alterations in reproductive capacity. Indeed, 
in vitro experiments using interstitial Leydig cells support that 
suppression of oxidative stress by the flavonoid quertcetin pre-
vents atrazine-induced toxicity by attenuating oxidative stress 
partially by modulating the NFκB pathway (118). One of the 
reputed actions of atrazine is the regulation of NO production 
(119), an important bioactive molecule which can have pro-
found impact on cancer development by contributing to angio-
genesis, suppressing apoptosis, and limiting the host immune 
response to the tumor itself (120). Although atrazine is consid-
ered to be a weak mutagen with low oncogenic potential [see 
recent re-evaluation by the EPA (121)], the immunotoxic poten-
tial of atrazine raises concerns regarding cancer susceptibility 
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(119). In swine granulosa cells, there was induction of both NO 
and VEGF by atrazine, supporting that, in this context, atrazine 
may have the potential to contribute to angiogenesis during 
cancer development (122). In a mouse model, administration 
of atrazine also caused features of immunotoxicity, including 
an inhibitory effect on both cell-mediated and humoral immu-
nity (123), findings that may have important implications for 
the development of lymphoma due to a reduction in immune 
defense mechanisms. Of the effects noted, there was a signifi-
cant decrease in NO production by peritoneal macrophages 
(123), phagocytic cells whose production and release of NO 
are important cytotoxic elements in immune surveillance and 
inhibition of tumor growth (124). Whether changes in NO lev-
els are reflective of induction/inhibition of iNOS expression in 
mammalian systems is not known. Atrazine also significantly 
decreased cytokine production (e.g. TNFα, IFN-γ) (123,125) as 
well as impaired lymphocyte proliferation and natural killer 
cell function (74).
Pthalates
As a group, the widely used chemical plasticizers known col-
lectively as ‘phthalates’ and the esters of phthalic acid used 
to soften vinyl products are of significant concern simply as a 
result of the level and ubiquitous nature of exposure to these 
chemicals. Humans are exposed through multiple routes 
that include food and drink, inhalation, skin absorption and 
even medical procedures such as blood transfusions. Body 
burden studies suggest that diethylhexyl phthalate (DEHP), 
a high molecular species used in plastic wrapping of foods, 
is a major source of exposure for humans as a result of con-
tamination from the packaging, an effect made greater with 
microwave heating. Health concerns related to phthalates 
have focused largely on reproductive health and, specifi-
cally, spermatogenesis. As with other environmental expo-
sures, there is particular concern for early life exposures 
where pthalates are largely accepted as weak anti-androgens 
that exhibit metabolite-specific effects on testosterone syn-
thesis by Leydig cells. High levels among children from toy 
products as well as exposure to breakdown products of the 
smaller molecular weight diethyl phthalate in personal skin 
care items such as lotion and soap have attracted the most 
concern.
More recently, an interest in the effects of phthalates and 
related metabolites on inflammation has emerged where the 
focus has been on risk of asthma (126). Research on asthma 
evolved from the observation of a ‘meat-wrappers’ asthma 
linked to heating of polyvinyl chloride film or the heating of 
price labels on foods (127). This and other population studies 
have suggested phthalates act as immune disruptors (126). 
While findings across in vitro and in vivo studies confirm 
effects of phthalates on macrophages, lymphocytes, eosino-
phils and neutrophils, no consistent effect has emerged, and 
the actual consequence of exposure appears to be contex-
tually dependent. For example, chronic exposure to airborne 
DEHP increased the numbers of eosinophils, lymphocytes 
and neutrophils in the lung and lavage fluid, but only at very 
high (not human exposure-related) concentrations (128). In 
a separate study of the major metabolite of DEHP (MEHP), 
exposure at much lower doses showed similar pro-inflam-
matory effects, indicating the importance of metabolism in 
effect dose (128). This result, in part confirms studies show-
ing acute airway irritation and increased macrophages in 
lavage fluid at high occupational but not low exposure lev-
els (129). However, and paradoxically, in a human challenge 
study with immune biomarkers, exposure of allergic subjects 
to house dust containing low DEHP induced granulocyte 
colony stimulating factor, IL-5 and IL-6, whereas exposure to 
high DEHP suppressed granulocyte colony stimulating factor 
and IL-6 (130). These findings have led to the conclusion that 
phthalates exhibit immune disrupting activity that includes 
adjuvant effects on the proinflammatory Th2 responses as 
well as immunomodulatory and immunosuppressive effects 
depending on the conditions of exposure (dose, duration, tis-
sue type, development). These complex and often paradoxical 
observations have made translation to humans a challenge 
but do not dismiss the potential relevance of these exposures 
in human diseases.
The immune disrupting nature of phthalates is evident in 
The Comparative Toxicogenomics Database. Recently, Singh 
et al. (131) found that five of the top ten toxicity networks dis-
rupted by phthalates involved inflammation, with evidence 
for pathogenic effects for prostate, uterus, ovary and breast, 
all sites of common human cancers. Consistent with the evi-
dence observed for endocrine disruptors, phthalates disrupt 
gene expression in a pattern very similar to that of BPA, where 
the compounds exhibit a high degree of sharing of effects on 
interacting genes and proteins in an immune-disrupting signa-
ture. The latter has been suggested as a potential tool for future 
research efforts to characterize the inflammatory potential of a 
compound.
Cross-talk between tumor-promoting 
inflammation and the other hallmarks 
of cancer
The carcinogenicity of low-dose exposures to chemical mix-
tures in our environment probably depends, in large part, on the 
capacity of such exposures to act on several tumor-promoting 
mechanisms and/or to disrupt innate tumor defence mecha-
nisms. Thus, characterizing the potential of chemical combi-
nations as ‘carcinogenic’ will ultimately involve investigating 
mixture effects across the range of mechanisms known to be 
relevant in tumor development. Accordingly, we undertook a 
thorough cross-validation activity to illustrate the importance 
of the prioritized target sites for disruption that were identified 
by this team (i.e. across multiple aspects of cancer biology) to 
illustrate the extent to which the prototypical chemical disrup-
tors that we identified may act to disrupt other mechanisms rel-
evant to carcinogenesis.
TAI has been identified as an epithelial-stroma interaction 
that enables tumor development by acting across the cancer 
hallmarks (6). Herein, we have identified six common environ-
mental chemicals for which current evidence supports their role 
as putative ‘immune disruptors’. In other words, exposures to 
these chemicals are hypothesized to act in tumorigenesis by 
deregulating and promoting inflammation. For each chemical, 
we identified a single ‘high priority’ target molecule as a puta-
tive mediator of cellular and molecular events linking chemical 
exposure to carcinogenesis. The chemicals we have identified 
are (i) bisphenol A  (BPA), (ii) PBDE, (iii) vinclozolin, (iv) NP, (v) 
phthalates and (vi) atrazine, with their main priority targets 
being the estrogen receptor, iNOS, NFκB, IL-6, COX-2 and TNFα, 
respectively.
As will be recognized, there is a strong relationship between 
the prioritized targets, inflammation, and a number of the other 
cancer hallmarks. The prioritized chemicals proposed here to 
promote inflammation have also been shown to act on a num-
ber of the other hallmarks of cancer that in some reports are 
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complementary to the effects observed for TAI and for others 
are contrary or are inconsistent across reports. Exceptions are 
a lack, or limited study, of effect of these chemicals on tumor 
evasion of the immune system and on the tumor microenviron-
ment. Given that inflammation contributes directly to changes 
in the microenvironment, which includes immune system eva-
sion, these chemicals may act directly on the microenvironment 
and/or the function of anti-tumor immune cells. Details of the 
selected chemicals, the prioritized target, and affected pathways 
are presented below in support of the summary results shown 
in Tables 2 and 3.
Bisphenol A
Treatment of cell lines with BPA results in a number of cellular 
and molecular changes, including those associated with the can-
cer hallmarks and inflammation as already discussed. However, 
there is no clear singular molecular target of BPA, and the role 
of BPA in human disease remains controversial. Consistently, 
BPA deregulates metabolism by disrupting the activity of res-
piratory chain complex II (204–207). At low exposure levels, BPA 
has been shown to activate the mammalian target of rapamy-
cin (mTOR) pathway, an intracellular signalling pathway that 
integrates the growth signals, such as insulin and insulin-like 
growth factors, to promote survival (211,240). Treatment of cells 
with BPA blocks the induction of p53, thereby mediating evasion 
of anti-growth signals (211) and promoting angiogenesis (213). 
BPA has also been shown to promote genetic instability through 
anti-estrogenic activity (216) and upregulation of hTERT, an indi-
cator of replicative immortality (241). In breast cancer cell lines, 
BPA exposure promotes a sustained proliferative signal (230). In 
other studies, tumor cell invasion and metastasis were shown 
to be promoted by BPA exposure (235–237). In contrast, BPA has 
also been reported to induce apoptosis and cytotoxicity in HL-60 
and ovarian granulosa cells (221,222), effects that are more con-
sistent with an anti-cancer activity.
BPA has been extensively studied as an endocrine disrup-
tor given its binding affinity for ERβ is greater than that of 
ERα. This topic has been reviewed extensively (239). Of note 
is that, similar to the ambiguous relationships described ear-
lier, ER and BPA display paradoxical effects in tumor develop-
ment that are context-dependent. For example, loss of ERα 
promotes hepatocarcinogenesis (133), and activation of ERβ 
impairs mitochondrial oxidative metabolism, thereby suppress-
ing tumor growth (134). The loss of ERα also showed the same 
effect when its mechanism was antagonized by binding to p53 
in evasion of anti-growth signalling (135,136). The introduction 
of ERβ into malignant cells inhibits their growth and prevents 
tumor expansion by inhibiting angiogenesis (137). In contrast, 
ER signalling can promote genetic instability by promoting 
DNA double strand breaks and chromosomal aberrations (138). 
Estrogen also promotes resistance to cell death by preventing 
p53-dependent apoptosis, as well as stimulating cell growth and 
inhibiting apoptosis (139–141). Estrogen downregulates YPEL3, 
a growth suppressive gene, and activates hTERT transcription 
and replicative immortality via binding of ligand-activated ERα 
(142,143). Ligand-bound ERs can either bind directly to estrogen 
response elements in the promoters of target genes or they can 
interact with other transcription factor complexes like Fos/Jun 
(AP-1-responsive elements) in sustained proliferative signalling 
(144). There is also a potential crosstalk between ERβ and AR in 
the tumor microenvironment (150). Plausibly, the ERβ has effects 
in tissue invasion and metastasis, in which ERβ ligation could 
protect tumor cells from acquiring aggressive epithelial to mes-
enchymal transition features by blocking loss of e-cadherin and 
translocation of β-catenin to the nucleus (145). These paradoxi-
cal effects of ER are well known in the breast cancer field, where 
synthetic estrogens, for which BPA was originally studied, pre-
vent tumorigenesis in one tissue while promoting it in another 
(e.g. tamoxifen in breast and endometrium, respectively) (146–
148). Short exposure to BPA induces ERα and/or ERβ loading to 
DNA changing target gene transcription (132,242).
Polybrominated diphenyl ethers
PBDEs represent another class of chemicals which have been 
reported to disrupt glucose and lipid metabolism (208) promote 
genetic instability (218). PBDEs have been reported to be both 
pro-apoptotic in one context (223) yet anti-apoptotic in the pres-
ence of 17β-estradiol in the MCF7 breast tumor cell line (224). 
The putative target of PBDE, iNOS, has been associated with the 
accumulation of p53 in a feedback mechanism that both protects 
the genome from DNA damage but also results in p53-mediated 
transrepression of iNOS (149,152–154). In the absence of p53 
activated iNOS fails to return to basal levels due to the lack of 
transrepression. This may partially explain high rates of tumor 
development in p53 knockout mice (151). Elevated intracellular 
levels of NO are genotoxic to cells and promote genetic instabil-
ity (156), with strong evidence for iNOS as a contributing factor 
in angiogenesis and tumor invasion and metastasis—hallmarks 
that often occur later in tumorigenesis when p53 is more prob-
ably to be lost (155,157,159–161), as well as in sustained prolif-
erative signalling (158). As a product of inflammation, NO plays 
a major role in wound healing type inflammation (i.e. a mac-
rophage prominent inflammatory response) and acts as a per-
missive factor in tumor invasion and metastasis (243).
Vinclozolin
Like BPA, vinclozolin is considered an endocrine disruptor with 
activity for AR as well as ER and progesterone receptor. As with 
most endocrine disruptors, a number of cellular and molecular 
activities have been attributed to vinclozolin. With regard to the 
cancer hallmarks, vinclozolin has been shown to promote the 
evasion of anti-growth signals (104), induce oxidative damage 
leading to inflammation, and cause DNA damage and genetic 
instability (217). In rats, in utero exposure to vinclozolin for 5 days 
did not impair prostate gland development but decreased AR 
expression in the pubertal prostate. Exposed animals develop a 
prostatitis during puberty that has been mechanistically linked 
to phosphorylation and nuclear translocation of NFκB, with sub-
sequent induction of pro-inflammatory NFκB-dependent genes 
(IL-8 and transforming growth factor-β1). Of note, early life 
exposure to vinclozolin persists into adulthood with evidence 
of epigenetic deregulation of NFκB, which resulted in inflam-
mation in the prostate. Findings of heritable alterations and 
transgenerational effects on reproductive, immune, and neu-
rologic systems raise concern about the transmission of new 
traits associated with carcinogenesis, for which little research 
has been conducted. In the rat prostatitis model, exposure to 
vinclozolin alone was insufficient for tumor development, sug-
gesting that the exposure is not genotoxic in nature. However, 
like other endocrine disruptors, vinclozolin induces a spectrum 
of molecular and cellular effects, including increased apoptotic 
germ cell numbers in the testis of pubertal and adult animals 
(244). Effects on NFκB, particularly if transmissible across gen-
erations, are noteworthy, given the well documented role that 
unrepressed NFκB plays in tumorigenesis (163,164). NFκB has 
also been reported to promote sustained proliferative signalling 
(167) and, via its critical role in propagating a wound healing 
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type inflammatory mechanism, has potent effects on the tumor 
microenvironment (168). On activation, the NFκB signalling 
pathway decreases p53 stabilization (165) and inhibits TNFα-
induced apoptosis, promoting resistance to cell death (166)—all 
critical hallmarks in the evolution of cancers.
Nonylphenol
As with the other endocrine disruptors, NP exerts estrogenic 
action and stimulates proliferation in estrogen responsive 
ovarian cancer PEO4 cells (219). Derivatives of NP, such as 4-NP, 
exhibit genotoxic affects in Saccharomyces cerevisiae supporting a 
role in genetic instability (245). In contrast, NP in other models 
has been shown to exhibit anti-cancer properties including trig-
gering, inducing, or enhancing apoptosis in various tumor cells 
(225). NP has been shown to induce expression of a pro-inflam-
matory cytokine, TNF-α, and to suppress regulatory cytokines, 
including IL-10, IFN-α and IFN-β (246).
The regulatory cytokine IL-6 has been linked to a number of 
the cancer hallmarks (247). NP exposure that results in chronic 
activation of IL-6 thus, has potential to act on a number of the 
tumor hallmarks through local and systemic effects on metabo-
lism (169), growth signalling (170–172), cell death mechanisms 
(173–176), enhancement of replicative immortality by altering 
telomerase activity (177,248), and chronic exposure that leads 
to sustained proliferative signals (178). Effects of IL-6 on tissue 
invasion and metastasis have been shown for a number of can-
cers including ovarian (179), melanoma (179) and head and neck 
tumor metastasis (180). As with NFκB, IL-6 promotes a wound 
healing type inflammatory response contributing suppression 
of immune effectors with potent effects on the tumor microen-
vironment, leading to greater permissiveness and tumor inva-
sion (7).
Phthalates
Phthalates have been shown to act on a number of the cancer 
hallmarks, though we found no studies investigating effects on 
replicative immortality or tumor microenvironment. Evidence 
that exposure of hepatocytes to diisononyl phthalate increases 
proliferation, palmitoyl-CoA oxidase activity, and levels of 
enzymes involved in β- and ω-oxidation of fatty acids dependent 
on another nuclear receptor, PPARα, support effects on metabo-
lism (214). In addition, benzyl butyl phthalate, a common plas-
ticizer use in manufacturing polyvinyl chloride and recognized 
developmental toxicant, has been shown to increase angiogen-
esis in vivo (238,249). Phthalates have been reported to promote 
tumor growth and invasion of cancer cells in vitro via regulation 
of cyclin D, PPARα and AhR (231,232,250). Direct effects of phtha-
lates on p53 have been proposed that would support effects of 
phthalates on evasion of anti-growth signals, though this is con-
troversial (251,252). A  recent study by Lee et  al. (212), reported 
growth promoting effects of di-n-buthyl phthalate in the LNCaP 
mouse xenograft model of prostate cancer that was in part medi-
ated by reduction of Smad. This observation was similar to that 
observed with estradiol and was found to be reversible with an 
ER antagonist. These findings suggest that phthalates may act 
on tumor growth by disrupting important crosstalk between 
TGF-β and ER signals leading to evasion of anti-growth signals. 
In addition, exposure of human oropharangeal and nasal mucosa 
cells to the phthalates di-n-buthyl phthalate and diisobutyl 
phthalate increases DNA strand breaks and the possibility of 
increasing genetic instability (253). As with a number of environ-
mental chemicals, phthalates exhibit a wide array of both anti-
carcinogenic and carcinogenic activities. For example, phthalate 
esters induce apoptosis in bovine testicular pluripotent stem 
cells through an AhR-mediated mechanism (226) and inhibit 
tamoxifen-induced apoptosis in MCF7 human breast cancer cells 
(254). Reported induction of COX-2 expression by these chemi-
cals would support a protumorigenic action. Overexpression of 
COX-2 has been consistently shown to contribute to a number 
of the hallmarks of cancer including effects on metabolism (182), 
enhancement of cell motility and invasiveness (187), promotion 
of resistance to pro-apoptotic activity associated with NFκB acti-
vation (188–190). Genetic instability via chromosomal aberrations 
is a common phenotype associated with COX-2 overexpression 
(255), as is the induction of proangiogenic signaling pathways 
(186), sustained proliferative signalling (191), and effects on 
the tumor microenvironment (192). Nevertheless, the effects of 
COX-2 are inhibited in the presence of wildtype p53 and, as with 
a number of the other chemicals, the effect of exposure in terms 
of carcinogenic potential is probably dependent on the cellular 
type and molecular context in which the exposure occurs (e.g. 
p53 wildtype or mutant background) (183–185).
Triazine herbicides
The triazine herbicide atrazine has been extensively studied for 
its effects in promoting tumor immune system evasion (220) and 
sustained proliferative signalling via the ERα signalling pathway 
(233). Atrazine significantly increases the formation of micronu-
clei and DNA strand breaks in erythrocytes of Carassius auratus, 
a model fish species (256). Interestingly, atrazine exposure has 
been reported to decrease cancer by suppressing prostate car-
cinogenesis through metabolic deregulation that manifests as 
bodyweight reduction (209). In contrast, atrazine exhibits car-
cinogenic effects by promoting obesity and insulin resistance 
by blocking the activities of oxidative phosphorylation com-
plexes I and III (210). The effects of atrazine on female reproduc-
tive health have been extensively studied with exposure being 
associated with deregulated sterodoigenesis and angiogenesis 
(215). There are no studies specifically addressing anti-cancer 
hallmark properties, but a number of studies have demon-
strated that triazine derivatives suppress replicative immortality 
(229,257,258). For effects on inflammation, the proposed target 
molecule is TNFα (197–199). An extensive body of work on TNFα 
supports its role in promoting evasion of anti-growth signals 
(158,193–196,200–202,259,260), promotion of angiogenesis (196), 
direct effects on promoting myeloid suppressors cell and tumor 
immune system evasion (unpublished data) replicative immor-
tality (163), and sustained proliferative signalling (200,260). In 
addition, TNFα promotes epithelial to mesenchymal transition 
and tumor invasiveness in breast and colon cancer cell lines 
(201–203) as well as alters the local metabolic and microenviron-
ment including promoting tumor-associated fibroblasts (7,193).
Future directions
While there is clearly intriguing evidence for a role of environ-
mental chemicals to act as immune disruptors, there is a large 
paucity of information for how such effects on the immune sys-
tem would ultimately influence individual cancer risk in humans. 
Given the potential transgenerational inheritance of some expo-
sures, there are new concerns that traditional exposure asso-
ciation studies would entirely fail to capture any relationship 
between the exposure and long-term, multigenerational impacts 
of chemically exposed individuals. Because of the tremendous 
paucity of information on the role of immune disruption and 
risk of cancer, the co-authors identified specific areas for future 
research that included identifying promising novel technologies 
to expand our understanding of the effects of exposures, as well 
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as, using observations from the past to guide future experimen-
tal design considerations. These have been broken down into a 
few key areas that, while no means comprehensive, should serve 
to stimulate discussion and innovation in the field.
Systematic approaches to study the role of immune 
disruptors (stimuli) in carcinogenesis
Given the crucial status of host tissue immune cell responses in 
cancer, systematic understanding of the host (resident) immune 
and non-immune interactions with those of recruited cells with 
environmental toxicants are important when deciding on accu-
rate risk assessment formulations.
The following is a proposed list of priorities for future direc-
tions in understanding the role of environmental immune dis-
ruptors in alteration of immune dynamics, inflammation and 
individual cancer susceptibility.
i. Need for systematic approaches to characterize the nature 
of specific chemicals that would alter immune response pro-
files toward cellular growth and site-specific cancers.
ii. Experimental models to gain a better understanding of the 
nature of heterogeneities in immune response profiles, 
since the extent of chemical exposure and access to inter-
epithelial and sub-epithelial cells may produce significantly 
different outcomes.
iii. More comprehensive modeling of the cumulative processes 
of immune disruptors (e.g. mixtures, low-doses) that pro-
mote chronic inflammation in host tissues that lead to dis-
ruption of cellular compartments in the multistep carcino-
genesis toward angiogenesis and metastasis.
iv. In line with item (iii), attention to time-course kinetics of de-
velopmental phases of immune response alterations during 
early stages of tumorigenesis and angiogenesis that might 
be preventable, reversible or correctable.
v. Experimental constructs to identify key interactions/play-
ers between stimuli and host immune and non-immune 
responses in tissues considering the influence of the resi-
dent (local) and recruited cell compositions in future studies 
of inflammation and cancer (e.g. Kupfer myeloid cell in the 
liver, inflammation and HCC).
vi. More complete monitoring of the early changes of immune 
dynamics (e.g. induction of mediators such as histamine, 
heparin, PGs, enzymes and neurotransmitters) that reflect 
important changes in early responses that include neuro-
logic stress response effectors that are also prone to disrup-
tion by environmental chemicals as early and preventable 
pro-inflammation/pro-tumor targets.
vii. Incorporation of information on genetic background (gene 
polymorphisms), sex-specific effects and life-span exposure 
periods as modifiers of susceptibility to environmental im-
mune toxicants in carcinogenesis.
The hypothalmic-pituitary-adrenal axis, stress, 
chemicals and inflammation
Given that the hypothalmic-pituitary-adrenal (HPA) axis is an 
endocrine-driven system, it is highly plausible that individual 
chemical exposures such as atrazine and other chlorotriazine 
herbicides (and metabolites) may have the potential to dis-
rupt and deregulate the immune system including the cellular 
makeup and chemokine/cytokine composition of the inflam-
matory response mechanism (261). The HPA-axis operates in a 
cascade-fashion whereby relatively small secretions of cortico-
trophin releasing hormone in the hypothalamus result in more 
substantial secretions of adrenocorticotropic hormone from 
the pituitary leading to substantial changes in adrenal output 
of cortisol. The cumulative effects of combinations of low doses 
of endocrine-disrupting chemicals that mimic and/or impact 
corticotrophin releasing hormone or adrenocorticotropic hor-
mone through indirect mechanisms are thus a concern given 
the impact of cortisol on a number of cytokine and chemokine 
molecules including macrophage migration inhibiting factor 
(MIF). As an example, MIF is a potent pro-inflammatory cytokine 
that binds to the CD74 molecule on immune cells and activates 
acute immune responses; coupling the HPA axis to inflam-
mation (262,263). Similarly, the cumulative effects of other 
chemicals such as PBDE that act directly on the adrenal gland 
(264,265) could further; disrupt this system While transgenera-
tional effects such as those that have been demonstrated for 
BPA, may act by disrupting the HPA-axis, cause adrenal abnor-
malities, and alter the basal levels of circulating hormones in 
rodent offspring exposed in utero (266,267). These observations 
strongly suggest that such chemical exposures can have long-
lasting and profound effects on the HPA stress axis, which in 
turn lead to altered sensitivity to immune perturbagens; an 
evolving field that has received little attention in cancer biology 
and risk assessment.
Since MIF and a number of other HPA-induced immune 
molecules have been separately implicated in tumor growth 
and progression (268–272), basic research is needed to screen 
and identify environmentally relevant chemicals that have 
disruptive potential for different aspects of the entire system. 
Moreover, empirical research is needed to determine whether 
or not low dose combinations of common chemical exposures 
deregulate the HPA-axis, and impact adrenal output such that 
MIF and other pro-inflammatory cytokines are not well con-
trolled (i.e., instead become tumor-promoting). This is a criti-
cally important area in need of research given the consistent 
and unexplained higher risk of more life-threatening cancers 
in poor populations that experience a disproportionate burden 
of exposure to environmental chemicals and to stressful living 
conditions.
Environmental chemicals, the human microbiome, 
inflammation and cancer
It is increasingly clear that the human microbiome shapes the 
immune system and plays a major role throughout life in the 
health of immune responses. A  question in need of further 
study is whether or not chemical exposures (low-dose, mixed) 
influence the composition of our microbiome and, if so, to what 
effect on our immune system and long-term cancer risk (273).
Ongoing and planned epidemiology cohorts, 
environmental chemicals and cancer
There are currently several large prospective population-based 
cohort studies underway that will facilitate the evaluation of 
cancer risks from exposures to environmental contaminants 
that occur individually and in combination with other expo-
sures and modifying factors. These studies include the UK 
Biobank, the Canadian Partnership for Tomorrow Project (CPT) 
and the European Prospective Investigation into Cancer and 
Nutrition (EPIC) (274,275). These studies, which are prospec-
tive in design and biomarker based, may allow for the evalu-
ation of intermediate inflammatory effects of exposures to 
environmental chemicals and mixtures across genetically 
diverse populations and the eventual evaluation of associated 
cancer risks. Although sufficiently powered for the more com-
mon cancers, such as breast, lung, colorectal and prostate, it is 
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probably that sample sizes will not be sufficient for the evalu-
ation of risks for some of the less common cancers that may 
be induced or promoted via inflammatory response mecha-
nisms. Also, given the evidence of transgenerational mecha-
nisms of inheritance, consideration of off-spring cohorts, may 
ultimately prove useful and possibly necessary to establish the 
long-term risks of cancer with certain exposures and thought 
should be given to how population cohorts will translate the 
findings from the early life exposure evidence in experimental 
models to humans.
Advanced technologies in the study of 
environmental chemicals and cancer
There is a need to integrate more experimental platforms that 
facilitate the study of the dynamic and complex response of sys-
tem perturbation. This is true for all the Hallmarks, as noted in 
the capstone that accompanies this article. One such example 
includes evolving techniques to study cellular protein dynamics 
upon stressor binding in three dimension to investigate latent 
stages and early stages of carcinogenesis involving inflamma-
tion, immune system evasion and/or tumor microenvironment 
related pathways. Combinations of high-quality imaging and 
high-dimension omics in complex culture systems aided by 
computational techniques with knowledge from pathway-based 
databases and structure-based virtual ligand screenings of envi-
ronmental toxins (276,277) offer systems biology approaches to 
assess the permutable nature of tissue/cell responses to environ-
mental chemicals. Emerging techniques hold significant prom-
ise as results of pathway and systems perturbation will guide 
development of novel animal models that, perhaps coupled 
with live animal monitoring strategies, would promote work to 
obtain much needed information on immediate, early and late 
exposure-related effects across the human lifespan on organs 
and tissues including detection of subtle perturbation leading 
to later life cancer risk or cancer risk in subsequent generations. 
Success in such efforts has the potential to enhance discovery 
and development of novel tissue/body fluid biomarkers as sur-
rogates for risk stratification, risk prediction and cancer surveil-
lance in humans. Ultimately, it is imaginable that integration 
of such information would advance prevention by eliminating 
potentially harmful exposures, establishing safe exposure levels 
and for those adversely exposed individuals who might be par-
ticularly vulnerable, insights on disease prevention.
Summary
Here, we have provided a molecular and cellular mechanistic 
framework on which to consider the role of common environ-
mental chemicals as cancer enabling through activity as immune 
disruptors. While limited and mixed, the experimental evidence 
to date strongly suggests a role for common environmental 
chemicals as perturbagens of key immune and non-immune 
cell target molecules that have been mechanistically linked 
with tumor-associated immune responses, tumor invasion and 
metastasis. These observations warrant attention given the wide-
spread use and exposures to a number of these chemicals. This 
is made particularly compelling by the emerging evidence that 
in utero and early-life exposures may lead to disordered immune 
responses in adulthood and lead to heritable, epigenetic modifi-
cations in the immune responses of subsequent generations. It 
is important to point out, that few studies have been conducted 
that relate chemically induced disturbances on inflammatory to 
the ability of a chemical to contribute to carcinogenesis. In the 
absence of active research, the role of chemical exposures acting 
in carcinogenesis by disrupting TAI is unknown. As such, we 
focused on the few examples of chemicals and their putative tar-
get molecules that have been mechanistically linked with TAI. It 
is important to recognize that the target molecules identified here 
exhibit a plurality of function and derive from immune and non-
immune cells, including for example COX2, TNFα, NFκB. Many of 
these molecules are also overexpressed by epithelial tumor cells 
as well as associated immune cells in the microenvironment 
where they exhibit an array of cellular and molecular effects—
not all of which are to elicit an inflammatory response. This 
plurality probably explains the high degree of complementarity 
between the target molecules of environmental chemicals that 
we identified as important in TAI with those identified for other 
cancer hallmarks. The potential for action across the cancer hall-
marks speaks strongly to the potential role that environmental 
chemicals may play in disrupting biological systems as opposed 
to acting on a single target molecule or single cell type. With the 
rate at which new chemicals have and continue to enter the 
human environment, the paucity of research and of innovation 
in methods to study the effects of chemical mixtures in systems 
perturbation in cancer etiology represents a significant research 
gap. Importantly, with the tremendous benefits that these chemi-
cals provide to society—facilitation of mass food production and 
distribution, use in medicine and medical devices, clothing, jobs 
generation and numerous other impactful contributions to soci-
ety—there is a real need to fully understand how these chemicals 
act on human biological. This includes conducting experiments 
that consider effects across the lifespan of the exposed to bet-
ter clarify the role of in utero and early life exposure on cancer 
and other diseases for both current and future generations. More 
comprehensive integration of knowledge on chemical effects 
on and across biological systems, considering the multifactorial 
pathogenesis of carcinogenesis will both inform the industry and 
the public on the safe use of these chemicals as single agents and 
as they occur in complex mixtures in the environment.
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Abstract
An increasing number of studies suggest an important role of host immunity as a barrier to tumor formation and 
progression. Complex mechanisms and multiple pathways are involved in evading innate and adaptive immune responses, 
with a broad spectrum of chemicals displaying the potential to adversely influence immunosurveillance. The evaluation 
of the cumulative effects of low-dose exposures from the occupational and natural environment, especially if multiple 
chemicals target the same gene(s) or pathway(s), is a challenge. We reviewed common environmental chemicals and 
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discussed their potential effects on immunosurveillance. Our overarching objective was to review related signaling 
pathways influencing immune surveillance such as the pathways involving PI3K/Akt, chemokines, TGF-β, FAK, IGF-1, HIF-
1α, IL-6, IL-1α, CTLA-4 and PD-1/PDL-1 could individually or collectively impact immunosurveillance. A number of chemicals 
that are common in the anthropogenic environment such as fungicides (maneb, fluoxastrobin and pyroclostrobin), 
herbicides (atrazine), insecticides (pyridaben and azamethiphos), the components of personal care products (triclosan and 
bisphenol A) and diethylhexylphthalate with pathways critical to tumor immunosurveillance. At this time, these chemicals 
are not recognized as human carcinogens; however, it is known that they these chemicalscan simultaneously persist 
in the environment and appear to have some potential interfere with the host immune response, therefore potentially 
contributing to promotion interacting with of immune evasion mechanisms, and promoting subsequent tumor growth and 
progression.
Introduction
Individuals are routinely exposed to various combinations 
of chemicals at low doses; however, the combined, long-term 
effects of such exposures on human health remain unclear. The 
non-governmental and not-for-profit organization known as 
‘Getting to Know Cancer’ (www.gettingtoknowcancer.org) solic-
ited and then selected teams of scientists to review the possi-
bility and consider the hypothesis that chemicals common in 
the anthropogenic environment chemicals may contribute to 
human carcinogenesis, even though they are not considered 
human carcinogens by the International Agency for Research on 
Cancer (IARC). An overarching framework of this analysis was 
a review of environmental chemical carcinogenesis, with spe-
cific points of focus on one of the individual characteristics of 
cancer cells widely recognized by modern cancer scientists as 
one of the ‘hallmarks of cancer’ (1,2). Although each of the indi-
vidual hallmarks is reviewed in companion reviews by scientist 
with expertise in each hallmark, this specific review is focused 
on the more recently recognized emerging hallmark of cancer 
‘immune evasion mechanisms of carcinogenesis’ (2) and the 
potential interactions of these mechanisms with environmental 
chemicals.
The ‘hallmarks of cancer’ originally described in a seminal 
publication by Hanahan et al. (1) included sustained proliferative 
signaling, evasion of suppressed growth, activation of invasion 
and metastasis, enabling replicative immortality, induction of 
angiogenesis, resistance to cell death and underlying genomic 
instability and inflammation. Of note, immune evasion was 
not listed among these original ‘hallmarks’; however, Hanahan 
et al. (2) recognized that tumor evasion from immune system 
recognition and destruction is an emerging hallmark of cancer 
in their most recent update. These changes have occurred as 
observational data from genetically engineered mice to clini-
cal epidemiology studies suggested that the ‘immune system 
operates as a significant barrier to tumor formation and pro-
gression, at least in some forms of non-viral induced cancer’ 
(2). Consequently, multiple chemicals from the anthropogenic 
environment may contribute to carcinogenesis through this 
mechanism.
In part, because this element of carcinogenesis has been only 
recently widely recognized, there is a paucity of data in animal 
models, in human cell model systems and in clinical studies 
that are related to putative associations between the immune 
response to tumor cells and exposures to various chemicals 
from the anthropogenic environment. Nonetheless, the spe-
cific assessment of environmental exposures that might affect 
immunosurveillance faces many challenges, so this is a relatively 
new area of research. For example, we cannot currently list the 
precise chemicals that affect immune evasion mechanisms due 
to an insufficient knowledge base in this relatively novel field. 
Consequently, additional investigations will be needed to dem-
onstrate the impact of environmental chemical exposures on 
the immune system to better understand whether or not it can 
be compromised or dysregulated with a subsequent loss of an 
effective tumor immunosurveillance network. Nonetheless, this 
review is an opportunity to recognize and discuss this knowl-
edge gap. In this review, we discuss a number of environmental 
chemicals of interest based on reports of their potential inter-
actions with the mechanisms involved in immunosurveillance.
Overview of immune evasion as a hallmark 
of cancer: immunologic perspective and 
mechanisms
Since the late 19th century, rare spontaneous tumor regressions 
were noted in patients following episodes of infection, which 
suggested that immune response could inhibit or modify the 
behavior of cancers (3). However, early attempts at treating 
cancer patients by simply giving them bacterial extracts failed 
because the nature and role of host immunity in cancer remis-
sion was not well understood, and a simplistic view that a ‘toxic 
factor’ contained in the bacterial extracts was the one that pre-
vailed (4–10). The more sophisticated concept of tumor immune 
surveillance was introduced in the mid-20th century (11,12) as 
the host immune system was characterized as capable of both 
recognizing and responding to nascent transformed cells in an 
organism and destroying them. Later, molecular mechanisms of 
antigen processing and presentation and the role of the major 
histocompatibility complex in this process were discovered 
(13), with the realization that a variety of tumor-associated 
and tumor-specific antigens contained within membrane and 
intracellular compartments of tumor cells could serve as targets 
of the immune system. More recently, it has been recognized 
that the presence of antigen alone is insufficient to generate a 
potent immune response, and activation by costimulatory mol-
ecules may also be required for effective immune stimulation 
(14). Finally, potent immunomodulatory checkpoints, both at 
the activation phase and the effector phase, have been recog-
nized, and therapeutic blockade of the checkpoints has resulted 
in dramatic antitumor responses in clinical studies, creating a 
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new era of enthusiasm for immune-based therapies targeting 
cancer (15–20).
A number of clinical observations have also supported the 
evidence for intrinsic immunosurveillance of tumors. For exam-
ple, in immunodeficient patients with advanced human immu-
nodeficiency virus infection with low levels of circulating CD4+ 
T cells often developed malignancies known to be associated 
with viral infections (e.g. Kaposi’s sarcoma, non-Hodgkin’s lym-
phoma, invasive cervical carcinoma and anal cancer) (21,22) and 
also with some non-viral etiologies (e.g. increased risk of lung 
cancer after adjusting for smoking status) (23,24). An important 
role of T cells in preventing recurrent leukemia following allo-
geneic bone marrow transplantation was also reported (25,26). 
Other observations have been less profound; nonetheless, a low 
natural killer (NK) cell activity has been reported in patients 
with breast cancer that had a family history of this tumor and 
in their first-degree relatives that were clinically asymptomatic 
(27). Recent clinical studies also supported the existence of an 
antitumoral immune response in cancer patients (28–30) and an 
important role of cytotoxic T cells (CTLs) and NK cells in this 
process (30,31). These findings are complemented by the devel-
opment of cancer vaccines and studies of new combination of 
these with immunological inhibitory checkpoints (17–20). This 
combination of data has resulted in a contemporary view of 
cancer as a disorder of cell growth, survival and movement, with 
a major facilitator of that progression being disruption and dys-
regulation of the immune response (32).
In trying to characterize the immune response to tumors, 
it must be understood that both innate and adaptive immuni-
ties participate in the control of tumor cell death and survival. 
Innate response typically used germ line-encoded receptors to 
respond to highly conserved structural motif found on patho-
gens, whereas adaptive responses rely on specialized under-
going specific somatic mutations to generate highly specific, 
high-affinity immunologic receptors such as T-cell receptors 
and immunoglobulins that can be highly specific to pathogens 
and generate immunologic memory. Highly specialized and pro-
fessional antigen-presenting cells, termed dendritic cells (DCs), 
play a central role in activation of the adaptive immune response 
and the highly efficient eradication of tumor cells. DCs do this 
by taking up foreign antigens, becoming activated by appropri-
ate costimulation and migrating to lymphoid organs to present 
their antigenic payload to adaptive immune cells (33–36).
Although the recognized immunomodulatory elements can 
modify this adaptive response to the tumor, additional meth-
ods of immune escape can occur due to specific behavior of the 
tumor cells. For example, an effective antigen-specific immune 
response may lead to epigenetic changes within the tumor that 
can result in loss of expression of tumor antigens. This process 
represents a form of tumor escape from the host’s immune con-
trol mechanisms (37,38). In addition, the malignant cells are 
advantage if they can create a microenvironment that creates 
poor conditions to stimulate T cells or poor conditions for the 
function of tumor-specific cytotoxic T cells (39).
The molecular mechanisms of evading host immunity have 
become increasingly clear and include a variety of strategies such 
as (i) loss of antigen processing and presentation via downregu-
lation of surface molecule expression (e.g. low-affinity T cells 
recognizing tumor-associated antigens), (ii) modulation of the 
systemic immune response by production of immunosuppres-
sive cytokines and other factors (e.g. tumor-induced immune 
suppression) and (iii) tumor escape and relapse under immune 
pressure by recruiting immunosuppressive cells into the tumor 
microenvironment (39–43). Among the tumor-released soluble 
factors and cytokines that can augment the normal immune 
response are tumor necrosis factor-alpha (44), small molecules 
of prostaglandin E2, histamine and epinephrine (45). In addi-
tion, tumor release of indoleamine 2,3-dioxygenases (46,47), 
arginase I (48), tumor-associated gangliosides (49–51), interleu-
kin (IL)-10 (52–56), transforming growth factor-beta (TGF-β) (57) 
and granulocyte-macrophage colony-stimulating factor (58) are 
also detected. Moreover, tumor microenvironments that favor 
chronic inflammation enable a population of tumor cells to 
escape from antitumor immunity, thus supporting carcinogenic 
progression (33,59,60).
Recent transplantation experiments showed that cancer 
cells that had originated in immunodeficient animals were 
often unable to initiate secondary tumors in syngeneic immu-
nocompetent hosts. In contrast, cancer cells from tumors that 
originated in immunocompetent animals could initiate tumors 
when adoptively transferred in both immunocompetent and 
immunodeficient mice (61,62). These observations suggest the 
existence of tumor ‘immunoediting’, which is a form of tumor 
escape. This means that when highly immunogenic cancer cells 
are eliminated by immunocompetent hosts, weakly immuno-
genic cancer cells can escape host immunity with a capacity 
to form tumors in both immunodeficient and immunocom-
petent hosts, thus conferring immunological protection of the 
tumor cells from immunological detection and destruction 
(2,63). Another broader process, i.e. ‘immunosculpting’, includes 
immune-mediated changes in the tumor including amino acid 
substitutions in key antigenic proteins that can promote func-
tional cellular reprogramming (e.g. epithelial to mesenchymal 
transition) with both mutations and non-permanent cytokine 
production (64).
Environmental exposures to chemicals and 
immune evasion mechanisms
As part of the ‘Halifax Project’ initiative that was instigated 
by the Getting to Know Cancer, we selected chemicals based 
on preestablished criteria that were provided to each team. 
Specifically, we were tasked to identify ‘prototypical’ chemi-
cals with disruptive potential that are common in anthro-
pogenic environment but not known as established human 
carcinogens (i.e. not IARC class 1 carcinogens). We also looked 
for chemicals that may potentially target the genes/pathways 
related to an immune evasion hallmark of cancer (Table  1). 
The objective of this review is to discuss possible pathways 
that could be involved in the modulation of immunosurveil-
lance rather than to provide a full toxicological evaluation of 
the chemicals.
It is now understood that exposure to many naturally occur-
ring and anthropogenic chemicals can influence the initiation 
and/or progression of tumors in animals and humans (97). In 
addition to genotoxic and/or epigenetic mechanisms of this 
process that are now well established, immunotoxic and immu-
nomodulatory effects can be considered (97,98). Immunotoxicity 
can be defined as any modulation (activation, suppression or 
deviation) of immune responses by chemicals that cannot be 
related to the infection with a certain type of the pathogen (99). 
For some chemicals, significant immune effects occur at doses 
that are below those where acute cellular toxicity is observed 
(100–103). Most of in vivo immunological experiments are usu-
ally performed on healthy adult animals. However, immunotoxic 
effects may change when the immune system is compromised 
due to existing disease or when immune system is not yet fully 
developed (i.e. in young individuals) (104–106).
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In fact, the concordance between immunotoxicity and car-
cinogenicity of chemical compounds can be as high as 81% 
(P = 0.019), suggesting that immunotoxic chemicals may also be 
carcinogenic (107–109). Thus, the following can be postulated: 
(i) if a chemical is immunotoxic and it modulates innate and 
adaptive cell-mediated immunity, then that chemical could 
affect immunosurveillance; (ii) if the effect of a chemical on 
the immune system is independent of its genotoxic/epige-
netic effects, that chemical could increase cancer risk alone by 
impacting changes induced by other factors and/or exposures; 
(iii) exposures to chemicals that dramatically increase the num-
ber of tumor cells can overwhelm immune surveillance and (iv) 
a compromised immunity may be inefficient in managing the 
development and progression of tumor cells. This would permit 
greater likelihood of tumor cells escaping host immunity and 
establishing a malignant condition.
A number of chemicals with immunotoxic potential have 
been identified in previous studies and shown to increase the 
risk of cancer for exposed individuals. For example, perfluori-
nated compounds, polychlorinated biphenyls and organochlo-
rine pesticides might increase cancer risk, especially among 
individuals that have genetic polymorphisms associated with 
metabolism of those compounds (110–113). Others have shown 
that maternal and perinatal exposures to pesticides were asso-
ciated with increased risk of lymphoma later in life (114,115). 
Factors other than exposures to chemicals from anthropogenic 
environment can potentially interfere with the relationships 
between chemical compounds and the host immune response 
and might thus modify the risk of tumor development and pro-
gression. An example of such a modifying factor is the immune 
status of the organism at the time of chemical exposure. Animal 
studies showed that an immunocompromised status was asso-
ciated with a higher risk of spontaneous and chemically induced 
tumors (60,116–122). And chemically induced immunosuppres-
sion might impact the ability of an animal to reject cancer cells, 
depending on the severity of immunosuppression (109) and the 
type of defect (e.g. defects in both NK and T-cell functional activ-
ity) (61,62).
However, information on the role of coexisting immunosup-
pression, relative susceptibility to chemical exposures and their 
effects on malignant risk are sparse for human. Clinical observa-
tions of human immunodeficiency virus-infected patients and 
organ transplant recipients that had displayed increased risk of 
malignant development or transformation are consistent with 
the role of immunosurveillance in carcinogenesis (123–130). 
These observations led to the hypothesis that immunodeficient 
or immunosuppressed individuals might have a higher risk 
of tumor development when exposed to chemicals that affect 
immune responsiveness compared with immunocompetent 
individuals.
On an individual level, many disparate factors influence the 
capacity of any particular compound to affect host immunity. 
These include genetic variability in the capacity to metabo-
lize chemicals, coexisting immunosuppressive conditions (e.g. 
human immunodeficiency virus-infected individuals or patients 
receiving immune-suppressive medications), the age of an indi-
vidual on exposure to the chemical (e.g. in utero, in children, in 
adults), differential dose, route and duration of exposure and 
the frequency of exposure (131,132). But if a sufficiently large 
population (i.e. number of people) is exposed to certain environ-
mental chemicals, even the most modest impacts on immuno-
surveillance competence might increase the risk of disease (e.g. 
cancer) at the population level (133). Chemical compounds can 
affect the immune response through different pathways. For 
example, certain endocrine-disrupting chemicals can increase 
breast cancer risk through genes that are involved in estrogen-
dependent induction of immune evasion, including estrogen 
receptor-mediated genes (EGR3) (134).
Polycyclic aromatic hydrocarbons inhibit differentiation and 
maturation of DCs (135). Moreover, phytoestrogens, phthalates, 
bisphenol A, parabens and various pesticides, herbicides and 
fungicides accumulate in human tissues and in wildlife, thus 
increasing the time of exposure. For example, atrazine, which 
is a widely used broad-spectrum chloro-s-triazine herbicide, 
impacts the maturation of DCs (136,137) and decreases expres-
sion levels of major histocompatibility complex class  I  (138). 
Moreover, atrazine persists in the soil and surface water for sev-
eral months (139–142) and its effects on the immune system can 
persist long after initial exposure (143,144).
In addition to the complicating impact of bioaccumulation, 
the non-monotonic dose response to these chemicals makes 
evaluation of the health impacts of such chemicals even more 
challenging (145). Since the effects seen at high doses of expo-
sure cannot be used for extrapolations into the low-dose range, 
direct low-dose testing is required to evaluate the effects. In the 
risk assessment procedure, the low-dose effects are observed 
at the doses near the lower end of the dose–response curve. 
The low-dose estimates for each chemical are based on vari-
ous parameters of dose–response analysis, including the refer-
ence dose, which is an estimate (with uncertainty that can span 
an order of magnitude) of a daily oral exposure to the human 
population, including susceptible populations, which is likely 
to be without an appreciable risk of deleterious effects dur-
ing a lifetime. The reference dose is generally derived from the 
no observed adverse effect level or lowest observed adverse 
effect level. Both the no observed adverse effect level and low-
est observed adverse effect level are two commonly used toxi-
cological endpoints (146) (presented in Table  4). Generally, the 
reference dose is used in the U.S. Environmental Protection 
Agency’s (EPA) non-cancer health assessments. Additionally, the 
no observed adverse effect level is a concentration of a chemi-
cal or compound that is associated with no observed adverse 
effects in tested organisms, and the lowest observed adverse 
effect level is a concentration of a chemical or compound that 
is associated with the lowest observed level of adverse effects in 
test organisms.
In a recent study, the low-dose effects have been observed 
in chemicals from a number of classes, with the affected health 
endpoints covering a large range of targets (147): for example, 
the low-dose cutoff for atrazine was 200 μg/l (for male sexual 
differentiation/development endpoint), for bisphenol A 400 μg/
kg/day (for immune system, prostate, mammary gland, brain 
development, reproduction and metabolism), for maneb 5 mg/
kg/day (for testosterone release) and for triclosan 12 mg/kg/day 
(for altered uterine responses to ethinyl estradiol). However, it is 
a challenging task to identify the levels of chemicals that could 
be considered ‘low dose’ and have no adverse effects on human 
health because multiple factors and conditions could influence 
such low-dose exposures. Additionally, individuals are exposed 
to many environmental chemicals over the lifetime, along with 
other stressors and anthropogenic exposures in a cumulative 
manner (referred to as the ‘human exposome’), so the evaluation 
of the health effects that result from multiple acute, subacute, 
chronic and subchronic occupational and non-occupational 
exposures remains a significant challenge (148,149).
Another factor that makes chemical exposure studies in car-
cinogenesis challenging is the latency period. This is because 
the moment of exposure that is required for cancer initiation 
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and the development of a tumor (or the latency period) vary 
from ~7 to 35 years, depending on the cancer type, specific organ 
and tissue site and the grade of the tumor. For example, the 
shortest latency is often observed in the settings of pancreatic 
and cervical cancer, and the longest latency is seen in the set-
tings of prostate and grade I breast cancer (150,151). Moreover, 
when multiple chemical compounds act synergistically, the 
effects can occur at much lower doses compared with the dose 
at which a single chemical exposure might exert a detectable 
health effect in human subjects.
The National Report on Human Exposure to Environmental 
Chemicals (152–154) provides some information on population 
heterogeneity by the level of bioaccumulation and excretion of 
various compounds (155). For instance, ~5% of the U.S. popula-
tion have 3–10 times higher concentrations of certain chemicals 
in their blood, serum or urine that might be explained by either 
higher exposures and/or altered individual metabolic capac-
ity. Examples of such compounds that demonstrate a highly 
heterogeneous distribution in a population include benzophe-
none-3 (used as a sunscreen in lotions, conditioners, cosmetics 
and in plastic surface coatings) and triclosan (2,4,4′-trichloro-
2′-hydroxyphenyl ether, which is a preservative and antiseptic 
agent used in soaps, toothpastes, mouthwashes, acne medica-
tions, deodorants, kitchen utensils, toys and medical devices). 
Other examples are pesticide metabolites including 2,4- and 
2,5-dichlorophenols, phytoestrogens (e.g. daidzein, genistein 
and O-desmethylangolensin that are present in soy-based 
foods) and butyl parabens (used as preservative and food and 
pharmaceutical industry flavoring additives as well as in per-
sonal care and cosmetic products). Additional examples include 
ethyl paraben (an antifungal preservative also known as food 
additive E214) and n-propyl paraben (used as a preservative in 
water-based cosmetics and as food additive E216), metabolites 
of pesticides [e.g. the cypermethrin-related chemicals cis-3-(2,2-
dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid and 
3-phenoxybenzoic acid], metabolites of organophosphorus (e.g. 
dimethylphosphate, dimethylthiophosphate and dimethyldithi-
ophosphate) and organochlorine insecticides (e.g. 2,4,5-trichlo-
rophenol, which is also used as a wood preservative and for 
chlorinating drinking water). Other compounds that display a 
highly heterogeneous population distribution include dibromo-
chloromethane (a disinfection by-product in drinking water and 
swimming pools), 2,2′,4,4′,5-pentabromodiphenyl ether (a fire 
retardant), phthalate metabolites like mono-ethylphthalate and 
mono-2-ethylhexyl phthalate (that are used as plasticizers in 
adhesives, detergents, solvents, vinyl tiles and flooring, personal 
care products, plastic bags, intravenous injection medical tub-
ing and children’s toys). Finally, 1-hydroxynaphthalene (1-naph-
thol), which is a metabolite of carbaryl, is used in plasticizers, 
dyes, synthetic leather tanning chemicals and in moth repel-
lents. It also displays heterogeneity in bioaccumulation and 
excretion studies in the U.S. population (155).
Note that compared with currently unrecognized human 
carcinogenic chemicals, bioaccumulation and excretion of com-
pounds that are already recognized as human carcinogens (155) 
appear to be less heterogeneous in the U.S.  population. This 
allows one to hypothesize that known carcinogenic compounds 
may have more unified bioaccumulation and excretion pat-
terns in the population, which also assists in recognizing them 
already as carcinogens.
The U.S. EPA’s ToxCast program (http://www.epa.gov/ncct/
toxcast/) and the Tox21 collaboration (http://www.epa.gov/ncct/
Tox21/) with the National Toxicology Program and National 
Institutes of Health Chemical Genomics Center have reported 
a large number of in vitro high-throughput screening assays and 
high-content screening information for numerous environmen-
tal chemicals (156,157). One important focus of ToxCast is the 
measurement of chemically induced perturbation of critical cel-
lular signaling pathways that may represent potential modes of 
chemical toxicity (158).
In vivo animal model studies have suggested the following 
genes with the highest odds ratios for the potential disruption 
of immunosurveillance: receptor designated opioid receptor-
like 1 (for thyroid tumor), chemokine C–C motif ligand 2 (CCL2; 
for spleen and liver tumors) and IL-1α, interferon-γ-inducible 
9-kd (CXCL9) and 10-kd protein (CXCL10) (for liver and thy-
roid tumors) (159). These genes are associated with effective 
immune response in both animals and humans (160). When 
multiple chemicals impact antitumor immune responses, the 
resultant cumulative effects of these exposures may impart a 
greater relative risk of carcinogenesis and tumor development, 
particularly in the context of multiple exposures affecting the 
same genetic targets (161).
Immune evasion mechanisms: 
opportunities for target genes and 
pathways
The list of chemicals and the targets that they disrupt is 
based on EPA’s 2009 ToxCast data. The EPA-screened chemicals 
included in Table  1 carried the highest scores for the ToxCast 
immune system disruption counts with the respective number 
of activated associated genes. A dose of ~100 μM of each individ-
ual chemical was used in each assay. The potency of an assayed 
chemical that gave a positive (i.e. gene activation) response was 
summarized using the AC50 value (i.e. at a concentration of 50% 
of the maximal activity) or the lowest effective concentration 
values. Note that the use of nominal potency in determining 
hazard identification has been challenged because in vitro assays 
cannot account for in vivo impacts of a compounds bioavailabil-
ity, metabolic clearance and exposure (162). The in vitro to in vivo 
extrapolation using information on human dosimetry and expo-
sure is valuable in assessing the validity of high-throughput in 
vitro screening to provide hazard predictions at the level of the 
organism (163,164).
We referred to the ToxCast database to determine which 
chemicals aligned with immune system evasion mechanisms 
that were relevant in carcinogenesis. Since chronic inflammation 
and immune responsiveness in carcinogenesis are both linked 
to, and initiated at the premalignant stages of tumor develop-
ment (165,166), it is understandable that ToxCast data sets 
describe pathways that are related to both inflammation and 
immune evasion as putative immune disruption mechanisms 
(158,159). We selected the pathways that were related specifi-
cally to immune evasion as a cancer hallmark by comparative 
analysis of existing studies in the settings of both inflammation 
and immunosurveillance with the results on immune disrup-
tion presented by ToxCast. Consequently, several genes from the 
ToxCast immune disruption list were selected since they were 
associated with immune evasion based on an overview of the 
literature: for example, ADORA1 (adenosine A1 receptor); AKT1 
(v-akt murine thymoma viral oncogene homolog 1 or protein 
kinase alpha); CCL2; CCL26; CD40, CD69, COL3A1 (type III col-
lagen of extracellular matrix); CXCL10 (interferon-inducible pro-
tein-10); CXCL9 (monokine induced by interferon-gamma); EGR1 
(early growth response protein 1); HIF-1α (hypoxia-inducible fac-
tor); IGF1R (insulin-like growth factor 1 receptor) and IL-1α and 
IL-6 (Table 1).
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Specifically, ADORA1 was involved in the immune response to 
thyroid cancer (167) by encoding adenosine receptors that inhib-
ited T-cell responses. This was achieved in part by augmenting 
FOXP3 expression in CD4+ helper T cells (65). Another study has 
also shown that tumors grew slower in ADORA (i.e. ADORA2A) 
knockout mice (66). Other examples included the participation 
of CCL2 in immune system evasion by recruiting immune sup-
pressor cells to the tumor microenvironment (67), and CCL26, 
which helped to promote a Th2-dominant tumor microenviron-
ment that was beneficial for tumor cells (69). Similarly, others 
showed that CD69, which is among the earliest cell-surface 
expressed molecules, was induced during lymphocyte activa-
tion (70), and COL3A1, which might be involved in tumor cell 
evasion of immune surveillance (71). Finally, another group 
found that CXCL10, which is the ligand for CXCR3, was a che-
moattractant for activated T cells (72). Moreover, the expression 
of the EGR1 gene participates in immune evasion mechanisms 
of infectious agents (73), although its role in tumor evasion (e.g. 
as a tumor suppressing factor) remains unclear (74). IL-1α par-
ticipates in mechanisms that permit prostate tumor escape, 
and downregulation of dampened expression of MIP-1α might 
be associated with decreased IL-1α and tumor necrosis factor-
alpha during the advanced stages of cancer (75). Finally, IL-6 is 
crucial for both tumor growth and immunosuppression (78). IL-6 
also inhibits maturation of DCs, and NK cell activation, and may 
promote NK cell anergy (79,80).
Additional pathways contribute to immune surveillance that 
is also associated with carcinogenesis and tumor progression. 
These pathways include activation of the PI3K/AKT pathway, 
which represents a new mechanism of immunological tumor 
escape (81). For HIF-1α, the studies have linked hypoxia-induced 
accumulation of D-subunits with expression of ADAM10 and 
decreased surface major histocompatibility complex class I pol-
ypeptide-related sequence A levels that can lead to tumor cell 
resistance to innate immune effector-mediated lysis (68). The 
local immune response of Epstein–Barr virus-associated tumors 
to infiltrating T cells might be suppressed by enhancing cytokine 
and cellular growth factors like IGF1 (76).
The collection of genes involved suggests several candidate-
signaling pathways that are capable of participating in chemi-
cally induced immune evasion. These pathways include PI3K/
Akt, chemokine pathways (e.g. CCL2, CCL26, CXCL9, CXCL10), 
TGF-β1 and FAK (including COL3A1), the IGF-1, the HIF-1α, the 
IL-6 and the IL-1α signaling pathways (summarized in Table 2). 
Indeed, some pathways (e.g. chemokine, TGF-β, FAK and IL-1α 
signaling pathways) are targets of multiple chemicals (Table 2). 
However, some pathways (e.g. PI3K/Akt, IGF-1, HIF-1α and IL-6) 
have greater chemical-specific involvement. In addition, sign-
aling pathway cross talk might play a role in affecting host 
immunity.
There are also intracellular signaling pathways that are 
critical in regulating DC differentiation, survival and activity, 
which could be activated or inhibited through signal-mediated 
cross talk. For example, the MAPK (mitogen-activated protein 
kinase signaling cascade) pathway cross talks with CCL2, Akt, 
IL-6 and IGF-1. The PI3K/Akt (phosphatidylinositol-3-kinase/
protein kinase B) pathway cross talks with IGF-1 and IL-6. Also, 
the JAK/STAT3 (Janus kinase/signal transducer and activator 
of transcription 3)  pathway cross talks with IL-6. Additionally, 
chemicals in the environment affect several candidate immune 
evasion pathways that are involved in antitumor immunity. For 
example, CTLA-4 (cytotoxic T-lymphocyte-associated protein 
4)  and the PD-1/PDL-1 (programmed death-ligand 1)  signaling 
pathways are involved in the immune evasion of tumor cells. 
Monoclonal antibodies inhibiting these pathways have demon-
strated the effectiveness of anticancer effects in certain types 
of tumor (77,168). The α-enolase (ENO1) antigen that is coded by 
the ENO1 gene has been recently detected in pancreatic (169), 
lung and hepatocellular cancers (170,171). ENO1 has also been 
tested as a vaccine target (172–174); it has the cross talks with 
CXCL9, CXCL10 and CD40. Consequently, these pathways rep-
resent excellent candidates for further studies of the effects of 
disruptive or agonistic chemicals of the immune response in 
human carcinogenesis.
Factors other than exposures to chemicals from anthropo-
genic environment can potentially interfere with the relation-
ship between chemical compounds and host immunity, which 
might modify the risk of tumor development and progression. 
One such factor is the immunological status of the organism 
at the time of environmental chemical exposure. Animal stud-
ies showed that an immunocompromised state was associ-
ated with a higher risk of spontaneous and chemically induced 
tumors (60,116–122). Chemically induced immunosuppression 
can impact the ability of an animals to reject cancer cells, and 
this depends on the extent of immunosuppression (109) and 
the type of defect (e.g. defects in one or in both NK and T-cell 
functional behavior) (61,62). However, information on the role of 
coexisting immunosuppression in the human system and their 
susceptibility to chemical exposures is sparse and is currently 
insufficient to suggest the role of immunosuppression in chemi-
cal carcinogenesis.
Environmental chemicals that impact multiple pathways 
associated with immune dysfunction may also increase the risk 
of diseases other than cancer. The dysfunction of the immune 
system caused by some endocrine-disrupting chemicals may 
lead to lower effectiveness of immune response to infection 
or to the allergy and autoimmune diseases due to the hyper-
reactivity of immune response (175). For example, exposures to 
pesticides, solvents and air pollutants have been shown to be 
associated with the immune response dysregulation and inflam-
matory dysfunction and contributed to higher risk of asthma 
and allergies (176). Specifically, human bronchial epithelial cells 
treated with butylbenzyl phthalate, bis(2-ethylhexyl) phthalate, 
dibutyl phthalate and diethyl phthalate increased bronchial 
smooth-muscle cell proliferation and migration, suggesting a 
role of these chemicals in asthma airway remodeling (177,178). 
There are also increasing evidence from the animal studies that 
in utero or neonatal exposures to bisphenol A  are associated 
with higher risk of immune system dysregulation and meta-
bolic syndrome that may develop later in life (179–182). Another 
example can be a pesticide-induced asthma in agriculture work-
ers that may be due to the indirect effects of pesticides on the 
immune system, including interfering with the Th1/Th2 balance 
or pesticide-induced oxidative stress (183). For addition, certain 
environmental chemicals may cause the changes in response 
of immune system to infectious agents, thus increasing risk of 
adverse outcomes of respiratory infections (184). For example, it 
has been shown that higher bisphenol A levels were associated 
with lower levels of anticytomegalovirus antibodies in humans, 
thus suggesting that exposure to this chemical may attenuate 
antiviral immunity (185).
Cross talk between immune evasion and 
other hallmarks of cancer
Based on the number of variables involved in this field and 
the paucity of data in this area of research, we believe that 
future research will need to focus on environmentally relevant 
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low-dose exposures to mixtures of chemicals that are known to 
have a disruptive impact on immune system tumor surveillance 
and elimination. Given that the pathways involved in immune 
evasion might also participate in other hallmarks of cancer, we 
undertook a mapping exercise to identify cross-hallmark rela-
tionships that have been reported for the key mechanisms and 
the disruptive chemicals that we identified. This was done by a 
cross-validation study to show how the target pathways and/or 
chemical disruptors (i.e. those that potentially interact with the 
pathways involved in immune evasion) might also be involved 
in other cancer hallmarks (Tables 3 and 4). In particular, this 
heuristic could be useful for researchers who would like to try 
to predict potential synergies that might emerge when testing 
low-dose exposures to mixtures of chemicals for this purpose.
To conduct this cross-hallmark activity, our team selected 
nine prototypic chemicals drawn from a list of 20 chemicals (as 
listed in Table 1). The prototypic chemicals chosen were maneb, 
pyridaben, pyraclostrobin, fluoxastrobin, azamethiophos, tri-
closan, atrazine, bisphenol A  and diethylhexyl phthalate. 
Several examples of the interrelations of the pathways involved 
in immune evasion and other cancer hallmarks are presented 
in Table  3. This analysis shows that some of the mechanisms 
and pathways that are important for the immune system in 
cancer are also highly relevant for aspects of cancer’s biology. 
For example, chemical exposures that affect chemokine sign-
aling pathways could also deregulate metabolism, the evasion 
of antigrowth signaling, angiogenesis, resistance to cell death, 
sustained proliferative signaling, tissue evasion and metastasis, 
tumor-promoting inflammation and affect the tumor microen-
vironment. Similarly, the disruption of the HIF-1α and of the 
PI3K/Akt pathways can influence most of the other hallmarks 
of cancer. Disruption of the IGF-1 signaling pathway could affect 
metabolism, evade antigrowth signaling, resistance to cell death, 
sustained proliferative signaling, tissue evasion, tumor-promot-
ing inflammation and tumor microenvironment hallmarks.
Table 4 shows where there have been reports of cross-hall-
mark effects by the chemicals that we selected. For example, 
maneb displays the widest spectrum of potential effects on 
multiple pathways among fungicides, i.e. it has complemen-
tary effects on dysregulated metabolism, sustained proliferative 
signaling, genetic instability and tumor promoting inflamma-
tion. Two other fungicides (pyraclostrobin and fluoxastrobin) 
affected only the hallmarks of genetic instability and tumor-pro-
moting inflammation. Among fungicides, currently only maneb 
is reported to exhibit limited carcinogenicity in humans as 
determined by the U.S. EPA (250), but it remains ‘not classifiable 
as to its carcinogenicity to humans’ by the IARC (155). Maneb is 
also a cortisol disruptor that inhibits 11β-HSD2 (251). Maneb was 
registered in the USA in 1962 for use on food (including potatoes 
and tomatoes) and ornamental crops to prevent their damage in 
the field and to protect the harvested crops from deterioration 
during storage and transportation (252,253). Pyraclostrobin and 
fluoxastrobin (the chemical class of strobins) have been used 
since the early 2000s; therefore, there are less data available on 
these fungicides compared with longer periods of observation 
for maneb. Pyraclostrobin is a broad-spectrum fungicide that is 
used in both agricultural (cereal grains, fruits and vegetables) 
and non-agricultural settings (e.g. flowers and grass, includ-
ing golf courses). Pyraclostrobin is one of the most frequently 
applied fungicides for grapes, apricots, tomatoes, sweet cherries 
and plums. Fluoxastrobin is used to prevent diseases in crops 
such as wheat, barley, corn, soybean, potato, tomato, pepper, 
strawberry and turf plots (i.e. in the context of landscaping). It is 
likely that both fluoxastrobin and pyroclostrobin are also endo-
crine-disrupting fungicides (254).
In addition to immune system evasion, atrazine (a triazine 
herbicide that is used primarily in corn production) may also 
interfere with other hallmarks including dysregulated metabo-
lism, genetic instability, sustained proliferative signaling and 
tumor-promoting inflammation. Similar to the classification 
ascribed to maneb, atrazine is listed by IARC as ‘not classifiable 
as to its carcinogenicity to humans’ (155). Atrazine is the most 
common pesticide contaminant of ground and surface water in 
the USA (255,256). Since 2000, atrazine has been reported as an 
endocrine disruptor for both androgen- and estrogen-mediated 
processes (257,258).
Additionally, two insecticides, pyridaben and azamethip-
hos, have broader potential effects related to cancer hallmark 
pathways, in addition to their effects on immunosurveillance, 
i.e. pyridaben exposure can dysregulate metabolism and tumor-
promoting inflammation. Moreover, exposure to azamethiphos 
impacts genetic instability. Pyridaben is a pyridazinone derivate 
that is widely used as an acaricide and insecticide to control 
mites, white flies and aphids. Azamethiphos is a widely used 
organophosphate pesticide in the control of cockroaches and 
flies in buildings and warehouses. This compound was also 
used in fish farming to control external parasites in Atlantic 
salmon. Neither pyridaben nor azamethiphos are listed by the 
IARC as carcinogens (155). However, the majority of insecticides 
are designed to be disruptors of various physiological functions 
in insects; therefore, these compounds are likely disruptive for 
humans, too. Recent studies showed that pyridaben can activate 
the estrogen receptor alpha in experimental rodents (259).
Triclosan and bisphenol A are commonly found in personal 
care products. Bisphenol A  is a monomer that is also used in 
the production of polycarbonates and epoxy resins for coating 
Table 2. Candidate-signaling pathways potentially involved in chemically induced tumorigenesis and related to immune evasion hallmark: 
























Maneb (fungicide) +a (85,87) + (85) + (83,85,86) + (85) + (84) − + (82,83) + (83)
Pyridaben (insecticide) − + (83,92) + (83) + (83) − + (91,92) − + (92)
Triclosan (preservative 
and antiseptic agent)
− + (93) + (94) + (95) − − − + (93)
‘+’, the pathway is likely involved when the organism is exposed to respective chemical; ‘−’, the pathway is unlikely involved when the organism is exposed to 
respective chemical.
aThe involvement of the candidate pathways that are constructed from the data on every single gene is described in the ToxCast data (90) (as shown in Table 1).
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beverage and food packages, baby milk bottle and optical lenses 
(260). It is ‘not classifiable as to its carcinogenicity to humans’ 
by the IARC (155). Triclosan is a broad-spectrum antimicro-
bial agent. In addition to its use in personal care products, tri-
closan is also used in carpets and sportswear production. These 
chemicals are among the most frequently detected compounds 
in waters downstream of densely urbanized areas (261,262). 
Compounds like triclosan and bisphenol A act as endocrine dis-
ruptors, e.g. bisphenol A has antiandrogenic (263) and triclosan 
has androgenic and antiestrogenic activities (264,265). As shown 
in Table  4, bisphenol A  affects nearly all hallmarks of cancer, 
except of the tumor microenvironment hallmark for which the 
data are still currently unknown. The effect of triclosan might 
dysregulate metabolism, genetic instability, sustained prolifera-
tive signaling and tumor-promoting inflammation.
Diethylhexylphthalate (DEHP), which is one of the most 
extensively used phthalates worldwide in the plastic, coating 
and cosmetics industries, is another class of compounds that 
might promote hallmarks of cancer (266). DEHP influences 
resistance to cell death, evasion of antiproliferative signaling, 
sustained proliferative signaling and tumor-promoting inflam-
mation as hallmarks of cancer. Since the mid-1990s, DEHP was 
reported as an endocrine disruptor (267). Perinatal exposure to 
DEHP might also be associated with an increased incidence of 
obesity due to its endocrine disrupting impact during the devel-
opmental ‘window of susceptibility’ that affects adipogenesis 
(268). In 2000, the designation of DEHP as ‘possibly carcinogenic 
to humans’ (based on animal studies) has been changed to ‘can-
not be classified as to its carcinogenicity in humans’ (269,270).
Overall, this heuristic shows that a number of chemicals that 
we considered also have the potential to interact with several 
other cancer hallmark pathways. Therefore, researchers who 
plan to consider these chemicals for exposure research on mix-
tures should carefully evaluate these potential synergies.
Further studies
Cancer has a complex and multifactorial etiology impacted by 
both inherited factors and environmental exposures over the 
life course of an individual. Although genetic risks have been 
identified, most studies suggest that substantial contributions 
to cancer risk are derived from the environment. This viewpoint 
remains consistent with the recent observations that cancer risk 
is associated with the potential number of stem cells divisions 
needed to maintain a tissue integrity (271). Coupled with the 
importance of evaluating an already extensive (and expanding) 
number of chemicals of unknown cancer-promoting potential, 
there is a clear need for more efficient in vitro screening tools 
that should be complemented with in silico virtual ligand screen-
ing approaches to help construct a target and pathway-based 
understanding of specific chemicals or groups of chemicals 
(159,272). Specific genes and pathways could be further meas-
ured by experiments that are designed to arrive at quantified 
information for each chemical studied.
Due in part to low relative risks attributed to low-dose expo-
sures and the knowledge that multiple chemicals have the 
potential to contribute to these exposures over sustained and 
durable periods of time, it remains challenging to evaluate the 
effects of such exposures on human health by classical epide-
miological approaches. Dose–response analyses could provide 
information on quantitative ‘sensitivity’ of each ‘barrier’ (e.g. 
apoptosis and DNA repair system) following exposure to specific 
chemicals or to complex mixtures of chemicals, both in the con-
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hallmarks. Attempts at quantifying these measured ‘barriers’ 
can be incorporated into models of carcinogenesis (273).
Future studies should focus on linking population data 
on cancer-specific incidence and mortality (e.g. for cancers of 
breast, prostate, testicular, ovarian and thyroid, wherein the risk 
of developing that cancer is affected by endocrine-disrupting 
chemicals). Studies should also focus on information of the 
measured characteristics of immune system evasion, and other 
established hallmarks of cancer, which collectively could be fur-
ther incorporated into biologically motivated models of carcino-
genesis, in a manner similar to those developed by Moolgavkar 
et  al. (274) and Tan (275). Further extensions of these models 
were developed over the past decade including the two-stage 
clonal expansion model, the multistage clonal expansion model 
and other biologically motivated models of human carcinogen-
esis (150,276–278). These models are capable of providing valu-
able insight into the relative risks of environmental exposures.
In this article, we have reviewed some common chemicals 
that are known or suspected to be present in anthropogenic 
environment. We have also discussed their potential effects on 
host immunity and proposed mechanisms by which they poten-
tially interact with specific hallmark pathways. Based on a com-
prehensive review of the literature on environment and health, 
we recognized that immune evasion has only been recently 
widely accepted as an emerging cancer hallmark, and we sug-
gest that it may be among the least studied of the hallmarks. 
The literature describing the potential effects of chemical expo-
sures on the immune evasion, in particular the impact in the 
context of low-dose exposures from ubiquitous anthropogenic 
environmental chemicals, is sparse.
The causal relationship between chemical exposures from 
compounds that are not currently recognized as human carcin-
ogens and the increased risk of cancer development (including 
the potential impacts of such chemicals on the pathways that 
are related to immune evasion mechanisms) cannot be formally 
established at this time. However, based on available studies, 
several candidate-signaling pathways that are related to the 
host immune response can be identified for further study, e.g. 
the pathways involving PI3K/Akt, chemokines, TGF-β, FAK, IGF-
1, HIF-1α, IL-6, IL-1α, CTLA-4 and PD-1/PDL-1. At least several 
groups of environmentally ubiquitous chemical contaminants—
including fungicides (maneb, fluoxastrobin, pyroclostrobin), 
herbicides (atrazine), insecticides (pyridaben and azamethip-
hos), personal care products (triclosan and bisphenol A) and the 
extensively used industrial compound DEHP—are among those 
that might potentially interrelate with mechanisms of tumor 
immunosurveillance.
Although none of these chemicals are currently recognized 
as human carcinogens, as ubiquitous in anthropogenic environ-
ment and as eliciting a long-term and low-dose exposure, the 
research of these chemicals may be valuable. Ultimately, we 
should know whether or not these exposures interfere with the 
host immune response and thus augment the risk of tumor cell 
survival. Further detailed studies, including screening of lesions 
at the premalignant stage of development, will help shed more 
light on this topic. This will be made possible by determining 
the role of such exposures and their influence on host immunity 
and in the evaluation of their potential to increase the risk of 
carcinogenesis and tumor development.
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Abstract
Cell death is a process of dying within biological cells that are ceasing to function. This process is essential in regulating 
organism development, tissue homeostasis, and to eliminate cells in the body that are irreparably damaged. In general, 
dysfunction in normal cellular death is tightly linked to cancer progression. Specifically, the up-regulation of pro-
survival factors, including oncogenic factors and antiapoptotic signaling pathways, and the down-regulation of pro-
apoptotic factors, including tumor suppressive factors, confers resistance to cell death in tumor cells, which supports 
the emergence of a fully immortalized cellular phenotype. This review considers the potential relevance of ubiquitous 
environmental chemical exposures that have been shown to disrupt key pathways and mechanisms associated with this 
sort of dysfunction. Specifically, bisphenol A, chlorothalonil, dibutyl phthalate, dichlorvos, lindane, linuron, methoxychlor 
and oxyfluorfen are discussed as prototypical chemical disruptors; as their effects relate to resistance to cell death, as 
constituents within environmental mixtures and as potential contributors to environmental carcinogenesis.
Introduction 
Cancer death is one of the major causes of mortality worldwide. 
According to the World Health Organization, there were ~32.6 
million cancer patients in the world in 2012 (http://www.iarc.
fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf). The projected fig-
ures show that this year alone >14 million new cancer cases will 
be diagnosed and ~8.2 million cancer estimated deaths within 
5 years of diagnosis worldwide. Among these, 57% (8 million) of 
new cancer cases, 65% (5.3 million) of the cancer deaths and 48% 
(15.6 million) of the 5 year prevalent cancer cases occurred in 
the less/under-developed regions of the world (http://www.iarc.
fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf). In all cancers, an 
abnormal and ongoing division of damaged/dysfunctional cells 
initially leads to the formation of a tumor (initiation), where 
the immortalized cells that have avoided cell death continue 
to proliferate in an unregulated manner (progression) and then 
ultimately invade other tissues at later stages in the disease 
(metastasis).
The immortalized cellular phenotypes that emerge in most 
cancers have largely avoided cell death, which can be defined as 
a terminal failure of a cell to maintain essential life functions, 
and can be classified according to its morphological appear-
ance, as apoptosis, necrosis, autophagy or mitotic catastrophe. 
During cell death, numerous enzymes and signaling pathways 
are modulated [nucleases, distinct classes of proteases (e.g. 
caspases, calpains, cathepsins and transglutaminases, protein 
binding signaling intermediates and so on)], which can exhibit 
immunogenic or non-immunogenic responses (1). Tumor cells 
are genetically programmed to undergo apoptotic and non-
apoptotic death pathways (e.g. necrosis, autophagy, senescence 
and mitotic catastrophe). Normally, apoptotic resistance is ren-
dered by the up-regulation of antiapoptotic molecules and the 
down-regulation, inactivation or alteration of pro-apoptotic 
molecules. However, dysfunction in these cell-death pathways 
is associated with initiation and progression of tumorigenesis. 
An increased resistance to apoptotic cell death (involving the 
inhibition of both intrinsic and extrinsic apoptotic pathways) is 
therefore an important hallmark for cancer cells.
Several tumor suppressor proteins, such as TP53, recognize 
DNA damage and activate DNA repair processes. Irreparable 
DNA damage can induce apoptosis and prevent neoplastic 
transformation (2) and can also trigger cellular senescence of 
transformed cells. Regulation of apoptosis is influenced by 
BCL-2 family members of pro-apoptotic and antiapoptotic fac-
tors, death receptors and the caspase network. Alterations of 
proto-oncogenes, tumor suppressor genes and de-regulation 
in epigenetic factors such as microRNAs are potent causes of 
cancer growth. Proto-oncogenes encode proteins that stimulate 
cell proliferation, inhibit apoptosis or both. They are classified 
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into six broad groups: transcription factors, chromatin remodel-
ers, growth factors, growth factor receptors, signal transducers 
and apoptosis regulators. Normally, they are activated by genetic 
alterations (e.g. mutations or gene fusions, amplification during 
tumor progression or by juxtaposition to enhancer elements into 
an oncogene) (3–5). These genetic changes can alter oncogene 
structure or increase/decrease its expression. Similarly, tumor 
suppressor genes, which are involved in DNA repair, regulation 
of cell division (cell cycle arrest) and apoptosis, when mutated 
or inactivated by epigenetic mechanisms can cause cancer (4,5).
In this review, we discuss these mechanisms, their rela-
tionship to resistance to apoptosis and the importance of this 
hallmark characteristic of cancer as a potential enabler of envi-
ronmental carcinogenesis. In 2011, a non-profit organization 
called Getting to Know Cancer launched an initiative called ‘The 
Halifax Project’ with the aim of producing a series of overarch-
ing reviews to assess the relevance of biologically disruptive 
chemicals (i.e. chemicals that are known to have the ability to 
act in an adverse manner on important cancer-related mecha-
nisms) for carcinogenesis. To that end, our team was specifically 
tasked to review the hallmark of cancer ‘resistance to cell death’ 
and its relationships to other hallmarks of cancer. We were also 
tasked to identify a list of important, prototypical target sites for 
chemical disruption and a corresponding list of environmental 
chemicals that have been shown to have the potential to act 
on these targets. Ultimately, this review was not intended as 
a means to implicate specific chemicals in environmental car-
cinogenesis. Rather we undertook this review to explore what is 
known on this topic to provide a basis for further discussion of 
this idea and to help us identify future research needs.
To begin, we offer a brief review of several key mecha-
nisms and pathways that are related to resistance to cell death. 
Specifically, we highlight apoptotic pathways, necrosis and 
necroptosis, the role of autophagy and the relationship that these 
mechanisms and pathways have with cancer (Table 1). For those 
who are seeking more in-depth treatment of these topics, several 
recent reviews can provide additional information (6,7). In doing 
so, we also focus on a number of important mechanisms and 
pathways that are relevant for disruption [i.e. binding to estrogen 
receptor α (ERα), P53, ErbB-2/HER-2 tyrosine kinase, extracellular 
signal-regulated kinase (ERK)/mitogen-activated protein kinase 
(MAPK), MAP kinase, P16/P53, BCL-2/P53, peroxisome proliferator-
activated receptor-α (PPAR-α), gap junctional intracellular com-
munication (GJIC), hypersecretion of luteinizing hormone (LH) 
by gonadotroph cells in pituitary gland].  This list of target sites 
is not intended to be comprehensive. Other targets exist, includ-
ing well-known mechanisms such as ALK, CD20/22/79b, MDM2, 
PD-L1, VEGF, HER receptors, BRAF, Rho-associated protein kinase, 
fibroblast growth factor-9, cathepsins, cyclooxygenases, prosta-
glandins and so on. We selected these targets because each of 
them are actively involved in resistance to cell death and all of 
them have been shown to be of considerable importance.
Apoptotic pathways
The extrinsic pathway: death receptor-mediated apoptosis
Receptor-mediated pathways are initiated by death ligands 
that bind to their specific death receptors, which include TNF-
receptor 1, Fas/CD95 and TNF-related apoptosis-inducing ligand 
(TRAIL) receptor (8). All of these receptors contain the death 
domain, which is essential for the transduction of an apoptotic 
signal. After death ligands bind to their receptors, adapter mol-
ecules including Fas-associated death domain (FADD) or TNF 
receptor-1-associated death domain (TRADD) recruit the procas-
pase-8 for forming the death-inducing signaling complex. This 
leads to the initiation of the caspase cascade through activation 
of CASP-8 or -10, followed by subsequent activation of executive 
caspases such as CASP-3 and -7, and an irreversible commit-
ment to apoptosis (9).
The intrinsic pathway: mitochondria-mediated apoptosis 
Mitochondria play a pivotal role in cell survival as well as in 
apoptotic cell death, and defects in mitochondrial function might 
contribute to cancer initiation and progression. The mitochon-
dria-mediated intrinsic pathway is initiated by various stimuli, 
such as high cytoplasmic Ca2+ levels, reactive oxygen species 
(ROS), ultraviolet irradiation, viral infections or xenobiotics (10). 
Mitochondrial control of apoptosis is evolutionary conserved 
and tightly regulated by the BCL-2 proteins divided into 20 pro-
apoptotic and antiapoptotic members, which share conserved 
BCL-2 homology (BH) domains. The antiapoptotic members 
(BCL-2, BCL-XL, BCL-w, MCL-1, BCL-B) exhibit four BH domains 
(BH1-4). The pro-apoptotic members are categorized as BH3-only 
proteins (BAX, BAK, BIK, BAD, BIM, HRK, BCL-G HRK/DP5, NOXA 
and PUMA/BPC3), as reviewed in ref. 11. In normally proliferating 
cells, the pro-apoptotic BH3-only proteins are sequestered away 
from the antiapoptotic BCL-2 proteins. Although the antiapop-
totic members such as BCL-2, BCL-XL or BCL-w are integral pro-
teins of the outer mitochondrial membrane, the pro-apoptotic 
BCL-2 members are located predominantly in the cytoplasm. 
After an apoptotic signal, the free pro-apoptotic BH3-only pro-
teins associate with BCL-2 on mitochondria. Additionally, pro-
apoptotic BAX and BAK undergo conformational changes leading 
to homo- or oligo-merization at the mitochondrial outer mem-
brane (12). Consequently, this leads to a mitochondrial outer 
membrane permeabilization, the decisive event that delimits the 
frontier between survival and death. Upon apoptosis induction, 
the voltage-dependent anion channel protein plays a critical 
role in the dissipation of mitochondrial transmembrane poten-
tial (13,14). After mitochondrial membrane disruption followed 
by osmotic swelling, soluble pro-apoptotic mitochondrial inter-
membrane space proteins like cytochrome c, apoptosis-inducing 
factor, endonuclease G, second mitochondrial activator of cas-
pases (SMAC/DIABLO) and OMI/HTRA2 are released into cytosol 
resulting in activation of intrinsic apoptotic signaling cascades. 
The released cytochrome c, along with apoptosis-activating fac-
tor-1 (APAF-1) and procaspase-9, form the cytosolic apoptosome 
complex, which leads to the activation of CASP9, and in turn trig-
gers the caspase cascade, resulting in apoptotic cell death (15,16). 
However, inhibitor of apoptosis proteins (IAPs) can directly bind 
to CASP-3, -6 and -7 and antagonize their proteolytic activities. 
In contrast, IAPs are inactivated, and caspase activity restored by 
proteins released from the mitochondria, such as SMAC/DIABLO 
or HTRA2/OMI (17). The intrinsic pathway might also operate 
independently of the caspase cascade by utilizing the release of 
the apoptosis-inducing factor and endonuclease G from mito-
chondria, and their translocation to the nucleus. Apoptosis-
inducing factor is linked to chromatin condensation and the 
high-molecular-mass chromatin fragments, and after nuclear 
translocation, endonuclease G elicits DNA fragmentation (15). 
Because mitochondria-mediated apoptosis plays a critical role in 
cancer development and in the cellular response to anticancer 
agents, the significance of mitochondrial DNA mutations in can-
cer is currently an important area of investigation (18) (Figure 1).
The novel PIDDosome-mediated apoptotic pathway
CASP2 was identified as the first apoptotic and the most con-
served caspase (19). CASP2 was detected at various compart-
ments in the cell including the nucleus, the Golgi apparatus, 
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Table 1. Characteristics of apoptosis, autophagy and necrosis pathways
Morphological and biochemical features and modulators of cell deathMethods of detection
Apoptosis Morphological features: cellular shrinking, condensation and 
margination of chromatin, nuclear fragmentation and DNA 
laddering, plasma membrane budding and formation of 
apoptotic bodies in cytoplasm. Not surrounded by tissue injury of 
inflammation. Biochemical features: caspase-dependent cell death 
pathway. Activation: activation of intrinsic apoptotic pathway;  
BCL-2, c-FLIP, survivin IAP–antisense mRNA technology; 
recombinant TRAIL for DR4 and/or DR5 receptor; E2F-1 gene 
therapy; TWEAK (tumor necrosis factor-related weak inducer of 
apoptosis) is a cytokine belonging to TNF-ligand family for  
Tweak-receptor inducing apoptosis. Inhibition: natural and 
synthetic inhibitors of caspases; nitrosylation of caspase 9 or 3; 
c-Jun–mRNA antisense technology; CEP 1347–inhibitor of JNK 
signaling blocks Aβ-induced cortical neuron apoptosis.
Microscopic techniques: cellular features by light 
microscopy, nuclear DNA analysis by fluorescent 
stains (annexin V), confocal laser microscopy 
and electron microscopy. Assessment of DNA 
fragmentation: enzyme-linked immunosorbent 
assay, terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling assay, comet 
method, DNA diffusion, immunohistochemistry 
for single-stranded DNA and gel electrophoresis. 
Flow cytometry: cell cycle. Laser scanning 
cytometry: DNA content, phosphatidylserine 
translocation, inner mitochondrial transmembrane 
potential and caspase activity. Gene expression: 
northern blot, RNA protection assay, reverse 
transcription–polymerase chain reaction and 
immunohistochemistry. Evaluation of  
apoptosis-associated proteins: enzyme-linked 
immunosorbent assay, western blot and 
electrophoretic mobility shift assay.
Autophagy Morphological features: partial chromatin condensation, no DNA  
laddering, cell membrane blebbing and formation of more 
autophagosome. Biochemical features: caspase-independent 
cell death pathway. Activators: conventional cytotoxic drugs and 
irradiation; BCR-ABL tyrosine kinase inhibitor–imatinib;  
anti-EGFR–cetuximab; proteasome inhibitors; TRAIL and histone 
deacetylase inhibitors; mTOR inhibitors and its analogs; ATP-
competitive inhibitors of mTORC1 and mTORC2; dual PI3K-mTOR 
inhibitor; antidiabetic drug–metformin; serotonin reuptake 
inhibitor–fluoxetine; norepinephrine reuptake  
inhibitor–maprotiline; antiepileptic drug–valproic. Inhibitors: 
antibody against EGFR–cetuximab; Class III PI3K  
inhibitors-3-methyadenine, wortmannin and LY294002; 
antimalarial drugs–hydroxychloroquine; vacuolar 
ATPase–bafilomycin A1; lysosomotropic drug–monensin; 
microtubule-disrupting agents–taxanes, nocodazole, colchicine, 
vinca alkaloids; antidepressant drug–clomipramine; antischistome 
agent–lucanthone (autophagosome degradation) .
Electron microscopy, immunohistochemical staining of 
microtubule-associated protein 1 light chain 3 (LC3) 
as a general marker for autophagic membranes, 
monodansylcadaverine staining of autophagic 
vacuoles and protein degradation assays.
Necrosis Morphological features: cell size increases, clumping and random 
degradation of nuclear DNA, cell membrane swelling and  
rupture, swelling of organelles, gain in cell volume (oncosis), 
organelle degeneration mitochondrial swelling and increased 
vacuolation. Activation: hyperactivation of poly(ADP-ribose) 
polymerase 1 (PARP1) enzyme with depletion of β-nicotinamide 
adenine dinucleotide and of ATP, hypoxic injury and oxida-
tive stress (ROS/reactive nitrogen species); chetomin–inhibi-
tor of tumor growth by inducing necrosis in vivo; dimethoxy-
naphthoquinone–generation of ROS and induces apoptosis or 
necrosis; myristoleic acid methyl ester–induces apoptosis and 
necrosis in prostate cancer cells; sterigmatocystin–a mycotoxin 
inhibits DNA synthesis and causes necrosis. Inhibition: necrox-2 
[5-(1,1-dioxo-thiomorpholin-4-ylmethyl)-2-phenyl-1H-indol-
7-yl]-(1-methanesulfonyl-piperidin-4-yl)-amine] and necrox-5 
[5-(1,1-dioxo-thiomorpholin-4-ylmethyl)-2-phenyl-1H-indol-7-yl]-
(tetrahydro-pyran-4-ylmethyl)-amine]–is a cell-permeable necrosis 
inhibitor selectively locks oxidative stress-induced necrosis with 
antioxidant property; tyrphostin AG 126–reduces LPS-induced 
tyrosine phosphorylation of p42MAPK; cyclosporin A–inhibitor of the 
mitochondrial permeability transition pore (MPTP) and prevents 
necrosis; IM-54 (indolylmaleimide derivative)–inhibits necrotic cell 
death induced by H2O2 in promyelocytic leukemia HL-60 cells; PARP 
inhibitor VIII, PJ34 [2-(dimethylamino)-N-(6-oxo-5,6-dihydrophen-
anthridin-2-yl)acetamide hydrochloride]–inhibitor of PARP-1 and 
PARP-2 and inhibits necrosis; IM-54 [2-(1H-indol-3-yl)-3-pentylami-
no-maleimide]—a selective inhibitor of oxidative stress-induced 
necrosis.
Electron microscopy; nuclear negative staining; 
ethidium homodimer III DNA assay; detection of 
inflammation and damage in surrounding tissues.
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endoplasmic reticulum and cytoplasm. Previous studies have 
shown that CASP2 can be activated by DNA damage induced by 
anticancer drugs, such as cisplatin and etoposide, or by ultravio-
let and γ-irradiation, and it is a critically involved in genotoxic 
stress-induced apoptosis (19). CASP2 activation leads to the 
release of cytochrome c, indicating that CASP2 acts upstream 
of mitochondria-mediated intrinsic pathway (20). Moreover, the 
treatment of cells with the CASP2 inhibitor and/or small interfer-
ing RNA to block CASP2 from inducing the release of cytochrome 
c is followed by the activation of CASP9 and 3. Similar to other 
initiator caspases, pro-caspase-2 contains a Caspase Activation 
and Recruitment Domain at the N-terminus. CASP2 recognizes 
a pentapeptide VDVAD for cleavage of target proteins, and its 
known target proteins are BID, PARP, Plakin, Huntingtin and 
DNA fragmentation factor 45. Because CASP2 is activated by a 
proximity-induced self-cleavage mechanism, it obtains proxim-
ity by forming a PIDDosome, which is composed of three protein 
components, PIDD (TP53-induced protein with death domain), 
RAIDD (RIP-associated Ich-1/Ced-3-homolog protein with a 
death domain) and CASP2, whose interaction supported by their 
respective death domains. PIDD death domain can also interact 
with the death domain of receptor-interacting protein-1 kinase 
implicated in the nuclear factor-κB (NF-κB) activation (21). PIDD 
appears to act as a molecular switch, controlling the balance 
between life and death upon DNA damage (Figure 1).
Necrosis and necroptosis
In contrast with apoptosis, necrosis is a genetically controlled 
process; necrosis involves an uncontrolled and progressive loss 
of cytoplasmic membrane integrity, a rapid influx of Na+, Ca2+ and 
water, resulting in cytoplasmic swelling, nuclear pyknosis and the 
release of lysosomal and granular contents into the surrounding 
extracellular space (22). Although the molecular mechanisms 
underlying apoptosis are better understood, little is known about 
the molecular events leading to necrosis. Necrosis has recently 
emerged as an important and physiologically relevant signal-
ing process contributing to ovulation, immune defense, death of 
chondrocytes controlling the longitudinal growth of bones and 
cellular turnover in the intestine (23). In vivo studies indicated that 
removal of interdigital cells in the paws of Apaf1−/− mice during 
embryogenesis occurs by a caspase-independent necrotic-like 
process (24). However, accumulating evidence by many research-
ers suggests that necrosis is not just an unregulated and uncon-
trollable process. Rather, it involves a programmed and actively 
regulated process (aptly named necroptosis), which is regulated 
by the kinase activity of RIPK1 and RIPK3 that form the necro-
some complex (25). This leads to the plasma membrane per-
meabilization, release of cell contents and exposure of damage/
danger-associated molecular patterns (DAMPs), such as HMGB1, 
S100 protein, IL33 and mitochondrial DNA. Under normal physi-
ological conditions, autophagy and the caspase-8-FLIPL-FADD 
platform are apparently gatekeepers preventing necroptosis (26).
The paradoxical role of autophagy in cancer
Autophagy is the basic catabolic mechanism in response to 
starvation or other stressful conditions whereby unnecessary 
or dysfunctional misfolded or aggregated proteins and cellular 
components (e.g. mitochondria, endoplasmic reticulum and 
peroxisomes) are engulfed within double-membrane vesicles 
called autophagosomes and are eventually digested by lyso-
somal enzymes to sustain cellular metabolism (27,28). During 
macroautophagy, a cytoplasmic cargo is delivered to the lyso-
some through an autophagosome, which fuses with the lyso-
some to form an autolysosome. Microautophagy involves the 
inward folding of the lysosomal membrane, which delivers a 
small portion of cytoplasm into the lysosomal lumen. Both 
macro- and micro-autophagy can be either non-selective or 
selective in the removal of large cellular components and pro-
tein aggregates (29). Autophagy involves several key steps for the 
final degradation of cellular components in lysosomes: (i) initia-
tion and nucleation of phagophore; (ii) expansion and matura-
tion of autophagosomes; (iii) fusion of the autophagosome with 
the lysosome to form the autolysosome and (iv) execution of 
autophagy (degradation). These steps are tightly regulated by 
highly conserved Atg genes and non-Atg genes (30). 
Disorders in autophagic signaling pathways are frequently 
observed in cancer patients. Autophagy has been referred to as 
a ‘double-edged sword’ because it acts as an activator of tumor 
cell death (tumor suppression) as well as it plays a part in tumor 
cell survival during tumor development and in cancer therapy. 
Impaired autophagy was shown leading to failure of removing 
damaged protein and organelles, and exerting genomic instabil-
ity and aneuploidy, which promotes tumorigenesis (31–33). The 
loss of BECN1 was found in human breast and ovarian cancers 
(34), whereas Becn1 null mice were shown to be tumor prone 
(35). In contrast, the BECN1 forced expression can inhibit tumor 
development. Additionally, sustained p62 (SQSTM1) expres-
sion, which results from autophagy defects, was found to be 
Figure 1. Apoptotic and non-apoptotic signaling pathways and the involvement of anthropogenic chemicals. 
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important in the promotion of tumorigenesis through de-regu-
lation of NF-κB expression (33). Tumor cells experience elevated 
cytotoxic and metabolic stresses (e.g. hypoxia and deprivation 
of growth factor and oxygen), which can activate autophagy to 
maintain cellular biosynthesis and survival (28). Recent data 
indicate that suppression of autophagic proteins inhibited cell 
growth and conferred or potentiated the induction of cell death, 
indicating that autophagy contributes to cell survival in human 
cancer cells, as well as plays a role in adaptive response of tumor 
cells to anticancer therapies (36). A careful examination of the 
literature shows that an increased level of autophagic markers 
in the dying cell might not be the result of increased autophagic 
flux but due to a blockage of autophagy at its maturation. 
Therefore, the simple determination of numbers of autophago-
somes is insufficient for an overall estimation of autophagic 
activity. It is necessary to distinguish by performing ‘autophagic 
flux’ assays whether autophagosome accumulation is due to 
autophagy induction or, alternatively, a blockade of steps in the 
downstream of autophagosome formation. Now, it is agreed that 
the true meaning of ‘autophagic cell death’ should be cell death 
by autophagy, not cell death with autophagy (Figure 1).
Dysfunctional apoptosis in cancers
The fundamental link between malignancy and apoptosis is 
exemplified by the ability of oncogenes, such as MYC and RAS, 
and tumor suppressors, such as TP53 and RB (Retinoblastoma), 
to actively engage apoptosis as well as the aberrant alterations 
of apoptosis regulatory proteins such as BCL-2 and c-FLIP in vari-
ous solid tumors (37–39). Acquired apoptosis resistance is a hall-
mark of most human cancers. With regard to apoptosis triggers, 
a variety of signals (irradiation, growth/survival factor depletion, 
hypoxia, oxidative stress, DNA damage, cell cycle checkpoints 
defects, telomere malfunction and oncogenic mutations, chemo-
therapeutic agents and heavy metals) appear to provide the selec-
tive pressure needed to alter apoptotic programs during tumor 
development in support of tumor evolution (40–42). The ability of 
tumor cells to acquire resistance to apoptosis is a compensatory 
mechanism, which gives tumor cells a distinct (survival) advan-
tage over normal cells. Defects in apoptosis have been implicated 
in many events relevant to tumorigenesis: (i) cell accumulation 
from the imbalance of cell proliferation and cell death or a fail-
ure of normal turnover process; (ii) permissive cell survival in the 
face of antigrowth signals, for example, hypoxia in tumor mass, 
cell–matrix and cell–cell adherence or contact inhibition; (iii) 
promoting resistance to the killing mechanisms of immune cell 
attack and (iv) fostering tumor metastasis by promoting cell sur-
vival in the circulation under detachment conditions, also known 
as anoikis resistance (43). The importance of this sort of dysfunc-
tion is underscored by the fact that tumor cells that possess 
alterations in proteins involved in apoptosis are often resistant to 
chemotherapy and are more difficult to treat (because anticancer 
drugs primarily work by inducing apoptosis). Tumor cell survival, 
unlike the survival of normal cells, is therefore highly dependent 
on aberrations of apoptosis signaling pathways (37).
Emerging evidence indicates that cancer stem cells (CSCs), 
the rare subpopulation of undifferentiated tumorigenic cells, are 
potential driving force for tumor growth and maintenance (44). 
To date, CSCs have been identified and isolated from various 
solid tumors including the lung, brain, breast, colon and skin. 
These CSCs are highly capable of self-renewal and are able to 
generate a progeny of differentiated cells that constitute a large 
majority of cells in the tumors (45). Most importantly, CSCs are 
apoptosis resistant and very likely responsible for tumor resist-
ance to chemotherapy and irradiation (46). This can be attrib-
uted to the undifferentiated status of CSCs and to the extrinsic 
factors such as the tumor microenvironment and adhesion-
based interactions, which also support their apoptotic resist-
ance (47). Furthermore, the epithelial/mesenchymal transition 
(EMT) mechanism has been found to underlie the CSC charac-
teristics that are linked to anoikis resistance (48). Accumulating 
evidence also suggests that this inherent resistance in CSCs 
shares similar extrinsic and intrinsic apoptotic pathway as nor-
mal stem cells and differentiated cancer cells (49,50).
Regulation of apoptosis in cancer
Evasion of apoptotic pathways allows cells to sustain chronic 
proliferation, which is a hallmark of cancer. Recently, two work-
ing models of apoptosis (both regulated by BCL-2 family and BH3-
only proteins) were reviewed (51). The direct model proposes 
that the activator BH3-only proteins (BIM, BID and PUMA) can 
directly activate BAX and/or BAK oligomerization in addition to 
neutralizing BCL-2-like proteins, whereas the sensitizer BH3-only 
proteins (BAD and NOXA) release activator from activator/pro-
survival protein complex. The indirect model suggests that BAX 
is primed in normal cells by BH3-only protein and bound with 
BCL-2. In excess of pro-apoptotic signaling, BH3-only proteins 
compete with BCL-2 allowing oligomerization of BAX and BAK 
leading to apoptosis (52). The BAX/BAK oligomerization loosens 
the integrity of mitochondria and culminates with mitochon-
drial outer membrane permeabilization facilitating the release 
of cytochrome c into the cytoplasm, which interacts with APAF-
1, and leads to the ATP-dependent formation of apoptosome, 
and the recruitment and activation of the CASP-9, -3 and -7. In 
the absence of APAF-1 and CASP-9, cytochrome c release itself is 
not sufficient to induce apoptosis (53–55). Cytochrome c diffu-
sion and death receptor signaling mediates modulation of XIAP 
by SMAC/DIABLO and OMI/HTRA2, and activation of caspases 
(56) (Figure 1). Up-regulation of XIAP, survivin and down-regula-
tion of APAF-1 has been observed in several tumors.
Cellular stress and DNA damage are regulated through two 
tumor suppressor genes TP53, which induces expression of 
NOXA, PUMA and RB upon various environmental and chemical 
stresses.  Recently, a bona fide tumor suppressor gene neurofi-
bromin 2 (NF2/Merlin) was shown to regulate apoptosis through 
the Hippo pathway (57). RB integrates outside inhibitory signals, 
whereas TP53 senses irreparable damage in genomic integrity, 
intracellular organelles and nucleotides, as well as subopti-
mal level of glucose, and growth inhibitory signals (58). TP53 
activities are tightly regulated by a network of protein–pro-
tein interactions, microRNAs and a range of post-translational 
modifications, including phosphorylation, acetylation, methyla-
tion and ubiquitination (59,60). TP53 activity is suppressed by a 
direct binding of TP53 to murine double minute 2 (MDM2), which 
targets TP53 for proteasomal degradation. NOXA also induces 
apoptosis in TP53/TP73-dependent manner in response to DNA 
damage, whereas PUMA, the most potent pro-apoptotic regula-
tor, induces apoptosis both in a TP53-dependent and -independ-
ent fashion (61–63).
Cellular metabolism is a key for the survival of cells, whereas 
altered metabolism in cells induces either apoptosis or resist-
ance to apoptotic stimuli. Metabolic enzymes and its inter-
mediates from glycolysis, pentose phosphate pathway and 
tricarboxylic acid cycle have shown deregulated in many cancer 
types to provide nicotinamide adenine dinucleotide phosphate 
(NADPH), citrate, acetyl CoA and various other metabolites for 
high demand of biosynthesis and proliferation (64). Chronic pro-
liferating cells short circuit their metabolic pathways and mostly 
depend on aerobic glycolysis to sustain the massive biosynthe-
sis of intracellular structures. Various post-translational modi-
fication regulates cellular growth especially phosphorylation 






K.B.Narayanan et al. | S95
and acetylation and increase apoptotic sensitivity. Metabolic 
intermediates also regulate pro- and anti-apoptotic regulators 
(BCL-2 family protein). Perturbations in acetyl-CoA production 
may extend to other oncogenic contexts beyond that of BCL-xL 
(65–67). Redox status of tissues/cells affects their sensitivity to 
cytochrome c. Reduced glutathione mostly produced by NADPH 
inactivates cytochrome c, whereas apoptotic agents produce 
ROS to activate cytochrome C and apoptosis (68). Key regulatory 
metabolic enzymes, which affect apoptosis (e.g. hexokinase, 
fructose 2,6-bisphosphate kinase, lactate dehydrogenase M and 
pyruvate dehydrogenase kinase), are also implicated in cancer 
(55). Growth factors/cytokines regulate pro-survival signaling by 
RAS- and PI3K-AKT pathways through cognate receptor tyrosine 
kinase (RTK). Most human cancers harbor mutations in AKT and 
PTEN, which leads to AKT activation and resistance to apopto-
sis (69,70). Death receptor signaling triggers the recruitment of 
FADD and TRADD adapter proteins to induce dimerization of 
CASP-8 and subsequent activation of CASP-3 and -7. In some cell 
types, CASP-8 directly cleaves BH3-only protein BID to localize it 
to the mitochondria and activate BAX (71).
Additionally, ‘anoikis’, the detachment of cells, is another 
major regulator of apoptosis. The detachment of adherent cells 
(loss of critical interaction between the cell and the extracellu-
lar cell matrix) leads to apoptosis due to the loss of integrin α-5 
or β-5 signaling and the loss of focal adhesion kinase, a reduc-
tion of talin–integrin interaction, and of c-Jun N-terminal kinase 
signaling (72).
Oncogenes, tumor suppressor genes and apoptosis
Human health is continuously challenged by exposure to a wide 
range of environmental chemicals that affect DNA integrity (73). 
When DNA repair capacity is exhausted, DNA damage accumu-
lates in cells at a higher level, and this excess damage causes an 
increased frequency of mutation and/or epigenetic alterations 
of specific genes (oncogenes and tumor suppressors) resulting 
in the disruption of the cellular networking that controls cellu-
lar homeostasis and leads to cellular transformation and cancer 
development (74). The inactivation of expression of tumor sup-
pressor genes via genetic and epigenetic changes (DNA hyper-
methylation, histone deacetylation/methylation and microRNA 
targeting) often leads to tumor initiation and progression, 
whereas amplification and overexpression of oncogenes result 
in the similar tumorigenic phenotype (75). Tumor suppressor 
‘driver’ genes include: genes for retinoblastoma protein (RB), 
tumor protein TP53 (TP53), BRCA1 and 2, PTEN, VHL, APC, CD95, 
ST5, 7 and 14, YPEL3, whereas ‘driver’ oncogenes include: growth 
factors (e.g. C-SIS, WNT), RTKs (EGFR, PDGFR, VEGFR, TRK, ERBB2), 
cytoplasmic tyrosine (SRC, ABL and BTK) and serine/threonine 
(ATM, MTOR, ERK, PI3KCA, AKT1, 2 and 3, LKB1 and RAF) kinases, 
transcriptional factors (MYC and E2F), GTP-ases (RAS) and oth-
ers (CCND1), as reviewed by Lee et al. (74). Discovery of microRNA 
genes added new members to both tumor suppressor (e.g. miR-
34a) and oncogene (e.g. miR-17–92) families (76).
As part of the DNA damage response to genotoxic stress, 
apoptosis is triggered by chemical-induced DNA lesions and 
represents a first line of defense allowing the organism to elimi-
nate damaged cells. Notably, cells respond to stress-induced 
DNA damage by increasing their levels of TP53 (77). The wild-
type TP53 prevents cancer formation through the activation of 
cell cycle arrest or apoptosis via transcriptional regulation of 
hundreds of specific gene targets or via multiple protein–pro-
tein interactions. TP53 and its evolutionary older relatives, TP63 
and TP73, exhibit a similar modular structure and share signifi-
cant structural and functional homologies; however, their tumor 
suppressive role is not as straightforward as TP53. Genes for all 
TP53 family members produce proteins with the transactivation 
domain displaying a tumor suppressive function and proteins 
without transactivation domain acting as oncoproteins (78). 
TP53 is mutated in >50% of human cancers, whereas in other 
cancers, its function is compromised by de-regulation of the 
TP53 pathway. Both TP63 and TP73 are rarely mutated or epi-
genetically altered in human cancers. Tp53−/− mice develop 
tumors with short latency and 100% penetrance (77). Tumor 
suppressive function for TP73 was confirmed using Tp73−/− 
mice (79). Tp53+/− and tp63+/+ mice are less cancer prone than 
Tp53−/− and tp63+/− mice, respectively. 
The synergistic effects of the TP53 family members in tumor 
suppression were highlighted using mice heterozygous for 
mutations in both TP53 and TP63, or TP53 and TP73 displaying 
higher tumor burden and metastasis, compared with tp53+/− 
mice (80). Accumulating data show that TP53 family proteins 
can regulate cell survival via cell cycle arrest, senescence and 
apoptosis and are abnormally expressed in different cancer 
types (breast tumors, acute myeloid leukemia, head and neck 
tumors, melanoma, renal cell carcinoma, colon, ovarian and 
lung tumors) suggesting that their differential expression may 
disrupt the TP53 response and contribute to tumor initiation/
progression and linked to cancer prognosis and treatment (78).
Although mutations of TP63 mutations are almost non-exist-
ent in human cancers, >80% of primary head and neck squamous 
cell carcinomas, other squamous cell epithelial malignancies 
and non-small cell lung cancer retain TP63 expression, where 
it is often over-expressed and occasionally amplified. The TP63 
expression strongly influences the tumor cell response to gen-
otoxic stress (81). TP63 activates death domain receptor- and 
mitochondria-mediated apoptosis pathways, which are clearly 
reinforced by concomitant treatment with genotoxic stress. 
However, ΔNp63α confers resistance to apoptosis via a transcrip-
tional regulation of AKT1, as well as via down-regulation of sev-
eral microRNAs (miR-181a, -519a and -374a) and up-regulation 
of miR-630, which targets proteins involved in cell cycle arrest 
and apoptosis for down-regulation, hence conferring tumor cell 
chemoresistance (82,83). It is likely that apoptosis sensitivity to 
genotoxic agents may be determined not only by TP53 but also 
by TP73 and TP63 function, and its isoforms (84).
The disruption of normal cell death
From a disruption standpoint, the inactivation or attenua-
tion of the TP53 apoptotic response, achieved by mutations or 
epigenetic alterations, is known to promote cell transforma-
tion (77). For example, non-polycyclic aromatic hydrocarbon 
components present in tobacco smoke condensate are able to 
attenuate the TP53 apoptotic response, as suggested by studies 
in mouse epidermal cells (78). The transcription factor C/EBPβ, 
which is induced by cigarette smoke has also been involved 
in TP53 repression (85,86). Following a prolonged exposure 
to environmental chemicals, bulky DNA adducts may not be 
removed by DNA repair mechanisms but converted into muta-
tions. Subsequent DNA replication cycles may lead to hot spot 
mutations in key growth regulatory genes, thereby resulting in 
malfunction of tumor suppressor genes and amplification/over-
expression of oncogenes (74). 
Similarly, mutated RAS oncogenes were found in the experi-
mental tumors of rodents that had been exposed to chemical or 
physical compounds, as well as in many human cancers (87). For 
example, exposure to hydrocarbon solvents has been associated 
with an increased risk of exocrine pancreatic cancer, the human 
tumor with the highest prevalence of K-RAS mutations (88). And 
heterocyclic amines have been implicated in both initiation and 
maintenance of breast tumorigenesis mediated by upregulated 
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H-RAS expression, ERK pathway activation, NOX1 expression and 
elevation of ROS (89). Although the sustained activation of the 
NF-κB transcription factor is another important element involved 
in chemical tumorigenesis, tobacco, alcohol, high-fat diet, envi-
ronment pollutants, cancer-causing viruses (human papillomavi-
rus, hepatitis B and C viruses, human immunodeficiency virus and 
bacteria (Helicobacter pylori), ultraviolet light, ionizing radiation, 
obesity and oxidative stress are all potent NF-κB stimuli (90,91). 
The following proteins: pro-inflammatory proteins (cyclooxyge-
nase-2, inducible nitric oxide synthase, TNF, interleukin-8); prolif-
erative/pro-survival factors (bone morphogenetic proteins, stem 
cell factor, vascular endothelial growth factor, granulocyte–mono-
cyte colony stimulating factor) and antiapoptotic proteins [TRAF-1 
and -2, the CASP-8 inhibitor (FLIP), IAPs, XIAP, BCL2 and its homo-
logues and matrix metalloproteinases] are overall involved in 
tumor promotion, initiation and progression (92).
The critical research gaps for a clear understanding of chem-
ical carcinogenesis include the following:
1. Understanding how genetic modifications by low-dose 
environmental mixtures can disrupt/overcome normal cell 
death.
2. Understanding the molecular processes and pathways 
activated/blocked by individual chemicals and mixture of 
chemicals with disruptive potential.
3. Understanding the low-dose effects of environmental 
chemicals (single and mixtures) on cell death within differ-
ent tissues and organs of human.
4. Clearly distinguishing the differences between the contri-
butions of both carcinogenic and non-carcinogenic chemi-
cals (individually and in mixtures) in environmental car-
cinogenesis by experimental methods.
Key target sites for disruption
In this review, we wanted to look at several key target sites that 
disrupt normal cell death and potentially have relevance for envi-
ronmental carcinogenesis. It is generally agreed that many can-
cers arise from a single cell that has accumulated genetic and 
epigenetic mutations of a few crucial genes of proto-oncogenes 
and tumor suppressors, and that this is caused by random errors 
in DNA replication or a reaction of the DNA with free radicals or 
other chemical species of endogenous or exogenous origin (93). 
However, we also know that chemicals with disruptive potential 
are capable of a wide range of additional cellular level effects that 
are relevant to cancer (94), and the general population now faces 
ongoing exposures to thousands of environmental chemicals that 
are present in consumer products, our food, our water and in the 
air (95). At the same time, regulators worldwide have remained 
largely focused on the effects of single chemicals while placing 
very little emphasis on the effects of exposures to mixtures of 
chemicals in the environment (96). Accordingly, in this review, we 
emphasize the pivotal and enabling role that resistance to cell 
death plays in carcinogenesis and we highlight some of the key 
mechanisms and pathways that can be chemically disrupted (i.e. 
in a manner that results in dysfunction of normal cell death rou-
tines) and that have the potential to be supportive of the emer-
gence of an immortalized cellular phenotype.
To that end, we first identify and review a number of key tar-
gets of this nature that have been shown to be active sites for 
chemical disruption in the past as follows:
Binding to ERα
Given that many anthropogenic agents are xenoestrogens, a 
considerable amount of environmental health research has 
focused on ER level disturbances (97). Many xenoestrogens 
binds to ER and either activates it or inhibits it. ERα activation 
stimulates cell proliferation and initiates cancer through tumor 
promotion, whereas the activation of ERβ stimulates terminal 
cell differentiation and disrupts cancer progression, which is 
an anticancer effect. For example, many of the organochlorine 
(OC) pesticides such as lindane or their metabolites fall into the 
category of xenoestrogens that disrupt endocrine processes by 
acting as agonists of ERα and/or antagonists of ERβ and by exert-
ing antiandrogenic effects (by binding to androgen receptors). 
ERα and tumor suppressor protein p53 exert opposing effects 
on cellular proliferation. ERα’s repression of p53-mediated cell 
death has been widely investigated, especially in breast cancer 
(98), but emerging evidence suggests a much more complex role 
for ERα-controlled pathways in other tumor-related phenom-
ena. ERα interacts with p53 bound to promoters of Survivin and 
multidrug resistance gene 1(MDR1), and inhibits p53-mediated 
transcriptional repression of these genes in human cancer cells 
in vivo. It was found that p53 is necessary for ERα to access the 
promoters and there is cross-talk between the pathways medi-
ated by ERα and p53 (99). It has been also been shown that an 
increase of ERα messenger RNA (mRNA) level in ERα-positive 
breast cancer is associated with de-regulation of metabolism, 
which produce a complementary effect on cell differentiation 
and proliferation (100). On the other hand, evidence of ERα’s 
role in the EMT has also been reported. In endometrial carci-
nomas and breast cancer, ERα’s activity is negatively associated 
with the activation of EMT via the Wnt, Sonic Hedgehog and 
transforming growth factor-β (TGF-β) signaling (101,102). EMT 
involves the loss of cell–cell adhesion and a consequent increase 
in mobility and invasiveness. It has been proposed that ERα acts 
to promote invasive growth in breast cancer cells by a direct, 
ERα-dependent expression of metastasis-associated genes, such 
as the MTA-3 protein. It is important to note that a physiological 
feedback mechanism regulates the efficiency of ERα activation 
through the state of cell–cell interactions that are mediated by 
E-cadherin (103). Although EMT promotes a decrease in cellular 
contacts, it also inhibits ERα transcription thus limiting its own 
ERα-dependent activation. Although no effects on genetic insta-
bility and immune system evasion of systematic ERα activation 
have been reported, the synergy of action involved in these dif-
ferent (deregulated) pathways may be very important for cancer 
onset and progression. 
Gap junctional intracellular communication
In addition to tumor promotion ability, some environmental 
chemicals directly or indirectly cause DNA mutations through 
free radical production (ROS/reactive nitrogen species) and may 
cause both tumor initiation and tumor promotion by inhibiting 
GJICs and connexins (Cxs) (104,105).  Blockage of GJIC between 
the normal and the pre-neoplastic cells creates an intra-tissue 
microenvironment in which tumor-initiated pre-neoplastic cells 
are isolated from growth controlling factors of normal surround-
ing cells resulting in clonal expansion (106). Gap junction chan-
nels and Cxs control cell apoptosis by facilitating the influx and 
flux of apoptotic signals between adjacent cells and hemi-chan-
nels between the intracellular and extracellular environments. 
Recently, it has also been demonstrated that Cx proteins in con-
junction with their intracytoplasmic localization, may act as 
signaling effectors that are able to activate the canonical mito-
chondrial apoptotic pathway (107). Tumor-promoting chemicals 
such as phenobarbital, dichlorodiphenyltrichloroethane (DDT) 
and 12-O-tetradecanoylphorbol 13-acetate block apoptosis and 
also block GJIC, whereas several antitumor chemicals, such 
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as retinoids and dexamethasone, increase GJIC and increase 
apoptosis. So, it has been hypothesized that GJIC is necessary 
for apoptosis and blockage of apoptosis with chemicals/car-
cinogens could therefore promote the initiation of premalignant 
cells in tumorigenesis (108). For example, knockdown of con-
nexin 43 (Cx43) had an inhibitory effect on GJIC and resulted 
in a reduction of cell death after treatment with cisplatin and 
Salmonella (109), and Kang et al. (105) reported on the inhibition 
of GJICs in normal human breast epithelial cells by pesticides, 
polychlorinated biphenyls, polybrominated biphenyls and halo-
genated hydrocarbons (when given as single compounds or as 
mixtures), and suggested that they may contribute to carcino-
genesis through this mechanism.
Peroxisome proliferator-activated receptor-α
PPAR-α receptors are mainly found in the liver and belong to the 
steroid hormone receptor superfamily that functions as a tran-
scription factor for genes involved in glucose, lipid and amino 
acid metabolism, and that also induces enzymes involved in the 
metabolism of xenobiotics. Upon ligand binding, PPARs heter-
odimerize with the retinoid X receptor and bind to the specific 
promoter sequence and trigger the expression of target genes 
(110). A  variety of chemicals including certain herbicides and 
plasticizers induce peroxisome proliferation with increased rep-
licative DNA synthesis, suppression of apoptosis and increased 
expression of peroxisomal acyl-CoA oxidase in rodent liver and 
other tissues. In rodents, these peroxisome proliferating chemi-
cals act as non-genotoxic carcinogens that promote the devel-
opment of tumors (111). Chemicals of industrial importance 
such as diethylhydroxylamine and chlorinated solvents are per-
oxisome proliferators (PP) that induce elevated S-phase in rat 
and mouse and play an important role in hepatocarcinogenicity. 
The molecular mechanisms of altered expression of cell cycle 
regulatory proteins resulting in the elevation of S-phase, and 
suppression of apoptotic cell death and induction of prolifera-
tion are evidenced by the activation of PPAR-α and survival sign-
aling by p38 MAPK in hepatocellular carcinomas (112).
Hypersecretion of LH by gonadotroph cells in pituitary gland 
Neuroendocrine disruptors are environmental pollutants that 
are agonists/antagonists or modulators of the synthesis and/or 
metabolism of neurohormones, neuropeptides and neurotrans-
mitters. Sustained hypersecretion of LH occurs following the 
disruption of the hypothalamic–pituitary–testicular axis. The 
tumorigenic response to a chemical in an endocrine tumor is 
generally dose responsive. As the dose of environmental chemi-
cal increases, the extent of perturbation of normal endocrine 
homeostasis increases resulting in a stronger trophic stimulus 
to the target cell (113). LH up-regulates the expression of apop-
totic inhibitor, survivin in a dose-dependent manner via ERK1/2 
signaling pathway and inhibits apoptosis in ovarian epithelial 
tumors in vitro (114).
p53 
As noted previously, p53 is a tumor suppressor gene and has 
been described as the ‘guardian of the genome’. p53 is a tran-
scriptional activator regulating the expression of Mdm2 (nega-
tive regulator of p53) and genes involved in growth arrest (p21, 
Gadd45 and stratifin), DNA repair (p53R2) and apoptosis (Bax, 
Apaf-1, PUMA and NoxA). Its activity disrupts the formation of 
tumors by arresting growth and inducing apoptosis. This 53 kDa 
phosphoprotein induces apoptosis by stimulating BAX and FAS 
antigen expression, or by repression of BCL-2 expression. p53 
mutations are found in most of the tumors and contribute to the 
complex molecular network events leading to tumor formation. 
Notably, the progression of cancers which overcome cell death 
[via the inactivation of tumor suppressor genes (p53) and acti-
vation of oncogenes (c-Ha-ras)] after exposures to organophos-
phorus pesticides is also associated with an increase in genome 
instability (115). Accordingly, one the most important candi-
dates, as a key regulator of malignant transformation, is P53. 
Somatic mutations of this gene or perturbations in its pathways 
are among the most frequent alterations in human cancers 
(116). Arguably, the most important decision maker in cellu-
lar process that unfold in response to every kind of stress and 
harm, P53 is involved in cell cycle arrest, apoptosis, regulation of 
metabolism, DNA repair and every pathway connected to them. 
Its action is therefore opposed to evasion from growth control, 
genetic instability, sustained proliferative signaling and cellular 
motility, whereas it can be an important promoter of metabolic 
changes and even replicative immortality. Cross-talk between 
P53 pathways and most molecular mechanisms that trans-
duce external signals (to promote or inhibit cell proliferation) is 
branched and efficient so chemical disruptors that systemati-
cally impair P53 can readily produce harmful effects on almost 
all of the hallmarks involved in malignant transformation.
p16/p53
p16INK4A (p16) and p53 are tumor suppressor genes (antionco-
genes). p16 is known as cyclin-dependent kinase (CDK) inhibi-
tor and specifically blocks the activity of CDK4 and CDK6. The 
binding of 16 kDa protein p16INK4A to CDK4 inhibits the phos-
phorylation of retinoblastoma protein (pRB) and subsequently 
inhibits the transcription factor (E2F), the release and arrest of 
the G1 phase of cell cycle and the suppression of cellular pro-
liferation. p16 also inhibits the growth of breast cancer cells by 
inhibiting the VEGF signaling pathway and angiogenesis. And 
recently, it has been demonstrated that the anticancerous abil-
ity of p16 is additionally attributed to its ability to induce tumor 
cells to enter senescence. It also induces apoptosis both in vitro 
and in vivo (117). The functional or structural loss of p16INK4A 
therefore leads to the cell cycle propagation of genetically dam-
aged/mutated cells and increases the subsequent risk of tumor 
development. p16 is encoded by INK4a gene and an alternative 
reading frame of INK4a transcribes to p14ARF, which mediates 
the link between p16 and p53 pathways. So, loss of the INK4a 
gene disrupts p16INK4A/CDK4/6/pRB and p14ARF/MDM2/p53 path-
ways, which controls cell proliferation (118). Notably, the p16 
locus was found to be inactivated in many cancers such as lung, 
breast, melanoma, pancreatic, brain and >80% of squamous cell 
carcinoma of the head and neck tumors (119). Thus, p16INK4A, 
p14ARF and p53 genes involved in cell cycle pathways are major 
targets of inactivation in carcinogenesis. Occupational exposure 
to chemicals and metal dusts form ROS and reactive nitrogen 
species in humans through oxidant-mediated responses, which 
causes hypermethylation of p16INK4A and p53 along with the acti-
vation of MAP kinase to induce carcinogenesis.
BCL-2/p53 
BCL-2 is a proto-oncogene, which regulates cell cycle progres-
sion and apoptosis (antiapoptotic), whereas p53 is a tumor sup-
pressor gene. BCL-2 constitutively suppresses p53-dependent 
apoptosis. The BCL-2/p53 axis requires pro-apoptotic protein 
(Bax) and the effector molecule (CASP-2) as essential apop-
totic mediators following the silencing of Bcl-2 or Bcl-xL. p53 
possesses pro-apoptotic properties that appear to be constitu-
tively active despite its suppression by Bcl-2 (120). Both p53 and 
Bcl-2 are strong predictors of recurrence and survival in rectal 
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cancer (121). And the chemical 7,12-dimethyl benz-(a)-anthra-
cene induces tumor growth in breast cancer that is apparently 
due to the inactivation of p53 aided by the absence of Bcl-2 (122).
ErbB-2/HER-2 tyrosine kinase 
The human epidermal growth factor receptor (EGFR/HER) family 
consists of ErbB/HER lineage of receptor proteins (ErbB1–4) as it 
shows similarity to the v-ErbB oncogene of avian erythroblasto-
sis virus (123). The ErbB-2/HER protein tyrosine kinase receptor 
contains an extracellular domain followed by a single trans-
membrane segment and intracellular tyrosine kinase activity, 
which regulates cell growth and differentiation particularly 
during embryogenesis (124). Overexpression of ErbB2/HER2 is 
related with cancer. Binding of epidermal growth factor ligands 
to their cognate ErbB receptors induces homo- or hetero-dimer-
ization of ErbB2 and autophosphorylation of phosphotyrosine 
residues in the cytoplasmic domain, which serve as docking 
sites for adaptor proteins to downstream signals for growth and 
survival. Up-regulation of PI3K/AKT signaling pathway is found 
in ErbB2+ breast cancers, where it exerts pro-survival effects 
overcoming cell death (125).
The PI3K/AKT/mammalian target of rapamycin (mTOR) 
pathway is important for cell growth and survival, and it is 
also frequently activated in cancer. PI3Ks are a family of intra-
cellular signal transducer enzymes involved in many cellular 
functions such as cellular growth, proliferation, differentiation 
and survival playing an important role in tumorigenesis (126). 
Upon activation of the RTKs by growth factors, PI3Ks con-
vert phosphatidylinositol-4,5-biphosphate into phosphati-
dylinositol-3,4,5-triphosphate, which provides docking sites 
for pleckstrin homology domain containing proteins, includ-
ing phosphoinositide-dependent kinase-1 and protein kinase 
B.  This conversion is mainly controlled by the phosphatase 
and tensin homolog (PTEN), which dephosphorylates PIP3 
into phosphatidylinositol-4,5-biphosphate, thereby regulat-
ing the uncontrolled activation of AKT pathway. Loss of PTEN 
tumor suppressor is common in malignancies and correlates 
with increased AKT activity. AKT is activated by phosphoryla-
tion of Thr308 by phosphoinositide-dependent kinase-1 (PDK1) 
and Ser473 by the mammalian target of rapamycin complex 2 
(mTORC2). Activated AKT phosphorylates glycogen synthase 
kinase 3, forkhead box transcription factors, BCL-2 family 
members and the tuberous sclerosis complex (TSC1/2) thereby 
regulating a range of pathways involved in protein synthesis, 
proliferation, metabolism and apoptosis (127).
The mTOR pathway is the main target of the rapamycin, a 
natural compound produced by the Streptomyces hygroscopicus, 
which displays potent immunosuppressant and antiprolif-
erative properties. The mTOR pathway integrates stimuli from 
diverse upstream pathways including the PI3K/AKT pathway 
and is responsible for the synthesis of a wide range of proteins 
involved in cell growth, proliferation, survival and tumorigen-
esis. mTOR can act in complex with Raptor (mTORC1) or Rictor 
(mTORC2) and these complexes regulate entirely different pro-
grams in the cell. When activated, mTORC2 activates and stabi-
lizes AKT by its phosphorylation at Ser473, and controls actin 
cytoskeleton organization and cell migration, whereas mTORC1 
increases mRNA translation by phosphorylation of the down-
stream molecules p70S6K (S6K) and 4E binding protein 1 (4EBP1). 
Phosphorylation of p70S6K leads to mRNA biogenesis, transla-
tion of ribosomal proteins and cellular proliferation. 4EBP1, in 
the hypophosphorylated state, binds the eukaryotic initiation 
factor 4E preventing its binding to eIF4G, and thereby to form 
the translational initiation complex eIF4F. Once phosphorylated, 
4EBP1 is unable to bind to eukaryotic initiation factor 4E, which 
results in increase of translation of proteins related to cell pro-
liferation and viability (128,129).
AKT activation affects components of the apoptosis regula-
tory machinery, including the BCL-2 family, the caspase family 
or the function of death domain receptors. AKT directly phos-
phorylates the BAD protein, which is a pro-apoptotic member 
of the BCL-2 family, whereas the dephosphorylated BAD pro-
motes apoptosis (130,131). AKT might also prevent apopto-
sis by phosphorylation and inactivation of glycogen synthase 
kinase-3, CASP-9 and indirect activation of NF-κB leading to 
the altered transcription of pro-survival genes (e.g. IAP1, IAP2), 
as reviewed in refs 132–134. The mTOR pathway has also been 
linked by several studies to play a role in cell death by apoptosis 
and autophagy (135). One of the proposed pathways by which 
mTOR regulates autophagy was discovered in studies from yeast 
essential autophagy genes (Atgs), as reviewed in ref. 136. Atg1/
Atg13/Atg17 complex is required for maximal catalytic activ-
ity of mTOR leading to Atg13 phosphorylation, subsequently 
destabilizing the complex and inactivating Atg1. In the mam-
malian cells, unc-51-like kinase 1 (ULK1) and focal adhesion 
kinase interacting protein of 200 kD (FIP200) form the complex 
with mammalian ATG13. mTORC1 activation correlates with 
the phosphorylation of ULK1-ATG13-FIP200 complex and inhi-
bition of autophagy. Activation of P70S6k by mTOR may block 
apoptosis by increasing antiapoptotic BCL-2/BCL-xL protein 
expression and inactivating the pro-apoptotic protein BAD (137). 
In human prostate cancer cell lines, ErbB-2 kinase activity was 
increased by OC insecticides such as lindane, DDT and fungicide 
chlorothalonil. DDT induces cellular proliferation of the andro-
gen-dependent human prostate cancer cell line LNCaP by phos-
phorylation of MAP kinase. However, no proliferative effect was 
induced in androgen-independent PC-3 cell line (138).
Mitogen-activated protein kinase 
MAPK are serine/threonine kinases that transduce extracel-
lular signals from a diverse range of stimuli and elicit cellular 
responses such as proliferation, differentiation, survival, migra-
tion, development, inflammatory responses and apoptosis. In 
mammalian cells, three MAPK families have been characterized 
namely classical MAPK (ERK), C-Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK) and p38 kinase. MAPK 
pathways involve a series of protein kinase cascades, and each 
cascade consists of more than three enzymes that are activated 
in a series: a MAPK kinase kinase (MAPKKK/MAP3K), a MAPK 
kinase (MAPKK/MAP2K/MEK) and a MAP kinase (MAPK) (139). 
MAPK has a pleiotropic role in cancer, especially p38 and JNK 
MAPK pathways that are involved in the cross-talk between 
autophagy and apoptosis induced by genotoxic stress. p38 
MAPK plays a dual role in genotoxic stress-induced apoptosis. 
Rottlerin-induced apoptosis of HT29 colon carcinoma cells was 
contributed by the up-regulation of non-steroidal anti-inflam-
matory drug activated gene-1 (NAG-1) via a p38 MAPK-dependent 
mechanism (140). However, under certain circumstances, it also 
involved in mediating resistance to apoptosis. The phospho-
rylation of p38 significantly increased the resistance to doc-
etaxel-induced apoptosis in prostate cancer cells (141). And the 
suppression of p38 MAPK reversed the overexpression of micro 
RNA-214, which is linked to the radiotherapy resistance of non-
small-cell lung carcinoma cells (142). It also regulates autophagy 
both as a positive and negative regulator. Platinum compounds 
such as E-platinum induced autophagic cell death in gastric 
carcinoma BGC-823 cells via suppression of mTOR by decreas-
ing phosphorylation of p38 MAPK (143). On the other hand, 
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suppression of the p38 signaling pathway induced autophagic 
and necroptotic cell death in TNFα-treated L929 cells. JNK MAPK 
promotes the phosphorylation of c-Jun and activating transcrip-
tion factor-2 (ATF-2) resulting in the activation of AP-1 and the 
expression of Fas/FasL signaling pathway proteins, which sub-
sequently activate effector caspase 3 and trigger apoptosis (144). 
JNK activation is associated with transformation in many onco-
gene and growth-factor-mediated pathways, whereas p38 MAPK 
activation involves in cell differentiation processes such as adi-
pocytes, erythroblasts, myoblasts, cardiomyocytes and neurons. 
Regulation of the cell cycle is critical in cellular proliferation 
and development of multicellular organisms, and abnormalities 
in MAPK signaling play a critical role in the development and 
progression of cancer. MAP kinases are reported to be involved 
in several pathological conditions such as cancer and other 
diseases. MEK4/MKK4 is involved in stress-activated pathways 
such as JNK, and p38 is consistently inactivated by mutation in 
many cancers including cancers of the ovary, breast, pancreas, 
bile duct, lung, colon and testes (145).
ERK/MAPK 
ERK pathway is a well-characterized MAPK signaling cascade 
with the Raf-MEK-ERK pathway. The stimulation of RTKs initi-
ates the multistep cascade process resulting in the phospho-
rylation of p44MAPK (ERK1) and p42MAPK (ERK2) and increasing 
its enzymatic activity. The activated ERKs translocate into the 
nucleus and transactivate many transcription factors and regu-
late expression of genes to promote cell growth, differentiation 
or mitosis (139). It also regulates post-translational regulation of 
the assembly of cyclin D-cdk4/6 complexes, which subsequently 
phosphorylates the RB protein causing the activation of tran-
scription factor E2F and regulates the genes involved in G1/S 
progression of cell cycle.  In human hepatocytes, TGF-β induces 
apoptosis by the up-regulation of Rac-independent NADPH oxi-
dase NOX4 mediating the production of ROS, which precedes 
the loss of mitochondrial transmembrane potential, cytochrome 
c release and caspase activation, for an efficient mitochondrial-
dependent apoptosis (146). However, NOX4 up-regulation was 
inhibited by intracellular antiapoptotic signals such as PI3K and 
ERK/MAPK pathways. The overactivation of the MEK/ERK path-
way in hepatocellular carcinoma HCC cell line confers resist-
ance to TGF-β-induced apoptosis by impairing the up-regulation 
of the NADPH oxidase NOX4 expression (147). De-regulation of 
ERK activity is common in cancer leading to proliferation, migra-
tion, resistance to apoptosis and loss of differentiated pheno-
types. In particular, cancerous mutations are mostly affecting 
Ras and B-Raf along with the overexpression of EGFR and ERBB2 
in the ERK-signaling pathway. ERK signaling also plays a crucial 
role in disrupting the antiproliferative effects of ligands such as 
TGF-β (145). OC pesticides or their metabolites (endosulfan, diel-
drin and DDE) and p-nonylphenol, a detergent by-product from 
plastic manufacturing, all produced dose-dependent ERK-1/2 
phosphorylation in a pituitary tumor cell line GH3/B6/F10, which 
expresses high levels of membrane receptors for ER-α (148).
Environmental chemicals that confer resistance to 
cell death
In this review, we wanted to further consider the possibility that 
low-dose exposures to combination of environmental chemicals 
might have a role to play in environmental carcinogenesis. To 
that end, we developed a list of environmental chemicals that 
had been shown to act disruptively on the key target sites men-
tioned previously. Specifically, we sought to identify chemicals 
that were ubiquitous in the environment and not known to 
be carcinogenic, or classified as carcinogenic to humans. We 
focused on bisphenol A  (BPA), chlorothalonil, dibutyl phtha-
late (DBP), diethylhexyl phthalate (DEHP), dichlorvos (DDVP), 
lindane, methoxychlor (MXC), linuron, and oxyfluorfen. These 
reported actions of these chemicals on these important target 
sites are described below. 
Bisphenol A 
Ubiquitous environmental anthropogenic chemicals such as BPA 
(4,4ʹ-(propane-2,2-diyl)diphenol) and phthalates are commonly 
found in consumer products, and act as obesogens by disrupting 
the metabolic homeostasis pathway. This involves the activation 
of PPARγ, which is a critical regulator of fat formation and also 
regulates lipid, glucose and energy in humans. BPA in particular 
is an estrogenic mimic which does not cause mutations per se, 
but increases breast cancer incidence (149–151). BPA-exposed to 
HRBEC cell lines and T47D breast cancer cells showed markedly 
reduced pro-apoptotic negative regulators of the cell cycle (p53, 
p21WAF1 and BAX) with concomitant increases in proliferation 
initiating gene products (proliferating cell nuclear antigen, cyc-
lins, CDKs and phosphorylated pRB). It also induced an increase 
in the ERα: ERβ ratio (152). In addition, TP53 loss of function pro-
moted activation of mTOR pathway, together with PI3K, AKT and 
4EBP1 and, concurrently, PTEN was suppressed which resulted 
in enhanced cell growth and proliferation, and ultimately breast 
tumorigenesis (153). Besides increasing the risk of breast cancer, 
BPA neutralizes the effects of tamoxifen, undermining a widely 
used preventive measure to control disease. It has been shown 
that BPA affects the P53 pathway, inducing a prominent evasion 
of apoptosis coupled by an increased proliferation (152), and the 
GPER/EGFR/ERK pathway influencing proliferation and migra-
tion (154). This action seems to be delivered mainly through a 
substantial activation of mTOR pathways and a negative regula-
tion of pro-apoptotic proteins like P53, P21 and BAX. In a num-
ber of cases, this BPA-induced cellular misbehavior persists even 
after BPA has been removed thus providing additional evidences 
of the chronic potential of this chemical disruptor. BPA has also 
been shown to disrupt double-strand break repair machinery 
in vivo suggesting that consistent environmental exposure to 
BPA may severely and dangerously affect the stability of DNA in 
mammalian cells (155). And BPA exerts a pro-metastatic influ-
ence in at least one mouse model of mammary carcinogenesis 
(156).
Chlorothalonil 
Chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile) is a broad-
spectrum, non-systemic, OC pesticide (fungicide). It is used to 
control pathogenic fungi that attack vegetables, fruits, trees and 
agricultural crops. It is predominantly used on peanuts, potatoes 
and tomatoes and as an antifungal additive in paints, emulsion 
and resin. The carcinogenicity of chlorothalonil was evalu-
ated in rodents, and the studies have shown evidence of renal 
tubular carcinomas and adenomas, and stomach tumors (157). 
Chlorothalonil up-regulates the expression of ErbB-2 tyrosine 
kinase and MAP kinase leading to cell proliferation in a prostate 
cancer cell line (138). Chlorothalonil readily reacts and conju-
gates with glutathione in the liver, and chlorothalonil metabo-
lites consist of a mixture of di- and tri-glutathione conjugates, 
cysteine S-conjugates and mercapturic acids. In the proximal 
tubules of kidney, glutathione conjugates are completely cleaved 
by enzymes γ-glutamyl transpeptidase and dipeptidases to the 
cysteine S-conjugates, which are further cleaved by enzyme 
β-lyases to the corresponding thiol derivatives. The production 






S100 | Carcinogenesis, 2015, Vol. 36, Supplement 1
of thiol derivatives is thought to be responsible for the toxicity 
seen in the kidneys (158). In a eukaryotic system, chlorothalonil 
reacted with proteins and decreased cell viability by formation 
of substituted chlorothalonil-reduced glutathione (GSH) deriva-
tives and inhibition of specific NAD thiol-dependent glycolytic 
and respiratory enzymes (159). Caspases (cysteine-dependent 
proteases) and transglutaminase are some of the thiol-depend-
ent enzymes involved in apoptosis. So, inhibition of these thiol-
dependent enzymes in tumor-initiated cells (by chlorothalonil) 
may disrupt apoptotic cell death and aid in tumor survival. 
Chlorothalonil is considered to be non-genotoxic but classified 
as ‘likely’ to be a human carcinogen by all routes of exposure 
(95). It may also act as cytochrome P-450 inducer with the for-
mation of ROS and peroxisome proliferation, which increases 
the subsequent risk of tumor development (160).
DBP and DEHP
Diesters of phthalic acid are commonly referred to as phtha-
lates. These man-made chemicals are widely used in con-
sumer products, food processing and medical applications. 
They are measured in residential indoor environments (indoor 
air and house dust) and also in foods, milk and drinking water. 
High-molecular-weight phthalates are used as plasticizers in 
the manufacturing of polyvinyl chloride and low-molecular-
weight phthalates are used in making varnishes, lacquers and 
personal-care products. All of the phthalates have been shown 
to disrupt reproductive tract development in male rodents in 
an antiandrogenic manner (161). Phthalate compounds such 
as DBP, butyl benzyl phthalate and DEHP mimic the function 
or activity of the endogenous estrogen 17β-estradiol (E2) and 
bind to ERs. Interestingly, phthalates can mimic estrogen in 
the inhibition of tamoxifen-induced apoptosis in human breast 
cancer cell lines by increasing intracellular BCL-2/BAX ratio, 
which promotes drug resistance to the ER antagonist tamoxifen 
in breast cancer (162). DEHP also up-regulates the expression 
of antiapoptotic activating transcription factor-3 (ATF-3) and 
down-regulates the pro-apoptotic P53 transcription and thereby 
suppresses apoptotic cell death in fetal mouse genital tubercle 
(163). It also inhibited apoptosis of Syrian hamster embryo cells 
(164). DBP induces proliferation and invasiveness of ER-negative 
breast cancer through AhR/HDAC6/c-Myc signaling pathway 
(165) and induces cell proliferation of ovarian cancer cells by 
inducing the expression of cyclin D and cdk-4 (166), whereas 
butyl benzyl phthalate promotes breast cancer progression by 
inducing the expression of lymphoid enhancer-binding factor 
1 (165). DEHP induces hepatocarcinogenesis in rodents by acti-
vating PPARα and peroxisomal genes or cell proliferation and 
also decreases GJIC with enhanced replicative DNA synthesis 
(167,168), whereas DEHP and its main metabolite mono(2-eth-
ylhexyl) phthalate induce ROS species and activate nuclear p53 
and p21 in a human prostate adenocarcinoma cell line (169). 
DDVP
DDVP (2,2-dichlorovinyl dimethyl phosphate) is an organo-
phosphate insecticide used on crops and animals, and to con-
trol household pests. It is effective as an external insecticide 
against flies, aphids, spider mites and caterpillar, and also as 
anthelmintic in the treatment of parasitic worm infections in 
dogs, livestock and humans (170). It acts as a cholinesterase 
inhibitor on the nervous systems of insects. The United States 
Environmental Protection Agency (USEPA) has classified DDVP 
as a probable carcinogen, and DDVP administration induced 
adenomas of the pancreatic acinar in male rats, mononuclear 
cell leukemia in male rats, mammary gland fibroadenomas in 
female rats and squamous cell papilloma of the forestomach in 
both male and female mice (171). DDVP is also both mutagenic 
and clastogenic, actions that probably involve the alkylation of 
DNA or protein (172,173), and it generates ROS species, which 
induce oxidative stress in human erythrocytes in vitro (174). 
It also significantly induced the levels of DNA repair enzyme, 
ataxia telangiectasia mutated in primary rat microglial cells 
(175), and it has been shown to cause cancer in mouse gastric 
tissues by upregulating the expression of p16, Bcl-2 and c-myc 
genes. DDVP induces DNA methylation in multiple tissues in an 
animal toxicity study. Pro-apoptotic gene silencing mediated by 
DNA hypermethylation causes apoptosis resistance (176) and 
it is the link between DDVP and cancer risk observed in some 
epidemiology studies (177). However, its impact on resistance to 
apoptosis is not entirely clear. For example, it was also reported 
to cause an increase in the expression of caspase-1 and TNF-α in 
brain tissues and intracellular caspase-3 in natural killer cells (in 
a dose- and time-dependent manner) inducing apoptosis (178).
Lindane 
Lindane (γ-hexachlorocyclohexane) is a pesticide that has been 
used heavily in the past. Its long-term use and the dumping of 
its production waste have resulted in a widespread and persis-
tent environmental presence. Recently, the effects of lindane, as 
an activator of ERα and a promoter of angiogenesis, have been 
investigated both in vitro and in vivo (179). It has been demon-
strated that this pesticide positively influences endothelial cell 
proliferation and migration. Lindane strongly potentiates met-
alloprotease activity and nitric oxide production through the 
enhancement of eNOS. Lindane also exerts a cytotoxic effect 
on human peripheral blood lymphocytes (180) and disrupts 
the autophagic pathway by activating MAPK/ERK pathway. This 
high constitutive induction of MAPK/ERK pathways impedes the 
tumor suppressive function and provides a malignant advantage 
to tumors. Lindane disrupts the autophagic process evidenced 
by enlarged acidic vesicles labeled with specific autophagic 
vacuole maturation markers LC3, Rab7 and LAMP1, the conver-
sion of cytosolic form of LC3-I into membrane-bound LC3-II and 
enhanced formation of the Bcl-xL/Beclin 1 complex.
Lindane also inhibits mitochondrial apoptotic cell death by 
the up-regulation of Bcl-xL, Bax down-expression, prevention of 
cytochrome c release and inhibition of caspase-3 and -9 activities 
in rat hepatocytes. So, the disruption of two pro-survival mech-
anisms (autophagic and apoptotic pathways) occurs in parallel 
with necrosis induction (181). Lindane also up-regulates antiapop-
totic isoforms of protein kinase C in rat hepatocytes by increas-
ing oxidative stress in a cytochrome P-450 (CYP)-dependent 
manner. Overall, these events clearly demonstrate that the 
acute and chronic effects of lindane in vivo with the induction 
of necrotic cell death and tumor promotion, respectively (182). In 
vivo studies demonstrated a decline in the activity of tricarbox-
ylic acid cycle dehydrogenase enzymes with the modulation of 
acid phosphatase and lactic dehydrogenase in hepatocarcino-
genesis induced by lindane in mice (179,180). Lindane also acti-
vates ERK1/2 and c-Jun cascades in human HaCaT keratinocytes 
cells, but had no effect on p38 MAPK activation. The activation 
of ERK1/2 results in the activation of Raf and MEK1/2 as well as 
activation of protein kinase C. It also stimulated ROS generation, 
which activated ERK and JNK cascades through ROS-dependent 
mechanism with no effect on MEK1/2 phosphorylation.
Linuron 
Linuron (3-(3,4-dichlorophenyl)-1-methoxy-1-methylurea) is a wide-
spectrum herbicide and applied to soils to control pre-emergent 
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and post-emergent broad-leaved and annual grasses amongst 
cultivated crops and vegetables. It enters humans either through 
contaminated food or drinking water, or by dermal contact. It is an 
endocrine disruptor structurally related to the non-steroidal antian-
drogen (androgen receptor antagonist), flutamide, which inhibits 
5α-reductase enzyme. It produces Leydig cell tumors via an antian-
drogenic mechanism, where sustained hypersecretion of LH and 
increased serum estradiol follow the disruption of hypothalamic–
pituitary–testicular axis, and appears to be responsible for the devel-
opment of dose-dependent increase in Leydig cell hyperplasia and 
adenomas (113). Linuron showed in vitro influence on the cell growth 
rate and GJIC on the endothelial cell line F-BAE GM 7373 and demon-
strated tumor-promoting activity. The inhibition of GJIC by linuron 
(between the normal and pre-neoplastic cells) creates an environ-
ment in which tumor-initiated pre-neoplastic cells are isolated from 
several growth regulators and results in clonal expansion. Several 
tumor-promoting chemicals have been reported to block GJIC and 
thereby disrupt apoptosis (108). The loss of lymphocytes after expo-
sure to the pesticide may also lead to a severely impaired immuno-
logical function (183).
Methoxychlor 
MXC (1,1,1-trichloro-2,2-bis(4-methoxyphenyl)ethane) is a 
DDT-derivative OC pesticide that was developed after the ban 
of DDT and exhibits antiandrogenic and estrogenic activity. It 
disrupts prolactin secretion by inhibition of dopamine in the 
hypothalamus and decreases circulatory LH. MXC blocks the 
surge in LH and follicle-stimulating hormone secretion during 
the female reproductive cycle (184). MXC stimulates prolifera-
tion and human breast cancer cell growth by the up-regulation 
of genes that involve cell cycle (cyclin D1), and the down-regu-
lation of genes p21 and Bax affecting G1/S transition and apop-
tosis, respectively, through ERα signaling (185). MXC reduces 
fertility in female rodents by causing ovarian atrophy and 
antral follicle atresia (apoptotic cell death) by inducing oxida-
tive stress through mitochondrial production of ROS (186). MXC 
induced premature nuclear expression of ER gene in neonatal 
uterine epithelium of mice (187). MXC itself exhibits ER binding 
potential and the metabolism of MXC forms monohydroxy and 
dihydroxy metabolites exhibiting estrogenic activity. Another 
MXC metabolite 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane 
exhibits reproductive toxicity by binding to ERα receptor and 
acts as an AR antagonist (188). Chronic exposure to estrogenic 
chemicals such as MXC leads to persistent cell proliferation 
causing the formation of neoplastic lesions. MXC interact with 
nuclear receptors and activates either pregnane X receptor (PXR) 
or both PXR and constitutive androstane receptor (CAR) (189). 
In recent years, researches have revealed most unsuspected 
roles for PXR and CAR in modulating hormone, lipid and energy 
homeostasis as well as cancer (190). Activation of both PXR and 
CAR induces CYP3A, and there is a positive association between 




trophenyl ether) is a diphenyl-ether herbicide used to control 
pre-emergent and post-emergent broadleaf and grass weeds in 
agriculture. Mostly, handlers (mixers, loaders and applicators) 
are exposed during the use of liquid or granular formulations of 
oxyfluorfen. It is rapidly absorbed and excreted unchanged in 
feces and urine with little remaining in the tissues of humans. 
The primary toxic effects of oxyfluorfen are related to blood 
and liver disorders. In rodents, it inhibits protoporphyrinogen 
IX oxidase enzyme resulting in the inhibition of heme bio-
synthesis and also induces the symptoms consistent with 
the expression of human variegate porphyria. The USEPA has 
classified it as a possible human carcinogen (as an increased 
incidence of combined hepatocellular adenomas and carci-
nomas was observed in mice treated with oxyfluorfen). It has 
also been demonstrated to have the potential to induce mouse 
liver tumors by non-genotoxic means, but it is not predicted 
to be carcinogenic in humans (192). Toxicological studies in 
male mice showed expression of Cyp2b10 and Cyp4a10 tran-
scripts, markers of CAR and PPARα nuclear receptor activation 
(192). PPs cause hepatomegaly, peroxisome proliferation and 
increased fatty acid catabolism. Chronic administration of PPs 
causes liver tumors in rodents (193). Chemicals that interact 
with PPARα are known to induce or facilitate liver tumors (194). 
Though the molecular mechanisms involved in PPARα-induced 
hepatocarcinogenesis has not been fully uncovered, recently, 
it has been demonstrated that PPs may induce severe liver 
toxicity causing mortality in mice with hepatocyte-restricted 
PPARα activation in the absence of ligand (VP16PPARα). Long-
term exposure to PPs results in hepatocellular carcinomas in 
VP16PPARα mice by modulating DNA damage response signal-
ing network especially Chek1 and its checkpoint signaling cas-
cade causing increase in DNA synthesis, cell proliferation and 
apoptosis suppression (195) (Figure 1).
Cross-hallmark relationships
Given that the carcinogenicity of low-dose exposures to chemi-
cal mixtures in any given tissue will likely depend upon simul-
taneous instigation of several important tumor promotion 
mechanisms and the disruption of several important defense 
mechanisms, it was felt that one way of visualizing the poten-
tial synergies of combinations of chemicals could involve a thor-
ough review of disruptive actions of each chemical across the 
full range of mechanisms that are known to be relevant in can-
cer biology. Accordingly, we undertook a cross-validation activ-
ity to illustrate the cross-hallmark relationships that are known 
for the target sites that we identified and to illustrate the extent 
that these chemicals are also known to disrupt other mecha-
nisms that are also relevant to carcinogenesis.
These relationships are depicted in Tables 2 and 3. Target 
sites and chemicals that were not only relevant for resistance to 
cell death but also known to be relevant for other areas of can-
cer biology were noted as pro-carcinogenic in the areas where 
evidence existed. Targets and chemicals that were found to have 
anticarcinogenic potential in other areas of cancer biology were 
also highlighted where supporting evidence could be found. In 
instances where reports on relevant actions in other aspects of 
cancer biology were mixed (i.e. reports showing both pro-car-
cinogenic potential and anticarcinogenic potential), this was 
also noted. Finally, in instances where no literature support was 
found to document the relevance of a target site or chemical 
in a particular aspect of cancer’s biology, this was documented 
as well.
Perspective
Cell death is intrinsically connected to different kinds of biologi-
cal damage caused by environmental pollutants. For example, 
chemicals that promote genetic instability usually trigger apop-
tosis (a defensive mechanism intended to prevent functionally 
compromised cells from harming the system). So, hypotheti-
cally speaking, exogenous exposures to combinations of disrup-
tive chemicals that act on the mechanisms described previously 
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(conferring resistance to cell death) could exacerbate the effects 
of unrepaired cellular damage. The potential for dysfunction 
in this key safeguard is therefore an important consideration 
because this sort of genetic instability increases the overall 
probability of damage and mutations that could support the 
emergence of a fully immortalized cellular phenotype.
Past studies have indicated that several cancer hallmark pro-
cesses are impacted by a variety of chemical carcinogens and 
oncogenes (95,96), and there are various agencies worldwide 
such as USEPA and International Agency for Research on Cancer 
working on classifying the environmental chemicals based 
on the carcinogenic potential with the purpose of protecting 
human health. However, the effects of environmental chemical 
mixtures have had much less attention, and in this project, we 
have looked specifically at a number of prototypical chemicals 
with disruptive potential that is relevant to apoptosis. The con-
cern that we have relates to the possibility that individual chem-
icals that are disruptive of these key mechanisms and pathways 
may have the potential to contribute to environmental carcino-
genesis without being carcinogenic per se.
For example, as we noted previously, BPA strikingly impairs TP53 
activity and its downstream targets, cell cycle regulators, p21WAF1 
and RB, or pro-apoptotic BAX, thereby enhancing the threshold for 
apoptosis (152). BPA activates mTOR pathway and enhances cell 
growth and proliferation (351). It also activates PPAR-α (which sup-
presses apoptosis and enhances cell proliferation), and it inhibits 
GJIC through a modulation of the gating of gap junction channels, 
which contributes to tumor formation by increasing intracellular 
signaling and enhancing proliferation (352). And BPA influences 
cell proliferation and migration by GPER/EGFR/ERK pathway. But 
despite a significant and growing body of literature that has docu-
mented all of these mechanistic contributions, researchers and 
regulators have had considerable difficulty proving whether or not 
BPA has carcinogenic effects in humans (319).
From this perspective, it seems that the longstanding focus 
on the carcinogenic potential of individual chemicals is really 
too narrow (given the wide range of environmental chemi-
cal exposures that we now face). Instead, it would seem more 
prudent to focus on mechanistic contributions and anticipated 
synergies of mixtures of individual constituents that have been 
shown to individually exert disruptive effects on hallmark 
cancer processes (at dose levels that are environmentally rel-
evant). In this case, BPA is a good example because it is ubiq-
uitous in the environment and it has also been shown to exert 
its effects on TP53 at low-dose levels (353). So, even if it cannot 
be definitively categorized as a human carcinogen, it appears 
to have potential to play a contributing role in environmental 
carcinogenesis. Future research will therefore need to illustrate 
how chemicals that have the potential to produce this sort of 
a disruptive effect can be experimentally combined with other 
environmental chemicals that disrupt other hallmark processes 
to enable carcinogenesis.
We fully recognize that much of the evidence in the toxico-
logical literature that documents the disruptive actions of these 
chemicals has been produced under a wide range of differing 
experimental circumstances, and it is not our intent to jump to 
conclusions about the role that aggregated exposures to mix-
tures of these chemicals might play in environmental carcino-
genesis. But it is our contention that the ubiquitous presence of 
these (and other) chemicals with disruptive potential needs to 
be carefully considered, even if these chemicals are not individ-
ually carcinogenic. Moreover, researchers who investigate this 
possibility will also need to consider other mechanisms that are 
affected by these individual chemicals as well (see Tables 2 and 
3). In some cases, dose–response research may reveal thresholds 
that make these actions unlikely at levels of exposure that are 
seen in the environment, but to the extent that low-dose effects 
can been found, these additional disruptive effects may also be 
important factors to consider.
Conclusions
The disruption of the mechanisms that regulate cell death is 
fundamentally important to our understanding of environmen-
tal carcinogenesis. The enablement of an immortalized cellular 
phenotype can only occur when many important safeguards 
have been bypassed. It therefore appears reasonable to consider 
the effects of ubiquitous environmental chemicals that have 
been shown to disrupt cell death as it is a very important safe-
guard. Although a considerable amount of research has been 
done to characterize the effects that many chemicals have on the 
mechanisms that are relevant for normal cell death, very little 
attention has been given to the combined effects of this chemi-
cals on this hallmark of cancer, or the role that these sorts of 
disruptions at the mechanistic level might serve to contribute to 
environmental carcinogenesis. In this review, we have identified 
a number of important targets that are highly relevant for cell 
death and we have identified a number of ubiquitous environ-
mental chemicals that have been shown to act disruptively on 
these targets. Future research is needed that looks carefully the 
role of these prototypical disruptors and other disruptive chemi-
cals that can act on these same mechanisms at levels of expo-
sure that are commonly seen in the environment. Regulators 
who now focus solely on determining the carcinogenic potential 
of individual chemicals would be well served to additionally con-
sider the synergies that might occur when chemicals that are 
disruptive at the mechanistic level are combined with other dis-
ruptive chemicals (i.e. those that can enable other complemen-
tary processes that are similarly instrumental and enabling in 
carcinogenesis). To anticipate the sorts of synergies that might be 
produced, the pleiotropic nature of these chemicals will need to 
be considered as well. Individual chemicals may produce a range 
of disruptive effects that are relevant for a multitude of mecha-
nisms, yet individual constituents in any given combination of 
exposures may not need to be carcinogenic per se. Combinations 
of these chemicals may produce foundational effects that enable 
carcinogenesis, so progress in our understanding of this poten-
tial will help us to refine our approach to cancer risk assessment.
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Abstract
Environmental contributions to cancer development are widely accepted, but only a fraction of all pertinent exposures 
have probably been identified. Traditional toxicological approaches to the problem have largely focused on the effects of 
individual agents at singular endpoints. As such, they have incompletely addressed both the pro-carcinogenic contributions 
of environmentally relevant low-dose chemical mixtures and the fact that exposures can influence multiple cancer-
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associated endpoints over varying timescales. Of these endpoints, dysregulated metabolism is one of the most common 
and recognizable features of cancer, but its specific roles in exposure-associated cancer development remain poorly 
understood. Most studies have focused on discrete aspects of cancer metabolism and have incompletely considered both 
its dynamic integrated nature and the complex controlling influences of substrate availability, external trophic signals 
and environmental conditions. Emerging high throughput approaches to environmental risk assessment also do not 
directly address the metabolic causes or consequences of changes in gene expression. As such, there is a compelling 
need to establish common or complementary frameworks for further exploration that experimentally and conceptually 
consider the gestalt of cancer metabolism and its causal relationships to both carcinogenesis and the development of 
other cancer hallmarks. A literature review to identify environmentally relevant exposures unambiguously linked to both 
cancer development and dysregulated metabolism suggests major gaps in our understanding of exposure-associated 
carcinogenesis and metabolic reprogramming. Although limited evidence exists to support primary causal roles for 
metabolism in carcinogenesis, the universality of altered cancer metabolism underscores its fundamental biological 
importance, and multiple pleiomorphic, even dichotomous, roles for metabolism in promoting, antagonizing or otherwise 
enabling the development and selection of cancer are suggested.
Introduction
Environmental contributions to cancer development are widely 
recognized and involve factors as diverse as diet, tobacco and 
alcohol use, reproductive and sexual behaviors, occupational 
exposures, environmental pollutants, medical therapies, geo-
physical factors and infectious agents (1,2). Corresponding 
effects on intermediary metabolism and specific metabolic con-
tributions to the development of cancer, however, have been 
incompletely explored. Little is known about the specific causal 
and spatiotemporal relationships between exposures, dysregu-
lated metabolism and the development of cancer and its associ-
ated phenotypic hallmarks (Figure 1) (3), including the ‘missing 
hallmark’ of dedifferentiation (4).
Biochemical characterization of cancers in the early-to-mid 
20th century established many of the fundamental metabolic 
characteristics of cancer cells (5–8). Interest in cancer metabo-
lism subsequently waned with the advent of genetic sequencing 
and molecular biology, shifting instead to the study of muta-
genic effects and the regulation of gene expression. Interest 
has subsequently rebounded over the course of the past few 
decades, however, as investigators sought to better delineate 
the mechanistic underpinnings and functional importance of 
demonstrable genetic and epigenetic changes associated with 
dysregulated cancer metabolism. Alterations in the expression 
of numerous genes encoding metabolic enzymes, transporters 
and regulatory effectors have been associated with cancer. Many 
address known biochemical features of cancer, whereas oth-
ers may suggest novel unexplored or previously unappreciated 
associations. Warburg originally proposed that fixed mitochon-
drial defects were primarily responsible for both cancer devel-
opment and its associated highly glycolytic phenotype, but his 
own data and that of his contemporaries (6,9,10) demonstrated 
not only preservation of oxidative metabolism in cancer (5,11), 
but also its persistence in the absence of exogenous substrates 
(5), suggesting an expanded metabolic repertoire and an intrin-
sic capacity to oxidatively utilize endogenous substrates when 
exogenous substrates are not available (6,12).
Cancer-associated changes in metabolism may reflect altera-
tions in either metabolic capacity or control—or both. Changes 
in capacity are well described, although altered control may ulti-
mately be of greater relative importance (13). Since control does 
not reside at a single point in any metabolic pathway (13) and 
controlling factors differ between intact cells and in vitro assays, 
observed changes in individual pathway elements do not always 
translate into metabolic flux changes and vice versa. Cancer cell 
phenotypes are also neither fixed nor specific for cancer (4,14,15), 
Abbreviations 
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and it is a basic biological truism that distinct cell types or tissues 
respond differently to common extrinsic stimuli, including hor-
mones, physical stimuli, environmental stress or chemical expo-
sures (16,17). Although metabolic derangements in cancer are 
widely recognized and accepted as fundamental to the nature 
of cancer, much, if not most, of the literature in this domain is 
descriptive or associative in nature. At present, there are limited 
data directly supporting a primary metabolic link between envi-
ronmental exposures and cancer development. The continually 
‘evolving, dynamic, and heterogeneous’ nature of cancer (4,15) 
thus poses problems for the treatment, as well as the study, of 
cancer, so a better understanding of the determinants and func-
tional consequences of such heterogeneity is needed (16).
The identification and characterization of specific causal 
relationships between common environmental exposures, car-
cinogenesis and associated metabolic changes is methodologi-
cally challenging, in part, because exposures typically occur in 
the context of complex mixtures at concentrations not com-
monly examined in standard toxicity or carcinogenicity testing. 
Biological effects of individual ‘low dose’ exposures also fre-
quently reflect biphasic dose–response relationships, sometimes 
with directionally opposite biological responses that would 
not be anticipated on the basis of traditional testing (17,18). 
The term ‘low dose’ can also easily—and inappropriately—be 
misconstrued as suggesting an absence of biological effects. In 
contradistinction to conventional toxicological dogma, however, 
there may be no basal exposure threshold below which is com-
pletely bereft of biological effects (17–19).
The present review—reflecting the efforts of 30 authors rep-
resenting 21 institutions in 8 countries—broadly addresses these 
issues and is a direct outgrowth of ‘The Halifax Project’, an inter-
national initiative launched in 2011 by the non-profit organization 
Getting to Know Cancer (http://gettingtoknowcancer.org/) with the 
explicit aim of producing a series of overarching reviews assessing 
the contributions of environmentally relevant exposures to the 
development of cancer and its associated phenotypic hallmarks. 
This review was specifically undertaken to explore what is—and 
is not—presently known about the roles of dysregulated metabo-
lism in environmental carcinogenesis, and it was conducted with 
the hope of stimulating additional interest in cancer metabo-
lism and identifying critical knowledge gaps and unmet research 
needs to help direct future research. The authors were also spe-
cifically tasked to identify key metabolic targets for disruption or 
dysregulation, as well as a corresponding list of prototypical envi-
ronmental exposures with the potential to act on these targets. 
Prototypical exposures were selected on the basis of environmen-
tal ubiquity and the demonstrated ability to act on selected targets 
to mimic specific cancer-associated phenotypes. To focus efforts 
Figure  1. Dysregulated metabolism in cancer development due to environmental exposures and potential relationships to other cancer hallmarks. The specific 
sequence, priority and relevance of reprogramming and dysregulated metabolism in the (often decades-long) carcinogenic continuum between environmental expo-
sures and cancer development are incompletely understood. Specific relationships between altered metabolism and other cancer hallmarks are also poorly delineated. 
Much of our specific knowledge of cancer metabolism is largely associative in nature, and a deeper understanding of the numerous remaining mechanistic ‘black 
boxes’ (A) is needed before specific metabolic changes can be optimally exploited for preventative or therapeutic benefit. For example, it is not clear whether altered 
metabolism is a cause or a consequence of cancer development—or both. In principle, the contributions of metabolism to carcinogenesis may operate in series (B, C), 
in parallel (D, E) or even in opposition (E) to the contributions of other hallmarks of cancer (e.g. via modulation of oxidative stress). Temporally, changes in metabolism 
may also precede (C), follow (B) or coincide with (D, E) other key determinants of the carcinogenic program. Since metabolism is not a singular entity, the specific type 
of relationship observed for a given aspect of metabolism is not mutually exclusive of different types of relationships with other aspects of metabolism.
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on the identification of novel and underexplored exposures, both 
lifestyle-related exposures and chemicals known as ‘Carcinogenic 
to Humans’ (e.g. Group  1 carcinogens, International Agency for 
Research on Cancer) were specifically excluded from primary con-
sideration (see the accompanying capstone article in this issue for 
details (20)). The focus on environmentally relevant exposures was 
also intentionally restrictive to provide insights that would be of 
value to cancer researchers interested in the effects of complex 
environmental chemical mixtures, as well as investigators and 
policymakers involved in environmental risk assessment and 
management.
Given the importance and complexity of the subject mat-
ter and to obviate common misconceptions, this review briefly 
addresses our present understanding of cancer metabolism 
before tackling its potential roles in exposure-associated car-
cinogenesis. The metabolism of carbohydrates, lipids and pro-
teins are individually considered for characteristic changes 
associated with cancer, as well as catabolic and anabolic con-
tributions to its highly proliferative phenotype. Dichotomous 
roles for metabolism in both the promotion and amelioration 
of cellular stress (e.g. oxidative, hypoxic, nutritional and physi-
cal stress) are also considered. Finally, individual relationships 
between dysregulated metabolism and other hallmarks of can-
cer (e.g. apoptotic resistance, genomic mutability, replicative 
immortality, sustained proliferation, angiogenesis, tissue inva-
sion and metastasis) are briefly addressed.
Metabolic reprogramming and 
dysregulation in cancer
Metabolic dysregulation is one of the most common and recog-
nizable features of cancer (21,22), although associated metabolic 
phenotypes are not necessarily fixed (4) and can change in 
response to substrate availability and the metabolic demands 
of proliferation, growth and cell survival. Proliferative can-
cer cells alter their ability to metabolize carbohydrates, lipids 
and peptides to meet increased energy demands and provide 
anabolic precursors needed to support obligatory nucleic acid 
and protein biosynthesis and membrane biogenesis (21,23,24). 
These processes are intimately intertwined and result in an 
expanded metabolic repertoire that affords increased flexibility 
to adapt to increased cellular demands, changing environmen-
tal conditions and fluctuating substrate availability.
Carbohydrate metabolism in cancer
All mammalian cells require amphibolic glucose (Glc) metab-
olism via glycolysis and the tricarboxylic acid (TCA) cycle to 
meet catabolic demands and support anabolic carbon needs 
(Figures 2 and 3). It has been recognized for nearly a century 
that cancer cells increase glycolytic lactate production inde-
pendent of O2 availability (5,6,8,11,23). Glycolytic capacity and 
Glc flux rates, however, greatly exceed the anabolic and cata-
bolic needs of both normal and cancer cells (13,25). In normal 
cells, lactate production is reduced in the presence of O2, a 
suppressive response commonly known as the Pasteur effect. 
Although partially preserved in cancer (7), increased lactate 
generation is still observed in the presence, as well as absence, 
of O2 (5,6). This so-called aerobic glycolysis probably reflects 
simultaneous NAD+/NADH coupling between glyceraldehyde 
phosphate dehydrogenase (GAPDH) and both lactate dehydro-
genase (LDH) and the mitochondrial malate–aspartate shuttle 
system (Figure 3, right panel), which is not typically observed 
in normal cells (12,26). Mitochondrial uncoupling associated 
with cancer may contribute to cytosolic NADH recycling to 
Figure 2. Selected metabolic pathways and targets implicated in cancer development and progression. Major interactions between Glc and lipid metabolism are 
highlighted, and the fundamental interchangeability of corresponding metabolic intermediates with amino acid metabolism via the major amphibolic pathways, 
glycolysis and the TCA cycle, is indicated. Gln and Ser metabolism and coupled processes such as glyceroneogenesis and one-carbon metabolism are not depicted 
but are addressed in the text. Major anaplerotic inputs needed to counterbalance cataplerotic carbon losses from the TCA cycle are indicated by dashed arrows. Major 
transport mechanisms for the transcellular movement of Glc (GLUT), amino acids (l-type amino acid transporters [LAT], A-type Na+-linked amino acid transporters 
[SNAT]), FA (CD36) and monocarboxylates such as pyruvate and lactate (monocarboxylate transporters [MCT]) are also depicted. Both intracellular (MAGL, SCD) and 
extracellular (LPL) lipases are responsible for the liberation of FA moieties from more complex intracellular and extracellular lipids such as TAG and lysophospholipids.
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NAD+ to support glycolytic flux in the setting of persistent oxi-
dative metabolism (Figure 3) (27,28). However, given the het-
erogeneity and pleiomorphic nature of cancer (4,29,30), it is 
likely that no single mechanism fully accounts for this effect 
(6,24). The corresponding Crabtree (or reverse Pasteur) effect—
the converse ability of glycolysis to inhibit respiration—plays 
a reciprocal role in the bidirectional coordination of oxida-
tive metabolism and glycolysis in both normal cells and can-
cer cells (6,31,32). The Crabtree effect has been attributed to 
competition between glycolysis and oxidative phosphoryla-
tion for available adenosine diphosphate (ADP) and inorganic 
phosphate (6,8,32) and may also involve feedback inhibition 
of hexokinase (HK) activity (8,32) or HK–mitochondria inter-
action (23,33,34). The precise mechanisms underlying both 
effects remain incompletely delineated, however, and neither 
the Pasteur effect nor the Crabtree effect may have a single 
mechanistic explanation (8).
HK catalyze the first committed step of Glc metabolism, and 
thereby promote cellular Glc uptake and catalyze the initial step 
of all major pathways of Glc utilization (23). The high-affinity 
HK1 and HK2 isoforms also physically and functionally interact 
with mitochondria (33,35) to coordinate intra- and extramito-
chondrial metabolism, promote cell survival and directly antag-
onize apoptogenic signals converging on mitochondria (23,33). 
HK1 is constitutively expressed in most cells, whereas inducible 
HK2 is commonly overexpressed in cancer (23). Both isoforms 
compete for mitochondrial interaction (35), but the functional 
determinants and implications of this competition and the 
relative contributions of individual isoforms are still unknown. 
HK1 and HK2 are kinetically suited for distinct functional roles 
and are well positioned to direct both location-specific (33) and 
isoform-specific metabolic channeling. For example, HK1 is 
suited to direct Glc metabolism in a catabolic direction, whereas 
HK2 is better suited to channel Glc flux into anabolic path-
ways (35–38). Increased HK2 expression in cancer thus probably 
affords increased metabolic flexibility to respond to increases in 
both the catabolic and anabolic demands of rapid proliferative 
growth (36).
Pyruvate conversion to lactate by LDH is fully reversible, 
whereas its oxidative decarboxylation by the pyruvate dehy-
drogenase (PDH) complex irreversibly commits it to TCA cycle 
metabolism. PDH thus represents an important point of integra-
tion for regulatory feedback by its principal reaction products, 
acetyl-coA and NADH. As such, PDH plays a key role in coor-
dinating intra- and extramitochondrial metabolism that can be 
disrupted by a variety of factors, including thiamine availability 
(39). Cancer cells also utilize exogenous lipids and proteins, as 
well as carbohydrates, but exhibit a hierarchy of substrate pref-
erences. Cancers generally show a preference for Glc if multi-
ple substrates are available (5,6,10,40), illustrating the extent to 
which substrate metabolism is intertwined at the cellular level 
(Figure 2).
Branched pathway flux via the pentose phosphate pathway 
(PPP) directly supports cancer proliferation via provision of ribose 
moieties and reducing equivalents needed for nucleotide and 
nucleic acid biosynthesis (41). PPP flux via glucose-6-phosphate 
dehydrogenase and 6-phosphogluconate dehydrogenase (6PD) 
is also redox-coupled to reduced glutathione (GSH) generation 
required to support glutathione peroxidase (GPx)-mediated detox-
ification of both organic and inorganic peroxides (23,42). Catalase 
can also detoxify inorganic peroxides, but not organic peroxides. 
As such, GSH and GPx activity assume predominant roles in cel-
lular responses to chronic oxidant stress involving lipid peroxi-
dation. Interestingly, PPP flux is also directly coupled to caspase 
inhibition and the antagonism of apoptogenic signaling (23,43,44).
Hexosamine biosynthesis from Glc is increased in cancer 
and is a prerequisite for glycoprotein, glycosaminoglycan and 
glycosphingolipid generation (45–47). Associated O-linked pro-
tein glycosylation also contributes to several cardinal features 
of cancer, including increased proliferation, apoptotic resistance 
and enhanced invasive potential (48,49). Hexosamine flux also 
activates trophic factor signaling coupled to glutamine (Gln) 
Figure 3. Major cellular metabolic coupling mechanisms. Energetic coupling between ATP generating mechanisms (i.e. glycolysis and the TCA cycle) and cellular aden-
osine triphosphatase (ATPase) activity is depicted (left panel). General redox coupling mechanisms for both the PPP (G6PDH and 6PD; upper center panel) and glycolytic 
(GAPDH, upper right panel) flux are similarly depicted alongside representative competing NAD(P)H-regenerating mechanisms (unshaded boxes). Ongoing metabolic flux 
through these pathways and cellular energy homeostasis are critically dependent upon the maintenance of these coupling mechanisms.
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uptake, providing a specific mechanism for coordinating Glc and 
Gln metabolism in cancer (45).
Gluconeogenesis is not a major feature of most cell types, 
including cancers, but both glycolysis and glycyeroneogenesis 
share common enzymatic steps with gluconeogenesis that 
are relevant to cancer (50,51). Steps shared with glycolysis are 
sequentially and directionally reversed, and gluconeogenesis 
requires separate enzymes to bypass irreversible rate-control-
ling glycolytic reactions catalyzed by HK, phosphofructokinase 
(PFK) and pyruvate kinase (PK). As such, glycolysis and gluco-
neogenesis are reciprocally regulated and spatiotemporally seg-
regated in different cell types and intracellular compartments. 
Although glycolysis is the principal source of 3-phosphoglycer-
ate (3-PG) for glycerol and triacylglycerol (TAG) synthesis, glyc-
eroneogenesis can also generate 3-PG to support lipogenesis, 
serine (Ser) biogenesis and one-carbon metabolism essential for 
cancer progression and growth (50,51).
Lipid metabolism in cancer
Although most early attention to cancer metabolism focused on 
dysregulated glycolysis, alterations in lipid metabolism are also 
widely recognized (6,21,52,53). In fact, increased lipogenesis is 
considered a hallmark of many aggressive cancers (54,55), with 
de novo fatty acid (FA) synthesis supporting membrane biogen-
esis, as well as the energetic demands of proliferation, even 
if extracellular lipid is available (21,54–56). Lipogenesis also 
increases membrane lipid saturation, thereby reducing suscep-
tibility to direct peroxidation and cellular damage (55).
Acetyl-coA is required for de novo FA synthesis (57) and is 
largely generated from pyruvate by intramitochondrial PDH, 
which irreversibly directs glycolytic flux into the TCA cycle 
(Figure 2) (50). Cataplerotic citrate derived from this cycle is then 
converted back to acetyl-coA in the cytosol by adenosine triphos-
phate (ATP)–citrate lyase (ACL) (58) before conversion to mal-
onyl-coA by acetyl-coA carboxylase (ACC). Fatty acid synthase 
(FASN) then catalyzes the condensation of malonyl-coA and 
acetyl-coA to form long-chain FA. Both ACC and FASN are rate 
controlling and are overexpressed in cancer (54). Interestingly, 
ACC also contributes to epigenetic regulation by directly com-
peting with histone acetylation for available acetyl-coA (59). 
Elevated Glc utilization supports lipogenesis at multiple levels 
(54,58). In addition to generating pyruvate for acetyl-coA pro-
duction, increased glycolytic flux supplies 3-PG for glyceroneo-
genesis, and parallel branched pathway flux via the PPP provides 
reducing power in the form of NADPH for lipid biosynthesis. The 
TCA cycle is carbon-neutral, so cataplerotic citrate carbon losses 
for lipogenic acetyl-coA formation must be offset by anaplerotic 
carbon input for the cycle to proceed (50). Although Glc-derived 
pyruvate is most important in this regard, other anaplerotic 
inputs such as Gln-derived α-ketoglutarate (αKG) also help bal-
ance these losses in support of de novo lipid biosynthesis. For 
example, reductive synthesis of acetyl-coA from Gln-derived 
αKG can occur under hypoxic conditions (57,60,61) or when HK2 
cannot properly direct Glc flux into anabolic fates (38).
Lipolytic metabolism of both endogenous and exogenous 
lipids is also observed in cancer (6,40,53). Monoacylglycerol 
lipase (MAGL; Figure  2) is overexpressed in cancer and medi-
ates FA retrieval from neutral intracellular lipids (62), whereas 
stearoyl-coA desaturase (SCD) mediates FA retrieval from exog-
enously scavenged lysophospholipids (60). In addition to these 
intracellular lipases, cancer cells express extracellular lipases, 
and co-expression of cell surface lipoprotein lipase (LPL) with 
CD36, which mediates FA uptake, permits the uptake and 
utilization of FA derived from extracellular TAG de-esterification 
(Figure 2) (53,63,64).
Both lipogenic and lipolytic phenotypes can co-exist in cancer 
(6,40,53), where FA are channeled into biosynthesis of both struc-
tural and signaling lipids (65). Lipophagy is also increasingly rec-
ognized as a regulated mechanism for intracellular lipid recycling 
to meet catabolic and anabolic demands (66–68). The existence 
of multiple FA-generating mechanisms to meet cellular needs 
(53,69) suggests an expanded metabolic repertoire well suited for 
adaptative flexibility to respond to changing substrate availability 
that could provide important selection advantages for cancer.
Protein metabolism in cancer
Cancer cells conserve endogenous proteins and their constituent 
amino acids more avidly than normal cells (70). They also scav-
enge systemic nitrogen and maintain positive nitrogen balance, 
serving as ‘nitrogen sinks’ that contribute to cancer cachexia 
(6,70). Warburg and his contemporaries observed ammoniagen-
esis in cancers that was increased in the absence of exogenous 
substrate and reduced in the presence of Glc (5,10,14), suggest-
ing both a capacity to utilize endogenous proteins and protein-
sparing effects of Glc. Since cancer cells lack intracellular storage 
forms of protein, endogenous recycling of functional and struc-
tural proteins is likely, although selectivity in targeting specific 
proteins for proteolysis remains to be directly addressed. The 
anabolic or catabolic benefits of such recycling have historically 
been viewed as by-products of other primary cellular processes, 
rather than their raison d’etre. Autophagy plays important roles 
in recycling excess or damaged intracellular components for 
internal consumption (68,71,72) and likely represents one con-
tributor to these processes.
Amino acid biosynthesis supports cellular needs that cannot 
be met by substrate abstraction from the environment. These 
processes are intimately intertwined with Glc metabolism and 
require anabolic input from glycolysis or the TCA cycle. Ser bio-
synthesis, in particular, is upregulated in cancer (38,51,73,74), 
providing methylene groups for one-carbon reactions important 
for nucleotide synthesis involving the folate pathway and homo-
cysteine methylation to yield methionine in the methionine 
cycle (51,74). Both Ser and homocysteine serve as important sub-
strates for the biosynthesis of other amino acids (51), including 
cysteine, which is a substrate for GSH generation important for 
the maintenance of cellular redox status. The methionine cycle 
also supports methyltransferase reactions important for histone 
modification and other post-translational changes of epigenetic 
relevance (74,75). Ser biosynthesis is initiated by phosphoglycer-
ate dehydrogenase, which is strongly induced by protein restric-
tion and employs glyceroneogenic 3-PG as a substrate (51). In 
principle, phosphoglycerate dehydrogenase competes with gly-
colytic GAPDH for required NAD+ cofactors, which could favor 
the use of glyceroneogenic 3-PG derived from malate and the 
TCA cycle (51). As much as half of all anapleurotic Gln flux in 
cancer cells may be linked to Ser biosynthesis (73). Cancer cells 
avidly abstract exogenous Gln from their environment and are 
also capable of Gln biosynthesis, which plays key roles in solid 
tumor adaptation to nutrient deprivation and/or hypoxia (76).
Gln also plays other important roles in cancer metabolism 
(77,78). Gln supports transamination reactions important for 
purine and pyrimidine biosynthesis, and Gln-derived αKG sup-
ports reductive biosynthesis of acetyl-coA for lipogenesis under 
hypoxic conditions (57,61), suggesting additional metabolic flex-
ibility to adapt to variations in substrate availability and envi-
ronmental conditions. It is also of considerable interest that 






R.B.Robey  et al. | S209
only a fraction of available Gln is oxidized or otherwise diverted 
for anabolic purposes (79). High rates of metabolic flux support 
sustained proliferation (79), but the rate of glutaminolysis—like 
that of glycolysis—still greatly exceeds the catabolic and ana-
bolic needs of cancer cells (8,13,80,81). These high rates of major 
pathway flux have important metabolic control implications for 
anabolic branched pathways (13).
The gestalt of intermediary metabolism 
in cancer
Altered cellular metabolism crucially supports the increased 
anabolic and catabolic demands of rapidly proliferating cancer 
cells (21). These demands can vary widely in both magnitude 
and direction in different anatomic locations and across diverse 
cell populations (4,12,15). Endergonic and exergonic processes, 
however, cannot operate independently of one another and must 
be coupled. Energy metabolism is closely coupled to anabolic 
activity and other energy-requiring processes like active trans-
port (Figure 3, left panel) (6,8). The fundamental balance between 
ATP generation and its hydrolysis has been recognized for dec-
ades (8,80–83), but the importance of this coupling is still widely 
underappreciated. Cells cannot function at an energy deficit, and 
the potential for cellular energy generation uniformly exceeds its 
utilization in intact cells (8,25,80,81). ATP conservation is central 
to metabolic regulation, and consumption is a key driver of ATP 
generation (8,12,84). Recognition of these fundamental relation-
ships originally led to the concept of cellular adenylate energy 
charge (AEC) as a major controlling factor in metabolic regula-
tion (82,85), Low AEC values correspond to elevated adenosine 
monophosphate (AMP) levels and favor catabolic processes, 
whereas high AEC values correspond to increased ATP abun-
dance and favor anabolic processes. These counterbalancing 
effects serve to assure that dynamic cellular demands can be 
met by appropriate diversion of cellular resources.
The metabolic changes associated with cancer are highly 
integrated—just as they are in normal cells (6,8,86) —and can-
not be properly considered outside the context of the cellular 
gestalt (12). As such, a holistic understanding of how myriad 
cancer-associated changes interact with one another is essen-
tial. Examination of individual enzymes or pathways in isolation 
risks overlooking crucial organizational and control principles 
in intact cells (87,88). Consideration of cancer metabolism as 
a system will require multiple complementary experimental 
approaches drawn from classical biochemistry, as well as molec-
ular biology. Metabolic flux and control analysis is crucial to 
understanding such changes, insofar as alterations in substrate 
or product abundances alone give limited information regard-
ing metabolic flux (13). Similarly, if metabolic capacity is not 
limiting and exceeds cellular demands, then changes in indi-
vidual enzyme or transporter abundances may not accurately or 
fully reflect either cellular needs or metabolic flux. Even where 
increased metabolic capacity can be demonstrated, it does not 
necessarily follow that cancer cells always—or ever—operate at 
maximum capacity (8,13,25,80).
Intermediary metabolism is a complex interconnected series 
of processes that can individually drive, augment or counterbal-
ance each other (Figures 1 and 2). As such, secondary, compensa-
tory or coupled responses may be of greater pathophysiological 
importance to carcinogenesis than primary initiating direct 
changes (Figure  2). Metabolic flux through one pathway may 
promote pathology development, whereas flux via another path 
may have the opposite effect. As such, relative counterbalanc-
ing or augmenting contributions may be more important than 
the absolute magnitude of individual processes (Figure  4). As 
an example, oxidative metabolism represents a major source of 
reactive oxygen species (ROS) (89), whereas PPP flux is a major 
driver of counteracting antioxidant quenching mechanisms 
(41,42). The end products of glycolysis, pyruvate and lactate, may 
also directly detoxify ROS (90–95).
All metabolic flux occurs under non-equilibrium conditions, 
and for individual enzymatic reactions, displacement from 
equilibrium represents a major determinant of the magnitude 
and direction of associated flux (96). All steps within a pathway 
exert some level of control over flux (79,96), but under steady-
state conditions, reactions that reside farthest from equilib-
rium are best positioned to restrict flux and exert control (96). 
In open systems like cancer cells, substrate and cofactor avail-
ability, as well as downstream product removal and metabolic 
feedback, also dynamically contribute to flux control (96). These 
factors are of particular importance to metabolic phenotype 
development in cancer cells, which must depend upon de novo 
synthesis or macromolecular recycling for substrates that are 
unreliably or only intermittently available from extracellular 
sources. Cancer cells demonstrating the ability to utilize multi-
ple substrates exhibit hierarchical preferences, with Glc gener-
ally favored over other substrates (6). Such preferences probably 
serve to conserve endogenous lipids and proteins when alter-
nate exogenous substrates are available.
Catabolic and anabolic support of 
cancer growth
Both glycolysis and the TCA cycle are amphibolic pathways that 
support the anabolic, as well as catabolic, needs of rapidly pro-
liferating cancer cells (21,23,50,51). Catabolic support roles have 
historically garnered the most attention, but the importance of 
anabolic support for the proliferative cancer phenotype is also 
now widely recognized (21,23). All rapidly proliferating cells 
require increased nucleic acid biosynthesis, membrane biogen-
esis and protein synthesis to increase biomass (24). Newly syn-
thesized proteins also require post-translational modifications 
for proper targeting and function (51,97–99). These biosynthetic 
processes and asymmetric secondary active transport of exoge-
nous substrates and ions are both supported, in turn, by cellular 
energy derived from both glycolysis and oxidative metabolism. 
Specific requirements for TCA cycle carbon balance (50) and 
specific cofactor coupling arrangements (Figure 3) serve to help 
coordinate these catabolic and anabolic contributions.
Metabolic cancer cell phenotypes can reflect primary changes 
in metabolic control, as well as capacity (12,22,79,82,83), and 
both substrate availability and cellular catabolic and anabolic 
demands represent major phenotypic determinants. A  direct 
relationship exists between cellular adenosine triphosphatase 
(ATPase) activity and ATP generation (8,80,83), and in the setting 
of non-limiting substrate availability, cellular energy production 
largely changes in response to demand, not vice versa. This well-
described, albeit underappreciated, relationship is an important 
driver of metabolism in normal cells and cancer cells alike.
Metabolic contributions to—or antagonism 
of—cellular stress
Cellular stress is a net function of the balance between the mag-
nitude and nature of all incident stressors and the corresponding 
adequacy of intrinsic cellular coping strategies (Figure 4A). There 
is considerable heterogeneity in both stress responses and out-
comes associated with different cell types or tissues, even under 
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identical conditions. In principle, metabolic reprogramming can 
contribute to both the propensity for cancer development and 
cancer cell selection via either metabolic promotion or allevia-
tion of stress. An expanded metabolic repertoire may enhance 
the inherent flexibility of cancer cells (12,73,100,101), thereby 
enabling them to thrive under highly variable conditions and to 
favorably adapt to changing microenvironments and the myriad 
associated stresses encountered by rapidly proliferating cancer 
cells. Metabolic stress, including oxidant stress, has been associ-
ated with carcinogenesis, although the ability of metabolism to 
antagonize, as well as promote, such stress suggests both direct 
and indirect mechanisms whereby metabolism can contribute to 
cancer genesis, progression, selection and control. Several forms 
of stress relevant to cancer are briefly considered below.
Oxidative stress
By definition, cellular oxidative stress reflects the net effects of 
both oxidant stressors and intrinsic antioxidant coping mecha-
nisms (102). As such, oxidant stress may mechanistically arise 
from increased oxidant stressors, reduced antioxidant coping 
capacity or both (Figure  4A). Oxidant stress can also represent 
either a cause or a consequence of metabolic alterations (103) that 
serve to antagonize or promote oxidant stress—or both. The anti-
oxidant coping strategies of cancer cells ostensibly mimic those 
of normal cells and are intimately intertwined with metabolism, 
which can both generate and detoxify oxidant species (Figure 4B). 
Direct non-enzymatic oxidant quenching has historically received 
less attention than redox-coupled antioxidant mechanisms. 
Several metabolic intermediates of the major amphibolic path-
ways, however, possess known antioxidant properties that com-
plement their canonical catabolic and anabolic roles. For example, 
α-ketoacids such as pyruvate and αKG are potent antioxidants 
(90,91,93,104), and α-hydroxyacids such as lactate exert similar 
protective effects (92,94). These observations suggest intrinsic 
mechanisms for buffering any pro-oxidant effects of metabolism 
and the possibility of specific antioxidant roles for glycolysis and 
the TCA cycle that are in addition to those traditionally ascribed to 
PPP flux and glutathione reductase activity.
Both inorganic and organic peroxides contribute to endog-
enous oxidant stress, although organic peroxides, particularly 
lipid peroxides, are of greater potential biological importance. 
Catalase detoxifies inorganic but not organic peroxides, whereas 
GPx is capable of detoxifying both. Glc flux via the PPP plays a 
major role in this process through NADP+/NADPH redox cou-
pling with glutathione reductase, and primary increases in HK 
Figure 4. (A) Oxidant stress reflects the dynamic balance between oxidant stressors (e.g. ROS) and antioxidant coping mechanisms. As such, unmatched primary 
increases in ROS or primary decreases in antioxidant capacity—or both—may lead to phenotypically indistinguishable increases in net oxidant stress. (B) Intermediary 
metabolism contributes to both ROS generation and opposing antioxidant coping mechanisms. Imbalances resulting in net oxidant stress can lead to oxidative modi-
fication of macromolecules, organelles and cellular effectors with functional consequences that directly or indirectly contribute to cancer development (highlighted 
area). Net oxidant stress can also feedback to influence metabolic flux and thereby attenuate or intensify these contributions.
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activity, which gates entry into this pathway, increases PPP flux 
and protects against oxidative stress (23). It also bears noting 
that ROS can transduce mitogenic signals at low levels where 
oxidant stress and macromolecular damage may be less of a 
consideration (105,106), suggesting additional mechanisms 
whereby metabolism interacts with realistic environmental 
exposures.
Hypoxic stress
Cells in rapidly growing tumors are subject to widely varying 
O2 tensions (61,107). Cancer-associated adaptations to hypoxic 
stress are well described, but the specific roles played by hypoxia 
in the earliest origins of cancer are still incompletely defined. 
Hypoxic signal transduction plays established roles in regulat-
ing gene expression associated with both cancer development 
and metabolism (61), suggesting causal contributions. Warburg 
hypothesized that repeated exposures to sublethal concentra-
tions of respiratory poisons (so-called chemical hypoxia) was 
sufficient to induce cancer formation due to associated pri-
mary structural and functional changes in mitochondria (11). 
Although a primary role for mitochondrial damage in cancer 
genesis is now widely discounted (6,12,23,108), the reported 
ability of chronic intermittent hypoxia to promote the carcino-
genic transformation of cultured myocardial fibroblasts (109) 
is consistent with the notion that chronic hypoxia or hypoxia-
associated changes may directly or indirectly contribute to 
metabolic reprogramming and cancer development. However, 
these findings have not been independently validated during 
the course of the intervening half-century, and hypoxia per se 
has not been shown to unambiguously increase either sponta-
neous or inducible cancer development in vivo (6). Nonetheless, 
the ability to tolerate widely varying O2 tensions has profound 
implications for cancer cell survival and selection during tumor 
growth, tissue invasion and metastasis. As such, the contribu-
tions of hypoxia to metabolic reprogramming are probably nec-
essary, if not sufficient, prerequisites for cancer development 
and progression.
Nutritional stress
Cancer cells, particularly metastatic cells, are exposed to highly 
variable nutrient concentrations (6). Given the increased ana-
bolic and catabolic demands placed on these cells by rapid and 
uncontrolled proliferative growth, nutrient variability poses 
major challenges for both carcinogenesis and cancer progres-
sion that may help explain metabolic reprogramming require-
ments in cancer. This can also serve as a basis for selection 
when individual cells compete for limited available resources.
Physical stress
Cancer cells are also subject to highly variable physical forces 
during both tumor growth and metastasis. Rapidly grow-
ing tumors are subject to intrinsic and extrinsic compression 
associated with increased tumor biomass, heterogeneous tis-
sue densities and altered extracellular matrix composition. 
Hydrostatic and oncotic pressure changes also contribute to 
elevated interstitial fluid pressure within solid tumors (110,111). 
In addition to shear stresses associated with cellular migration 
through interstitial and vascular compartments, cancer cells 
are exposed to varying hydrostatic and oncotic pressures during 
metastasis. Deforming stresses play a major role in metastatic 
selection (112), and malignant cancer cells exhibit increased 
resistance to shear stress (113). Since intermediary metabolism 
influences membrane composition and fluidity and also powers 
membrane repair functions (114,115), it is reasonable to specu-
late that these differences have metabolic determinants.
Other forms of cellular stress
As a consequence of systemic homeostasis and the constancy 
of the milieu intérieur (116), most normal cells are not exposed to 
significant physicochemical stresses under physiological condi-
tions. In contrast, the structural and functional changes associ-
ated with rapidly growing tumors subject cancer cells to stresses 
that differ qualitatively and quantitatively from their normal 
counterparts. As such, other potential forms of stress capable 
of influencing or selecting for cellular metabolism also warrant 
brief consideration. These conditions can have a primary meta-
bolic basis or induce metabolic adaptive responses—or both. For 
example, tumors exhibit lower pH than normal tissues (6,107). 
Glycolytic metabolism’s ability to influence microenvironmental 
pH is well described, and extracellular pH measurements are fre-
quently used interchangeably to monitor glycolytic responses. 
However, traditional attributions of extracellular acidification 
to associated lactate production ignore the fact that the pKa of 
3.87 for lactate strongly disfavors acid formation under broad 
physiological conditions (117). Microenvironmental pH changes 
in tumors thus reflect oxidative CO2 elaboration (118) and the 
variable contributions of metabolic H+ generation coupled to 
extracellular extrusion via secondary active Na+/H+ antiport-
ers and monocarboxylate cotransporters (61,119). H+ extrusion, 
accompanied by the export of monocarboxylates such as lac-
tate, helps explain the fidelity of lactate as a marker of extracel-
lular acidification. Both intratumoral pO2 and pH are spatially 
heterogeneous and poorly correlated with each other (120), and 
a corresponding lack of concordance between extracellular pH 
and lactate accumulation also exists (121,122). The ability of gly-
colysis-deficient Ras-transformed cells to acidify their extracel-
lular environment like their glycolysis-competent counterparts 
is also compatible with such a contention (118). Nonetheless, 
just as cellular metabolism can influence environmental pH, the 
converse is also probably true.
Relationships between dysregulated 
metabolism and other hallmarks of cancer
It is unlikely that dysregulated metabolism is functionally inde-
pendent of other cancer hallmarks given the number of known 
shared regulatory factors involved (21,38,123–126) and the fun-
damental anabolic and catabolic demands placed on cancer 
cells by core hallmarks such as sustained proliferation (6,21). 
Metabolism probably plays critical deterministic and supporting 
roles in cancer development, just as it does in normal develop-
ment. Not surprisingly, a number of metabolic parallels, includ-
ing similar glycolytic phenotypes, have been drawn between 
normal developing tissue and cancer (6,30). The phenotypic 
heterogeneity and unrestrained proliferative behavior of cancer 
may ultimately limit the generalizability of such comparisons 
to specific cancer types or stages, but dysregulated metabolism 
remains well positioned to serve as a fundamental enabler of 
other cancer hallmarks (3,127).
Metabolic dysregulation and reprogramming are strongly 
associated with cancer development (21), but there is limited 
evidence to support primary oncogenic roles for these changes. 
There is also a general tendency to discuss carcinogenesis and 
cancer progression interchangeably, as if they share a common 
metabolic basis. Although plausible, this inference has not been 
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experimentally validated or characterized. Similar roles are 
assumed, but the specific underlying changes and precise role(s) 
played by dysregulated metabolism in cancer genesis need not 
be identical to those associated with cancer progression. An 
understanding of the specific temporal and mechanistic rela-
tionships between exposures, altered metabolism, carcinogene-
sis and the development of other cancer hallmarks—along with 
an assessment of the persistence and potential reversibility of 
individual changes along the cancer continuum (Figure  5)—is 
needed to provide important mechanistic insights into funda-
mental cancer biology that can ultimately be exploited for ther-
apeutic benefit or cancer prevention.
Interactions between metabolism and apoptotic 
resistance
Growth factor signaling antagonizes apoptogenic stimuli and 
regulates intermediary metabolism (23,44). These dual inter-
secting functions may have a conserved evolutionary basis (33). 
PI3K–Akt–mTOR signaling, in particular, plays important roles 
in coordinating metabolism and promoting cell survival, and 
the specific contributions of Akt hyperactivation to oncogenesis 
have been attributed to fundamental roles in cellular energy 
metabolism that combine to inhibit apoptosis, increase cell 
proliferation and accelerate oncogenic mutation rates (34). The 
Glc dependence of anti-apoptotic growth factor and Akt signal-
ing contrasts markedly with the Glc independence of the cor-
responding effects of anti-apoptotic Bcl-2 family members (33). 
In fact, it was the recognition of this fundamental difference in 
metabolic requirements that initially led to the identification of 
the novel anti-apoptotic and pro-survival roles played by mito-
chondrial HK1 and HK2 (33). These high-affinity HK isoforms 
physically and functionally interact with mitochondria at outer 
membrane contact sites where both pro- and anti-apoptotic 
signals are known to converge (23,33). They mediate the anti-
apoptotic functions of growth factors by specifically promoting 
mitochondrial metabolite exchange that directly couples intra- 
and extramitochondrial metabolism and via direct antagonism 
of pro-apoptotic Bcl-2 protein interactions with mitochondria 
(23,33). Similar integrated roles for other mitochondria-coupled 
ATPases (e.g. glycerol kinases) have been suggested but not yet 
demonstrated (23).
Interactions between metabolism and genomic 
instability
Mutagenic carcinogens may act either directly or indirectly to 
produce genotoxic effects. Indirect effects on genomic stability 
can also be mediated through primary effects on intermediary 
metabolism and the cellular environment. Mechanisms contrib-
uting to such changes include—but are not restricted to—oxi-
dant stress. There is evidence to support the notion that chronic 
oxidative stress is a major contributor to nuclear genomic insta-
bility via secondary genotoxicity, although the magnitude and 
relevance of these effects have been questioned in the absence 
of accompanying DNA repair mechanism defects. Chronic oxi-
dative stress is strongly associated with cancer development 
(128,129) and correlates with DNA structural changes that pre-
date the appearance of overt histopathological changes or typi-
cal features of cancer (130,131). Functional mutational changes 
may involve either coding or cis-acting regulatory regions of 
genes encoding either the primary metabolic machinery or 
its upstream regulators (Figure  6). Similarly, mitochondrial 
genomic instability due to metabolism-associated oxidant 
stress is commonly invoked as an explanation for observed 
mutations in cancer-derived mitochondrial DNA, although this 
has not been directly demonstrated. A recent report of reduced, 
rather than increased, mitochondrial genomic instability in can-
cer tissue (132) is therefore of considerable interest. Intriguingly, 
these findings, which still remain to be validated, could chal-
lenge conventional dogma by suggesting that the mitochondrial 
genome is somehow stabilized in cancer, possibly via metabolic 
alterations that serve to reduce the accumulation of mitochon-
drial mutations that normally contribute to aging (132,133). It 
remains for future studies to address this apparent discrepancy 
between mitochondrial and nuclear genomic stability and its 
relevance to cancer and dysregulated metabolism.
Interactions between metabolism and replicative 
immortality
Cancer cells overexpress telomerase (134). In addition to its roles 
in maintaining chromosomal length, telomerase expression has 
been associated with increased Glc utilization, lactate accu-
mulation and glycolytic enzyme expression (135). Interestingly, 
telomerase can also be imported into mitochondria where it 
Figure 5. The metabolic phenotypes associated with carcinogenesis and during latency—and their specific relationship(s) to both parental cell phenotypes and the 
metabolic hallmarks of established cancer—represent key knowledge gaps. Carcinogenic exposure(s) may not result in characteristic cancer phenotypes for years 
or even decades. It is not presently known, however, whether the classical hallmarks of metabolic reprogramming and dysregulated metabolism precede or follow 
development of other recognizable cancer phenotypes. Little is known about the metabolic phenotype(s) of cells or tissues destined to produce cancer during periods 
of latency between exposure and the development of overt histopathological changes. Where metabolic changes occur in this disease continuum remain to be estab-
lished, and their direction, magnitude, reversibility and relationships to established cancer phenotypes will require careful characterization. Once delineated, it will be 
incumbent on future studies to establish whether or not such changes are binary and whether they are necessary and/or sufficient for cancer development.
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can protect mitochondrial function and cellular growth (136). 
The mechanisms underlying these effects and their specificity 
for—and relevance to—cancer have not been delineated, but 
the ability of ROS to activate telomerase suggests bidirectional 
mechanisms for adaptive or maladaptive interactions between 
metabolism and telomere maintenance important to both repli-
cative viability and survival.
Interactions between metabolism, tumor-promoting 
inflammation and immune system evasion
Inflammation promotes the development and progression of 
many cancers and enjoys an interactive, cyclical relationship with 
metabolism. Glc and lipid metabolism directly influence immune 
cell function (137–139), and specific metabolic dependencies of 
innate and adaptive immune cells can promote direct competi-
tion with cancer cells for limited intratumoral resources—includ-
ing O2 and nutrients—thereby promoting immune evasion (140). 
Altered microenvironmental pH or redox changes can also affect 
immune cell function and local cancer surveillance (138,140–142).
In addition, immune cells directly interact with cancer cells 
via bidirectional proinflammatory signals mediated by a vari-
ety of factors, including cytokines and extracellular metabo-
lites. For example, extracellular adenine nucleotides, succinate, 
NAD+ and urate can serve as proinflammatory metabolic signals 
promoting immune responsiveness (139,143), suggesting spe-
cific mechanisms whereby metabolism may help drive inflam-
mation. The reciprocal ability of proinflammatory cytokines to 
influence metabolism in diverse cell types (140,144–147) sug-
gests that trophic cytokines can directly couple inflammation to 
metabolism, providing a potential basis for vicious cycle devel-
opment between inflammation and cancer metabolism.
Interactions between metabolism and sustained 
proliferative signaling
Cellular transformation by oncogenic viruses or cellular onco-
genes is characterized by altered metabolism (6,8,107,148–150) 
and increased proliferative growth (151). Tumor suppressor inac-
tivation, like oncogene activation, is also linked to metabolic 
dysregulation. Specific changes vary by cancer type and indi-
vidual oncogenic effector involvement, but alterations in both 
Glc and Gln metabolism are common (107,152).
Many oncogenes and most proteins with known cancer-
associated somatic mutations are tyrosine kinases capable of 
mediating proliferative and trophic signals (24,153). Alterations 
in receptor and non-receptor tyrosine kinase signaling can have 
metabolic, as well as trophic, proliferative and anti-apoptotic 
consequences (44,154). As such, exposures that activate onco-
genes or mimic their trophic actions can contribute to meta-
bolic reprogramming and dysregulation. For example, oncogenic 
Ras promotes the development of multiple cancer hallmarks, 
including metabolic reprogramming (3) and proliferative sign-
aling pathway activation (86). It promotes glycolysis, reduces 
oxidative TCA cycle metabolism and enhances both Glc and Gln 
channeling into anabolic pathways (46,107,149,155). Oncogenic 
Ras also decouples Glc and Gln metabolism in support of can-
cer cell growth (156), and Ras-induced cancers characteristically 
exhibit heightened Glc dependence (157). Akt hyperactivation 
is also commonly observed in cancer and contributes to mul-
tiple cancer hallmarks, including proliferation and dysregu-
lated metabolism. Akt also mediates the anti-apoptotic effects 
of growth factors—phosphorylatable hexose-dependent effects 
that involve the interaction between HK and mitochondria 
(23,29,34,52). The ability of Akt to regulate metabolism is phy-
logenetically more conserved than its anti-apoptotic functions, 
Figure 6. Direct and indirect genotoxic and non-genotoxic contributions to metabolic dysregulation. Genotoxicity may directly influence metabolism by mutagenic 
disruption of either metabolic gene product function (a) or cis-acting elements important for expression (b). By extension, genotoxicity may indirectly influence the 
same processes via disruption of upstream regulatory gene product function (c) or expression (d). Alternatively, genotoxic effects (e,f) may disrupt important epistatic 
interactions between distant genetic loci. Non-genotoxic effects (g,h) may also contribute to metabolic phenotype development. By definition, both direct and indirect 
genotoxic effects, as well as non-genotoxic effects, must interact with other dynamic drivers of metabolism to determine the ultimate metabolic phenotype. As a con-
sequence, this phenotype may not always be fixed
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which correlate with the appearance of apoptogenic mitochon-
drial functions, suggesting an evolutionary basis for these inter-
actions (23).
Transcriptional regulators represent another important class 
of cellular oncogenes, and cancer-associated somatic muta-
tions in trans-acting factors are second only to protein tyrosine 
kinase mutants (153). For example, Myc upregulation is capable 
of promoting the development of multiple cancer hallmarks (3) 
via transcriptional coordination of gene expression promoting 
proliferation and metabolism (124). Myc-overexpressing cells 
exhibit both increased glycolysis and glycolytic gene expression 
(158).
The tumor suppressor p53, is activated by DNA damage, cel-
lular stress and oncogenic signal transduction (151) and exhib-
its pleiotropic anti-proliferative and metabolic effects that 
include metabolic cell cycle arrest (52,159). p53 also induces 
factors involved in DNA repair and maintenance of cellular 
redox homeostasis (150,151,160). Among these factors, Tp53-
induced glycolysis and apoptosis regulator (TIGAR) redirects Glc 
flux from glycolysis into the PPP, thereby augmenting NADPH-
dependent GPx activity and enhancing antioxidant capacity 
(161). Based on sequence homologies, TIGAR was originally 
classified as a fructose bisphosphatase capable of directionally 
opposing the actions of PFK (161). Recent biochemical character-
izations of this enzyme have suggested alternate metabolic sub-
strates and have called this primary classification into question 
(162). Nonetheless, TIGAR still provides an important mechanis-
tic link between p53 and its pleiotropic effects on metabolism. 
Interestingly, TIGAR also interacts with anti-apoptotic mito-
chondrial HK2 (163), although the functional implications of 
this interaction are incompletely delineated. Other p53 effects 
on metabolism include the promotion of oxidative Glc and lipid 
metabolism and reduced lipogenesis (125,150,164). Effects on FA 
oxidation are observed even in the presence of physiological Glc 
concentrations (164). The ability of p53 to regulate autophagy 
(165) also has catabolic implications, particularly in the setting 
of nutritional stress, and suggests additional potential influ-
ences on metabolic phenotype development (71).
Cell cycle-associated changes in metabolism are also recog-
nized (166) but poorly understood. A metabolic cell cycle check-
point requiring adenosine monophosphate (AMP)-activated 
protein kinase (AMPK)-induced p53 activation normally cou-
ples cell cycle to nutritional status (159) and other interactions 
between AMPK, p53 and PI3K–Akt–mTOR signaling are known 
(125). Collectively, they may serve to coordinate energy metabo-
lism with both trophic and stress-induced cellular responses.
Interactions between metabolism and angiogenesis
Many of the same factors and conditions favoring angiogenesis 
also modulate metabolism (107), suggesting coordinated regula-
tion. Angiogenesis also places catabolic and anabolic demands 
on poorly vascularized tissues with restricted access to O2 and 
metabolic substrates. Intermediary metabolism in resource-con-
strained environments thus plays crucial catabolic and anabolic 
support roles in rapidly growing angiogenic tumors. Hypoxia, in 
particular, represents an important stimulus for both angiogen-
esis and metabolic change, with hypoxia-inducible factor (HIF) 
serving as a master integrator for many of these responses that, 
in aggregate, advantage cancer cells subjected to hypoxic stress 
(61,107). Mitochondria-derived ROS also play important roles in 
HIFα stabilization and hypoxic signaling (167). There is a bidirec-
tional relationship between hypoxic signaling and metabolism, 
with αKG serving as an important metabolic substrate for prolyl 
hydroxylases regulating HIFα turnover (61).
Interactions between metabolism, tissue invasion 
and metastasis
Of all the cancer hallmarks identified by Hanahan and Weinberg 
(3,127), the capacity for tissue invasiveness and metastasis is 
arguably the most specific for cancer (15). Other hallmarks can 
be individually shared with many normal and benign tumor cells 
(15), and associated gene expression patterns vary considerably 
across intratumoral cell populations (168). As such, delineating 
the specific relationships between dysregulated metabolism 
and successfully invasive or metastatic cancer phenotypes are 
of paramount importance to understanding the contributions 
of metabolism. Metastasis is a highly selective and inefficient 
process (112,169). Studies comparing metastatic cells to parental 
tumor cells have confirmed significant heterogeneity in meta-
static potential and are consistent with the notion that meta-
static success is determined by selection (149,168). The ability to 
successfully invade tissue or metastasize is therefore probably a 
function of the intrinsic characteristics of the cell, as well as the 
environment (168). By definition, both local tissue invasion and 
distant metastasis involve cell migration through heterogeneous 
environments (168). So adaptations that equip cells to tolerate 
and survive environmental transitions are likely candidates for 
selection. Given the inherent variability in environmental condi-
tions, including O2 and nutrient availability, metabolism seems 
ideally suited to fulfill this criterion (149).
Cancer cells are bidirectionally interactive with the local 
tumor microenvironment, which is both shaped by—and selects 
for—altered metabolism (149,170). This relationship is not fixed 
for cancer cells within rapidly growing tumors or during local 
tissue invasion or metastasis, a fact that probably contributes 
to cancer heterogeneity (4,120). From a selection perspective, 
it can be argued that environmentally restrictive or inflexible 
metabolic phenotypes could be potentially maladaptive for cells 
exposed to the widely varying conditions anticipated within 
rapidly growing tumors and during invasion or metastasis (12).
The ability of cancer cells to influence their local microenviron-
ment can also directly enhance their invasive and/or metastatic 
potential. For example, microenvironmental reducing conditions 
activate matrix metalloproteinases via direct effects on redox-
sensitive cysteine residues that can promote both extracellular 
matrix remodeling and local tumor invasiveness (171).
Interactions between metabolism and epigenetic 
regulation relevant to multiple hallmarks
Epigenetic changes play important roles in carcinogenesis and 
have been associated with the development of multiple can-
cer hallmarks. Many of these changes can also be transgen-
erationally retained, like mutational changes (76,154,172,173). 
Intermediary metabolism has been linked to epigenetic gene 
regulation via a number of non-exclusive mechanisms (173). 
First, AMPK directly phosphorylates histones and mediates 
stress-induced changes in gene transcription (174), suggesting 
specific mechanisms whereby cellular energy status can be cou-
pled to transcriptional stress responses. In addition, ACC cata-
lyzes the initial rate-controlling step of de novo FA synthesis—the 
carboxylation of acetyl-coA to yield malonyl-coA—and globally 
competes with protein acetylation for available acetyl-coA (59). 
Given the central importance of histone acetylation in chroma-
tin remodeling (175) and established roles for acetylation in the 
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regulation of core elements of the transcriptional machinery 
(99), this represents another potentially important link between 
intermediary metabolism and epigenetic transcriptional regula-
tion. Inhibition of histone deacetylases by lactate accumulation 
(176) also suggests additional coupling mechanisms.
Mitochondrial ROS overproduction activates hexosamine 
pathway activation and O-linked transcription factor glycosyla-
tion and activation (177). This plays myriad roles in gene regu-
lation that are relevant to both proliferation and metabolism. 
Reciprocal relationships between O-linked glycosylation and 
phosphorylation of transcription factors have also been reported 
(97,177). Interestingly, AMPK regulates histone O-linked glyco-
sylation and vice versa (178), suggesting additional mechanisms 
coupling gene regulation to nutrient and energy status. Lastly, 
ornithine decarboxylase is essential for cell growth and prolif-
eration (179) and directly couples metabolism to gene regulation 
by catalyzing the synthesis of cationic polyamines, which inter-
act with anionic DNA and influence both DNA structure and the 
ability of trans-acting nuclear regulatory factors to bind their 
cognate cis-acting DNA binding sites.
Potential metabolic targets for 
environmental exposures
Against this important biological backdrop, major metabolic 
pathways (e.g. glycolysis, lipogenesis, the PPP and the TCA cycle) 
and signaling pathways associated with metabolic regulation 
were considered as potential metabolic targets, and selected 
prototypical targets were examined for evidence of cross-
talk with other cancer hallmarks in the published literature. 
Corresponding evidence for pro-carcinogenic environmental 
exposures capable of promoting metabolic reprogramming and 
dysregulation was then considered and used to identify pro-
totypical exposures with the potential to act on these targets. 
Both lists, merely intended to provide representative examples 
of potential starting points for future directed study, are subject 
to a number of caveats related to both underlying assumptions 
and gaps in our present understanding of the metabolic features 
of exposure-associated carcinogenesis that are addressed below. 
Limitations in the ability of existing risk assessment frame-
works to inform our understanding of the underpinnings and 
specific contributions of cancer metabolism are also considered.
Conceptual overview of potential metabolic targets
Pro-carcinogenic exposures can target cellular metabolism 
at a number of different levels via both direct and indirect 
mechanisms. In principle, multiple contributing mechanisms 
can also combine in different manners to yield the same phe-
notype (Supplementary Figure S2, available at Carcinogenesis 
Online), and changes in a given metabolic pathway can engen-
der reciprocal or complementary changes in other competing 
or coupled pathways. Distinguishing between primary and sec-
ondary metabolic alterations is thus crucial to understanding 
the relationships between specific exposures and associated 
pro-carcinogenic and metabolic changes, particularly follow-
ing prolonged latent periods accompanying exposure-associ-
ated cancer development. Durable cancer-specific effects must 
also be distinguished from similar short-term toxic or adaptive 
responses. In general, exposures can directly target discrete 
gene products responsible for (i) key metabolic reactions, (ii) cel-
lular transport or (iii) regulatory factors responsible for the coor-
dination, control or integration of sequential metabolic steps. 
The possibility must also be entertained that pro-carcinogenic 
effects may be indirectly mediated by changes in substrate or 
cofactor availability, allosteric feedback or environmental alter-
ations that physicochemically favor or disfavor pro-carcinogenic 
events (Figures 2 and 3). Exposures may also target metabolism 
at the cellular organizational level by perturbing supramolecular 
complex formation important for cellular structure or function 
or by disrupting metabolic compartmentalization important for 
metabolic channeling or its control.
Identification of potential targets for metabolic 
dysregulation
Selected metabolic processes with established functional 
importance or regulatory differences in cancer are depicted 
in Figure 2, and key associated metabolic or regulatory factors 
are listed in Table  1. Given their established biological impor-
tance, any of these factors could potentially serve as direct or 
indirect targets for metabolic dysregulation. To focus the search 
for such targets, a more limited set of prototypic targets ame-
nable to modulation by environmentally relevant exposures 
were also selected (Table 2; Supplementary Table S1, available 
at Carcinogenesis Online), and iterative cross-hallmark com-
parisons were made to identify possible interactions between 
specific dysregulated metabolic features and other cancer hall-
marks as described in both the Introduction and the accompa-
nying capstone article (20). A major limitation of these searches 
involved the unexpected paucity of unambiguous evidence for 
direct causal relationships between dysregulated metabolism 
and carcinogenesis. In general, the published literature was 
found to be highly biased by associative and descriptive stud-
ies that were neither designed nor intended to directly address 
specific metabolic contributions to carcinogenesis. In Table  2 
and Supplementary Table S1, available at Carcinogenesis Online, 
changes in selected prototypic targets were classified as having 
the potential to promote or antagonize development of non-
metabolic hallmarks based on directional responses to com-
mon exposures. In some cases, evidence of both promotion and 
antagonism was identified. Exposure and/or model differences, 
and dissimilar endpoints could account for some of these obser-
vations, although it bears noting that dysregulated metabolism 
is not a singular entity, so multiple directionally divergent rela-
tionships between ‘metabolism’ (broadly defined) and individ-
ual hallmarks are not only possible but expected.
Potential metabolic targets generally fall into several broad 
functional categories listed in Table 1. For potential targets with 
multiple molecular forms, targeting may be restricted to spe-
cific isoforms. The central amphibolic roles played by glycolysis 
and the TCA cycle make these pathways particularly attractive 
targets for primary or secondary dysregulation. By virtue of its 
essential involvement in every aspect of intermediary metabo-
lism and as a major determinant of flux through both anabolic 
branched pathways and the TCA cycle, glycolysis has naturally 
garnered the greatest attention. Other metabolic pathways may 
also constitute primary targets, but they would, of necessity, 
involve accompanying changes in amphibolic flux via glycolysis 
and the TCA cycle to fully support the anabolic and catabolic 
needs of rapidly proliferating cancer cells. As such, this list is 
not intended to be either comprehensive or definitive. Rather, 
it provides biologically plausible examples of primary meta-
bolic or regulatory targets suitable for additional study that are 
derived from our knowledge of the types of metabolic changes 
associated with cancer, our understanding of their underlying 
biochemical mechanisms and their regulatory characteristics. 
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Table 1. Selected metabolic pathway targets with established importance in cellular metabolism
Individual pathway targets Metabolic importance
Glycolysis (amphibolic)
HK •   Catalyzes the first committed step of Glc metabolism, which represents the entry 
point to all major physiologic pathways of Glc utilization (23)
•   High-affinity HK1 and HK2 isoforms physically and functionally interact with mi-
tochondria and directly couple intra- and extramitochondrial metabolism; major 
mediators of the anti-apoptotic functions of trophic factors (23,34) 
•   The inducible HK2 isoform is overexpressed in cancer and favors anabolic metabo-
lism, whereas the constitutive HK1 isoform favors catabolic Glc flux (35,37,38)
PFK •   Major irreversible rate-controlling step of glycolysis (180,181)
•   PFK1 regulated by AEC, as well as PFK2; PFK2 activated by AMPK
GAPDH •   Mediates critical binary NAD+/NADH coupling with either mitochondria or LDH to 
maintain glycolytic flux in the presence or absence of O2, respectively
PK •   Major irreversible rate-controlling step of glycolysis
•   The low affinity PKM2 isoform is strongly expressed in cancers and may serve to 
redirect glycolytic flux into anabolic pathways supporting lipid, nucleotide and Ser 
biosynthesis (182–186)
LDH •   Catalyzes the reversible NAD+/NADH-dependent interconversion of pyruvate and lactate
•   Important source for NAD+ required for glycolytic flux via GAPDH in the  
absence of O2 (187,188)
PDH complex •   Mediates the critical step committing the products of glycolysis to an oxidative fate 






phogluconate dehydrogenase, represents the principal source of NADPH for both 




•   Contributes to reductive synthesis of acetyl-coA from Gln-derived αKG under hypoxic 
conditions (57)
Fumarate hydratase •   Cancer-associated mutations; loss of activity can result in fumarate accumulation and 
disruptive non-enzymatic succination of cysteine residues in other proteins (191)
SDH •   Shared component of both the TCA cycle and the ETC (Complex II) (195)
•   Oxidizes succinate to form fumarate and reduced flavin adenine dinucleotide, 
thereby mediating e− transfer to ubiquinone in the ETC
•   Cancer-associated mutations (191)
Lipogenesis
ATP–citrate lyase •   Generates acetyl-coA for lipogenesis and regulatory protein acetylation from  
cataplerotic citrate
•   Upregulated in cancers (22)









Phosphoglycerate dehydrogenase •   Major role in Ser biosynthesis (51,73,183,199)
•   Commonly amplified in cancer (195)





Complex II (SDH) •   Only membrane-bound member of the TCA cycle
•   See SDH above




•   The Qo site serves as a cellular O2 sensor and serves to transduce a hypoxic signal 
and stabilize HIFα stabilization via ROS release (167)





affinity for O2 (202)
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Prototypic targets selected for cross-hallmark comparison based 
on current available evidence are also listed in Table 2.
Major rate-controlling steps in essential metabolic pathways 
are obvious potential targets for metabolic reprogramming, 
insofar as they represent important nodes for the integration 
and control of both major and branched pathway flux. In prin-
ciple, however, any essential step in a series of non-redundant 
reactions can be targeted to alter metabolism and/or its control. 
The overall metabolic impact of individual changes are likely to 
be dictated by a number of considerations, including the pres-
ence or absence of multiple functionally redundant isoforms, 
the presence or absence of major kinetic barriers to alternate 
paths of flux and relative cellular dependence on the affected 
pathway(s).
Glycolysis
In glycolysis, HK, PFK and PK are logical targets by virtue of 
established roles in controlling glycolytic flux (Figure 2). GAPDH 
also warrants consideration due to the fact that flux at this step 
is dependent upon either mitochondria- or LDH-derived NAD+ 
to proceed in the presence or absence of O2, respectively (23). 
In normal cells, this coupling is typically binary and reciprocal 
(23,122,187,188), whereas both couplings appear simultaneously 
permissible in cancer. Specific isoforms of HK and PK have par-
ticular relevance to cancer. For example, HK2 is overexpressed in 
cancer and promotes both anabolic metabolism and cell survival 
(23,38). Cancer cells also strongly express a highly regulated and 
less active form of PK (PKM2) that promotes diversion of Glc flux 
into anabolic pathways such as the PPP and Ser biosynthesis 
(182,183). PKM2 interacts with a number of cellular regulatory 
factors (208) and has multiple pleiotropic actions, including 
novel moonlighting functions (209) as a transcriptional coactiva-
tor and a protein tyrosine kinase (184,210,211). Major moonlight-
ing functions described for other glycolytic enzymes, including 
HK1, HK2 and GAPDH, suggest the possibility that metabolic 
enzymes may contribute to carcinogenesis via mechanisms dis-
tinct from their canonical enzymatic functions (209).
Lipogenesis, lipolysis and the PPP
Key enzymatic targets in both de novo FA synthesis (e.g. ATP–
citrate lyase [ACL], ACC and FASN) and lipolysis (e.g. LPL, MAGL 
and SCD) and their control have already been implicated in can-
cer development (52–54) and warrant additional scrutiny, both 
individually and in combination (Figure 2). Given the essential 
support roles played by PPP flux in lipogenesis, nucleic acid 
biosynthesis and resistance to oxidative stress (41), glucose-
6-phosphate dehydrogenase and 6-phosphogluconate dehydro-
genase (6PD) also represent major candidate targets meriting 
additional study (Figure 2).
TCA cycle
Within the TCA cycle, heritable cancer-associated mutations 
have been identified in both succinate dehydrogenase (SDH; 
ETC complex II) and fumarate hydratase (89,191). ROS genera-
tion and mitochondrial mutagenesis have been implicated in 
cancer pathogenesis associated with these mutations (89). 
Mitochondrial NAD+-dependent isocitrate dehydrogenase (IDH3) 
irreversibly catalyzes ETC-linked isocitrate oxidation, whereas 
mitochondrial (IDH2) and cytosolic (IDH1) NADP+-dependent iso-
forms can mediate bidirectional isocitrate–αKG interconversion 





GlcNAc modification of proteins
•   Hexosamine biosynthetic pathway flux is required to support trophic signaling and 
maintain Gln uptake needed for both growth and survival (45)
Cellular transport mechanisms





Monocarboxylate transporters •   Mediate the coupled extracellular extrusion of protons and monocarboxylates such 
as lactate (61)
VDAC •   Outer mitochondrial membrane channel that partners with the adenine nucleotide 
translocator in the inner mitochondrial membrane to form anionic metabolite ex-
change conduits at contact sites
•   Implicated in mitochondrial permeability transition pore formation and apoptogenic 
cytochrome c release following pro-apoptotic Bcl-2 protein binding
•   Molecular target of GSK3β signaling and mitochondrial HK binding responsible for 
regulating anion exchange and antagonizing apoptogenic signals above
Others
TIGAR •   Promotes Glc entry into the PPP in cancer cells to enhance nucleotide biosynthesis 
and antioxidant activity (163); originally classified as a low affinity fructose bisphos-






Sirtuins •   NAD+-dependent deacylases that regulate post-translational acylation (i.e. acetyla-
tion, succinylation and malonylation) of diverse target proteins, including histones 
(206,207)
Table 1. Continued
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(192). The latter reaction can directly couple with lipogenesis 
and epigenetic acetylation via reductive acetyl-coA formation 
by ACC (57,59). Cancer-associated mutations in both IDH1 and 
IDH2 occur early in carcinogenesis (212) and lead to NADPH-
dependent generation of the novel oncometabolite 2-hydrox-
yglutarate (2HG) which inhibits αKG-dependent enzymes 
important for hypoxic gene regulation and competes with bio-
synthetic reactions and GSH generation for available NADPH, 
thereby affecting lipogenesis, antioxidant protection, signal 
transduction, and epigenetic regulation (57,191–193,212–214).
Organizational or compartmental targets
The specific intracellular locations where metabolic events 
occur can help determine both the ultimate fate and func-
tional importance of individual metabolic reaction products. 
Widespread metabolic compartmentalization (37,87,88,215) and 
the archetypal example of mitochondria–HK coupling (23,35,37) 
are both compatible with this notion. As such, some abnormali-
ties observed in cancer could relate to altered compartmentali-
zation that redirects metabolic channeling and/or favors specific 
physical and functional interactions that promote cancer cell 
growth and survival (23,33,216).
In principle, pro-carcinogenic exposures can also affect 
intermolecular interactions required for the formation and 
function of complex organizational structures, including cell 
membranes, organelles, chromatin, and supramolecular meta-
bolic enzyme complexes such as metabolons (217,218) or ETC 
supercomplexes (219). Such targeting can be considered in both 
structural and functional terms and can involve both individual 
components and higher order integrated complexes. For exam-
ple, fundamental contributions by mitochondrial ETC activity to 
carcinogenesis are widely accepted and can reflect both func-
tional and structural mitochondrial changes (5). All respiratory 
complexes except complex II (SDH) can physically and function-
ally associate in dynamic supercomplexes such as the complex 
I-, III-, and IV-containing respirasome (219,220). Formation of 
these complexes influences both overall ETC function and indi-
vidual respiratory complex turnover (219), suggesting mecha-
nisms whereby ETC function may be targeted at the level of 
supercomplex assembly rather than at the level of individual 
respiratory complex components. As such, both individual ETC 
complex activities and supercomplex assembly represent poten-
tially attractive targets for carcinogenic disruption (200,219,221). 
Mitochondrial targeting could also involve altered ETC func-
tional coupling with transmembrane metabolite exchange and/
or redox-driven extramitochondrial processes. In addition to 
their fundamental catabolic and anabolic roles, mitochondria 
also serve as major ROS generators (102,171). If not counterbal-
anced by intrinsic antioxidant coping mechanisms (102), ROS 
accumulation can lead to oxidant stress, activation of oncogenic 
signaling and promotion of genomic instability. Mitochondria 
also importantly buffer cytosolic calcium concentrations (171) 
and initiate and control apoptosis via permeability transition 
pore formation and apoptogenic cytochrome c release (33,171).
Other organellar targets include the endoplasmic reticulum 
and the plasma membrane, the latter incorporating both cell 
surface trophic factor receptors and specific transport mecha-
nisms for transmembrane metabolite exchange (Figure  2). In 
addition to direct targeting of transport or signal transduc-
tion (addressed below), membrane organization and function 
can also be targeted through changes in membrane composi-
tion or structure that influence cellular function by altering 
membrane integrity or fluidity or via generation of cell surface 
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all intracellular compartmentalization is bounded by cellular 
membranes, so exposures that alter the normal establishment 
of non-organellar compartments or intracellular chemical gra-
dients (e.g. involving H+, Ca++, adenine nucleotides, or nicotina-
mide adenine nucleotides) could also contribute to metabolic 
dysregulation.
Metabolite transport mechanisms
Specific cellular uptake mechanisms are required for internali-
zation of exogenous substrates, including hexoses (e.g. GLUT 
[facilitated Glc transporters]), lipids (e.g. CD36), amino acids 
(222,223) and monocarboxylates such as lactate and pyru-
vate (218) (Figure 2). As such, transport mechanisms represent 
an important general class of potential carcinogenic targets. 
Mitochondrial and plasmalemmal ATPase activity coupled to 
transmembrane ion translocation critical for electrochemical 
gradient maintenance needed to support asymmetric metabo-
lite partitioning is also intimately coupled to cellular energy 
metabolism (8).
Mitochondrial HK also promote cell survival, in part, via 
direct coupling with mitochondrial metabolite exchange (33). 
The voltage-dependent anion channel (VDAC) in the outer mito-
chondrial membrane and the adenine nucleotide translocator in 
the inner mitochondrial membrane partner to allow movement 
of anionic metabolites such as adenine nucleotides, inorganic 
phosphate, pyruvate and succinate into—and out of—mito-
chondria. ATP–ADP exchange via this conduit directly couples 
intramitochondrial ATP generation with extramitochondrial ATP 
hydrolysis (Figure 3) (33) and is controlled by HK binding through 
mechanisms involving supramolecular complex assembly at 
mitochondrial contact sites (23,33,224). It is therefore of consid-
erable interest that VDAC and the adenine nucleotide translo-
cator have also been implicated in mitochondrial permeability 
transition pore formation. Competition between HK and pro-
apoptotic signals converging at VDAC-enriched mitochondrial 
contact sites is thought to directly couple metabolism to the 
antagonism of apoptogenic stimuli (23). As noted previously, 
these coupling mechanisms may also directly contribute to the 
Crabtree effect and the coordination of metabolism in different 
intracellular compartments (23).
Signal transduction targets
Numerous signaling effectors can transduce trophic, stress and 
energy status signals within cells. Although not metabolism-
specific, they frequently serve to couple metabolism with pro-
liferative and cell survival functions crucial for all cells. These 
pathways frequently overlap or intersect with oncogenic sign-
aling mechanisms and can assume particular importance in 
cancer. Trophic signal transduction pathways constitute par-
ticularly attractive targets for metabolic reprogramming and 
dysregulated metabolism (21,34,123). Hypoxic regulation of 
metabolism is also highly integrated with cellular signaling 
cascades involved in proliferation and stress responsiveness. 
As such, metabolism can be indirectly targeted via a variety of 
factors capable of modulating signal transduction pathways or 
associated coupling mechanisms that are capable of exerting 
metabolic control.
AMPK is a major sensor and regulator of cellular energy 
balance that may mediate the tumor suppressor effects of 
(LKB1) (225). LKB1 activates AMPK under appropriate condi-
tions, and its loss is common in cancer (225). AMPK is stimu-
lated by AMP levels and low corresponding AEC values, and 
its activation promotes a shift from anabolic to catabolic 
processes (226). Direct metabolic effects attributed to AMPK 
include increased Glc utilization and FA oxidation with cor-
responding reductions in lipogenesis and protein synthesis, 
which can be partly attributed to altered activation of key bio-
synthetic enzymes (205). These changes partly underlie the 
rationale for using pharmacologic activators of AMPK (e.g. 
metformin and salicylates) to treat selected cancers (225,227). 
The relationships between metabolism and energy signals 
are not fixed, and both metabolism and its regulation by LB1/
AMPK/mTOR signaling are highly contextual in nature (228). 
Similar relationships exist between metabolism and trophic 
factor signaling.
Sirtuins are NAD+-dependent deacylases with established 
roles in intermediary metabolism, cellular stress responsive-
ness and DNA maintenance and repair (206,207). They influence 
genomic stability via primary effects on Glc and lipid metabo-
lism and secondary effects on oxidant stress resistance and 
epigenetic histone acylation (206,229). In addition to effects in 
cancer cells, sirtuins can indirectly influence cancer cell sur-
vival and growth via immunomodulatory effects in activated 
immune cells (139,230).
Metabolic pathways importantly transduce cellular signals 
in addition to their conventional enzymatic and metabolic 
functions (Supplementary Figure S1, available at Carcinogenesis 
Online) (231). As such, metabolic disruption may have profound 
extra-metabolic consequences not fully reflected in conven-
tional metabolic profiles or assays. The metabolic effects of 
altered flux through a given pathway may also be mediated by 
exhaustion of—or competition for—limited quantities of shared 
cofactors that alter normal metabolic coupling mechanisms (e.g. 
disruption of oxidoreductase coupling via development of redox 
sinks) (Figure 3). Signal transduction pathways responsible for 
metabolic niche signaling or capable of influencing cancer dor-
mancy or reactivation are also attractive candidates for study 
(232).
Given its contextual and dynamic nature, efforts to better 
understand cancer metabolism must obligatorily consider the 
complexity and heterogeneity of cancer cells, their environ-
ment and their interactions. Cancer biology can vary consider-
ably over dimensions of both time and space (4) and may be 
amplified by deterministic considerations such as anabolic and 
catabolic demands imposed by proliferation or cellular stress. 
As such, variations in substrate or O2 availability or extracellu-
lar pH may provide logical platforms for investigation, but the 
corresponding importance of individual molecular targets may 
vary in parallel.
Evidence for pro-carcinogenic 
environmental exposures capable of 
promoting metabolic reprogramming and 
dysregulation
Toxicological data, available for many suspected or known envi-
ronmental carcinogens, frequently lack mechanistic and func-
tional information regarding their specific roles as determinants 
of metabolic hallmark development. Effects of agents examined 
in isolation also cannot be simply extrapolated to complex 
mixtures, particularly at low concentrations (1,17–19). The fun-
damental contributions of—and requirements for—metabolic 
restructuring in carcinogenesis are still incompletely delineated 
and, in many cases, have not been directly examined. Thus, nei-
ther a sufficient understanding of the potential pro-carcinogenic 
effects of realistic everyday exposures nor their potential meta-
bolic targets is available. As such, more rigorous experimental 
attention to fundamental underlying perturbations in cellular 
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metabolism by both individual exposures and the exposome 
(233) is clearly needed.
In principle, pro-carcinogenic exposures may be directly 
genotoxic, indirectly genotoxic or non-genotoxic (234,235). 
Exposures that are not directly genotoxic may be indirectly gen-
otoxic via mechanisms involving cellular metabolism (Figure 6), 
which can represent either a cause or a consequence of geno-
toxicity (Figures 1 and 7). For example, exposures with primary 
effects on oxidant stress or its amelioration can indirectly pro-
mote genotoxic injury. Both direct and indirect genotoxic or 
mutagenic stresses affect the mitochondrial genome, as well as 
the nuclear genome. They may also reflect the induction or repair 
of nuclear or mitochondrial DNA leading to reactive changes 
that may involve altered metabolism. Many toxicants are capa-
ble of damaging mitochondria (236), but toxicant-induced mito-
chondrial dysregulation with the potential to incur metabolic 
shifts to a pro-oncogenic state has been poorly studied, and 
not every toxic reaction resulting in changes mimicking can-
cer hallmarks is necessarily carcinogenic. Ultimately, rigorous 
validation is still needed to ensure that environmentally real-
istic exposures, including mixtures, are unequivocally linked to 
the development of both cancer and accompanying phenotypic 
hallmarks such as dysregulated metabolism. Ubiquitous agents 
present the most obvious opportunities for widespread continu-
ous exposure, but there is nothing to preclude substantive con-
tributions by more environmentally restricted or discontinuous 
exposures as well. Even universal exposures may vary in degree 
and need not be fixed to be pertinent to cancer development. 
These complex interactional possibilities, coupled with the fact 
that low-dose combinatorial effects on metabolism-supported 
and/or-limited cancer development and progression have not 
been rigorously or comprehensively addressed, speak to major 
gaps in our understanding of environmental cancer risk and 
the specific roles played by metabolism in associated cancer 
development.
Selected prototypical exposures with the potential to 
act on metabolic targets
A cross-hallmark search analogous to that employed for molec-
ular target selection was used to identify prototypical expo-
sures with the potential to promote metabolic reprogramming 
or dysregulation. Exposure classes identified as candidates 
for further scrutiny included organophosphates (e.g. diazinon 
and malathion), pyrethroids (e.g. cypermethrin), heavy metals 
(e.g. Fe, Cu, Ni and Cd), ETC poisons (e.g. rotenone) and reac-
tive aldehydes (e.g. acrolein) (Table 3; Supplementary Table S2, 
available at Carcinogenesis Online). Agents were selected for 
further study based on perceived environmental ubiquity and 
evidence of the ability to either directly or indirectly promote 
cancer hallmark-like effects and are intended as representa-
tive examples only.
Organophosphates
Low dose exposures to organophosphate insecticides such as 
diazinon and malathion are common and have been associ-
ated with increased cancer risk (237–241). Members of this 
chemically diverse group of agents share the common abil-
ity to irreversibly inactivate cholinesterases and other Ser 
hydrolases via covalent modification of catalytically active Ser 
residues (242). Organophosphates are also known endocrine-
disrupting chemicals (17,241), which makes them ideal can-
didates for the study of low-dose metabolic effects given the 
intrinsic sensitivity of the endocrine system (17) and estab-
lished endocrine actions relevant to many of the hallmarks 
Figure  7. Possible hierarchical relationships between environmental exposures, carcinogenesis and metabolism. (A) Metabolic changes may be either a direct (d) 
or indirect (i) consequences of environmental exposure. Only those subsets of exposure associated with both carcinogenesis and dysregulated metabolism (i and d) 
are considered above. The metabolic hallmarks of cancer may represent either a cause (B) or a consequence (C) of cancer development. (D) In principle, associated 
metabolic changes could also represent epiphenomena arising in parallel but bearing no direct causal relationship to cancer development per se. The absence of such 
a direct causal relationship does not preclude important roles for adaptive metabolic selection advantages. Most experimental approaches to the study of metabolic 
reprogramming and dysregulated metabolism in cancer have not been designed to distinguish between these scenarios.
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of cancer, including effects on metabolism, apoptotic suscep-
tibility and proliferation (17,154). Although direct cholinergic 
contributions to cancer development have been suggested, 
organophosphate-induced oxidant stress and associated gen-
otoxicity are thought to play more important etiologic roles 
(242). Interestingly, low level exposures during development 
have been associated with persistent postnatal abnormalities 
in both Glc and lipid homeostasis in rodents (243). The ability 
of organophosphates to covalently modify and inhibit cellular 
lipases, which are Ser hydrolases like acetylcholinesterases 
(244), suggests a least one mechanism whereby these agents 
may directly influence intermediary metabolism and promote 
compensatory reprogramming. Other direct metabolic effects 
are not well delineated.
Pyrethroids
Environmental exposures to pyrethroids, such as cypermethrin, 
are also common (245) and have been associated with oxidant 
stress (242,246) and alterations in both carbohydrate and lipid 
metabolism (247,248). Although the molecular underpinnings 
of these metabolic changes have been incompletely defined, 
pyrethroids are classified as EDC (17,154) and directly influence 
ion transport (246,249,250), suggesting several potential mecha-
nisms for interaction with metabolism.
Reactive aldehydes.
Reactive aldehydes, such as acrolein, are ubiquitous in the 
environment and possess demonstrated carcinogenic poten-
tial in animals (251). Acrolein, in particular, directly forms DNA 
adducts and inhibits DNA repair mechanisms that can amplify 
the toxicity of other agents. Mitochondrial DNA is particularly 
susceptible to such mutagenic damage due to absent nucleotide 
excision repair mechanisms (252). Acrolein and other reactive 
aldehydes like hydroxynonenal and oxynonenal are also pro-
duced endogenously by lipid peroxidation (251), suggesting both 
endogenous and exogenous sources of exposure and a specific 
basis for mechanistic interactions with other classes of agents 
that promote oxidant stress. Interestingly, these compounds are 
detoxified by the promiscuous metabolic enzyme aldose reduc-
tase, which has much greater affinity for these agents than for 
Glc (253) and is overexpressed in cancers (254).
Metals
Metals are ubiquitous in both biological systems and the 
environment (245,255–257). Their biocatalytic importance is 
underscored by the fact that roughly half of all enzymes are 
metalloproteins (255,258). It is therefore not surprising that dis-
ruption of metal homeostasis can have profound pathophysi-
ological consequences. Carcinogenic roles for both organic and 
inorganic forms of heavy metals are well-established (245,257). 
Unliganded metal ions such as iron (Fe), cadmium (Cd), copper 
(Cu), cobalt (Co), chromium (Cr) and vanadium (V) are capable of 
disrupting normal biocatalytic functions and generating ROS via 
either Haber–Weiss or Fenton-type reactions (256). Arsenic (As) 
and Cr are also capable of direct free radical generation (256). 
Metal ions thus represent important exogenous sources of ROS, 
and metal-induced oxidant stress and lipid peroxidation have 
been implicated in carcinogenesis (242,256). Although selec-
tive enzyme inactivation via covalent modification of thiols and 
other metal-reactive groups are well described (259), low-dose 
As exposure has been reported to augment metabolism in a 
manner reminiscent of cancer, possibly via induction of hypoxic 
signaling (259a, 259b, 259c). Metalloestrogenic contributions to 
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class of agents, metals have been identified as potentially capa-
ble of promoting the development of multiple cancer hallmarks 
(Table 3) and are thus attractive candidate effectors in both car-
cinogenesis and cancer hallmark development. Broad low level 
environmental exposures to barium (Ba), molybdenum (Mo), 
cesium (Cs), thorium (Th), tungsten (W) and uranium (U) are also 
well documented (245), although their relative pro-carcinogenic 
importance and metabolic effects are incompletely understood.
Specific caveats in cross-hallmark comparisons to 
prototypic pro-carcinogenic exposures
Prototypic exposure selection biases
Only previously studied exposures found in the published litera-
ture are included in the list of prototypic exposures selected for 
cross-hallmark comparison (Table  3). By definition, important 
unstudied or understudied exposures will be underrepresented 
in such a list. As a consequence, this list is incomplete and 
reflects fundamental literature biases that require special con-
sideration when planning or conducting experiments address-
ing pro-carcinogenic responses to environmental exposures. 
The listed prototypic exposures are merely intended as possible 
starting points for future studies addressing these deficiencies.
Implicit assumptions in cross-hallmark comparisons
Assessment of the ability of prototypic exposures to influence 
multiple cancer hallmarks warrants brief discussion. The very 
notion that an exposure can monolithically either promote or 
oppose the development of a given phenotype belies the dichoto-
mous nature of metabolism and presumes singular contribu-
tions and common underlying mechanisms, as well as similar 
time courses of action and directional congruence across models. 
Since no single model is sufficient for the study of cancer metabo-
lism, all such studies should ideally be experimentally validated 
in diverse cancer-relevant models under non-monotonic condi-
tions (18). Selected comparisons were largely between monotonic 
exposures and the development of individual hallmarks with no 
set requirements for evidence of either cancer specificity or the 
concomitant or sequential development of multiple hallmarks in a 
common model under identical—preferably environmentally rel-
evant—conditions. These may not be trivial considerations given 
the intrinsic heterogeneity of cancer cells (4,29,30,120,168,261) 
and the fact that the various hallmarks examined are neither 
fixed nor specific for cancer (4,15,262). A disproportionate focus of 
the current literature on the effects of industrial chemicals may 
also overlook many important exposures to natural carcinogens, 
radiant energy and infectious agents (1,263). Given the paucity 
of relevant functionally validated data and known publication 
biases against low dose non-monotonic responses (17), it is likely 
that many important environmentally relevant exposures were 
not captured by these searches. Other promising exposures iden-
tified during the course of this review, but not captured by the 
prototypic exposure search, were not included due to space con-
straints or prior classification as known or probable carcinogens. 
Of these, benzo[a]pyrene probably warrants brief mention as one 
of the few known agents capable of inducing sustained metabolic 
alterations in vivo following a single systemic exposure (264).
Selectivity requirements for prototypic pro-carcinogenic 
exposures
Although an attempt was made to identify exposures with the 
potential to selectively modulate metabolism, not all pro-car-
cinogenic exposures need to selectively affect metabolism to 
contribute to cancer development. Recognizing that multiple 
simultaneous or sequential insults or defects may be required 
for carcinogenesis (1,127,265), it is conceivable that any mecha-
nistic selectivity required for cancer development may be pro-
vided by a subset, rather than all, of the required promotional 
insults, whether simultaneous or sequential. Non-selective 
exposures may combine with more selective insults to yield 
selective derangements. For example, if oxidant stress is an 
important determinant of disease development, the nature of 
the stress—including its magnitude, duration, location and phys-
icochemical basis—may be more important than its source(s). In 
principle, a non-selective agent could simply lower the suscep-
tibility threshold for other, more selective agents or vice versa. 
Underlying comorbid disease states and genetic susceptibilities 
also play important roles in the establishment of predisposing 
or permissive conditions conducive to cancer development. 
The roles for multiple simultaneous, sequential or cumulative 
effects may also differ between targets, effectors and individual 
hosts. Metabolism itself may serve as an enabler of other car-
cinogenic contributors. For example, general permissive effects 
on cell metabolism could indirectly support cancer development 
by supporting associated proliferation and growth and/or by pro-
viding selection advantages via the flexibility to utilize alternate 
substrates to adapt to varying environmental conditions.
Implicit assumptions and corresponding knowledge gaps related 
to the metabolic features associated with early carcinogenesis 
and latency
It is reasonable to assume that metabolic phenotypes associ-
ated with early carcinogenesis share at least some features 
with established cancers, although this has not been firmly 
established. The temporal relationships between environ-
mental exposures and cancer development are frequently 
extended (so-called latency; Figure 5), which increases exper-
imental complexity due to the sheer number of potential 
intermediate effectors and the extended timeframes over 
which direct and indirect effects may evolve. As such, there 
is a need for early surrogate markers of cancer development. 
Cancers arise from phenotypically diverse tissues and retain 
core parental cell gene expression patterns (22), suggesting 
alternate paths to common shared phenotypes that can differ 
both qualitatively and quantitatively during cancer develop-
ment (Figure 5). For example, a highly glycolytic cancer phe-
notype arising from a glycolysis-dependent parental tissue 
such as brain would presumably develop via fundamentally 
different mechanisms than a similarly glycolytic cancer aris-
ing from tissues with a lower dependence on glycolysis such 
as liver or the endocrine pancreas. Since the metabolic phe-
notype of cancer is neither fixed nor specific for cancer (4), 
it is plausible to assume that changes associated with car-
cinogenesis may vary similarly. As such, there is a compelling 
need to both define and better understand the changes asso-
ciated with both early carcinogenesis and established cancer. 
The persistence and reversibility of effects associated with 
the entire spectrum of cancer development and their identity 
with fully established cancer phenotypes warrant particular 
attention (Figure  5). The ability of discontinuous exposures 
to mimic continuous exposures and cumulative effects also 
require careful scrutiny.
Assessment of pro-carcinogenic potential in complex 
environmentally relevant mixtures
Implicit in the concept of exposome-specific effects (233) are 
notions of additive and synergistic contributions to the aggre-
gate carcinogenicity of complex low concentration chemical 
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mixtures (266,267). As such, compounds or classes of chemicals 
already considered—or suspected as—isolated carcinogens in 
the classical sense may contribute to cancer genesis and pro-
gression in complex mixtures at concentrations not tradition-
ally deemed carcinogenic. These compounds thus warrant 
reconsideration as well. It is not practical to assume that indi-
vidual contributions to the effects of complex mixtures can be 
simply deduced from aggregate responses. It is also perhaps not 
practical to assume that common mechanisms of action are 
always a given for agents within classes (250), nor can it be con-
fidently assumed that agents from different classes have differ-
ent mechanisms or modes of action. Not every pro-carcinogenic 
compound in a low-dose chemical mixture need act with the 
same mechanism of action, on the same cells, or even at the 
same time, so spatiotemporal considerations may be as impor-
tant as specific mechanisms of action. For these reasons, con-
ventional approaches for study, such as those specified within 
the World Health Organization/International Programme on 
Chemical Safety framework (268), may miss meaningful low 
dose interactions in promoting metabolic changes, the develop-
ment of other phenotypic hallmarks and cancer development. 
Future studies must be specifically designed to address these 
issues.
Acutely toxic versus long-term pro-carcinogenic effects
Another major experimental difficulty encountered in the selec-
tion and study of exposures with the potential to reprogram 
metabolism involves the fact that candidate exposures fre-
quently exhibit acute toxicity or elicit acute cellular responses 
that can be qualitatively or quantitatively indistinguishable 
from changes associated with true long-term carcinogenic 
effects. As such, it can be inherently difficult to distinguish acute 
toxic effects from cellular responses mimicking known cancer 
hallmarks if unambiguous relevance to cancer development is 
not demonstrated. There is, however, no established require-
ment that pro-carcinogenic agents must be acutely toxic nor 
that toxicity obligatorily leads to carcinogenicity. In fact, it can 
be argued that many, if not most, pertinent environmental expo-
sures need not be demonstrably toxic.
Limitations of current toxicology screening 
approaches and future directions
Experimental approaches to carcinogenesis have historically 
focused on high level exposures associated with robust short-
term effects. Given the practical limitations and expense of in 
vivo testing for carcinogenic potential (19), increasing emphasis 
has been placed on probabilistic in vitro high throughput screen-
ing (HTS) approaches that rely on surrogate in vitro ‘single point’ 
pathway activation testing in a standard cell model (235). Much 
of the focus has also shifted to the establishment of ‘safe’ single 
agent exposure thresholds in these models (19). In this regard, 
conventional toxicological assays and current HTS methods 
alone are ill-suited to define or focus the specific role(s) of dys-
regulated metabolism in carcinogenesis. Many screening plat-
forms rely on the ability to discern ‘toxicity signatures’ and may 
provide associative information with limited specificity for—or 
mechanistic insights into—cancer metabolism per se. Given 
the highly contextual nature of metabolism, both assay condi-
tions and the biochemical appropriateness of specific metabolic 
changes may be as important as their fundamental nature or 
direction. Alterations in control may also be as important as 
alterations in capacity (12,13) and may be missed in screens spe-
cifically targeting gene expression changes. Additional testing, 
including metabolic flux analysis, is thus needed to establish 
metabolic relevance, provide associated mechanistic insights 
and identify specific pro-carcinogenic inputs. Specificity for indi-
vidual cancer types and the generalizability of results obtained 
in single models must also be assessed. Promiscuous assays are 
likely to identify non-specific agents or effects. Newer systems 
biology approaches to toxicological screening and evidence-
based toxicology bring numerous strengths to the table and, 
in theory, have the power to markedly expand chemical test-
ing capabilities. Unfortunately, they are also uniquely limited 
in their ability to address dysregulated metabolism. For exam-
ple, the United States Environmental Protection (EPA) Agency 
Toxicology Forecaster (ToxCast) and associated multiagency 
Toxicology in the 21st Century Program (Tox21) screening plat-
forms address toxicity or toxic response pathway activation, but 
they do not yield cancer-specific results.
The ToxCast platform is a heterogeneous collection of in vitro 
HTS assays used to identify agents capable of promoting gene 
expression changes that mimic toxicity or disease develop-
ment in vivo. None of these assays directly assess metabolism, 
and their monotonic single-point nature limits their ability to 
provide important spatiotemporal and functional information 
needed to delineate specific metabolic contributions, address 
the reversibility of observed changes or distinguish between 
acute toxicity and more sustained carcinogenic effects involving 
common effectors. They also do not recapitulate the complexity 
and heterogeneity of in vivo biological responses to the expo-
some (233). For example, trans-activation by the Myc oncogene 
has been associated with alterations in both Glc and Gln metab-
olism (152), and numerous metabolic gene transcripts have been 
identified in the Myc-induced transcriptome. The MYC gene has 
also been mapped to the hallmark of ‘energy metabolism’ by 
an EPA literature review process (235). It is somewhat discon-
certing, however, that ToxNet screening using a standard MYC 
reporter gene assay has not validated this association (235). This 
negative result may have any number of potential explanations, 
none of which exclude Myc involvement in metabolic changes 
associated with cancer. This assay presumes a unitary mode of 
trans-activation and employs a single hepatocellular carcinoma 
cell line stably transfected with a chimeric reporter gene con-
struct driven by a canonical cis-acting Myc-binding motif fused 
in a non-native context to a minimal heterologous promoter 
sequence (269,270). Positive results thus require validation of 
endogenous target gene transcript changes in representative 
cancer models, and negative results can be completely unin-
formative. The Tox21 program will seek to expand the reach 
of ToxCast by pooling the combined HTS resources of multiple 
United States federal agencies (270a). The emphasis of these 
HTS platforms, however, is still firmly on new monotonic in 
vitro assays not designed nor equipped to specifically address 
metabolism per se. As such, they have limited direct utility in the 
detection or characterization of metabolic changes associated 
with cancer development.
No universal metabolic gene expression changes have yet 
been identified in cancer, and cellular origin strongly impacts 
overall metabolic gene expression patterns (22). Approaches 
designed to detect large gene expression changes assume 
that changes in capacity are sufficient to account for met-
abolic phenotype development and do not address the 
dynamic controlling influences of substrate availability, 
allosteric feedback or cellular energy demands in intact 
cells (Supplementary Figure S1, available at Carcinogenesis 
Online). As such, they may fail to detect crucial determi-
nants of dysregulated metabolism. The routine use of fixed 
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non-physiological culture conditions for HTS assays also rep-
resents a methodological cause for concern, as the nutrient 
largesse associated with standard culture conditions fail to 
recapitulate pertinent in vivo growth and selection conditions 
and may strongly influence results.
Genomic sequencing initiatives launched to identify somatic 
mutations associated with cancer development (271,272) have 
been driven, in part, by identification of specific mutations 
associated with trophic signaling and oncometabolite genera-
tion (191,273). The metabolic consequences of such mutations—
which may occur on the background of germline or somatic 
mutations in susceptibility genes important for DNA repair and 
maintenance (153)—require empiric determination via conven-
tional biochemical methods for which few experimental short-
cuts exist. Given the predominance of non-coding mutations 
(273,274) and the increasingly recognized importance of nonlin-
ear epistatic gene interactions and epigenomic cis-acting regu-
latory element modifications in disease development (Figure 6) 
(274), more comprehensive systems-based approaches incor-
porating such biological knowledge into genotype analysis and 
interpretation are also needed (274).
Despite their conceptual appeal, unitary toxicological 
modes of action are not always predictable (255) and must be 
empirically validated, especially for dynamic and interactive 
processes such as intermediary metabolism. These considera-
tions assume even greater importance in carcinogenesis, which 
is a complex, multistage process where no universal mecha-
nistic requirements have yet been identified. Given the inher-
ent limitations of existing systems biology frameworks and 
platforms, novel or complementary approaches are needed to 
address the metabolic consequences of environmental expo-
sures and their specific contributions to carcinogenesis and 
associated hallmark development. Genomic, transcriptomic, 
proteomic and metabolomic approaches (Supplementary Figure 
S1, available at Carcinogenesis Online) provide powerful oppor-
tunities to identify specific patterns of gene expression and/
or metabolite accumulation that distinguish cancer cells and 
help focus additional targeted study, albeit with the caveat that 
metabolomic data, in its simplest form, provides static infor-
mation in the form of contextual snapshots of highly dynamic 
metabolic processes (86,275). Multiple distinct pathways may 
share individual metabolic intermediates (96), so conventional 
metabolic flux analysis under biologically relevant conditions 
is still needed to fully interpret this information. By definition, 
the experimental relationships between the exposome and 
the metabolome are not fixed (Supplementary Figure S1, avail-
able at Carcinogenesis Online), so such studies need to be care-
fully designed and standardized, as the type and magnitude of 
metabolic flux within cells will dynamically reflect a variety of 
intrinsic and extrinsic experimental variables, including sub-
strate availability, cell cycle stage, environmental conditions 
and extant energy demands. As such, perturbational profiling 
strategies (155,188) may enhance or complement conventional 
transcriptomic, proteomic, metabolomic and functional screen-
ing approaches to the identification of mechanistic determi-
nants of metabolic change.
Finally, no single model is probably sufficient to address 
the complex and heterogeneous metabolic changes that sup-
port cancer development and progression, and common cel-
lular phenotypes—such as proliferation—can exhibit diverse 
underlying mechanistic bases and metabolic dependencies 
(16). However, a better understanding of the fundamental met-
abolic requirements and associated molecular prerequisites 
for cancer development is likely to accelerate progress in the 
field. Recent advances in targeted genomic modification and 
the availability of CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats)/Cas9-based genome-wide muta-
tional screening libraries makes phenotypic screening for 
obligatory metabolic gene requirements in cancer hallmark 
development and selection feasible (276–278). As such, this 
represents a promising new screening platform for address-
ing the underlying requirements of functional alterations not 
currently amenable to study via HTS approaches. The abil-
ity to screen for specific metabolic phenotypes and selective 
growth or survival advantages, without a priori assumptions, 
should facilitate the identification of specific gene expres-
sion requirements for (i) metabolic phenotype development or 
loss, (ii) changes in metabolic control or (iii) the development 
of tolerance or flexibility to respond to altered growth condi-
tions or stresses. In theory, screens can be specifically devised 
to mimic microenvironmental conditions to identify genetic 
requirements for the ability to thrive under nutrient-limited, 
hypoxic, oxidative, acidotic or other stressful physicochemical 
conditions, both individually and in combination. In principle, 
they can also be designed to select for co-development of other 
cancer hallmarks or to identify specific genetic requirements 
for carcinogenic susceptibility.
Discussion
Metabolic reprogramming and dysregulation are widely recog-
nized correlates of—if not absolute prerequisites for—both can-
cer genesis and progression. If and where metabolic changes 
constitute obligatory steps on the path of carcinogenesis, how-
ever, remain incompletely delineated (Figure  5). Most work 
in the field has focused on the hallmarks of established can-
cer, but the metabolic features associated with cancer genesis 
could fundamentally differ in nature, magnitude or direction 
from those associated with established cancer or its progres-
sion. As such, there is a compelling need for additional basic 
research to understand the timing of appearance and subse-
quent natural history of characteristic metabolic changes, as 
well as their mechanistic underpinnings and specific functional 
contributions to cancer development and progression. In their 
seminal 1981 report to Congress, Doll and Peto (1) argued that 
both ‘mechanistic’ and ‘black box’ approaches to the study of 
cancer were needed to reduce avoidable environmental risks. 
Now, over three decades later, this assessment is still valid. It 
can be argued, however, that our mechanistic understanding of 
carcinogenesis has failed to keep pace with our ability to iden-
tify risk. In the specific case of cancer metabolism, current HTS 
strategies for risk assessment have the potential to widen this 
gap if not obligatorily coupled to rigorous functional analysis 
under biologically relevant conditions.
Warburg’s proposed primary role for fixed mitochondrial 
defects in cancer development (5,11,279) has now been largely 
discounted (6,7,23,280). Nonetheless, it does not follow that 
mitochondria cannot—or do not—contribute to cancer genesis 
and progression (6,281), albeit perhaps not in the manner that 
Warburg originally envisioned. Given their vital amphibolic roles, 
fundamental involvement seems likely, if not obligatory (171). 
Consistent with this notion, most cancer cells have unimpaired 
or increased capacities for oxidative metabolism (6,7,23), and the 
cataplerotic and catabolic support roles played by mitochondria 
in anabolic cancer metabolism are increasingly recognized. As 
such, simple characterizations of cancer metabolism as reflect-
ing a discrete shift from one type of metabolism to another are 
probably invalid (12,23) and owe more to Warburg’s original 
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hypotheses than his data or the subsequent literature (5,6,8,12). 
While it is reasonable to speculate that metabolic changes asso-
ciated with cancer are necessary but insufficient for carcinogen-
esis, additional basic research is needed to address the specific 
roles played by such changes in cancer susceptibility, genesis 
and progression, as well as their timing, interrelationships and 
importance relative to other fundamental hallmarks of cancer. It 
remains to be seen whether dysregulated metabolism is a cause 
or a consequence of cancer development—or both (Figures 1 and 
7). Given their ubiquity, it seems highly unlikely that metabolic 
changes associated with cancer are simply non-deterministic 
by-products of cancer development. The robust catabolic and 
anabolic requirements of rapidly proliferating cancer cells and 
the associated stresses that accompany rapid cell growth make it 
more likely that dysregulated metabolism provides an expanded 
metabolic repertoire serving to remove or minimize constraints 
limiting cancer development, growth or selection.
Cellular metabolism is inherently complex and dynami-
cally responsive to intrinsic and extrinsic factors relevant 
to cancer development and its progression (16). These fac-
tors are neither necessarily fixed nor specific for cancer and 
include ambient growth conditions, intrinsic and extrinsic 
trophic signals, substrate availability, proliferative state and 
associated catabolic and anabolic cellular demands. These 
complex interrelated variables may differ both quantitatively 
and qualitatively within or between cells and may fluctuate 
in direction, duration and intensity. Accordingly, metabolic 
phenotypes may vary widely between cancer cells at differ-
ent intratumoral locations and at sites of metastasis (16,168). 
They may also reflect changes in intrinsic substrate prefer-
ences independent of—or in addition to—substrate availabil-
ity or metabolic capacity. These factors and the reversibility 
of associated phenotypic changes must be rigorously interro-
gated when comparing cancer cells with their normal counter-
parts or parental precursors. The capacity for cellular energy 
generation greatly exceeds its utilization (8,25,80), and only a 
fraction of the potential energy available to cells is ultimately 
required for their survival (12,81). As such, metabolic control 
is probably a greater phenotypic determinant than metabolic 
capacity (12,13). Conventional biochemical analysis and flux 
studies are thus still needed to complement epidemiological 
and genetic approaches to the problem. Strictly statistical or 
‘gene’s eye’ views (282) of carcinogenesis and cancer metabo-
lism are unlikely to fully address these issues.
Experimental approaches to carcinogenesis have typi-
cally been designed to address the simplest and most robust 
responses and interactions—the so-called low hanging fruit in 
cancer development. Although justifiable on practical grounds, 
these approaches frequently involve untested or unproven fun-
damental assumptions regarding the functional or environ-
mental relevance of demonstrable changes—or their absence. 
Foremost among these considerations is the common tendency 
to assume that the largest changes are biologically most impor-
tant and the converse inference that a lack of demonstrable 
change betokens an absence of biological effects. The latter can 
be particularly problematic in studying intermediary metabo-
lism, insofar as (i) changes in metabolic flux need not be accom-
panied by steady-state changes in the absolute abundance of 
metabolic intermediates and (ii) very small changes in the direc-
tion or magnitude of flux may have profound functional conse-
quences and a disproportionately large phenotypic impact.
In addition to addressing common misconceptions, this 
review has attempted to broadly outline key unmet needs and 
unresolved issues in the field, in part, to provide a concep-
tual framework for future efforts focused on the mechanistic 
understanding of metabolism’s roles in exposure-associated 
cancer development. A number of major questions and experi-
mental challenges remain. For example, the reversibility of 
identifiable determinants of metabolic change associated with 
cancer development needs to be addressed. The relationships 
between short-term actions of candidate effectors and persis-
tent metabolic changes also require mechanistic interrogation 
to identify key transitional events and critical coupling mecha-
nisms linking metabolism to cancer development. The ability 
of discontinuous exposures to mimic continuous exposures 
also needs to be addressed. To effectively prognosticate, treat 
and ultimately prevent cancer, a fundamental understanding 
of its underlying biology—particularly its mechanistic origins, 
its spatiotemporal evolution and its fundamental phenotypic 
determinants—will ultimately be required. Environmental 
exposures do not occur in vacuo, however, and associated meta-
bolic changes will, by definition, occur against the backdrop of 
complex interactions with other environmental, genetic and 
epigenetic factors associated with cancer development and 
progression. Associations between some cancers and expo-
sures incurred during embryonic development suggest specific 
developmental context requirements (283,284) and are illustra-
tive of this concept.
Our fundamental understanding of cancer metabolism, its 
underlying mechanistic determinants, its control, its limits of 
capacity and its causal relationships with the development of 
both cancer and its accompanying hallmarks would be best 
served by the following general recommendations in designing 
follow-on research:
1. Both known and suspected carcinogens should be systemati-
cally examined for metabolic effects at environmentally rel-
evant concentrations and exposures. Metabolism should also 
be interrogated as both a potential cause and consequence of 
carcinogenesis (Figures 1 and 7), with the caveats that cancer 
is heterogeneous and relationships between metabolism and 
cancer development may differ according to both cellular ori-
gin and stage of progression (4). Given the long latent periods 
associated with cancer development following implicated 
exposures (Figure 5) (285–287), a better understanding of the 
temporal and causal relationships between carcinogenic 
exposures and the intermediate effectors linking them to 
their ultimate targets is required (Figures 1 and 7). Early sur-
rogate markers of carcinogenesis or carcinogenic commit-
ment are also needed to facilitate these efforts (288).
2. Rather than examining individual exposure-related out-
comes in isolation, the field would also be well served by 
more integrated approaches to the study of cancer biology 
that remain firmly anchored to unambiguous cancer-spe-
cific endpoints. The integration of multidisciplinary exami-
nation of environmentally relevant complex exposures into 
existing experimental frameworks should be a research 
priority for policy makers, and systems biology approaches 
to the study of carcinogenesis should fully incorporate cur-
rent biological and biochemical knowledge. In addition, 
correlative high throughput data should be viewed as criti-
cal translational research platforms for the generation of 
specific mechanistic hypotheses that can be taken back to 
the laboratory for refinement and definitive testing.
3. Metabolic studies of exposure-associated cancer devel-
opment should obligatorily be conducted under environ-
mentally and biologically relevant conditions, with special 
attention to dynamic controlling factors such as substrate 
availability, metabolic feedback, environmental condi-
tions and extrinsic trophic signals. Studies should also be 
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designed to explore non-monotonic relationships, as well 
as the sequence and natural evolution of individual pheno-
typic characteristics. The assumption of linear-no threshold 
models provides some rationale (albeit controversial) for 
studying high dose exposures, but there is no theoretical 
support for the idea that results of high-dose chemical per-
turbations can be simply extrapolated to low dose scenarios.
4. Finally, better triangulation and causal interrogation of 
the specific spatiotemporal and mechanistic relationships 
between environmental exposures, carcinogenesis and 
cancer hallmark development—particularly for dysregu-
lated metabolism—is needed.
These recommendations directly address crucial gaps in our 
present understanding of the metabolic contributions to envi-
ronmental carcinogenesis. They are intended to extend or com-
plement, but not supplant, existing efforts to identify, target and 
characterize mechanistic contributions to carcinogenesis.
The lifetime exposome, cancer and intermediary metabolism 
are all inherently complex and pleiomorphic entities, and their 
study, both individually and in combination, is subject to numer-
ous caveats and experimental limitations. Simple solutions to 
important complex problems are always desirable, but inherent 
complexity also sometimes demands intricate approaches and 
answers. There are few viable shortcuts in the study of metabo-
lism, and individual changes must always be considered in the 
context of the cellular gestalt. With this in mind, a pair of quotes 
pertinent to both metabolic complexity and its study—and used 
by Efraim Racker to close his now-classic tome on bioenergetics 
(8)—are reproduced as an epilogue below:
I have yet to see a problem however complicated that, when you 
look at it the right way, does not become more complicated.—Paul 
Adleston
Everything should be made as simple as possible but not sim-
pler.—Albert Einstein
Supplementary material
Supplementary Figures S1 and S2, Tables S1 and S2 and other 
Supplementary Information can be found at http://carcin.
oxfordjournals.org/.
Note Added in Proof
Space requirements precluded specific review of many impor-
tant aspects of normal system-wide metabolic homeostasis (e.g. 
the Cori and Randle cycles), as well as detailed treatment of 
tumor-host relationships. It is therefore important to emphasize 
in closing that cancer metabolism, in all its forms, is ultimately 
an open system engaged in metabolic exchange with the host, a 
fact that must be taken into account in both experimental and 
therapeutic approaches to cancer.
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Abstract
Lifestyle factors are responsible for a considerable portion of cancer incidence worldwide, but credible estimates from the 
World Health Organization and the International Agency for Research on Cancer (IARC) suggest that the fraction of cancers 
attributable to toxic environmental exposures is between 7% and 19%. To explore the hypothesis that low-dose exposures to 
mixtures of chemicals in the environment may be combining to contribute to environmental carcinogenesis, we reviewed 
11 hallmark phenotypes of cancer, multiple priority target sites for disruption in each area and prototypical chemical 
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disruptors for all targets, this included dose-response characterizations, evidence of low-dose effects and cross-hallmark 
effects for all targets and chemicals. In total, 85 examples of chemicals were reviewed for actions on key pathways/
mechanisms related to carcinogenesis. Only 15% (13/85) were found to have evidence of a dose-response threshold, whereas 
59% (50/85) exerted low-dose effects. No dose-response information was found for the remaining 26% (22/85). Our analysis 
suggests that the cumulative effects of individual (non-carcinogenic) chemicals acting on different pathways, and a variety 
of related systems, organs, tissues and cells could plausibly conspire to produce carcinogenic synergies. Additional basic 
research on carcinogenesis and research focused on low-dose effects of chemical mixtures needs to be rigorously pursued 
before the merits of this hypothesis can be further advanced. However, the structure of the World Health Organization 
International Programme on Chemical Safety ‘Mode of Action’ framework should be revisited as it has inherent weaknesses 
that are not fully aligned with our current understanding of cancer biology.
Introduction
Cancer is a burden on humanity and among the leading causes 
of morbidity and mortality worldwide, with ~14 million new 
cases and 8.2 million cancer-related deaths in 2012 (1). In gen-
eral, both genetic and environmental factors play a role in an 
individual’s cancer susceptibility (2,3), so there has been a long-
standing emphasis on avoidable ‘lifestyle’ factors (i.e. those 
that can be modified to reduce the incidence of the disease) and 
a parallel focus on exogenous chemical exposures (e.g. agricul-
tural, occupational and so on) (4). But advances in our under-
standing of the complexity of cancer biology have resulted in 
serious critiques of current risk assessment practices related 
to exogenous exposures (5) along with calls for an expanded 
focus on research that will allow us to evaluate the (potentially 
carcinogenic) effects of in-utero exposures and low-level expo-
sures to combinations of chemicals that occur throughout our 
lifetime (6,7).
The 2008–09 President’s Cancer Panel Annual Report in the 
USA (8) opined that the ‘true burden of environmentally induced 
cancer has been grossly underestimated’ (7), whereas Parkin 
et al. (9) estimated in a British study that the fraction of cancer 
that can now be attributed to both lifestyle and environmen-
tal factors is only 43% (i.e. the underlying cause of 57% of all 
cancers is still unexplained). However, an expanded focus on 
research that will allow us to evaluate the (potentially carcino-
genic) contribution of low-level exposures to combinations of 
chemicals that occur in utero and throughout our lifetime is not 
a trivial undertaking. 
First of all, the number of chemicals to which we are exposed 
is substantial, and many have not been adequately tested. 
Christiani (6) cited increased and persistently high incidence 
rates of various cancers and called on the National Institutes of 
Health to expand their investigation of environmental causes 
of cancer noting that ‘Massive gaps exist in toxicologic data, 
even in the case of widely used synthetic chemicals. Only about 
50% of chemicals classified by the Environmental Protection 
Agency (EPA) as “high production volume” have undergone 
even minimal testing for carcinogenicity’. But even though the 
incidence of cancer attributable to environmental exposures 
has not been definitively established (3,6), it remains an impor-
tant focus of our prevention efforts [with credible estimates 
from the World Health Organization [WHO] and the IARC sug-
gesting that the fraction of cancers attributable to toxic envi-
ronmental exposures is between 7% and 19%] (10,11).
The possibility that unanticipated low-dose effects (LDE) are 
also a factor in environmental carcinogenesis further compli-
cates matters. Vandenberg et al. (12) recently reviewed the accu-
mulating evidence that points to LDE that occur at levels that are 
well below those used for traditional toxicological studies. This 
review identified several hundred examples of non-monotonic 
dose-response relationships (i.e. examples where the relation-
ship between dose and effect is complex and the slope of the 
curve changes sign—from positive to negative or vice versa—
somewhere within the range of doses examined). Drawing on 
the known actions of natural hormones and selected environ-
mental chemicals examined in cell cultures, animals and epi-
demiology, the authors emphasized that when non-monotonic 
dose-response curves occur, the effects of low doses cannot be 
predicted by the effects observed at high doses. However, endo-
crine disruption research to this point has been aimed primarily 
at chemicals that disrupt developmental processes through a rel-
atively small subset of hormones (e.g. estrogen, androgen, thyroid 
and so on), and thus, many commonly encountered chemicals 
have not been tested at all for these effects (at environmentally 
relevant dose levels) and, to date, mechanisms that relate to car-
cinogenesis have typically not been the focus of these studies.
Generally for chemical risk assessments, toxicity stud-
ies are conducted with individual chemicals in animal mod-
els based on regulatory test guidelines [e.g. Organization for 
Economic Co-operation and Development (OECD) test guide-
lines (13)] with a key objective of providing a dose-response 
assessment that estimates a point of departure [traditionally 
the no-observed-adverse-effect level or the lowest-observed-
adverse-effect level (LOAEL)], which is then used to extrapo-
late the quantity of substance above which adverse effects can 
be expected in humans. The no-observed-adverse-effect level, 
combined with uncertainty factors (which acknowledge gaps 
in the available data), is then used to establish safety criteria 
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for human exposure. However, in order to be able to detect 
adverse effects utilizing classical toxicological endpoints, dose 
selection has historically involved the use of high dose levels 
and appropriate dose level spacing to obtain the LOAEL or no-
observed-adverse-effect level thresholds. Techniques such as 
linear extrapolation or benchmark dose modeling (14) are then 
employed to predict safety margins for low-dose exposures. 
This approach to risk assessment depends on the use of appro-
priate and sensitive endpoints, and on valid assumptions for 
extrapolation estimates (e.g. dose-response linearity) and cal-
culations, and on the existence of thresholds of effects (15–17). 
So when the potential for non-linear dose-response relation-
ships is combined with the possibility of synergism between 
and amongst low doses of mixtures of individual chemicals in 
the environment, it appears plausible that chemicals that are 
not individually carcinogenic may be capable of producing car-
cinogenic synergies that would be missed using current risk 
assessment practices.
The complex nature of the biology of cancer adds another 
layer of complexity for risk assessment. In a landmark paper 
in 1979, Ames (18) noted that damage to DNA appeared to 
be a major cause of most cancers and suggested that natu-
ral chemicals in the human diet and the tens of thousands 
of man-made chemicals that had been introduced into the 
environment in the preceding decades be tested for their abil-
ity to damage DNA. In doing so, he sketched out the difficulty 
of dealing with complex chemical mixtures and he proposed 
the use of rapid mutagenicity assays to identify environ-
mental mutagens and carcinogens. The strategy was sound 
at the time, but it led to a scientific and regulatory emphasis 
on ‘mutagens as carcinogens’, whereas the issue of complex 
environmental mixtures, or carcinogens that are not muta-
gens, was never vigorously pursued. Instead, what followed 
was an international quest to find individual chemicals and 
a few well-defined mixtures (e.g. diesel exhaust) that could be 
shown to be ‘complete’ carcinogens (i.e. substances that could 
cause cancer on their own).
However, advances in cancer biology have revealed the 
limitations of this approach. Armitage and Doll first laid out 
a multistage theory of carcinogenesis in 1954 (19), and by 
1990, initiation and promotion were well established as dis-
crete steps in the evolution towards malignancy, along with 
the influence of ‘free radicals’, proto-oncogenes, oncogenes, 
epigenetic mechanisms and other synergistic or antagonistic 
factors (20). In 2000, Hanahan et al. (21) gave structure to this 
rapidly growing field of research with the proposal that ‘the 
vast catalog of cancer cell genotypes [could be organized into] 
a manifestation of six essential alterations in cell physiology 
that collectively dictate malignant growth’. They called these 
alterations the Hallmarks of Cancer, defined as ‘… acquired 
capabilities’ common to most cancers that ‘… incipient cancer 
cells … [must acquire to] enable them to become tumorigenic 
and ultimately malignant.’ The hallmarks delineated at the 
time were as follows:
•	 Self-sufficiency in growth signals (later renamed proliferative 
signaling)—cancer cells grow at a seemingly unlimited rate.
•	 Insensitivity to antigrowth signals (evading growth suppres-
sors)—cancer cells are not subject to antigrowth signals or 
withdrawal of normal growth signals.
•	 Evading apoptosis (resisting cell death)—cancer cells avoid the 
usual process whereby abnormal or redundant cells trigger 
internal self-destroying (as opposed to cell death) mecha-
nisms.
•	 Limitless replicative potential (enabling replicative immortal-
ity)—cancer cells do not senesce (or age) and die after a lim-
ited number of cell divisions.
•	 Sustained angiogenesis (inducing angiogenesis)—cancer cells 
elicit new blood vessels to sustain growth.
•	 Tissue invasion and metastasis (activating invasion and 
metastasis)—in situ or non-invasive cancers, e.g. ductal carci-
noma in situ in the breast or carcinoma in situ in colon polyps, 
grow into pre-existing spaces but invasive tumors must cre-
ate a space to expand into normal tissue.
From this perspective risk assessments based on limited ‘mode 
of action’ information, assumptions of linear dose-response 
relationships and a focus on individual chemicals (as complete 
carcinogens) appeared to be inadequate to estimate human can-
cer risks. So in 2005, a scientist at the United States EPA called 
for a shift in risk assessment practices that would move the field 
towards the development of biomarkers directly related to the 
pathways found within the Hallmarks of Cancer framework (22). 
The Hallmarks of Cancer framework was subsequently revis-
ited by Hanahan et  al. (21) and expanded to encompass addi-
tional areas suggested by subsequent cancer research (23). This 
expansion included the following:
•	 Two enabling characteristics:
•	 Genome instability and mutation, which allows changes in one 
cell to pass to daughter cells through mutation or epigenetic 
changes in the parent cell DNA.
•	 Tumor-promoting inflammation, which helps cancer cells grow 
via the same growth signals normal cells provide to each 
other during wound healing and embryonic growth; inflam-
mation further contributes to the survival of malignant cells, 
angiogenesis, metastasis and the subversion of adaptive 
immunity (24).
•	 Two ‘emerging’ hallmarks:
•	 Avoiding immune destruction whereby tumor cells avoid 
immune surveillance that would otherwise mark them for 
destruction.
•	 Dysregulated metabolism, one of the most recognizable fea-
tures of cancer; its exclusion from the original list of hall-
marks (21) probably represented a significant oversight, as it 
constitutes one of the earliest described hallmarks of cancer 
(25,26). It is needed to support the increased anabolic and cat-
abolic demands of rapid proliferation and is likely an enabler 
of cancer development and its other associated hallmarks.
Unfortunately, risk assessment practices that are currently used 
to assess the carcinogenic potential of chemicals have changed 
very little (despite the vast literature that now underpins the 
main tenants of the Hallmarks of Cancer framework). For exam-
ple, a chemical that disrupts DNA repair capacity might prove 
to be non-carcinogenic at any level of exposure (when tested on 
its own), but that very same chemical may have the potential to 
be an important contributor to carcinogenesis (e.g. in the pres-
ence of mutagens that cause DNA damage). Similarly, a chemical 
that has immuno-suppressive qualities may not be carcinogenic 
on its own, but if it acts to suppress the immune response, it 
may contribute to carcinogenesis (by dismantling an important 
layer of defense) in the presence of other disruptive chemicals. 
Considering the multistep nature of cancer and the acquired 
capabilities implied by each of these hallmarks, it is therefore 
a very small step to envision how a series of complementary 
exposures acting in concert might prove to be far more carci-
nogenic than predictions related to any single exposure might 
suggest (see Figure  1). Interacting contributors need not act 
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simultaneously or continuously, they might act sequentially or 
discontinuously. So a sustained focus on the carcinogenicity of 
individual chemicals may miss the sorts of synergies that might 
reasonably be anticipated to occur when combinations of disrup-
tive chemicals (i.e. those that can act in concert on the key mech-
anisms/pathways related to these hallmarks) are encountered.
To address the biological complexity issue associated with 
chronic diseases, the EPA and other agencies have begun to pursue 
risk assessment models that incorporate biological information. 
This is the basis of the Adverse Outcome Pathway concept, a con-
struct that is gaining momentum because it ties existing knowl-
edge of disease pathology (i.e. concerning the linkage between 
a direct molecular initiating event and an adverse outcome at a 
biological level of organization) to risk assessment (27,28). This 
line of thinking inspired a recent initiative by the EPA, where 
the agency tested a proposal for characterizing the carcinogenic 
potential of chemicals in humans, using in-vitro high-through-
put screening (HTS) assays. The selected HTS assays specifi-
cally matched key targets and pathways within the Hallmarks 
of Cancer framework. The authors tested 292 chemicals in 672 
assays and were successfully able to correlate the most disrup-
tive chemicals (i.e. those that were most active across the vari-
ous hallmarks) with known levels of carcinogenicity. Chemicals 
were classified as ‘possible’/‘probable’/‘likely’ carcinogens or des-
ignated as ‘not likely’ or with ‘evidence of non-carcinogenicity’ 
and then compared with in-vivo rodent carcinogenicity data in 
the Toxicity Reference Database to evaluate their predictions. The 
model proved to be a good predictive tool, but it was developed 
only as a means to help the EPA prioritize many untested indi-
vidual chemicals for their carcinogenic potential (i.e. in order to 
establish priorities for individual chemical testing (29)).
What is still needed, is an approach employing the Hallmarks 
of Cancer framework that can be used to identify priority 
mixtures (i.e. those with substantive carcinogenic potential). 
Without a way to anticipate the carcinogenicity of complex 
mixtures, an important gap in capability exists and it creates 
a significant weakness in current risk assessment practices. 
Countries around the globe have made a significant investment 
in the regulatory infrastructure and risk assessment practices 
that protect us from unwanted exposures to harmful chemicals 
and carcinogens, so we wanted to review the biology of cancer 
to map out the challenges associated with the development of 
an approach that would help us assess the carcinogenic poten-
tial of low-dose exposures to chemical mixtures in the envi-
ronment. Such an approach was seen as a reasonable step to 
provide impetus for progress in this area of research and ulti-
mately to inform risk assessment practices worldwide.
Materials and methods
In 2012, the non-profit organization ‘Getting to Know Cancer’ instigated 
an initiative called ‘The Halifax Project’ to develop such an approach using 
the ‘Hallmarks of Cancer’ framework as a starting point. The aim of the 
project was to produce a series of overarching reviews of the cancer hall-
marks that would collectively assess biologically disruptive chemicals (i.e. 
chemicals that are known to have the ability to act in an adverse manner 
on important cancer-related mechanisms, but not deemed to be carcino-
genic to humans) that might be acting in concert with other seemingly 
innocuous chemicals and contributing to various aspects of carcinogen-
esis (i.e. at levels of exposure that have been deemed to be safe via the 
traditional risk assessment process). The reviews were to be written by 12 
writing teams.
The writing teams were recruited by Getting to Know Cancer circu-
lating an email in July 2012 to a large number of cancer researchers, ask-
ing about their interest in the project. Respondents were asked to submit 
personal details through a dedicated webpage that provided additional 
project information. A  total of 703 scientists responded to the email, 
and from that group, 11 team leaders were selected to lead reviews of 
each hallmark (10 Hallmarks plus an 11th team to consider the tumor 
microenvironment as a whole) and one leader for the cross-validation 
Figure 1. Disruptive potential of environmental exposures to mixtures of chemicals. Note that some of the acquired hallmark phenotypes are known to be involved in 
many stages of disease development, but the precise sequencing of the acquisition of these hallmarks and the degree of involvement that each has in carcinogenesis 
are factors that have not yet been fully elucidated/defined. This depiction is therefore only intended to illustrate the ways in which exogenous actions might contribute 
to the enablement of these phenotypes. 
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team (see below). Writing group leaders were asked to form individual 
teams drawn from the pool of researchers who expressed interest in 
the project and from their own circles of collaborators. Leaders were 
encouraged to engage junior researchers as well. Team leaders received 
project participation guidelines and ongoing communication from the 
project leaders, L.Lowe and M.Gilbertson. Each team included: a lead 
author with a published expertise in the hallmark area; domain experts 
who assisted in the production of the descriptive review of the biology; 
environmental health specialists (e.g. specialists in toxicology, endo-
crine disruption, or other related disciplines) and support researchers.
Each writing team was charged to describe the hallmark, its systemic 
and cellular dysfunctions and its relationships to other hallmarks. A pri-
ority list of relevant (i.e. prototypical) target sites for disruption was to 
be developed by the team and a list of corresponding chemicals in the 
environment that have been shown to have the potential to act on those 
targets was requested, along with a discussion of related issues and future 
research needed (in the context of project goals).
Selection of target sites for disruption
A ‘target’ was broadly defined as a procarcinogenic disruption at the sys-
tem level (e.g. the hypothalamic–pituitary–gonadal axis), organ level, tis-
sue level or cellular level. It was assumed from the outset that a project 
intended to develop an approach for the assessment of the carcinogenic 
potential of low-dose exposures to chemical mixtures in the environment 
would encounter a practical upper limit to the number of potential targets 
that any given team could realistically review. Therefore, each team was 
asked to identify up to 10 relevant targets for their domain (bearing in 
mind that each target would also serve as a starting point for the identi-
fication of a disruptive environmental chemical that had already shown 
a demonstrated ability to act on that target). In theory, it was understood 
that this could lead to as many as 110 targets for the entire project, and 
as the teams were also asked to select one disruptive chemical for each 
target, a maximum of 110 chemicals. 
In this phase, teams were asked to focus on specific gene changes 
common to many cancers as identified by The Cancer Genome Project 
(30) in order to estimate how the function of specific genes might be 
altered, not by specific gene mutations, but rather either by direct 
action or by epigenetic changes that might lead to the same functional 
ends. Most of these pathways and processes are found within both 
the hallmarks of cancer and the genomic frameworks, so teams were 
asked to evaluate both models and consider non-mutagenic/epigenetic 
pathways of interference as well (given that epigenetic changes such as 
DNA methylation and histone acetylation are relevant for cancer and 
often inducible by chemicals and may be transmitted to daughter cells).
Selection of disruptive chemicals
Teams were then asked to identify ‘prototypical’ chemicals in the envi-
ronment that had demonstrated an ability to act on the selected targets. 
During workshops in Halifax, the teams settled on the following criteria 
to guide their choices:
•	 Chemicals should be ubiquitous in the environment because we 
wanted the broadest possible relevance for the general popula-
tion.
•	 Chemicals should selectively disrupt individual targets such as 
specific receptors, specific pathways or specific mechanisms. Hypo-
thetically speaking, a chemical could affect more than one pathway, 
receptor and so on; indeed, we expected that most chemicals would 
likely exert a multitude of actions. However, we used the term ‘selec-
tively disruptive’ to encourage teams to avoid choosing mutagens 
that are randomly destructive in their action (i.e. unpredictable and 
capable of producing varying types of damage across a wide range 
of pathways).
•	 Chemicals should not be ‘lifestyle’ related, such as those encountered 
from tobacco, poor diet choices (e.g. red meats, French fries, lack of 
fruit and vegetables and so on), alcohol consumption, obesity, infec-
tions (e.g. human papillomavirus) and so on.
•	 Chemicals should not be known as ‘carcinogenic to humans’ (i.e. not 
IARC Group 1, carcinogens).
The choice to focus on environmental pollutants in this project was 
intentionally restrictive. Countries around the globe have made sig-
nificant investments in regulatory infrastructure and risk assessment 
practices to protect us from unwanted exposures to harmful chemicals 
and carcinogens. Therefore, we focused on chemicals that are com-
monly encountered in the environment. Primarily, we wanted to gen-
erate insights that would be valuable for cancer researchers who are 
specifically interested in environmental chemical exposures to chemical 
mixtures and/or those who are focused on risk assessment practices in 
general.
Dose-response characterizations and LDE
Given that much of the evidence in the toxicological literature that docu-
ments the disruptive actions of various chemicals has been produced 
under a wide range of differing experimental circumstances, we wanted 
to assess the quality and relevance of data that were gathered for expo-
sures discussed in this review. Specifically, for each chemical selected 
and each mechanism identified, teams were additionally tasked to iden-
tify any dose-response characterization results and/or relevant low-dose 
research evidence that might exist. The term ‘low dose’ was defined using 
the European Food Safety Authority definition (i.e. responses that occur at 
doses well below the traditional lowest dose of 1 mg/kg that are used in 
toxicology tests) and the definition for ‘LDE’ was based on the EPA defini-
tion (31)—as follows:
Any biological changes occurring
(a) in the range of typical human exposures or
(b)  at doses lower than those typically used in standard testing proto-
cols, i.e. doses below those tested in traditional toxicology assess-
ments (32), or
(c)  at a dose below the lowest dose for a specific chemical that has 
been measured in the past, i.e. any dose below the lowest observed 
effect level (LOEL) or LOAEL (33)
(d)  occurring at a dose administered to an animal that produces blood 
concentrations of that chemical in the range of what has been 
measured in the general human population (i.e. not exposed oc-
cupationally, and often referred to as an environmentally relevant 
dose because it creates an internal dose relevant to concentrations 
of the chemical measured in humans) (34,35).
Each team was then asked to categorize each chemical by using one of 
five possible categories (to determine the relevance and relative strength 
of the underlying evidence for each of the chemicals being considered). 
The categories were as follows: (i) LDE (i.e. levels that are deemed relevant 
given the background levels of exposure that exist in the environment); 
(ii) linear dose-response with LDE; (iii) non-linear dose-response with LDE; 
(iv) threshold (i.e. this action on this mechanism/pathway does not occur 
at low-dose levels) and (v) unknown. Additional details of the descriptions 
for each of these categories are shown in Table 1.
Cross-hallmark relationships
In recognition of the network of signaling pathways involved and the 
degree of overlap/interconnection between the acquired capabilities 
described in each hallmark area, the project included a cross-validation 
step to create a more complete mapping of the actions that might be 
anticipated as the result of an action on the target sites identified or by 
the disruptive effects of the chemicals selected. Given the diversity of the 
targets involved in the 11 hallmark areas, it was anticipated that inhibit-
ing or stimulating a target relevant to one hallmark may have an impact 
on other targets that are relevant, especially if both are linked via signal-
ing pathways.
Accordingly, the cross-validation team conducted additional back-
ground literature review of submitted targets and chemicals from each 
writing team, searching for evidence to identify cross-hallmark activity. 
Each potential target-hallmark or approach-hallmark interaction was 
assessed to determine whether the inhibition or activation of each tar-
get and the corresponding biological activity of each chemical might 
reasonably be expected to have either a procarcinogenic or anticarcinogenic 
effect on key pathways/processes in the various hallmark areas.
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The cross-validation team also sought out controversial interactions 
(i.e. mixed indications of hallmark-like effects) and instances where no 
known relationship existed. It was our belief that target sites or chemicals 
that demonstrated a substantial number of ‘anticarcinogenic’ effects in 
other hallmark areas would be less suitable to serve as instigating con-
stituents in the design of carcinogenic mixtures (where procarcinogenic 
synergy was being sought).
It is important to note that the cross-validation team was not 
given any restrictions for literature selection for this effort, and con-
tributing authors were restricted neither to results from low-dose 
testing, nor to that of cancer-related research. This approach was 
taken because it was realized at the outset that this sort of breadth 
and homogeneity (of low-dose evidence) does not yet exist in the lit-
erature. As a result, the types and sources of data gathered in this 
effort varied considerably, resulting in an admixture of reviews and 
original studies. Moreover, many studies that were cited in this effort 
only considered a chemical’s ability to instigate or promote an action 
that mimics a hallmark phenotype in a manner directionally consist-
ent with changes that have been associated with cancer. So, although 
we have referred to these actions as procarcinogenic and anticarci-
nogenic, as these changes are frequently neither fixed nor specific 
for cancer, the specificity of these changes and implications for car-
cinogenesis cannot and should not be immediately inferred from this 
data set. Short-term toxicity and toxic responses—particularly in data 
from in-vitro HTS platforms—must be distinguished from truly ‘carci-
nogenic’ long-term changes. In other words, the tabularized results 
from this particular aspect of the project were only compiled to serve 
as a starting point for future research. Where cross-hallmark effects 
were reported (at any dose level and in any tissue type), we wanted 
samples of that evidence to share with researchers who might be try-
ing to anticipate the types of effects that might be encountered in 
future research on mixtures of chemicals (in a wide range of possible 
research contexts).
Results
The results are presented roughly sequenced in a manner that 
captures the acquired capabilities found in many/most cancers. 
The section begins with two enabling characteristics found in 
most cancers Genetic instability and Tumor-promoting inflam-
mation, followed by Sustained proliferative signaling and 
Insensitivity to antigrowth signals, the two related hallmarks 
that ensure that proliferation is unabated in immortalized cells. 
These sections are followed by Resistance to cell death and 
Replicative immortality, two critical layers of defense that are 
believed to be bypassed in all cancers and then by dysregulated 
metabolism. Sections on Angiogenesis and Tissue invasion and 
metastasis follow and speak to the progression of the disease, 
and finally, the Tumor microenvironment and Avoiding immune 
destruction sections offer summaries related to the very last 
lines of defense that are defeated in most cancers. Additionally, 
dose-response characterizations and evidence of LDE are then 
presented for all of these areas and the results from the cross-
validation activity are summarized and reviewed.
Genetic instability
The phenotypic variations underlying cancer result from interac-
tions among many different environmental and genetic factors, 
occurring over long time periods (199). One of the most important 
effects of these interactions is genome instability—loosely defined 
as an increased likelihood of the occurrence of potentially muta-
genic and carcinogenic changes in the genome. The term is used 
to describe both the presence of markers of genetic change (such 
as DNA damage and aneuploidy) and intrinsic factors that per-
mit or induce such change (such as specific gene polymorphisms, 
defective DNA repair or changes in epigenetic regulation).
DNA damage—which can be caused by exposure to external 
chemicals or radiation, or by endogenous agents such as reactive 
oxygen or faulty replication—is an event that can initiate the 
multistep process of carcinogenesis (200). Protection is afforded 
at different levels; removal of damaging agents before they 
reach the DNA, by antioxidant defenses and the phase I/phase 
II xenobiotic metabolizing enzymes; a second line of defense, 
DNA repair, operating on the damage that occurs despite the 
primary protection; and as a last resort, apoptosis (programmed 
cell death), disposing of heavily damaged cells.
A clear sign of genome instability is aneuploidy—a deviation 
from the normal number of chromosomes (201). Aneuploidy is 
a very common feature of human cancers. Another hallmark of 
cancer is loss of the normal mechanism of telomere shortening, 
which allows abnormal cells to escape senescence, by avoid-
ing the body’s ‘editing’ processes that normally eliminate aging 
cells with their accumulated genome aberrations (202,203).
The genes of most significance for cancer are the (proto)-
oncogenes which, if defective, or abnormally expressed, lead 
to uncontrolled cell proliferation; tumor suppressor genes, the 
normal products of which tend to switch off replication to allow 
repair, and promote cell death if damage is excessive; and genes 
such as those involved in DNA repair that can—if faulty—lead 
to a ‘mutator phenotype’. Mutated proto-oncogenes and tumor 
suppressor genes are found in most if not all cancers and 
play key roles in cancer etiology (204–207). Rare mutations in 
DNA repair genes greatly increase the risk of cancer (208,209). 
However, the evidence for links between common variants of 
repair genes and cancer is generally inconclusive (210).
The term ‘epigenetics’ refers to covalent modifications of the 
DNA (methylation of cytosine in ‘CpG islands’ within regula-
tory regions of genes) or of the histones. These modifications 
can control gene expression and the pattern of modifications 
is altered in many cancers (211,212). For instance, hypometh-
ylation of proto-oncogenes can lead to overexpression, which 
is undesirable. MicroRNAs (miRNAs) are responsible for specific 
down-regulation of gene expression at a post-transcriptional 
level, by preventing translation from messenger RNAs. miRNAs 
participate in DNA damage responses and some miRNAs are 
deregulated in many cancers (213–215).
Mutations in germ and stem cells are potentially more seri-
ous than those in other cells as they are passed to the cells’ 
progeny within the developing embryo or regenerating tissue 
(216,217). There is a presumed survival benefit when stem cells 
tend to show a particularly stringent maintenance of genome 
integrity through cell cycle regulation and enhanced responses 
to DNA damage (218).
The selected ‘chemical disruptors’ that induce genome 
instability include chemicals that not only directly damage DNA 
or cause mutations, but act indirectly, via pathways such as DNA 
damage signaling, DNA repair, epigenetic regulation or mito-
chondrial function. They include the following:
Metals such as lead, nickel, cobalt and mercury (common 
water pollutants) are known to disrupt DNA repair (181,219), 
whereas nickel also affects epigenetic histone modification 
(189,191) and lead causes defective telomere maintenance 
(184,220). Alloy particles, containing tungsten, nickel and cobalt, 
can be inhaled and disrupt redox signaling (193,221). Titanium 
dioxide nanoparticles are also common in many consumer prod-
ucts and foods and have been reported to disrupt mitochondrial 
function and increase oxidative stress, as well as inhibit DNA 
repair and disrupt mitosis (194,222,223).
Acrylamide occurs in many fried and baked food products, 
and (apart from the well-known DNA adduct formation) can 
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inactivate many critical proteins by binding sulfhydryl groups 
(186).
Bisphenol A  (BPA) is a plasticizer used for manufactur-
ing polycarbonate plastics and epoxy resins, and it can leach 
from plastics into food and water. It is implicated in disruption 
of DNA methylation, histone acetylation and disturbance of 
miRNA binding (192,224,225), redox signaling (226) and induc-
tion of micronuclei through spindle defects in mitosis (227).
The fungicide benomyl is metabolized to carbendazim; 
both are classified as possible human carcinogens at present. 
The route of exposure is most likely ingestion via residues in 
crops. Benomyl disrupts the microtubules involved in the func-
tion of the spindle apparatus during cell division, leading to 
production of micronuclei (Frame,S.R. et al., unpublished report, 
Schneider,P.W. et al., unpublished report, (228)).
Halobenzoquinones are disinfection by-products in chlo-
rinated drinking water (229). Quinones are electrophilic com-
pounds, known to react with proteins and DNA to form adducts. 
These electrophylic chemicals can interact with functional thiol 
groups via Michaelis–Menton type addition, causing modifica-
tion of enzymes involved in methylation and demethylation 
(188). This mechanism might be shared by other xenobiotics 
that increase reactive oxygen species (ROS).
Human exposure to nano-sized materials used in cosmetics, 
biomedical compounds, textiles, food, plastics and paints has 
increased not only in a conscious way but also passively by the 
leakage of nanomaterials from different objects. Nanoparticles 
can induce genome instability via mitochondrial-related apop-
tosis (230), decreased DNA repair (222,230,231), hypoacetyla-
tion of histones (232), disruption of DNA methylation (231), 
up-regulation of miRNA (233), reducing telomerase activity 
(220) and—more specifically for carbon nanotubes—interact-
ing with components of the mitotic spindle during cell division 
or interacting with proteins directly or indirectly involved in 
chromosome segregation (197,234). Nano-sized materials can 
also produce inflammation and alteration of the antioxidant 
defenses that can lead to genome instability.
Tumor-promoting inflammation
One of the earliest hypothesized causes of tumors subsequently 
supported experimentally was the irritation hypothesis pro-
posed by Virchow. Although it was recognized initially that injury 
alone was insufficient for carcinogenesis, it was also recognized 
that ‘irritation may have an accessory or predisposing influence 
in tumor formation, and that it may be enough finally to upset 
the balance of a group of cells which for some other reason were 
already hovering on the brink of abnormal growth’ (235). Indeed, 
it is now recognized that inflammatory responses, similar to 
those associated with wound healing or infection, support the 
development of invasive carcinomas by altering the microen-
vironment in favor of proliferation, cell survival, angiogenesis 
and tumor cell dissemination while also disrupting antitumor 
immune surveillance mechanisms. In other words, inflamma-
tion plays a critical role in tumorigenesis (23,24).
Inflammation is an immediate and necessary host defense 
mechanism in response to infection or tissue injury by noxious 
stimuli. In tumor-associated inflammation, both the epithelium 
and the immune cells express receptors that signal the activa-
tion and production of a wide array of biologically active proteins 
most analogous to an unhealed wound. The sustained or uncon-
trolled release of potent and reactive molecules such as prosta-
glandins, cytokines, ROS and chemokines from both the tumor 
cell and the microenvironment constituents lead to progressive 
genomic instability, alterations in the integrity and function of 
the microenvironment including alterations in the vasculature 
(e.g. vascular hyperpermeability, neovascularization and angio-
genesis), as well as alterations in local immune dynamics. The 
cellular and molecular mechanisms include a diverse array of 
immune- and tumor-cell-derived effector molecules such as the 
proinflammatory reactive oxygen and nitrogen species, a num-
ber or cytokines, chemokines as well as cyclooxygenase-2 and 
its product, prostaglandin E2.
In general, there is a paucity of experimentation, and when 
present, inconsistent findings for the role of environmental 
chemicals as proinflammatory molecules and more so for a pro-
inflammatory action as a co-factors in carcinogenesis. However, 
some recent studies provide a credible mechanistic basis, par-
ticularly early life exposures that might act by disrupting the 
immune cell balance toward inflammation, and that manifest in 
adulthood. One example is BPA, one of the most abundant and 
best studied environmental endocrine disruptors, and its con-
troversial role as an immune disruptor. Specifically, studies in 
male rats found that early life BPA exposure leads to the devel-
opment of prostate intraepithelial neoplasia (a prostate cancer 
precursor lesion) through a pathological process that includes 
BPA-dependent epigenetic reprogramming of genes involved in 
the development of lateral prostate inflammation in adulthood 
(236,237).
This work in prostate is complemented by a much more 
extensive study of BPA effects on immune cell components, 
particularly the T-cell compartment, demonstrating that BPA 
acts as an immune disruptor by promoting ‘immune’ cell pro-
liferation though the exact nature of the effect on specific cells 
of the immune system is poorly delineated. Most interesting is 
the work by Yan et  al. (122), who reported findings suggesting 
that the timing of BPA exposure during development (prenatally, 
early life or adult) alters the effect of BPA on regulatory T cells. 
BPA actions also map over to the effects on the immune sys-
tem including the promiscuity of BPA for a number of nuclear 
receptors relevant to immune cells such as the estrogen recep-
tor and the aryl hydrocarbon receptor (AhR). As well, bulky BPA 
analogs may act as antagonists of members of the peroxisome 
proliferator-activated receptor (PPAR) family, an important fam-
ily of nuclear receptors with potent anti-inflammatory function 
(238,239). Effects on the PPAR nuclear receptors may also explain 
inflammation-associated phenotypes observed with exposures 
to certain phthalates and nonylphenol (4-NP).
A second example is the reported immunotoxic effects of 
atrazine (6-chloro-N-ethyl-N-(1-methylethyl)-1,3,5-triazine-2,4-
diamine) (240), a chemical that is the most commonly detected 
triazine herbicide in USA soil and water. Atrazine is banned 
by the European Union and drinking water exposures are sup-
posed to be limited in the USA to <3 µg/l (although exposures 
exceed this limit regularly), but the use of this chemical is high 
and increasing in Asia and other countries. Thus, atrazine is an 
important pesticide to which humans are exposed. Atrazine 
exhibits weak mutagenicity and low oncogenic properties, but 
research by a number of authors is emerging that suggests that 
immune system disruption might be a concern (132,240,241).
Although the majority of work on atrazine has been focused 
on its endocrine disrupting properties, there is also evidence 
to support immunotoxicity including effects on T-lymphocytes 
composition with oral dosing (242,243), modulation of nitric 
oxide production (244) and potential generation of ROS (245,246). 
The local production of reactive nitrogen species and ROS 
by mast cells and macrophages are among the better stud-
ied immune modulatory molecules for which recent evidence 
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supports important roles both in the tumor microenvironment 
and in the tumor progression (247–249). Notably, these reactive 
species trigger oxidative/nitrosative modifications, which can 
initiate redox signaling that tightly modulates the inflammatory 
response in a manner that is highly relevant for carcinogenesis 
(250,251).
We also looked at polybrominated diphenyl ethers (PBDEs) 
and their effects on inflammatory cytokines. Peltier et al. (128) 
recently found that placental explants treated with a mix-
ture of the cogeners BDE-47, -99 and -100 and then exposed 
to Escherichia coli were ‘reprogrammed’ toward a proinflam-
matory response (increased IL-1β and tumor necrosis factor 
α) and away from the expected anti-inflammatory response 
(decreased IL-10) compared with untreated placenta. Although 
these studies are preliminary, chronic PBDE exposure may 
lower the threshold for bacteria to stimulate a proinflammatory 
response, which has potential relevance given the established 
link between bacteria and certain cancers (e.g. Helicobacter pylori 
and gastric cancer), where tumor development is dependent on 
inflammation.
Vinclozolin was also of particular interest as an environmen-
tal chemical because transient early life exposures in utero have 
been linked to both adult-onset disease and transgenerational 
disease that involves inflammation (134,135). For example, tran-
sient vinclozolin exposure in utero has been shown to promote 
inflammation in the prostate (prostatitis) of postpubertal rats 
coupled with a down-regulation of the androgen receptor and 
increase in nuclear factor-κB (NF-κB). The late or delayed effect 
of exposure is hypothesized to reflect a mechanism whereby 
vinclozolin exposure during a critical development window 
imprints an irreversible alteration in DNA methyltransferase 
activity, leading to reprogramming of the androgen receptor (AR) 
gene(s), which manifest as inflammation in early adult life with 
adverse effects on spermatid number.
Similarly, 4-NP has been shown to increase progenitor white 
adipose levels, body weight and overall body size in rodents 
exposed prenatally. Like vinclozolin, 4-NP effects on adipogen-
esis in the perinatal period confer transgenerational inheritance 
of the obesogenic effects observable in F2 offspring, consistent 
with genome reprogramming through an epigenetic process 
(252) and others have reported immune and inflammation-
related effects (137,138) making it relevant to carcinogenesis a 
deserving further investigation.
Sustained proliferative signaling
Sustained proliferative potential is an essential component of 
cancerous growth. Progressive conversion of normal cells into 
cancer cells requires a series of genetic alterations, where each 
alteration confers one or more types of growth advantage. One 
such alteration that affords the transformed cell a distinct 
growth advantage over its normal counterparts is the acquired 
capacity of the cancer cell to proliferate in a sustained manner, 
so as to crowd out and outnumber the normal cell population 
(23). One of the fundamental differences between a normal and 
a transformed cell is that normal cells halt proliferation when 
subjected to growth inhibitory signals or in the absence of 
growth stimulatory signals (253). But tumor cells act to sustain 
proliferative signaling in several different ways. They can acti-
vate specific genes to produce relevant growth factors, which in 
turn bind to signaling receptors giving rise to an autocrine loop 
(254). Growth factors produced by tumor cells can also stimulate 
the proliferation of stromal cells that in turn produce growth 
factors to sustain tumor cell proliferation (255). Sustained pro-
liferation can additionally be maintained at the receptor level 
by truncation of signaling receptor proteins whereby the ligand-
activated switch is missing (256). Alternatively, the number of 
high-affinity receptor proteins may be increased to levels that 
will sustain proliferative signaling in otherwise normal growth 
factor levels. Finally, sustained proliferative signaling may well 
be the result of perpetual activation of the intracellular sign-
aling chain independent of growth factors or receptors (e.g. 
mutated ras (257) or truncated src (258) are intermediaries of a 
normal proliferation signaling chain responsible for sustained 
proliferation).
We hypothesized that disruptive environmental chemicals 
acting in a procarcinogenic manner by inducing what is referred 
to as ‘sustained cell proliferation’ likely exerted their action by 
interfering with some basic control mechanisms (23,253). For 
instance, they could achieve this by positively regulating tar-
gets within and outside the cell known to promote cell prolif-
eration or negatively regulating targets within and outside the 
cell known to halt cell proliferation. In this way, such chemicals 
could confer proliferative advantage to a distinct cell population 
and contribute to that population’s capability to successfully 
breach innate anticancer defense mechanisms and to become 
progressively autonomous.
Specifically, we identified a total of 15 ubiquitous chemical 
disruptors capable of producing sustained cell proliferation. The 
majority of these chemicals interacted with multiple targets, 
and we have tabled this information in our review. In summary, 
we identified several commonly used insecticides and fungi-
cides capable of causing sustained proliferation. These included 
cyprodinil, etoxazole, imazalil, lactofen, maneb, methoxychlor 
(MXC), phosalone, prochloraz and pyridaben, all of which tar-
geted estrogen receptor α and frequently other steroid hormone 
receptors such as androgen receptor (102,259–275). Most of 
these chemicals also targeted growth factors and their recep-
tors (264,267) and induced cytokines and cytokine receptors 
(identified by ToxCast high throughput assay). Top disrupting 
chemical fungicides and insecticides were MXC and cyprodinil, 
which each interacted with a total of six individual targets that 
further included the AhR (100), B-lymphocyte markers (ToxCast 
2009 high-throughput assay, both chemicals), AP-1 proteins/
transcription/translation regulators, downstream signaling 
molecules and cell cycle regulators (276,277). Other strong per-
formers for sustained proliferation were BPA (activated all tar-
gets activated by the insecticides and fungicides above except 
growth factors and their receptors, B lymphocyte markers and 
PPAR, but included cell cycle regulators alongside AP-1 proteins/
transcription/translation regulators and downstream signaling) 
(272,276,278,279) (also identified in ToxCast high-throughput 
assay, 2009), polyfluorinated octinoid sulfate and polybromi-
nated diphenylethers (flame retardants) that either activated 
AhR (280,281) or up to five other targets that included steroid 
receptors, growth factors, cytokines and cell cycle regulators 
(109) (ToxCast high-throughput assay 2009). Three other con-
tenders were phthalates (plasticizers that acted via three tar-
gets that included AhR, steroid hormone receptors and PPAR) 
(282–285), trenbolone acetate (a synthetic anabolic steroid 
that unsurprisingly acted through steroid hormone receptors) 
(120,286–290) and finally, edible oil adulterants (food contami-
nants produced during food processing that acted via down-
stream signaling) (291,292).
We have shown estrogen and androgen receptors to be 
important targets in relation to sustained proliferative signaling 
(293), and note that environmental estrogens and androgens are 
frequently recognized as prototypical disruptor(s) of this hall-
mark. Although this is a small sample, there are a great number 
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of chemicals in the environment, both naturally occurring and 
man-made, are estrogenic, interact with estrogen receptor and 
produce estrogen metabolites (just as naturally derived ovarian 
estrogen does during metabolic breakdown). Catechol estrogens 
(hydroxyl derivatives of estrogens), which are formed during 
estradiol metabolism, are also potentially important mediators 
of endogenous estradiol levels, and therefore of sustained pro-
liferative signaling and oncogenesis (294).
Insensitivity to antigrowth signals
Cell cycle arrest is important for maintaining genomic integrity 
and for preventing genetic errors from being propagated. The 
normal cell cycle contains multiple checkpoints to safeguard 
against DNA-damaging agents. Specific proteins at these check-
points are activated in response to harmful stimuli, ensuring 
that cellular proliferation, growth and/or division of cells with 
damaged DNA are blocked.
There are multiple key mediators of growth inhibition that 
may become compromised during carcinogenesis. Some, such 
as p53, RB1, and checkpoint kinases cause cells to arrest at the 
G1–S phase transition when they are activated by DNA damage. 
Mutations in the p53 gene occur in ~50% of all cancers, although 
certain tumor types, such as lung and colon, show a higher than 
average incidence (295). Similarly, pRb hyperphosphorylation 
(296), direct mutations (297), loss of heterozygosity (298) and dis-
ruption of the INK4–pRb pathway (INK4–CDK4/6–pRb–E2Fs) (299) 
are common events in the development of most types of can-
cer. Cancer cells may also evade the growth inhibitory signals 
of transforming growth factor-β (TGF-β) (300) and modulate the 
action of downstream effectors as well as crosstalk with other 
pathways.
Cells also receive growth inhibitory signals through intercel-
lular communication via gap junctions. Gap junctions disperse 
and dilute growth-inhibiting signals, thereby suppressing cell 
proliferation. In contrast, loss of gap junctions increases intra-
cellular signaling, leading to enhanced proliferation and tumor 
formation. The molecular components of gap junctions are the 
connexin proteins (301). Connexins are recognized as tumor sup-
pressors and have been documented to reduce tumor cell growth. 
Numerous environmental stimuli have been reported to directly 
affect gap junction intercellular communication. Adherens junc-
tion machinery mediates contact inhibition of growth, and loss 
of contact inhibition is a mediator of tumor cell growth.
Chemicals that may contribute to insensitivity to antigrowth 
signals through multiple targets of this hallmark are BPA, a 
common constituent of everyday plastics, and pesticides such 
as DDT, folpet and atrazine. BPA promotes proliferation by dis-
rupting the growth inhibitory signals of p53 and gap junction 
communication (171,302). DDT has also been shown to enhance 
proliferation by increasing the expression of Ccnd1 (cyclin D1)/
E2f, inducing phosphorylation of pRb, increasing the expression 
of p53-degrading protein Mdm2 (a negative regulator of p53) 
(162) and disrupting gap-junctional intercellular communica-
tion (163,164). Folpet down-regulates the functions of p53 and 
ATM/ATR checkpoint kinases (167) and promotes proliferation, 
whereas atrazine shows genotoxic effects at subacute dose on 
Wistar rats. Genotoxicity was also associated with increased 
transcription of connexin accompanied with increased oxida-
tive stress (303). 
Resistance to cell death
Cell death is an actively controlled and genetically regulated 
program of cell suicide that is essential for maintaining tis-
sue homeostasis and for eliminating cells in the body that are 
irreparably damaged. Cell death programs include: apoptosis, 
necrosis, autophagy senescence and mitotic catastrophe (21). 
Defects in these pathways are associated with initiation and 
progression of tumorigenesis. Normally, cells accumulate from 
an imbalance of cell proliferation and cell death, permissive cell 
survival amidst antigrowth signals such as hypoxia and con-
tact inhibition, resistance to the killing mechanisms of immune 
cell attack and anoikis resistance (304). Increased resistance to 
apoptotic cell death involves inhibition of both intrinsic and 
extrinsic apoptotic pathways.
The link between malignancy and apoptosis is exemplified 
by the ability of oncogenes, such as MYC and RAS, and tumor 
suppressor genes, such as TP53 and RB, to engage both apop-
tosis and the aberrant alterations of apoptosis regulatory pro-
teins such as BCL-2 and c-FLIP in various solid tumors (305). This 
variety of signals driving tumor evolution provides the selective 
pressure to alter apoptotic programs during tumor development. 
Some chemical carcinogens and sources of radiation cause DNA 
damage and increase genetic and/or epigenetic alterations of 
oncogenes and tumor suppressor genes leading to loss of cel-
lular homeostasis (306). Other signals include growth/survival 
factor depletion, hypoxia, oxidative stress, DNA damage, cell 
cycle checkpoint defects, telomere malfunction and oncogenic 
mutations, and exposure to chemotherapeutic agents and heavy 
metals (307,308).
Cancer cells resist apoptotic cell death by up-regulation of 
antiapoptotic molecules and the down-regulation, inactivation 
or alteration of pro-apoptotic molecules. Activation of p53 usu-
ally induces expression of pro-apoptotic proteins (Noxa and 
PUMA) and facilitates apoptotic cell death (309). Antiapoptotic 
Bcl-2 family proteins suppress pro-apoptotic Bax/Bak [which 
would otherwise inhibit mitochondrial outer membrane perme-
abilization]. Mitochondrial outer membrane permeabilization 
releases cytochrome c and triggers apoptosis through an intrin-
sic pathway (310). Thus, regulation of apoptosis can be achieved 
by inhibiting the antiapoptotic Bcl-2 family proteins and Bcl-XL 
proteins as this restores a cell’s ability to undergo apoptosis. In 
the process, mitochondrial outer membrane permeabilization, 
mitochondrial proteins (Smac/DIABLO and Omi/HtrA2), which 
inhibit the X-linked inhibitor of the apoptosis protein, are leaked 
to trigger caspase activity in apoptosis (311,312). 
Normal cellular metabolism is important for the sur-
vival of cells, whereas dysregulated metabolism in cells (see 
Dysregulated metabolism) can induce either apoptosis or resist-
ance to apoptotic stimuli (313). In the liver, nearly every enzyme 
in glycolysis, in the tricarboxylic acid cycle, in the urea cycle, in 
gluconeogenesis and in fatty acid and glycogen metabolism is 
found to be acetylated, and this N-α-acetylation confers sensi-
tivity to apoptotic stimuli (314). The antiapoptotic protein, Bcl-xL 
reduces the efflux of acetyl-CoA from the mitochondria to the 
cytosol in the form of citrate and decreases N-α-acetylation of 
apoptotic proteins, which enables cells less sensitive toward 
apoptotic stimuli to mediate cell proliferation, growth and sur-
vival. Thus, N-α-acetylation might be a major factor in overcom-
ing apoptotic resistance in cancer cells (315,316).
Death receptor ligands such as TRAIL—which is bound to 
DR4/DR5—induce receptor oligomerization and recruitment of 
FADD and caspase-8 to form death-inducing signaling com-
plex, which leads to subsequent cell death via apoptosis. Thus, 
expression of death receptors and their decoy receptors (Dcr1/2) 
mediates apoptosis in tumor cells (317). When normal cells lose 
contact with their extracellular matrix or neighboring cells, they 
undergo an apoptotic cell death pathway known as ‘anoikis’ 
(304). During the metastatic process, cancerous cells acquire 
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anoikis resistance and dissociate from primary sites, travel 
through the vascular system and proliferate in distant target 
organs.
A blockage of gap junction intracellular communication 
(GJIC) between normal and preneoplastic cells also creates an 
intra-tissue microenvironment in which tumor-initiated prene-
oplastic cells are isolated from growth controlling factors of nor-
mal surrounding cells resulting in clonal expansion (318). Gap 
junction channels and Cxs control cell apoptosis by facilitating 
the influx and flux of apoptotic signals between adjacent cells 
and hemi-channels between the intracellular and extracellular 
environments, and Cx proteins in conjunction with their intra-
cytoplasmic localization, may act as signaling effectors that are 
able to activate the canonical mitochondrial apoptotic pathway 
(319).
Several anthropogenic chemicals can affect resistance to cell 
death. For example, BPA has been shown to strikingly impair 
TP53 activity and its downstream targets, cell cycle regulators, 
p21WAF1 and RB, or pro-apoptotic BAX, thereby enhancing the 
threshold for apoptosis (172).
Chlorothalonil, a broad-spectrum fungicide that is used on 
vegetables, fruit trees and agricultural crops, is considered to be 
non-genotoxic but classified as ‘likely’ to be a human carcino-
gen by all routes of exposure (29). In a eukaryotic system, chlo-
rothalonil reacted with proteins and decreased cell viability by 
formation of substituted chlorothalonil-reduced glutathione 
derivatives and inhibition of specific nicotinamide adenine dinu-
cleotide thiol-dependent glycolytic and respiratory enzymes (320). 
Caspases (cysteine-dependent proteases) and transglutaminase 
are some of the thiol-dependent enzymes involved in apoptosis, 
so inhibition of these thiol-dependent enzymes in tumor-initiated 
cells may disrupt apoptotic cell death and aid in tumor survival.
Dibutyl phthalate and diethylhexyl phthalate (DEHP) are 
diesters of phthalic acid and commonly referred to as phtha-
lates. In general, mimic the function or activity of the endoge-
nous estrogen 17β-estradiol (E2) and bind to estrogen receptors. 
Interestingly, phthalates can mimic estrogen in the inhibition 
of TAM-induced apoptosis in human breast cancer cell lines by 
increasing intracellular Bcl-2/Bax ratio in breast cancer (321).
Lindane, an organochlorine pesticide, bioaccumulates in 
wildlife and humans. Exposure to lindane induces tumor for-
mation in the mouse 42GPA9 Sertoli cell line by disrupting the 
autophagic pathway and sustained activation of the mitogen-
activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) pathway (322).
MXC (1,1,1-trichloro-2,2-bis(4-methoxyphenyl)ethane) is a 
DDT derivative that was developed after the ban of DDT and 
it exhibits antiandrogenic and estrogenic activity. MXC stimu-
lates proliferation and human breast cancer cell growth by the 
up-regulation of genes that involve cell cycle (cyclin D1), and the 
down-regulation of genes p21 and Bax affecting G1/S transition 
and apoptosis, respectively, through ERα signaling (323).
Replicative immortality
Cellular senescence is a state of irreversible arrest of cellular 
proliferation characterized by changes in transcription, chro-
matin conformation, cytoplasmic and nuclear morphology, 
DNA damage signaling and a strong increase in the secretion of 
proinflammatory cytokines (324) Senescence is the first line of 
defense against potentially transformed cells (325). Progression 
to malignancy correlates with a bypass of cellular senescence. 
Thus, senescence inhibits the activation of the tumorigenic 
process (325). Senescence has been observed in vitro and in vivo 
in response to various stimuli, including telomere shortening 
(replicative senescence), oncogenic stress, oxidative stress and 
chemotherapeutic agents (326).
Cellular senescence exhibits several layers of redundant 
regulatory pathways. These pathways converge to arrest the cell 
cycle through the inhibition of CDKs. The best-known effector 
pathways are the p16INK4a/pRB, the p19ARF/p53/p21CIP1 and 
the PI3K/mammalian target of rapamycin (mTOR)/FOXO path-
ways (327–330), which show a high degree of interconnection. 
Additionally, the pRb and the mTOR pathways are two routes 
that have been proposed to be responsible for permanent arrest 
of the cell cycle (331). More pathways and genes are being dis-
covered, increasing the complexity of our knowledge of this 
physiological process (329). Most, if not all of these genes have 
been related to human tumorigenesis.
Despite the relevance of senescence as a gatekeeper in the 
process of tumorigenesis, there is not a large body of infor-
mation exploring the effect of chemicals on this safeguard. 
Little research has been undertaken on chemicals that alter 
gene expression regulating senescence and few genes have 
been identified (e.g. telomerase, p53, pRb, INK4a) (83,332,333). 
Traditional protocols for the assessment of the carcinogenic 
risk rely on the detection of tumors induced by agents that 
alter many different pathways at the same time (includ-
ing senescence). These agents are mainly unspecific muta-
gens or epigenetic modifiers. The effect of some compounds 
is being explored including nickel-derived compounds (e.g. 
nickel chloride), diethylstilbestrol, reserpine or phenobarbital 
(83,334–337).
There may be environmental chemicals that are not muta-
gens or epigenetic modifiers, but that target specific proteins on 
the senescence pathways and may affect the initiation of tumo-
rigenesis by other compounds allowing senescence bypass. The 
contribution of these compounds to the carcinogenesis process 
is largely unknown. A  few compounds bypass senescence in 
this specific manner—acetaminophen, cotinine, nitric oxide, 
Na-selenite and lead. Other chemicals known to alter senes-
cence only are mostly unknown (86,88–91,338–341).
Senescence has strong fail-safe mechanisms, and experi-
mental attempts to bypass senescence are usually recognized 
as unwanted signals and trigger a senescence response anyway. 
However, these conclusions are based on the interpretations of 
experimental designs in which acute molecular or cellular alter-
ations are produced. There are few experiments regarding the 
effects of chronic, low-dose alterations and even fewer studies 
that consider the different cellular and molecular contexts that 
can arise over the course of a lifetime.
Dysregulated metabolism
The highly glycolytic cancer phenotype described by Warburg 
et al. (25) in the early 20th century determined much of the initial 
direction in cancer research (26). Other characteristic metabolic 
abnormalities have also been described (25,26,342,343) and have 
recently garnered increased attention (344–348). These changes 
are neither fixed nor specific for cancer (349–351), but the uni-
versality of metabolic dysregulation suggests major roles in can-
cer genesis, maintenance and progression. Precise definitions of 
what constitutes cancer metabolism, and when such changes 
first occur during the course of cancer development, are lacking. 
From a teleological perspective, alterations in both intermediary 
metabolism and its control are not surprising insofar as highly 
proliferative cancer cells exhibit increased energy demands 
and expanded requirements for macromolecular precursors to 
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support nucleic acid and protein biosynthesis, as well as mem-
brane biogenesis, for increased biomass. Metabolic reprogram-
ming ostensibly equips cancer cells to cope with these demands, 
as well as accompanying cellular stresses. Although much of 
the attention on cancer metabolism has focused on enhanced 
glucose utilization via glycolytic and pentose phosphate path-
ways, cancer cells are also capable of the oxidative utilization of 
carbohydrates, lipids and peptides, and the metabolism of these 
individual substrate classes remain intimately intertwined as in 
normal cells (26,345,352).
Major control of glycolysis is traditionally ascribed to glu-
cose transport, hexokinase, phosphofructokinase and pyru-
vate kinase (352). Glyceraldehyde-3-phosphate dehydrogenase 
also normally couples glycolytic flux to mitochondrial metabo-
lism in the presence of oxygen and to lactate generation in its 
absence, but this relationship is fundamentally altered in can-
cer (26,345,353,354). Given the central importance of the pen-
tose phosphate pathway to anabolic metabolism and redox 
homeostasis, glucose-6-phosphate dehydrogenase and its redox 
coupling partners represent similarly attractive carcinogenic 
targets (355). In addition, the enzymes of the tricarboxylic acid 
cycle, such as fumarate hydratase, succinate dehydrogenase 
and isocitrate dehydrogenase, play crucial roles in oxidative 
energy metabolism and the interconversion of metabolic inter-
mediates, making them appealing candidates for study as well 
(356,357).
The central importance of the mitochondrial electron trans-
port chain to oxidative energy metabolism and its established 
role in toxic responses and dysregulated mitochondrial func-
tion in cancer makes its assembly and function attractive topics 
for study (358–360). Despite well-established roles for lipid and 
amino acid metabolism in cancer development and progression, 
they have historically received less attention than carbohydrate 
metabolism (26). Lipogenic, lipolytic and lipophagic pheno-
types are now widely recognized (344,361–363), so targets such 
as acetyl-CoA carboxylase, fatty acid synthase, cellular lipases 
and lipid transporters represent additional attractive targets 
for study. Amino acid metabolism—particularly glutamine and 
serine metabolism—also has well-established roles in cancer 
(364–366), providing additional potential targets for study that 
include 3-phosphoglycerate dehydrogenase (346,365,367,368) 
and cellular transaminase coupling mechanisms. Study of 
both lipid and protein metabolism must accommodate the fact 
that cancer cells exhibit substrate preferences, including well-
described endogenous lipid- and protein-sparing effects of 
exogenous glucose availability in cancer cells.
The metabolic capacity of both normal cells and cancer cells 
generally exceed their catabolic and anabolic requirements 
(364,369,370), and only a fraction of the available potential energy is 
ultimately required for cell survival (371,372). Moreover, very small 
changes in metabolic flux can have profound phenotypic conse-
quences, and metabolic control analysis has suggested that the 
importance of increased cancer-associated glycolytic and glutami-
nolytic fluxes may lie not in their magnitudes, but in the mainte-
nance and control of smaller branched pathway fluxes (364). For 
these reasons, rigorous functional validation is needed for all can-
cer-associated changes in gene expression or metabolite accumu-
lation. Well-described moonlighting functions for many metabolic 
enzymes (373–375), including the novel antiapoptotic roles of mito-
chondrial hexokinases (376), cannot be simply extrapolated from 
our knowledge of classical roles in cellular metabolism.
These enzymes and their pathways constitute broad cat-
egories of potential targets for disruption that could serve to 
enable the observed metabolic phenotypes of cancer cells (377). 
Although metabolic control is broadly distributed over all indi-
vidual steps for a given pathway (352,378), the most obvious 
targets for conceptual and experimental scrutiny involve major 
rate-controlling elements of pathways capable of supporting the 
anabolic and catabolic needs of rapidly proliferating cancer cells.
Numerous studies have demonstrated cancer-associated 
changes in metabolism or related gene expression (26). We 
looked at acrolein, copper, cypermethrin, diazinon, hexythi-
azox, iron, malathion and rotenone as chemicals that had been 
reported to show relevant disruptive potential (51,379–383); 
however, the toxicological data that are available for many 
suspected or known environmental disruptors, generally lacks 
mechanistic information regarding their potential roles as 
determinants of the observed metabolic hallmarks of cancer. 
Even prior metabolic screening platforms, including tetrazolium 
reduction assays, have limited specificity and can be profoundly 
influenced by experimental screening conditions. Unfortunately, 
standardized chemical screening has typically not been con-
ducted under controlled or limiting substrate conditions that 
would directly inform our understanding of the functional rel-
evance of observed changes. None have established unambigu-
ous causal relationships between specific chemical exposures 
and the parallel or sequential development of dysregulated 
metabolism of cancer in the same model, and most observed 
changes in gene expression with potential relevance to cancer 
metabolism have not been accompanied by validating func-
tional studies.
Angiogenesis
Angiogenesis, the process of formation of new blood vessels 
from existing blood vessels, is a critical process for normal organ 
function, tissue growth and regeneration (e.g. wound healing, 
female menstruation, ovulation and pregnancy) as well as for 
pathological conditions (e.g. cancer and numerous non-cancer-
ous diseases, such as age-related macular degeneration, dia-
betic retinopathy, rheumatoid arthritis, endometriosis, diabetes 
and psoriasis) (384,385).
Tumor angiogenesis is an early critical event for tumor 
development: A tumor cannot grow beyond 1 mm3 (by estimate) 
without angiogenesis (386). Tumor growth, invasion and metas-
tasis depend on blood vessels and neovascular development 
to provide nutrients, oxygen and removal of metabolic waste 
as tumors grow in primary sites, invade adjacent tissues and 
metastasize to distant organs (387,388). Inhibition or eradication 
of tumor angiogenesis by antiangiogenic inhibitors (389,390) or 
by antineovascular agents (such as vascular-disrupting agents 
(391–393) and fVII/IgG Fc (394), the latter also called ICON (395–
397)) can treat pathological angiogenesis-dependent diseases, 
including cancer and many non-cancerous diseases.
Under physiological conditions, angiogenesis is well bal-
anced and controlled by endogenous proangiogenic factors 
and antiangiogenic factors. Factors produced by cancer cells 
can shift the balance to favor tumor angiogenesis. Such factors 
include vascular endothelial growth factor (VEGF) and tissue 
factor (TF). VEGF, one of the most potent proangiogenic factors 
produced by cancer stem cells and cancer cells, binds to vascular 
endothelial cells via its receptor VEGFR, initiating VEGF/VEGFR 
intracellular signal transduction pathways and activating many 
gene transcriptions and translations toward angiogenesis. TF 
is a transmembrane receptor (398) not expressed on quiescent 
endothelial cells (399,400). Upon stimulation of VEGF, TF is selec-
tively expressed by angiogenic endothelial cells, the inner layer 
of the tumor neovasculature. Thus, TF is a specific biomarker 
for tumor angiogenesis (408–410). Both of the membrane-bound 
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receptors VEGFR and TF can mediate separate intracellular sign-
aling pathways that contribute to tumor angiogenesis.
Environmental exposures can promote tumor development, 
but the role of chemicals in tumor angiogenesis, particularly the 
role of low-dose non-carcinogens, is largely unknown. Some food-
use pesticides that are non-genotoxic act as tumor promoters, 
and other chemicals affect various hallmarks such as apoptosis, 
proliferative signaling, evading growth suppression, enabling 
replicative immortality, metastasis, avoiding immune destruc-
tion, tumor-promoting inflammation and deregulating cellular 
energetics—in addition to tumor angiogenesis.
Chemical disruptors that may promote tumor angiogenesis 
included diniconazole, 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichlo-
roethane (HPTE), methylene bis(thiocyanate), perfluorooctane 
sulfonate (PFOS), Ziram, biphenyl, chlorothalonil, tributyltin 
chloride and bisphenol AF. Diniconazole (pesticide), for exam-
ple, targets certain angiogenic molecules (CXCL9, CXCL10, 
MMP1, uPAR, VCAM1 and THBD) in vitro (29). MXC (the parent 
compound to HPTE) induces histological expression of angio-
genic factors such as VEGF, VEGFR2 and ANG1 in rat pituitary 
and uterus (39), and exposure to PFOS induces actin filament 
remodeling, endothelial permeability changes and ROS produc-
tion in human microvascular endothelial cells (41). Ziram can 
induce angiogenesis through activation of MAPK and decreases 
cytolytic protein levels in human natural killer (NK) cells 
(404,405).
Tissue invasion and metastasis
Tissue invasion and metastasis are also key processes of tumor 
progression. In normal cells, E-cadherin holds the epithelial 
cells together as a society of cells that are well differentiated 
and otherwise quiescent (406). Carcinomas constitute almost 
90% of cancers and upon oncogenic transformation, the process 
of tissue invasion and metastasis begins with the down-regu-
lation of E-cadherin. Concomitant with this down-regulation of 
E-cadherin is the conversion of epithelial to mesenchymal cells 
(EMT) (407). The transcription factors that control EMT, such as 
snail, slug, Twist and Zeb1/2, are some of the best-character-
ized signaling molecules in biology (408,409). During the pro-
cess of EMT, a number of inflammatory cells are attracted to 
the growing tumor mass (410). Upon attaining mesenchymal 
characteristics, tumor cells are able to move out of their natu-
ral environment, aided by cross talk between them and stromal 
cells, resulting in the secretion of matrix degrading enzymes 
such as matrix metalloproteinases (411). This process is accel-
erated by chronic inflammation mediated by NF-κB (410). Other 
invasion mediating molecules include hepatocyte growth fac-
tor, secreted mainly by tumor-associated fibroblasts to signal 
metastatic cells to move upon their interactions with their cell 
surface receptor cMet (412).
Attracted by chemokines, metastatic cells move to the near-
est blood vessel or lymphatic vessel, where they complete the 
process of intravasation, entering the capillaries and are then 
transported to the capillary bed in their colonized site or new 
environment (413). In this new location, tumor cells undergo 
extravasation where they come out of the capillaries or lym-
phatic vessels, most likely again following the cues emanat-
ing from the chemokines in their new microenvironments. To 
survive in their new home, they may have to revert back and 
assume the cuboidal morphology of epithelial cells-undergo-
ing the reversal of EMT otherwise known as mesenchymal to 
epithelial transition (414). At this point, they may remain dor-
mant for a very long time until conditions for their division and 
growth become favorable.
Mounting evidence supports the involvement of exosomes 
(nano-vesicles secreted by tumor or cancer-associated fibro-
blasts) in adhesion and motility of metastatic cells. The secretion 
of exosomes is accelerated by increases in intracellular cal-
cium ions, and low-dose environmental mixtures that increase 
intracellular calcium may promote the secretion of exosomes 
and the subsequent invasion and metastasis processes of the 
tumor cells.
Environmental chemicals, such as tetrabromobisphenol 
A and its metabolites, BPA and tetrabromobisphenol A dimethyl 
ether, which mediate the activation of EMT enzymes or drive 
their synthesis, may also contribute to the process of tissue 
invasion (415). Low-dose exposure to hexavalent chromium may 
accelerate the EMT transition (416). Other contributing factors 
may also be low-dose environmental contaminants, such as for-
maldehyde, or bacteria, e.g. H. pylori, that drive the transcription 
of NF-κB and exacerbate the process (417,418).
Tumor microenvironment
The tumor microenvironment is a complex mix of cells in addi-
tion to tumor cells themselves; it is constructed of a complex 
balance of blood vessels that feed the tumor, the extracellu-
lar matrix that provides structural and biochemical support, 
signaling molecules that send messages, soluble factors such 
as cytokines and many other cell types. Tumors can influence 
the microenvironment and vice versa. The micro-environmental 
reaction to early tumor cells begins with the recruitment and 
activation of multipotent stromal cells/mesenchymal stem cells, 
fibroblasts, endothelial cell precursors, antigen-presenting cells 
such as dendritic cells (DCs) and other white blood cells. All of 
these tumor stromal cells secrete a variety of growth factors and 
chemokines that, together with the tumor cells and secreted 
factors, culminate in the generation of the tumor microenviron-
ment (419–422).
The tumor microenvironment is important because any cell 
within this process has the potential to be affected by carcino-
gens, either alone or in mixtures, or by the inflammation that 
results from the carcinogenic insult (423). Although often asso-
ciated with infection, chronic inflammation can be caused by 
exposure to carcinogens such as irradiation or environmental 
chemicals. Carcinogenesis can also be fostered via effects on the 
tissue context surrounding preneoplastic lesions. For example, 
transplantation experiments of preneoplastic cells have clearly 
documented that a growth-constrained tissue microenviron-
ment can promote the growth and progression of preneoplastic 
cell populations (424).
Several compounds appear to influence the complex het-
erogeneity that forms the support network for cancer growth. 
The exposure to nickel chloride has been associated with the 
generation of ROS and inflammation (425). ROS are impor-
tant because they can stimulate the induction of angiogenesis 
growth factors, such as VEGF, and can promote cell proliferation 
and immune evasion and play a role in cell survival (57,426–428). 
Prenatal exposure to BPA in experimental animals disrupts ERα 
and triggers angiogenesis, and other BPA exposure studies have 
demonstrated that BPA interplays with cell proliferation (226), 
genomic instability (429), inflammation (430) and cell immor-
talization (431). Butyltins, and specifically tributyltin, which is 
suspected to act as an endocrine disruptor, have been found 
to inhibit the cytotoxic activity of NK cells (432), affect inflam-
mation (432) and disrupt membrane metalloproteinases (432). 
Cooperatively, disruption of these processes can lead to prolif-
eration, migration and angiogenesis. Methylmercury (MeHg) is a 
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neurotoxic compound deriving from metallic mercury through 
bacteria-supported metabolism in an aquatic environment. 
Bio-concentration in fish and shellfish poses a risk for sensi-
tive population categories such as pregnant women and infants. 
MeHg-induced ROS production may be involved in inflamma-
tion and apoptosis (433) as well as endothelial cell cytotoxicity 
(434). We also looked at paraquat, which may also have rele-
vance for the tumor microenvironment via its role in oxidative 
stress (435,436).
Avoiding immune destruction
The concept of immune surveillance suggests that the host 
immune system could identify tumor cells and destroy them. 
If this is true, tumor cells need to be poor stimulators of or 
challenging targets for the host immune system. To provide 
an effective immune response, multiple types of the cells are 
involved within innate and adaptive immune ‘arm’ with some 
cells (e.g. DCs and the NK cells) ‘bridging’ these two types 
of immunity (437). To avoid a strong immune response of the 
host, the expression of tumor antigens may be down-regulated 
or altered (resulting in decreased or impossible recognition of 
malignant cells) (438) and various soluble factors and cytokines 
may be released resulting in subverted effectiveness of antitu-
mor immune response (439–441). Tumor cells can also escape 
host immune response by inducing apoptosis in activated T 
cells (442).
Multiple genes involved in immune evasion mechanisms 
and, therefore, can interfere with chemical exposures from 
anthropogenic environment: ADORA1 (adenosine A1 receptor), 
AKT1 (v-akt murine thymoma viral oncogene homolog 1), CCL2 
(chemokine C-C motif ligand 2), CCL26 (chemokine C-C motif 
ligand 26), CD40, CD69, COL3A1 (type III collagen of extracellu-
lar matrix), CXCL10 (also called interferon-inducible protein-10), 
CXCL9 (monokine induced by interferon-γ), EGR1 (early growth 
response protein 1), HIF-1α (hypoxia-inducible factor), IGF1R 
(insulin-like growth factor 1 receptor) and interleukins (IL) such 
as IL-1α and IL-6. Based on available studies, several candi-
date signaling pathways that are related to the host immune 
response can be identified for further study; e.g. the pathways 
involving PI3K/Akt, chemokines, TGF-β, FAK, IGF-1, HIF-1α, IL-6, 
IL-1α, CTLA-4 and PD-1/PDL-1.
Biologically disruptive environmental chemicals can affect 
the host immune responses as follows: (i) if a certain chemical 
is immunotoxic, and, in particular, if it affects activity of DCs, T 
cells or NK cells, it is also likely to affect tumor immuno-surveil-
lance and enable malignant growth to proceed; (ii) if a chemi-
cal targets the immune system, it can increase the cancer risk 
related to other factors/exposures; (iii) exposures to certain tox-
ins or toxicants can dramatically increase the number of can-
cerous cells and impact immuno-regulatory signals suppressing 
the mechanisms of immune control. Collectively, these sorts of 
actions suppress the immune system, so it cannot be effectively 
stimulated and cannot eliminate tumor cells, thus allowing 
some tumor cells to escape and metastasize.
We looked at several groups of environmentally ubiqui-
tous chemicals such as pesticides and personal care products 
that might potentially interrelate with mechanisms of tumor 
immuno-surveillance. Although none of them are recognized as 
human carcinogens (443–445), the research on these chemicals 
and their interactions with the immune response may be valu-
able. For example, the fungicide maneb is a cortisol disruptor 
(446) that has shown a wide spectrum of potential effects on 
multiple pathways, including some that are relevant to immune 
evasion (139,156–158,447). By comparison, pyraclostrobin and 
fluoxastrobin (448) interfere with a narrower spectrum of can-
cer hallmarks (36,449–452). Atrazine has also shown potential 
to impact immune system evasion by directly targeting matura-
tion of DCs and decreasing the levels of major histocompatibility 
complex class I molecules (243,453). The insecticides pyridaben 
and azamethiphos can also both be disruptive to immuno-sur-
veillance (139,140,454,455).
Commonly used in personal care products, triclosan and BPA 
(456), are endocrine disruptors (457–459) that are often detected 
in waters downstream in urban areas (460,461). In addition to 
immune evasion mechanisms (36,142,145), they interfere with 
wide spectrum of cancer-related mechanisms (36,173,429,462–
464). DEHP (472) is also an endocrine disruptor (466,467) that can 
impact multiple hallmarks such as immune evasion, resistance 
to cell death, evasion of antiproliferative signaling, sustained 
proliferative signaling and tumor-promoting inflammation 
(36,288,468,469).
Knowing whether or not cumulative low-dose exposures to 
these chemicals interfere with the host immune response can 
help to stimulate further studies (e.g. on screening of lesions at 
the pre-malignant stage of tumor development) to determine 
the influence of such exposures on host immunity and to evalu-
ate their potential to increase the risk of tumor cell survival.
Dose-response characterizations and LDE
For all the chemicals selected and target sites for disruption that 
were identified, dose-response characterization results and/or 
relevant low-dose research evidence were reviewed and catego-
rized using the criteria mentioned in the Materials and meth-
ods. Table 1 sets out these results and the supporting references.
In total, 85 examples of environmental chemicals were 
reviewed (for specific actions on key pathways/mechanisms that 
are important for carcinogenesis) and 59% of them (i.e. 50/85) 
were found to exert LDE (at levels that are deemed relevant given 
the background levels of exposure that exist in the environment) 
with 15 of the 50 demonstrating their LDE in a non-linear dose-
response pattern. Indeed, all of the teams selected at least one or 
more disruptive chemicals that exerted their effects on the tar-
get sites at low-dose levels. In contrast, only 15% of the chemicals 
reviewed (i.e. 13/85) showed evidence of a threshold.
The remaining 26% of the chemicals reviewed (i.e. 22/85) 
were categorized as ‘unknown’. Some of these chemicals (5 of 
the 22)  had been tested using human primary cell data from 
ToxCast and had showed statistically significant activity across 
a full range of doses against the specified targets (i.e. they 
were active even at the lowest test concentrations of ~0.01 µM). 
However, even though no threshold could be discerned for these 
chemicals, we did not characterize them as having LDE (because 
it was not clear that the lowest test concentrations were low 
enough to be equated to levels of exposure that are normally 
seen in the environment).
Evidence of cross-hallmark relationships
Teams then evaluated the chemicals selected and target sites for 
disruption for known effects on the other cancer hallmark path-
ways. Evidence in the literature that showed procarcinogenic 
actions or anticarcinogenic actions in other hallmark areas were 
reported, and in instances where no literature support was found, 
this was documented as well. The same approach was used for 
the chemicals that were reviewed. A sample of these cross-hall-
mark results is provided in Table  2—Sample of cross-hallmark 
relationships of target pathways/mechanisms and in Table  3—
Cross-hallmark relationships of selected chemical disruptors.
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Note that Tables 2 and 3 contain just a single set of unref-
erenced results from the review on the hallmark insensitivity to 
antigrowth signals. This is intended only to illustrate the catego-
ries of cross-hallmark effects that were reviewed and to show 
how they were presented. Fully referenced results for each hall-
mark area can be found in each of the individual reviews within 
this special issue.
The decision to review target sites for disruption and proto-
typical disruptors for cross-hallmark effects was driven by the 
fact that many individual studies and reviews of chemical expo-
sures fail to account systematically for the spectrum of inci-
dental actions that can result from exposures to a single given 
chemical. It was our belief that this approach constitutes a bet-
ter way to ensure that we had assembled a reasonably complete 
view of the literature (i.e. where any sort of evidence of cross-
hallmark activity had been reported). Future research will likely 
involve empirical testing of mixtures, so we wanted to create a 
heuristic that could serve as a starting point for other research-
ers who might be considering such research.
For researchers focused on low-dose exposure research 
intended to produce carcinogenesis, we anticipated that there 
would be interest in chemicals that had been reported to exhibit 
a large number of procarcinogenic actions across a number of 
hallmarks and we anticipated that a lack of anticarcinogenic 
potential would be important to identify (as targets or approaches 
that exert anticarcinogenic actions would potentially represent 
a confounding influence/factor in empirical research aimed at 
the identification of carcinogenic synergies). To that end, Table 4 
provides a summary of the aggregated number of procarcino-
genic actions, anticarcinogenic actions and instances where 
mixed actions (i.e. procarciniogenic and anticarcinogenic) have 
been found for each pathway/mechanism (across the full range 
of hallmark domains—i.e. from all of the areas covered by the 
reviews in this special issue). Similarly, Table 5 provides a sum-
mary of the aggregated number of procarcinogenic actions, 
anticarcinogenic actions and mixed actions (i.e. procarcinogenic 
and anticarcinogenic), where cross-hallmark effects have been 
reported for each chemical (across the full range of hallmark 
domains—i.e. from all of the areas covered by the reviews in this 
special issue).
Note that, in some instances, the underlying evidence used 
to support the indication of cross-hallmark relationships was 
robust, consisting of multiple studies involving detailed in-vitro 
and in-vivo findings. In other instances, the underlying evidence 
that was used to report the existence of a cross-hallmark rela-
tionship was quite weak (e.g. consisting of only a single in-vitro 
study involving a single cell-type). The selected prototypical dis-
ruptors are likely biased towards agents that have been exten-
sively studied, and not necessarily those that will prove to be 
the most important biologically. Finally, there are examples of 
chemicals that are known to exert different effects at different 
dose levels, but dose levels were not used to discriminate when 
gathering evidence of cross-hallmark effects. So, the referenced 
cross-validation results in the individual tables (reported in the 
many reviews within this special issue) should be seen only as 
a starting point for those who are pursuing mixtures research 
(e.g. references would need to be further scrutinized to deter-
mine whether or not the dose levels noted for specific results 
are suitable points of reference for the type of research that is 
being undertaken).
Particular attention should also be given to results related to 
the endocrine system due to mechanistic complexity. For exam-
ple, xeno-estrogen compounds are typically compared with 
estradiol based on binding affinity strength. However, many 
xeno-estrogens that are ‘weak’ by this measure can alter the 
steroidogenic cascade (e.g. significantly up-regulate the activ-
ity of P450 aromatase, the enzyme that increases intracellular 
estradiol synthesis within estrogen-sensitive cells (470–473) or 
alter levels of ERα or the ratio of ERα:ERβ (260)). In other words, a 
weak xeno-estrogen can stimulate the production of estradiol, a 
potent endogenous carcinogen (474) or alter the receptors with 
which a cell will respond to estrogen.
Nonetheless, given that the overarching goal in this project 
was to create a foundation that would allow researchers to look 
systematically across the literature in each of these areas, the 
tables should serve as a useful starting point as long as they 
are approached with these caveats in mind. We believe that 
this heuristic will be useful to consider synergies that might be 
anticipated in testing that involves certain target sites for dis-
ruption and/or mixtures of chemical constituents that are being 
considered for procarcinogenic effects. Future research efforts 
to improve this approach could involve a large-scale collabora-
tive effort to generate high-quality in-vitro data and low-dose in-
vivo data in a range of predefined tissues.
Discussion
Getting to Know Cancer hosted the initial project meeting in 
Halifax, Nova Scotia giving participants an opportunity to have 
presentations, break-out sessions, and chances for conversation 
and debate among experts who came from a range of different 
disciplines. Cancer biologists with specialized expertise in areas 
related to individual hallmarks met with specialists from other 
areas such as environmental health, toxicology and endocrinol-
ogy. Although some researchers in the field of environmental 
health are cancer scientists in their own right, many conference 
participants commented on the novelty of having an oppor-
tunity to work so closely with cancer biology specialists. As a 
result, many interdisciplinary barriers were removed and the 
discussions that ensued were challenging but productive.
At the outset, participants overwhelmingly agreed that the 
Hallmarks of Cancer provides a useful organizing heuristic for 
systematic review of ways that biologically disruptive chemicals 
might exert procarcinogenic and anticarcinogenic influences in 
biological systems. Most of the individual writing teams were 
then readily able to identify ubiquitous environmental contami-
nants with disruptive potential in their respective areas of study. 
The only teams that had significant challenges in this regard 
were the ones that focused on the bypassing of senescence (i.e. 
replicative immortality) and dysregulated metabolism, both being 
areas of cancer research that have not yet received a lot of atten-
tion from researchers in the field of toxicology.
Considerable discussion was devoted to the criteria that 
were used to select prototypical disruptors from the long list of 
known potential contaminants. Indeed, it seems that much of 
the population is now exposed to a wide variety of exogenous 
chemicals that have some disruptive potential, but we did not 
have any intention of implicating any of the selected chemicals 
as being carcinogenic per se. It was simply agreed that chemi-
cals would be chosen that met the basic criteria and that then 
could be used as ‘prototypical’ disruptors. In other words, the 
chemicals that were selected for this review were not deemed to 
be the most important, and they were not selected to somehow 
imply (based on current information) that they are endanger-
ing us. Rather, we simply wanted to illustrate that many non-
carcinogenic chemicals (that are ubiquitous in the environment) 
have also been shown to exert effects at low doses, which are 
highly relevant to the process of carcinogenesis. We also wanted 
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Table 5. Aggregated evidence of cross-hallmark effects for selected chemical disruptors
Chemicals Originating review Procarcinogenic Anticarcinogenic Mixed
12-O-Tetradecanoylphorbol-13-acetate SPS 5 1 0
HPTE ANG 4 0 0
Acetaminophen RI 0 4 2
Acrolein DM 3 3 3
Acrylamide GI 3 1 1
Atrazine ISE 3 0 1
EAS 4 0 1
TPI 3 0 1
Azamethiphos ISE 1 0 0
Benomyl GI 0 3 1
Benzo(a)pyrene SPS 8 1 0
Biorhythms TIM 3 2 0
Biphenyl ANG 2 2 1
BPA EAS 6 0 1
GI 6 0 1
ISE 7 0 1
RCD 7 0 0
SPS 6 0 1
TIM 7 0 1
TM 7 0 1
TPI 6 0 1
Bisphenol AF ANG 5 1 0
Butyltins (such as tributyltin) TM 4 2 0
C.I. solvent yellow 14 ANG 4 0 0
Carbendazim GI 0 2 1
Carbon black GI 5 1 0
Chlorothalonil ANG 5 1 0
RCD 5 0 0
Cobalt GI 5 2 0
Copper DM 6 0 3
Cotinine RI 4 1 0
Cypermethrin DM 5 0 0
DDT EAS 6 0 0
Diazinon DM 2 3 0
Dibutyl phthalate RCD 4 0 0
Dichlorvos RCD 4 0 0
DEHP ISE 4 0 1
RCD 4 0 0
Diniconazole ANG 2 0 0
Fluoxastrobin ISE 2 1 0
Folpet EAS 2 1 0
Hexachlorobenzene TIM 5 2 0
Hexythiazox DM 0 0 0
Imazalil SPS 3 1 0
Iron DM 5 1 3
TIM 5 1 2
Lactofen SPS 2 0 0
Lead GI 3 1 0
RI 3 1 0
Lindane RCD 5 0 0
Linuron RCD 2 0 0
Malathion DM 5 0 0
Maneb ISE 4 2 0
Mercury GI 3 2 1
MXC RCD 3 0 0
Methylene bis(thiocyanate) ANG 2 1 0
MeHg TM 5 2 0
Na-selenite RI 0 4 2
Nickel GI 6 1 1
TM 6 1 1
Nickel chloride RI 6 0 2
Nitric oxide RI 5 2 2
4-NP TPI 2 1 0
Oxyfluorfen RCD 4 0 0
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to lay out a heuristic framework that would be helpful for other 
researchers who are interested in considering these and other 
chemicals as potential constituents for low-dose mixtures 
research.
LDE, chemical mixtures and carcinogenicity
Although we did not specifically ask the teams to focus on 
disruptive chemicals that were known to exert LDE, the sum-
mary of dose-response characterizations for the chemicals 
that were selected by these teams is dominated by chemi-
cals (i.e. 50/85) that have been shown to produce LDE, and 
15 of the 50 showed evidence of a non-linear dose-response. 
Surprisingly, only 15% of the chemicals reviewed (i.e. 13/85) 
showed evidence of a threshold. We believe that this helps to 
validate the idea that chemicals can act disruptively on key 
cancer-related mechanisms at environmentally relevant lev-
els of exposure.
Historically, the axiom ‘the dose makes the poison’ has had 
some merit, so many people remain skeptical about the idea 
that adverse outcomes can result from minute exposures to 
commonly encountered chemicals. But we are now at a point in 
time where our knowledge of the biology of cancer has advanced 
considerably, and we know that carcinogenesis can begin when 
key events have occurred in a single cell, between cells or in 
the surrounding microenvironment. So the idea that LDE from 
many environmental chemicals (acting together) might serve 
to instigate, support or fully enable carcinogenesis, no longer 
appears to be an unreasonable assertion.
At this stage, we are not making any assumptions about 
whether or not future empirical research will find support for 
this hypothesis, nor are we assuming that this a significant 
problem. We are simply impressed by the fact that we are now 
starting to see evidence of a wide range of LDE (that are directly 
related to carcinogenesis) that can be exerted by chemicals that 
are ubiquitous and unavoidable in the environment. As a result, 
we are compelled to explore and consider this possibility.
In-utero exposures and transgenerational effects
Additionally, a number of the teams cited in-utero exposure 
studies in their reviews and presented evidence on transgen-
erational effects. Although this detail is not fully captured in 
the team summaries offered in this capstone paper (please see 
the individual reviews in this special issue for complete details), 
these effects are important to acknowledge. For example, the 
inflammation team noted that transient early life exposures in 
utero to vinclozolin have been linked to both adult-onset dis-
ease and transgenerational disease that involves inflamma-
tion. Similarly, the immune system evasion team reported that 
there is increasing evidence from animal studies that in-utero 
or neonatal exposures to BPA are associated with higher risk of 
immune system dysregulation that may develop later in life.
Taken together, these and other similar types of examples 
raise intriguing possibilities about vulnerabilities at the popu-
lation level, and the contributions that in utero and early life 
exposures to mixtures of those chemicals might make towards 
cancer susceptibility. Single-generation experimental models 
are inadequate to detect this sort of disruptive activity (for expo-
sures to a given chemical or to mixtures of chemicals), but these 
sorts of effects may increase cancer risks by promoting and/or 
enabling tumorigenesis.
The interplay between genetic factors and 
environmental factors
Given the number of key cancer-related mechanisms that can 
apparently be disrupted by chemicals that are commonly found 
in the environment, and the possibility that in-utero and/or early 
life exposures may also contribute to population vulnerabil-
ity, the interplay between genetic factors and environmental 
Chemicals Originating review Procarcinogenic Anticarcinogenic Mixed
Paraquat GI 4 2 0
TM 4 2 0
PFOS ANG 4 1 0
SPS 4 1 0
Phosalone SPS 1 1 0
Phthalates TIM 6 0 1
TPI 6 0 1
PBDEs TPI 2 0 2
Pyraclostrobin ISE 2 1 0
Pyridaben ISE 1 3 1
Quinones GI 1 6 1
Rotenone DM 2 5 1
Sulfur dioxide TIM 5 1 0
Titanium dioxide NPs GI 3 1 1
Tributyltin chloride ANG 3 1 0
Triclosan GI 2 2 1
ISE 3 2 1
Tungsten GI 2 1 1
Vinclozolin TPI 2 1 0
Ziram ANG 3 1 1
Aggregated number of procarcinogenic actions, anticarcinogenic actions and mixed actions (i.e. procarciniogenic and anticarcinogenic) where cross-hallmark effects 
have been reported (for each chemical across the full range of hallmark domains—i.e. from all of the areas covered by the reviews in this special issue)—see samples 
of this how this data were reported in Table 3. Note: fully referenced data for these cross-hallmark effects can be found in each of the reviews in this special issue. 
ANG, angiogenesis; DM, dysregulated metabolism; EAS, evasion of antigrowth signaling; GI, genetic instability; ISE, immune system evasion; RCD, resistance to cell 
death; RI, replicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TM, tumor microenvironment; TPI, tumor-promoting 
inflammation.
Table 5. Continued
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factors should also be mentioned. For example, a hereditary 
genetic vulnerability (such as mutations to BRCA1/2 genes 
which greatly increase the lifetime risk of breast and ovarian 
cancer (482)) can predispose someone to a higher risk of cancer. 
But many hereditary genetic mutations and somatic mutations 
do not result in cancer, presumably because additional actions 
(e.g. sustained proliferative signaling) are needed or additional 
biological safeguards still need to be suppressed or defeated 
(e.g. apoptosis, senescence, immuno-surveillance and so on) 
before a fully immortalized cellular phenotype can emerge. In 
these instances, cancer may not be assured, but it is easy to 
see how the disruptive effects of low-dose exposures to certain 
chemicals might act on key pathways/mechanisms and play a 
supporting role in the steps involved in carcinogenesis and/or 
increase the overall risk of getting cancer.
This same issue applies to other sensitive subpopulations 
who might be predisposed to higher levels of cancer risk. In some 
instances, vulnerabilities that exist are genetic in nature (e.g. 
cancer patients in remission), due to endogenous factors (e.g. 
due to obesity) or due to external influences (i.e. smoking). But 
in all cases, the enhanced risks in these subpopulations leave 
the affected individuals vulnerable to carcinogenesis. Although 
a detailed investigation of this type of interaction is beyond the 
scope of this project, it is important to consider that low dose, 
disruptive chemical effects on key pathways and mechanisms 
in these subpopulations may serve to further enhance cancer 
susceptibility, or even fully enable carcinogenesis.
The low-dose carcinogenesis hypothesis
It is important to reiterate that this group has no interest in 
implicating any of the chemicals that were reviewed in this 
project as individual carcinogens per se. We fully realized 
at the outset that much of the evidence in the toxicological 
literature that documented the disruptive actions of these 
chemicals had been produced under a wide range of differing 
experimental circumstances. So it was agreed at the beginning 
that we would not make leaps between different lines of evi-
dence nor draw any specific conclusions about chemical mix-
tures that might prove to be carcinogenic. Nonetheless, we are 
intrigued by the number of chemicals that we reviewed that 
were found to be capable of disruptive LDE on key pathways/
mechanisms across all of the areas that were reviewed. Many 
of the environmental chemicals that we chose are well known 
as environmental contaminants, but they represent only a 
small fraction of the thousands of chemicals that are now 
ubiquitous and unavoidable in the environment. So although 
we cannot draw any firm conclusions at this stage, we emerge 
from this effort with a better understanding of the evidence 
that is available to support the merits of our initial hypothesis 
(i.e. that low-dose exposures to disruptive chemicals that are 
not individually carcinogenic may be capable of instigating 
and/or enabling carcinogenesis).
Although the breadth and scope of this review effort was 
daunting, we now believe that we have enough supporting evi-
dence to offer a holistic overview of this issue. At a minimum, 
we hope that the studies cited in this review, the gaps that we 
have identified and the framework that we have proposed for 
future research will be useful to researchers who are encour-
aged to explore this hypothesis in greater detail.
The implications for risk assessment
Thirty-five years ago, the work of Ames and others who fol-
lowed set in motion a quest for individual chemicals as (com-
plete) ‘carcinogens’ that became a dominant paradigm that has 
shaped our thinking for decades (226). So dominant has the 
focus been on single chemicals, that combinations of chemi-
cals are rarely tested or even considered. For example, although 
IARC has focused on extensive monographs of the carcinogenic 
nature of individual chemicals, little has been done to evaluate 
the possibility of carcinogenic effects attributable to chemical 
mixtures except in a few instances where mixtures of concern 
are encountered during occupational exposures (e.g. polychlo-
rinated dibenzo-p-dioxins and polychlorinated dibenzofurans) 
or as a result of personal and cultural habits (e.g. cigarette 
smoke, diesel and gasoline engine exhausts).
But the search for mutagenic carcinogens was never 
matched with a corresponding search for chemicals that might 
contribute to the promotion of carcinogenesis along with other 
chemicals. We now know that individual chemicals can produce 
unique disruptions of cellular biology and specific combinations 
of non-carcinogenic chemicals have been able to demonstrate 
potent carcinogenic effects. Yet, we have only scratched the sur-
face of the biology of mixtures, and we need to look carefully at 
the synergistic effects.
In risk assessments, the risks associated with exposures to 
mixtures of chemicals are often estimated using relatively sim-
ple, component-based approaches (476). Risk analysts evalu-
ate information regarding the mode of action associated with 
individual mixture components and then use either ‘dose addi-
tion’ or ‘response addition’ to predict effects. Dose addition is 
an appropriate approach to assess mixtures risks, when the 
chemicals of interest act through a common mode of action. 
Although response addition assumes that constituent agents 
act independently of each other (cause the same outcome via 
different modes of action). In general, a dose addition approach 
would be appropriate for mixtures risk assessment if we wanted 
to consider a series of chemicals that were carcinogenic in their 
own right, and if they all produced the cancer by the same mode 
of action. The Hallmarks of Cancer framework suggests that 
we should be equally, if not more, concerned about mixtures of 
chemicals that are not individually carcinogenic but disruptive 
in a manner that is collectively procarcinogenic (i.e. potentially 
capable of producing carcinogenic synergies when combined 
with other chemicals that are acting on the diverse series of 
mechanisms involved in carcinogenesis).
With this in mind, there should be concern that the World 
Health Organization International Programme on Chemical 
Safety (WHO IPCS) has spent the past decade developing a 
risk analysis agenda predicated mainly on a ‘Mode of Action’ 
framework (477–480), where ‘mode of action’ is defined as a 
sequence of key events and processes, starting with interaction 
of an agent with a cell, proceeding through operational and ana-
tomical changes and resulting in an adverse outcome, in this 
case, cancer formation. The OECD guidance on the conduct and 
design of chronic toxicity and carcinogenicity (which is followed 
by many nations) now also reflects this approach (480). This 
analysis of risks from cumulative effects of chemical exposures 
is restrictive because it suggests that regulators should only 
focus on groupings of individual chemicals that are as follows:
(a)  known to act via a common sequence of key events and 
processes;
(b)  known to act on a common target/tissue and
(c)  known to produce a common adverse outcome (e.g. 
cancer).
So, for example, in the USA, the Food Quality Protection Act pro-
vides legislated guidance on testing for cumulative effects by 
using the term ‘common mechanism of toxicity’ (481), which is 
interpreted to mean ‘mode of action’ or ‘the major steps leading 
to an adverse health effect following interaction of a pesticide 
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with biological targets’. Similarly, in Canada, the Pest Control 
Products Act requires the government to assess the cumulative 
effects of pest control products that have a ‘common mecha-
nism of toxicity’. In the USA, there has also been a tradition of 
employing an additional restriction requiring chemical struc-
tural similarity when selecting groups of chemicals to be sub-
jected to mixtures risk assessment (other than a few instances 
where whole mixtures have been assessed, e.g. diesel exhaust, 
combinations of chemicals that are not similar structurally have 
been largely ignored (489)). In light of current knowledge of can-
cer biology, these criteria appear to be inappropriately restric-
tive, and thus demand a number of considerations—as follows:
Cumulative risk assessment should anticipate synergies of chemicals 
acting via dissimilar sequences/processes. From the Hallmarks of 
Cancer framework, it becomes evident that chemicals that act 
via dissimilar pathways/targets or that produce different sorts 
of key events and/or employ different processes could very 
well produce synergies within carcinogenesis that would be 
relevant for cumulative risk assessment purposes. For example, 
ethylenediaminetetraacetic acid (EDTA) is a ubiquitous, 
presumably non-carcinogenic chemical that disrupts DNA 
repair (483,484), and it is well established that it influences 
chromosome breakage by mutagenic agents. In particular, 
when applied in combination with chemical mutagens, EDTA 
enhances mutagen-induced aberration frequencies and 
contributes to genetic instability (485). But within the mode of 
action framework, a chemical that is a mutagenic carcinogen, 
would not be assessed for the cumulative risks associated with 
an additional exposure to a chemical that disrupts DNA repair (a 
key layer of cancer defense) because it is not known to produce 
a common sequence of key events and processes.
A 2008 report on phthalates and cumulative risk assess-
ment emphasized that the chemicals considered for cumula-
tive risk assessment should be ones that cause the same health 
outcomes or the same types of health outcomes, not ones that 
cause the health outcomes only by a specific pathway (486). 
Similarly, The European Food Safety Authority Panel on Plant 
Protection Products and their Residues (PPR Panel) produced a 
scientific opinion on the relevance of dissimilar modes of action 
and their relevance for cumulative risk assessment of pesticides 
residues in food (482). The PPR Panel found good evidence that 
combination effects can arise from co-exposure to chemicals 
that produce common (adverse) outcomes through entirely 
different modes of action and recommended cumulative risk 
assessment methods to evaluate mixtures of pesticides in foods 
that have dissimilar modes of action (396).
Cumulative risk assessment should anticipate synergies of chemicals 
acting on different targets/tissues. The Hallmarks of Cancer 
framework suggest that spatiotemporal aspects of chemical 
exposures are likely important as well. For example, the many 
constituent parts of the immune system and its distributed 
nature (e.g. lymph vessels, thymus, bone marrow and so on), the 
hypothalamic–pituitary–adrenal axis and cortisol in circulation, 
which are used to suppress macrophage migration inhibitory 
factor and control inflammation (487–489) and the surrounding 
tissues of the tumor microenvironment, are all relevant targets 
that could be chemically disrupted to produce procarcinogenic 
contributions to carcinogenesis.
For example, as noted previously, maneb is a fungicide with 
a potentially disrupting effect on cortisol (446), which could 
impact the body’s response to inflammation suppression, 
whereas atrazine affects the host immune response by directly 
targeting maturation of DCs and decreasing the levels of major 
histocompatibility complex class  I  molecules (243,453). Both 
are highly relevant forms of disruption for carcinogenesis, but 
within the mode of action framework, the cumulative effects 
of these chemicals (and other chemicals acting on these and 
similarly distributed targets) would never be assessed together 
because they do not act on a common biological target.
The PPR Panel recently pointed out that there is no empiri-
cal evidence for the validity of independent action as a predic-
tive concept for multicomponent mixtures in the mammalian 
toxicological literature. Further, they argued that although over-
lapping toxic effects in different organs/systems may exist, it is 
difficult to identify a combination effect. Thus, the panel specifi-
cally restricted their focus to chemicals that ultimately produce 
a common adverse outcome (e.g. cancer) in the same target 
organ/system (482). Although it may be difficult to identify this 
sort of an effect, that does not mean, however, that we should 
ignore this possibility (i.e. now that our understanding of the 
biology of cancer has improved).
Cumulative risk assessment should anticipate synergies of non-
carcinogens. The WHO IPCS mode of action framework accepts 
the notion of a common toxic endpoint and therefore that 
chemicals need to first be carcinogens themselves before they 
can be considered as possible constituents of carcinogenic 
mixtures. However, it is now evident that not every 
procarcinogenic action resulting from a chemical exposure 
must be the result of a chemical that is a carcinogen itself. 
Continued focus on individual carcinogens reflects a lingering 
paradigm that overlooks the examples of synergies such as 
those highlighted in this project. Low-dose mechanistic 
effects may be very important so approaches are needed 
that take this into account. In chronic and complex diseases, 
establishing dose thresholds using the whole disease as the 
endpoint (e.g. cancer) may be inappropriate, especially when 
exposures to individual chemicals can produce relevant (but 
not disease causing) mechanistic effects at much lower dose 
levels. 
Cumulative risk assessment should anticipate synergies of 
structurally dissimilar chemicals. The EPA’s emphasis on 
structurally similar classes of chemicals for mixtures risk 
assessments is unnecessarily restrictive. The dissimilar 
chemicals reviewed within this special issue are testament to 
the fact that similar disruptive effects can be produced by a wide 
range of chemical structures and failure to adapt testing to this 
fact is no longer acceptable (486).
In sum, it is concerning that the WHO IPCS approach is so 
highly restrictive when it comes to the assessment of cumu-
lative effects. The OECD guidelines acknowledge that cancers 
originating from at least some cell types may arise by a vari-
ety of independent pathways, but the guidance is fundamen-
tally focused on the identification of individual carcinogens and 
cumulative effects of carcinogens, specifically noting that the 
approach is intended to ‘avoid misidentification of non-tumorigenic 
compounds as possible human carcinogens’ (480). But in practice, as 
in-vitro and in-vivo evidence for many chemicals is frequently 
not available (i.e. to prove that they individually act via a com-
mon sequence of key events or process a common target/tissue 
to produce cancer), it means that risk assessments of the cumu-
lative effects of exposures to mixtures of chemicals on carcino-
genesis are rarely conducted.
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The International Life Sciences Institute, which is a non-
profit organization with members comprised largely of major 
corporate interests from the food and beverage, agricultural, 
chemical and pharmaceutical industries, has worked closely 
with the WHO IPCS to support this approach. But while it may 
serve to ensure the avoidance of the misidentification of (non-
tumorigenic) chemicals/compounds as possible human car-
cinogens, it simultaneously discourages regulatory agencies 
from exploring the sorts of synergies that might plausibly be 
expected to occur. Indeed, the biology of cancer suggests that 
the cumulative effects of non-carcinogenic chemicals acting on 
different pathways that are relevant to cancer, and on a variety 
of cancer-relevant systems, organs, tissues and cells may very 
well conspire to produce carcinogenic synergies that will be 
overlooked entirely as long as the mode of action framework 
(and the restrictions that it imposes) remains in use.
As mentioned briefly previously, a considerable effort has 
been made by toxicologists to advance a new approach called 
the Adverse Outcome Pathway framework. This is an extension 
of the Mode of Action framework and is primarily being devel-
oped as an alternative solution to in-vivo toxicity testing. The 
framework is based on the idea that any adverse human health 
effect caused by exposure to an exogenous substance can be 
described by a series of causally linked biochemical or biologi-
cal key events with measurable parameters (28,490). Although 
the Adverse Outcome Pathway framework anticipates the pos-
sibility that multiple pathways may need to be defined (i.e. dif-
ferent pathways that can produce the same adverse human 
health effect), the concept is currently aligned with the mode 
of action approach and focuses mainly on individual chemi-
cal effects that follow a well-described pathway to produce an 
adverse health outcome. So as it is currently conceived, it has 
some of the same limitations that apply to the mode of action 
framework.
Nonetheless, this focus at a mechanistic level is progressive 
in nature and some researchers in this area are starting to call 
for the adoption of practices within the framework that can 
account for epigenetic effects, transgenerational effects and 
chronic toxicity (detrimental effects arising in individual or at 
the population level following long-term continuous or fluctu-
ating exposure to chemicals at sublethal concentrations—i.e. 
concentrations not high enough to cause mortality or directly 
observable impairment following acute, short-term exposure, 
but able to induce specific effects potentially leading to adverse 
outcomes occurring at a later point in time) (28).
So this framework may be suitable for research that is 
focused on mixtures of chemicals and the pathways involved 
in carcinogenesis, so long as the adherents to this approach 
are open to the possibility that all relevant pathways need not 
have adverse health outcomes as endpoints, and that synergies 
between pathways may need to be anticipated. In other words, 
a series of seemingly benign actions on different pathways may 
be needed to conspire to produce the adverse health outcome 
that is of interest. This is the case in cancer. There are so many 
layers of redundancy and safeguards in place that individual 
disruptions of certain pathways may never cause disease on 
their own. Yet, when a number of these pathways are enabled, 
they can produce a discernable adverse health outcome (i.e. 
cancer). If this approach is robust enough to anticipate this type 
of complexity, it may be a model that will allow us to move past 
the limitations imposed by the mode of action model.
Many regulatory agencies that conduct chemical risk assess-
ments also have a mandate to ensure that adequate safety 
margins are in place to protect sensitive subpopulations. So 
they will need to place an increasing emphasis on the inter-
play between environmental factors and genetic factors and 
also consider in-utero exposures and the potential for transgen-
erational effects. Some progress has been made in tackling the 
gene-environment interaction problem using pathway analysis 
to demonstrate the role of genetic variants in exposure-related 
cancer susceptibility (c.f. Malhotra et  al. (498)), but very little 
research has been done on in-utero exposures to mixtures of 
chemicals that act on cancer-related mechanisms. An approach 
that focuses on defining mixtures of constituents that act dis-
ruptively on key mechanisms that are related to individual hall-
marks may serve as a useful starting point to find evidence of 
relevant transgenerational effects (c.f. Singh et  al. (499)). This 
is definitely an area where additional research and regulatory 
input is needed.
Research needs: cancer versus carcinogenesis
One of the main challenges in this project has been the need 
to better understand carcinogenesis as a process characterized 
by a long latency—and the corollary possibility of both direct 
and indirect effects—rather than cancer as a disease endpoint 
that must occur rapidly and in the majority of exposed persons 
to be relevant. This was also accompanied the recognition that 
the Hallmarks of Cancer are frequently neither fixed nor spe-
cific for cancer (349–351). Numerous experimental models have 
been used in cancer research over the years, and Vineis et  al. 




(c)  Models based on non-genotoxic mechanisms, clonal 
expansion and epigenetics
(d) ‘Darwinian’ or ‘somatic cellular selection’, and
(e) ‘Tissue organization’.
All of these models have had significant support in the scientific 
literature (based upon empirical evidence) and there is consid-
erable overlap between them. But our collective understanding 
of carcinogenesis is still largely constrained by a historically 
monolithic toxicology-based approach that has been focused on 
the effects of mutagens and the disease itself. So although the 
Hallmarks of Cancer framework helps us to better conceptualize 
the many acquired capabilities of the disease, it leaves much to 
the imagination when it comes to advancing our understanding 
of carcinogenesis per se. This lacuna was recently highlighted by 
Brash et al. (494,495) in an article on what they called ‘the mys-
terious steps in carcinogenesis’.
Carcinogenesis appears to be an evolution of factors that 
ultimately conspire towards various acquired capabilities (i.e. 
those delineated within the Hallmarks of Cancer framework), 
but how much does the sequencing of these acquired capabili-
ties matter and in what order are these capabilities acquired? 
Figure  1 implies a rough sequencing of these capabilities, but 
do we know for certain that all hallmarks for established cancer 
are important for carcinogenesis as well (i.e. which hallmarks 
are necessary for all tumors, and of those, which are sufficient 
or perhaps distinct for certain cancers?). Other important ques-
tions to ask relate to whether or not the individual hallmarks 
are a cause or a consequence of cancer development? Do the 
individual hallmarks need to be expressed simultaneously or 
sequentially along the continuum of carcinogenesis (from expo-
sure to unambiguous cancer phenotype development)? More 
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importantly, how does our understanding of this framework 
inform our general approach to the study of carcinogenesis?
We have partial answers to some of these questions, but 
some of these questions remain unanswered, and given the 
prolonged latency of many cancers, these are important ques-
tions. Our lack of knowledge in this regard makes it difficult to 
draw immediate conclusions about the effects that exposures to 
mixtures of disruptive chemicals might cause and the synergies 
they might produce. Public health protection is challenged by 
the combinatorial complexity posed, not only by multiple expo-
sures to chemicals at environmentally relevant doses (either 
simultaneously or sequentially) but also through the different 
mechanisms played out in temporospatial manners (includ-
ing life stages of development, which are different from those 
applied in traditional toxicologic and carcinogenic screening).
We, therefore, need to consider an expanded research agenda 
to include the origins, determinants and temporospatial evolu-
tion of the various cancer hallmarks and their interrelatedness. 
The key questions of reversibility and of cause versus conse-
quence must also be rigorously addressed at every step from ini-
tiating carcinogenic exposure to established cancer, recognizing 
that not all hallmarks are either fixed or specific for any given 
cancer type.
Research needs: the Hallmarks of Cancer
Current approaches to the study of chemical exposures and car-
cinogenesis have not been designed to address effects at low 
concentrations or in complex mixtures. Procarcinogenic agents 
may be directly genotoxic, indirectly genotoxic or non-genotoxic. 
In principle, not every disruptive effect resulting in a change 
that mimics a cancer hallmark is necessarily carcinogenic. Such 
associations, when observed, still require rigorous validation to 
ensure that exposures are unequivocally linked to the develop-
ment of both cancer and accompanying phenotypic hallmarks. 
These complex interactional possibilities, coupled with the fact 
that low-dose combinatorial effects on cancer development 
and progression have not been rigorously or comprehensively 
addressed, speak to major gaps in our understanding of envi-
ronmental cancer risk and the specific role that mixtures of 
environmental chemical exposures might play in the incidence 
of cancer at the population level.
Unfortunately, the known effects for chemicals examined in 
isolation and at higher concentrations cannot be readily extrap-
olated to effects at lower concentrations. Interactions within 
complex mixtures will also occur against the backdrop of com-
plex interactions with other environmental, genetic and epige-
netic factors, so there is a need for expanded or complementary 
conceptual and experimental frameworks to better understand 
the determinants and specific functional contributions of envi-
ronmental exposures in cancer.
A considerable amount of energy is now being placed on the 
development of research and technologies that can support the 
‘exposome’ (496), an emerging concept aimed at representing 
the totality of chemical exposures received by a person during 
a lifetime. This approach encompasses all sources of toxicants 
and is intended to help researchers discern some of the contrib-
uting factors that are driving chronic diseases such as cancer. 
Related projects are expected to involve extensive biomoni-
toring (e.g. blood and urine sampling) and other techniques to 
assess biomarkers that might be relevant, and this information 
should be extremely helpful. Longitudinal studies should also 
be carried out in animal models to assess the tissue distribution 
of mixtures of chemical metabolites. To truly make good use 
of this information, we are going to need a better mechanistic 
understanding of the process of carcinogenesis itself and better 
early markers of cancer development.
It therefore makes sense to pursue empirical research based 
on our current understandings of the disease to test the effects 
of real-world environmental mixtures at relevant dose levels. 
Basic studies should be designed to test joint toxic action (of 
carefully designed combinations of chemicals) to assess both 
dose additivity (via common mode of action) and response addi-
tivity (via disparate modes of action). Research designs should 
anticipate the many layers of inherent defense and incorporate 
chemical constituents specifically intended to demonstrate pre-
dictable synergies and mechanistic relevance. It would also be 
useful to know whether or not the chemical induction of certain 
numbers/combinations of hallmarks is sufficient to consistently 
produce in-vivo carcinogenesis.
Mixtures research that focuses on the carcinogenic synergies 
of non-carcinogenic constituents would be particularly useful. 
In addition, compounds or classes of chemicals already consid-
ered to be (complete) carcinogens in the classical sense may also 
contribute to carcinogenesis in complex mixtures at concentra-
tions not traditionally deemed carcinogenic. For this reason 
and for completeness, ‘classic’ carcinogens with an established 
environmental presence at levels that are presumed to be incon-
sequential may still have pathogenic relevance and should be 
routinely included in the analysis.
Target sites that are being manipulated and disruptive chem-
icals that are being selected to produce carcinogenic effects 
should be scrutinized for confounding effects. Table 4 contains 
aggregated evidence of cross-hallmark effects for selected path-
ways/mechanisms, and although some target sites for disrup-
tion may be compelling starting points for researchers focused 
on a given phenotype (e.g. genetic instability), cross-hallmark 
relationships should be explored. So, for example, telomere loss 
is seen as a disruptive (procarcinogenic) effect from the per-
spective of the the genetic instability team (i.e. the group in this 
project who selected this target) and it has also been shown to 
exert procarcinogenic effects in four other hallmark areas. But 
evidence also exists that suggests that telomere loss can have 
anticarcinogenic effects in four other hallmark areas. The exact 
circumstances of the various studies that support these cross-
hallmark relationships would need to be reviewed to better 
understand the implications/relevance of these reported effects. 
But checking planned disruptions of each target across all of 
the other hallmark areas is a way to ensure that confounding 
(i.e. anticarcinogenic) effects are not inadvertantly introduced 
into experiments that are aimed at producing carcinogenesis, 
or phenotypes that can support/contribute to carcinogenesis. 
Similarly, Table  5 contains aggregated evidence of cross-hall-
mark effects for the chemical disruptors in this review, so this 
table can be used for the same purpose.
It may also be productive to identify ‘reference compounds’ 
(ideal and prototypical disruptors) for each hallmark path-
way as a guide to predict different combinations of chemicals 
that might act in a procarcinogenic manner on any one of 
the hallmarks. This may involve different systems and organs 
that have relevance to cancer and this sort of research could 
also be combined with similar sorts of research on other refer-
ence compounds or mixtures that are shown to enable other 
hallmarks. In doing so, researchers should evaluate epigenetic 
changes in multiple samples/organs/tissues from exposed ani-
mals/other experimental models using gene array technology, 
‘omics’ approaches, real-time imaging of tumors in 3D both in-
vitro (primary cells) and in-vivo models combined with molecu-
lar biomarkers of disease progression, and cellular immune 
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parameters. The combination of use of computational chemical 
genomics virtual screening (497), system biology/pharmacology 
and high-quality imaging techniques should help us find quan-
titative-structure-activity-relationship correlations between the 
chemical structure of dissimilar disruptors and experimental 
data on biological activity, physiological changes, in-vivo toxicity 
and 3D cellular protein dynamics.
It is also conceivable that the combined effects of hundreds of 
chemicals in the environment may be involved in the process of 
enabling carcinogenesis at the population level, so basic empiri-
cal research that can demonstrate carcinogenic effects with min-
imalistic combinations may initially be needed to reveal the more 
granular aspects of carcinogenesis. For example, initial research 
might test our assumptions of the step-wise progression of car-
cinogenesis using targeted mixtures of chemicals that exert LDE 
to test combinations of 2, 3, 4 chemicals etc. against specific 
hallmarks and then adding additional targets to move through 
the various steps that are believed to be needed to fully enable 
the process. Experiments of this nature may reveal increases 
as well as decreases in cancer risk when different mechanisms 
are disrupted and corresponding hallmark phenotypes are ena-
bled (depending on the timing of various disruptive exposures). 
Batteries of tests may ultimately be needed to evaluate whole 
mixtures and key components individually and in various com-
binations. HTS approaches will be particularly helpful here, and 
a tiered approach may make sense to look for disruptive combi-
nations, which can then be applied in vivo. Exposure sequenc-
ing and dosage may also be important and should be evaluated 
based on our current understandings of the biology of cancer.
In terms of setting research priorities, tissue fate is also a 
matter for consideration. It has been known for many years that 
certain chemicals have affinities for certain tissues, and radi-
otracer labeling studies that have been conducted on chemicals 
for regulatory purposes illustrate how certain chemicals tend 
to accumulate in certain tissues. Additionally, it is well known 
that some tissue types give rise to human cancers millions of 
times more often than other tissue types (498). So, researchers 
may want to focus their work on mixtures of disruptive chemi-
cals that prove to be complementary at a mechanistic level and 
individually known to accumulate in the same types of tissues, 
while at the same time choosing tissue types that are known to 
produce cancers more rapidly.
The work that has been done by the WHO IPCS on mode of 
action has been very useful. Understanding when chemicals 
operate through the same mode of action is definitely good 
information for analytical purposes, but given that we now rec-
ognize that non-carcinogens acting at very low-dose levels on 
different targets and mechanisms can still activate carcinogen-
esis-related pathways, the combined (carcinogenic) potential of 
the many commonly encountered chemicals within the envi-
ronment still needs to be evaluated.
Increasingly, our information is improving and there are 
several tools that researchers can use to improve their research 
designs. For example, ToxCast™ is an approach launched by 
the EPA in 2007 to develop ways to predict potential toxicity of 
chemicals and to develop a cost-effective approach for prior-
itizing the thousands of chemicals that need toxicity testing. 
The ToxCast™ database was used in this project by a number 
of the teams and an incredible amount of data are available on 
in-vitro tests (produced using HTS) for a wide range of chemi-
cals. For example, there are many results that are direct meas-
ures of actions related to important mechanisms found within 
the Hallmarks of Cancer framework, which would be useful for 
research focused along these lines.
Although the hallmark phenotypes in this project repre-
sent areas of cancer research for which there is considerable 
agreement, one critique of this framework is that it ignores the 
‘missing hallmark’ of dedifferentiation (351). As well, the com-
plexity encompassed by each of these areas of research is hum-
bling. Moreover, cancer is not a singular or fixed entity, which 
frequently limits the ability to generalize about cancer biology 
(349–351). In a recent reflection on his career, Weinberg et  al. 
(499) noted not only widespread acceptance of the ‘Hallmarks of 
Cancer’ heuristic but also that this attempt to simplify the dis-
ease is rapidly being eclipsed by calls from the next generation 
of researchers who are now focused on assembling and analyz-
ing enormous data sets to gain an increasingly sophisticated 
understanding of cancer (e.g. genomes, transcriptomes, pro-
teomes—including isoforms, post-translational modifications 
and proteoforms, epigenomes, kinomes, methylomes, glycomes 
and matrisomes—each one of which encompasses staggering 
amounts of accumulated information) (499).
Many researchers have called for an analytical use of sys-
tems biology to transcend the study of individual genes/proteins 
and to integrate this complexity into higher order phenotypes 
(500,501). Systems biology enables researchers to identify prop-
erties that emerge from complex chemical–biological systems 
by probing how changes in one part affect the others and the 
behavior of the whole system. The combined effects of tens, 
if not hundreds, of simultaneous exposures may need to be 
accounted for. The fundamental challenge is that such models 
require parameters that are driven by data, but there are very 
few good examples of research on mixtures at environmentally 
relevant dose levels (502) (c.f. Porter et al. (510)), and there are 
fewer still that are focused on cancer.
Nonetheless, in the near term, this basic framework should 
serve as a useful starting point for foundational research and 
government funding agencies should consider new ways to 
support large-scale, team-based holistic approaches to this 
problem.
Regulatory priorities (in the face of combinatorial 
complexity)
It will take time before we fully understand the carcinogenic 
potential of low-dose exposures to chemical mixtures in the 
environment. Nonetheless, we cannot afford to lose sight of 
the fact that the incidence of cancer remains unacceptably 
high, and that the unavoidable (i.e. not lifestyle related) causa-
tive factors that are, in part, underpinning this trend are still 
not fully understood (9–11,504,505). Populations worldwide are 
continually exposed to a wide range of chemicals, so keeping 
the precautionary principle in mind (506), there is a need to take 
the risks related to the cumulative effects of these chemicals 
seriously (422). Of primary concern is the fact that WHO IPCS 
mode of action framework (477) and the OECD guidelines for 
risk assessment (480) are restrictive to the point that regulators 
could be underestimating the risks posed by exposures to low 
doses of mixtures of chemicals.
National regulatory agencies and cancer research founda-
tions must proactively pursue empirical research programs to 
assess any basic relationships that can be discerned between 
exposures to mixtures of commonly encountered chemicals and 
carcinogenicity. For example, systematic exploratory research in 
appropriate rodent models exposed to ‘whole-mixtures’ that 
consist of multiple chemical constituents at environmentally 
relevant dose levels could demonstrate the carcinogenic poten-
tial of complex mixtures that are relevant to the population. 
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There is also a compelling need for complementary basic 
research to address specific causal relationships between envi-
ronmental exposures and the associated development of cancer 
and its characteristic hallmarks.
Hypothetically speaking, such a ‘whole mixture’ should be 
composed of non-carcinogens and potential carcinogens given 
that individual chemicals that are not carcinogenic could act on a 
range of different systems, tissues and/or cells and act synergisti-
cally with other chemicals to instigate carcinogenesis. The goal of 
such investigations would not be to single out any given chemical 
as a carcinogen, but rather to determine whether or not unantici-
pated (procarcinogenic) synergies of many commonly encoun-
tered chemicals when combined are endangering public health.
In line with the 3Rs (Reduction, Replacement and Refinement) 
guiding principles for more ethical use of animals in scientific 
experiments, there has been a significant push for research-
ers and regulatory agencies to move away from in-vivo testing 
(e.g. European Union REACH legislation and in the USA, the NRC 
Toxicology for the 21st Century vision (507)) to take advantage 
of HTS and other new technologies. The EPA’s effort to search 
for environmental chemicals that are most active in relevant 
assays across the various cancer hallmarks, and then to com-
pare those results with in-vivo rodent carcinogenicity data for 
the same chemicals, was a definite step in this direction (29). 
However, HTS models of carcinogenicity will require validation, 
and significant hurdles remain before this sort of testing will 
be ready to replace in-vivo research (508). Therefore, in the near 
term, in-vivo testing still remains an important avenue for devel-
oping data sets to address cancer risks of complex mixtures. 
Summary/Conclusions
For several decades, there has been a concerted effort to iden-
tify individual chemicals and other agents that are carcinogenic. 
At the same time, however, little has been done to determine 
whether or not chronic lifetime exposures to mixtures of non-
carcinogenic chemicals in the environment (at low-dose lev-
els) have carcinogenic potential. Many chemicals are known to 
accumulate in bodily tissues over time, but little is known about 
their combined effects at a mechanistic level and their impact 
on cancer-related mechanisms and carcinogenesis. In this pro-
ject, teams of cancer biologists worked with researchers in the 
field of environmental health for the very first time to explore 
this possibility.
Teams that reviewed these cancer-related phenotypes (i.e. 
genetic instability, tumor-promoting inflammation, sustained 
proliferative signaling, insensitivity to antigrowth signals, resist-
ance to cell death, angiogenesis, tissue invasion and metastasis, 
the tumor microenvironment and avoiding immune destruc-
tion) readily identified individual (non-carcinogenic) chemicals 
that are ubiquitous in the environment that have some poten-
tial to act on key/priority functional targets in each of these 
domains. In contrast, the teams focused on replicative immortality 
and dysregulated metabolism found examples of chemicals to con-
sider but noted a significant lack of useful toxicological research 
in these areas.
In total, 85 examples of environmental chemicals were 
reviewed as prototypical disruptors (for specific actions on key 
pathways/mechanisms that are important for carcinogenesis) 
and 59% of them (i.e. 50/85) were found to exert LDE (at levels that 
are deemed relevant given the background levels of exposure that 
exist in the environment) with 15 of the 50 demonstrating their 
LDE in a non-linear dose-response pattern. Only 15% of the chem-
icals reviewed (i.e. 13/85) were found to have a dose-response 
threshold and the remaining 26% (i.e. 22/85) were categorized as 
‘unknown’ due to a lack of dose-response information.
Cross-hallmark effects for all target sites for disruption and 
for all chemicals were found, but the evidence supporting these 
results varied considerably in strength and in context.
A number of the teams also cited relevant in-utero expo-
sure studies in their reviews and presented data on transgen-
erational effects related to different aspects of the disease (e.g. 
inflammation, immune evasion and so on). These examples 
raise intriguing possibilities about vulnerabilities at the popu-
lation level, and the contributions that in-utero and early life 
exposures to mixtures of those chemicals might make towards 
cancer susceptibility.
Therefore, current regulations in many countries (that con-
sider only the cumulative effects of exposures to individual 
carcinogens that act via a common sequence of key events and 
processes on a common target/tissue to produce cancer) should 
be revisited. Our current understanding of the biology of can-
cer suggests that the cumulative effects of (non-carcinogenic) 
chemicals acting on different pathways that are relevant to 
cancer, and on a variety of cancer-relevant systems, organs, tis-
sues and cells could conspire to produce carcinogenic synergies 
that will be overlooked using current risk assessment methods. 
Cumulative risk assessment methods that are based on ‘com-
mon mechanisms of toxicity’ or common ‘modes of action’ may 
therefore be underestimating cancer-related risks. In-utero and 
early life exposures, transgenerational effects and the interplay 
between the low-dose mechanistic effects of chemical mixtures 
in the environment and the vulnerabilities of subpopulations 
who are predisposed to cancer (i.e. via genetics or other influ-
ences) must also be considered. Current policies and practices 
do not adequately address these issues and should therefore be 
revisited if regulatory agencies hope to better understand and 
assess these risks.
Finally, given the long latency period in most cancers, early 
detection to cancer is key so an improved understanding of the 
biology within originating tissues (during the latency period) 
would be very helpful. If we can use the heuristic presented in 
this review to better assess the combined effects of common 
exposures to chemical mixtures in the environment, it will help 
us improve our understanding of carcinogenesis and identify 
exogenous triggers and enabling factors (in utero and during 
this important latency period), all of which will be key for the 
development of effective strategies for prevention and early 
detection.
Contributions
The first draft of this manuscript (prepared by W.H.G.) was distrib-
uted to all of the contributors within the task force for feedback 
and additional inputs. The many responses that followed were 
managed by W.H.G. (with the assistance of L.Lo., M.G. and D.O.C.). 
Then, multiple rounds of inputs were solicited from the entire task 
force with several subsequent rounds of revisions and refinements 
prior to submission. In addition to the contributions mentioned 
previously, The Halifax Project also benefited from the involve-
ment of D.J.C. (who provided details, at the workshop in Halifax, 
Nova Scotia, Canada, of National Institute of Environmental 
Health Sciences priorities and the agency’s interest in unravel-
ling the health effects of environmental mixtures) and from Glenn 
Rice (who gave a Halifax workshop presentation on the chemical 
mixtures as a consideration in cancer risk assessment). Both of 
these presenters were included in the iterative rounds of manu-
script revisions mentioned previously, and both offered inputs that 
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resulted in refinements to the manuscript. Finally, the journal’s 
peer-review process was important, and resulted in the collection 
of additional evidence from the teams that related to thresholds, 
LDE and of non-monotonic dose-response relationships. The 
reviewer’s critical analysis on these topics resulted in a substantial 
improvement to the data presented in this capstone document, 
which ultimately served to highlight the extent to which low-dose 
exposures to individual chemical constituents (within mixtures of 
environmental chemicals) might have relevance for the process of 
carcinogenesis. Dose-response characterization data and inputs 
were then submitted by all teams and subsequently reviewed and 
compiled by N.K., A.Co. and R.M.
The Halifax Project Task Force that worked on this manuscript 
involved nearly 200 people, many of whom contributed to, and 
signed on to this capstone article. The design of the Halifax Project 
was conceived by L.Lo. with scientific advice from M.G. Funding 
provided by the National Institute for Environmental Health 
Sciences was arranged by D.O.C., and this manuscript was first 
drafted by W.H.G. Starting with the Hallmarks of Cancer frame-
work (Hanahan et al. (21)), 11 teams of international cancer biolo-
gists and toxicologists were established to review the literature 
on key cancer-related mechanisms/pathways in their respective 
domains and to also look at the disruptive potential of low-dose 
exposures to chemicals commonly encountered in the environ-
ment (i.e. as it relates to those same mechanisms/pathways). 
Each team had a leader and each team was responsible for con-
tributing a section of related content within the capstone manu-
script. The contributing authors from these teams are as follows: 
(1) Angiogenesis (Z.H., C-W.H., H-Y.H., L-T.L., M.X., N.K., S.A.B., 
T.M., V.D., W.K.R.); (2) Dysregulated metabolism (R.B.R., A.C.S., 
A.B., E.Ry., D.B., F.C., F.L.M., G.Wi., J.We., N.B.K., R.P.); (3) Evasion of 
antigrowth signaling (R.N., A.L., C.C.N., D.W.L., D.R., G.S.G., G.M.C., 
H.Kr., J.V., K.A.C-S., M.W., N.C., P.A.M., P.De., R.A-V., R.V., R.D.F., R.P-
C., R.C.C., S.N.B.), (4) Genetic instability (S.A.S.L., A.L.d.C.S., A.Az., 
A.K.C., A.R.C., A-K.O., E.Ro., F.D., F.J.V.S., G.K., G.B., L.Go., L.Le., L.Z., 
M.Val., M.K-V., N.v L., P.O-W., S.Pav., T.C.); (5) Immune system eva-
sion (H.K.L., E.C., J.K., M.A.W., M.H.M., T.O., W.K.D.), (6) Replicative 
immortality (A.Ca., C.B-A., H.Y., H.Ko., J.P.W., J.F.M-L., M.L., S.S.W.); 
(7) Resistance to cell death (H.H.P., A.M.A., B.J.B., C.Y., E.R., K.B.N., 
L.S.D’A., L.Li., M.F.R., M.J.G., P.M.G., P.S.L., Q.(S.) C., R.K.S., R.D., S.Ro., 
S.L., T-J.L., Y.R.); (8) Sustained proliferative signaling (W.E., A.W., 
G.Wa., H.S., J.E.K., J.R., K.M., L.Gu., M.V.K., P.V., P.Da., R.M., S.Er., 
T.S., T.H.); (9) Tissue invasion and metastasis (J.O., B.P.Z., C.D., G.N., 
G.T.W., I.K., I.R.M., L.J.M., N.A., O.O., P.N-M., S.El., S.Pap., V.O-M., Y.L., 
Z.C.); (10) Tumor microenvironment (D.W.F., C.S.C., D.C.K., E.L., 
F.M., J.Ro., J.C., J.R.W., L.S., L.V., M.C., P.K.K., P.H., S.Ry., S.C.C., V.M-
S.) and (11) Tumor-promoting inflammation (P.T., C.B., E-Y. M., J.S., 
L.J., M.K., S.H., T.G., V.S.).** Additionally, a special cross-functional 
team was established to investigate whether or not the chemi-
cals that were identified by the teams as having disruptive poten-
tial for key mechanisms/pathways in a particular domain might 
also have been shown in other research to exert relevant effects 
on mechanisms/pathways in other domains. The results of the 
efforts from this team have been compiled and summarized in 
this article and can be found within Table 4. This team was com-
prised as follows: W.H.B., A.Am., I.S., A.Co., C.M., D.B., E.Ry., F.A-
M., H.A.H., H.K.S., J.Ra., J.Wo., K.R.P., L.M., M.Vac., N.S., R.A-T., R.R., 
R.A.H. and S.F.** **Note that team leaders are denoted by the first 
set of initials in each team list.
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The Halifax Project was an ambitious undertaking, but the response to the recruitment effort 
for the chemical mixtures task force was impressive, the team leaders who were selected were 
outstanding cancer biologists with impressive publishing track records, and the depth of 
expertise on the individual teams was outstanding.  My aim in this project was to determine 
whether or not we now have enough evidence to illustrate that low dose exposures to complex 
chemical mixtures in the environment may be an important underlying factor for environmental 
carcinogenesis.  To accomplish that task, one of my key objectives was to assemble experts in 
all of the areas of cancer biology that are encompassed by the hallmarks of cancer and then 
allow them to consider what we know about low dose chemical effects and the ways in which 
traditional risk assessment is conducted.  The workshop in Halifax was ideal for this purpose, 
and many of the scientists who attended offered feedback that indicated that they appreciated 
having the opportunity to understand the issues.   
 
The team leaders overwhelmingly agreed that the aberrant cellular phenotypes described in the 
Hallmarks of Cancer framework are a very useful heuristic for organizing the ways in which 
disruptive chemicals might produce pro-carcinogenic synergies in biological systems.  So this 
conceptual approach represents a novel advance that should have considerable utility for years 
to come.  With this structure in place, most of the teams easily identified unavoidable and 
ubiquitous disruptive environmental contaminants in their respective areas of study.  However, 
there were two teams (one focused that was focused on replicative immortality and the other 
focused on dysregulated metabolism) that found this task more difficult because these areas of 




Nonetheless, the approach that was taken was a significant success because in the areas where 
the teams were easily able to find disruptive environmental chemicals of relevance, the reviews 
that they assembled provided a concise review of the literature and identified gaps where 
additional research is needed. Thus, they will all serve as a solid foundation for future research.  
In the two instances where the teams were challenged to find disruptive environmental 
chemicals of relevance, the reviews that were assembled will also be extremely valuable 
because the reviews highlighted the fact that two important areas of cancer biology need much 




8.2 Relevance of evidence gathered  
 
Collectively, the teams in the Halifax Project chemical mixtures task force reviewed eleven 
hallmark phenotypes of cancer, then each team produced a series of priority target sites for 
disruption (i.e., actions that would produce pro-carcinogenic effects), and they all identified 
prototypical chemical disruptors for those targets. As well, all of teams documented dose-
response characterizations, and evidence of low dose effects (when that information was 
available), and cross-hallmark effects were identified for all targets and all chemicals and then 
tabularized and included in each of the reviews.   
 
As noted above, these reviews were important individually, but a project of this scale had never 
been undertaken previously to thoroughly investigate whether or not we should be concerned 
about the pro-carcinogenic synergies that might be produced by disruptions in each of these 
areas at the mechanistic level.  The priority target sites for disruption delineated by each of the 
teams were developed in each of the respective areas of research, after considering mutational 
‘drivers’ emerging from the Cancer Genome Project, by looking at upstream and downstream 
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hierarchical relationships in the various cellular pathways, and by drawing on the collective 
expertise of the team members in each of their respective areas of study.  This produced a high 
level summary of priority targets that would have otherwise been very difficult for any single 
researcher to assemble.   
 
At the workshops, it was agreed that the intent in this project was not to implicate any of the 
chemicals that were reviewed as individual carcinogens per se.  Instead, each team committed 
to a review of the toxicological literature to identify prototypical chemical disruptors for 
illustrative purposes.  This meant that the experimental results from each chemical were 
produced under a wide range of differing experimental circumstances.  So it was important not 
to make leaps between different lines of evidence, nor to draw any specific conclusions about 
chemical mixtures that might prove to be carcinogenic.  Nonetheless, given the ease with which 
the teams were able to identify unavoidable and ubiquitous environmental chemicals capable 
of disruptive low dose effects on key pathways/mechanisms, it appears plausible that these 
constituents may have a role to play in environmentally induced cancers.  This is particularly 
concerning given that the chemicals that we chose represent only a small fraction of the 
thousands of chemicals that are now present in the environment (Wambaugh et al., 2014).   
 
The details of the finding of the teams were ultimately summarized in the capstone paper which 
was undertaken as a synthesis for the entire project (Goodson et al., 2015).  In total, 85 
examples of chemicals were reviewed for actions on key pathways/mechanisms related to 
carcinogenesis.  Only 15% (13/85) of the examples were found to have evidence of a dose-
response threshold, while 59% (50/85) exerted low dose effects (15 of which exhibited a non-
linear low dose response).  No dose-response information could be found for the remaining 




This fact that a very small percentage of the chemicals reviewed had a dose-response threshold 
was particularly remarkable because the risk assessment process for individual chemicals 
involves a process whereby an incremental series of high dose tests is supposed to produce a 
point-of-departure which allows regulators to establish a NOEL for each chemical.  Then linear 
extrapolations are typically used to establish safe levels of exposure for each chemical.  But 
while this may be adequate for determining safe levels of exposure for individual chemicals 
from a carcinogenicity standpoint, it ignores the possibility that those very same chemicals may 
be capable of producing disruptive pro-carcinogenic effects on important mechanisms that are 




8.3 The Low Dose Carcinogenesis Hypothesis 
 
 
Although we cannot draw any firm conclusions at this stage, we emerge from this effort with 
a better understanding of the evidence that is available to support the merits of our initial 
hypothesis (i.e., that low dose exposures to disruptive chemicals that are not individually 
carcinogenic may be capable of instigating and/or enabling carcinogenesis).  In sum, it appears 
that commonly encountered mixtures of low dose chemical exposures that are individually 
capable of supporting the enablement of the various hallmark phenotypes may very well be 
capable of producing carcinogenic synergies.  Figure 7 illustrates how this might occur from a 
conceptual standpoint and Figure 8 shows the specific chemicals that were found to disrupt key 
mechanisms/pathways at environmentally relevant dose levels.   
 
While we cannot immediately assume that all of these chemicals are acting on the same cells 
or tissues to instigate carcinogenesis, this analysis moves us forward considerably.  Because 
the extent to which these chemicals are active at environmentally relevant dose levels and their 
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relevance to the enablement of the different cancer hallmark phenotypes has never been 
vigorously explored.  At this stage, the picture that has been painted is very compelling because 
it is now quite clear that the risks that low dose exposures to these chemicals pose are highly 
relevant for disease causation.  Therefore, we should be concerned about the very real 
possibility that these (and other) chemicals are combining and contributing to environmental 
carcinogenesis. This is something that was not understood previously, so this way of looking 
at the problem opens up entirely new avenues for research on environmental linkages to cancer 
causation.  
 
While many narrowly scoped studies have documented the disruptive effects of individual 
chemicals in the environment, this is the first time that a complete picture of the combined (low 
dose) effects of these chemicals has ever been assembled.   Given the number of mutations that 
have been found in cancers, the many epigenetic events that are known to contribute to the 
disease, and complexity of the interactions that are known to occur during carcinogenesis, it is 
entirely understandable that this sort of endeavour has not been undertaken previously (i.e., 
because the scope exceeds that of most researchers and labs).  So the creation of an NGO to 
support this activity was both timely and instrumental as it served as a focal point for the 
organization that was needed to accomplish an undertaking of this breadth.  Moreover, the 
choice of the hallmarks of cancer framework, which was selected as a heuristic to organize and 
characterize the disruptive effects of environmental chemicals, proved to be an excellent tool 
for this purpose.  
 
At a minimum, the reviews that were produced, the gaps that were identified, and the analytical 
framework that has been proposed for future research, should all be useful to researchers who 








Figure 7– Disruptive potential of environmental exposures to mixtures of chemicals** 
(Goodson et al., 2015) 
 
**Note - Some of the acquired hallmark phenotypes are known to be involved in many stages of 
disease development, but the precise sequencing of the acquisition of these hallmarks and the degree 
of involvement that each has in carcinogenesis are factors that have not yet been fully 
elucidated/defined.  This depiction is therefore only intended to illustrate the ways in which 















8.4 The Implications for Risk Assessment  
 
The implications of this research for traditional risk assessment are far reaching.  The World 
Health Organization International Programme on Chemical Safety (WHO IPCS) currently 
supports and promotes a risk analysis agenda that relies upon the “Mode of Action” framework 
(Boobis et al., 2006; Dellarco & Fenner-Crisp, 2012; Meek et al., 2003; "OECD Guidance 
Document 116 On The Conduct And Design Of Chronic Toxicity And Carcinogenicity Studies, 
Supporting Test Guidelines 451, 452 And 453," 2012).  As noted previously, the main problem 
with this framework is that the term “mode of action” is defined as “a sequence of key events 
and processes, starting with interaction of an agent with a cell, proceeding through operational 
and anatomical changes, and resulting in an adverse outcome”.  Chemicals are therefore only 
considered for joint toxic effects when they are (1) known to act via a common sequence of 
key events and processes; (2) known to act on a common target/tissue; and (3) known to 
produce a common adverse outcome (e.g., cancer). 
 
But taking into consideration what is now known about cancer biology shows that chemicals 
that act on dissimilar key events and processes could very well produce synergies within 
carcinogenesis that would be relevant for risk assessment purposes.  For example, ethylene-
diamine-tetra-acetic acid (EDTA) is a ubiquitous, non-carcinogenic chemical that disrupts 
DNA repair (Driedger & Grayston, 1971; Mason, Matheson, Hall, & Lightowlers, 2003) and 
enhances mutagen-induced aberration frequencies (Heindorff, Aurich, Michaelis, & Rieger, 
1983).  But despite the fact that DNA damage that is induced endogenously can result in 
mutations, genomic instability, and ultimately cancer if not properly repaired (C. Li, Wang, & 
Wei, 2009; Loeb, 2011), within the mode of action framework, a chemical that is a mutagenic 
would not be assessed for the cumulative risks associated with an additional exposure to a 
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chemical that disrupts DNA repair.  This is because the two chemicals do not produce “a 
common sequence of key events and processes”.  
 
In support of this notion, a recent review undertaken by The European Food Safety Authority 
(EFSA) on this issue found good evidence that combination effects can arise from co-exposure 
to chemicals that produce common (adverse) outcomes through entirely different modes of 
action and they also recommended that cumulative risk assessment methods should evaluate 
mixtures of pesticides in foods that have dissimilar modes of action ("EFSA Panel on Plant 
Protection Products and their Residues, Scientific Opinion on the relevance of dissimilar mode 
of action and its appropriate application for cumulative risk assessment of pesticides residues 
in food," 2013). 
 
Similarly, disruptive chemical exposures acting on dissimilar targets/tissues could also produce 
carcinogenic synergies of concern. The immune system (e.g., lymph vessels, the thymus, bone marrow, 
and individual immune cells etc.), the hypothalamic-pituitary-adrenal axis (HPA-axis) and cortisol in 
circulation, and various components of the tumor microenvironment (e.g., fibroblasts, blood vessels 
etc.), are all relevant targets (see Figure 9) that could be chemically disrupted to produce pro-
carcinogenic contributions to carcinogenesis in unrelated tissues but these sorts of effects are simply 
not considered within the mode of action approach to risk assessment.  For example, Maneb is a 
fungicide (widely used on food crops) that can block glucocorticoid receptor function (Odermatt & 
Gumy, 2008), which could directly influence inflammation suppression which is highly relevant for 
many cancer-types (Lim et al., 2014), but within the mode of action framework, the cumulative effects 
of this chemical would never be assessed with chemicals acting on other tissues (unless the chemicals 








Figure 9 – Examples of different targets and tissues that can influence carcinogenesis 




Finally, the mode of action framework is predicated on the notion that chemicals must have a 
common toxic endpoint before the combined effects of those chemicals are considered.   
However, it is now quite evident that there are a great number of pro-carcinogenic actions that 
can impact important targets within the hallmarks of cancer framework that can result from 
exposures to chemicals that are not carcinogens.  So a focus only on the combined effects of 
individual carcinogens (that act via the same mode of action on the same tissues) completely 
misses important pro-carcinogenic synergies that may very well be contributing to 
environmental carcinogenesis.  This is not just applicable to cancer, but should be considered 
as a lesson for a wide range of chronic and complex diseases.   Establishing a dose-response 
threshold using the whole disease as the endpoint may be entirely inappropriate, given that 
exposures to individual chemicals at much lower doses may still produce disruptive effects that 
can contribute to the stepwise progression of a complex disease.   
 
 
8.5 Future research needs 
 
 
8.5.1 Cancer versus Carcinogenesis 
 
An important and significant challenge in this project has been the need to better understand 
carcinogenesis. While the Hallmarks of Cancer framework is powerful heuristic that can be 
used to help us organize what is known about cancer, we still know remarkably little about 
steps involved in the unfolding of the disease.  Figure 3 illustrates a rough sequencing of these 
steps, but important questions about how this process unfolds remain unanswered, even 
whether or not the individual hallmarks are a cause or a consequence of cancer development.  
This lacuna was recently highlighted by Brash and Cairns in an article on what they called “The 
mysterious steps in carcinogenesis” (Brash & Cairns, 2009a, 2009b).  Specifically they note 
that “it is hard to imagine how the numerous genetic changes found in cancer cells could have 
been produced in any cell as the result of a single exposure to a DNA-damaging agent, or why 
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months or years should have to elapse before the effect of these changes is observed. Past 
speculations about the process of carcinogenesis (as opposed to the characteristics of the end 
product) have had little popularity and negligible impact.” So although the Hallmarks of 
Cancer framework helps us organize the many acquired capabilities of the disease, it does little 
to advance our understanding of carcinogenesis per se.   
 
In this project, we have speculated that the multi-stage, multi-step progression of the disease 
(however it unfolds) may be influenced by pro-carcinogenic disruptions that are supportive of 
each of the hallmarks and the need for cooperation from within the tumor microenvironment.  
However, the temporal aspects of disease progression clearly need to be better understood.  
Hlatky & Hahnfeldt conceptualize this step-wise progression as being contrained by 
population- and tissue-level bottleneck events (precipitated by interactions among cancer cells 
and between cancer and host cells). (Hlatky & Hahnfeldt, 2014).  The point is simply that a 
mutation-based risk assessment process (which is the conventional transformation-based 
paradigm), misses the dynamics of carcinogenesis, a poorly characterized but seemingly 
complex process that appears to involve a number of stages that make the ultimate progression 
to cancer quite uncertain (see Figure 10).    
 
Without a better understanding of carcinogenesis, it is impossible to draw conclusions about 
the effects that low dose exposures to mixtures of disruptive chemicals might produce.  We 
therefore need a research agenda that includes a thorough investigation into the origins, 
determinants, and temporospatial evolution of the cancer hallmarks. It is difficult to imagine 
after so many years of cancer research that this process is so poorly defined, but the highly 
specialized nature of the many sub-disciplines within cancer biology has resulted in a highly 
diffused knowledge base.  Future research along these lines will need to be coordinated and 





Figure 10 - Risk implications comparing the standard carcinogenesis-risk paradigm 




8.5.2 Test Systems 
 
Basic research related to carcinogenesis will need to involve tools that can instigate basic 
cellular- and tissue-level mechanisms to elucidate the various steps and pathways that are 
involved in the process.  To that end, common environmental chemicals with known low dose 
capabilities should be employed to simultaneously test their effects in sequence and in 
combination.  In particular, it would be helpful to know how the chemical induction of certain 
numbers/combinations of hallmarks might advance or impede carcinogenesis.   
 
Chemical mixtures research should also be aggressively pursued.  The population is chronically 
exposed to low doses of many chemicals on an ongoing basics.  Chemicals that the population 
is routinely exposed to (i.e., those that are known to exert low dose hallmark-enabling effects) 
should be selectively grouped and specifically designed to produce pro-carcinogenic synergies 
to test hallmark enablement, and demonstrate how these mixtures might produce contributions 
that could lead to cancer.  Some of the basic cellular-level hallmark effects may be tested in 
vitro, but tissue-level effects (e.g., in the tumor microenvironment) and system level effects 
(e.g., immune system, HPA-axis etc.) will need to be tested using in vivo systems.  Researchers 
should evaluate both genetic and epigenetic changes in multiple cells/organs and tissues in 
exposed animals.  Gene array technology, and real-time imaging of tumors in vitro and in vivo 
models can be combined with molecular biomarkers to characterize effects.  
 
The US EPA ToxCast™ database will be a useful tool for the identification of chemicals that 
might be used for this purpose.  The database contains a significant amount of hallmark-related 
data from in vitro tests obtained using high-throughput screening for a wide range of chemicals.  
Researchers testing chemical mixtures in this manner should also be careful of confounding 
(i.e., anti-carcinogenic) effects of individual mixture constituents. Cross-hallmark effects were 
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documented for all of the selected pathways/mechanisms, and chemicals in the 11 reviews in 
this project and can be found in the appendices of each review.     
 
In terms of setting research priorities, tissue fate is an important matter that will require detailed 
investigations.  Certain chemicals have affinities for certain tissues, and some tissue types give 
rise to human cancers millions of times more often than other tissue types (Tomasetti & 
Vogelstein, 2015).   So researchers may want to focus their work on chemical mixtures 
comprised of constituents that are individually known to accumulate in the same types of 
tissues, and by choosing tissue types that are known to produce cancers more rapidly.   
 
Finally, although there has been a significant push for researchers and regulatory agencies to 
move away from in vivo testing (Pohl, Chou, Ruiz, & Holler, 2010) significant hurdles remain 
before this sort of testing will be ready to replace in vivo research (Tice, Austin, Kavlock, & 
Bucher, 2013).  Therefore, in the near term, in vivo testing will remain an important avenue for 
developing datasets to address cancer risks of complex mixtures. 
 
 
8.5.3 Systems biology 
 
 
Cancer is a complex disease involving many mechanisms, pathways, cell types, and tissues, so 
many researchers have suggested that use of systems biology might help us to study cancer 
(Alberghina, Chiaradonna, & Vanoni, 2004; Koutsogiannouli, Papavassiliou, & Papanikolaou, 
2013).  In theory, systems biology is a powerful approach that would allow us to identify 
properties that emerge from complex chemical-biological systems (by probing how certain 
changes in one part of the system impact other parts, and the behavior of the whole system). 
Data emerging from cancer genome initiatives, cancer biomarkers that are being identified are 
producing an incredible amount of information that can be related to different cancer hallmarks.  
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For example, Ha and Hunter explain that by using expression profiling and network analyses 
to find metastasis-specific signatures and by identifying relevant biomarkers, that a systems 
biology analytical approach should help them better understand metastasis and predict disease 
outcomes (Ha & Hunter, 2014).  A similar approach may be relevant for all of the individual 
hallmarks and even cancer as a disease (see Figure 11).    
 
However, in chemically induced environmental cancers, the combined effects of thousands of 
simultaneous low dose chemical exposures may need to be reconciled and yet the development 
of models to simulate these sort of exposures will definitely require a detailed understanding 
of how these exposures impact cells and tissues, and more importantly, a much better 
understanding of carcinogenesis. At this stage, research on mixtures at environmentally 
relevant dose levels is very limited (Carvalho et al., 2014) and we are missing key information 
on carcinogenesis, so it may be some time before systems biology can be employed in this 









Figure 11 - A Systems Biology Approach to Study and Understand Cancer Hallmarks 
Adapted from (Ha & Hunter, 2014) 
(A) Understanding that cancer is a complex disease involving many mechanisms, pathways, cell types, 
and tissues. 
(B) Using genetics and next-generation sequencing to understand and study different cancer hallmarks. 
(C) Employing expression profiling and network analyses to find hallmark-specific signatures 





Chapter 9 – Summary and Conclusions 
 
Although it has been known for decades that environmental factors play an important role in the 
incidence of cancer, the role of chronic, low-level exposures to combinations of chemicals has been 
trivialized over time.  Our historic emphasis on mutagens as carcinogens resulted in a somewhat 
narrowly scoped search for individual chemicals that could cause cancer (a quest that continues to this 
day). And while this effort has been helpful, our understanding of the multifaceted biology of cancer 
has revealed that there are many key mechanisms and pathways that are instrumental in the enablement 
of the hallmark phenotypes that are found in most cancers, and many commonly encountered chemicals 
that have been shown to be capable of acting on this cellular machinery.     
 
This project was unique in that it was the very first time that anyone has used the hallmarks of cancer 
framework as a heuristic to review the ways in which commonly encountered (non-carcinogenic) 
chemicals in the environment might conspire to enable these hallmarks and contribute to environmental 
carcinogenesis.  In hindsight, the use of this framework to inform environmental toxicology seems 
obvious, but our understanding of cancer biology has improved rapidly so this was a significant and 
important step that has allowed us to better understand the nature of this risk. 
 
In this dissertation, my aim was to determine whether or not we now have enough evidence to 
illustrate that low dose exposures to complex chemical mixtures in the environment may be an 
important underlying factor for environmental carcinogenesis.  Although it took a very large 
task force to assess this possibility in earnest, this project drew together evidence that does suggest 
that this is a very real possibility.   
 
Non-carcinogenic chemicals that impact genetic instability, tumor-promoting inflammation, sustained 
proliferative signalling, insensitivity to antigrowth signals, resistance to cell death, angiogenesis, tissue 
invasion and metastasis, the tumor microenvironment and the avoidance (by tumor cells) of immune 
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destruction were  readily identified.   Fewer examples of chemicals that act on replicative immortality 
and dysregulated metabolism were found and this appeared to be due to a lack of toxicological research 
in this area.  So out of the 85 examples of disruptive chemical actions that were reviewed, 59% (50/85) 
were found to exert low-dose effects on some of the most important mechanisms and pathways that 
support these aberrant hallmark phenotypes. 
   
More troubling still is the fact that this was only a relatively small group of chemicals from the many 
thousands of untested chemicals that we are now exposed to on a day to day basis.  This work has 
therefore illuminated a very complex problem that needs to be aggressively explored.  Indeed, this 
analysis suggests that we may have underestimated the potential seriousness of this issue by a wide 
margin.   
 
Fortunately, there appears to be a lot of interest in this approach, and this project has resulted in high-
impact peer-reviewed publications that should make this problem much easier to understand for many 
scientists.  Indeed, the work cuts across many sub-disciplines of cancer research and therefore represents 
a holistic synthesis of cancer biology that should inform the fields of toxicology and risk assessment 
for years to come.    
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Introduction 
“Getting to Know Cancer” is a non-profit organization that is focused on the cancerous effects of low 
dose exposures to chemical mixtures in the environment.  Presently the organization has plans for an 
important series of scientific reviews and two, 2-day workshops that will be held in the summer of 2013 
in Halifax, Nova Scotia, Canada.  One of the workshops is related to the influence of environmental 
chemical exposures, while the other is related to improved therapeutic design. 
 
You are receiving this invitation because we are currently seeking expressions of interest and quotations 
from cancer journals that would be interested in publishing a special issue that will capture the reviews 
that will be produced in this groundbreaking project.  A task force of nearly 100 scientists will be 
assembled to prepare a series of reviews in advance of the workshop, and a synthesis and capstone 
review will be produced by all of the teams after the workshop has been held.   
 
A novel approach is being employed in this project. The hallmarks of cancer framework (Hanahan and 
Weinberg, 2011) be used to categorize and prioritize notoriously disrupted targets in each of the 
hallmark areas, and then chemicals that are found in the environment will be identified that appear to 
have the greatest potential to combine to act on those targets and instigate cancer. The goal will to 
develop an integrated way of approaching research on the potential carcinogenicity of low dose 
environmental exposures to chemical mixtures.      
 
We know that this is an extraordinarily complex undertaking, but with the right people involved, we are 
confident that something exceptional is going to result.  This will be a seminal attempt at something that 
has never been done before, so if your journal is potentially interested in acting as the publisher of the 
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The World Health Organization’s International Agency for Research on Cancer (IARC) has indicated that 
cancer has stubbornly persisted as one of the leading causes of death worldwide, and the global burden 
of cancer has more than doubled in the past 30 years.  Fortunately, there have been some remarkable 
advances in the science of cancer in the past two decades and that has given us some hope.  
 
We now know that only a very small percentage of cancers are caused by hereditary defects. Most 
cancers are caused by lifestyle factors and other environmental exposures that people encounter on a 
day-to-day basis.  Disruptive exposures to various environmental agents result in insults to cells within 
the body and/or they interfere with chemical signalling, and we now understand the nature of these 
actions in precise biochemical and genetic terms.   However, our collective efforts to prevent cancer to 
date have not been nearly as successful as most of us had hoped.   
 
Historically, researchers and regulators have sought to identify and limit our exposures to carcinogens 
(i.e., individual agents that can cause cancer).  But as the decades have passed, we have come to realize 
that relatively few chemicals are complete carcinogens.  It is now known that many of the hallmark 
mechanisms of cancer can be independently enabled by individual chemicals, and that realization 
changes everything.  Because we can now see that we also need to be seriously concerned about the 
ways in which cumulative low dose exposures to combinations of disruptive, but otherwise non-
carcinogenic, environmental agents may also be combining to instigate cancer, and that is an additional 
cause for concern.   
 
Given the wide range of suspected environmental and occupational carcinogens that are already known 
to exist, we believe that prevention efforts will benefit considerably from improved modeling.  With a 
more powerful analytical framework, researchers in the field of environmental and occupational health 
will be better equipped to identify the types of mixtures that are most likely to have the greatest 
carcinogenic potential. And this will have profound implications for the manner in which we conduct 
environmental and occupational risk assessments, the ways in which we approach other research that is 
concerned with multi-factorial causation in the field of cancer epidemiology, and ultimately the way we 
approach cancer prevention.   
 
The Approach 
To address this issue, Getting to Know Cancer ( www.gettingtoknowcancer.org ) is planning to assemble 
a task force for a two-day workshop that will take place in Halifax, Nova Scotia in August of 2013.   We 
believe that the timing is right for a series of overarching reviews that can collectively assess and 
prioritize the many molecular targets that are instrumental in cancer, and to identify common 
environmental chemicals that may be combining to enable the hallmark characteristics of various 
cancers, thereby contributing to the overall burden of cancer at the population level.     
 
To that end, it is envisioned that eleven teams of researchers will work in advance of the workshop to 
produce eleven reviews using a novel approach that is based upon the ten areas that are described 
within the “hallmarks of cancer” framework and one review of the tumor microenvironment (see 
Hanahan and Weinberg, 2001 and 2011).  
 




The Hallmarks of Cancer 
The Hallmarks of Cancer framework has been chosen because it is a state-of-the-art model that helps us 
to quickly organize the many forms of cellular-level disruption (both genetic and epigenetic) that 
underpin all cancer types – these are listed as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
 
Tissue interactions within the tumor microenvironment are also considered extremely important.   
 
The goal of this project will be for each team to produce a detailed description of the domains that are 
encompassed by each of the elements of this framework, and then to identify common environmental 
exposures that are known to act disruptively on the mechanisms within each of these areas.  In each of 






1. Provide an overview of the area that the team has been tasked to review 
2. Describe the types of systemic or cellular-level dysfunction in that area that enable the immortalization of cells 
3. Describe any relationships that exist between the topic area and any of the other topic areas being studied 
4. Categorize, and prioritize the disrupted mechanisms that are most critical for that particular topic area 
5. Identify environmental and/or occupational chemical exposures that are known to selectively disrupt the 
prioritized mechanisms that are most relevant for that particular topic area 
6. Consider the implications of using this particular framework to assess the individual contributions of disruptive 




It could be argued that the cancer genome is so large that no single review in any one of these hallmark 
areas would be adequate to capture the detail that is needed for this sort of an exercise.  And an even 
greater layer of complexity is imposed on this problem when one considers that many disruptive 
chemicals are known to act on multiple molecular targets, and that many molecular targets (e.g., 
receptors) are known to be important instigators in more than one hallmark area.  But the challenge 
that is being offered to each of these teams is to try to produce a compact synthesis of the literature 
that categorizes and prioritizes the disrupted mechanisms for each of the hallmark areas while clarifying 
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the nature of any important relationships that exist with the hallmark being reviewed and other 
hallmarks.  
Each group will then build a list of contaminants of concern for the areas under review, and the teams 
will also be asked to share lists of contaminants between the groups.  The task force will then be able to 
assemble the various lists into a single table in the final synthesis paper to illustrate the extent to which 
various contaminants impact the range of hallmarks/areas of concern.   This exercise isn’t intended to 
characterize all possible environmental contaminants that impact the various hallmarks.  Rather, the 
idea of this project is to map the disruptive effects of a wide range of environmental and occupational 
contaminants to the hallmark areas as a way to introduce this analytical model to those in the field of 
environmental and/or occupational health.   
 
From a mixtures perspective, researchers and regulators will then be able to begin to look at suspected 
carcinogens in a new light.  Rather than assigning vague categories such as “probable carcinogen”, 
“possible carcinogen” etc, researchers who adopt this model will then be able to characterize 
contaminants in much more precise terms (i.e., based on each chemical’s ability to enable specific 
hallmark characteristics that are important in cancer biology) which should help them to more quickly 
anticipate logical (carcinogenic) synergies. 
 
Many researchers already report on the impact that exposures to various chemicals have on the various 
aspects of cancer biology but a reference to a complete and holistic model of the disease that 
encompasses all of the hallmark areas of cancer is rarely provided, if ever.   However, by using a number 
of teams, with significant breadth of expertise, the goal of this project is therefore to produce a series of 
powerful reviews that can inform the design for a much improved approach to exposure-based cancer 
research with an emphasis that is grounded in the practical (i.e., what can be done now, with what we 
know so far?).   
A thorough and holistic review of all of the hallmarks is needed at this stage because a truly 
sophisticated approach to environmental and occupational risk assessment will only emerge once this 
has been done.  The research community will therefore benefit considerably from this project, as the 
special issue that captures this review will serve as a benchmark reference that will inform research 
designs and risk assessment practices for years to come. 
 
The Teams 
Accordingly, “Getting to Know Cancer” will soon seek expression of interest from a wide range of 
scientists to find those who are interested in being selected to join any of the eleven teams that will be 
asked to produce the reviews that are planned.  Ten teams will tackle the ten hallmark areas and one 
additional team will consider the tumor microenvironment.  Once responses have been received, we will 
be inviting team leaders to serve as the lead author for each of the teams by using the following three 
criteria: 
1. A demonstrated level of expertise in one of the eleven areas  
2. A distinguished track record of peer-reviewed publications  
3. A solid history of collaboration in the peer-reviewed literature  
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Once the lead authors have been selected, the remaining team members for each team will be invited 
to participate as well.  The team member choices will be made in cooperation with the lead authors for 
each team.    
1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other 
experts who will collectively be responsible for producing a descriptive overview that encompasses 
the topic area, as well as a description the types of systemic or cellular-level dysfunction in that 
topic area that contribute to the immortalization of cancerous cells and any relationships that exist 
between that particular topic and the other topic areas under consideration.  Given the scale of the 
cancer genome, the task of this group will be to produce a compact synthesis of the literature that 
categorizes and to prioritize the disrupted mechanisms that are most important.  
 
2. Environmental/Occupational Health Research Specialists – Each team will also have a number of 
cancer scientists who specialize in environmental and/or occupational health research who will 
focus on the effects of chemicals that are found in the environment and/or workplace.  Their role 
will be to identify disruptive chemicals of concern. 
 
3. Post-doctoral Researchers - Senior scientists who are selected to join the task force will also be 
able to nominate a single post-doctoral researcher within their own lab to participate in the team’s 
work.   
 
The team leader will then also be responsible for making recommendations for any significant gaps in 
the literature and any additional research that will be needed.   
 
Consensus and Recommendations 
The two-day workshop will involve one day of presentations from each of the eleven teams to allow for 
questions and answers, followed by a collaborative series of meetings on the second day that will give 
the teams an opportunity to consider the implications of the model for risk assessment purposes.  The 
teams will be asked to build consensus around the next steps that will be needed to validate the utility 
of the model.  The team leads from each team will subsequently collaborate to produce a capstone 
review that will summarize the integrated findings from the second day of the workshop and make 
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Request for Quotation 
 
Getting to Know Cancer is now seeking expressions of interest and quotations from suitable peer-
reviewed journals that would potentially be interested in publishing the special review that will result 
from this project.  We are seeking a reputable journal with a strong impact factor because we want to 
ensure that this work reaches a broad audience.  It is also our intent to bring considerable media 
attention to this project, so this should be a high profile project that will enhance the reputation of the 
journal that publishes the results.   
 
We believe that a more nuanced research approach than can better address low dose exposures to 
mixtures of chemicals in the environment is needed, and that this represents a promising future 
direction for cancer research and prevention efforts.  So we will also be inviting a select number of 
scientific representatives from cancer charities and other funding agencies to attend the workshop 
presentations as we also want to build awareness of the need for funding in this area.  Success in this 
regard will drive additional research that will draw on this original work. 
  
In sum, we believe that this special issue will be an important reference for years to come, because we 
believe that that the project has the potential to yield landmark results.  We will need approximately 
250 pages (electronic only) to capture this work – as follows: 
Introductory Editorial (Guest Editors)    6 pages 
11 Reviews X 20 pages each (references included) 220 pages 
Capstone review (references included)   24 pages 
Perpetual open access to the articles is also a desired option, so please also provide a pricing option for 




If your journal has an interest in publishing the special issue for this project, please reply as soon 
as possible with the details.    Submissions and questions about the project can be directed to 
Leroy Lowe, Cofounder and President, Getting to Know Cancer  
 
 Email:  leroy.lowe@gettingtoknowcancer.org 
 
 
IMPORTANT - Proposals in excess of $50,000 USD will not be considered. 
 
 
DEADLINE FOR SUBMISSIONS – June 1st, 2012 
 
 
   



























The Halifax Project 
 
  
 Page 1 
 
 
Table of Contents 
 
Introduction .............................................................................................................................................. p. 2 
Background ............................................................................................................................................... p. 3  
The Approach ............................................................................................................................................ p. 3  
 The Hallmarks of Cancer ....................................................................................................... p. 4 
 Complexity ............................................................................................................................ p. 4  
The Teams  .............................................................................................................................................. p. 5  
Consensus and Recommendations ........................................................................................................... p. 6 
The Audience ............................................................................................................................................ p. 6 
The Outcome ............................................................................................................................................ p. 6  
The Workshop Organizing Committee ...................................................................................................... p. 7 
Lead Authors ............................................................................................................................................. p. 8 






Halifax is a scenic city located on 
the East Coast of Canada.  In the 
summer, the historic port attracts 
many cruise ships as the city is well 
known for its park and gardens, 
and it boasts a downtown that is 
both beautiful and historic. Visitors 
can enjoy the rich culture and 
vibrant atmosphere found in the 
many shops, restaurants, and pubs 
that are clustered around the 
boardwalk and the waterfront. 
While the more adventurous can 
choose from a wide range of 
activities such as bus tours, harbor 
cruises, golf and eco-tourism (e.g., 
sea kayaking), since all of these 








“Getting to Know Cancer” is a non-profit organization that is focused on the cancerous effects of low 
dose exposures to chemical mixtures in the environment.  Presently the organization has plans for an 
important series of scientific reviews and two, 2-day workshops that will be held in the summer of 2013 
in Halifax, Nova Scotia.  One of the workshops is related to the influence of environmental chemical 
exposures (8-9 August 2013), while the other is related to improved therapeutic design (12-13 August 
2013). 
 
You are receiving this invitation because we are currently seeking expressions of interest from scientists 
who would be willing to consider serving on any one of eleven teams that will be part of an 
environmental mixtures task force that is being recruited for this groundbreaking project.  The teams 
will all be preparing the reviews in advance of the workshop, and the reviews that result from the 
project will be submitted for peer-review and publication in a special issue of the journal, 
“Carcinogenesis” (Oxford Journals, 2010 Impact Factor 5.402).   
 
A novel approach is being employed in this project. The hallmarks of cancer framework (Hanahan and 
Weinberg, 2011) be used to categorize and prioritize notoriously disrupted targets, and then chemicals 
that are found in the environment will be identified that appear to have the greatest potential to 
combine to act on those targets and instigate cancer. The goal will to develop an integrated way of 
approaching research on the potential carcinogenicity of low dose environmental exposures to chemical 
mixtures.      
 
If you are potentially interested in being part of this task force, please read the remainder of this 
document for the details.  We are seeking senior cancer scientists with a breadth of knowledge, a strong 
track record of peer-reviewed publishing and a history of collaboration.  We know that this is an 
extraordinarily complex undertaking, but with the right people involved, we are confident that 







President and Cofounder  
Getting to Know Cancer 




    
 




The World health Organization International Agency for Research on Cancer (IARC) has indicated that 
cancer has stubbornly persisted as one of the leading causes of death worldwide, and the global burden 
of cancer has more than doubled in the past 30 years.  Fortunately, there have been some remarkable 
advances in the science of cancer in the past two decades and that has given us some hope.  
 
We now know that only a very small percentage of cancers are caused by hereditary defects. Most 
cancers are caused by lifestyle factors and other environmental exposures that people encounter on a 
day-to-day basis.  Disruptive exposures to various environmental agents result in insults to cells within 
the body and/or they interfere with chemical signalling, and we now understand the nature of these 
actions in precise biochemical and genetic terms.   However, our collective efforts to prevent cancer to 
date have not been nearly as successful as most of us had hoped.   
 
Historically, researchers have sought to identify and limit our exposures to carcinogens (i.e., individual 
agents that can cause cancer).  But as the decades have passed, we have come to realize that relatively 
few chemicals are complete carcinogens (i.e., have the potential to enable all of these hallmarks on their 
own).  It is now known that many of the hallmark mechanisms of cancer can be independently enabled 
by individual chemicals. So we also need to be concerned about the ways in which cumulative exposures 
to combinations of disruptive, but otherwise non-carcinogenic, environmental agents may also be 
combining to instigate cancer. 
 
Given the wide range of suspected environmental and occupational carcinogens that are already known 
to exist, we believe that improved modeling is needed to better address this issue.  With a more 
powerful analytical framework, researchers in the field of environmental and occupational health will be 
better equipped to identify the types of mixtures that are most likely to have the greatest carcinogenic 
potential. And this will have profound implications for the manner in which we conduct environmental 
and occupational risk assessments, and the ways in which we approach other research that is concerned 
with multi-factorial causation in the field of cancer epidemiology.   
 
The Approach 
To address this issue, Getting to Know Cancer ( www.gettingtoknowcancer.org ) is planning to assemble 
a task force for a two-day workshop that will take place in Halifax, Nova Scotia in August of 2013.   We 
believe that the timing is right for a series of overarching reviews that can collectively assess and 
prioritize the many molecular targets that are instrumental in cancer, and to identify common 
environmental chemicals that may be combining to enable the hallmark characteristics of various 
cancers, thereby contributing to the overall burden of cancer at the population level.     
 
To that end, it is envisioned that eleven teams of researchers will work in advance of the workshop to 
produce eleven reviews using a novel approach that is based upon the ten areas that are described 
within the “hallmarks of cancer” framework and one review of the tumor microenvironment (see 
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The Hallmarks of Cancer 
The Hallmarks of Cancer framework has been chosen because it is a state-of-the-art model that helps us 
to quickly organize the many forms of cellular-level disruption (both genetic and epigenetic) that 
underpin all cancer types – these are listed as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
 
Tissue interactions within the tumor microenvironment are also considered extremely important.   
 
The goal of this project will be for each team to produce a detailed description of the domains that are 
encompassed by each of the elements of this framework, and then to identify common environmental 
exposures that are known to act disruptively on the mechanisms within each of these areas.  In each of 






1. Provide an overview of the area that the team has been tasked to review 
2. Describe the types of systemic or cellular-level dysfunction in that area that enable the immortalization of cells 
3. Describe any relationships that exist between the topic area and any of the other topic areas being studied 
4. Categorize, and prioritize the disrupted mechanisms that are most relevant for that particular topic area 
5. Identify environmental and/or occupational chemical exposures that are known to selectively disrupt the 
prioritized mechanisms that are most relevant for that particular topic area 
6. Consider the implications of using this framework to assess the individual contributions of disruptive 




It could be argued that the cancer genome is so large that no single review in any one of these hallmark 
areas would be adequate to capture the detail that is needed for this sort of an exercise.  And an even 
greater layer of complexity is imposed on this problem when one considers that many disruptive 
chemicals are known to act on multiple molecular targets, and that many molecular targets (e.g., 
receptors) are known to be important instigators in more than one hallmark area.  But the challenge 
that is being offered to each of these teams is to try to produce a compact synthesis of the literature 
that categorizes and prioritizes the disrupted mechanisms for each of the hallmark areas while clarifying 
the nature of any important relationships that exist with the hallmark being reviewed and other 
hallmarks.  
A thorough and holistic review of all of the hallmarks is needed at this stage because a truly 
sophisticated approach to environmental and occupational risk assessment will only emerge once this 
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has been done.  By using a number of teams, with significant breadth of expertise, the goal is to produce 
a series of powerful reviews that can inform the design for a much improved approach to exposure-
based cancer research with an emphasis that is grounded in the practical (i.e., what can be done now, 
with what we know so far?).   
The Teams 
Accordingly, “Getting to Know Cancer” is now seeking expressions of interest from scientists who would 
be interested in being selected to join any of the eleven teams that will be asked to produce the reviews 
that are planned.  Ten teams will tackle the ten hallmark areas and one additional team will consider the 
tumor microenvironment.  Once responses have been received, we will invite team leaders to serve as 
the lead author for each of the teams by using the following three criteria: 
1. A demonstrated level of expertise in one of the eleven areas  
2. A distinguished track record of peer-reviewed publications  
3. A solid history of collaboration in the peer-reviewed literature  
 
Once the lead authors have been selected, the remaining team members for each team will be invited 
to participate as well.  The team member choices will be made in cooperation with the lead authors for 
each team.    
1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other 
experts who will collectively be responsible for producing a descriptive overview that encompasses 
the topic area, as well as a description the types of systemic or cellular-level dysfunction in that 
topic area that contribute to the immortalization of cancerous cells and any relationships that exist 
between that particular topic and the other topic areas under consideration.  Given the scale of the 
cancer genome, the task of this group will be to produce a compact synthesis of the literature that 
categorizes and to prioritize the disrupted mechanisms that are most important.  
 
2. Environmental Health Research Specialists – Each team will also have a number of cancer 
scientists who specialize in environmental health research that focuses on the effects of chemicals 
that are found in the environment.  Their role will be to help identify disruptive chemicals of 
concern, characterize their disruptive abilities using the hallmarks of cancer framework, and provide 
insights on cumulative effects, low dose exposure issues, and on traditional toxicological 
perspectives. 
 
3. Post-doctoral Researchers - Senior scientists who are selected to join the task force will also be 
able to nominate a single post-doctoral researcher within their own lab to participate in the team’s 
work.  These researchers will also receive authorship recognition for their contributions to the 
team’s work.  However, in instances where a post-doctoral researcher has been nominated as a 
contributing author, only one of the two (i.e., the nominator or nominee) will be able to attend the 
workshop in Halifax in August of 2013.  We know that it is important to get post-doctoral 
researchers involved, but in this particular project it is equally important that we ensure that the 
number of attendees at the working sessions in Halifax remains manageable.      
 
 
Consensus and Recommendations 
 Page 6 
 
 
The two-day workshop will involve one day of presentations from each of the eleven teams to allow for 
questions and answers, followed by a collaborative series of meetings on the second day that will give 
the teams an opportunity to consider the implications of the model for risk assessment purposes.  The 
teams will be asked to build consensus around the next steps that will be needed to validate the utility 
of the model.  The team leads from each team will subsequently collaborate to produce a capstone 
review and synthesis that will summarize the integrated findings from the second day of the workshop 
and make recommendations for the way ahead. 
 
The Audience 
It is our intent to bring considerable media attention to this project, and we will be inviting a select 
number of scientific representatives from cancer charities and other funding agencies to attend the 
workshop presentations.  We believe that a more powerful framework for modelling cancer is an 
important next step and  we want to build awareness of this need to ensure there will be funding for 
additional research that will be able to move this initiative forward.    
 
The Outcome  
 
Why take part in the Halifax Project?  The first reward for participation in this unique task force is a 
substantial publication opportunity.  All of the aforementioned reviews that will be produced in this 
project will be submitted for peer-review and compiled in a special issue of the top ranked journal, 
“Carcinogenesis: Integrative Cancer Research”.  Each task force member will have an authorship role in 
one of the initial reviews, and will also be a named as a contributing author in the capstone synthesis 
that will be prepared collaboratively (post-workshop) by all of the teams (i.e., each task force member 





Carcinogenesis: Integrative Cancer Research  
 
A multi-disciplinary journal that brings together all the varied aspects of research that will 
ultimately lead to the prevention of cancer in man. The journal publishes papers that warrant 
prompt publication in the areas of Biology, Genetics and Epigenetics (including the 
processes of promotion, progression, signal transduction, apoptosis, genomic instability, 
growth factors, cell and molecular biology, mutation, DNA repair, genetics, etc.), Cancer 
Biomarkers and Molecular Epidemiology (including genetic predisposition to cancer, and 
epidemiology), Inflammation, Microenvironment and Prevention (including molecular 
dosimetry, chemoprevention, nutrition and cancer, etc.), and Carcinogenesis (including viral, 
chemical and physical carcinogenesis, metabolism of carcinogens, and the formation, 
detection, identification and quantification of environmental carcinogens).       
 
2010 Impact Factor 5.402 
 
 
Additionally, this is an opportunity to be part of a bold project that has the potential to be 
groundbreaking.   This task force is being asked to take on an incredibly challenging problem.  Cancer’s 
complexity has stymied scientists for decades, but we are rapidly gaining new knowledge and we believe 
that the timing is right for this unique approach, and that it has incredible potential.  So with the right 
people involved, we are confident that something truly extraordinary will result.  
  





Firouz Darroudi MD, PhD (Committee Chair) - Senior research scientist in Radiation Genetics and Chemical Mutagenesis at the Department of 
Toxicogenetics, Leiden University Medical Centre in The Netherlands. Dr Darroudi has 30 years of experience in Radiation Genetics and 
Chemical Mutagenesis, and in classical and state of art cytogenetics. Dr Darroudi has explored the application of different cytogenetic assays 
such as dicentric, micronuclei, premature chromosome condensation and fluorescence in situ hybridization (FISH)-based translocation assays 
for biological dosimetry following acute and chronic exposure in scenarios of accidental and occupational exposure. Dr Darroudi has 
contributed to the development and application of new FISH assays, such as multi-colour FISH, M-FISH and application of telomeric probe 
with chromosome painting probes and pancentromeric probes to investigate the origin of radiation induced chromosomal aberrations, 
mechanisms , spectra, and repair kinetics and to assess biological dosimetry, immediately and retrospectively . Moreover, he has been 
involved in pioneering development and validation of in vitro assays as alternatives to use of vertebrate animals to detect and characterize 
genotoxic, anti- and co-genotoxic potential of human dietary components. He is leading and coordinating the section of 




David O. Carpenter, MD - Director, Institute for Health and the Environment, University at Albany, SUNY, New York, USA. Dr Carpenter’s 
research is focused on investigations into the modes and causes of human disease using both animal model systems, humans as experimental 
subjects and analysis of human illness databases to elucidate the mechanistic basis and distribution of various human diseases. He is mainly 
focused on the relationship between exposure to environmental chemicals and risk of chronic diseases, including cancer, diabetes, 
hypertension and cardiovascular disease. In some of these studies he and his group obtain medical information, blood or urine for clinical 
chemistry indicators and for levels of environmental contaminants (PCBs, pesticides, radioactivity, etc.) in order to determine relationships 
between exposure and development of disease. In other studies he and his colleagues utilize state datasets for birth, death or hospitalization 
in order to correlate factors such as place of residence in relation to proximity to waste sites or socioeconomic class with rates of disease in 
the whole population. Recent investigations have focused on health effects of air pollution. The Institute for Health and the Environment is a 
Collaborating Center of the World Health Organization in environmental health. 
 
 
Philippa D. Darbre, PhD - Reader in Oncology, School of Biological Sciences, University of Reading in England. Dr Darbre’s research focuses on 
the cellular and molecular basis of action of oestrogen and oestrogen-mimicking compounds on the development, growth and progression of 
breast cancer cells. Her research is focused on the role of the many environmental chemicals which possess estrogenic activity and which can 
enter the human breast through diet, the domestic environment and use of cosmetic products. Studies are focused on determining the 
cellular and molecular actions of estrogenic compounds which can be measured in the human breast and on trying to understand how 
exposure to multiple compounds in the long-term may impact on breast biology. If exposure to complex mixtures of oestrogenic chemicals is 
a factor in breast cancer development, then a strategy for prevention of breast cancer might become a reality. As well, Dr Darbre has 
developed human breast cancer cell culture models to investigate molecular mechanisms, and studies are currently focused on finding new 
ways of inhibiting the oestrogen-independent cells which might have therapeutic benefit. 
 
 
Thomas Sanderson, PhD - Professor within the Environmental Toxicology and Biotechnology group at the National Institute of Scientific 
Research (INRS) - Institute Armand-Frappier in Quebec, Canada. Dr Sanderson’s research interests concern the interactions of chemicals with 
the expression and function of enzymes involved in steroid biosynthesis, and their relation to the development of hormone-dependent cancers 
and endocrine disruption. Current research activities, funded by the Natural Sciences and Engineering Research Council of Canada (NSERC) and 
Canadian Institutes of Health Research (CIHR) aim to elucidate the mechanism by which a wide variety of chemicals, including environmental 
contaminants, drugs and compounds of natural origin interfere with androgen and estrogen biosynthesis and receptor signalling in human and 
animal models of cancer.  
  
 
Andreas Kortenkamp, PhD - Professor in the Institute for the Environment, Brunel University, UK.   Dr Kortenkamp believes that traditional 
chemical risk assessment has quite an artificial orientation: It treats chemicals as if they act in isolation, when in reality there is exposure to 
multiple substances. For more than 15 years, his team has been engaged in efforts to find ways of improving risk assessment by taking 
“cocktail effects” into account. This work has proceeded in stages: Firstly, when his group had information about the toxicity of individual 
mixture components, they asked whether or not is was possible to predict the effects of the combination? Working with mixtures of endocrine 
disrupting chemicals they have shown that this is achievable. Secondly, they asked whether or not the composition of mixtures was of 
environmental relevance, and the effects they produced. Work on that aspect of the mixtures issue is currently proceeding in his group. He is 
also interested in making an impact on chemical regulation by addressing the questions: Which chemicals should be grouped together for 
mixtures risk assessment? What are scientifically sound grouping criteria? He and his team have prepared scientific reports for the European 
Commission, including the State of the Art Report on Mixture Toxicology. Currently they are writing a State of the Art Assessment for 
Endocrine Disrupters, a project also commissioned by the European Commission.  Another research interest his team is unravelling is related 
to estrogen signalling and estrogen-mediated effects with a view to understanding hormonal cancers, especially breast cancer. This is an area 








Sustained Proliferative Signalling 
 
Wilhelm Engström, MD (Sweden) - Professor of Pathology in the Department of Biosciences and Veterinary Public Health, Faculty of 
Veterinary Medicine, Swedish University of Agricultural Sciences. Dr. Engstrom’s research has primarily been focused on cell cycle 
regulation and growth factor gene transcription control. His most recent research has focused on fibrous proteins and the relationship 
between protein structure and biomechanics, as well as epigenetic regulation of growth factor gene expression. He is Chairman of The 
European Cell Proliferation Society, and a Fellow of both the Royal Society of Sciences in Uppsala and the Royal College of Pathologists 
(UK).  
 
Evading Growth Suppressors 
 
Rita Nahta, PhD (USA) - Assistant Professor at the Emory University School of Medicine, Department of Pharmacology, and the Winship 
Cancer Institute, Emory University in Atlanta, Georgia. Dr Nahta focuses on the biological and therapeutic implications of growth factor 
signaling crosstalk in breast cancer. Significant advances in the treatment of metastatic breast cancer include the development of 
therapies targeted against specific cancer-causing molecules. However, the success of these mono-targeted therapies is often limited by 
cross-talk between multiple signaling pathways. Dr Nahta is specifically interested in understanding how cross-talk between HER2 and 
other growth factor signaling pathways affects the biology of HER2-overexpressing breast cancers, including how signaling cross-talk 
promotes resistance to targeted therapies. 
Resisting Cell Death 
 
Hyun Ho Park, PhD (South Korea) – Assistant professor at the Yeungnam University. Dr. Park’s group studies protein-protein interactions 
involved in the intracellular signaling that are closely linked to human health and disease, with an emphasis on cancer. Their main targets 
are cell death signaling pathways (apoptosis, necrosis, and autophagy), using X-ray crystallography in conjunction with other biochemical 
and biophysical methods to elucidate the interaction mechanism and protein-protein interface (PPI) at the atomic level. The ultimate goal 
of Dr Park’s research team is to develop chemical or peptide drugs that can regulate targeted signaling pathways. 
Replicative Immortality 
 
Rob Newbold PhD, DSc (UK) - Director of Brunel Institute of Cancer Genetics and Pharmacogenomics at Brunel University, Uxbridge, UK. 
Dr Newbold’s institutewas established in 2000 with the primary aim of identifying and characterizing new genes and molecular pathways 
involved in human cancer development that can be exploited as targets for novel therapeutic intervention. Other major aims include 
identification of novel cancer related DNA repair genes, molecular characterization of the role of telomeres in DNA repair, identification of 
novel human DNA repair genes influencing radiosensitivity and the identification of novel T-cell mechanisms in human tumor immunology. 
Emphasis continues to be placed on translational research. 
 
Tumor Promoting  Inflammation 
 
Patricia Thompson PhD (USA) - Associate Professor and Director of the Cancer Prevention and Control Program at the University of 
Arizona. Dr. Thompson is a molecular epidemiologist whose research in breast cancer includes development of molecular marker based 
risk prediction models of early stage breast cancer to guide patient decision making about treatment. She also has an active research 
interest in chemoprevention of breast cancer targeting high risk patient populations using non-hormone based therapies like non-
steroidal anti-inflammatory agents. She focuses on research related to primary and secondary prevention of colon and breast cancer, and 
has a specific interest in the role of inflammation in carcinogenesis and the factors that contribute to inflammation. 
Evading Immune Destruction 
 
H. Kim Lyerly MD (USA) - Professor of Cancer Research at Duke University and a senior member of the Duke global health team. He was, 
until recently, the director of the Duke Comprehensive Cancer Center. In 2008, Dr. Lyerly was appointed to the National Cancer Advisory 
Board by President George Bush. He was also named by his peers as one of North Carolina's most outstanding clinical physicians and was 
invited by North Carolina Governor Michael Easley to serve on the Advisory Commission of the NC State Museum of Natural Sciences. Dr. 
Lyerly has been a faculty member of the AACR/ASCO Methods in Clinical Cancer Research, and has served as a faculty member of ACORD 
Workshops. He is currently a member of the Scientific Advisory Board of Susan G. Komen for the Cure and the Burroughs Wellcome 
Foundation. He has previously served as chairperson of the executive committee of the integration panel of the Congressionally Directed 
Medical Research Programs in Breast Cancer. He also serves on American Society of Clinical Oncology's (ASCO) Grants Selection Committee, 
of which he served as chair in 2006. Dr. Lyerly is a member of the American College of Surgeons, of which he is a fellow. 
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Tissue Invasion and Metastasis 
 
Josiah Ochieng, PhD (USA) - Professor in the Department of Cancer Biology and Director of the Cancer Biology Program at Meharry 
Medical College in Nashville, Tennessee. Dr. Ochieng and his colleagues are exploring the significance of galectin-3 in integrin functions 
during malignant progression of breast and prostate carcinomas. Gene disruption strategies have reduced expression of galactin-3 in 
cell culture models and revealed the important role of changes in galectin-3 expression on cell-cell interactions and cell-matrix 
interactions. A similar conceptual framework underlies the studies on the role of fetuins in tumorigenesis and metastasis. Preliminary 
data have led to the hypothesis that fetuin is able to localize matrix metalloproteinases (MMPs) on the surface of tumor cells 
modulates their activation processes; and, as such, serves as a critical accessory protein for activation of MMPs. Testing hypotheses 
regarding galectin 3 and fetuin is of importance in identifying novel therapeutic targets for tumor proliferation and progression through 
metastasis. 
 
Reprogramming Energy Metabolism 
  
R. Brooks Robey, MD (USA) - Dr. Robey is the Associate Chief of Staff for Research, Chief of Nephrology at the White River Junction 
VA Medical Center as well as a funded biological laboratory science investigator. He has been at White River Junction since 2005 and 
holds a dual appointment Associate Professor of Medicine and of Physiology, Dartmouth Medical School and Faculty Program in 
Experimental and Molecular Medicine. Dr. Robey's lab studies the regulation and function of hexokinases which play a central role in 




Zhiwei Hu MD, PhD (USA) - Research Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at 
Yale School of Medicine. Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature 
for development of novel dual neovascular- and cancer cell-targeted therapy for cancer. Currently his laboratory is focusing on 
further elucidating the mechanisms of action and improving the efficacy of factor VII-targeted immunotherapy and photodynamic 
therapy for human cancers. His laboratory is also studying tumor angiogenesis, natural killer cells and cancer stem cells and their 
interaction in tumor microenvironment. Dr. Hu is member of the Yale Cancer Center, American Association for Cancer Research, and 
The American Association of Immunologists. Dr. Hu is a peer reviewer for numerous scientific journals in immunology, photodynamic 
therapy and cancer research and serves as an editor or editorial (review)/board member of The Journal of Immune Based Therapies, 
Vaccines and Antimicrobials, The Journal of Analytical & Bioanalytical Techniques, The Journal of Solid Tumors and Open Journal of 
Immunology. Starting February 2012, Dr. Hu serves as Editor-in-Chief of The Journal of Analytical & Bioanalytical Techniques. 
Genetic Instabiliy 
 
Firouz Darroudi MD, PhD (The Netherlands) - Senior research scientist in Radiation Genetics and Chemical Mutagenesis at the 
Department of Toxicogenetics, Leiden University Medical Centre in The Netherlands. Dr Darroudi has 30 years of experience in 
Radiation Genetics and Chemical Mutagenesis, and in classical and state of art cytogenetics. Dr Darroudi has explored the 
application of different cytogenetic assays such as dicentric, micronuclei, premature chromosome condensation and fluorescence in 
situ hybridization (FISH)-based translocation assays for biological dosimetry following acute and chronic exposure in scenarios of 
accidental and occupational exposure. Dr Darroudi has contributed to the development and application of new FISH assays, such as 
multi-colour FISH, M-FISH and application of telomeric probe with chromosome painting probes and pancentromeric probes to 
investigate the origin of radiation induced chromosomal aberrations, mechanisms , spectra, and repair kinetics and to assess 
biological dosimetry, immediately and retrospectively. Moreover, he has been involved in pioneering development and validation of 
in vitro assays as alternatives to use of vertebrate animals to detect and characterize genotoxic, anti- and co-genotoxic potential of 
human dietary components. He is leading and coordinating the section of genotoxicity/carcinogenicity of Global Harmonization 
Initiative Platform. He is also a senior consultant to WHO, UNESCO and IAEA on biological dosimetry  
 
The Tumor Microenvironment 
 
Dean Felsher, MD, PhD (USA) - Associate Professor of Medicine and of Pathology at Stanford School of Medicine, Stanford 
University, California, USA. Dr Felsher’s research interests include both basic science and translational research studies that 
investigate how oncogenes initiate and sustain tumorigenesis. He is a 1996 Lymphatic Research Foundation Fellow and 2001 Junior 
Faculty Award Recipient. His laboratory has developed model systems that can conditionally activate oncogenes in normal human 
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Introduction 
This document has been produced by Getting to Know Cancer, a non-profit organization that is based in Nova 
Scotia, Canada and focused on integrative cancer research.  The document is intended to provide guidance to lead 
authors who have been selected to participate in the Halifax Project task force that will be focused on “Assessing 
the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment”.    
 
As you well know, the impact of cancer on society is an enormous burden that exacts an incredible toll.   And while 
the precise percentage of cancers that can be attributed to environmental causes (i.e., those that are not lifestyle-
related) remains a matter of considerable contention, we believe that the historical scientific and regulatory 
emphasis on “mutagens as carcinogens” and the ongoing search for individual chemicals and precisely defined 
mixtures that are “complete” carcinogens (i.e., can cause cancer on their own) is an incomplete approach that has 
serious limitations.   
 
The last few decades have given us breathtaking advances in our understanding of the disease. Mutation research 
has shown us that cancer can be enabled by a series of key events, and chemical exposure research has shown us 
that many of these key events can be independently instigated.  So it now appears that a prohibitively narrow focus 
on the carcinogenicity of individual chemicals or precisely defined mixtures may underestimate the carcinogenic 
synergies of complex mixture effects that are encountered in the environment.  For example, while a chemical that 
disrupts DNA repair may not be carcinogenic at any dose level, it may actually be quite an important enabling factor 
in the presence of other mutagens that cause DNA damage.  Similarly, a chemical that has immuno-suppressive 
qualities may not be carcinogenic on its own, but it may serve as an important contributing factor in the presence 
of other disruptive chemicals that would normally have only weak carcinogenic potential.   
 
In other words, since many key events are involved in the multi-step process that leads to the cancer, it now 
appears plausible that ongoing exposures to complex mixtures of disruptive chemicals in the environment may be 
capable of carcinogenic effects that have yet to be fully appreciated.  Accordingly, this project is aimed at studying 
the fundamental nature of this problem, because we believe that this line of inquiry will have relevance for a wide 
range of stakeholders.   
 
So thank you for your willingness to assume a leadership role in the initiative.  We appreciate your commitment to 
this important line of inquiry and we are confident that this task force is going to produce a body of work that will 
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Background 
In 1981 Richard Doll and Richard Peto wrote a landmark paper in the Journal of the National Cancer Institute called 
“The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today”.   In that 
article the authors looked at ranges of acceptable estimates for the proportion of cancer deaths that could be 
attributed to various factors and then offered a series of best estimates for causation.  The results of this study can 
be summarized as follows: 
 
 
Lifestyle – related Factors 
 Diet    35% 
 Tobacco    30% 
 Infection     10%  
 Reproductive and sexual behaviour  7%  
 Alcohol    3%  
 Geophysical  (mainly solar radiation) 3%  
 Medicines and medical procedures 1% 
 
Other Chemical Exposures 
 Occupation    4% 
 Pollution    2% 
 Industrial Products    <1% 
 Food additives     <1% 
 






Figure 1 – Table compiled from estimates found in Doll R, Peto R, The causes of cancer: quantitative estimates of  
avoidable risks of cancer in the United States today, J Natl Cancer Inst. 1981 Jun; 66(6):1191-308. 
 
This extensive study was well received at the time and it would become a landmark reference for best estimates of 
cancer causation in the decades that followed.  In essence, the paper gave the impression that we understood 97% 
of the causative factors (only 3% of causation unknown) and it also suggested that industrial sources (e.g., 
occupational exposures and pollution) and chemicals in foods were a very small part of the problem.   
 
This work did not go entirely unchallenged.  German researchers (Schmähl et al, “Causes of cancer--an alternative 
view to Doll and Peto (1981)”, 1989) later argued that the cause of only one third of all cancers in Germany could 
realistically be attributed to known sources, and that the 97% of attribution offered by Doll and Peto was 
unrealistically high.  Davis et al, (“Trends in cancer mortality in industrial countries” (1989) and Landrigan et al 
(“Cancer Prevention and Control”, 1995) also critiqued the methods used, the conclusions reached and the degree 
of certainty implied in Doll and Peto’s estimates.   But in 1996, the Harvard Center for Cancer Prevention published 
a volume on causes of human cancer in which they updated Doll and Peto’s estimates of “avoidable causes”, and 
that summary essentially duplicated the earlier estimates of the proportion of cancer deaths attributed to 
environmental pollution and occupation.   
 
As a result, momentum began to develop that placed an emphasis on lifestyle factors as the main causative 
influences of cancer, and a corresponding lack of emphasis was given to other factors.  Indeed, the lifestyle-factors 
bias has become a deeply entrenched paradigm over the past three decades and it has had a significant influence 
on cancer-related prevention policies in Western nations. Prevention-related research has been heavily skewed 
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towards studies that improve our understanding of lifestyle-related factors while prevention programs have 
focused heavily on initiatives aimed at changing population-level behaviors.   While researchers who have been 
focused on chemical exposures in the environment from industrial sources (e.g. pollution and occupational) and 
chemicals in foods have received much less attention and funding.   
 
However, when Sir Richard Doll died in 2005, it was discovered in his private papers that he had been receiving 
undisclosed consultancy payments from Monsanto from 1976 to 2002, and that he had also received money from 
companies whose products he had defended in court and in the academic literature. This included a longstanding 
financial relationship with Turner and Newall (the asbestos company), payments from General Motors (for work he 
did on lead as a gasoline additive), and money paid to him by the Chemical Manufacturers’ Association (for 
research he did on Vinyl Chloride), which caused some observers to revisit his work.  Some observers have since 
raised the issue of potential for bias, and a certain amount of renewed scrutiny was placed on the estimates that he 
and Richard Peto assigned to industry-related causes in their seminal report in 1981.   
 
Clapp et al. challenged these estimates again in 2006 (”Environmental and Occupational Causes of Cancer Re-
visited”) calling for a renewed emphasis on occupational and industrial exposures.  And more recently, in a special 
issue of the British Journal of Cancer titled “The Fraction of Cancer Attributable to Lifestyle and Environmental 
Factors in the UK in 2010“  http://www.nature.com/bjc/journal/v105/n2s/index.html , epidemiologists estimated 
that the fraction of cancer that can now be attributed to both lifestyle and environmental factors is only 43%.   In 
other words, more than 30 years after Doll and Peto’s landmark report which implied so much certainty about 
causal attribution, it seems that we are now far less certain about the causes of cancer than ever before.  Ironically, 
it was Sir Richard Peto (i.e., Sir Richard Doll’s co-author from the landmark work in 1981) who wrote the forward to 
this special issue in the British Journal of Cancer, so we contacted him directly by email in 2012 to ask him what he 
thought might account for the other 57% of cancer causation.  In his brief reply he simply offered that this 
was  “…probably due to undiscovered avoidable causes”.    
 
So we are working on the assumption that “other chemical exposures” may be more of an issue than many have 
been led to believe.  This was certainly the message in the 2008-2009 President’s Cancer Panel Annual Report in 
the United States titled “Reducing Environmental Cancer Risk: What We Can Do Now”.  In that report the authors 
noted that the “true burden of environmentally induced cancer has been grossly underestimated”, and they 
pointed to the fact that there are “nearly 80,000 chemicals on the market in the United States, many of which are 
used by millions of Americans in their daily lives and are un- or understudied and largely unregulated” and that 
“exposure to potential environmental carcinogens is widespread”.   
 
Nonetheless, critics of these assertions have subsequently argued that there is not good evidence to substantiate 
these concerns.  But unfortunately, there doesn’t appear to be any unequivocal evidence to resolve this debate.  A 
recent and extensive review of the epidemiological literature that was undertaken by McGuinn et al at the Division 
of Cancer Control and Population Sciences at the National Cancer Institute, USA (“Cancer and environment: 
definitions and misconceptions”, 2012) determined that a reliable estimate for the proportion of cancers 
attributable to environmental factors is currently unavailable (citing wide discrepancies in definitions, methodology 
and approaches to reporting). So with considerable uncertainty remaining in the area of causal attribution, we 
simply believe that cancer scientists need to remain open to the ways in which cancer may be caused.  
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In some of the earliest research on the carcinogenic effects of exposures to tobacco smoke, researchers were 
perplexed by the fact that many smokers didn’t get cancer.  However the last two decades of scientific advances 
have helped us to understand that there are several important lines of biological defense that must be defeated or 
bypassed before cancer can be caused by chemical exposures.  For example, normal xenobiotic metabolism and 
detoxification act as a first line of defense, then DNA repair systems can address a wide range of damage, while 
cell-cycle controls can prevent cellular replication when repairs are being undertaken. Moreover, apoptosis can 
ensure that lineages of dysfunctional cells aren’t replicated, properly functioning senescence can prevent sustained 
proliferation, and many immune system components also function to suppress tumors. In other words, we have a 
fault-tolerant biological system that can handle many defects and still suppress tumors under most conditions.   
 
Unfortunately, this multi-layered system of defenses has complicated matters from a research perspective, and it 
has made testing for carcinogenicity rather difficult.  In the field of environmental health, researchers are often 
faced with inconsistent results in “in vivo” exposure testing of single chemicals and precisely defined mixtures 
because there are very few chemicals that can disrupt all of these lines of defense simultaneously.  So tumor 
production in test animals is frequently inconsistent and subject to considerable variability. Consequently, the 
degree of carcinogenicity that can be attributed to any single chemical is often subject to interpretation and results 
can be contentious.  The International Agency for Research on Cancer (IARC) and many other prominent 
environmental/regulatory agencies worldwide have had to grapple with this issue and they have adopted 
classification systems that acknowledge this uncertainty by using terms such as “possibly carcinogenic to humans”, 
“probably carcinogenic to humans”, “carcinogenic to humans” etc..   
 
In regulatory work, matters are also not straight forward.  Cancer researchers and regulators have established 
methods for in vivo carcinogenicity testing of chemicals in rodents that typically involve high dose exposures to 
establish toxicity tolerance followed by a series of lower dose exposure experiments.  When clear evidence of 
carcinogenicity is found at higher dose levels, tests at lower dose levels are then conducted and the results 
scrutinized until a “no observable effect level” can be seen.  In many instances, safety margins for exposure are 
then estimated using linear extrapolations and safe levels of exposure are estimated for regulatory purposes.   
 
However, in a recent review of low dose effects by Vandenberg et al (“Hormones and endocrine-disrupting 
chemicals: low-dose effects and non-monotonic dose responses” June 2012), the team produced an impressive set 
of arguments that challenges the very basis of this logic.  This group of authors presented a substantial review of 
the literature and provided a detailed discussion of the mechanisms responsible for generating low dose effects 
(those that occur in the range of human exposures or effects observed at doses below those used for traditional 
toxicological studies) and non-monotonic dose-response curves (defined as a nonlinear relationship between dose 
and effect where the slope of the curve changes sign somewhere within the range of doses examined).  By offering 
hundreds of examples from the cell culture, animal, and epidemiology literature, the team cogently explains that 
non-monotonic responses and low-dose effects are remarkably common in studies of natural hormones and 
endocrine disrupting chemicals. And they conclude by noting that when non-monotonic dose-response curves 
occur, the effects of low doses cannot be predicted by the effects observed at high doses.   
 
While endocrine disruption research has been primarily aimed at chemicals that disrupt a relatively small subset of 
hormones (e.g., estrogen, androgen, thyroid etc.), it has revealed a wide range of disruptive biological effects from 
a great number of commonly encountered chemicals that appear to be more potent at low dose levels of exposure 
than they are at higher dose levels of exposure.  This has important implications for cancer research because we 
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have sought in the past to identify complete carcinogens (i.e., individual agents or precisely defined mixtures that 
can cause cancer) and limit our exposures to those chemicals, but we have done so using safety margins for many 
chemicals that have been founded on assumptions of dose-response linearity.  Yet it is now apparent that these 
assumptions may not always hold true and that casts considerable doubt on the validity of the safe exposure levels 
that we have developed using these assumptions. 
 
Furthermore, and perhaps most importantly, the current approaches to testing simply do not contemplate the 
carcinogenic potential of mixtures of biologically disruptive chemicals.  It is now known that many of the hallmark 
mechanisms of cancer can be enabled by individual chemicals, so it is conceivable that mixtures may actually be 
needed to dismantle the many lines of biological defense that would otherwise serve to obfuscate and/or diffuse 
the potency of an exposure to any given chemical.   
When we combine the issue of low dose effects with the possibility for synergism amongst mixtures of chemicals in 
the environment, we believe that we may be facing a substantial problem that needs to be better articulated.  So 
this project will consider the ways in which low dose exposures to combinations of disruptive, but otherwise non-
carcinogenic, environmental chemicals may be combining to instigate the disease.  It is not a trivial matter, and 
very little research has been done on this issue so far, but this task force has been created to study this issue.  
 
The Approach 
To study this problem, an expansive and rapidly growing body of cancer research will need to be considered, so this 
project has been conceived using a task force model.  Nearly 300 formal expressions of interest have been received 
from a wide range of senior cancer researchers from around the globe.  And a “first principles” approach is going to 
be used for this project.  Eleven teams will be formed to allow us to encompass as much of the cancer research 
literature as possible.    A 2-day workshop will then take place in Halifax, Nova Scotia in August 2013 (i.e., part way 
through the project) so the teams will have an opportunity to come together for discussion and to work through a 
series of important issues that will require considerable collaboration.  This will lay the groundwork for a post-
workshop synthesis that will result in a capstone article that will be jointly authored by all of the teams to capture 
some of the collaborative work, prepare a set of consensus statements and formulate recommendations of the task 
force.   
 
The specific objectives that are being pursued in this project can be summarized as follows.  Specifically we plan to 
produce: 
 A foundational series of research design recommendations that will lay the groundwork for future research 
that will be able to demonstrate the carcinogenic potential of low dose exposures to mixtures of disruptive 
chemicals in the environment 
 
 Suggestions and guidance that will help global regulators introduce more effective risk assessment 
strategies that can better account for the carcinogenic risks associated with low dose exposures to mixtures 
of disruptive chemicals in the environment 
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 Precautionary advice that can be used by physicians and other health-care professionals to help cancer 
patients, cancer survivors and other high-risk individuals who need to avoid environmental exposures that 
may have the potential to contribute to the onset or recurrence of the disease. 
 
The Scope of the Planned Reviews  
Since this is a large scale problem that needs to be studied in a holistic manner, we have decided that a series of 
overarching reviews will be undertaken that can collectively assess the key events that enable the various hallmarks 
of the disease, and also identify a roster of selectively disruptive chemicals that are ubiquitous in the environment, 
not related to “lifestyle factors” and potentially causing adverse (i.e., carcinogenic) effects when combined.  If 
combinations of chemicals in the environment are causing cancer in the general population in a way that has yet to 
be fully appreciated or recognized, we believe that we should be able to reverse-engineer the problem by 
identifying the most likely offenders and laying out a testing strategy to determine whether or not the concerns 
that have been raised by so many are indeed a threat to population-level health.  
To that end, the “Hallmarks of Cancer” framework (Hanahan and Weinberg, 2000 and 2011) was used to help us 
develop an initial organizing framework for the many key events that are known to be important in all cancer types 
and we settled on eleven overarching review topics –as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
11. The Tumor Microenvironment 
 
Each of these topics will be tackled by a separate team and each lead author will be provided with an electronic 
copy of both Hallmarks of Cancer reviews (Hanahan and Weinberg, 2000 and 2011).  Each team will then be 
expected to review one of these topics.  However, the Hallmarks of Cancer framework as a very broad review is, by 
necessity, quite succinct (since each of these topic areas are underpinned by a very large body of scientific 
literature).  So as experts who have been asked to lead these reviews, each of you will have a degree of latitude in 
the way in which you approach your own topic area.  Your own reviews will require much greater depth in each of 
these areas, so we are quite open to your team’s perspective and interpretation of the literature in your respective 
domains.    
 Page 8 
 
For example, if you identify subtopics that aren’t mentioned in the Hanahan and Weinberg framework, you are free 
to include that detail in your review so long as it doesn’t create overlap with any of the other work that is being 
done by any of the other teams.  If there is a subtopic that you weren’t aware was going to be covered in your 
review, you should look specifically at the composition of your team to ensure you have the expertise to cover it.   
And if there is any other ambiguity over what should or shouldn’t be included in your particular review, please 
don’t hesitate to contact Leroy Lowe (leroy.lowe@gettingtoknowcancer.org) with the details and he will liaise with 
the guest editor(s) and organizing committee as needed to provide additional clarification.   
The goal of each of the individual reviews is to undertake a high-level review of each domain, while also considering 
the most important ways in which each of these areas can be chemically disrupted.    
As a starting point for prioritization, some assistance can be gleaned from the work that is emerging in the many 
cancer genome projects that are beginning to help us categorize mutations for each cancer type.   Sian Jones et al. 
authored one of the early studies that mapped these mutations in a 2008 article in Science titled “Core Signaling 
Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses”.  This is seen as an important paper 
because the authors performed a comprehensive genetic analysis of 24 pancreatic cancers by determining the 
sequences of 23,219 transcripts, representing 20,661 protein-coding genes, and they searched for homozygous 
deletions and amplifications in the tumor DNA and they found that pancreatic cancers contain an average of 63 
genetic alterations, the majority of which are point mutations. Then they organized the alterations and defined a 
core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the 
tumors (see Figure 2 below).   
 
Figure 2 - The 12 pathways and processes whose component genes were genetically altered in most pancreatic cancers 
 
While this research was only focused on a single cancer type, one of the contributing authors to that project was 
Dr. Bert Vogelstein and he has since been tracking the results of 852 studies that have now been published 
describing the genomes of 23 different cancers.   At a recent NIH lecture (Feb 2012), Vogelstein explained that 
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researchers have generated vast amounts of data about cancer genomes in more than 125 whole genome studies 
and more than 725 whole exome studies to date which has “really revealed the details of what the cancer genomes 
look like and has greatly illuminated the genetic basis as well as the physiologic basis of cancers”.  Surprisingly, 
most cancer tumors have only 20 to 80 key mutations (which includes mutations that affect coding for amino acids 
and with exceptions being in tumors that have a DNA repair defect where a rapid accumulation of mutations per 
tumor can be expected).   So we now know that the mutation rate in cancer genomes—at the DNA base-pair 
level—is only marginally higher than for normal cells, but cancers can have other kinds of alterations in their 
genome as well that cause structural changes in tumors, particularly deletions of tumor suppressor genes, 
amplifications of cancer-promoting oncogenes and translocations of either of those genes1.   
It also appears that the tumors in many cancer types tend to have similar mutations that align themselves with the 
same 12 pathways and processes that were initially found to be disrupted in pancreatic cancer.  So as part of your 
analysis, your team should look at each of these 12 pathways and processes to determine which of them are 
relevant for the area that your team is reviewing.    
These reviews should also consider non-mutagenic/epigenetic pathways of interference as well.  Epigenetic 
changes such as DNA methylation and histone acetylation are known to be relevant for cancer and these sorts of 
modifications are also known to be chemically inducible directly. 
Practical Emphasis 
It is crucial to bear in mind that our first objective of this initiative is to produce a foundational series of research 
design recommendations that will lay the groundwork for future research that will be able to demonstrate the 
carcinogenic potential of low dose exposures to mixtures of disruptive chemicals in the environment.  So while 
each of the teams is being tasked to undertake a traditional academic review of their topic area, it’s not enough to 
just highlight the main pathways and mechanisms that are relevant for the area under study.  The highest priority 
biomarkers in that area (i.e. target sites for disruption that will have the greatest effect on disease progression) also 
need to be identified, and we need the discussion and conclusion sections of each paper to be focused in a manner 
that will feed directly into the research challenge that will follow.   
Specifically, the task force will be asked to use the information gleaned from these reviews to make 
recommendations for future research that help us to investigate whether or not chronic exposure to low doses of a 
carefully selected mixture of (selectively disruptive) chemicals that are ubiquitous in the environment cause cancer.   
Therefore each team should ultimately produce and include a short list of no more than ten prioritized biological 
target sites for disruption (rank ordered if possible, based on estimation of importance) for their area of concern.  A 
“target” could be at the system level (e.g., the stress-axis”), organ level, tissue level, or cellular-level.   And for each 
of the prioritized targets, a single favored approach for chemical disruption should be identified from the literature 
and recommended for inclusion.   
In many cases, there could be many possible disruptive chemicals that might be suitable choices for the prioritized 
target sites for disruption that the team has identified.  The following criteria can be used to help your team in this 
regard: 
                                                          
1
 Extracted from the NIH Record article Vogelstein Considers Cancer Genome at Trent Lecture By Raymond MacDougall 
http://nihrecord.od.nih.gov 
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 Ubiquitous in the Environment - A “favored” chemical should be one that is ubiquitous in the environment.  
This is important because we want to produce a set of disruptive chemicals that, in principle, have the 
broadest possible relevance for the population at large.  
  
 Selectively Disruptive – Greatest potential to achieve the desired action on the intended target site for 
disruption across the widest possible range of cancer types.  For example, chemicals that are agonists or 
antagonists of specific receptors would be suitable choices. Similarly, chemical mutagens that tend to 
consistently produce adducts or damage that impacts a specific pathway or mechanism would be 
acceptable.  However, mutagens that cause indiscriminate damage across a wide range of pathways should 
be avoided.  
 
 Not “lifestyle” related – A tremendous amount of research has already gone into lifestyle factors of 
causation such as tobacco, poor diet choices (e.g., red meats, french fries, lack of fruit and vegetables, etc.), 
alcohol consumption, obesity, excessive sun exposure, infections (e.g., HPV) etc.  In this project we are 
interested in chemicals that may have received much less attention because they are not associated with 
“poor” lifestyle decisions. 
 
 Not a Known “Carcinogen to Humans” - The task force should focus on selectively disruptive agents that 
are not currently known as carcinogenic to humans.   
Ultimately, we want each team to produce specific recommendations for a multi-pronged approach for chemical 
disruption in their respective areas of study.  These combinations should have the potential to be disruptive in a 
manner that will be complementary to the actions of the disruptive chemicals that will be suggested by the other 
teams.   Currently, testing in the literature that involves mixture effects is often limited in scope (e.g., two or three 
chemicals) due to variable constraints that are often invoked as part of the research design.  But in this project, we 
want to consider the widest possible range of environmental sources of exposure to identify discretely disruptive 
chemicals that are of greatest interest to each of the teams.  If chronic exposure to low doses of this subset of 
environmental chemicals is an issue, we should be able to reverse-engineer the problem and then illustrate these 
effects if we approach the problem systematically.    
In some of the areas of study, there may be a paucity of literature that can support a role for chemical disruption.  
In this situation it will still be important for the team to consider the most critical aspects of cancer biology in their 
area of concern (i.e., target sites for disruption that would, in theory, have the greatest effect on disease 
progression).  This will help the task force in their development of research recommendations and it will also 
provide a useful roadmap for researchers in environmental health (i.e., those who may want to investigate the 
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Format of the Reviews 





Describe the approach being taken and place the research in the context of the larger 
project.   
 
Topic Area Overview  Provide a high-level overview of the progress that has been made in the understanding of 
the area that the team has been tasked to review, with a particular emphasis on the various 
levels of dysfunction that are known to contribute to the enablement of the immortalization 
of cells.  This should include both areas of broad agreement and any major areas of 




Describe any fundamental interactions or relationships that exist between the topic area 





Categorize, and prioritize the target sites for disruption that the team believes will have the 




Using the criteria provided above, identify specific chemicals in the environment that appear 




Drawing on the existing literature in the field of environmental health, provide reflective 
commentary on whether or not it appears likely that environmental chemical exposures 
have been suspected as being disruptive in the area under review.  Also consider the effect 
of synergies that would be realized if all of the prioritized targets are simultaneously 






Each review should be approximately twenty pages in length including references.  Oxford’s Carcinogenesis journal 
format allows for roughly 1200 words per page (this is obviously affected by any artwork or tables that are needed).  





Assembling the Teams 
 
We now have nearly 300 expressions of interest from researchers who want to take part in the project.  Our first 
priority is to quickly assemble the teams that are needed.  Eleven lead authors have been recruited, and we are 
envisioning eleven teams that will each have 10-12 contributing authors.  As the lead author for one of the teams, 
you will be provided with a list of prospective candidates and asked to identify 10-15 priority candidates from the 
list that appear to be well suited to the task (i.e., based on their ability to contribute to the review that needs to be 
produced).  As noted above, the team composition should be cross-functional and roughly align itself with the 
following structure.    
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1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other experts 
who will collectively be responsible for producing a descriptive overview that encompasses the topic area, as 
well as a description of the types of systemic or cellular-level dysfunction in that topic area that contribute to 
the immortalization of cancerous cells, any relationships that exist between that particular topic and the other 
topic areas under consideration, and a reflective strategic commentary.  Given the scale of the cancer genome, 
the task of this group will be to produce a compact synthesis of the literature that categorizes and prioritizes 
target targets for disruption.  
 
2. Environmental Health Specialists – Each team will also have a number of cancer scientists who specialize in 
exposure based cancer research (i.e., those who investigate the carcinogenic effects of chemicals found in the 
environment).  Their backgrounds could be in epidemiology, traditional toxicology, endocrine disruption and/or 
other related fields.  Whatever their specialty, it is important they have a good grasp of cancer biology and 
experience in the field of environmental health because they will be asked to help the team identify selectively 
disruptive chemicals that appear well suited to reach the prioritized targets. 
 
3. Assisting Researchers - Scientists who are selected to join the task force will also be able to nominate a 
single assisting researcher (e.g. colleague, post-doctoral researcher, or PhD candidate) within their own lab to 
participate in the team’s work at no extra cost.  These researchers will receive authorship recognition for their 
contributions to the team’s work.  However, in instances where a support researcher has been nominated as a 
contributing author, only one of the two (i.e., the nominator or the nominee) will be able to attend the 
workshop in Halifax in August of 2013.  This is mainly intended to help senior researchers alleviate their 
workload and to give more junior researchers an opportunity to get involved, but this policy is intended to also 
ensure that the number of attendees at the working sessions in Halifax remains manageable.  These 
contributing authors will need to be identified as soon as the teams are fully assembled.   
 
Since the cost of participation is the only fee that needs to be collected (to cover the publication costs), a selection 
bias should be shown for researchers who have indicated that they have funding for the participation fee.  
However, some buffer has been built into the project to allow for fee waivers for other researchers (i.e., if we have 
strong applicants who do not have funding).  Therefore, as a lead author, you should keep this in mind as you are 
selecting prospective team members. You are also encouraged to identify researchers in your own lab, or 
institution, or even peers who you have worked with in the past that might be interested in joining your team and 
being part of the effort.  If anyone plans to take part in the project, please make sure that they have filled out the 
expression of interest form (found online at http://www.gettingtoknowcancer.org/thehalifaxproject ).  Once you 
have had a chance to look at the candidates who have applied to take part in the project, and consider others who 
might be willing to help you, you will also need to identify any capability gaps that you see, so additional research 
expertise will be recruited for your team (if necessary).   
We expect that your team will ultimately be comprised of 10-12 researchers, but the exact number of team 
members will ultimately be collaboratively determined based on your suggestions and inputs from the Getting to 
Know Cancer President, Leroy Lowe.  We have some flexibility in the numbers needed for team construction and 
we will work with each of you to ensure you have the expertise needed to successfully complete the task.    
Your list of top prospective candidates and your assessment of any capability gaps should therefore be returned to 
Leroy Lowe ( leroy.lowe@gettingtoknowcancer.org ) as soon as possible.  Offers will then be extended to those 
who have been identified as prospective team members, and new invitations will be extended to outside 
researchers as we try to fill any capability gaps that have been identified.     
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The Biomarker and Approach Validation Team  
All of the teams will also have the support of a substantial, cross-functional group of scientists who will be part of 
the “Biomarker and Disruptor Validation Team”.   This team will validate the prioritized targets and disruptive 
chemicals that are selected by each team by taking target and chemical recommendations and then conducting 
background literature research to identify instances when a particular target or chemical that is of interest to one 
of the teams also has relevance for the topics being studied by other teams.   
 
For example, if the team reviewing sustained proliferative signalling selected HER-2 (the EGFR receptor) as a 
prioritized disruption site, the Biomarker and Disruptor Validation Team would then review the literature to 
determine whether or not disruptive action at that particular site would be expected to produce complementary 
contributions for any of the other areas under review (see Figure 3 shown below).  This same process will be 
undertaken for all of prioritized disruption sites that are selected by each of the teams.  And similarly, all of the 
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If the task force is going to focus on future research that will involve a mixture of selectively disruptive chemicals 
that are carcinogenic at environmentally relevant dose levels, it will be important to ensure that none of the 
selections being made by any of the teams are working at cross purposes to the recommendations being made by 
the other teams. So these validation efforts and inputs will be very important, and they will be captured in tabular 
form in each of the planned reviews, and the contributions of this team will also be acknowledged and credited in 
the list of contributing authors for each of the planned reviews.   
 
Capstone Synthesis and Review 
When all of the initial reviews are beginning to take form (first draft is due July 1st, 2013), the goal is to have an 
initial inventory of prioritized sites for disruption and a corresponding list of selectively disruptive chemicals that 
can be considered as part of a complex mixture that will be suitable for future testing.  At the two day workshop in 
Halifax, Nova Scotia in August of 2013, these inputs will then be used to help the task force assess whether or not 
they feel that that there are enough known disruptors in each area to consider this issue important, and to develop 
a foundational series of research design recommendations that will lay the groundwork for future research that will 
allow us  to investigate the carcinogenic potential of low dose exposures to mixtures of disruptive chemicals in the 
environment. 
Additionally, a number of presentations and workshops will be organized to help the task force develop suggestions 
and guidance that will help global regulators introduce more effective risk assessment strategies that can better 
account for the carcinogenic risks associated with low dose exposures to mixtures of disruptive chemicals in the 
environment.  And we will discuss the possibility of offering precautionary advice that could, in theory, be used by 
physicians and other health-care professionals to help cancer patients, cancer survivors and other high-risk 
individuals who need to avoid environmental exposures that may have the potential to contribute to the onset of 
the disease. 
The workshop will involve presentations and a collaborative series of meetings and the lead authors from each of 
the teams will subsequently collaborate to help the organizing committee produce a capstone synthesis and review 
that will summarize the integrated findings from the workshop and make recommendations for the way ahead.  
This work will be circulated for review and inputs from all of the team members and all of the contributing authors 
on the task force will therefore also be named as authors of this final article.    
 
Timelines 
Key dates for the various aspects of the project are as follows:  
 
 Lead Authors Appointed:   Dec 20th, 2012 
 Teams Fully Assembled;   January 31st, 2012 
 First Draft of Individual Reviews:  July 1st, 2013 
 Halifax 2-day Workshop:   August 7th-8th , 2013 
 Final Draft of Individual Reviews November 1st, 2013 
 Final Draft of Capstone Synthesis November 15th, 2013 






If any aspect of this document is not clear, or if you want clarification on any aspect of the project, please contact 
Leroy Lowe ( leroy.lowe@gettingtoknowcancer.org ) ASAP and we will provide additional guidance as needed.  
 




1. Please read both Hallmarks of Cancer reviews (Hanahan and Weinberg, 2000 and 2011) with an 
emphasis on the topic area that you have been asked to review.  Make sure that you understand 
the nature of the various subtopics that have been included in each of the areas and then draft 
your own outline based on any additional coverage that you foresee as being needed.  
   
 
2. Review the list of prospective candidates that has been provided to you and consider asking your 
own colleagues or other peers to join your team.  Also identify any capability gaps that exist 
(recruiting for your team that is needed) and send a list of 10-15 priority candidates to 
leroy.lowe@gettingtoknowcancer.org as soon as it is ready 
Deadline – December 31st, 2012  
 
 
3. Draft an outline of the subtopics that you plan to cover in the “Topic Area Overview” section of 
your review and send this to leroy.lowe@gettingtoknowcancer.org as soon as it is ready  
Deadline – January 31st, 2013  
 
  




Firouz Darroudi MD, PhD (Committee Chair) - Senior research scientist in Radiation Genetics and Chemical Mutagenesis at the Department of 
Toxicogenetics, Leiden University Medical Centre in The Netherlands. Dr Darroudi has 30 years of experience in Radiation Genetics and Chemical 
Mutagenesis, and in classical and state of art cytogenetics. Dr Darroudi has explored the application of different cytogenetic assays such as dicentric, 
micronuclei, premature chromosome condensation and fluorescence in situ hybridization (FISH)-based translocation assays for biological dosimetry 
following acute and chronic exposure in scenarios of accidental and occupational exposure. Dr Darroudi has contributed to the development and 
application of new FISH assays, such as multi-colour FISH, M-FISH and application of telomeric probe with chromosome painting probes and 
pancentromeric probes to investigate the origin of radiation induced chromosomal aberrations, mechanisms , spectra, and repair kinetics and to 
assess biological dosimetry, immediately and retrospectively . Moreover, he has been involved in pioneering development and validation of in vitro 
assays as alternatives to use of vertebrate animals to detect and characterize genotoxic, anti- and co-genotoxic potential of human dietary 
components. He is leading and coordinating the section of genotoxicity/carcinogenicity of Global Harmonization Initiative Platform. He is also a 
senior consultant to WHO, UNESCO and IAEA on biological dosimetry 
  
 
David O. Carpenter, MD - Director, Institute for Health and the Environment, University at Albany, SUNY, New York, USA. Dr Carpenter’s research is 
focused on investigations into the modes and causes of human disease using both animal model systems, humans as experimental subjects and 
analysis of human illness databases to elucidate the mechanistic basis and distribution of various human diseases. He is mainly focused on the 
relationship between exposure to environmental chemicals and risk of chronic diseases, including cancer, diabetes, hypertension and 
cardiovascular disease. In some of these studies he and his group obtain medical information, blood or urine for clinical chemistry indicators and for 
levels of environmental contaminants (PCBs, pesticides, radioactivity, etc.) in order to determine relationships between exposure and development 
of disease. In other studies he and his colleagues utilize state datasets for birth, death or hospitalization in order to correlate factors such as place 
of residence in relation to proximity to waste sites or socioeconomic class with rates of disease in the whole population. Recent investigations have 
focused on health effects of air pollution. The Institute for Health and the Environment is a Collaborating Center of the World Health Organization 
in environmental health. 
 
 
Philippa D. Darbre, PhD - Reader in Oncology, School of Biological Sciences, University of Reading in England. Dr Darbre’s research focuses on the 
cellular and molecular basis of action of oestrogen and oestrogen-mimicking compounds on the development, growth and progression of breast 
cancer cells. Her research is focused on the role of the many environmental chemicals which possess estrogenic activity and which can enter the 
human breast through diet, the domestic environment and use of cosmetic products. Studies are focused on determining the cellular and molecular 
actions of estrogenic compounds which can be measured in the human breast and on trying to understand how exposure to multiple compounds in 
the long-term may impact on breast biology. If exposure to complex mixtures of oestrogenic chemicals is a factor in breast cancer development, 
then a strategy for prevention of breast cancer might become a reality. As well, Dr Darbre has developed human breast cancer cell culture models 
to investigate molecular mechanisms, and studies are currently focused on finding new ways of inhibiting the oestrogen-independent cells which 
might have therapeutic benefit. 
 
 
Thomas Sanderson, PhD - Professor within the Environmental Toxicology and Biotechnology group at the National Institute of Scientific Research 
(INRS) - Institute Armand-Frappier in Quebec, Canada. Dr Sanderson’s research interests concern the interactions of chemicals with the expression 
and function of enzymes involved in steroid biosynthesis, and their relation to the development of hormone-dependent cancers and endocrine 
disruption. Current research activities, funded by the Natural Sciences and Engineering Research Council of Canada (NSERC) and Canadian Institutes 
of Health Research (CIHR) aim to elucidate the mechanism by which a wide variety of chemicals, including environmental contaminants, drugs and 
compounds of natural origin interfere with androgen and estrogen biosynthesis and receptor signalling in human and animal models of cancer.  
  
 
Andreas Kortenkamp, PhD - Professor in the Institute for the Environment, Brunel University, UK.   Dr Kortenkamp believes that traditional chemical 
risk assessment has quite an artificial orientation: It treats chemicals as if they act in isolation, when in reality there is exposure to multiple 
substances. For more than 15 years, his team has been engaged in efforts to find ways of improving risk assessment by taking “cocktail effects” into 
account. This work has proceeded in stages: Firstly, when his group had information about the toxicity of individual mixture components, they asked 
whether or not is was possible to predict the effects of the combination? Working with mixtures of endocrine disrupting chemicals they have shown 
that this is achievable. Secondly, they asked whether or not the composition of mixtures was of environmental relevance, and the effects they 
produced. Work on that aspect of the mixtures issue is currently proceeding in his group. He is also interested in making an impact on chemical 
regulation by addressing the questions: Which chemicals should be grouped together for mixtures risk assessment? What are scientifically sound 
grouping criteria? He and his team have prepared scientific reports for the European Commission, including the State of the Art Report on Mixture 
Toxicology. Currently they are writing a State of the Art Assessment for Endocrine Disrupters, a project also commissioned by the European 
Commission.  Another research interest his team is unravelling is related to estrogen signalling and estrogen-mediated effects with a view to 
understanding hormonal cancers, especially breast cancer. This is an area of research where he collaborates closely with Dr Elisabete Silva. 
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Lead Authors 
Sustained Proliferative Signalling 
 
Wilhelm Engström, MD (Sweden) - Professor of Pathology in the Department of Biosciences and Veterinary Public Health, Faculty of 
Veterinary Medicine, Swedish University of Agricultural Sciences. Dr. Engstrom’s research has primarily been focused on cell cycle 
regulation and growth factor gene transcription control. His most recent research has focused on fibrous proteins and the relationship 
between protein structure and biomechanics, as well as epigenetic regulation of growth factor gene expression. He is Chairman of The 
European Cell Proliferation Society, and a Fellow of both the Royal Society of Sciences in Uppsala and the Royal College of Pathologists (UK).  
 
Evading Growth Suppressors 
 
Rita Nahta, PhD (USA) - Assistant Professor at the Emory University School of Medicine, Department of Pharmacology, and the Winship 
Cancer Institute, Emory University in Atlanta, Georgia. Dr Nahta focuses on the biological and therapeutic implications of growth factor 
signaling crosstalk in breast cancer. Significant advances in the treatment of metastatic breast cancer include the development of therapies 
targeted against specific cancer-causing molecules. However, the success of these mono-targeted therapies is often limited by cross-talk 
between multiple signaling pathways. Dr Nahta is specifically interested in understanding how cross-talk between HER2 and other growth 
factor signaling pathways affects the biology of HER2-overexpressing breast cancers, including how signaling cross-talk promotes resistance 
to targeted therapies. 
Resisting Cell Death 
 
Hyun Ho Park, PhD (South Korea) – Assistant professor at the Yeungnam University. Dr. Park’s group studies protein-protein interactions 
involved in the intracellular signaling that are closely linked to human health and disease, with an emphasis on cancer. Their main targets 
are cell death signaling pathways (apoptosis, necrosis, and autophagy), using X-ray crystallography in conjunction with other biochemical 
and biophysical methods to elucidate the interaction mechanism and protein-protein interface (PPI) at the atomic level. The ultimate goal 
of Dr Park’s research team is to develop chemical or peptide drugs that can regulate targeted signaling pathways. 
Replicative Immortality 
 
Rob Newbold PhD, DSc (UK) - Director of Brunel Institute of Cancer Genetics and Pharmacogenomics at Brunel University, Uxbridge, UK. Dr 
Newbold’s institutewas established in 2000 with the primary aim of identifying and characterizing new genes and molecular pathways 
involved in human cancer development that can be exploited as targets for novel therapeutic intervention. Other major aims include 
identification of novel cancer related DNA repair genes, molecular characterization of the role of telomeres in DNA repair, identification of 
novel human DNA repair genes influencing radiosensitivity and the identification of novel T-cell mechanisms in human tumor immunology. 
Emphasis continues to be placed on translational research. 
 
Tumor Promoting  Inflammation 
 
Patricia Thompson PhD (USA) - Associate Professor and Director of the Cancer Prevention and Control Program at the University of 
Arizona. Dr. Thompson is a molecular epidemiologist whose research in breast cancer includes development of molecular marker based 
risk prediction models of early stage breast cancer to guide patient decision making about treatment. She also has an active research 
interest in chemoprevention of breast cancer targeting high risk patient populations using non-hormone based therapies like non-steroidal 
anti-inflammatory agents. She focuses on research related to primary and secondary prevention of colon and breast cancer, and has a 
specific interest in the role of inflammation in carcinogenesis and the factors that contribute to inflammation. 
Evading Immune Destruction 
 
H. Kim Lyerly MD (USA) - Professor of Cancer Research at Duke University and a senior member of the Duke global health team. He was, until 
recently, the director of the Duke Comprehensive Cancer Center. In 2008, Dr. Lyerly was appointed to the National Cancer Advisory Board by 
President George Bush. He was also named by his peers as one of North Carolina's most outstanding clinical physicians and was invited by 
North Carolina Governor Michael Easley to serve on the Advisory Commission of the NC State Museum of Natural Sciences. Dr. Lyerly has been 
a faculty member of the AACR/ASCO Methods in Clinical Cancer Research, and has served as a faculty member of ACORD Workshops. He is 
currently a member of the Scientific Advisory Board of Susan G. Komen for the Cure and the Burroughs Wellcome Foundation. He has 
previously served as chairperson of the executive committee of the integration panel of the Congressionally Directed Medical Research 
Programs in Breast Cancer. He also serves on American Society of Clinical Oncology's (ASCO) Grants Selection Committee, of which he served 
as chair in 2006. Dr. Lyerly is a member of the American College of Surgeons, of which he is a fellow. 
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Tissue Invasion and Metastasis 
 
Josiah Ochieng, PhD (USA) - Professor in the Department of Cancer Biology and Director of the Cancer Biology Program at Meharry Medical 
College in Nashville, Tennessee. Dr. Ochieng has investigated the role of fetuin-A (a liver derived glycoprotein) in the progression of solid 
tumors for the past several years.  The working hypothesis for this project is that fetuin-A, promotes tumor cell growth via exosomes that 
mediate adhesive and motility signaling mechanisms.   Dr. Ochieng believes fetuin-A is not only relevant in the in vitro cell growth (it is the 
major serum protein in fetal bovine serum) but more importantly, in the in vivo growth of tumor cells in rodents and humans. Cell and 
molecular biology techniques are routinely used to uncover the mechanisms involved. He believes the exosomes released by fetuin-A in 
tumor cells are major growth, motility and invasion drivers during cancer metastasis. The long term goal is to define the growth mechanisms 
involved in this novel pathway to enable us to design small molecules capable of blocking specific stages of the pathway to blunt or abrogate 
tumor cell growth in vivo. 
 
Reprogramming Energy Metabolism 
  
R. Brooks Robey, MD (USA) - Dr. Robey is the Associate Chief of Staff for Research, Chief of Nephrology at the White River Junction VA 
Medical Center as well as a funded biological laboratory science investigator. He has been at White River Junction since 2005 and holds a 
dual appointment Associate Professor of Medicine and of Physiology, Dartmouth Medical School and Faculty Program in Experimental and 
Molecular Medicine. Dr. Robey's lab studies the regulation and function of hexokinases which play a central role in glucose uptake and 




Zhiwei Hu MD, PhD (USA) - Research Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale 
School of Medicine. Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature for 
development of novel dual neovascular- and cancer cell-targeted therapy for cancer. Currently his laboratory is focusing on further 
elucidating the mechanisms of action and improving the efficacy of factor VII-targeted immunotherapy and photodynamic therapy for 
human cancers. His laboratory is also studying tumor angiogenesis, natural killer cells and cancer stem cells and their interaction in tumor 
microenvironment. Dr. Hu is member of the Yale Cancer Center, American Association for Cancer Research, and The American Association 
of Immunologists. Dr. Hu is a peer reviewer for numerous scientific journals in immunology, photodynamic therapy and cancer research 
and serves as an editor or editorial (review)/board member of The Journal of Immune Based Therapies, Vaccines and Antimicrobials, The 
Journal of Analytical & Bioanalytical Techniques, The Journal of Solid Tumors and Open Journal of Immunology. Starting February 2012, 
Dr. Hu serves as Editor-in-Chief of The Journal of Analytical & Bioanalytical Techniques. 
Genetic Instabiliy 
 
Firouz Darroudi MD, PhD (The Netherlands) - Senior research scientist in Radiation Genetics and Chemical Mutagenesis at the 
Department of Toxicogenetics, Leiden University Medical Centre in The Netherlands. Dr Darroudi has 30 years of experience in Radiation 
Genetics and Chemical Mutagenesis, and in classical and state of art cytogenetics. Dr Darroudi has explored the application of different 
cytogenetic assays such as dicentric, micronuclei, premature chromosome condensation and fluorescence in situ hybridization (FISH)-
based translocation assays for biological dosimetry following acute and chronic exposure in scenarios of accidental and occupational 
exposure. Dr Darroudi has contributed to the development and application of new FISH assays, such as multi-colour FISH, M-FISH and 
application of telomeric probe with chromosome painting probes and pancentromeric probes to investigate the origin of radiation 
induced chromosomal aberrations, mechanisms , spectra, and repair kinetics and to assess biological dosimetry, immediately and 
retrospectively. Moreover, he has been involved in pioneering development and validation of in vitro assays as alternatives to use of 
vertebrate animals to detect and characterize genotoxic, anti- and co-genotoxic potential of human dietary components. He is leading and 
coordinating the section of genotoxicity/carcinogenicity of Global Harmonization Initiative Platform. He is also a senior consultant to 
WHO, UNESCO and IAEA on biological dosimetry  
 
The Tumor Microenvironment 
 
Dean Felsher, MD, PhD (USA) - Associate Professor of Medicine and of Pathology at Stanford School of Medicine, Stanford University, 
California, USA. Dr Felsher’s research interests include both basic science and translational research studies that investigate how 
oncogenes initiate and sustain tumorigenesis. He is a 1996 Lymphatic Research Foundation Fellow and 2001 Junior Faculty Award 
Recipient. His laboratory has developed model systems that can conditionally activate oncogenes in normal human and mouse cells in 
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Introduction 
This document has been produced by Getting to Know Cancer, a non-profit organization that is based in Nova 
Scotia, Canada and focused on integrative cancer research.  The document is intended to provide guidance to 
contributing authors who have been selected to participate in the Halifax Project task force that will be focused on 
“Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment”.    
 
As you well know, the impact of cancer on society is an enormous burden that exacts an incredible toll.   And while 
the precise percentage of cancers that can be attributed to environmental causes (i.e., those that are not lifestyle-
related) remains a matter of considerable contention, we believe that the historical scientific and regulatory 
emphasis on “mutagens as carcinogens” and the ongoing search for individual chemicals and precisely defined 
mixtures that are “complete” carcinogens (i.e., can cause cancer on their own) is an incomplete approach that has 
serious limitations.   
 
The last few decades have given us breathtaking advances in our understanding of the disease. Mutation research 
has shown us that cancer can be enabled by a series of key events, and chemical exposure research has shown us 
that many of these key events can be independently instigated.  So it now appears that a prohibitively narrow focus 
on the carcinogenicity of individual chemicals or precisely defined mixtures may underestimate the carcinogenic 
synergies of complex mixture effects that are encountered in the environment.  For example, while a chemical that 
disrupts DNA repair may not be carcinogenic at any dose level, it may actually be quite an important enabling factor 
in the presence of other mutagens that cause DNA damage.  Similarly, a chemical that has immuno-suppressive 
qualities may not be carcinogenic on its own, but it may serve as an important contributing factor in the presence 
of other disruptive chemicals that would normally have only weak carcinogenic potential.   
 
In other words, since many key events are involved in the multi-step process that leads to the cancer, it now 
appears plausible that ongoing exposures to complex mixtures of disruptive chemicals in the environment may be 
capable of carcinogenic effects that have yet to be fully appreciated.  Accordingly, this project is aimed at studying 
the fundamental nature of this problem, because we believe that this line of inquiry will have relevance for a wide 
range of stakeholders.   
 
So thank you for your willingness to get involved in this initiative.  We appreciate your commitment to this 
important line of inquiry and we are confident that this task force is going to produce a body of work that will be 





President and Cofounder  
Getting to Know Cancer 
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Background 
In 1981 Richard Doll and Richard Peto wrote a landmark paper in the Journal of the National Cancer Institute called 
“The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today”.   In that 
article the authors looked at ranges of acceptable estimates for the proportion of cancer deaths that could be 
attributed to various factors and then offered a series of best estimates for causation.  The results of this study can 
be summarized as follows: 
 
 
Lifestyle – related Factors 
 Diet    35% 
 Tobacco    30% 
 Infection     10%  
 Reproductive and sexual behaviour  7%  
 Alcohol    3%  
 Geophysical  (mainly solar radiation) 3%  
 Medicines and medical procedures 1% 
 
Other Chemical Exposures 
 Occupation    4% 
 Pollution    2% 
 Industrial Products    <1% 
 Food additives     <1% 
 






Figure 1 – Table compiled from estimates found in Doll R, Peto R, The causes of cancer: quantitative estimates of  
avoidable risks of cancer in the United States today, J Natl Cancer Inst. 1981 Jun; 66(6):1191-308. 
 
This extensive study was well received at the time and it would become a landmark reference for best estimates of 
cancer causation in the decades that followed.  In essence, the paper gave the impression that we understood 97% 
of the causative factors (only 3% of causation unknown) and it also suggested that industrial sources (e.g., 
occupational exposures and pollution) and chemicals in foods were a very small part of the problem.   
 
This work did not go entirely unchallenged.  German researchers (Schmähl et al, “Causes of cancer--an alternative 
view to Doll and Peto (1981)”, 1989) later argued that the cause of only one third of all cancers in Germany could 
realistically be attributed to known sources, and that the 97% of attribution offered by Doll and Peto was 
unrealistically high.  Davis et al, (“Trends in cancer mortality in industrial countries” (1989) and Landrigan et al 
(“Cancer Prevention and Control”, 1995) also critiqued the methods used, the conclusions reached and the degree 
of certainty implied in Doll and Peto’s estimates.   But in 1996, the Harvard Center for Cancer Prevention published 
a volume on causes of human cancer in which they updated Doll and Peto’s estimates of “avoidable causes”, and 
that summary essentially duplicated the earlier estimates of the proportion of cancer deaths attributed to 
environmental pollution and occupation.   
 
As a result, momentum began to develop that placed an emphasis on lifestyle factors as the main causative 
influences of cancer, and a corresponding lack of emphasis was given to other factors.  Indeed, the lifestyle-factors 
bias has become a deeply entrenched paradigm over the past three decades and it has had a significant influence 
on cancer-related prevention policies in Western nations. Prevention-related research has been heavily skewed 
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towards studies that improve our understanding of lifestyle-related factors while prevention programs have 
focused heavily on initiatives aimed at changing population-level behaviors.   While researchers who have been 
focused on chemical exposures in the environment from industrial sources (e.g. pollution and occupational) and 
chemicals in foods have received much less attention and funding.   
 
However, when Sir Richard Doll died in 2005, it was discovered in his private papers that he had been receiving 
undisclosed consultancy payments from Monsanto from 1976 to 2002, and that he had also received money from 
companies whose products he had defended in court and in the academic literature. This included a longstanding 
financial relationship with Turner and Newall (the asbestos company), payments from General Motors (for work he 
did on lead as a gasoline additive), and money paid to him by the Chemical Manufacturers’ Association (for 
research he did on Vinyl Chloride), which caused some observers to revisit his work.  Some observers have since 
raised the issue of potential for bias, and a certain amount of renewed scrutiny was placed on the estimates that he 
and Richard Peto assigned to industry-related causes in their seminal report in 1981.   
 
Clapp et al. challenged these estimates again in 2006 (”Environmental and Occupational Causes of Cancer Re-
visited”) calling for a renewed emphasis on occupational and industrial exposures.  And more recently, in a special 
issue of the British Journal of Cancer titled “The Fraction of Cancer Attributable to Lifestyle and Environmental 
Factors in the UK in 2010“  http://www.nature.com/bjc/journal/v105/n2s/index.html , epidemiologists estimated 
that the fraction of cancer that can now be attributed to both lifestyle and environmental factors is only 43%.   In 
other words, more than 30 years after Doll and Peto’s landmark report which implied so much certainty about 
causal attribution, it seems that we are now far less certain about the causes of cancer than ever before.  Ironically, 
it was Sir Richard Peto (i.e., Sir Richard Doll’s co-author from the landmark work in 1981) who wrote the forward to 
this special issue in the British Journal of Cancer, so we contacted him directly by email in 2012 to ask him what he 
thought might account for the other 57% of cancer causation.  In his brief reply he simply offered that this 
was  “…probably due to undiscovered avoidable causes”.    
 
So we are working on the assumption that “other chemical exposures” may be more of an issue than many have 
been led to believe.  This was certainly the message in the 2008-2009 President’s Cancer Panel Annual Report in 
the United States titled “Reducing Environmental Cancer Risk: What We Can Do Now”.  In that report the authors 
noted that the “true burden of environmentally induced cancer has been grossly underestimated”, and they 
pointed to the fact that there are “nearly 80,000 chemicals on the market in the United States, many of which are 
used by millions of Americans in their daily lives and are un- or understudied and largely unregulated” and that 
“exposure to potential environmental carcinogens is widespread”.   
 
Nonetheless, critics of these assertions have subsequently argued that there is not good evidence to substantiate 
these concerns.  But unfortunately, there doesn’t appear to be any unequivocal evidence to resolve this debate.  A  
recent and extensive review of the epidemiological literature that was undertaken by McGuinn et al at the Division 
of Cancer Control and Population Sciences at the National Cancer Institute, USA (“Cancer and environment: 
definitions and misconceptions”, 2012) determined that a reliable estimate for the proportion of cancers 
attributable to environmental factors is currently unavailable (citing wide discrepancies in definitions, methodology 
and approaches to reporting). So with considerable uncertainty remaining in the area of causal attribution, we 
simply believe that cancer scientists need to remain open to the ways in which cancer may be caused.  
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In some of the earliest research on the carcinogenic effects of exposures to tobacco smoke, researchers were 
perplexed by the fact that many smokers didn’t get cancer.  However the last two decades of scientific advances 
have helped us to understand that there are several important lines of biological defense that must be defeated or 
bypassed before cancer can be caused by chemical exposures.  For example, normal xenobiotic metabolism and 
detoxification act as a first line of defense, then DNA repair systems can address a wide range of damage, while 
cell-cycle controls can prevent cellular replication when repairs are being undertaken. Moreover, apoptosis can 
ensure that lineages of dysfunctional cells aren’t replicated, properly functioning senescence can prevent sustained 
proliferation, and many immune system components also function to suppress tumors. In other words, we have a 
fault-tolerant biological system that can handle many defects and still suppress tumors under most conditions.   
 
Unfortunately, this multi-layered system of defenses has complicated matters from a research perspective, and it 
has made testing for carcinogenicity rather difficult.  In the field of environmental health, researchers are often 
faced with inconsistent results in “in vivo” exposure testing of single chemicals and precisely defined mixtures 
because there are very few chemicals that can disrupt all of these lines of defense simultaneously.  So tumor 
production in test animals is frequently inconsistent and subject to considerable variability. Consequently, the 
degree of carcinogenicity that can be attributed to any single chemical is often subject to interpretation and results 
can be contentious.  The International Agency for Research on Cancer (IARC) and many other prominent 
environmental/regulatory agencies worldwide have had to grapple with this issue and they have adopted 
classification systems that acknowledge this uncertainty by using terms such as “possibly carcinogenic to humans”, 
“probably carcinogenic to humans”, “carcinogenic to humans” etc..   
 
In regulatory work, matters are also not straight forward.  Cancer researchers and regulators have established 
methods for in vivo carcinogenicity testing of chemicals in rodents that typically involve high dose exposures to 
establish toxicity tolerance followed by a series of lower dose exposure experiments.  When clear evidence of 
carcinogenicity is found at higher dose levels, tests at lower dose levels are then conducted and the results 
scrutinized until a “no observable effect level” can be seen.  In many instances, safety margins for exposure are 
then estimated using linear extrapolations and safe levels of exposure are estimated for regulatory purposes.   
 
However, in a recent review of low dose effects by Vandenberg et al (“Hormones and endocrine-disrupting 
chemicals: low-dose effects and non-monotonic dose responses” June 2012), the team produced an impressive set 
of arguments that challenges the very basis of this logic.  This group of authors presented a substantial review of 
the literature and provided a detailed discussion of the mechanisms responsible for generating low dose effects 
(those that occur in the range of human exposures or effects observed at doses below those used for traditional 
toxicological studies) and non-monotonic dose-response curves (defined as a nonlinear relationship between dose 
and effect where the slope of the curve changes sign somewhere within the range of doses examined).  By offering 
hundreds of examples from the cell culture, animal, and epidemiology literature, the team cogently explains that 
non-monotonic responses and low-dose effects are remarkably common in studies of natural hormones and 
endocrine disrupting chemicals. And they conclude by noting that when non-monotonic dose-response curves 
occur, the effects of low doses cannot be predicted by the effects observed at high doses.   
 
While endocrine disruption research has been primarily aimed at chemicals that disrupt a relatively small subset of 
hormones (e.g., estrogen, androgen, thyroid etc.), it has revealed a wide range of disruptive biological effects from 
a great number of commonly encountered chemicals that appear to be more potent at low dose levels of exposure 
than they are at higher dose levels of exposure.  This has important implications for cancer research because we 
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have sought in the past to identify complete carcinogens (i.e., individual agents or precisely defined mixtures that 
can cause cancer) and limit our exposures to those chemicals, but we have done so using safety margins for many 
chemicals that have been founded on assumptions of dose-response linearity.  Yet it is now apparent that these 
assumptions may not always hold true and that casts considerable doubt on the validity of the safe exposure levels 
that we have developed using these assumptions. 
 
Furthermore, and perhaps most importantly, the current approaches to testing simply do not contemplate the 
carcinogenic potential of mixtures of biologically disruptive chemicals.  It is now known that many of the hallmark 
mechanisms of cancer can be enabled by individual chemicals, so it is conceivable that mixtures may actually be 
needed to dismantle the many lines of biological defense that would otherwise serve to obfuscate and/or diffuse 
the potency of an exposure to any given chemical.   
When we combine the issue of low dose effects with the possibility for synergism amongst mixtures of chemicals in 
the environment, we believe that we may be facing a substantial problem that needs to be better articulated.  So 
this project will consider the ways in which low dose exposures to combinations of disruptive, but otherwise non-
carcinogenic, environmental chemicals may be combining to instigate the disease.  It is not a trivial matter, and 
very little research has been done on this issue so far, but this task force has been created to study this issue.  
 
The Approach 
To study this problem, an expansive and rapidly growing body of cancer research will need to be considered, so this 
project has been conceived using a task force model.  Nearly 300 formal expressions of interest have been received 
from a wide range of senior cancer researchers from around the globe.  And a “first principles” approach is going to 
be used for this project.  Eleven teams will be formed to allow us to encompass as much of the cancer research 
literature as possible.    A 2-day workshop will then take place in Halifax, Nova Scotia in August 2013 (i.e., part way 
through the project) so the teams will have an opportunity to come together for discussion and to work through a 
series of important issues that will require considerable collaboration.  This will lay the groundwork for a post-
workshop synthesis that will result in a capstone article that will be jointly authored by all of the teams to capture 
some of the collaborative work, prepare a set of consensus statements and formulate recommendations of the task 
force.   
 
The specific objectives that are being pursued in this project can be summarized as follows.  Specifically we plan to 
produce: 
 A foundational series of research design recommendations that will lay the groundwork for future research 
that will be able to demonstrate the carcinogenic potential of low dose exposures to mixtures of disruptive 
chemicals in the environment 
 
 Suggestions and guidance that will help global regulators introduce more effective risk assessment 
strategies that can better account for the carcinogenic risks associated with low dose exposures to mixtures 
of disruptive chemicals in the environment 
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 Precautionary advice that can be used by physicians and other health-care professionals to help cancer 
patients, cancer survivors and other high-risk individuals who need to avoid environmental exposures that 
may have the potential to contribute to the onset or recurrence of the disease. 
 
The Scope of the Planned Reviews  
Since this is a large scale problem that needs to be studied in a holistic manner, we have decided that a series of 
overarching reviews will be undertaken that can collectively assess the key events that enable the various hallmarks 
of the disease, and also identify a roster of selectively disruptive chemicals that are ubiquitous in the environment, 
not related to “lifestyle factors” and potentially causing adverse (i.e., carcinogenic) effects when combined.  If 
combinations of chemicals in the environment are causing cancer in the general population in a way that has yet to 
be fully appreciated or recognized, we believe that we should be able to reverse-engineer the problem by 
identifying the most likely offenders and laying out a testing strategy to determine whether or not the concerns 
that have been raised by so many are indeed a threat to population-level health.  
To that end, the “Hallmarks of Cancer” framework (Hanahan and Weinberg, 2000 and 2011) was used to help us 
develop an initial organizing framework for the many key events that are known to be important in all cancer types 
and we settled on eleven overarching review topics –as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
11. The Tumor Microenvironment 
 
Each of these topics will be tackled by a separate team and each of the contributing authors on each team will be 
provided with an electronic copy of both Hallmarks of Cancer reviews (Hanahan and Weinberg, 2000 and 2011).  
Each team will then be expected to review one of these topics.  However, the Hallmarks of Cancer framework as a 
very broad review is, by necessity, quite succinct (since each of these topic areas are underpinned by a very large 
body of scientific literature).  So the lead authors who are spearheading the reviews will all have a degree of 
latitude in the way in which they approach each topic area.   
 
 Page 8 
 
For example, if your team identifiers subtopics that aren’t mentioned in the Hanahan and Weinberg framework, 
the team can include that detail in the review so long as it doesn’t create overlap with any of the other work that is 
being done by any of the other teams.  If there is a subtopic that needs to be covered by the team, you team leader 
has been asked to look specifically at the composition of the team to ensure you have the expertise to cover it.   
And if there is any other ambiguity over what should or shouldn’t be included in your particular review, your team 
leader has been asked to contact Leroy Lowe (leroy.lowe@gettingtoknowcancer.org) with the details so he can 
liaise with the organizing committee as needed to provide additional clarification.   
The goal of each of the individual reviews is to undertake a high-level review of each domain, while also considering 
the most important ways in which each of these areas can be chemically disrupted.    
As a starting point for prioritization, some assistance can be gleaned from the work that is emerging in the many 
cancer genome projects that are beginning to help us categorize mutations for each cancer type.   Sian Jones et al. 
authored one of the early studies that mapped these mutations in a 2008 article in Science titled “Core Signaling 
Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses”.  This is seen as an important paper 
because the authors performed a comprehensive genetic analysis of 24 pancreatic cancers by determining the 
sequences of 23,219 transcripts, representing 20,661 protein-coding genes, and they searched for homozygous 
deletions and amplifications in the tumor DNA and they found that pancreatic cancers contain an average of 63 
genetic alterations, the majority of which are point mutations. Then they organized the alterations and defined a 
core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the 
tumors (see Figure 2 below).   
 
Figure 2 - The 12 pathways and processes whose component genes were genetically altered in most pancreatic cance rs 
 
While this research was only focused on a single cancer type, one of the contributing authors to that project was 
Dr. Bert Vogelstein and he has since been tracking the results of 852 studies that have now been published 
describing the genomes of 23 different cancers.   At a recent NIH lecture (Feb 2012), Vogelstein explained that 
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researchers have generated vast amounts of data about cancer genomes in more than 125 whole genome studies 
and more than 725 whole exome studies to date which has “really revealed the details of what the cancer genomes 
look like and has greatly illuminated the genetic basis as well as the physiologic basis of cancers”.  Surprisingly, 
most cancer tumors have only 20 to 80 key mutations (which includes mutations that affect coding for amino acids 
and with exceptions being in tumors that have a DNA repair defect where a rapid accumulation of mutations per 
tumor can be expected).   So we now know that the mutation rate in cancer genomes—at the DNA base-pair 
level—is only marginally higher than for normal cells, but cancers can have other kinds of alterations in their 
genome as well that cause structural changes in tumors, particularly deletions of tumor suppressor genes, 
amplifications of cancer-promoting oncogenes and translocations of either of those genes1.   
It also appears that the tumors in many cancer types tend to have similar mutations that align themselves with the 
same 12 pathways and processes that were initially found to be disrupted in pancreatic cancer.  So as part of your 
analysis, your team should look at each of these 12 pathways and processes to determine which of them are 
relevant for the area that your team is reviewing.    
These reviews should also consider non-mutagenic/epigenetic pathways of interference as well.  Epigenetic 
changes such as DNA methylation and histone acetylation are known to be relevant for cancer and these sorts of 
modifications are also known to be chemically inducible directly. 
Practical Emphasis 
It is crucial to bear in mind that our first objective of this initiative is to produce a foundational series of research 
design recommendations that will lay the groundwork for future research that will be able to demonstrate whether 
or not low dose exposures to mixtures of disruptive chemicals in the environment have carcinogenic potential.  So 
while each of the teams is being tasked to undertake a traditional academic review of their topic area, it’s not 
enough to just highlight the main pathways and mechanisms that are relevant for the area under study.  The 
highest priority biomarkers in that area (i.e. target sites for disruption that will have the greatest effect on disease 
progression) also need to be identified, and we need the discussion and conclusion sections of each paper to be 
focused in a manner that will feed directly into the research challenge that will follow.   
Specifically, the task force will be asked to use the information gleaned from these reviews to make 
recommendations for future research that help us to investigate whether or not chronic exposure to low doses of a 
carefully selected mixture of (selectively disruptive) chemicals that are ubiquitous in the environment cause cancer.   
Therefore each team should ultimately produce and include a short list of no more than ten prioritized biological 
target sites for disruption (rank ordered if possible, based on estimation of importance) for their area of concern.  A 
“target” could be at the system level (e.g., the stress-axis”), organ level, tissue level, or cellular-level.   And for each 
of the prioritized targets, a single favored approach for chemical disruption should be identified from the literature 
and recommended for inclusion.   
In many cases, there could be many possible disruptive chemicals that might be suitable choices for the prioritized 
target sites for disruption that the team has identified.  The following criteria can be used to help your team in this 
regard: 
                                                             
1
 Extracted from the NIH Record article Vogelstein Considers Cancer Genome at Trent Lecture By Raymond MacDougall 
http://nihrecord.od.nih.gov 
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 Ubiquitous in the Environment - A “favored” chemical should be one that is ubiquitous in the environment.  
This is important because we want to produce a set of disruptive chemicals that, in principle, have the 
broadest possible relevance for the population at large.  
  
 Selectively Disruptive – Greatest potential to achieve the desired action on the intended target site for 
disruption across the widest possible range of cancer types.  For example, chemicals that are agonists or 
antagonists of specific receptors would be suitable choices. Similarly, chemical mutagens that tend to 
consistently produce adducts or damage that impacts a specific pathway or mechanism would be 
acceptable.  However, mutagens that cause indiscriminate damage across a wide range of pathways should 
be avoided.  
 
 Not “lifestyle” related – A tremendous amount of research has already gone into lifestyle factors of 
causation such as tobacco, poor diet choices (e.g., red meats, french fries, lack of fruit and vegetables, etc.), 
alcohol consumption, obesity, excessive sun exposure, infections (e.g., HPV) etc.  In this project we are 
interested in chemicals that may have received much less attention because they are not associated with 
“poor” lifestyle decisions. 
 
 Not a Known “Carcinogen to Humans” - The task force should focus on selectively disruptive agents that 
are not currently known as carcinogenic to humans.   
Ultimately, we want each team to produce specific recommendations for a multi-pronged approach for chemical 
disruption in their respective areas of study.  These combinations should have the potential to be disruptive in a 
manner that will be complementary to the actions of the disruptive chemicals that will be suggested by the other 
teams.   Currently, testing in the literature that involves mixture effects is often limited in scope (e.g., two or three 
chemicals) due to variable constraints that are often invoked as part of the research design.  But in this project, we 
want to consider the widest possible range of environmental sources of exposure to identify discretely disruptive 
chemicals that are of greatest interest to each of the teams.  If chronic exposure to low doses of this subset of 
environmental chemicals is an issue, we should be able to reverse-engineer the problem and then illustrate these 
effects if we approach the problem systematically.    
In some of the areas of study, there may be a paucity of literature that can support a role for chemical disruption.  
In this situation it will still be important for the team to consider the most critical aspects of cancer biology in their 
area of concern (i.e., target sites for disruption that would, in theory, have the greatest effect on disease 
progression).  This will help the task force in their development of research recommendations and it will also 
provide a useful roadmap for researchers in environmental health (i.e., those who may want to investigate the 
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Format of the Reviews 





Describe the approach being taken and place the research in the context of the larger 
project.   
 
Topic Area Overview  Provide a high-level overview of the progress that has been made in the understanding of 
the area that the team has been tasked to review, with a particular emphasis on the various 
levels of dysfunction that are known to contribute to the enablement of the immortalization 
of cells.  This should include both areas of broad agreement and any major areas of 




Describe any fundamental interactions or relationships that exist between the topic area 





Categorize, and prioritize the target sites for disruption that the team believes will have the 




Using the criteria provided above, identify specific chemicals in the environment that appear 




Drawing on the existing literature in the field of environmental health, provide reflective 
commentary on whether or not it appears likely that environmental chemical exposures 
have been suspected as being disruptive in the area under review.  Also consider the effect 
of synergies that would be realized if all of the prioritized targets are simultaneously 






Each review should be approximately twenty pages in length including references.  Oxford’s Carcinogenesis journal 
format allows for roughly 1200 words per page (this is obviously affected by any artwork or tables that are needed).  





Assembling the Teams 
 
We now have nearly 300 expressions of interest from researchers who want to take part in the project.  Our first 
priority is to quickly assemble the teams that are needed.  Eleven lead authors have been recruited, and we are 
envisioning eleven teams that will each have 10-12 contributing authors.  As a contributing author for one of the 
teams, you have been selected based on your own research and your team leader’s assessment of your ability to 
contribute to the review that needs to be produced.   
 
The team composition is intended to be cross-functional and roughly align itself with the following structure:   
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1. Domain Experts -   The team lead for each of the eleven chosen topics is to be supported by other experts 
who will collectively be responsible for producing a descriptive overview that encompasses the topic area, as 
well as a description of the types of systemic or cellular-level dysfunction in that topic area that contribute to 
the immortalization of cancerous cells, any relationships that exist between that particular topic and the other 
topic areas under consideration, and a reflective strategic commentary.  Given the scale of the cancer genome, 
the task of this group will be to produce a compact synthesis of the literature that categorizes and prioritizes 
target targets for disruption.  
 
2. Environmental Health Specialists – Each team will also have a number of cancer scientists who specialize in 
exposure based cancer research (i.e., those who investigate the carcinogenic effects of chemicals found in the 
environment).  Their backgrounds could be in epidemiology, traditional toxicology, endocrine disruption and/or 
other related fields.  Whatever their specialty, it is important they have a good grasp of cancer biology and 
experience in the field of environmental health because they will be asked to help the team identify selectively 
disruptive chemicals that appear well suited to reach the prioritized targets. 
 
3. Assisting Researchers – All scientists who are selected to join the task force will also be able to nominate a 
single assisting researcher (e.g. colleague, post-doctoral researcher, or PhD candidate) within their own lab to 
participate in the team’s work at no extra cost.  These researchers will receive authorship recognition for their 
contributions to the team’s work.  However, in instances where a support researcher has been nominated as a 
contributing author, only one of the two (i.e., the nominator or the nominee) will be able to attend the 
workshop in Halifax in August of 2013.  This policy is mainly intended to help senior researchers alleviate their 
workload and to give more junior researchers an opportunity to get involved, but it is also intended to ensure 
that the number of attendees at the working sessions in Halifax remains manageable.  These contributing 
authors will need to be identified as soon as the teams are fully assembled.   
 
We expect that your team will ultimately be comprised of 10-12 researchers, but the exact number of team 
members will ultimately be collaboratively determined based on the suggestions and inputs put forward by each 
team lead, and on inputs from the Getting to Know Cancer President, Leroy Lowe.  We have some flexibility in the 
numbers needed for team construction and we will be working work with each team lead to ensure that every 
team has the expertise needed to successfully complete the task.    
 
The Biomarker and Approach Validation Team  
All of the teams will also have the support of a substantial, cross-functional group of scientists who will be part of 
the “Biomarker and Disruptor Validation Team”.   This team will validate the prioritized targets and disruptive 
chemicals that are selected by each team by taking target and chemical recommendations and then conducting 
background literature research to identify instances when a particular target or chemical that is of interest to one 
of the teams also has relevance for the topics being studied by other teams.   
 
For example, if the team reviewing sustained proliferative signalling selected HER-2 (the EGFR receptor) as a 
prioritized disruption site, the Biomarker and Disruptor Validation Team would then review the literature to 
determine whether or not disruptive action at that particular site would be expected to produce complementary 
contributions for any of the other areas under review (see Figure 3 shown below).  This same process will be 
undertaken for all of prioritized disruption sites that are selected by each of the teams.  And similarly, all of the 
disruptive chemicals that are selected by the teams will be reviewed in a similar manner. 
 









If the task force is going to focus on future research that will involve a mixture of selectively disruptive chemicals 
that are carcinogenic at environmentally relevant dose levels, it will be important to ensure that none of the 
selections being made by any of the teams are working at cross purposes to the recommendations being made by 
the other teams. So these validation efforts and inputs will be very important, and they will be captured in tabular 
form in each of the planned reviews, and the contributions of this team will also be acknowledged and credited in 
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Capstone Synthesis and Review 
When all of the initial reviews are beginning to take form (first draft is due July 1st, 2013), the goal is to have an 
initial inventory of prioritized sites for disruption and a corresponding list of selectively disruptive chemicals that 
can be considered as part of a complex mixture that will be suitable for future testing.  At the two day workshop in 
Halifax, Nova Scotia in August of 2013, these inputs will then be used to help the task force assess whether or not 
they feel that that there are enough known disruptors in each area to consider this issue important, and to develop 
a foundational series of research design recommendations that will lay the groundwork for future research that will 
allow us  to investigate the carcinogenic potential of low dose exposures to mixtures of disruptive chemicals in the 
environment. 
Additionally, a number of presentations and workshops will be organized to help the task force develop suggestions 
and guidance that will help global regulators introduce more effective risk assessment strategies that can better 
account for the carcinogenic risks associated with low dose exposures to mixtures of disruptive chemicals in the 
environment.  And we will discuss the possibility of offering precautionary advice that could, in theory, be used by 
physicians and other health-care professionals to help cancer patients, cancer survivors and other high-risk 
individuals who need to avoid environmental exposures that may have the potential to contribute to the onset of 
the disease. 
The workshop will involve presentations and a collaborative series of meetings and the lead authors from each of 
the teams will subsequently collaborate to help the organizing committee produce a capstone synthesis and review 
that will summarize the integrated findings from the workshop and make recommendations for the way ahead.  
This work will be circulated for review and inputs from all of the team members and all of the contributing authors 
on the task force will therefore also be named as authors of this final article.    
Timelines 
Key dates for the various aspects of the project are as follows:  
 
 Lead Authors Appointed:   Dec 20th, 2012 
 Teams Fully Assembled;   January 31st, 2012 
 First Draft of Individual Reviews:  July 1st, 2013 
 Halifax 2-day Workshop:   August 7th-8th , 2013 
 Final Draft of Individual Reviews November 1st, 2013 
 Final Draft of Capstone Synthesis November 15th, 2013 
 
Fees 
A task force participation fee of $475 USD is being levied on all participants, mainly for shared costs related to the 
publication of the articles that will be in a special issue of a peer-reviewed journal “Assessing the Carcinogenic 
Potential of Low Dose Exposures to Chemical Mixtures in the Environment”. 
 
Questions 
If any aspect of this document is not clear, or if you want clarification on any aspect of the project, please contact 
Leroy Lowe ( leroy.lowe@gettingtoknowcancer.org ) ASAP and we will provide additional guidance as needed.  




David O. Carpenter, MD - Director, Institute for Health and the Environment, University at Albany, SUNY, New York, USA. Dr Carpenter’s research is 
focused on investigations into the modes and causes of human disease using both animal model systems, humans as experimental subjects and 
analysis of human illness databases to elucidate the mechanistic basis and distribution of various human diseases. He is mainly focused on the 
relationship between exposure to environmental chemicals and risk of chronic diseases, including cancer, diabetes, hypertension and 
cardiovascular disease. In some of these studies he and his group obtain medical information, blood or urine for clinical chemistry indicators and for 
levels of environmental contaminants (PCBs, pesticides, radioactivity, etc.) in order to determine relationships between exposure and development 
of disease. In other studies he and his colleagues utilize state datasets for birth, death or hospitalization in order to correlate factors such as place 
of residence in relation to proximity to waste sites or socioeconomic class with rates of disease in the whole population.  Recent investigations have 
focused on health effects of air pollution. The Institute for Health and the Environment is a Collaborating Center of the Wor ld Health Organization 
in environmental health. 
 
 
Philippa D. Darbre, PhD - Reader in Oncology, School of Biological Sciences, University of Reading in England. Dr Darbre’s research focuses on the 
cellular and molecular basis of action of oestrogen and oestrogen-mimicking compounds on the development, growth and progression of breast 
cancer cells. Her research is focused on the role of the many environmental chemicals which possess estrogenic activity and which can enter the 
human breast through diet, the domestic environment and use of cosmetic products. Studies are focused on determining the cellular and molecular 
actions of estrogenic compounds which can be measured in the human breast and on trying to understand how exposure to multiple compounds in 
the long-term may impact on breast biology. If exposure to complex mixtures of oestrogenic chemicals is a factor in breast cancer development, 
then a strategy for prevention of breast cancer might become a reality. As well, Dr Darbre has developed human breast cancer cell culture models 
to investigate molecular mechanisms, and studies are currently focused on finding new ways of inhibiting the oestrogen-independent cells which 
might have therapeutic benefit. 
 
 
Thomas Sanderson, PhD - Professor within the Environmental Toxicology and Biotechnology group at the National Institute of Scientific Research 
(INRS) - Institute Armand-Frappier in Quebec, Canada. Dr Sanderson’s research interests concern the interactions of chemicals with the expression 
and function of enzymes involved in steroid biosynthesis, and their relation to the development of hormone-dependent cancers and endocrine 
disruption. Current research activities, funded by the Natural Sciences and Engineering Research Council of Canada (NSERC) and Canadian Institutes 
of Health Research (CIHR) aim to elucidate the mechanism by which a wide variety of chemicals, including environmental contaminants, drugs and 
compounds of natural origin interfere with androgen and estrogen biosynthesis and receptor signalling in human and animal mod els of cancer.  
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Lead Authors 
Sustained Proliferative Signalling 
 
Wilhelm Engström, MD (Sweden) - Professor of Pathology in the Department of Biosciences and Veterinary Public Health, Faculty of 
Veterinary Medicine, Swedish University of Agricultural Sciences. Dr. Engstrom’s research has primarily been focused on cell cycle 
regulation and growth factor gene transcription control. His most recent research has focused on fibrous proteins and the relationship 
between protein structure and biomechanics, as well as epigenetic regulation of growth factor gene expression. He is Chairman of The 
European Cell Proliferation Society, and a Fellow of both the Royal Society of Sciences in Uppsala and the Royal College of Pathologists (UK).  
 
Evading Growth Suppressors 
 
Rita Nahta, PhD (USA) - Assistant Professor at the Emory University School of Medicine, Department of Pharmacology, and the Winship 
Cancer Institute, Emory University in Atlanta, Georgia. Dr Nahta focuses on the biological and therapeutic implications of growth factor 
signaling crosstalk in breast cancer. Significant advances in the treatment of metastatic breast cancer include the development of therapies 
targeted against specific cancer-causing molecules. However, the success of these mono-targeted therapies is often limited by cross-talk 
between multiple signaling pathways. Dr Nahta is specifically interested in understanding how cross-talk between HER2 and other growth 
factor signaling pathways affects the biology of HER2-overexpressing breast cancers, including how signaling cross-talk promotes resistance 
to targeted therapies. 
Resisting Cell Death 
 
Hyun Ho Park, PhD (South Korea) – Assistant professor at the Yeungnam University. Dr. Park’s group studies protein-protein interactions 
involved in the intracellular signaling that are closely linked to human health and disease, with an emphasis on cancer. Thei r main targets 
are cell death signaling pathways (apoptosis, necrosis, and autophagy), using X-ray crystallography in conjunction with other biochemical 
and biophysical methods to elucidate the interaction mechanism and protein-protein interface (PPI) at the atomic level. The ultimate goal 
of Dr Park’s research team is to develop chemical or peptide drugs that can regulate targeted signaling pathways.  
Replicative Immortality 
 
Amancio Carnero Moya, PhD (Spain) - Dr Carnero leads the Molecular Biology of Cancer Lab at the Biomedical Institute of Seville 
(IBIS/CSIC). In the past, his research interests have focused on the ras signal transduction pathway, the cell cycle, senescence and cellular 
immortalization. His lab is currently focused on the identification and characterization of genes with therapeutic relevance in cancer; 
establishing causality in the initiation and progression of the tumoral process; and the validation of new therapeutic targets that could 
form the basis for the identification of new anti-tumor compounds  
Tumor Promoting  Inflammation 
 
Patricia Thompson PhD (USA) - Associate Professor and Director of the Cancer Prevention and Control Program at the University of 
Arizona. Dr. Thompson is a molecular epidemiologist whose research in breast cancer includes development of molecular marker based 
risk prediction models of early stage breast cancer to guide patient decision making about treatment. She also has an active research 
interest in chemoprevention of breast cancer targeting high risk patient populations using non-hormone based therapies like non-steroidal 
anti-inflammatory agents. She focuses on research related to primary and secondary prevention of colon and breast cancer, and has a 
specific interest in the role of inflammation in carcinogenesis and the factors that contribute to inflammation. 
Evading Immune Destruction 
 
H. Kim Lyerly MD (USA) - Professor of Cancer Research at Duke University and a senior member of the Duke global health team. He was, until 
recently, the director of the Duke Comprehensive Cancer Center. In 2008, Dr. Lyerly was appointed to the National Cancer Advisory Board by 
President George Bush. He was also named by his peers as one of North Carolina's most outstanding clinical physicians and was invited by 
North Carolina Governor Michael Easley to serve on the Advisory Commission of the NC State Museum of Natural Sciences. Dr.  Lyerly has been 
a faculty member of the AACR/ASCO Methods in Clinical Cancer Research, and has served as a faculty member of ACORD Workshops.  He is 
currently a member of the Scientific Advisory Board of Susan G. Komen for the Cure and the Burroughs Wellcome Foundation. He has 
previously served as chairperson of the executive committee of the integration panel of the Congressionally Directed Medical Research 
Programs in Breast Cancer. He also serves on American Society of Clinical Oncology's (ASCO) Grants S election Committee, of which he served 
as chair in 2006. Dr. Lyerly is a member of the American College of Surgeons, of which he is a fellow. 
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Tissue Invasion and Metastasis 
 
Josiah Ochieng, PhD (USA) - Professor in the Department of Cancer Biology and Director of the Cancer Biology Program at Meharry Medical 
College in Nashville, Tennessee. Dr. Ochieng has investigated the role of fetuin-A (a liver derived glycoprotein) in the progression of solid 
tumors for the past several years.  The working hypothesis for this project is that fetuin-A, promotes tumor cell growth via exosomes that 
mediate adhesive and motility signaling mechanisms.   Dr. Ochieng believes fetuin-A is not only relevant in the in vitro cell growth (it is the 
major serum protein in fetal bovine serum) but more importantly, in the in vivo growth of tumor cells in rodents and humans. Cell and 
molecular biology techniques are routinely used to uncover the mechanisms involved. He believes the exosomes released by fetuin-A in 
tumor cells are major growth, motility and invasion drivers during cancer metastasis. The long term goal is to define the growth mechanisms 
involved in this novel pathway to enable us to design small molecules capable of blocking specific stages of the pathway to blunt or abrogate 
tumor cell growth in vivo. 
 
Reprogramming Energy Metabolism 
  
R. Brooks Robey, MD (USA) - Dr. Robey is the Associate Chief of Staff for Research, Chief of Nephrology at the White River Junction VA 
Medical Center as well as a funded biological laboratory science investigator. He has been at White River Junction since 2005  and holds a 
dual appointment Associate Professor of Medicine and of Physiology, Dartmouth Medical School and Faculty Program in Experimental and 
Molecular Medicine. Dr. Robey's lab studies the regulation and function of hexokinases which play a central role in glucose u ptake and 




Zhiwei Hu MD, PhD (USA) - Research Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale 
School of Medicine. Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature for 
development of novel dual neovascular- and cancer cell-targeted therapy for cancer. Currently his laboratory is focusing on further 
elucidating the mechanisms of action and improving the efficacy of factor VII-targeted immunotherapy and photodynamic therapy for 
human cancers. His laboratory is also studying tumor angiogenesis, natural killer cells and cancer stem cells and their inter action in tumor 
microenvironment. Dr. Hu is member of the Yale Cancer Center, American Association for Cancer Research, and The American Association 
of Immunologists. Dr. Hu is a peer reviewer for numerous scientific journals in immunology, photodynamic therapy and cancer r esearch 
and serves as an editor or editorial (review)/board member of The Journal of Immune Based Therapies, Vaccines and Antimicrobi als, The 
Journal of Analytical & Bioanalytical Techniques, The Journal of Solid Tumors and Open Journal of Immunology. Starti ng February 2012, 
Dr. Hu serves as Editor-in-Chief of The Journal of Analytical & Bioanalytical Techniques. 
Genetic Instabiliy 
 
Andrew Collins, PhD, ScD, (Norway) - Professor, Nutritional Biology. Dr Collin's early research was focused on molecular mechanisms of 
DNA repair in mammalian cells, and in particular the manipulation of repair with the use of DNA synthesis inhibitors, which allowed 
identification of mutant phenotypes and analysis of the kinetics of repair. He then developed an interest in oxidative damage  to DNA, and 
the ability of phytochemicals to protect against this damage, pioneering a molecular epidemiological approach using the comet assay to 
measure DNA damage in lymphocytes from human subjects. Dr Collins also co-ordinated an international effort (ESCODD) to deal with 
serious methodological problems in the measurement of DNA oxidation. His lab has also developed high throughput biomarker assays for 
DNA damage and repair for use in large-scale human trials, in combination with genotyping. Future efforts will emphasize interactions of 
environment (including nutrition) with DNA repair phenotype and genotype. 
The Tumor Microenvironment 
 
Dean Felsher, MD, PhD (USA) - Associate Professor of Medicine and of Pathology at Stanford School of Medicine, Stanford University, 
California, USA. Dr Felsher’s research interests include both basic science and translational research studies that investigate how 
oncogenes initiate and sustain tumorigenesis. He is a 1996 Lymphatic Research Foundation Fellow and 2001 Junior Faculty Award 
Recipient. His laboratory has developed model systems that can conditionally activate oncogenes in normal human and mouse cel ls in 































The Halifax Project  
  
  




Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment   
8-9 August 2013   
The Westin Nova Scotian 
1181 Hollis Street, Halifax,  




The goal of this mixtures workshop is to identify and focus on key issues that present challenges in assessing the carcinogenic potential of low 
dose exposures to chemical mixtures in the Environment (for this workshop, "mixtures" includes combined independent exposures).  This 
workshop will generate inputs and recommendations for the scientific community for advancing mixtures research related to carcinogenicity.  
 
Specifically, this workshop will: 
• Provide participants with an update on the key areas of cancer biology that are relevant for mixtures research 
• Consider state-of-the-art toxicology methods  and risk assessment strategies related to mixtures research and carcinogenicity 
• Identify and prioritize the knowledge gaps and challenges in mixtures research specific to toxicology and risk assessment 
• Obtain advice on integrating multidisciplinary capabilities to address critical topics in future mixtures research related to carcinogenicity  
• Provide recommendations for research on key topics 




Discussions from the workshop will become part of a manuscript that will be prepared for the peer-reviewed literature. This will be part of a 
planned special issue in Oxford’s Carcinogenesis journal, which is slated for publication in 2014.  The article will capture the key issues and 
recommendations of workshop attendees, and describe suggestions for future directions in mixtures research.  
 
2-Day Workshop Package $250.00 USD (HST included) 
 2 Day workshop agenda ( shown below ) 
 Daily shuttles between Westin hotel and NSCC Waterfront Campus 
 Lunch and refreshments,  both days 
 Group dinner at the Westin Hotel (first evening) 
 Facility/Admin Expense  
 
DRAFT Schedule at a glance 
 
Day 1 – 8 August, 2013 
 
840am – 900am Welcome, Introductions, Overview -  
 Leroy Lowe, President and Cofounder, Getting to Know Cancer 
900am - 920am Keynote Address  
Rick Woychik, Deputy Director NIH/NIEHS 
  
920am - 940am Team report - Genetic Instability 
 Andrew Collins, PhD, ScD, University Of Oslo (Norway) 
940am-1000am Team report - Sustained Proliferative Signalling 
 Wilhelm Engstrom, MD, Swedish University Of Agricultural Sciences (Sweden) 
1000am  - 1020am Team report -  Evasion of Anti-growth Signalling 
 Rita Nahta, PhD, Emory University (United States) 
1020am – 1035 am Break 
  
1035am  - 1055am Team report -  Resistance to Cell Death 
 Hyun Ho Park, PhD, Yeungnam University (Korea South) 
1055am - 1115am Team report -  Replicative Immortality 
 Amancio Carnero Moya, PhD, Institute Of Biomedicine Of Sevilla (Spain) 
1115am - 1135am Team report -  Deregulated metabolism 
 R. Brooks Robey, MD FASN FAHA, Dartmouth College & White River Junction VA Medical Center (United States) 
1135am – 1155am Team report -  Tumor Microenvironment 
 Dean Felsher, MD, PhD, Stanford University (United States) 
Noon- 100pm Lunch 
  
 Team report -  Angiogenesis 
 Zhiwei Hu MD, PhD, The Ohio State University (United States) 
100pm – 120pm Team report -  Tissue Invasion and Metastasis 
 Josiah Ochieng, PhD, Meharry Medical College (United States) 
120pm – 140pm Team report -  Immune System Evasion 
 H. Kim Lyerly MD, FACS, Duke University (United States) 
140pm – 200pm Team report -  Tumor Promoting Inflammation 
 Patricia Thompson, PhD, The University Of Arizona Cancer Center (United States) 
200pm – 215pm Break 
  
215pm – 235pm Team report -  Target and Disruptor Validation Team 
 William Bisson, PhD, Oregon State University (United States) 
235pm – 315pm Panel Discussion – Q&A 
  
315pm-345pm In Vitro Perturbations of Targets in Cancer Hallmark Processes Predict Rodent Chemical Carcinogenesis  
 Richard Judson, Ph.D. 
345pm-415pm Unraveling the Health Effects of Environmental Mixtures: An NIEHS Priority 
 Danielle Carlin, PhD, DABT (Division of Extramural Research and Training/NIEHS) 
415pm-445pm A Systems Biology Approach for Assessing the Toxicity of Mixtures 
 Cynthia Rider, PhD, DABT (Division of National Toxicology Program/NIEHS) 
5pm Return to Westin Hotel 
  
7pm Group Dinner at the Westin 
  
730pm-800pm Low-Doses, Non-Monotonic Relationships 
Laura N. Vandenberg, PhD, Tufts University (United States) 
  
800pm-830pm Considering Chemical Mixtures in Cancer Risk Assessment  
 Linda K. Teuschler and  Glenn E. Rice, United States Environmental Protection Agency 
Office of Research and Development, National Center for Environmental Assessment 
 
 
Day 2 – 9 August, 2013 
840am – 900am Welcome and Overview 
 Leroy Lowe, President and Cofounder, Getting to Know Cancer 
900am - 1100am Breakout Session 1 - Toxcast Data, Selectively Disruptive Chemicals 
  
 Breakout Session 2 - Chemical Mixtures , Toxicological Approaches and Cancer Biology  
  
 Breakout Session 3 - Chemical Mixtures, Cancer Biology, Risk Assessment Practices 
  
1100 - Noon Report back / Discussion 
 Chairperson: TBD 
Noon- 1pm Lunch 
  
100pm – 300pm Breakout Session 1 - Implications and Recommendations for Future Research (knowledge gaps, modeling, testing) 
  
 Breakout Session 2 - Implications and Recommendations for Cancer Risk Assessment and Regulatory Decision 
Making 
  
 Breakout Session 3 - Implications and recommendations for Molecular Epidemiology 
  
 Breakout Session 4 – Strategic Issues, Barriers  
  
300pm – 400pm Report back / Discussion - Next Steps  
Chairperson: TBD 
  









A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy  
12-13 Aug 2013 
The Westin Nova Scotian 
1181 Hollis Street, Halifax,  




The goal of this mixtures workshop is to leverage the rapid advances in our knowledge of the mechanics of the disease, as well as the rapidly 
growing body of research on natural chemicals to develop a robust and non-toxic, broad-spectrum approach to both prophylaxis and therapy 
(i.e., one that will be aimed at many prioritized targets simultaneously). This workshop will lay the foundation for a ground-breaking new 
direction in translational research that should have a much better chance of preventing disease relapse caused by intra-tumoral heterogeneity 
and adaptive resistance. 
 
Specifically, this workshop will: 
• Provide participants with an update on the key areas of cancer biology and the most attractive therapeutic targets 
• Consider state-of-the-art clinical practices in integrative oncology 
• Identify and prioritize the knowledge gaps and challenges in research specific to targeted approaches to therapy 
• Lay out the foundation for a broad-spectrum approach in both prophylaxis and therapy 
• Provide recommendations for future research on key topics 




Discussions from the workshop will become part of a manuscript that will be prepared for the peer-reviewed literature. This will be part of a 
planned special issue in Elsevier’s Seminars in Cancer Biology journal, which is slated for publication in 2014.  The article will capture the key 
issues and recommendations of workshop attendees, and describe suggestions for future directions in mixtures research.  
 
2-Day Workshop Package  - $250.00 USD (HST included)  
 2 Day workshop agenda ( shown below ) 
 Daily shuttles between Westin hotel and NSCC Waterfront Campus 
 Lunch and refreshments,  both days 
 Group dinner at the Westin Hotel (first evening) 
 Facility/Admin Expense  
 
DRAFT Schedule at a glance 
 
Day 1 – 12 August, 2013 
 
840am – 900am Welcome, Introductions, Approach, Overview (Prophylaxis/Therapeutics) 
 Leroy Lowe, President and Cofounder, Getting to Know Cancer 
900am - 940am Integrative oncology research: Mechanistic understandings and clinical research 
 Jeffrey D. White, M.D., Director, Office of Cancer Complementary and Alternative Medicine, Division of Cancer 
Treatment and Diagnosis, National Cancer Institute (NIH) 
940am - 1030am Interactive tailored clinical approaches, targeting multiple pathways: Making a difference in patient outcomes. 
 Keith Block, MD 
1030am - 1045am Break 
  
1045am - 1145am Cancer Genome Landscape (Intratumoral Heterogeneity, Therapeutic Implications, Implications for Prevention) 
 Bert Vogelstein, MD, Johns Hopkins University (United States) 
1145am – 
1205am 
Team report - Genetic Instability 
 Lynnette Ferguson, DPhil, DSc, The University Of Auckland (New Zealand) 
Noon – 100pm Lunch 
  
100pm – 120pm Team report - Sustained Proliferative Signalling 
 Mark Feitelson, PhD, Temple University (United States) 
120pm – 140pm Team report -  Evasion of Anti-growth Signalling 
 Dong M. Shin, MD, FACP, Emory University (United States) 
140pm – 200pm Team report -  Resistance to Cell Death 
 Ramzi Mohammad, Ph.D., Karmanos Cancer Institute Wayne State University (United States) 
200pm – 220pm Team report -  Replicative Immortality 
 Paul Yaswen, PhD, Life Sciences Division, Lawrence Berkeley National Lab (United States) 
220pm – 235pm Break 
  
235pm – 255pm Team report -  Deregulated metabolism 
 Matthew Hirschey, PhD, Duke University (United States) 
255pm-315pm Team report -  Tumor Microenvironment 
 Nancy Boudreau, PhD, University Of California San Francisco (United States) 
315pm-335pm Team report -  Angiogenesis 
 Lasse Dahl Jensen, PhD, Karolinska Institutet And Linkoping University (Sweden) 
335pm-355pm Team report -  Tissue Invasion and Metastasis 
 Wen G Jiang, MD, PhD, Cardiff University School Of Medicine (United Kingdom) 
355pm-415pm Team report -  Immune System Evasion 
 Byoung S. Kwon, PhD, National Cancer Center (Korea South) 
415pm-435pm Team report -  Tumor Promoting Inflammation 
 Fredika M Robertson, PhD, The University Of Texas MD Anderson Cancer Center (United States) 
435pm-455pm Team report -  Target and Approach Validation Team 
Kanya Honoki, MD, PhD, Nara Medical University (Japan) 
5pm Return to Westin Hotel 
  




Day 2 – 13 August, 2013 
 
840am – 900am Welcome, Admin, Overview 
 Leroy Lowe, President and Cofounder, Getting to Know Cancer 
900am - 1100am Breakout Session 1 –  Phytochemicals review  
  
 Breakout Session 2 – Cancer genome (heterogeneity and the implications for target selections) 
  
 Breakout Session 3 – Clinical Issues: Personalizing protocols and alternate modalities to reach targeted pathways  
  
 Breakout Session 4 –  Safety issues, research barriers, follow-on testing 
  
1100 - Noon Report back / Discussion 
 Chairperson: TBD 
Noon- 1pm  
  
100pm – 300pm Breakout Session 1 – Target selections, range of approaches, recommendations for follow-on research 
  
 Breakout Session 2 - Implications and recommendations for integrative oncology  
  
 Breakout Session 3 – Strategic needs ( funding, resources, hurdles, barriers )  
  
300pm – 400pm Report back / Discussion / Next steps 
Chairperson: TBD 
  
400pm - 420pm Capstone article (roles, responsibilities) 
 TBD 















Workshop Facilities   - Daytime Schedule 
 
Workshop activities during the day will be held at the Nova Scotia Community College, Waterfront Campus.  Participants will be picked up at the 




This new, environmentally-friendly campus features:  
 modern design with open spaces 
 150 seat Presentation Theatre 
 Meeting/classroom/project rooms,  
 Library and computer labs 
 Full-service cafeteria/food court 
 State-of-the-art technology, including WIFI access 
 Daycare (please contact us in advance if you have 
daycare needs). 
 
**Note that daily transportation to from the facility (from the 
Westin Hotel) to and lunch at the full-service cafeteria is included 




















Workshop Facilities   - Evening Schedule 
 
At the end of the first day of each of the two-day workshops, participants will return to the Westin Halifax for a well deserved break and then 
the group will reconvene for dinner at the hotel.  Note that additional speakers will be slated during this dinner, so all workshop participants are 








Workshop Hotel Reservations 
 
We have been given a private reservations website for The Westin Hotel (where workshop participants will be staying).   This hotel is one of the 
very nicest properties in the city and we have negotiated an excellent group rate of only $159 Cdn per night, so if you want to make hotel 





















   















Request for Quotation – Peer-Reviewed Journal Special Issue 
 
Novel Integrative Design for Cancer Prevention and Therapy  
 
1 editorial and 12 review articles (100 scientists) 
 









The Halifax Project 
 
 Page 1 
 
 
Table of Contents 
 
Introduction .............................................................................................................................................. p. 2 
Background ............................................................................................................................................... p. 3 
The Approach ............................................................................................................................................ p. 4 
 The Hallmarks of Cancer ....................................................................................................... p. 4 
 Design Tradeoffs ................................................................................................................... p. 5 
 Complexity ............................................................................................................................ p. 6 
The Teams  .............................................................................................................................................. p. 6 
Team Support ............................................................................................................................................. p.7 
Design Recommendations ......................................................................................................................... p.7  















“Getting to Know Cancer” is a non-profit organization that is focused on instigating integrative cancer 
research to improve cancer therapy.  Presently the organization has plans for an important series of 
scientific reviews and two, 2-day workshops that will be held in the summer of 2013 in Halifax, Nova 
Scotia.  One of the workshops will be focused on a novel (broad-spectrum) therapeutic design, while the 
other is related to the influence of environmental chemical exposures. 
 
You are receiving this invitation because we are currently seeking expressions of interest and quotations 
from cancer journals that would be interested in publishing a special issue that will capture the reviews 
that will be produced in this groundbreaking project.  A task force of nearly 100 scientists will be 
assembled to prepare a series of reviews in advance of the workshop, and a synthesis and capstone 
review will be produced by all of the teams after the workshop has been held.   
 
The project will employ an integrative approach to therapeutic design that should have both 
prophylactic and therapeutic potential.   The hallmarks of cancer framework will be used to guide the 
development of a broad-spectrum of prioritized therapeutic targets, and natural chemicals that are 
found in plants and foods will then be identified that can reach those targets.  The goal is to develop an 
optimized broad-spectrum therapeutic design that is non-toxic that can overcome the problem of 
adaptive resistance that so frequently causes disease relapse.  Accordingly, this project has the potential 
to yield a landmark publication that will be referenced for years to come.    
 
We know that this is an extraordinarily complex undertaking, but with the right people involved, we are 
confident that something exceptional is going to result.  This will be a seminal attempt at something that 
has never been done before, so if your journal is potentially interested in acting as the publisher of the 








President and Cofounder  
Getting to Know Cancer 




    




Over the past two decades, our scientific knowledge of cancer has matured considerably, but the scale 
of the cancer genome has far exceeded what anyone had ever expected and the long list of oncogenes 
and tumor suppressor genes has created a daunting array of molecular targets. How do we now rapidly 
translate this incredible breadth of new scientific knowledge into a sophisticated and fully optimized 
chemotherapy? 
 
The toll that cancer takes on society, has resulted in an international cancer research community that is 
vast, but the complexity of the disease has necessitated an incredible amount of specialization.  
Consequently most cancer scientists are engaged in research that is very narrowly focused, and even the 
academic reviews that are produced in this field tend to be very narrowly scoped.  Similarly, granting 
bodies and academic journals have reinforced this need for specialization by also demanding highly 
focused research.  This approach has resulted in incredible advances in our understanding of the 
disease, but unfortunately this trend towards specialization has meant that very few researchers ever 
have the latitude or the opportunity to undertake projects that are very broad in scope.  So thousands of 
new research results are published each year, and the task of synthesizing all of this new information 
(for the purposes of therapeutic development) has been left to the pharmaceutical industry.  
 
At first blush, this handoff of research from the academic community to the private sector appears to 
represent a reasonable division of labor.  The pharmaceutical industry certainly has a significant pool of 
resources, and the demand for cancer chemotherapy has never been higher, so this has been a highly 
lucrative relationship that the industry has both fostered and embraced.  But what if the science is now 
telling us that that a fully optimized chemotherapy is going to need to employ chemicals that cannot be 
patented?  Can we really depend on profit-seeking partners to invest in a project that has greatly 
diminished potential for profitability?    
    
The concept of “oncogene addiction" has provided the industry with a compelling rationale for targeted 
therapeutics.  The idea that the growth and survival of cancer cells could be impaired by the inactivation 
of a single oncogene has been well aligned with the “one drug, one disease” model that the industry has 
relied upon for so many years. But we now know that narrowly targeted therapies are often met with 
adaptive resistance because most cancers contain a multitude of subpopulations of mutated cells which 
all gain their immortality in slightly different ways.  Of course, combination chemotherapy is one way 
that clinicians have tried to overcome adaptive resistance, but toxicity and multiple drug resistance 
issues are then complicating factors that place highly restrictive limitations on this approach. 
 
Meanwhile an enormous body of cancer research has emerged in the past decade that convincingly 
shows that many naturally occurring chemicals (e.g., phytochemicals) are every bit as promising for the 
purposes of molecular targeting.  Furthermore, these chemicals can typically be combined with far less 
danger of toxicity and much lower risk of encountering multiple drug resistance, which makes the 
concept of broad-spectrum targeting using complex combinations of chemicals a very real possibility.  
But the pharmaceutical industry has never embraced naturally occurring chemicals (presumably because 
their lack of patentability makes them far less likely to yield the sorts of profits that the industry 
expects), so the vast resources of the pharmaceutical industry have never really been used to explore 
this promising possibility in earnest. 
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Unfortunately, many traditional research funding agencies and journals have tended not to support anti-
cancer research involving too many biologically active ingredients either.  Anecdotal reports by 
numerous scientists suggest that this is because the number of variables involved would make the 
results from this type of research difficult to interpret.  But this seemingly innocuous constraint has 
resulted in an untenable situation.  In the absence of progressive solutions from industry, the highly 
complex endeavour of developing an optimized broad-spectrum chemotherapy (i.e., one that can reach 
many molecular targets simultaneously) has instead been shouldered by progressive clinical oncologists 
who have been forced to piece together their own solutions and test their ideas one-patient-at-a-time.  
In other words, this is a complex and very large scale problem that is presently being addressed in a very 
piecemeal fashion. 
“The Halifax Project” has therefore been proposed to create a task force that can address this problem.  
We believe that the timing is right for a large group of cancer scientists to study this large scale problem 
in a holistic and nuanced manner. 
The Approach 
To accomplish this task, Getting to Know Cancer ( www.gettingtoknowcancer.org ) is planning to 
assemble a task force of nearly 100 scientists for a two-day workshop that will take place in Halifax, 
Nova Scotia (tentatively slated for August 2013).   We believe that the timing is right for a series of 
overarching reviews that can collectively assess and prioritize the many target choices that exist for 
therapy, and also identify chemicals from plants or foods that could be employed to produce an 
optimized therapeutic solution (i.e., one that will have the sort of broad-spectrum of action that appears 
to be needed).  To that end, it is envisioned that eleven teams of researchers will work in advance of the 
workshop to produce eleven reviews using a novel approach that is based upon the ten areas that are 
described within the “hallmarks of cancer” framework and one review of the tumor microenvironment 
(see Hanahan and Weinberg, 2001 and 2011).  
The Hallmarks of Cancer 
The Hallmarks of Cancer framework has been chosen because it is a state-of-the-art model that helps us 
to quickly organize the many forms of cellular-level disruption (both genetic and epigenetic) that 
underpin all cancer types – these are listed as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
 
Tissue interactions within the tumor microenvironment are also considered extremely important.   
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The goal of this project will therefore be for each team to develop a detailed appreciation for the design 
considerations that must be taken into account if a broad-spectrum combination chemotherapy 
approach is going to be employed.  In each of these individual reviews, the teams involved will be 




1. Provide an overview of the area that the team has been tasked to review 
2. Describe the types of systemic or cellular-level dysfunction in that area that enable the immortalization of cells 
3. Describe any relationships that exist between the topic area and any of the other topic areas being studied 
4. Categorize, and prioritize the therapeutic targets that are relevant for that particular topic area 
5. Identify any naturally occurring chemicals that appear well suited to reach the identified targets 
6. Describe any strategic decisions or tradeoffs that are germane to that topic area that will need to be considered 
in the process of developing an optimized and holistic therapeutic design 




In particular, these reviews must ensure that the most important design tradeoffs are carefully 
considered. For example, exogenous chemical insults, and cellular-level oxidative stress can both be 
important sources of genetic instability, the first hallmark of cancer.  So one therapeutic strategy aimed 
at reducing genetic instability might involve the use of supplemental cysteine to boost glutathione 
levels. But some phyto-chemicals that have been found to have therapeutic promise (e.g., 
epigallocatechin-3-gallate) actually exert their potential by causing damage to the mitochondria, which 
induces the production of reactive oxygen species and causes oxidative stress which triggers apoptosis. 
So a tactic that focuses on boosting glutathione to address chemical insults and minimize oxidative 
stress may actually be acting in opposition to a therapeutic design that relies on oxidative stress as the 
instigating mechanism for apoptosis.  A better approach in this scenario might be to focus on 
mechanisms that can trigger apoptosis without having to rely on the production of reactive oxygen 
species. 
Similarly, we now have a decade of experience using anti-angiogenesis as a therapeutic strategy, but a 
number of studies have shown that cutting off the blood supply to tumors increases oxidative stress.  
While this approach does trigger apoptosis in many immortalized cells, in some cases it can contribute 
to genetic instability, which can result in additional mutations, therapeutic resistance, and ultimately 
more aggressive cancers that are even more difficult to treat.   Furthermore, one could argue that any 
strategy that intends to rely on the blood supply to deliver a great number of chemicals to a great 
number of molecular targets should avoid cutting off the blood supply to tumors.  So in the broader 
scheme of things, even though we know how to suppress angiogenesis, we may not want to use that 
strategy if we hope to emerge with a broad-spectrum therapeutic design that can reach many molecular 
targets. 
Of course these examples are by no means the only trade-offs/issues that need to be considered, but 
they are offered here to illustrate why the relationships between each of the hallmarks must be 
considered when categorizing and prioritizing therapeutic targets.   
  




It could be argued that the cancer genome is so large that no single review in any one of these hallmark 
areas would be adequate to capture the detail that is needed for this sort of an exercise.  And an even 
greater layer of complexity is imposed on this problem when one considers that many phyto-chemicals 
are known to act on multiple molecular targets, and that many molecular targets (e.g., receptors) are 
known to be important instigators in more than one hallmark area.  But the challenge that is being 
offered to each of these teams is to try to produce a compact synthesis of the literature that categorizes 
and prioritizes target mechanisms for each of the hallmark areas while clarifying the nature of any 
important relationships that exist with the hallmark being reviewed and other hallmarks.  
A thorough and holistic review of all of the hallmarks is needed at this stage because a truly 
sophisticated and optimized therapeutic regimen (one that has the very greatest chance of success) will 
only emerge once this has been done.  By using a number of teams, with significant breadth of 
expertise, the goal is to produce a series of powerful reviews that can inform the design for a much 
improved therapeutic approach with an emphasis that is grounded in the practical (i.e., what can be 
done now, with what we know so far).  In the bigger scheme of things, this may only serve as a starting 
point, but this appears to be a promising direction that needs serious consideration.    
The Teams 
Accordingly, “Getting to Know Cancer” will soon seek expression of interest from a wide range of 
scientists to find those who are interested in being selected to join any of the eleven teams that will be 
asked to produce the reviews that are planned.  Ten teams will tackle the ten hallmark areas and one 
additional team will consider the tumor microenvironment.  Once responses have been received, we will 
be inviting team leaders to serve as the lead author for each of the teams by using the following three 
criteria: 
1. A demonstrated level of expertise in one of the eleven areas  
2. A distinguished track record of peer-reviewed publications  
3. A solid history of collaboration in the peer-reviewed literature  
 
Once the lead authors have been selected, the remaining team members for each team will be invited 
to participate as well.  The team member choices will be made in cooperation with the lead authors for 
each team.    
1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other 
experts who will collectively be responsible for producing a descriptive overview that encompasses the 
topic area, as well as a description the types of systemic or cellular-level dysfunction in that topic area 
that contribute to the immortalization of cancerous cells and any relationships that exist between that 
particular topic and the other topic areas under consideration.  Given the scale of the cancer genome, 
the task of this group will be to produce a compact synthesis of the literature that categorizes and to 
prioritize the therapeutic targets that would be most relevant for a broad-spectrum therapeutic design.  
 
  




2. Anti-cancer Phyto-chemical Specialists – Each team will also have a number of cancer scientists who 
specialize in research that focuses on the anti-cancer effects of naturally occurring chemicals that are 
found in plants and foods.  Their role will be to identify chemicals that appear well suited to reach the 
identified targets. 
 
3. Oncologists from Integrative Care settings – where possible, each team will also have at least one 
oncologist who has both research experience and clinical experience in an integrative cancer care 
setting (human or veterinary).    
 
The team leader will then also be responsible for ensuring that the team describes any strategic 
decisions or tradeoffs that are relevant to the topic area that will need to be considered in the process 
of developing an optimized and holistic therapeutic design, and to ensure the team makes 
recommendations for any additional research that will be needed.   
 
Team Support 
Each team will also have the support of a small utility team of Getting to Know Cancer scientists (PhDs 
with backgrounds in molecular biology).  This utility team will assist the eleven teams by taking target 
recommendations from each of the teams and then conducting background literature research to 
identify instances when a particular target that is of interest to one of the teams also has relevance for 
the topics being studied by other teams.  This will help all of the teams to better understand the 
implications of making certain target choices since many receptors and intra-cellular mechanisms have 
functionality that is important for more than one of the hallmark areas.    
 
Design Recommendations 
As noted above, the two-day workshop will involve one day of presentations from each of the eleven 
teams to allow for questions and answers, followed by a collaborative series of meetings on the second 
day that will give the teams an opportunity to address trade-offs and then to build consensus around 
the next steps that will be needed to address obstacles and ultimately validate a proposed therapeutic 
design.  The team leads from each team will subsequently collaborate to produce a capstone review that 
will summarize the integrated findings from the second day of the workshop and make 
recommendations for the way ahead. 
 
  




Request for Quotation 
 
Getting to Know Cancer is now seeking expressions of interest and quotations from cancer journals that 
would potentially be interested in publishing the special review that will result from this project.  We are 
seeking a reputable journal with a strong impact factor and a strong recognition of the importance of an 
integrative approach to cancer therapy, because we want to ensure that this work reaches a broad 
audience of cancer researchers.  It is also our intent to bring considerable media attention to this 
project, so this should be a high profile project that will enhance the reputation of the journal that 
publishes the results.   
 
We will also be inviting a select number of scientific representatives from cancer charities and other 
funding agencies to attend the workshop presentations.  We believe that truly broad-spectrum 
combination chemotherapy is a promising future direction for cancer prevention and therapy and we 
want to build awareness of the need for funding in this area.  Success in this regard will drive additional 
research that will draw on this original work. 
  
In sum, we believe that this special issue will be an important reference for years to come, because we 
believe that that the project has the potential to yield landmark results.  We will need approximately 
250 pages (electronic only) to capture this work – as follows: 
Introductory Editorial (Guest Editors)    6 pages 
11 Reviews X 20 pages each (references included) 220 pages 
Capstone review (references included)   24 pages 
 
 
If your journal has an interest in publishing the special issue for this project, please reply as soon as 
possible with the details.    Submissions and questions about the project can be directed to Leroy Lowe, 
Cofounder and President, Getting to Know Cancer  
 
 Email:  leroy.lowe@gettingtoknowcancer.org 
 
 





DEADLINE FOR SUBMISSIONS - MAY 18th, 2012 
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Halifax is a scenic city located on 
the East Coast of Canada.  In the 
summer, the historic port attracts 
many cruise ships as the city is well 
known for its park and gardens, 
and it boasts a downtown that is 
both beautiful and historic. Visitors 
can enjoy the rich culture and 
vibrant atmosphere found in the 
many shops, restaurants, and pubs 
that are clustered around the 
boardwalk and the waterfront. 
While the more adventurous can 
choose from a wide range of 
activities such as bus tours, harbor 
cruises, golf and eco-tourism (e.g., 
sea kayaking), since all of these 








“Getting to Know Cancer” is a non-profit organization that is focused on instigating integrative cancer 
research to improve cancer therapy.  Presently the organization has plans for an important series of 
scientific reviews and two, 2-day workshops that will be held in August of 2013 in Halifax, Nova Scotia.  
One of the workshops is related to the influence of environmental chemical exposures (8-9 August 
2013), while the other is related to improved therapeutic design (12-13 August 2013). 
 
You are receiving this invitation because we are currently seeking expressions of interest from scientists 
who would be willing to consider serving on any one of eleven teams that will be part of a therapeutic 
design task force that is being recruited for this groundbreaking project.  The teams will all be preparing 
the reviews in advance of the workshop, and the reviews that result from the project will be submitted 
for peer-review and publication in a special issue of “Seminars in Cancer Biology”, a top ranked journal 
(2010 Impact Factor 7.758).   
 
A novel approach is being employed in this project. The hallmarks of cancer framework (Hanahan and 
Weinberg, 2011) be used to guide the development of a broad-spectrum of prioritized therapeutic 
targets, and then natural chemicals (from plants and other foods) will be identified that appear to have 
the greatest potential to be safely combined to reach those targets. The goal is to develop an optimized 
broad-spectrum, non-toxic regimen that has both prophylactic and therapeutic potential to overcome 
the problem of adaptive resistance.      
 
If you are potentially interested in being part of this task force, please read the remainder of this 
document for the details.  We are seeking senior cancer scientists with a breadth of knowledge, a strong 
track record of peer-reviewed publishing and a history of collaboration.  We know that this is an 
extraordinarily complex undertaking, but with the right people involved, we are confident that 
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Over the past two decades, our scientific knowledge of cancer has matured considerably, but the scale 
of the cancer genome has far exceeded what anyone had ever expected and the long list of oncogenes 
and tumor suppressor genes has created a daunting array of molecular targets. How do we now rapidly 
translate this incredible breadth of new scientific knowledge into a sophisticated and fully optimized 
chemotherapy? 
 
The toll that cancer takes on society, has resulted in an international cancer research community that is 
vast, but the complexity of the disease has necessitated an incredible amount of specialization.  
Consequently most cancer scientists are engaged in research that is very narrowly focused, and even the 
academic reviews that are produced in this field tend to be very narrowly scoped.  Similarly, granting 
bodies and academic journals have reinforced this need for specialization by also demanding highly 
focused research.  This approach has resulted in incredible advances in our understanding of the 
disease, but unfortunately this trend towards specialization has meant that very few researchers ever 
have the latitude or the opportunity to undertake projects that are very broad in scope.  So thousands of 
new research results are published each year, and the task of synthesizing all of this new information 
(for the purposes of therapeutic development) has been left to the pharmaceutical industry.  
 
At first blush, this handoff of research from the academic community to the private sector appears to 
represent a reasonable division of labor.  The pharmaceutical industry certainly has a significant pool of 
resources, and the demand for cancer chemotherapy has never been higher, so this has been a highly 
lucrative relationship that the industry has both fostered and embraced.  But what if the science is now 
telling us that that a fully optimized chemotherapy is going to need to employ chemicals that cannot be 
patented?   
    
The concept of “oncogene addiction" has provided the industry with a compelling rationale for targeted 
therapeutics.  The idea that the growth and survival of cancer cells could be impaired by the inactivation 
of a single oncogene has been well aligned with the “one drug, one disease” model that the industry has 
relied upon for so many years. But we now know that narrowly targeted therapies are often met with 
adaptive resistance because most cancers contain a multitude of subpopulations of mutated cells which 
all gain their immortality in slightly different ways.  Of course, combination chemotherapy is one way 
that clinicians have tried to overcome adaptive resistance, but toxicity and multiple drug resistance 
issues are then complicating factors that place highly restrictive limitations on this approach. 
 
Meanwhile an enormous body of cancer research has emerged in the past decade that convincingly 
shows that many naturally occurring chemicals (e.g., phytochemicals) are every bit as promising for the 
purposes of molecular targeting.  Furthermore, these chemicals can typically be combined with far less 
danger of toxicity and much lower risk of encountering multiple drug resistance, which makes the 
concept of broad-spectrum targeting using complex combinations of chemicals a very real possibility.  
But the pharmaceutical industry has never embraced naturally occurring chemicals (presumably because 
their lack of patentability makes them far less likely to yield the sorts of profits that the industry 
expects), so the vast resources of the pharmaceutical industry have never really been used to explore 
this promising possibility in earnest. 
  
 Page 4 
 
 
Unfortunately, many traditional research funding agencies and journals have tended not to support anti-
cancer research involving too many biologically active ingredients either.  Anecdotal reports by 
numerous scientists suggest that this is because the number of variables involved would make the 
results from this type of research difficult to interpret.  But this seemingly innocuous constraint has 
resulted in an untenable situation.  In the absence of progressive solutions from industry, the highly 
complex endeavour of developing an optimized broad-spectrum chemotherapy (i.e., one that can reach 
many molecular targets simultaneously) has instead been shouldered by progressive clinical oncologists 
who have been forced to piece together their own solutions and test their ideas one-patient-at-a-time.  
In other words, this is a complex and very large scale problem that is presently being addressed in a very 
piecemeal fashion. 
“The Halifax Project” has therefore been proposed to create a task force that can address this problem.  
We believe that the timing is right for a large group of cancer scientists to study this large scale problem 
in a holistic and nuanced manner. 
 
The Approach 
To accomplish this task, Getting to Know Cancer ( www.gettingtoknowcancer.org ) is planning to 
assemble a task force for a two-day workshop that will take place in Halifax, Nova Scotia in August of 
2013.   We believe that the timing is right for a series of overarching reviews that can collectively assess 
and prioritize the many target choices that exist, and also identify chemicals from plants or foods that 
could be safely combined to produce an optimized broad-spectrum solution that has both prophylactic 
and therapeutic potential.  To that end, it is envisioned that eleven teams of researchers will work in 
advance of the workshop to produce eleven reviews using a novel approach that is based upon the ten 
areas that are described within the “hallmarks of cancer” framework and one review of the tumor 
microenvironment (see Hanahan and Weinberg, 2001 and 2011).  
The Hallmarks of Cancer 
The Hallmarks of Cancer framework has been chosen because it is a state-of-the-art model that helps us 
to quickly organize the many forms of cellular-level disruption (both genetic and epigenetic) that 
underpin all cancer types – these are listed as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
 
Tissue interactions within the tumor microenvironment are also considered extremely important.   
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The goal of this project will therefore be for each team to develop a detailed appreciation for the design 
considerations that must be taken into account if a broad-spectrum combination chemotherapy 
approach is going to be employed.  In each of these individual reviews, the teams involved will be 




1. Provide an overview of the area that the team has been tasked to review 
2. Describe the types of systemic or cellular-level dysfunction in that area that enable the immortalization of cells 
3. Describe any relationships that exist between the topic area and any of the other topic areas being studied 
4. Categorize, and prioritize the therapeutic targets that are relevant for that particular topic area 
5. Identify any naturally occurring chemicals that appear well suited to reach the identified targets 
6. Describe any strategic decisions or tradeoffs that are germane to that topic area that will need to be considered 
in the process of developing an optimized and holistic therapeutic design 




In particular, these reviews must ensure that the most important design tradeoffs are carefully 
considered. For example, exogenous chemical insults, and cellular-level oxidative stress can both be 
important sources of genetic instability, the first hallmark of cancer.  So one therapeutic strategy aimed 
at reducing genetic instability might involve the use of supplemental cysteine to boost glutathione 
levels. But some phytochemicals that have been found to have therapeutic promise (e.g., 
epigallocatechin-3-gallate) actually exert their potential by causing damage to the mitochondria, which 
induces the production of reactive oxygen species and causes oxidative stress which triggers apoptosis. 
So a tactic that focuses on boosting glutathione to address chemical insults and minimize oxidative 
stress may actually be acting in opposition to a therapeutic design that relies on oxidative stress as the 
instigating mechanism for apoptosis.  A better approach in this scenario might be to focus on 
mechanisms that can trigger apoptosis without having to rely on the production of reactive oxygen 
species. 
Similarly, we now have a decade of experience using anti-angiogenesis as a therapeutic strategy, but a 
number of studies have shown that cutting off the blood supply to tumors increases oxidative stress.  
While this approach does trigger apoptosis in many immortalized cells, in some cases it can contribute 
to genetic instability, which can result in additional mutations, therapeutic resistance, and ultimately 
more aggressive cancers that are even more difficult to treat.   Furthermore, one could argue that any 
strategy that intends to rely on the blood supply to deliver a great number of chemicals to a great 
number of molecular targets should avoid cutting off the blood supply to tumors.  So in the broader 
scheme of things, even though we know how to suppress angiogenesis, we may not want to use that 
strategy if we hope to emerge with a broad-spectrum therapeutic design that can reach many molecular 
targets. 
Of course these examples are by no means the only trade-offs/issues that need to be considered, but 
they are offered here to illustrate why the relationships between each of the hallmarks must be 
considered when categorizing and prioritizing therapeutic targets.   
  




It could be argued that the cancer genome is so large that no single review in any one of these hallmark 
areas would be adequate to capture the detail that is needed for this sort of an exercise.  And an even 
greater layer of complexity is imposed on this problem when one considers that many phytochemicals 
are known to act on multiple molecular targets, and that many molecular targets (e.g., receptors) are 
known to be important instigators in more than one hallmark area.  But the challenge that is being 
offered to each of these teams is to try to produce a compact synthesis of the literature that categorizes 
and prioritizes target mechanisms for each of the hallmark areas while clarifying the nature of any 
important relationships that exist with the hallmark being reviewed and other hallmarks.  
A thorough and holistic review of all of the hallmarks is needed at this stage because a truly 
sophisticated and optimized therapeutic regimen (one that has the very greatest chance of success) will 
only emerge once this has been done.  By using a number of teams, with significant breadth of 
expertise, the goal is to produce a series of powerful reviews that can inform the design for a much 
improved therapeutic approach with an emphasis that is grounded in the practical (i.e., what can be 
done now, with what we know so far?).   
 
The Teams 
Accordingly, “Getting to Know Cancer” is now seeking expressions of interest from scientists who would 
be interested in being selected to join any of the eleven teams that will be asked to produce the reviews 
that are planned.  Ten teams will tackle the ten hallmark areas and one additional team will consider the 
tumor microenvironment.  Once responses have been received, we will invite team leaders to serve as 
the lead author for each of the teams by using the following three criteria: 
1. A demonstrated level of expertise in one of the eleven areas  
2. A distinguished track record of peer-reviewed publications  
3. A solid history of collaboration in the peer-reviewed literature  
 
Once the lead authors have been selected, the remaining team members for each team will be invited 
to participate as well.  The team member choices will be made in cooperation with the lead authors for 
each team.    
1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other 
experts who will collectively be responsible for producing a descriptive overview that encompasses 
the topic area, as well as a description the types of systemic or cellular-level dysfunction in that 
topic area that contribute to the immortalization of cancerous cells and any relationships that exist 
between that particular topic and the other topic areas under consideration.  Given the scale of the 
cancer genome, the task of this group will be to produce a compact synthesis of the literature that 
categorizes and to prioritize the therapeutic targets that would be most relevant for a broad-
spectrum therapeutic design.  
 
  




2. Anti-cancer Phytochemical Specialists – Each team will also have a number of cancer scientists 
who specialize in research that focuses on the anti-cancer effects of naturally occurring chemicals 
that are found in plants and foods.  Their role will be to identify chemicals that appear well suited to 
reach the identified targets. 
 
3. Oncologists from Integrative Care settings – where possible, each team will also have at least one 
oncologist who has both research experience and clinical experience in an integrative cancer care 
setting (human or veterinary).    
 
4. Support Researchers - Senior scientists who are selected to join the task force will also be able to 
nominate a single post-doctoral researcher (or PhD candidate) within their own lab to participate in 
the team’s work at no extra cost.  These researchers will receive authorship recognition for their 
contributions to the team’s work.  However, in instances where a support researcher has been 
nominated as a contributing author, only one of the two (i.e., the nominator or the nominee) will be 
able to attend the workshop in Halifax in August of 2013.  We know that it is important to provide 
opportunities for post-doctoral researchers to get involved, but in this particular project it is equally 
important that we also ensure that the number of attendees at the working sessions in Halifax 




Each team will also have the support of a small utility team of Getting to Know Cancer scientists (post-
doctoral researchers with backgrounds in molecular biology).  This utility team will assist the eleven 
teams by taking target recommendations from each of the teams and then conducting background 
literature research to identify instances when a particular target that is of interest to one of the teams 
also has relevance for the topics being studied by other teams.  This is a team that we have already 
recruited.  Their inputs will be recognized and credited in the author lists of each of the teams.  Their 
inputs will provide quick referencing to the literature that will help all of the teams to better understand 
the implications of making certain target choices (since many receptors and intra-cellular mechanisms 
have functionality that is important for more than one of the hallmark areas).    
 
Design Recommendations 
As noted above, the two-day workshop will involve one day of presentations from each of the eleven 
teams to allow for discussion, questions and answers, followed by a collaborative series of meetings on 
the second day that will give the teams an opportunity to address trade-offs and then to build consensus 
around the next steps that will be needed to address obstacles and ultimately validate a proposed 
therapeutic design.  The team leads from each team will subsequently collaborate to produce a 
capstone review that will summarize the integrated findings from the second day of the workshop and 
make recommendations for the way ahead. 
 
  





It is our intent to bring considerable media attention to this project, and we will be inviting a select 
number of scientific representatives from cancer charities and other funding agencies to attend the 
workshop presentations.  We believe that truly broad-spectrum combination chemotherapy is a 
promising future direction and want to build awareness of the need for funding and additional research 
and development work that will move this initiative forward.  
       
 
The Outcome  
 
Why take part in the Halifax Project?  The first reward for participation in this unique task force is a 
substantial publication opportunity.  All of the aforementioned reviews that will be produced in this 
project will be submitted for peer-review for a special issue of “Seminars in Cancer Biology”, a top-
ranked journal.  Each task force member will have an authorship role in one of the initial reviews, and 
will also be a named as a contributing author in the capstone synthesis that will be prepared 
collaboratively (post-workshop) by all of the teams (i.e., each task force member will be acknowledged 





Seminars in Cancer Biology  
 
Seminars in Cancer Biology is a review journal dedicated to keeping 
scientists informed of developments in the field of molecular oncology on a 
topic by topic basis. Each issue is thematic in approach, devoted to an 
important topic of interest to cancer biologists, from the underlying genetic 
and molecular causes of cellular transformation and cancer to the molecular 
basis of potential therapies. Every issue is edited by a guest editor, an 
internationally acknowledged expert in the field, and contains six to eight 
authoritative invited reviews on different aspects of the subject area. The 
aim of each issue is to provide a coordinated, readable, and lively review of 
a selected area, published rapidly to ensure currency.   
 
2010 Impact Factor  7.758 
 
 
Additionally, this is an opportunity to be part of a bold project that has the potential to be 
groundbreaking.   This task force is being asked to take on an incredibly challenging problem.  Cancer’s 
complexity has stymied scientists for decades, but we are rapidly gaining new knowledge and we believe 
that the timing is right for this unique approach, and that it has incredible potential.  So with the right 
people involved, we are confident that something truly extraordinary will result.  
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Guest Editors for the Special Issue 
 
 
Keith I. Block, MD - Internationally recognized expert in integrative oncology. Dr. Block combines cutting-edge conventional treatment with 
individualized and scientifically-based complementary and nutraceutical therapies. In 1980, he co-founded the Block Center for Integrative 
Cancer Treatment in Evanston, Illinois, the first such facility in North America, and serves as its Medical and Scientific Director. Dr. Block is 
currently Director of Integrative Medical Education at the University of Illinois College of Medicine at Chicago. Additionally, he is the Scientific 
Director of the Institute for Integrative Cancer Research and Education, where he has collaborated with colleagues at the University of Illinois 
at Chicago, the University of Texas M.D. Anderson Cancer Center in Houston and Bar Ilan University in Israel. In 2005, he was appointed to the 
National Cancer Institute’s Physician Data Query (PDQ) Cancer CAM Editorial Board, on which he continues to serve today. 
 
Anupam Bishayee, PhD – Founding Chair and Professor in the Department of Pharmaceutical and Administrative Sciences in the School of 
Pharmacy, American University of Health Sciences, Signal Hill, California. Dr Bishayee’s research for the last 17 years focuses on elucidation of 
the protective, chemopreventive and therapeutic effects of medicinal plants and natural products and their synthetic analogs in pre-clinical 
animal models of breast, prostate and liver cancer. His current research program aims to investigate mechanism-based chemopreventive and 
therapeutic modalities of dietary and plant-based phytochemicals, including resveratrol from grapes, anthocyanans from berries as well as 




Workshop Organizing Committee 
 
 
Shrikant Anant, PhD (Committee Chair) - Professor of Cancer Research, Department of Molecular and Integrative Physiology, and Medicine, The 
University of Kansas Cancer Center is a pioneering biologist who is focused on gastrointestinal cancer research. His laboratory is currently 
researching various aspects of cancer biology at the molecular level. Specific research areas include: (a) Regulation of gene expression at the 
levels of mRNA stability and translation, (b) Cancer Stem Cells, and (c) mechanism(s) of chemoprevention by dietary factors and novel 
derivatives. Prior to joining The University of Kansas Cancer Center, Dr. Anant led a team of researchers who discovered a new gene, RBM3, 
which can cause normal cells to turn into cancer cells; also, stopping its expression in cancer cells causes the cancer cells to die. Earlier, while on 
the faculty at Washington University in St. Louis, he discovered the first tumor-suppressing RNA-binding protein. At the University of Oklahoma 
Cancer Institute, Dr. Anant led the gastrointestinal cancers program. A professor of cell biology, medicine/gastroenterology and nutrition, he 
was also director of gastroenterology research at the University of Oklahoma Health Sciences Center, and until recently, the chair of the Basic 
Sciences Review Panel for complementary and alternative medicine at NIH. Currently he is a chartered member of the NIH Chemo-Dietary 
Prevention review panel. 
 
Elizabeth Ryan, PhD - Dr. Ryan is an Assistant Professor in the Department of Clinical Sciences at Colorado State University. Her research is 
currently focused on immune modulation and anti-cancer activity of bioactive components in rice bran. She actively evaluates genetically 
diverse rice cultivars from around the world supplied by collaborations at the International Rice Research Institute, USDA Rice Research Unit and 
Rice Researchers in India. In addition to mouse studies and human trials, she is developing the canine cancer model to investigate alternative 
medicine modalities during cancer treatment as a new scope of research at the CSU Animal Cancer Center. The hope is to expand and develop 
evidence-based research on complementary and alternative medicines that include phytochemically rich foods in oncology by using highly 
translational, naturally occurring cancers in companion animals. Phytochemicals from rice bran, beans, fermented Chinese tea, and milk thistle 
are the medicinal plants currently under investigation for their affects on modulating tumor metabolism 
 
Pradeep Kumar Goyal, PhD – Professor & Principal Investigator in the Radiation & Cancer Biology Laboratory, Department of Zoology, University 
of Rajasthan, Jaipur, India. Dr Goyal’s lab has been investigating the extracts of various medicinal plants e.g. Emblica officinalis (Amla), Rosemary 
officinalis (Rosemary), Alstonia scholaris (Sapthaparna), Aegle marmelos (Bael), Phyllanthus niruri (Bhumi amla), Syzgium cumini (Jamun), 
Tinospora cordifolia (Gloe), Averroa carambola (Kamrak) in various mouse models for the prevention and treatment of skin, stomach and liver 
cancers. It has been found that most of these plant extract have prophylactic potential in reducing the incidence of cancer and delaying the 
appearance of tumors. These results have been published in various national & International peer reviewed journals as well as presented in 
several international conferences. Investigations are ongoing to find out the active constituents / single molecule for the use in clinics for the 
cancer management. 
 
Gordon J. McDougall, PhD - Senior Research Scientist, Environmental and Biochemical Sciences Group, Enhancing Crop Productivity and 
Utilisation Theme at the James Hutton Institute in Dundee, Scotland. Dr McDougall’s research has four main overlapping and interdependent 
areas: (1) The establishment of bioactivities relevant to human health for berry polyphenols; (2) the analysis of the composition of polyphenols 
in bioactive extracts to confirm structure-activity relationships for effectiveness and to assess the stability and bioavailability of active 
components in the human body; (3) the development of high through-put methods to analyze the inheritance of bioactive polyphenols in 
berries, to link the ‘health' phenotype to the genotype of The James Hutton Institute’s elite germplasm collection and; (4) to assess 








Sustained Proliferative Signalling 
 
Mark Feitelson, PhD, Temple University (USA) - Professor in the Department of Biology and Co-Director of the Temple University 
Biotechnology Center at Temple since 2007, Dr Feitelson focuses his research on the hepatitis B and C viruses and their role in engendering 
liver cancer. The hepatitis B virus (HBV) is among the most common infections in the world, affecting approximately 2 billion people (mostly 
in developing countries in Asia and Africa). In effect, the hepatitis B and C viruses cause their host cells to acquire the quick growth and 
resistance to immune elimination characteristics of cancer cells in the course of promoting their own survival. Liver cancer itself often 
follows. The current model for managing aggressively mutating viral infections is combination therapies, or "drug cocktails."  Feitelson has 
formed strong ties with the HBV research community in China where HBV-associated diseases are a national priority. 
Evading Growth Suppressors 
 
Dong M. Shin, MD, FACP, Emory University (USA) - Professor of Hematology and Oncology, and Otolaryngology; Associate Director of 
Academic Development for Emory Winship Cancer Institute and Director of the Emory Winship Cancer Chemoprevention Program. Dr. Shin’s 
research focus is in head, neck and lung cancers. During the past 20 his research has been in the following areas: Establishing carcinogenesis 
models in preclinical and clinical settings for head, neck and lung cancer; developing biomarkers in animal and human carcinogenesis for 
head, neck and lung cancer; developing molecular targeted prevention and therapies using epidermal growth factor receptor (EGFR) 
signaling pathways (i.e., EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors cyclooxygenase-2 (COX-2) inhibitors and other 
molecular targeted molecules including green tea polyphenons; and developing novel therapeutics (clinical or translational protocols) for 
head and neck cancer, lung cancer, thymoma and mesothelioma. He is also currently focused on new drug delivery to cancer patients using 
nanotechnology.  
Resistance to Apoptosis 
 
Ramzi M. Mohammad, PhD, Wayne State University (USA) - Professor, Department of Oncology and Director of GI Research at the Wayne 
State University Karmanos Cancer Institute in Detroit, Michigan. Dr. Mohammad’s research is translational in nature and through his close 
work with clinicians he was able to introduce several experimental drugs into the clinic among which include Bryostatin-1, Aurastatin-PE, 
Dolastatin-10 and CA-4 (cambertastatin-4) and other small molecule inhibitors of Bcl-2 such as AT-101 (gossypol) and HMD2.  His lab has 
new BH3-mimetic small molecule inhibitor that disarms anti-apoptotic Bcl2-family proteins, by displacing natural pro-apoptotic proteins 
which use their BH3 domain to bind to Bcl-2. They have established mouse xenograft models from pancreatic cancer, colon cancer and 
lymphoma and leukemia, facilitating studies of drug efficacy and mechanism of action in vivo. Currently, his lab is also investigating several 
SMIs including novel HDM2 inhibitors and Mcl-1 inhibitors.. Dr. Mohammad has more than 25 years of cancer research experience, including 
extensive experience in molecular biology, animal models and tissue culture. He has established a number of pancreatic cancer and other 
hematological malignancies cell lines and was among the first to establish pancreatic orthotopic models, in which he has years of experience 
in studying the effects of new anticancer agents, marine products as well as standard chemotherapeutic drugs. Dr. Mohammad’s research is 
translational in nature and through his close work with clinicians. 
Replicative Immortality 
 
Paul Yaswen, PhD, Lawrence Berkeley National Laboratory (USA) - Staff Scientist, Life Sciences Division, Lawrence Berkeley National 
Laboratory.    Dr Yaswen’s lab studies developmental pathways that govern proliferative potential in normal and abnormal human epithelial 
stem and progenitor cells. While the p16INK4A gene is best known for its role in tumor suppression, it also has been shown to play a role in 
stem cell commitment. We have now shown that the repressive effect of p16 on a developmentally and oncogenically important gene, 
hTERT - encoding the catalytic subunit of telomerase, can be dissociated from the repressive effect of p16 on genes required for cell cycle 
progression, raising the possibility that there exists a heirarchy of p16 functions, and that p16-associated senscence is an aberrant 
differentiation response to internal or external stresses. Telomerase expression is critical for the unlimited proliferative potential of human 
stem cells, but is repressed in most other lineage restricted and differentiated somatic cells, probably as a mechanism for tumor 




Fredika Robertson, PhD, The University of Texas (USA) - Professor, Department of Experimental Therapeutics, The University of Texas MD 
Anderson Cancer Center, Department of Experimental Therapeutics; Director of Translational Research, Morgan Welch Inflammatory Breast 
Cancer Research Program, Houston, Texas and Regular Member of the Graduate Faculty at The University of Texas Graduate School of 
Biomedical Sciences, Houston, TX.  The research in Dr Robertson’s laboratory is directed at understanding the genomic and proteomic 
alterations that are hallmarks of cellular transformation in the breast, skin and head and neck. There is a strong interest in her laboratory to 
use proteins and peptides identified by proteomic analysis for development of approaches for earlier detection of tumors and as targets for 
development of novel therapies for specific tumor types which match their specific characteristics, post-transcriptional mechanisms 
regulating gene expression. In addition, her laboratory is also involved in multidisciplinary studies to use nanotechnology platforms as a 
means to accelerate development of diagnostics and therapeutic modalities for use in translational research and ultimately for clinical use 
  






Byoung S. Kwon, PhD,  National Cancer Center  (Korea) - Endowed Investigator in the Division of Cell and Immunobiology, R&D Center for 
Cancer Therapeutics, National Cancer Center Goyang , Republic of Korea and Professor of Ophthalmology at the Louisiana State University 
School of Medicine Eye Center, in New Orleans, Louisiana, USA.  Dr Kwon’s research interests include communication network of immune 
cells and he has published extensively on immunotherapy against cancers and autoimmune diseases.  
 
Tissue Invasion and Metastasis 
 
Wen G. Jiang, MD, PhD, Cardiff University School of Medicine (United Kingdom) - Professor of surgery and tumour biology at the Cardiff 
University School of Medicine, Cardiff, UK.  Dr Jiang leads a team with an interest in cancer. Professor Jiang graduated from the Beijing 
Medical University (presently Peking University Health Science Centre) in 1984 and had worked in Peking's First Teaching Hospital (BeiDa 
Hospital) as a Surgical Resident and Chief Surgical Resident. He came to Cardiff in 1989 and studied his M.D. degree at the University of 
Wales College of Medicine (currently Cardiff University School of Medicine) and received his M.D. degree in 1995. He was a Senior Lecturer 
and Reader at the Cardiff University and was appointed to the current Chair position in 2004. Professor Jiang's main academic interest is 
cancer metastasis and angiogenesis in solid tumours including breast and prostate cancer.  
Dysregulated Metabolism 
 
Matt Hirschey, PhD, Duke University (United States) - Assistant Professor in the Department of Medicine, Division of Endocrinology, 
Metabolism and Nutrition and in the Department of Pharmacology & Cancer Biology at Duke University Medical Center, and faculty member 
of the Sarah W. Stedman Nutrition and Metabolism Center at Duke. Dr Hirschey's research focuses on genes, proteins, and pathways that 
control metabolism, and his lab explores different aspects of the biology of mitochondrial energy production as a crucial cellular process 










Lynnette Ferguson, DPhil, DSc, University of Auckland (New Zealand) – Professor at the Auckland Cancer Society Research Centre and the 
Head of the Department Nutrition Department in the School of Medical Sciences at The University of Auckland in New Zealand. Dr 
Ferguson’s current research considers the interplay between genes and diet in the development of chronic disease, with particular focus on 
inflammatory bowel disease and prostate cancer.  
 
The Tumor Microenvironment 
 
Nancy Boudreau, Ph.D. University of California San Francisco (USA) - Professor, Department of Surgery and Director Surgical Research 
Laboratory at University of California San Francisco. Dr.Boudreau’s laboratory studies the role of the Homeobox (Hox) family of master 
transcriptional regulators and their impact on the tumor microenvironment.  The loss of key Hox factors has been linked to tumorigenic 
progression, with loss of Hox genes leading to disruption of epithelial cell polarity as well as activation of angiogenic vessels and increasing pro-
tumorigenic immune cell infiltration. As it is becoming increasingly appreciated that tumors are tissue rather than cell based diseases, the Hox 
morphoregulatory genes have the potential to coordinately impact various components of the tumor microenvironment.   Her laboratory has 
been developing genetic mouse models and gene therapy experimental approaches to demonstrate that restoration of normal Hox gene 
expression in tumorigenic tissue can significantly stabilize the tumor microenvironment. 
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This document has been produced by Getting to Know Cancer, a non-profit organization that is based in Nova 
Scotia, Canada and focused on integrative cancer research.  These terms of reference are intended to provide 
guidance for lead authors that have been selected to participate in the Halifax Project, an initiative that is focused 
on “A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy”.    
 
We believe that the current (mainstream) approach to cancer chemotherapy i.e., one that focuses mainly on 
cytotoxics and/or chemicals aimed at single targets, has serious limitations that must be improved upon.  While 
some important therapeutic gains have certainly been achieved using this approach in a number of cancer types, 
disease relapse (caused by adaptive resistance) continues to be a significant problem in the clinic.  At the same 
time, drug toxicities and multiple drug resistance issues have severely constrained the physician’s ability pursue 
more than just a handful of relevant targets in refractory cancers.   
 
Consequently, we intend to leverage the rapid advances in our knowledge of the mechanics of the disease to 
develop a more sophisticated non-toxic, broad-spectrum approach to prophylaxis and therapy (i.e., one that will be 
aimed at many prioritized targets simultaneously).  It is our belief that a broad spectrum approach of this sort will 
have a much better chance of success against a wide range of cancer types and in overcoming the problem of 
adaptive resistance.  
 
To accomplish this objective, an expansive and rapidly growing body of cancer research will need to be considered, 
so the project has been conceived using a task force model.  Hundreds of expressions of interest have now been 
received (from a wide range of senior cancer researchers from around the globe) and we now plan to assemble 11 
cross-functional teams that will each prepare an important review in advance of a planned workshop that will take 
place in Halifax, Nova Scotia in August 2013.  The teams will each cover a separate topic initially and the workshop 
will then give the task force an opportunity to come together to discuss the research,  and ultimately to map out a 
framework for an integrative broad-spectrum approach that should have prophylactic and therapeutic relevance.   
 
The work that will be undertaken in this project will be captured in a planned special issue of “Seminars in Cancer 
Biology”.  So if you have been selected as a lead-author for this project, it means that your specialized research 
focus, your publishing track record and your history of collaborative research are all truly impressive, and that you 
have definitely stood out amongst your peers. We believe that this initiative has the potential to result in a 
landmark publication that will make a significant contribution to the longstanding war on cancer.  I would therefore 
like to personally thank each of you for accepting a leadership role in this project.  We are confident in your abilities 






President and Cofounder  
Getting to Know Cancer 










The approach that will be used in this project will be guided by a number of key assumptions in the following areas:  
The Scope of Each Review  
The first assumption is that this is a large scale problem that needs to be studied in a holistic manner.  Accordingly, 
we decided that a series of overarching reviews that collectively assessed and prioritize the many therapeutic 
target choices that exist was needed.  To that end, the “Hallmarks of Cancer” framework was chosen as a 
framework to help us organize the many forms of cellular, tissue and systemic forms of disruption (both genetic 
and epigenetic) that are known to exist in all cancer types.   
With this framework as a starting point, we ultimately settled on eleven overarching review topics, as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
11. Tumor microenvironment (tissue interactions - i.e., not inflammation, immune system, deregulated metabolism 
or other topics)    
Each lead author will be provided with an electronic copy of both Hallmarks of Cancer reviews (Hanahan and 
Weinberg, 2000 and 2011) and you will be expected to review these topic areas as they are described in this 
framework.  However, as experts who have been asked to lead each of these reviews, each of you will have a 
degree of latitude in the way in which you approach your own topic.  We are not endorsing Hanahan and 
Weinberg’s views in each of these topic areas.  Rather we simply needed a way to organize the expanse of cancer 
research literature.   So, we are quite open to your team’s perspective and interpretation of the literature in each 
of these areas.    
For example, if you see one or more subtopics that aren’t mentioned in the Hanahan and Weinberg framework, but 
you believe that the subtopic(s) is/are important and need to be addressed, you can include that detail in your 
review, so long as the change doesn’t create overlap with any of the other work that is being done by any of the 
other teams.  If there is a subtopic that you weren’t aware was going to covered in your review, you should look 
specifically at the composition of your team to ensure you have the expertise to cover it.   And if there is any other 
ambiguity over what should or shouldn’t be included in your particular review, please don’t hesitate to contact 
Leroy Lowe (leroy.lowe@gettingtoknowcancer.org) with the details and he will liaise with the guest editors and 
organizing committee as needed to provide additional clarification.   
 
Prioritized Targets   
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The second assumption that we have made is that not all therapeutic targets are equal.  It is already well 
established that certain targets tend to be more immediately relevant than others in specific types of cancer (e.g. 
estrogen signalling in hormone-dependent breast cancer).  However, genetic instability results in mutated 
subpopulations of cells that often depend on non-canonical pathways for survival, so we aren’t asking the teams to 
focus on any one cancer type.  Instead, we want you and your team to start with the assumption that all cells have 
the same genetic machinery at their disposal and we want you to look at the fundamental enabling mechanisms 
that are relevant for your own review, and then we want you to identify and prioritize therapeutic targets that will 
have relevance for all cancer types.    
Given that cancer can be impacted by a number of bodily systems and by phenomena that occur at both the tissue-
level and the cellular-level, we understand that therapeutic targets can be chosen that act both directly and 
indirectly, and on any one of a number of different levels.   We also know that mutational analysis has revealed a 
wide range of mutations along many different signalling pathways.  Therefore it can be reasoned that certain 
therapeutic actions may be more powerful than others (depending on whether or not they occur upstream or 
downstream of the disrupted site).   Also targets that are unique to cancer cells, or that are not likely to cause 
negative side effects when acted upon, are obviously preferred.  So we think that a careful analysis of the 
kinds/categories of defects that can occur in each area will be needed combined with a parallel assessment of the 
kinds of therapeutic actions that will have the greatest potential to help (relevant in the greatest number of 
circumstances) and the least potential to harm (cause adverse side effects).  
Some assistance in this regard in analysis can be gleaned from the work that is emerging in the many cancer 
genome projects that are starting to categorize mutations for each cancer type.   One of the early studies that 
mapped these mutations was published as a 2008 article in the journal “Science”.  It was titled Core Signaling 
Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses and it was authored by Sian Jones et 
al.  This is an important analysis because the authors performed a comprehensive genetic analysis of 24 pancreatic 
cancers by determining the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, and they 
searched for homozygous deletions and amplifications in the tumor DNA and they found that pancreatic cancers 
contain an average of 63 genetic alterations, the majority of which are point mutations. These alterations defined a 
core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the 
tumors.    
While this was only for a single cancer type, one of the contributing authors to that project was Dr. Bert Vogelstein 
and he has since been tracking the results of 852 studies that have now been published describing the genomes of 
23 different cancers.   At a recent NIH lecture (Feb 2012), he explained that researchers have generated vast 
amounts of data about cancer genomes in more than 125 whole genome studies and more than 725 whole exome 
studies to date which has “really revealed the details of what the cancer genomes look like and has greatly 
illuminated the genetic basis as well as the physiologic basis of cancers”.  Surprisingly, most cancer tumors have 
only 20 and 80 key mutations (which includes mutations that affect coding for amino acids and with exceptions 
being in tumors that have a DNA repair defect where a rapid accumulation of mutations per tumor can be 
expected).   So we now know that the mutation rate in cancer genomes—at the DNA base-pair level—is only 
marginally higher than for normal cells, but cancers can have other kinds of alterations in their genome as well that 
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cause structural changes in tumors, particularly deletions of tumor suppressor genes, amplifications of cancer-
promoting oncogenes and translocations of either of those genes1.   
Nonetheless, it appears that the tumors in many cancer types tend to have a similar mutations that align 
themselves with the same 12 pathways and processes that were initially found to be disrupted in pancreatic 
cancer.  So as part of your analysis, your team should look at each of these 12 pathways and processes to 
determine which of them are relevant for the area that your team is reviewing, and use the ones that are relevant 
to consider how the presence of mutations in any of these categories will affect the sorts of target choices that will 
made for a therapeutic approach.    
Vogelstein et al at Johns Hopkins University have just published an impressive review and update on this topic titled 
“Cancer Genome Landscapes”.  The article was published in Science, 29 March 2013: Vol. 339 no. 6127 pp. 1546-
1558.   The review offers a compilation of important oncogenes and tumor suppressors and it directly speaks to the 
issue of genetic heterogeneity and the rationale for prioritizing therapeutic targets.  It is a “must read”, and should 




Figure 1 - The 12 pathways and processes whose component genes were genetically altered in most pancreatic cancers 
 
Similarly, commonly encountered and relevant forms of virally-induced disruption could also be considered.  
Obviously, given the number of possible sites for disruption, the review article that your team is producing will not 
need to include this sort of an analysis.  But certainly your team should consider the nature of these 12 pathways 
and processes along with any other common or well known categories of disruption, especially if this sort of 
                                                          
1
 Extracted from the NIH Record article Vogelstein Considers Cancer Genome at Trent Lecture By Raymond 
MacDougall http://nihrecord.od.nih.gov 
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mechanistic analysis can help your team rationalize why certain types of therapeutic targets are more important  
than others.  
Note that it is our stated goal to pursue a non-toxic and broad-spectrum approach to therapeutic targeting that will 
be focused on many targets simultaneously.  So one could argue that a prioritization of targets will not be needed 
(i.e., since all targets will be of interest). But there may still be practical limits (e.g., adverse interactions, combined 
toxicity, multiple drug resistance etc) that ultimately constrain the number of targets that can be realistically 
pursued, and there will likely be research gaps where no known chemicals have been identified that have shown 
potential to reach certain targets, so a prioritization of targets will be useful in any event.  
 
Strategic Concerns 
Another important assumption that we are making is that each team should consider the ways in which their 
particular area of study impacts the other areas that are being studied and the overall progression of the disease.  
This is important because each team should offer some reflective thoughts in their review on high-level or strategic 
issues that need to be considered and each team should critically consider whether or not therapeutic intervention 
in their area within the framework of a holistic broad spectrum approach even makes sense.  
For example, some researchers who study genetic instability are focused on ways in which we might make cancer 
cells more unstable to create the sort of instability that will result in cell death.  But if adaptive resistance is enabled 
by genetic instability do we really want to make cancer cells more unstable?   
Similarly, we now have a decade of experience using anti-angiogenesis as a therapeutic strategy, but a number of 
studies have shown that cutting off the blood supply to tumors increases oxidative stress.  While this approach 
does trigger apoptosis in many immortalized cells, in some cases it can contribute to genetic instability, which can 
result in additional mutations, therapeutic resistance, and ultimately more aggressive cancers that are even more 
difficult to treat.  So in the broader scheme of things, even though we know how to suppress angiogenesis, the 
team reviewing this area needs to consider this area strategically and determine whether or not we should be using 
an anti-angiogenic strategy if we hope to emerge with a broad-spectrum therapeutic design that can reach many 
molecular targets simultaneously. 
Note that neither of the two examples offered above are intended to limit or definitively shape the reflective 
commentary that will be offered by the lead authors and the teams that will need to provide insights into these two 
topic areas (i.e., genetic instability and angiogenesis).   Rather these examples are simply intended to illustrate that 
it will be important for each team to think critically about whether or not therapeutic targeting and intervention is 
warranted or advised given the relationships that exists between any given topic area that is being reviewed and 
the other areas that this task force is reviewing (i.e., if the overall approach will involve a broad spectrum of targets 
across many of the areas).     
Cutting-edge Therapeutic Research 
The third important assumption that will guide this project is the fact that clinical research that has already been 
conducted may help us understand the relevance and importance of various possible targets.  This may include 
clinical research that involves mainstream pharmaceuticals, but it should also include progressive clinical 
approaches that are now being employed in integrative cancer care settings where a much wider range of 
therapeutic targets are often pursued.  
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As a team lead, you will be provided with a copy of the book “Life over Cancer”.  The book was written by Keith I. 
Block, MD.  He is one of the editors of the planned special issue that will capture this work, and he is an 
internationally recognized expert in integrative oncology.  Referred to by many as the “father of integrative 
oncology,” Dr. Block combines cutting-edge conventional treatment with individualized and scientifically-based 
complementary and nutraceutical therapies.  In 1980, he co-founded with Penny B. Block, Ph.D. the Block Center 
for Integrative Cancer Treatment in Evanston, Illinois.  It was the first such facility in North America, and he still 
serves as its Medical and Scientific Director.  Dr. Block was also invited by Sage Science Press in 2000 to be the 
founding Editor-in-Chief of the Integrative Cancer Therapies journal.  The journal was the first medical journal 
devoted to exploring the research and science behind integrative oncology and he is still the Editor-in-Chief of this 
peer-reviewed publication.   
“Life over Cancer” was written for the public so it is not intended as a technical guide, but it will help each of you 
understand just how far progressive clinical oncologists have moved on their own towards a therapeutic approach 
that is aimed at broad-spectrum of relevant targets.  This is a field where clinicians are already trying to find non-
toxic combinations of biologically active therapeutics to help defeat adaptive resistance, and these clinics are using 
other non-chemical support techniques as well.  So the book is intended to serve as a useful reference to help you 
understand how this review effort can translate into advances in the clinic.  In addition, we suggest that each team 
should have team members who have either clinical experience or a good understanding of integrative cancer 
therapy, or both.  As the work that has been done in clinical trials and in these progressive clinics should help 
inform our work in this project.  
Phtyochemicals 
The fourth assumption that we have made is that phytochemicals are going to be important.  We have placed a 
considerable emphasis on phtyochemicals and other natural chemicals that are found in foods in this project, 
because once your team has identified a set of prioritized targets in your area of study, you are being asked to 
identify promising chemicals or compounds that might be employed to reach those targets.   Ideally, the most 
promising candidate chemicals (for a therapeutic approach aimed at a broad spectrum of targets) will the following 
attributes:  
1) A desired action on a biological target of interest 
2) Favorable pharmacokinetic properties  
3) A broad therapeutic index  
It isn’t that we think that all phtyochemicals are completely safe.  Nor do we think that all phtyochemicals of 
interest will have the full range of favorable attributes that we are seeking.  But there has been an abundance of 
promising research in this area in the past decade that has highlighted the potential offered by a wide range of 
phtyochemicals and other natural compounds that are potent in inhibiting tumor and/or cancer development 
without the sorts of toxicity that are typically associated existing (approved) chemotherapeutic agents, so we 
expect that this will be a fruitful area of research that should have considerable promise and relevance for this 
project.  To that end, we suggest that every team should have at least one or two anticancer researchers who 
specialize in phytochemical research.     
Again, we are not committed to phtyochemicals or natural compounds per se, and any synthetic chemicals that are 
identified that meet these same criteria can also be highlighted.  But the safety issue is a big concern that must be 
emphasized because the past decade of new synthetic therapies has apparently done little to solve this problem.    
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In the August 2012 issue of the Journal of Clinical Oncology, an article by S. Niraula et al. entitled “The Price We Pay 
for progress: A Meta-Analyis of Harms of Newly Approved Anti-cancer Drugs” reviewed 38 randomized controlled 
trials that each assessed a novel anticancer drug that was approved for the treatment of solid tumours by the FDA 
between 2000 and 2010 and compared the safety of “new” agents against that of traditional chemotherapy.   The 
meta-analysis of these clinical trials had three safety and tolerability end points: treatment-related death, 
treatment discontinuation related to toxicity, and grade 3 or 4 adverse events.   And the authors found that, 
compared with control groups, the odds of toxic death was greater for new agents (OR, 1.40; 95% CI, 1.15 to 1.70; P 
< .001) as were the odds of treatment-discontinuation (OR, 1.33; 95% CI, 1.22 to 1.45, P < .001) and grade 3 or 4 
adverse events (OR, 1.52; 95% CI, 1.35 to 1. 71; P < .001).  Moreover the authors added that, it could be anticipated 
that the use of drugs in clinical practice (i.e., where patients are less frequently screened for good performance 
status and fewer comorbidities) may lead to an even less favourable balance between efficacy and toxicity.  So 
while targeted anticancer therapies are often touted as having improved safety profiles (in comparison to the toxic 
effects associated with older forms of chemotherapy), this meta-analysis has shown that the therapies that were 
reviewed are even more toxic than their older counterparts. 
This importance of this issue cannot be emphasized enough.  We are focused on prioritized targets of relevance in 
each review and the identification of chemicals or compounds that appear to have promise to act favorably on each 
of those targets (i.e., without the sorts of characteristics that will quickly result in toxicity or induce multiple drug 
resistance mechanisms when employed in combination with other chemicals).  But evidence should be sought in 
each of these reviews for prospective chemicals that appear to have the widest possible margins of safety.    
Suggested therapeutic approaches that are ultimately employed could be via any one of a number of possible 
routes (e.g., oral, inhalation, transdermal, intravenous / intra-arterial infusion, intermittent infusion etc), and 
clinical approaches could involve the use of mixtures, sequentially administered individual chemicals, or an 
alternating regimen of chemicals administered over an extended period of time.      
Intellectual Property 
The fifth assumption that we have made is that, in a project where a long list of targets and possible chemical 
therapeutics are being delineated, issues over existing intellectual property could become an important problem.  
We therefore believe that our overall objectives will be best served if the teams focus on chemicals or compounds 
that are not patented and/or not patentable, and there are two primary reasons for this approach.   
First and foremost, once the conceptual groundwork that is being undertaken in this project is complete, it is our 
intent to further promote additional and incremental translational research that will hopefully be able to provide 
evidence to support the idea that a broad-spectrum approach to prophylaxis and therapy has merit.  And while 
intellectual property issues may not hinder these initial subsequent steps, we are acutely aware that each step 
forward in translational research relies on successes that have already been demonstrated.  So we do not want to 
rely on a patchwork of chemicals and compounds that have patent rights assigned to them, because this sort of 
obligation to patent holders could eventually derail translational research and/or clinical use at some future point 
in time (i.e., if any one of a number of patent holders were not amenable to the terms of use being proposed).      
The second reason relates to cost and public need.  The current trend in targeted therapies has served to degrade 
the economies of scale that are often achieved by pharmaceutical companies (i.e., when the costs of research, trials 
and regulatory approval for a single agent can be spread out over a very large patient population).  Instead, with 
the advent of targeted therapies, these costs, which can be very high, are increasingly being shouldered by smaller 
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and smaller groups of cancer patients who have a similar type of cancer, and that trend has resulted in escalating 
prices for cancer therapeutics.  Indeed many western nations are struggling to cope with the cost of these new 
targeted forms of cancer therapy, and many poorer nations have been effectively shut out of the market because 
they are simply unable to afford the new offerings).   Therefore we would prefer to focus on a broad spectrum 
approach that is not encumbered with patent rights, so that subsequent translational research (potentially at labs 
and government institutions around the globe) will not be hindered in any way.    
Having said that, we are quite aware that the trend at the university and institutional level is to leverage the 
monetary gains that can be earned with intellectual property, and we also know that many researchers on this task 
force are patent holders in their own right.  But our aims in this task force are not purely intellectual.  We are 
ultimately focused on the practical, so as each team identifies chemicals or compounds that can be used to reach 
specific prioritized targets, preference should be given to agents that are not being controlled by patent holders.  
And in instances where patents are being held, these should be noted.  This detail may not be included in the final 
published set of reviews, but we are keenly interested in making sure that these sorts of stumbling blocks are 
identified.     
Prophylaxis versus Therapy  
Given that cancer can take a long time to develop, and that it is a disease that can grow rapidly once it is fully 
developed (due to the exponential growth that is inherent in cells that are routinely doubling), by the time disease 
is detected the physician and the patient often very little time remaining to stop the disease.  Yet it is well known 
that a cancer diagnosis in the clinic often occurs many years after the disease began, so  it has long been 
understood that prevention and/or early intervention is the best approach.  We are therefore working under the 
assumption that an optimized broad-spectrum approach that is truly non-toxic and largely plant-based may also 
have the potential to be relatively low cost.   
Therefore it has been assumed that some part of the proposed approach may have the potential to be employed as 
a prophylactic measure.  This could take the form of a daily intervention at the population level, especially for high 
risk individuals.  Or perhaps it might be a useful approach as a rapid response (i.e., as soon as a patient is 
diagnosed), or even as a safeguard that is used by patients who have completed more aggressive therapy, such as 
radiation surgery or aggressive chemotherapy, and who are then at risk of relapse.     
While it may not be possible in this project to foresee all of the ways in which this approach might be employed.  
Teams will be asked to look specifically at the safety issues and determine whether or recommendations for a 
broad spectrum therapeutic approach would need to be altered or modified for chronically administered 
prophylactic applications.   
Format of the Reviews 
In summary, the goal of each review is for each team to develop a detailed appreciation for the design 
considerations that must be taken into account if a broad-spectrum combination chemotherapy approach is going 





Describe the approach being taken and place the research in the context of the larger 
project.   
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Topic Area Overview  Provide a high-level overview of the progress that has been made in the understanding of 
the area that the team has been tasked to review including areas of broad agreement and 
any major areas of contention within the field.   
Dysfunction 
 
Describe the kinds/categories of external disruption, and/or systemic or cellular-level 
dysfunction in the area under review that contribute to the enablement the immortalization 
of cancerous cells 
Contribution 
 
Describe any fundamental interactions or relationships that exist between the topic area 












Look specifically at the safety issues and determine whether or recommendations for a 
broad spectrum therapeutic approach would need to be altered or modified for chronically 
administered prophylactic applications 
Discussion  
 
Provide reflective commentary that describes any strategic decisions or tradeoffs that are 
germane to that topic area that will need to be considered in the process of developing an 
optimized and truly holistic therapeutic design. Also make recommendations for any 
additional research that will be needed 
 
 





Note that each of the review should also consider any research that is related to the unique nature of cancer stem 
cells and the tumor microenvironment, and germane to the topic area being reviewed.    
 
Each review should be approximately twenty pages in length including references.  The Seminars in Cancer Biology 
format allows for roughly 1200 words per page (this is obviously affected by any artwork or tables that are needed).  





It is crucial to bear in mind that our goal is to develop a framework for an approach to therapy (and also for 
prophylaxis) that will be focused at a broad spectrum of targets, and that the Halifax project is an undertaking that 
has an entirely practical outcome in mind.  That means that each team must be focused on one part of the problem 
in a way that results in very specific recommendations that can be translated into follow-on research, and 
eventually trials of some sort.   
Each of the teams has been tasked to undertake a traditional academic review, but the discussion and conclusion 
sections of these papers should push beyond where a traditional academic review would normally end.  In other 
words, it’s not enough to highlight the main pathways and mechanisms that are relevant for the area under study, 
the various approaches and/or targeted therapeutics in that area that have been identified.   We need the 
discussion and conclusion sections of each paper to be focused in a manner that will feed directly into the 
translational challenge that will follow.   
 Page 11 
 
 
Therefore each team should ultimately produce and include a short list of no more than ten prioritized targets 
(rank ordered if possible, based on estimation of importance) for their area of concern.  A “target” could be system 
level (e.g., the stress- axis”), organ level, tissue level, cellular-level or intra-cellular mechanistic level.   And for each 
of the prioritized targets, a single favored approach should be recommended.  An “approach” could be a technique 
that will cause the body to respond in a manner that will act on the target (e.g., fasting, exercise etc.), or it could be 
a procedure involving an entity that can act on the target (e.g., orally administered compound/chemical, 
vaccination with peptides, locally administered oncolytic virus etc).   
In many cases, there will many possible approaches that will emerge for each of the targets that the team 
prioritizes.  This is where you will need to make trade-offs to make selections.  A “favored” approach should first 
and foremost consider safety as a top priority.  This is paramount (above all else) and should serve as the first 
hurdle in your assessment of suitability.    
 Safety – Least likely to cause harm or side effects (even in combination with many other approaches)  
Additionally a “favored” approach should also serve the following three equally-weighted criteria: 
 Efficacy – Greatest potential to achieve the desired action on the intended target across the widest 
possible range of cancer types 
 Cost – Less expensive is better, and by no means cost prohibitive  
 Intellectual Property – Free of intellectual property constraints if at all possible.   Approaches that do not 
have patents, that cannot be patented, and/or those that have patents that are expired are to be given 
priority over those that have existing patents.  
Ultimately, we want each team to produce specific recommendations for a multi-pronged approach for prophylaxis 
and for therapy (in their area of study).  These should have the potential to be so benign that they could easily be 
employed alongside the great number of other approaches that will be suggested by the other teams.  Currently, 
combination approaches to therapy are typically limited to two or three chemicals due to toxicity constraints.  Yet if 
all 11 teams identify as many as 10 targets each and they all make suggestions for one approach per target.  We 
could easily end up with 100+ approaches which will create an enormous translational challenge, so each of these 
criteria need to be carefully weighed and considered.   
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Assembling the Teams 
 
We now have more than 300 expressions of interest from researchers who want to take part in the project.  Our 
first priority is to quickly assemble the teams that are needed.  Eleven lead authors are being recruited, and we are 
envisioning eleven teams that will each have 10-12 contributing authors.   
As the lead author for one of the teams, you will be provided with a list of prospective candidates and asked to 
identify 10-15 priority candidates from the list that appear to be well suited to the task (i.e., based on their ability 
to contribute to the review that needs to be produced).  As noted above, the team composition should be cross-
functional and roughly align itself with the following structure.    
1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other experts 
who will collectively be responsible for producing a descriptive overview that encompasses the topic area, as 
well as a description the types of systemic or cellular-level dysfunction in that topic area that contribute to the 
immortalization of cancerous cells, any relationships that exist between that particular topic and the other 
topic areas under consideration, and a reflective strategic commentary.  Given the scale of the cancer genome, 
the task of this group will be to produce a compact synthesis of the literature that categorizes and prioritizes 
the therapeutic targets that would be most relevant for a broad-spectrum therapeutic design.  
 
2. Anti-cancer Phytochemical Specialists – Each team will also have a number of cancer scientists who 
specialize in research that focuses on the anti-cancer effects of naturally occurring chemicals that are found in 
plants and foods.  Their role will be to identify chemicals that appear well suited to reach the identified targets. 
 
3. Clinical Oncologists – where possible, each team will also have at least one or two oncologist who have 
clinical research experience and/or clinical experience in an integrative cancer care setting (human or 
veterinary).    
 
4. Support Researchers - Senior scientists who are selected to join the task force will also be able to nominate a 
single post-doctoral researcher (or PhD candidate) within their own lab to participate in the team’s work at no 
extra cost.  These researchers will receive authorship recognition for their contributions to the team’s work.  
However, in instances where a support researcher has been nominated as a contributing author, only one of 
the two (i.e., the nominator or the nominee) will be able to attend the workshop in Halifax in August of 2013.  
We know that it is important to provide opportunities for post-doctoral researchers to get involved, but in this 
particular project it is equally important that we also ensure that the number of attendees at the working 
sessions in Halifax remains manageable.     These contributing authors will need to be identified as soon as the 
teams are fully assembled.   
 
Since the cost of participation is the only fee that needs to be collected (to cover the publication costs), a bias will 
be shown for researchers who have indicated that they have funding for the participation fee.  However, some 
buffer has been built into the project to allow for fee waivers for a small number of researchers if we have strong 
applicants who do not have funding.  Therefore, as a lead author, you should keep this in mind as you are selecting 
prospective team members. 
You are also encouraged to identify researchers in your own lab, or institution, or even peers who you have worked 
with in the past that might be interested in joining your team and being part of the effort.  If anyone plans to take 
part in the project, please make sure that they have filled out the expression of interest form (found online at 
http://www.gettingtoknowcancer.org/thehalifaxproject ).  Once you have had a chance to look at the candidates 
who have applied to take part in the project, and consider others who might be willing to help you, you will also 
need to identify any capability gaps that you see, so additional research expertise will be recruited for your team (if 
necessary).   
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We expect that your team will ultimately be comprised of 10-12 researchers, but the exact number of team 
members will ultimately be collaboratively determined based on your suggestions and inputs from the Getting to 
Know Cancer President, Leroy Lowe.  We have some flexibility in the numbers needed for team construction and 
we will work with each of you to ensure you have the expertise needed to successfully complete the task.    
Your list of top prospective candidates and your assessment of any capability gaps should therefore be returned to 
Leroy Lowe ( leroy.lowe@gettingtoknowcancer.org ) as soon as possible.  Offers will then be extended to those 
who have been identified as prospective team members, and new invitations will be extended to outside 
researchers as we try to fill any capability gaps that have been identified.     
 
The Biomarker and Approach Validation Team  
All of the teams will also have the support of a substantial, cross-functional group of scientists who will be part of 
the “Biomarker and Approach Validation Team”.   This team will validate the prioritized targets and approaches 
that are selected by each team by taking target and approach recommendations and then conducting a thorough 
background literature research to identify instances when a particular target or approach that is of interest to one 
of the teams also has relevance for the topics being studied by other teams.   
 
For example, if the team reviewing sustained proliferative signalling selected HER-2 (the EGFR receptor) as a 
prioritized target, the Biomarker and Disruptor Validation Team would then review the literature to determine 
whether or not a blocking action at that particular site would be expected to produce complementary contributions 
for any of the other areas under review (see Figure 3 shown below).  This same process will be undertaken for all of 
prioritized target sites that are selected by each of the teams, and for all of the approaches that are selected by the 
teams as well.   
 
Note that this group has been increased in size considerably because of the scale of their task.  Since we are asking 
each of the 11 teams to generate a list of prioritized targets (as many as 10) along with specific chemicals or 
approaches that can be used to act on each of those targets, the validation effort will be substantial.  As each team 
produces their priority list, we are then planning to use the biomarker and approach validation team to review each 
target and each of the proposed approaches/chemicals for known effects across all of the other ten areas that are 
being researched.  This is important because if the task force is going to focus on future research that will involve a 
mixture of chemicals and/or approaches to reach a significant number of targets, it will be important to ensure that 
none of the selections being made by any of the teams are working at cross purposes to the recommendations 
being made by the other teams.  So these validation efforts will be captured in tabular form in each of the planned 
reviews, and the contributions of this team will also be acknowledged and credited in the list of contributing 
authors for each of the planned reviews.   
 











Capstone Synthesis and Review 
As noted above, the two-day workshop will involve one day of presentations from each of the eleven teams to 
allow for discussion, questions and answers, followed by a collaborative series of meetings on the second day that 
will give the teams an opportunity to address trade-offs and then to build consensus around the next steps that will 
be needed to address obstacles and ultimately validate a proposed therapeutic design.   
 
The lead-authors from each team will subsequently collaborate to produce a capstone synthesis and review that 
will summarize the integrated findings from the second day of the workshop and make recommendations for the 
way ahead.  Although the lead authors will be primarily responsible for the final article, the team members should 
be engaged and consulted for inputs as the final article is coming together and all contributing author on the 
project will be named in the final article.    
 
Timelines 
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Key dates for the various aspects of the project are as follows:  
 
 Lead Authors Appointed:   July 31st, 2012 
 Teams Fully Assembled;   August 30th, 2012 
 First Draft of Individual Reviews:  July 1st, 2013 
 Halifax 2-day Workshop:   August 12th-13th , 2013 
 Final Draft of Individual Reviews November 1st, 2013 
 Final Draft of Capstone Synthesis November 15th, 2013 
 
Questions 
If any aspect of this document is not clear, or if you want clarification on any aspect of the project, please contact 
Leroy Lowe ( leroy.lowe@gettingtoknowcancer.org ) asap and we will provide additional guidance as needed.  
Priority Items Checklist 
 
 
1. Email the best delivery address (for parcel delivery) to leroy.lowe@gettingtoknowcancer.org asap so you be 
provided with a copy of the book “Life over Cancer”, which was written by Keith I. Block, MD.    
Deadline – August 10th, 2012  
   
 
 
2. Please read both Hallmarks of Cancer reviews (Hanahan and Weinberg, 2000 and 2011) with an emphasis 
on the topic area that you have been asked to review.  Make sure that you understand the nature of the 
various subtopics that have been included in each of the areas and then draft your own outline based on 
any additional coverage that you foresee as being needed.  
 
IMPORTANT - Note that the planned reviews on inflammation and the immune system should include 
discussions on the tumor microenvironment.  While the planned review on the tumor microenvironment 
will not encompass those topic areas. 
   
 
3. Draft an outline of the subtopics that you plan to cover in the “Topic Area Overview” section of your review  
and send this to leroy.lowe@gettingtoknowcancer.org as soon as it is ready  
Deadline – August 31st, 2012  
 
 
4. Review the list of prospective candidates that has been provided to you and consider asking your own 
colleagues or other peers to join your team.  Also indentify any capability gaps that exist (recruiting for your 
team that is needed) and send a list of 10-15 priority candidates to leroy.lowe@gettingtoknowcancer.org as 
soon as it is ready 
Deadline – August 31st, 2012  
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Guest Editors for the Special Issue 
 
 
Keith I. Block, MD - Co-founder, and Medical and Scientific Director of the Block Center for Integrative Cancer Treatment in Evanston, 
Illinois. Director of Integrative Medical Education at the University of Illinois College of Medicine at Chicago. Scientific Director of the 
Institute for Integrative Cancer Research and Education, where he has collaborated with colleagues at the University of Illinois at Chicago, 
the University of Texas M.D. Anderson Cancer Center in Houston and Bar Ilan University in Israel. In 2005, he was appointed to the 
National Cancer Institute’s Physician Data Query (PDQ) Cancer CAM Editorial Board, on which he continues to serve today. 
 
Anupam Bishayee, PhD – Founding Chair and Professor in the Department of Pharmaceutical Sciences in the School of Pharmacy, 
American University of Health Sciences, Signal Hill, California. Dr Bishayee’s research for the last 17 years focuses on elucidation of the 
protective, chemopreventive and therapeutic effects of medicinal plants and natural products and their synthetic analogs in pre-clinical 
animal models of breast, prostate and liver cancer. His current research program aims to investigate mechanism-based chemopreventive 
and therapeutic modalities of dietary and plant-based phytochemicals, including resveratrol from grapes, anthocyanans from berries as 




Workshop Organizing Committee 
 
 
Elizabeth Ryan, PhD, Colorado State University (USA)  - Dr. Ryan is an Assistant Professor in the Department of Clinical Sciences at Colorado 
State University. Her research is currently focused on immune modulation and anti-cancer activity of bioactive components in rice bran. She 
actively evaluates genetically diverse rice cultivars from around the world supplied by collaborations at the International Rice Research 
Institute, USDA Rice Research Unit and Rice Researchers in India. In addition to mouse studies and human trials, she is developing the canine 
cancer model to investigate alternative medicine modalities during cancer treatment as a new scope of research at the CSU Animal Cancer 
Center. The hope is to expand and develop evidence-based research on complementary and alternative medicines that include 
phytochemically rich foods in oncology by using highly translational, naturally occurring cancers in companion animals. Phytochemicals from 
rice bran, beans, fermented Chinese tea, and milk thistle are the medicinal plants currently under investigation for their affects on 
modulating tumor metabolism 
 
Pradeep Kumar Goyal, PhD, University of Rajasthan (India) – Professor & Principal Investigator in the Radiation & Cancer Biology 
Laboratory, Department of Zoology, University of Rajasthan, Jaipur, India. Dr Goyal’s lab has been investigating the extracts of various 
medicinal plants e.g. Emblica officinalis (Amla), Rosemary officinalis (Rosemary), Alstonia scholaris (Sapthaparna), Aegle marmelos (Bael), 
Phyllanthus niruri (Bhumi amla), Syzgium cumini (Jamun), Tinospora cordifolia (Gloe), Averroa carambola (Kamrak) in various mouse models 
for the prevention and treatment of skin, stomach and liver cancers. It has been found that most of these plant extract have prophylactic 
potential in reducing the incidence of cancer and delaying the appearance of tumors. These results have been published in various national 
& International peer reviewed journals as well as presented in several international conferences. Investigations are ongoing to find out the 
active constituents / single molecule for the use in clinics for the cancer management. 
 
Gordon J. McDougall, PhD, James Hutton Institute (Scotland)  - Senior Research Scientist, Environmental and Biochemical Sciences Group, 
Enhancing Crop Productivity and Utilisation Theme at the James Hutton Institute in Dundee, Scotland. Dr McDougall’s research has four 
main overlapping and interdependent areas: (1) The establishment of bioactivities relevant to human health for berry polyphenols; (2) the 
analysis of the composition of polyphenols in bioactive extracts to confirm structure-activity relationships for effectiveness and to assess the 
stability and bioavailability of active components in the human body; (3) the development of high through-put methods to analyze the 
inheritance of bioactive polyphenols in berries, to link the ‘health' phenotype to the genotype of The James Hutton Institute’s elite 








Sustained Proliferative Signalling 
 
Mark Feitelson, PhD, Temple University (USA) - Professor in the Department of Biology and Co-Director of the Temple University 
Biotechnology Center at Temple since 2007, Dr Feitelson focuses his research on the hepatitis B and C viruses and their role in engendering 
liver cancer. The hepatitis B virus (HBV) is among the most common infections in the world, affecting approximately 2 billion people (mostly 
in developing countries in Asia and Africa). In effect, the hepatitis B and C viruses cause their host cells to acquire the quick growth and 
resistance to immune elimination characteristics of cancer cells in the course of promoting their own survival. Liver cancer itself often 
follows. The current model for managing aggressively mutating viral infections is combination therapies, or "drug cocktails."  Feitelson has 
formed strong ties with the HBV research community in China where HBV-associated diseases are a national priority. 
Evading Growth Suppressors 
 
Dong M. Shin, MD, FACP, Emory University (USA) - Professor of Hematology and Oncology, and Otolaryngology; Associate Director of 
Academic Development for Emory Winship Cancer Institute and Director of the Emory Winship Cancer Chemoprevention Program. Dr. 
Shin’s research focus is in head, neck and lung cancers. During the past 20 his research has been in the following areas: Establishing 
carcinogenesis models in preclinical and clinical settings for head, neck and lung cancer; developing biomarkers in animal and human 
carcinogenesis for head, neck and lung cancer; developing molecular targeted prevention and therapies using epidermal growth factor 
receptor (EGFR) signaling pathways (i.e., EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors cyclooxygenase-2 (COX-2) inhibitors 
and other molecular targeted molecules including green tea polyphenons; and developing novel therapeutics (clinical or translational 
protocols) for head and neck cancer, lung cancer, thymoma and mesothelioma. He is also currently focused on new drug delivery to cancer 
patients using nanotechnology.  
Resistance to Apoptosis 
 
Ramzi M. Mohammad, PhD, Wayne State University (USA) - Professor, Department of Oncology and Director of GI Research at the Wayne 
State University Karmanos Cancer Institute in Detroit, Michigan. Dr. Mohammad’s research is translational in nature and through his close 
work with clinicians he was able to introduce several experimental drugs into the clinic among which include Bryostatin-1, Aurastatin-PE, 
Dolastatin-10 and CA-4 (cambertastatin-4) and other small molecule inhibitors of Bcl-2 such as AT-101 (gossypol) and HMD2.  His lab has 
new BH3-mimetic small molecule inhibitor that disarms anti-apoptotic Bcl2-family proteins, by displacing natural pro-apoptotic proteins 
which use their BH3 domain to bind to Bcl-2. They have established mouse xenograft models from pancreatic cancer, colon cancer and 
lymphoma and leukemia, facilitating studies of drug efficacy and mechanism of action in vivo. Currently, his lab is also investigating several 
SMIs including novel HDM2 inhibitors and Mcl-1 inhibitors.. Dr. Mohammad has more than 25 years of cancer research experience, 
including extensive experience in molecular biology, animal models and tissue culture. He has established a number of pancreatic cancer 
and other hematological malignancies cell lines and was among the first to establish pancreatic orthotopic models, in which he has years of 
experience in studying the effects of new anticancer agents, marine products as well as standard chemotherapeutic drugs. Dr. Mohammad’s 
research is translational in nature and through his close work with clinicians. 
Replicative Immortality 
 
Paul Yaswen, PhD, Lawrence Berkeley National Laboratory (USA) - Staff Scientist, Life Sciences Division, Lawrence Berkeley National 
Laboratory.    Dr Yaswen’s lab studies developmental pathways that govern proliferative potential in normal and abnormal human epithelial 
stem and progenitor cells. While the p16INK4A gene is best known for its role in tumor suppression, it also has been shown to play a role in 
stem cell commitment. We have now shown that the repressive effect of p16 on a developmentally and oncogenically important gene, 
hTERT - encoding the catalytic subunit of telomerase, can be dissociated from the repressive effect of p16 on genes required for cell cycle 
progression, raising the possibility that there exists a heirarchy of p16 functions, and that p16-associated senscence is an aberrant 
differentiation response to internal or external stresses. Telomerase expression is critical for the unlimited proliferative potential of human 
stem cells, but is repressed in most other lineage restricted and differentiated somatic cells, probably as a mechanism for tumor 




Fredika Robertson, PhD, The University of Texas (USA) - Professor, Department of Experimental Therapeutics, The University of Texas MD 
Anderson Cancer Center, Department of Experimental Therapeutics; Director of Translational Research, Morgan Welch Inflammatory Breast 
Cancer Research Program, Houston, Texas and Regular Member of the Graduate Faculty at The University of Texas Graduate School of 
Biomedical Sciences, Houston, TX.  The research in Dr Robertson’s laboratory is directed at understanding the genomic and proteomic 
alterations that are hallmarks of cellular transformation in the breast, skin and head and neck. There is a strong interest in her laboratory to 
use proteins and peptides identified by proteomic analysis for development of approaches for earlier detection of tumors and as targets for 
development of novel therapies for specific tumor types which match their specific characteristics, post-transcriptional mechanisms 
regulating gene expression. In addition, her laboratory is also involved in multidisciplinary studies to use nanotechnology platforms as a 
means to accelerate development of diagnostics and therapeutic modalities for use in translational research and ultimately for clinical use 
  





Byoung S. Kwon, PhD,  National Cancer Center  (Korea) - Endowed Investigator in the Division of Cell and Immunobiology, R&D Center for 
Cancer Therapeutics, National Cancer Center Goyang , Republic of Korea and Professor of Ophthalmology at the Louisiana State University 
School of Medicine Eye Center, in New Orleans, Louisiana, USA.  Dr Kwon’s research interests include communication network of immune 
cells and he has published extensively on immunotherapy against cancers and autoimmune diseases.  
Tissue Invasion and Metastasis 
 
Wen G. Jiang, MD, PhD, Cardiff University School of Medicine (United Kingdom) - Professor of surgery and tumour biology at the Cardiff 
University School of Medicine, Cardiff, UK.  Dr Jiang leads a team with an interest in cancer. Professor Jiang graduated from the Beijing 
Medical University (presently Peking University Health Science Centre) in 1984 and had worked in Peking's First Teaching Hospital (BeiDa 
Hospital) as a Surgical Resident and Chief Surgical Resident. He came to Cardiff in 1989 and studied his M.D. degree at the University of 
Wales College of Medicine (currently Cardiff University School of Medicine) and received his M.D. degree in 1995. He was a Senior Lecturer 
and Reader at the Cardiff University and was appointed to the current Chair position in 2004. Professor Jiang's main academic interest is 
cancer metastasis and angiogenesis in solid tumours including breast and prostate cancer.  
Dysregulated Metabolism 
 
Matt Hirschey, PhD, Duke University (United States) - Assistant Professor in the Department of Medicine, Division of Endocrinology, 
Metabolism and Nutrition and in the Department of Pharmacology & Cancer Biology at Duke University Medical Center, and faculty member 
of the Sarah W. Stedman Nutrition and Metabolism Center at Duke. Dr Hirschey's research focuses on genes, proteins, and pathways that 
control metabolism, and his lab explores different aspects of the biology of mitochondrial energy production as a crucial cellular process 






Yihai Cao, MD, PhD, Karolinska Institutet (Sweden) - Dr Cao is a Professor of Vascular Biology, in the Department of Microbiology and Tumor 
and Cell Biology (since 2004). His research group is focused on the regulation of angiogenesis, the mechanisms behind pathological 
angiogenesis, and on the development of novel therapeutic strategies based on angiogenesis and anti-angiogenesis for cancer and other 




Lynnette Ferguson, DPhil, DSc, University of Auckland (New Zealand) – Professor at the Auckland Cancer Society Research Centre and the 
Head of the Department Nutrition Department in the School of Medical Sciences at The University of Auckland in New Zealand. Dr 
Ferguson’s current research considers the interplay between genes and diet in the development of chronic disease, with particular focus on 




Nancy Boudreau, Ph.D. University of California San Francisco (USA) - Professor, Department of Surgery and Director Surgical Research 
Laboratory at University of California San Francisco. Dr.Boudreau’s laboratory studies the role of the Homeobox (Hox) family of master 
transcriptional regulators and their impact on the tumor microenvironment.  The loss of key Hox factors has been linked to tumorigenic 
progression, with loss of Hox genes leading to disruption of epithelial cell polarity as well as activation of angiogenic vessels and increasing 
pro-tumorigenic immune cell infiltration. As it is becoming increasingly appreciated that tumors are tissue rather than cell based diseases, the 
Hox morphoregulatory genes have the potential to coordinately impact various components of the tumor microenvironment.   Her laboratory 
has been developing genetic mouse models and gene therapy experimental approaches to demonstrate that restoration of normal Hox gene 




Kanya Honoki, MD, PhD, Nara Medical Univeristy (Japan) - Assistant professor and chief of musculoskeletal oncology unit in the 
Department of Orthopedic Surgery, Arthroplasty and Regenerative Medicine at Nara Medical University, Japan. Expertized in basic and 
clinical orthopedic oncology, cancer cell biology and stem cell biology, regenerative and restorative medicine. Has been working mainly on 
the pathogenesis of sarcomas using own-established rat sarcoma model and human materials, focusing on molecular and cellular 
mechanisms of disease progression such as invasion, metastasis and drug-resistance, which includes a role of stem cell population in 
sarcomas. Current research interest is stem cell aging and cancer development. Engaged as an active member of both American and 
European Association for Cancer Research, Japanese Cancer Association and International Society for Stem Cell Research, and also an 
editorial board member and reviewer of several international societies and journals 
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This document has been produced by Getting to Know Cancer, a non-profit organization that is based in Nova 
Scotia, Canada and focused on integrative cancer research.  These terms of reference are intended to provide 
guidance for lead authors that have been selected to participate in the Halifax Project, an initiative that is focused 
on “A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy”.    
 
We believe that the current (mainstream) approach to cancer chemotherapy i.e., one that focuses mainly on 
cytotoxics and/or chemicals aimed at single targets, has serious limitations that must be improved upon.  While 
some important therapeutic gains have certainly been achieved using this approach in a number of cancer types, 
disease relapse (caused by adaptive resistance) continues to be a significant problem in the clinic.  At the same 
time, drug toxicities and multiple drug resistance issues have severely constrained the physician’s ability pursue 
more than just a handful of relevant targets in refractory cancers.   
 
Consequently, we intend to leverage the rapid advances in our knowledge of the mechanics of the disease to 
develop a more sophisticated non-toxic, broad-spectrum approach to prophylaxis and therapy (i.e., one that will be 
aimed at many prioritized targets simultaneously).  It is our belief that a broad spectrum approach of this sort will 
have a much better chance of success against a wide range of cancer types and in overcoming the problem of 
adaptive resistance.  
 
To accomplish this objective, an expansive and rapidly growing body of cancer research will need to be considered, 
so the project has been conceived using a task force model.  The task force is comprised of 11 cross-functional 
teams that will each prepare an important review in advance of a planned workshop that will take place in Halifax, 
Nova Scotia in August 2013.  The teams will each cover a separate topic initially and the workshop will then give all 
of the teams in the task force an opportunity to come together to discuss the research,  and ultimately to map out 
a framework for an integrative broad-spectrum approach that should have prophylactic and therapeutic relevance.   
 
The work that will be undertaken in this project will be captured in a planned special issue of “Seminars in Cancer 
Biology” and we have fielded hundreds of expressions of interest from scientists around the globe.  So if you have 
been selected as a contributing author for this project, it means that your specialized research focus, your 
publishing track record and your history of collaborative research are all truly impressive, and that you have 
definitely stood out amongst your peers.  
 
We believe that this initiative has the potential to result in a landmark publication that will make a significant 
contribution to the longstanding war on cancer.  I would therefore like to personally thank each of you for 
accepting a role as a contributing author in this project.  We are confident in your abilities and we are optimistic 





President and Cofounder  
Getting to Know Cancer 










The approach that will be used in this project will be guided by a number of key assumptions in the following areas:  
The Scope of Each Review  
The first assumption is that this is a large scale problem that needs to be studied in a holistic manner.  Accordingly, 
we decided that a series of overarching reviews that collectively assessed and prioritize the many therapeutic 
target choices that exist was needed.  To that end, the “Hallmarks of Cancer” framework was chosen as a 
framework to help us organize the many forms of cellular, tissue and systemic forms of disruption (both genetic 
and epigenetic) that are known to exist in all cancer types.  With this framework as a starting point, we ultimately 
settled on eleven overarching review topics, as follows: 
1. Genetic Instability 
2. Tumor Promoting Inflammation 
3. Sustained Proliferative Signalling 
4. Evasion of Anti-growth Signalling 
5. Resistance to Apoptosis 
6. Replicative Immortality  
7. Deregulated Metabolism  
8. Immune System Evasion 
9. Angiogenesis 
10. Tissue Invasion and Metastasis 
11. Tissue Interactions in the Tumor Microenvironment (i.e., not inflammation, immune system, deregulated 
metabolism or other Tumor Microenvironment topics)    
You will be provided with an electronic copy of both Hallmarks of Cancer reviews (Hanahan and Weinberg, 2000 
and 2011) and you will be expected to review these topic areas as they are described in this framework.  However, 
the lead authors who have been asked to lead each of these reviews will have a degree of latitude in the way in 
which they approach each topic.  In other words, we are not endorsing Hanahan and Weinberg’s views in each of 
these topic areas.  Rather we simply needed a way to organize the expanse of cancer research literature.   So each 
will be free to review the literature and interpret the literature in their own topic area as they see fit.    
For example, if your team leader sees one or more subtopics that aren’t mentioned in the Hanahan and Weinberg 
framework, and believes that the subtopic(s) is/are important and need to be addressed, that topic can be included 
in your review, so long as the change doesn’t create overlap with any of the other work that is being done by any of 
the other teams. And if there is any other ambiguity over what should or shouldn’t be included in your particular 
review, please don’t hesitate to contact Leroy Lowe (leroy.lowe@gettingtoknowcancer.org) with the details and he 
will liaise with the guest editors and organizing committee as needed to provide additional clarification.   
  
 Page 4 
 
 
Prioritized Targets   
The second assumption that we have made is that not all therapeutic targets are equal.  It is already well 
established that certain targets tend to be more immediately relevant than others in specific types of cancer (e.g. 
estrogen signalling in hormone-dependent breast cancer).  However, in most cancers genetic instability results in 
mutated subpopulations of cells that often depend on non-canonical pathways for survival, so we aren’t asking the 
teams to focus on any one cancer type.  Instead, we want each team to start with the assumption that all cells have 
the same genetic machinery at their disposal and we want you to look at the fundamental enabling mechanisms 
that are relevant for your own review, and then we want you to identify and prioritize therapeutic targets that will 
have relevance for all cancer types.    
Given that cancer can be impacted by a number of bodily systems and by phenomena that occur at both the tissue-
level and the cellular-level, we understand that therapeutic targets can be chosen that act both directly and 
indirectly, and on any one of a number of different levels.   We also know that mutational analysis has revealed a 
wide range of mutations along many different signalling pathways.  Therefore it can be reasoned that certain 
therapeutic actions may be more powerful than others (depending on whether or not they occur upstream or 
downstream of the disrupted site).   Also targets that are unique to cancer cells, or that are not likely to cause 
negative side effects when acted upon, are obviously preferred.  So we think that a careful analysis of the 
kinds/categories of defects that can occur in each area will be needed combined with a parallel assessment of the 
kinds of therapeutic actions that will have the greatest potential to help (relevant in the greatest number of 
circumstances) and the least potential to harm (cause adverse side effects).  
Some assistance in this regard can be gleaned from the work that is emerging in the many cancer genome projects 
that are starting to categorize mutations for each cancer type.   One of the early studies that mapped these 
mutations was published as a 2008 article in the journal “Science”.  It was titled Core Signaling Pathways in Human 
Pancreatic Cancers Revealed by Global Genomic Analyses and it was authored by Sian Jones et al.  This is an 
important analysis because the authors performed a comprehensive genetic analysis of 24 pancreatic cancers by 
determining the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, and they searched for 
homozygous deletions and amplifications in the tumor DNA and they found that pancreatic cancers contain an 
average of 63 genetic alterations, the majority of which are point mutations. These alterations defined a core set of 
12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors.    
While this was only for a single cancer type, one of the contributing authors to that project was Dr. Bert Vogelstein 
and he has since been tracking the results of 852 studies that have now been published describing the genomes of 
23 different cancers.   At a Feb 2012 NIH lecture, Vogelstein explained that researchers have generated vast 
amounts of data about cancer genomes in more than 125 whole genome studies and more than 725 whole exome 
studies to date which has “really revealed the details of what the cancer genomes look like and has greatly 
illuminated the genetic basis as well as the physiologic basis of cancers”.  Surprisingly, he notes that most cancer 
tumors have only 20 and 80 key mutations (which includes mutations that affect coding for amino acids and with 
exceptions being in tumors that have a DNA repair defect where a rapid accumulation of mutations per tumor can 
be expected).   So we now know that the mutation rate in cancer genomes—at the DNA base-pair level—is only 
marginally higher than for normal cells.  But cancers can have other kinds of alterations in their genome as well that 
cause structural changes in tumors, particularly deletions of tumor suppressor genes, amplifications of cancer-
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promoting oncogenes and translocations of either of those genes1.  Nonetheless, it appears that the tumors in 
many cancer types tend to have a similar mutations that align themselves with the same 12 pathways and 
processes that were initially found to be disrupted in pancreatic cancer.     
Vogelstein et al at Johns Hopkins University have just published an impressive review and update on this topic titled 
“Cancer Genome Landscapes”.  The article was published in Science, 29 March 2013: Vol. 339 no. 6127 pp. 1546-
1558.   The review offers a compilation of important oncogenes and tumor suppressors and it directly speaks to the 
issue of genetic heterogeneity and the rationale for prioritizing therapeutic targets.  It is a “must read”, and should 
serve as an important reference for everyone involved in this project.   
So as part of your analysis, your team should be looking at each of these 12 pathways and processes to determine 
which of them are relevant for the area that your team is reviewing, and how the presence of mutations in these 
categories will affect the sorts of prioritized target choices that will made for a broad-spectrum therapeutic 




Figure 1 - The 12 pathways and processes whose component genes were genetically altered in most pancreatic cancers 
 
Similarly, commonly encountered and relevant forms of virally-induced disruption could also be considered.  
Obviously, given the number of possible sites for disruption, the review article that your team is producing will not 
include this sort of analysis.  But certainly your team should be informally considering the nature of these 12 
pathways and processes along with any other common or well known categories of disruption, especially if this sort 
                                                          
1
 Extracted from the NIH Record article Vogelstein Considers Cancer Genome at Trent Lecture By Raymond 
MacDougall http://nihrecord.od.nih.gov 
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of mechanistic analysis can help your team rationalize why certain types of therapeutic targets are likely to be more 
important than others.  
Note that it is our stated goal to pursue a non-toxic and broad-spectrum approach to therapeutic targeting that will 
be focused on many targets simultaneously.  So one could argue that a prioritization of targets will not be needed 
(i.e., since all targets will be of interest). But there will be practical limits to the number of therapeutic agents that 
can employed simultaneously in any attempt to use this sort of broad-spectrum approach in a clinical setting (e.g., 
adverse interactions, combined toxicity, multiple drug resistance etc), so some sort of a reasoned prioritization of 
possible targets will be important.  
 
Strategic Concerns 
Another important assumption that we are making is that each team should consider the ways in which their 
particular area of study impacts the other areas that are being studied and the overall progression of the disease.  
This is important because each team should offer some reflective thoughts in their review on high-level or strategic 
issues that need to be considered and each team should critically consider whether or not therapeutic intervention 
in their area within the framework of a holistic broad spectrum approach even makes sense.  
For example, some researchers who study genetic instability are focused on ways in which we might make cancer 
cells more unstable to create the sort of instability that will result in cell death.  But if adaptive resistance is enabled 
by genetic instability do we really want to make cancer cells more unstable?   
Similarly, we now have a decade of experience using anti-angiogenesis as a therapeutic strategy, but a number of 
studies have shown that cutting off the blood supply to tumors increases oxidative stress.  While this approach 
does trigger apoptosis in many immortalized cells, in some cases it can contribute to genetic instability, which can 
result in additional mutations, therapeutic resistance, and ultimately more aggressive cancers that are even more 
difficult to treat.  So in the broader scheme of things, even though we know how to suppress angiogenesis, the 
team reviewing this area needs to consider this area strategically and determine whether or not we should be using 
an anti-angiogenic strategy if we hope to emerge with a broad-spectrum therapeutic design that can reach many 
molecular targets simultaneously. 
Note that neither of the two examples offered above are intended to limit or definitively shape the reflective 
commentary that will be offered by those particular teams (i.e., genetic instability and angiogenesis).   Rather these 
examples are simply intended to illustrate that it will be important for each team to think critically about whether 
or not therapeutic targeting and intervention is warranted or advised given the relationships that exists between a 
given topic area that is being reviewed and the other areas that other teams on this task force are also reviewing 
(i.e., if the overall approach will involve a broad spectrum of targets across many of the areas).     
    
Cutting-edge Therapeutic Research 
The third important assumption that will guide this project is the fact that clinical research that has already been 
conducted may help us understand the relevance and importance of various possible targets.  This may include 
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clinical research that involves mainstream pharmaceuticals, but it should also include progressive clinical 
approaches that are now being employed in integrative cancer care settings where a much wider range of 
therapeutic targets are often pursued.  
Exemplary work along these lines has been undertaken by Keith I. Block, MD, who is one of the two co-editors of 
the planned special issue that will capture the work of this task force.   He is referred to by many as the “father of 
integrative oncology” and he combines cutting-edge conventional treatment with individualized and scientifically-
based complementary and nutraceutical therapies.  In 1980, he co-founded with Penny B. Block, Ph.D. the Block 
Center for Integrative Cancer Treatment in Evanston, Illinois.  It was the first such facility in North America, and he 
still serves as its Medical and Scientific Director.    Dr. Block was also invited by Sage Science Press in 2000 to be the 
founding Editor-in-Chief of the Integrative Cancer Therapies journal.  It was the first medical journal devoted to 
exploring the research and science behind integrative oncology and he is still the Editor-in-Chief of this peer-
reviewed publication.   
Dr Block recently authored a book called “Life over Cancer” (available at Amazon.com) which offers a good 
overview of his approach.  While the book was written for the public, it is a useful supplement if you want to know 
more about this topic because it can help you understand just how far progressive some practitioners have 
advanced on their own (i.e., towards a therapeutic approach that is aimed at broad-spectrum of relevant targets).   
In other words, clinicians are already trying to find non-toxic combinations of biologically active therapeutics to 
help defeat adaptive resistance, and these clinics are using other non-chemical support techniques as well.   
In any event, your team should have at least a couple of team members who have either clinical experience or a 
good understanding of integrative cancer therapy, or both.  As the work that has been done in clinical trials and in 
these progressive clinics should help inform your work in this project.  
 
Phtyochemicals 
The fourth assumption that we have made is that phytochemicals are going to be important.  We have placed a 
considerable emphasis on phtyochemicals and other natural chemicals that are found in foods in this project, 
because once your team has identified a set of prioritized targets in your area of study, you are being asked to 
identify promising chemicals or compounds that might be employed to reach those targets.   Ideally, the most 
promising candidate chemicals (for a therapeutic approach aimed at a broad spectrum of targets) will the following 
attributes:  
1) A desired action on a biological target of interest 
2) Favorable pharmacokinetic properties  
3) A broad therapeutic index  
It isn’t that we think that all phtyochemicals are completely safe.  Nor do we think that all phtyochemicals of 
interest will have the full range of favorable attributes that we are seeking.  But there has been an abundance of 
promising research in this area in the past decade that has highlighted the potential offered by a wide range of 
phtyochemicals and other natural compounds that are potent in inhibiting tumor and/or cancer development 
without the sorts of toxicity that are typically associated existing (approved) chemotherapeutic agents, so we 
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expect that this will be a fruitful area of research that should have considerable promise and relevance for this 
project.  To that end, we suggest that every team should have at least one or two anticancer researchers who 
specialize in phytochemical research.     
Again, we are not committed to phtyochemicals or natural compounds per se, and any synthetic chemicals that are 
identified that meet these same criteria can also be highlighted.  But the safety issue is a big concern that must be 
emphasized because the past decade of new synthetic therapies has apparently done little to solve this problem.    
In the August 2012 issue of the Journal of Clinical Oncology, an article by S. Niraula et al. entitled “The Price We Pay 
for progress: A Meta-Analyis of Harms of Newly Approved Anti-cancer Drugs” reviewed 38 randomized controlled 
trials that each assessed a novel anticancer drug that was approved for the treatment of solid tumours by the FDA 
between 2000 and 2010 and compared the safety of “new” agents against that of traditional chemotherapy.   The 
meta-analysis of these clinical trials had three safety and tolerability end points: treatment-related death, 
treatment discontinuation related to toxicity, and grade 3 or 4 adverse events.   And the authors found that, 
compared with control groups, the odds of toxic death was greater for new agents (OR, 1.40; 95% CI, 1.15 to 1.70; P 
< .001) as were the odds of treatment-discontinuation (OR, 1.33; 95% CI, 1.22 to 1.45, P < .001) and grade 3 or 4 
adverse events (OR, 1.52; 95% CI, 1.35 to 1. 71; P < .001).  Moreover the authors added that, it could be anticipated 
that the use of drugs in clinical practice (i.e., where patients are less frequently screened for good performance 
status and fewer comorbidities) may lead to an even less favourable balance between efficacy and toxicity.  So 
while targeted anticancer therapies are often touted as having improved safety profiles (in comparison to the toxic 
effects associated with older forms of chemotherapy), this meta-analysis has shown that the therapies that were 
reviewed are even more toxic than their older counterparts. 
This importance of this issue cannot be emphasized enough.  We are focused on prioritized targets of relevance in 
each review and the identification of chemicals or compounds that appear to have promise to act favorably on each 
of those targets (i.e., without the sorts of characteristics that will quickly result in toxicity or induce multiple drug 
resistance mechanisms when employed in combination with other chemicals).  But evidence should be sought in 
each of these reviews for prospective chemicals that appear to have the widest possible margins of safety.    
Suggested therapeutic approaches that are ultimately employed could be via any one of a number of possible 
routes (e.g., oral, inhalation, transdermal, intravenous / intra-arterial infusion, intermittent infusion etc), and 
clinical approaches could involve the use of mixtures, sequentially administered individual chemicals, or an 
alternating regimen of chemicals administered over an extended period of time.      
Intellectual Property 
The fifth assumption that we have made is that, in a project where a long list of targets and possible chemical 
therapeutics are being delineated, issues over existing intellectual property could become an important problem.  
We therefore believe that our overall objectives will be best served if the teams focus on chemicals or compounds 
that are not patented and/or not patentable, and there are two primary reasons for this approach.   
First and foremost, once the conceptual groundwork that is being undertaken in this project is complete, it is our 
intent to further promote additional and incremental translational research that will hopefully be able to provide 
evidence to support the idea that a broad-spectrum approach to prophylaxis and therapy has merit.  And while 
intellectual property issues may not hinder these initial subsequent steps, we are acutely aware that each step 
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forward in translational research relies on successes that have already been demonstrated.  So we do not want to 
rely on a patchwork of chemicals and compounds that have patent rights assigned to them, because this sort of 
obligation to patent holders could eventually derail translational research and/or clinical use at some future point 
in time (i.e., if any one of a number of patent holders were not amenable to the terms of use being proposed).      
The second reason relates to cost and public need.  The current trend in targeted therapies has served to degrade 
the economies of scale that are often achieved by pharmaceutical companies (i.e., when the costs of research, trials 
and regulatory approval for a single agent can be spread out over a very large patient population).  Instead, with 
the advent of targeted therapies, these costs, which can be very high, are increasingly being shouldered by smaller 
and smaller groups of cancer patients who have a similar type of cancer, and that trend has resulted in escalating 
prices for cancer therapeutics.  Indeed many western nations are struggling to cope with the cost of these new 
targeted forms of cancer therapy, and many poorer nations have been effectively shut out of the market because 
they are simply unable to afford the new offerings).   Therefore we would prefer to focus on a broad spectrum 
approach that is not encumbered with patent rights, so that subsequent translational research (potentially at labs 
and government institutions around the globe) will not be hindered in any way.    
Having said that, we are quite aware that the trend at the university and institutional level is to leverage the 
monetary gains that can be earned with intellectual property, and we also know that many researchers on this task 
force are patent holders in their own right.  But our aims in this task force are not purely intellectual.  We are 
ultimately focused on the practical, so as each team identifies chemicals or compounds that can be used to reach 
specific prioritized targets, preference should be given to agents that are not being controlled by patent holders.  
And in instances where patents are being held, these should be noted.  This detail may not be included in the final 
published set of reviews, but we are keenly interested in making sure that these sorts of stumbling blocks are 
identified.     
 
Prophylaxis versus Therapy  
Given that cancer can take a long time to develop, and that it is a disease that can grow rapidly once it is fully 
developed (due to the exponential growth that is inherent in cells that are routinely doubling), by the time disease 
is detected the physician and the patient often very little time remaining to stop the disease.  Yet it is well known 
that a cancer diagnosis in the clinic often occurs many years after the disease began, so  it has long been 
understood that prevention and/or early intervention is the best approach.  We are therefore working under the 
assumption that an optimized broad-spectrum approach that is truly non-toxic and largely plant-based may also 
have the potential to be relatively low cost.   
Therefore it has been assumed that some part of the proposed approach may have the potential to be employed as 
a prophylactic measure.  This could take the form of a daily intervention at the population level, especially for high 
risk individuals.  Or perhaps it might be a useful approach as a rapid response (i.e., as soon as a patient is 
diagnosed), or even as a safeguard that is used by patients who have completed more aggressive therapy, such as 
radiation surgery or aggressive chemotherapy, and who are then at risk of relapse.     
While it may not be possible in this project t o foresee all of the ways in which this approach might be employed.  
Teams will therefore be asked to look specifically at the safety issues and determine whether or recommendations 
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for a broad spectrum therapeutic approach would need to be altered or modified for chronically administered 
prophylactic applications.   
 
Format of the Reviews 
In summary, the goal of each review is for each team to develop a detailed appreciation for the design 
considerations that must be taken into account if a broad-spectrum combination chemotherapy approach is going 





Describe the approach being taken and place the research in the context of the larger 
project.   
Topic Area Overview  Provide a high-level overview of the progress that has been made in the understanding of 
the area that the team has been tasked to review including areas of broad agreement and 
any major areas of contention within the field.   
Dysfunction 
 
Describe the kinds/categories of external disruption, and/or systemic or cellular-level 
dysfunction in the area under review that contribute to the enablement the immortalization 
of cancerous cells 
Contribution 
 
Describe any fundamental interactions or relationships that exist between the topic area 












Look specifically at the safety issues and determine whether or recommendations for a 
broad spectrum therapeutic approach would need to be altered or modified for chronically 
administered prophylactic applications 
Discussion  
 
Provide reflective commentary that describes any strategic decisions or tradeoffs that are 
germane to that topic area that will need to be considered in the process of developing an 
optimized and truly holistic therapeutic design. Also make recommendations for any 
additional research that will be needed 
 
 





Note that each of the review should also consider any research that is related to the unique nature of cancer stem 
cells and the tumor microenvironment, and germane to the topic area being reviewed.    
 
Each review should be approximately twenty pages in length including references.  The Seminars in Cancer Biology 
format allows for roughly 1200 words per page (this is obviously affected by any artwork or tables that are needed).  









It is crucial to bear in mind that our goal is to develop a framework for an approach to therapy (and also for 
prophylaxis) that will be focused at a broad spectrum of targets, and that the Halifax project is an undertaking that 
has an entirely practical outcome in mind.  That means that each team must be focused on one part of the problem 
in a way that results in very specific recommendations that can be translated into follow-on research, and 
eventually trials of some sort.   
Each of the teams has been tasked to undertake a traditional academic review, but the discussion and conclusion 
sections of these papers should push beyond where a traditional academic review would normally end.  In other 
words, it’s not enough to highlight the main pathways and mechanisms that are relevant for the area under study, 
the various approaches and/or targeted therapeutics in that area that have been identified.   We need the 
discussion and conclusion sections of each paper to be focused in a manner that will feed directly into the 
translational challenge that will follow.   
Therefore each team should ultimately produce and include a short list of no more than ten prioritized targets 
(rank ordered if possible, based on estimation of importance) for their area of concern.  A “target” could be system 
level (e.g., the stress- axis”), organ level, tissue level, cellular-level or intra-cellular mechanistic level.   And for each 
of the prioritized targets, a single favored approach should be recommended.  An “approach” could be a technique 
that will cause the body to respond in a manner that will act on the target (e.g., fasting, exercise etc.), or it could be 
a procedure involving an entity that can act on the target (e.g., orally administered compound/chemical, 
vaccination with peptides, locally administered oncolytic virus etc).   
In many cases, there will many possible approaches that will emerge for each of the targets that the team 
prioritizes.  This is where you will need to make trade-offs to make selections.  A “favored” approach should first 
and foremost consider safety as a top priority.  This is paramount (above all else) and should serve as the first 
hurdle in your assessment of suitability.    
 Safety – Least likely to cause harm or side effects (even in combination with many other approaches)  
Additionally a “favored” approach should also serve the following three (equally-weighted) criteria: 
 Efficacy – Greatest potential to achieve the desired action on the intended target across the widest 
possible range of cancer types 
 Cost – Less expensive is better, and by no means cost prohibitive  
 Intellectual Property – Free of intellectual property constraints if at all possible.   Approaches that do not 
have patents, that cannot be patented, and/or those that have patents that are expired are to be given 
priority over those that have existing patents.  
Ultimately, we want each team to produce specific recommendations for a multi-pronged approach for prophylaxis 
and for therapy (in their area of study).  These should have the potential to be so benign that they could easily be 
employed alongside the great number of other approaches that will be suggested by the other teams.  Currently, 
combination approaches to therapy are typically limited to two or three chemicals due to toxicity constraints.  Yet if 
all 11 teams identify as many as 10 targets each and they all make suggestions for one approach per target.  We 
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could easily end up with 100+ approaches which will create an enormous translational challenge, so each of these 
criteria need to be carefully weighed and considered.   
 
The Composition of the Teams 
 
The task force is made up of eleven teams that are each headed by a lead author, and the composition of each 
team is intended to be cross-functional, such that it is roughly aligned with the following structure. 
    
1. Domain Experts -   The team lead for each of the eleven chosen topics will be supported by other experts 
who will collectively be responsible for producing a descriptive overview that encompasses the topic area, as 
well as a description the main types of systemic or cellular-level dysfunction in that topic area that contribute 
to the immortalization of cancerous cells, a discussion on the relationships that exist between that particular 
topic and the other topic areas under consideration, and a reflective strategic commentary.  Given the scale of 
the cancer genome, this task is not trivial but the group will need to produce a compact synthesis of the 
literature that takes the most frequent modes of dysfunction into account and then categorize and prioritize 
the therapeutic targets that would be most relevant for a broad-spectrum therapeutic design.  
 
2. Anti-cancer Phytochemical Specialists – Each team will also have a number of cancer scientists who 
specialize in research that focuses on the anti-cancer effects of naturally occurring chemicals that are found in 
plants and foods.  Their role will be to identify chemicals that appear well suited to reach the identified targets. 
 
3. Clinical Oncologists – where possible, each team will also have at least one or two oncologists with clinical 
research experience and/or clinical experience in an integrative cancer care setting (human or veterinary).    
 
4. Support Researchers - Senior scientists who are selected to join the task force will also be able to nominate a 
single post-doctoral researcher (or PhD candidate) within their own lab to participate in the team’s work at no 
extra cost.  These researchers will receive authorship recognition for their contributions to the team’s work.  
However, in instances where a support researcher has been nominated as a contributing author, only one of 
the two (i.e., the nominator or the nominee) will be able to attend the workshop in Halifax in August of 2013.  
We know that it is important to provide opportunities for post-doctoral researchers to get involved, but in this 
particular project it is equally important that we also ensure that the number of attendees at the working 
sessions in Halifax remains manageable.     These contributing authors will need to be identified as soon as the 
teams are fully assembled.   
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The Biomarker and Approach Validation Team  
All of the teams will also have the support of a substantial, cross-functional group of scientists who will be part of 
the “Biomarker and Approach Validation Team”.   This team will validate the prioritized targets and approaches 
that are selected by each team by taking target and approach recommendations and then conducting a thorough 
background literature research to identify instances when a particular target or approach that is of interest to one 
of the teams also has relevance for the topics being studied by other teams.   
 
For example, if the team reviewing sustained proliferative signalling selected HER-2 (the EGFR receptor) as a 
prioritized target, the Biomarker and Disruptor Validation Team would then review the literature to determine 
whether or not a blocking action at that particular site would be expected to produce complementary contributions 
for any of the other areas under review (see Figure 3 shown below).  This same process will be undertaken for all of 
prioritized target sites that are selected by each of the teams, and for all of the approaches that are selected by the 












Note that this group has been increased in size considerably because of the scale of their task.  Since we are asking 
each of the 11 teams to generate a list of prioritized targets (as many as 10) along with specific chemicals or 
approaches that can be used to act on each of those targets, the validation effort will be substantial.  As each team 
produces their priority list, we are then planning to use the biomarker and approach validation team to review each 
target and each of the proposed approaches/chemicals for known effects across all of the other ten areas that are 
being researched.  This is important because if the task force is going to focus on future research that will involve a 
mixture of chemicals and/or approaches to reach a significant number of targets, it will be important to ensure that 
none of the selections being made by any of the teams are working at cross purposes to the recommendations 
being made by the other teams.  So these validation efforts will be captured in tabular form in each of the planned 
reviews, and the contributions of this team will also be acknowledged and credited in the list of contributing 
authors for each of the planned reviews.   
 
Capstone Synthesis and Review 
As noted above, the two-day workshop will involve one day of presentations from each of the eleven teams to 
allow for discussion, questions and answers, followed by a collaborative series of meetings on the second day that 
will give the teams an opportunity to address trade-offs and then to build consensus around the next steps that will 
be needed to address obstacles and ultimately validate a proposed therapeutic design.   
 
The lead-authors from each team will subsequently collaborate to produce a capstone synthesis and review that 
will summarize the integrated findings from the second day of the workshop and make recommendations for the 
way ahead.  Although the lead authors will be primarily responsible for the final article, the team members should 
be engaged and consulted for inputs as the final article is coming together and all contributing author on the 
project will be named in the final article.    
 
Timelines 
Key dates for the various aspects of the project are as follows:  
 
 Lead Authors Appointed:   July 31st, 2012 
 Teams Fully Assembled;   August 30th, 2012 
 First Draft of Individual Reviews:  July 1st, 2013 
 Halifax 2-day Workshop:   August 12th-13th , 2013 
 Final Draft of Individual Reviews November 1st, 2013 
 Final Draft of Capstone Synthesis November 15th, 2013 
 
Questions 
If any aspect of this document is not clear, or if you want clarification on any aspect of the project, please contact 
Leroy Lowe ( leroy.lowe@gettingtoknowcancer.org ) asap and we will provide additional guidance as needed.  
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Guest Editors for the Special Issue 
 
 
Keith I. Block, MD - Co-founder, and Medical and Scientific Director of the Block Center for Integrative Cancer Treatment in Evanston, 
Illinois. Director of Integrative Medical Education at the University of Illinois College of Medicine at Chicago. Scientific Director of the 
Institute for Integrative Cancer Research and Education, where he has collaborated with colleagues at the University of Illinois at Chicago, 
the University of Texas M.D. Anderson Cancer Center in Houston and Bar Ilan University in Israel. In 2005, he was appointed to the 
National Cancer Institute’s Physician Data Query (PDQ) Cancer CAM Editorial Board, on which he continues to serve today. 
 
Anupam Bishayee, PhD – Founding Chair and Professor in the Department of Pharmaceutical Sciences in the School of Pharmacy, 
American University of Health Sciences, Signal Hill, California. Dr Bishayee’s research for the last 17 years focuses on elucidation of the 
protective, chemopreventive and therapeutic effects of medicinal plants and natural products and their synthetic analogs in pre-clinical 
animal models of breast, prostate and liver cancer. His current research program aims to investigate mechanism-based chemopreventive 
and therapeutic modalities of dietary and plant-based phytochemicals, including resveratrol from grapes, anthocyanans from berries as 




Workshop Organizing Committee 
 
 
Elizabeth Ryan, PhD, Colorado State University (USA)  - Dr. Ryan is an Assistant Professor in the Department of Clinical Sciences at Colorado 
State University. Her research is currently focused on immune modulation and anti-cancer activity of bioactive components in rice bran. She 
actively evaluates genetically diverse rice cultivars from around the world supplied by collaborations at the International Rice Research 
Institute, USDA Rice Research Unit and Rice Researchers in India. In addition to mouse studies and human trials, she is developing the canine 
cancer model to investigate alternative medicine modalities during cancer treatment as a new scope of research at the CSU Animal Cancer 
Center. The hope is to expand and develop evidence-based research on complementary and alternative medicines that include 
phytochemically rich foods in oncology by using highly translational, naturally occurring cancers in companion animals. Phytochemicals from 
rice bran, beans, fermented Chinese tea, and milk thistle are the medicinal plants currently under investigation for their affects on 
modulating tumor metabolism 
 
Pradeep Kumar Goyal, PhD, University of Rajasthan (India) – Professor & Principal Investigator in the Radiation & Cancer Biology 
Laboratory, Department of Zoology, University of Rajasthan, Jaipur, India. Dr Goyal’s lab has been investigating the extracts of various 
medicinal plants e.g. Emblica officinalis (Amla), Rosemary officinalis (Rosemary), Alstonia scholaris (Sapthaparna), Aegle marmelos (Bael), 
Phyllanthus niruri (Bhumi amla), Syzgium cumini (Jamun), Tinospora cordifolia (Gloe), Averroa carambola (Kamrak) in various mouse models 
for the prevention and treatment of skin, stomach and liver cancers. It has been found that most of these plant extract have prophylactic 
potential in reducing the incidence of cancer and delaying the appearance of tumors. These results have been published in various national 
& International peer reviewed journals as well as presented in several international conferences. Investigations are ongoing to find out the 
active constituents / single molecule for the use in clinics for the cancer management. 
 
Gordon J. McDougall, PhD, James Hutton Institute (Scotland)  - Senior Research Scientist, Environmental and Biochemical Sciences Group, 
Enhancing Crop Productivity and Utilisation Theme at the James Hutton Institute in Dundee, Scotland. Dr McDougall’s research has four 
main overlapping and interdependent areas: (1) The establishment of bioactivities relevant to human health for berry polyphenols; (2) the 
analysis of the composition of polyphenols in bioactive extracts to confirm structure-activity relationships for effectiveness and to assess the 
stability and bioavailability of active components in the human body; (3) the development of high through-put methods to analyze the 
inheritance of bioactive polyphenols in berries, to link the ‘health' phenotype to the genotype of The James Hutton Institute’s elite 









Sustained Proliferative Signalling 
 
Mark Feitelson, PhD, Temple University (USA) - Professor in the Department of Biology and Co-Director of the Temple University 
Biotechnology Center at Temple since 2007, Dr Feitelson focuses his research on the hepatitis B and C viruses and their role in engendering 
liver cancer. The hepatitis B virus (HBV) is among the most common infections in the world, affecting approximately 2 billion people (mostly 
in developing countries in Asia and Africa). In effect, the hepatitis B and C viruses cause their host cells to acquire the quick growth and 
resistance to immune elimination characteristics of cancer cells in the course of promoting their own survival. Liver cancer itself often 
follows. The current model for managing aggressively mutating viral infections is combination therapies, or "drug cocktails."  Feitelson has 
formed strong ties with the HBV research community in China where HBV-associated diseases are a national priority. 
Evading Growth Suppressors 
 
Dong M. Shin, MD, FACP, Emory University (USA) - Professor of Hematology and Oncology, and Otolaryngology; Associate Director of 
Academic Development for Emory Winship Cancer Institute and Director of the Emory Winship Cancer Chemoprevention Program. Dr. 
Shin’s research focus is in head, neck and lung cancers. During the past 20 his research has been in the following areas: Establishing 
carcinogenesis models in preclinical and clinical settings for head, neck and lung cancer; developing biomarkers in animal and human 
carcinogenesis for head, neck and lung cancer; developing molecular targeted prevention and therapies using epidermal growth factor 
receptor (EGFR) signaling pathways (i.e., EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors cyclooxygenase-2 (COX-2) inhibitors 
and other molecular targeted molecules including green tea polyphenons; and developing novel therapeutics (clinical or translational 
protocols) for head and neck cancer, lung cancer, thymoma and mesothelioma. He is also currently focused on new drug delivery to cancer 
patients using nanotechnology.  
Resistance to Apoptosis 
 
Ramzi M. Mohammad, PhD, Wayne State University (USA) - Professor, Department of Oncology and Director of GI Research at the Wayne 
State University Karmanos Cancer Institute in Detroit, Michigan. Dr. Mohammad’s research is translational in nature and through his close 
work with clinicians he was able to introduce several experimental drugs into the clinic among which include Bryostatin-1, Aurastatin-PE, 
Dolastatin-10 and CA-4 (cambertastatin-4) and other small molecule inhibitors of Bcl-2 such as AT-101 (gossypol) and HMD2.  His lab has 
new BH3-mimetic small molecule inhibitor that disarms anti-apoptotic Bcl2-family proteins, by displacing natural pro-apoptotic proteins 
which use their BH3 domain to bind to Bcl-2. They have established mouse xenograft models from pancreatic cancer, colon cancer and 
lymphoma and leukemia, facilitating studies of drug efficacy and mechanism of action in vivo. Currently, his lab is also investigating several 
SMIs including novel HDM2 inhibitors and Mcl-1 inhibitors.. Dr. Mohammad has more than 25 years of cancer research experience, 
including extensive experience in molecular biology, animal models and tissue culture. He has established a number of pancreatic cancer 
and other hematological malignancies cell lines and was among the first to establish pancreatic orthotopic models, in which he has years of 
experience in studying the effects of new anticancer agents, marine products as well as standard chemotherapeutic drugs. Dr. Mohammad’s 
research is translational in nature and through his close work with clinicians. 
Replicative Immortality 
 
Paul Yaswen, PhD, Lawrence Berkeley National Laboratory (USA) - Staff Scientist, Life Sciences Division, Lawrence Berkeley National 
Laboratory.    Dr Yaswen’s lab studies developmental pathways that govern proliferative potential in normal and abnormal human epithelial 
stem and progenitor cells. While the p16INK4A gene is best known for its role in tumor suppression, it also has been shown to play a role in 
stem cell commitment. We have now shown that the repressive effect of p16 on a developmentally and oncogenically important gene, 
hTERT - encoding the catalytic subunit of telomerase, can be dissociated from the repressive effect of p16 on genes required for cell cycle 
progression, raising the possibility that there exists a heirarchy of p16 functions, and that p16-associated senscence is an aberrant 
differentiation response to internal or external stresses. Telomerase expression is critical for the unlimited proliferative potential of human 
stem cells, but is repressed in most other lineage restricted and differentiated somatic cells, probably as a mechanism for tumor 




Fredika Robertson, PhD, The University of Texas (USA) - Professor, Department of Experimental Therapeutics, The University of Texas MD 
Anderson Cancer Center, Department of Experimental Therapeutics; Director of Translational Research, Morgan Welch Inflammatory Breast 
Cancer Research Program, Houston, Texas and Regular Member of the Graduate Faculty at The University of Texas Graduate School of 
Biomedical Sciences, Houston, TX.  The research in Dr Robertson’s laboratory is directed at understanding the genomic and proteomic 
alterations that are hallmarks of cellular transformation in the breast, skin and head and neck. There is a strong interest in her laboratory to 
use proteins and peptides identified by proteomic analysis for development of approaches for earlier detection of tumors and as targets for 
development of novel therapies for specific tumor types which match their specific characteristics, post-transcriptional mechanisms 
regulating gene expression. In addition, her laboratory is also involved in multidisciplinary studies to use nanotechnology platforms as a 
means to accelerate development of diagnostics and therapeutic modalities for use in translational research and ultimately for clinical use 
  





Byoung S. Kwon, PhD,  National Cancer Center  (Korea) - Endowed Investigator in the Division of Cell and Immunobiology, R&D Center for 
Cancer Therapeutics, National Cancer Center Goyang , Republic of Korea and Professor of Ophthalmology at the Louisiana State University 
School of Medicine Eye Center, in New Orleans, Louisiana, USA.  Dr Kwon’s research interests include communication network of immune 
cells and he has published extensively on immunotherapy against cancers and autoimmune diseases.  
Tissue Invasion and Metastasis 
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In addition to the practices of the Chinese, Greeks and Romans, 
one of the oldest and best-known records of civilized medicine was 
described in the Egyptian ‘Ebers Papyrus’ (circa 1500 BCE), which 
documented over 700 drugs, mostly of plant origin [1]. Throughout 
different civilizations humans have relied on nature to accommodate 
their basic needs, not the least of which are medicines for the treatment 
of a wide spectrum of diseases from coughs and colds to parasitic 
infections and inflammation.
A sobering statistic has recently shown that a person born in the 
United States today has a 41% lifetime risk of being diagnosed with 
cancer. This alarming fact has urged the health care community to 
identify effective methods of cancer prevention [2]. Cancer cells exhibit 
deregulation in multiple cellular signaling pathways, yet all cancers share 
a number of common hallmark capabilities, such as genetic instability, 
self-sufficiency in growth signals, insensitivity to anti-growth signals, 
avoidance of apoptosis, unlimited replication, sustained angiogenesis, 
and tissue invasion and metastasis [3]. Therefore, utilizing specific 
agents to target single pathways is a tactic that frequently fails in cancer 
therapy. Genetic instability produces intra-tumoral heterogeneity that 
enables adaptive resistance. Combination chemotherapy that targets a 
number of distinct molecular mechanisms is therefore preferable and 
considered more promising, but the use of multiple agents is often 
constrained due to corresponding increases in toxicity [4].
Accumulating evidence has shown that some natural products 
such as saffron [5,6] and curcumin [4] and many others have growth 
inhibitory and apoptosis inducing effects both in vivo and in vitro. 
Frequently this sort of action is made possible by site-specific action on 
multiple cellular signaling pathways without causing undesired toxicity 
in normal cells. Therefore, these non-toxic natural agents could be 
useful in combination with conventional chemotherapeutic agents for 
the treatment of human malignancies with lower toxicity and higher 
effectiveness.
The use of natural products has increased in the United States with 
approximately 18% of American adults in 2007 reported using natural 
products beyond a basic multivitamin. Individuals use natural products 
for a variety of health reasons, including treating and preventing disease, 
maintaining health, and promoting wellness [2]. So the potential of 
natural products is increasingly being recognized. At the same time, 
natural products remain one of the most important sources of new drug 
leads with more than half of all new chemical entities launched in the 
market are natural products or their derivatives or mimetics. In fact the 
borderline between food and medicine is as fuzzy as it is ever been [7].
The efficacy of natural products as chemopreventive agents for 
primary and tertiary cancer prevention has not yet been established. 
Observational studies have suggested that various vitamins, minerals, 
and dietary components reduce the risk of developing specific cancers. 
However, clinical trials have not always supported these observations 
and/or the trials have not been conducted to test the efficacy of the 
natural products as chemopreventive agents. And although there is 
also a common perception that natural products are safe because they 
are “natural”, a natural product is not necessarily a safe product. So, 
current guidelines from the American Institute of Cancer Research, 
the American Cancer Society, and the Society for Integrative Oncology 
recommend against the use of dietary supplements for cancer 
prevention based on the current evidence [2].
Unfortunately, how well these compounds might work in the 
inhibition of cancer has yet to be rigorously tested in Phase IV tests. 
There is also little known about the interactions of naturally occurring 
chemical (phytochemical) with other drugs prescribed by physicians 
and used by patients for the treatment of cancer or other diseases. 
Thus our current knowledge has many gaps that will need to be 
resolved before such compounds can receive approval by regulatory 
agencies, broad acceptance by the medical community and join other 
pharmaceuticals on drugstore shelves [8].
Nonetheless, our ability to address these knowledge gaps is rapidly 
improving. A large number of robust and specific biochemical- and 
genetics-based screens using transformed cells, a key regulatory 
intermediate in a biochemical or genetic pathway, or a receptor-ligand 
interaction (often derived from the explosion in genomic information 
since the middle 1990s) are now in routine use. These screens are 
enabling precise detection of the actions of bioactive components of 
natural product extracts [1]. And since many phytochemicals have 
characteristics that will allow them to be combined with far less danger 
of toxicity and a much lower risk of invoking multiple drug resistance, it 
makes the idea of targeting a broad-spectrum of mechanisms in cancer 
cells (using complex combinations of chemicals) a very real possibility.
Historically, the complexity of cancer necessitated an incredible 
amount of specialization that has led to very narrowly scoped research. 
In the past two decades this approach has resulted in significant 
advances in our understanding of the disease, but unfortunately this 
trend towards specialization has meant that very few researchers 
ever have the freedom or the opportunity to undertake projects that 
are broad in scope. For similar reasons, many conventional research 
funding agencies and journals have not been all that supportive of anti-
cancer research involving too many biologically active ingredients due 
to concerns over the number of variables that can be controlled in any 
given experiment. But we need to overcome these systemic barriers if 
we are going to match the complexity of the disease with an approach to 
prevention and therapy that is equally complex (i.e., capable of shutting 
down a wide range of immortalized cells by acting on many different 
mechanisms and pathways).
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In an attempt to address this problem, “The Halifax Project” has 
been initiated, and a task force of nearly 300 scientists will attempt to 
address this large-scale problem in a holistic manner [9]. In addition, 
new publishers such as OMICS Publishing group are readily accessible 
in different media and accepting research papers with far fewer 
constraints on the complexity of the bio-molecules used.
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Apoptosis  or  programmed  cell  death  is natural  way  of  removing  aged  cells  from  the  body.  Most of the  anti-
cancer  therapies  trigger  apoptosis  induction  and  related  cell  death  networks  to  eliminate  malignant  cells.
However,  in cancer,  de-regulated  apoptotic  signaling,  particularly  the  activation  of an  anti-apoptotic  sys-
tems,  allows  cancer  cells  to escape  this  program  leading  to uncontrolled  proliferation  resulting  in tumor
survival,  therapeutic  resistance  and  recurrence  of  cancer.  This  resistance  is a complicated  phenomenon
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Nuclear transporters, natural
chemopreventive agents
that  emanates  from  the  interactions  of various  molecules  and  signaling  pathways.  In  this  comprehensive
review we discuss  the various  factors  contributing  to apoptosis  resistance  in  cancers.  The key  resistance
targets that  are  discussed  include  (1)  Bcl-2  and  Mcl-1 proteins;  (2) autophagy  processes;  (3) necrosis
and necroptosis;  (4) heat  shock  protein  signaling;  (5)  the proteasome  pathway;  (6)  epigenetic  mecha-
nisms; and  (7)  aberrant  nuclear  export  signaling.  The  shortcomings  of  current  therapeutic  modalities  are
highlighted and  a broad  spectrum  strategy  using  approaches  including  (a)  gossypol;  (b)  epigallocatechin-
3-gallate; (c)  UMI-77  (d)  triptolide  and  (e)  selinexor  that  can be used  to overcome  cell  death  resistance
is presented.  This  review  provides  a roadmap  for the  design  of  successful  anti-cancer  strategies  that
















































According to the GLOBOCAN factsheet (http://globocan.iarc.fr/),
here  were approximately 14.1 million new cancer cases, 8.2 mil-
ion cancer deaths and 32.6 million people living with cancer
within 5 years of diagnosis) in the year 2012 worldwide. Among
hese, 57% (8 million) of new cancer cases, 65% (5.3 million) of
he cancer deaths and 48% (15.6 million) of the 5-year prevalent
ancer cases occurred in the less/under-developed regions of the
orld. Cancer treatment requires a careful selection of one or more
nterventions, such as surgery, radiotherapy, and chemotherapy.
owever, despite major advances in new targeted drug devel-
pment and tailored clinical trial designs, therapy resistance is
ommonly observed in most cancers.
Most cancers harbor significant genetic heterogeneity [1], and
atterns of relapse following many therapies are due to evolved
esistance to treatment. While efforts have been made to combine
argeted therapies, a lack of success, rising drug costs, and signifi-
ant levels of toxicity have stymied efforts to effectively treat cancer
ith multi-drug combinations using currently approved therapeu-
ics [2]. Therefore, overcoming therapy resistance mechanisms is
ne of the most sought-after goals in cancer research.
To  accomplish this goal, a non-profit organization entitled Get-
ing to Know Cancer launched an initiative called “The Halifax
roject in 2011 with the aim of producing a series of overarch-
ng reviews in each of the areas that are widely considered to be
ancer hallmarks [3]. This novel approach is premised on many of
he insights of genomic sequencing in cancers and it aims to target
any disease-specific pathways simultaneously. This is proposed
o be done by using low-cost chemistry with little to no toxicity
 to address this heterogeneity (in contrast to the limited number
f actionable targets that have become the norm in combination
hemotherapy).
Our task in the project was to assess the many target choices
hat exist for resistance to cell death, and to identify up to ten
mportant targets as well as prospective non-toxic approaches that
ould potentially be combined to produce a low-toxicity therapeu-
ic approach for this area of concern. So our intent here is to discuss
he inter-relationship between major mechanisms driving resis-
ance to apoptosis in cancer and then to define a broad-spectrum
herapeutic approach aimed at reaching these important targets
3]. In theory, this approach would then be combined with simi-
ar approaches being recommended for the other hallmark areas
nder review in this special issue.
Apoptosis or programmed cell death is evolutionarily conserved
rocess that plays an essential role in organism development
nd tissue homeostasis [4]. However, in pathological conditions,
articularly cancer, cells lose their ability to undergo apoptosis
nduced death leading to uncontrolled proliferation. Cancer cells
re often found to over express many of the proteins that playPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
mportant roles in resisting the activation of apoptotic cascade. Sev-
ral mechanisms allow cells to escape programmed cell death and
mong them is the over expression of the anti-apoptotic molecules.©  2015  Elsevier  Ltd.  All rights  reserved.
Originally  most of the research on apoptosis signaling focused on
BH3 pathway proteins leading to acceptance of the Korsmeyers
[5] rheostat model. This model predicted a balance between pro-
survival and pro-death BH3 members. When the balance shifts
toward pro-death signaling, apoptosis occurs, and in instances
when pro-survival molecules outnumber pro-death proteins, sur-
vival signaling is activated leading to pathological conditions such
as cancer and other diseases. With this simplistic model, the drug
discovery arena moved at a rapid pace developing small molecule
inhibitors (SMI) that interfere with the anti-apoptotic pathways
proteins such a B-Cell Lymphoma 2 (Bcl-2), B-Cell Lymphoma extra
large (Bcl-xL, Induced myeloid leukemia cell differentiation pro-
tein (Mcl-1), Bcl-2-like-protein-2 (BCL2L2/Bcl-w) and Bcl-2 related
protein A1 (A1/Bfl1). Nevertheless, most of these approaches have
shown little success, and in almost all instances tumor cells become
resistant to such apoptosis inducing drugs [6].
Emerging evidence shows that resistance to apoptosis is multi-
factorial and involves many secondary players that run either
parallel to Bcl-2 signaling or function in complete independence [7].
Here we review the known and emerging pathways that modulate
the apoptosis signaling and discuss strategies to overcome apopto-
sis resistance. We  anticipate that a comprehensive understanding
of the resistance molecules (and the strategies to target them) will
help in the design of clinically successful strategies for cancer in
general and specifically in patients who  show disease relapse.
2.  Role of Bcl-2 family proteins in resistance to apoptosis
One  of the major hallmarks of human cancers is the intrin-
sic or acquired resistance to apoptosis [8,9]. Evasion of apoptosis
may contribute to tumor development, progression, and also to
treatment resistance, since most of the anticancer therapies that
are currently available include chemotherapy, and radio- and
immunotherapy (which primarily act by activating cell death path-
ways i.e., apoptosis in cancer cells). Hence, a better understanding
of the molecular mechanisms underlying tumor resistance to apop-
totic cell death is expected to provide the basis for a rational
approach for the development of molecular targeted therapies.
There  are two  types of apoptosis programs i.e., intrinsic and
extrinsic. The Bcl-2 protein functions through hetero-dimerization
with pro-apoptotic members of the BH3 family to prevent mito-
chondrial pore formation and prevent cytochrome c release and
initiation of apoptosis [10] (Fig. 1). However, there is evidence sug-
gesting that Bcl-2 may  play an oncogenic role through survival
pathways other than its function at the mitochondrial membrane
[11]. It has been reported that Bcl-2 activates nuclear factor-B
(NF-B) by a signaling mechanism that involves Raf-1/MEKK-1-
mediated activation of inhibitor of NF-B kinase subunit beta
(IKK) [12]. Mortenson and colleagues [13] have shown that over-
expression of Bcl-2 increases the activity of AKT and IKK as wellng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
as NF-B transcriptional activity in cancer. While Kumar and col-
leagues [14] found that Bcl-2-induced tumor cell proliferation and
tumor cell invasion were significantly mediated by interleukin-8.
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Fig. 1. The apoptosis pathway: (A) The different paths that a cell can take during the activation of cell death. (B) Apoptosis can be triggered either by external receptor-
dependent stimulus (extrinsic) or through internal (intrinsic) mitochondria-mediated signaling. The extrinsic pathway is initiated by the attachment of death receptors with
their  death initiating ligands, such as FASL, TRAIL or TNF. Consequently, an adaptor molecule, FADD also known as FAS-associated death domain protein, couples the death
receptors and this subsequently leads to the activation of caspase-8. Activated caspase-8 can either directly cleave and activate caspase-7 or caspase-3, thereby promoting
apoptosis. On the other hand the intrinsic pathway is modulated by the activation of BH3-only proteins sensing different types of cell stress, such as DNA damage or ER stress,
and  then activating BAX/BAK at mitochondrial outer membrane (MOM). MOM  permeabilization (MOMP) leads to release of different apoptosis-mediating molecules, such
as  cytochrome c, which activates caspase-9. In turn, caspase-9 cleaves and activates caspase-3 and caspase-7, thus triggering apoptotic cell death. Both pathways interface at
the  point of caspase-3 activation. The formation of autophagosome formation requires activation of Beclin 1 which acts as a component of a multiprotein (PI3K) complex. The
crosstalk  between autophagy and apoptosis is mediated at least in part by the functional and structural interaction between Beclin 1 and the anti-apoptotic proteins BCL-2
a ase-m





























(nd  BCL-XL. Diverse apoptotic stimuli either intrinsic or extrinsic can lead to casp
aster  tumor suppressor p53 has essential roles in both apoptosis and autophagy. A
f  BCL-2, which antagonizes BAX. In addition to apoptosis, p53 can also induce auto
ecently, Tucker and colleagues [15] reported that Bcl-2 over-
xpression leads to the maintenance of cyclin D1a expression, an
ctivity that may  occur through p38 mitogen-activated protein
inase (MAPK)-mediated signaling pathways in human lymphoma
ell lines. Moreover, down-regulation of Bcl-2 could also modulate
he expression of carbonic anhydrase IX (CAIX), vascular endothe-
ial growth factor (VEGF), and pAKT in prostate cancer cell lines [16].
hese studies provide evidence in support for a multi-functional
ole of Bcl-2 in cancer biology that extends beyond its classical
ole in cell survival. However, even though these early studies
ncouraged the application of Bcl-2 targeted drugs in a clinical
etting, most of the ensuing trials have been rather disappoint-
ng [17]. Probably, the drugs are unable to target the entire set of
nti-apoptotic proteins or the inhibition efficiency is not robust.
hus, new molecular targets and novel concepts of combination
herapies need to gain access into clinical trials – either in neoad-
uvant/adjuvant or in palliative treatments.
Apoptosis is also deliberated as a stress induced process of
ellular communication [18]. In addition intrinsic and extrinsic
rocesses, there is another pathway that involves T-cell mediated
ytotoxicity and perforin-granzyme-dependent killing of the cell
here granzyme B and granzyme A proteases are responsible for
nducing cell death in this pathway [19]. These intrinsic, extrin-
ic, and granzyme B have different modes of initiation but have
he same outcome: they lead to the activation of a cascade of pro-
eolytic enzymes, members of caspase family [20]. Granzyme A,Please cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
 serine protease, causes cell death by DNA damage by single-
tranded nicks, independent of caspases [21]. The mitochondrial
intrinsic) pathway is regulated by the Bcl-2 family and activatedediated cleavage of Beclin 1 rendering it ineffective as an autophagy inducer. The
ranscriptional level, p53 upregulates BAX, PUMA and BID or reduces the expression
 through TOR inhibition and also through transcriptional activation of DRAM.
by  mitochondrial disruption with subsequent cytochrome c release.
Initiators of this pathway include UV irradiation and cytotoxic
drugs. An apoptosome is formed by the interaction of cytochrome c,
Apaf-1, d-ATP/ATP and procaspase-9 with subsequent initiation of
the caspase cascade [22]. Over-expression of Bcl-2 and associated
anti-apoptotic proteins Bcl-xL, Mcl-1, A1/Bf1 and Bcl-w occurs in
substantial subsets of common cancer types that include pancre-
atic, ovarian, lymphoma, multiple myeloma, lung adenocarcinoma,
prostate adenocarcinoma and others. These Bcl-2 proteins can
essentially make cancer cells resistant to a variety of chemothera-
peutic agents and therefore these proteins are currently important
targets for the development of new anti-cancer agents [23,24].
Myeloid  cell leukemia-1 (Mcl-1) is a potent anti-apoptotic pro-
tein, a member of the pro-survival Bcl-2 family, its role is emerging
as a critical survival factor in a broad range of human cancers
[25]. Functional studies have confirmed that Mcl-1 is capable of
blocking apoptosis induced by various apoptotic stimuli, includ-
ing chemotherapy and radiation [26]. Mcl-1 is highly expressed at
the protein level in cancer cells and is associated with resistance
to chemotherapeutic agents [27]. It has been demonstrated that
down-regulation of Mcl-1 enhances the induction of apoptosis and
sensitivity of cancer to chemotherapy and radiation [28]. Thus, Mcl-
1 represents attractive molecular target for development of a new
class of cancer therapy for treatment of cancer.
The most potent small molecule inhibitors of the Bcl-2 subfamily
described to date are the Bad-like BH3 mimetics [29]. ABT-737,ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
one of these mimetics, binds with high affinity (Ki 1 nM)  to Bcl-2,
Bcl-xL and Bcl-w but fails to bind to Mcl-1. It has been demon-
strated that resistance to ABT-737 is linked to high expression
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evels of Mcl-1 and in many instances this resistance can be over-
ome by treatment with agents that down-regulate, destabilize, or
nactivate Mcl-1 [30]. It was also shown that knockdown of Mcl-
 sensitizes human pancreatic cancer cells to ABT-737-induced
poptosis, indicating that Mcl-1 is a relevant therapeutic target
n these cancer cells [31]. Recently, a small molecule agent that
s a specific inhibitor of Mcl-1 has been developed [32]. The agents
howed activity against a panel of pancreatic and other cancer cell
ines and works through disruption of interaction between Mcl-1-
ax and Mcl-1-Bak with remarkable activity against sub-cutaneous
enograft models of pancreatic cancer.
Highlighting the importance apoptotic proteins, recently Stu-
rt Schreiber’s group [33] performed genomic and lineage cancer
ell line (CCL) profiling to identify cancer dependencies that
re targetable with small molecules and suggested combinations
f compounds that mitigate apoptosis resistance. Their Cancer
herapeutic Response Portal (CTRP) suggests candidate depend-
ncies associated with common oncogenes. The first version of
he CTRP resulted from the profiling of an Informer Set of Small
olecules (ISSM), many of which target non-altered proteins that
ork in partnership with oncogenes. Exploiting oncogene-induced
ependencies contrasts to an approach based on cancer “hall-
arks” [3,34] without first linking these “nononcogene addictions”
o specific genomic alterations. For example, navitoclax has been
ested in phase I/II clinical trials for small-cell lung cancer [35];
owever, the data suggested that navitoclax might best be tar-
eted to patients harboring catenin cadherin-associated protein 
 (CTNNB1) mutations, which are present in colorectal, hepatocel-
ular, gastric, and endometrial cancers. Indeed it was demonstrated
hat CTNNB1 mutant CCLs are sensitive to navitoclax in several
ineages, though more strongly in some (e.g., gastric) than others.
he same selectivity was not observed for ABT-199, a Bcl-2-specific
nhibitor [36], suggesting that inhibition of other Bcl-2 family mem-
ers underlies the differential response. Consistently, Rosenbluh
t al. [37] recently showed that knockdown of Bcl-xL in -catenin-
ctive CCLs impairs proliferation, implicating Bcl-xL as a relevant
arget for navitoclax in CTNNB1 mutant cancers. So drug specificity
nd selectivity is significant, however specificity should be broad
o cover secondary targets whose presence can lead to resistance
o the initial compound. Such is the argument for a “pan-Bcl-2” SMI
 a compound which may  not bind to all of its targets in the low
anomolar range, but binds to at least Bcl-2 and Mcl-1 to disarm the
ro-survival capacities of these key targets. As such, “dirty drugs”
ay prove useful to knock out a range of Bcl-2-family members.
his is the reason why natural compound gossypol from cotton
eed has attracted attention for it Bcl-2 inhibitory capacity and has
een developed as an anti-cancer agent for clinical application.
.  Autophagy and resistance of cancer
Autophagy serves to maintain intracellular homeostasis
hrough a process that involves lysosomal degradation and
ecycling of unnecessary or damaged cellular components, and
n turn promotes cell survival. Autophagy can prevent cellular
amage caused by chemotherapeutics as it attempts to maintain
ntracellular balance through removal of dysfunctional organelles
nd eliminating cellular stress. It has been suggested that this
emporal survival mechanism may  facilitate chemoresistance as
 byproduct of its function in keeping the cancer cells alive
38]. Indeed, autophagy has been observed to guard cancer cells
gainst apoptosis upon encountering certain anticancer drugsPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
39–41]. The majority of relevant preclinical studies using numer-
us chemotherapeutics including vorinostat, cyclophosphamide,
nd imatinib have demonstrated that autophagy significantly
nhibits the efficacy of several classes of anticancer agents and helps PRESS
ncer Biology xxx (2015) xxx–xxx
to  drive the acquired resistance [42–44]. Furthermore, accumulat-
ing evidence has indicated that autophagy is involved in adaptation
of cancer cells to chemotherapy [45,46]. These observations suggest
that under chemotherapeutic treatments, autophagy is often acti-
vated as a cytoprotective mechanism for tumor cell to survive the
effects of anticancer drugs which, in turn, may  drive chemoresis-
tance. Therefore, the effects of chemotherapy might be improved
by inhibiting cytoprotective autophagy to enhance the apoptosis of
cancer cells in response to anticancer drugs.
In contrast to its cytoprotective role, autophagy can also lead to
cell death (termed “type II programmed cell death”) when induced
by excessive cellular stress [47]. More importantly, autophagy-
mediated cell death can participate in the upregulation of apoptosis
[48,49], and the inhibition of autophagy has been observed to
reduce apoptosis in some cancer cells [50]. In this regard, apo-
ptosis and autophagic death may  engage each other and share
common mechanisms to polarize cellular death response. Further-
more, inhibition of caspase 8 can cause the subsequent activation
of autophagy related gene (Atg) Atg6-Atg7-dependent cell death
pathway [51], suggesting that autophagy-mediated cell death may
serve as a backup mechanism for cell demise in the absence of
apoptotic signaling. Due to its paradoxical role in both cell survival
and cell death, the outcome of autophagy in cancer cells treated
with chemotherapeutic drugs may  therefore depend on the type of
cancer and stimuli, the progress of tumorigenesis, and the apop-
totic status of the cancer cells [52]. As the key mediators in the
autophagic process are either products of tumor suppressor genes
or oncogenes that often cross the regulatory pathways of apoptosis,
clarifying their function during anticancer drug treatment may  also
help better understand the process of autophagy-driven chemore-
sistance.
Cell fate dictated by autophagy is regulated by several factors
including beclin-1, PI3K, mTOR, Bcl-2, and p53, which are associ-
ated with many human disorders [53]. Beclin-1, also called Atg6,
is a Bcl-2-homology domain 3 (BH3) protein, that interacts with
Vps34 (a class III PI3K), Vps15 (a myristoylated kinase), and UV
irradiation resistance-associated tumor suppressor gene (UVRAG)
to form a multi-protein interactome that controls the initiation of
autophagy, the autophagosome nucleation [54]. Negative regula-
tors to this process include the anti-apoptotic proteins of the Bcl-2
family, which can interact with beclin-1 and inhibit the function of
the Vps-UVRAG-beclin-1 multi-protein core complex [55].
It  has been suggested that increased apoptosis resistance via
anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-xL, and Mcl-
1 can inhibit autophagy induced by chemotherapy, most likely in
an attempt to protect cells from the autophagic cell death, and
by forming inhibitory complexes with beclin-1 [56]. For example,
sorafenib-activated autophagic death in hepatocellular carcinoma
(HCC) cells is mediated by the reduced expression of Mcl-1. On the
contrary, apogossypolone, a potent anticancer agent that inhibits
Bcl-2 and Bcl-xL, has been shown to abrogate the interaction
between beclin-1 and Bcl-2/xL and induces protective autophagy
in HCC cells [57]. The role of beclin-1 interactome in the crosstalk
between apoptosis and autophagy thus emphasizes that distur-
bances in beclin-1-dependent autophagy can have crucial impact
on the apoptotic resistance in chemotherapy.
The ADP ribosylation factor (ARF) tumor suppressor is expressed
and accumulated in response to mitogenic stimuli conveyed by
oncogenic signals. The majority of ARF localizes to the nucleo-
lus and nucleoplasm, where it antagonizes the E3 ubiquitin ligase
muring double minute 2 (MDM2) to provoke MDM2 degrada-
tion, thereby stabilizing p53 protein [58,59]. A minor fraction ofng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
ARF (smARF) with a smaller molecular weight variant that lacks
the nucleolar localization sequence and preferentially localizes
to mitochondria, has been shown to induce autophagy [60,61].





























































iARTICLESCBI-1176; No. of Pages 26
R.M. Mohammad et al. / Seminar
isrupt the complex formation of beclin-1 with Bcl-xL, leading to
n increased ability of beclin-1 to perform its autophagic functions
62,63]. Heat shock protein 70 (hsp70), a molecular chaperone that
s highly expressed in tumor cells, interacts with smARF and reg-
lates the mitochondrial trafficking of smARF, thereby acting as a
ritical regulator of ARF-mediated autophagy [64]. Recently, ARF
as also been identified as a marker for advanced tumors and a
ack of ARF function is associated with the inhibition of p53 tumor
uppressor function in response to DNA damaging agents as well as
onizing radiation [65,66]. Given that smARF is tightly regulated by
roteasomal degradation and preferentially stabilized by metabolic
tress, it is speculated that it plays both a pro-survival role and a
ytoprotective role in autophagy induced by stress.
Mounting evidence also indicates that ROS are implicated in
utophagy induction in cancer therapy. Importantly, the deregu-
ation of ROS formation during autophagic response is associated
ith cancer initiation, progression, and drug resistance [67,68].
OS, especially mitochondrial ROS, serve as signaling molecules in
nducing autophagy [69]. Atg4, a cysteine protease which cleaves
tg8/LC3 from the outer membrane of autophagosome, is targeted
nd inactivated by ROS, leading to the lipidation of autophagic pro-
ess [70]. At the same time, autophagy contributes to the regulation
f cellular ROS production by eliminating damaged organelles that
ay  produce high levels of ROS which, in turn, limits chromosomal
nstability [71].
The  selective clearance of damaged mitochondria or mito-
hondrial autophagy (“mitophagy”) has therefore been suggested
o represent an adaptive response to oxidative stress-mediated
ell death in several cancer cell lines, mitigating accumulated
OS and protecting cell integrity through the removal of ROS-
eaking mitochondria [72]. For instance, anticancer drugs such as
-fluorouracil (5-FU) elicit protective autophagy against cell death,
nd the inhibition of autophagy could enhance apoptosis via ROS
ormation.
Suppressed expression of essential autophagic genes such
s beclin-1 and ATG5 has also been observed to enhance the
xaliplatin-induced ROS production and cell death in Caco-2 cells,
ndicating the role of cytoprotective autophagy in eliminating ROS-
nduced cell death [73]. Furthermore, ROS-induced DNA damage
ctivates the enzymatic activity of poly(ADP-ribose) polymerase-
(PARP-1), which has been demonstrated to induce protective
utophagy through the AMP-activated protein kinase (AMPK) path-
ay and it instigates the resistance of cancer cells to ROS production
y chemotherapeutic drugs [74–76]. Thus, modulating the sensi-
ivity and regulatory mechanism of cells to ROS, such as through
he use of antioxidants, could potentially serve as a strategy in
hemosensitizing and reducing resistance of cancer cells by block-
ng ROS-mediated protective autophagy. Evidence of autophagy
esponding to treatments in cancer cells supports the view that this
hysiological process can help tumors escape drug-induced cyto-
oxicity (as a survival mechanism) or potentiate chemotherapeutic
fficacy (as a cell death pathway). Selective inhibition or induction
f autophagy may  therefore help sensitize resistant tumor cells to
hemotherapeutic treatments.
.  In vitro and in vivo necrotic cell death and necroptosis
Necrotic cell death is a cell death process that is morphologi-
ally characterized by a gain in cell volume, swelling of organelles,
lasma membrane rupture and subsequent loss of intracellular
ontents. This is in contrast to programmed cell death (apopto-Please cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
is), although it was long thought that necrosis is an uncontrolled
ell death that is characterized by progressive loss of cytoplasmic
embrane integrity, rapid influx of Na+, Ca2+, and water, resulting
n cytoplasmic swelling and nuclear pyknosis [77]. However, there PRESS
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is now an increasing realization that necrotic cell death represents a
more programmed form of necrosis, termed necroptosis [78]. The
former leads to cellular fragmentation and the release of lysoso-
mal and granular contents into the surrounding extracellular space,
with subsequent inflammation. A number of toxic chemicals or
physical stresses such as toxins, radiation, heat, trauma, lack of
oxygen due the blockage of blood flow, and other events can cause
necrosis. When necrotic cells begin to die, cells swell and holes
appear in the plasma membrane and intracellular materials spill
out into the surrounding environment [79].
Necrotic cell death is believed to be a consequence of physico-
chemical stress, such as freeze–thawing or severe hyperthermia,
and thus as accidental and uncontrolled [80]. Interestingly, necrotic
cell death has emerged as an important and physiologically rele-
vant signaling process that seems to contribute to ovulation [81,82],
immune defense [83], death of chondrocytes controlling the longi-
tudinal growth of bones [84], and cellular turnover in the intestine
[85]. In vivo studies indicated that removal of inter-digital cells
in the paws of Apaf 1−/− mice during embryogenesis occurs by a
caspase-independent necrotic-like process [86]. Noteworthy, the
occurrence of necrosis in these in vivo models is mostly defined
morphologically. Several reports also illustrate the occurrence of
necrotic cell death during viral and bacterial infections. For exam-
ple, HIV-1 shows to kill CD4+T lymphocytes by necrosis [87] and
Shigella and Salmonella can induce necrotic cell death of infected
neutrophils and macrophages [88]. Although necrosis has been
thought to be an unregulated process, recent research suggests that
necrosis may  occur in two  different pathways in a living organ-
ism. The first pathway of necrosis initiation involves oncosis, where
swellings of the cells occur. The cell then proceeds to blebbing, and
it is followed by pyknosis, in which nuclear shrinkage transpires. In
the final step of the primary necrosis, the nucleus is dissolved into
the cytoplasm known as karyolysis. The second pathway of necro-
sis involves a secondary form of necrosis that is shown to occur
after apoptosis and budding. In this case, cellular changes of necro-
sis occur in this secondary form of apoptosis, where the nucleus
breaks into fragments, which is known as karyorrhexis.
Unlike necrosis, necroptosis is a more programmed form of
necrosis that has been shown to be a defense mechanism in orga-
nisms against internal pathogens and intracellular infections [89].
Necroptosis was  first recognized as a caspase-independent form of
cell death that can be triggered by treatment with tumor necrosis
factor (TNF) only in the presence of a pan-caspase inhibitor, such as
zVAD fluoromethyl ketone. Unlike apoptosis, necroptosis requires
that the function of caspase 8 be inhibited or disrupted. Several of
the upstream signaling elements of apoptosis and necroptosis are
shared, and sensitivity to each death pathway is regulated (some-
times in opposing ways) by an overlapping cluster of regulatory
molecules, such as FLICE-like inhibitory protein (FLIP), the deu-
biquitinases A and cylindromatosis and the cellular inhibitors of
apoptosis proteins such as the Baculoviral IAP repeat-containing
protein (cIAP1 and cIAP2). At the molecular level, intracellular
assembly of a highly regulated complex, the necrosome, can be
triggered by death receptors (e.g., tumor necrosis factor receptor
1/TNFR1), by cell-surface toll-like receptors, by DAI (which may
act as a cytoplasmic viral RNA sensor). The continuing elucidation
of the molecular aspects of various forms of regulated necrosis,
including necroptosis, and the efficient design of combination ther-
apies hold promise for our ability to control regulated necrosis in
clinical settings.ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
5.  The role of hsp90 on apoptosis resistance in cancer cells
Heat  shock protein 90 (hsp90) is one of the most abundant pro-
teins in eukaryotic cells. It is an enzymatic chaperone molecule with
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TPase activity that is highly active in malignant cells and tissues
hen compared to non-neoplastic cells. In line with its activity
attern and expression profile it has been shown to drive tumor
rogression by enhancing proliferation, migration and metastasis.
n addition, it also confers resistance to programmed cell death
y several mechanisms. By its chaperoning activity, hsp90 stabi-
izes a number of mutated and non-mutated kinases and several
nti-apoptotic factors within the cytosol that overall favor resis-
ance to apoptosis and mostly drive proliferation and resistance of
umor cells to various treatment regimens. These factors include,
ut are not limited to Akt, mutated BRAF, EGFR, JAK2 and the
nhibitor of apoptosis protein survivin. Targeting cytosolic hsp90
licits inhibition of proliferation and depending on the compound
nd tumor cells involved also apoptosis. The kinase, JAK2, was
ecently shown to be an interacting partner of hsp90 in a model
f polycytemia vera [90], a myeloproliferative disorder that almost
lways harbors a JAK2 mutation. In line with the interaction of
sp90 and JAK2, a novel hsp90 inhibitor was shown to disrupt this
nteraction and depleted JAK2 protein levels in vitro and in vivo.
sp90 signaling also appears instrumental in mediating resis-
ance to tyrosine kinase inhibition (TKI) treatment, specifically with
GFR inhibitory molecules, such as erlotinib and gefitinib. These
olecules particularly target mutated EGFR within the intracel-
ular ATP binding domain, especially point mutations in exon 21
L858R) and deletion located in exon 19. With respect to hsp90, Shi-
amura et al. [91] have elegantly shown that in several non-small
ell lung cancer (NSCLC) cell lines geldanamycin (a prototype hsp90
nhibitor) preferentially elicited depletion of mutated EGFR with
ubsequent suppression of p-Akt, causing cell death. Moreover,
7-AAG, a derivative of geldanamycin, more efficiently suppressed
utated EGFR compared to the wild-type form. Another important
spect in lung adenocarcinomas is the fact that tumors that are ini-
ially responsive to EGFR inhibition due to selective EGFR mutation
n exon 19 or exon 21 recur eventually because in the presence
f EGFR sensitizing mutations, they generate secondary mutations,
uch as the T790M EGFR mutation, which in turn confers resistance
o erlotinib/gefitinib. One option to bypass a T790M mediated resis-
ance is the administration of so called irreversible tyrosine kinase
nhibitors. However, another option appears to be the enzymatic,
ytosolic inhibition of hsp90 by 17-AAG [92]. Shimamura et al. [93]
ave demonstrated in a murine model of lung cancer, harboring
oth an exon 21 (EGFR inhibitor sensitizing mutation) and the resis-
ance mutation (T790M), that 17-DMAG (a derivative of 17-AAG
ith optimized in vivo properties) also reduced tumor growth in
he presence of the T790M mutation, indicating that hsp90 inhibi-
ion may  be a worthwhile strategy to combat EGFR tyrosine kinase
nhibitor resistance. This was further supported by the depletion
f several hsp90 chaperones/downstream molecules in vivo. Given
he unfavorable properties of 17-AAG derived molecules, alterna-
ive molecules are being tested. One of which is Ganetespib that
as recently explored in several lung cancer models, including ones
arboring EGFR inhibitor resistance mediating mutations. Ganete-
pib behaved superiorly compared to 17-AAG and accumulated
ithin neoplastic tissue. Due to the favorable preclinical data it
as also recently assessed in a phase-II-clinical trial [94].
Most  of the hsp90 functions are ascribed to its presence and
unction in the cytosol, but recent evidence also suggests that hsp90
s over-expressed in tumor mitochondria and organizes a mito-
hondrial chaperoning network that antagonizes tumor cell death.
n terms of therapeutic applicability, inhibition of hsp90 elicits anti-
ancer activity in tumor cells of various origins and therefore has
merged as a viable treatment target for cancer therapy. In 2007,Please cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
ang et al. [95] have unraveled a novel tumor chaperone network
hat is situated in tumor mitochondria. This network consisted
f three major players, hsp90 (as referred now as mitochondrial
sp90; mHsp90), TNF receptor-associated protein 1 (TRAP1) and PRESS
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the cell death promoting protein Cyclophilin-D (Cyp-D). TRAP1 is a
molecule that shares significant similarities to hsp90 by exhibit-
ing both structural and enzymatic overlap with hsp90. Akin to
hsp90, TRAP1 reveals ATPase activity and its ATPase activity is
amenable to inhibition by geldanamycin derivatives, such as 17-
AAG. Favoring TRAP1 as a suitable “druggable” target, its expression
levels were increased in malignant neoplasms from lung, colon,
pancreas and breast, prostate and glioblastoma, whereas in non-
neoplastic counterparts expression levels were significantly lower
[95]. For example, Matsuda et al. [96] have demonstrated that
-hydroxyisovalerylshikonin, a plant derivative with anti-cancer
activity, depleted TRAP1 levels in mitochondria in DMS114 (lung
cancer) and HL60 (leukemia) cells, respectively. In the matrix of
tumor mitochondria, hsp90 and TRAP1 inhibit mitochondrial per-
meability transition pore (MTP)-dependent cell death initiated by
Cyclophilin-D in tumor cells almost independent of their entity.
Kang and colleagues also elaborated this concept further by devel-
oping two  different classes of molecules to specifically inhibit the
discovered chaperone network in tumor mitochondria. The first of
these molecules was  a modified 17-AAG (Ant-GA) molecule that
harbored an Antennapedia linker sequence (Ant), which allowed
the molecule to accumulate in the matrix of mitochondria and
inhibit both mhsp90 and TRAP1. Despite its modification Ant-GA
retained its hsp90 inhibitory properties. When incubated, Ant-
GA induces disruption of the mitochondrial membrane potential
of tumor cells, culminating in cell death independent of their
TP53 status, suggesting that a mitochondrial chaperone-targeted
treatment approach does not require presence of wild-type p53
which is amongst the most commonly mutated proteins in can-
cers. To further corroborate the importance of Cyclophilin-D, Kang
et al., [97] also made the case that Cyclophilin-D is implicated
and instrumental for the cell death elicited by Ant-GA, since
cyclosporine-A, an inhibitory molecule of MPT  mediated cell death
mitigated Ant-GA mediated apoptosis. The second molecule that
revealed inhibitory properties of the mitochondrial hsp90 chap-
erone network was  a peptide, called shepherdin. Shepherdin was
initially described as a compound that disrupted the interaction
of hsp90 and survivin. This peptide induced cell death in various
cancer cells with a remarkable efficacy without causing apopto-
sis in non-neoplastic cells, such as fibroblasts, epithelial cells or
astrocytes. The initial form of shepherdin had anti-cancer activ-
ity in several skin xenograft models, including prostate cancer.
Consistent with its inhibitory cytosolic properties of hsp90, shep-
herdin treated xenograft tumors exhibited depletion of the hsp90
chaperone client proteins, Akt, and survivin. Most notably, shep-
herdin was  not associated with organ toxicity as provided by a
necropsy analysis of shepherdin treated animals. Consistent with
this notion is the finding that animals did not exhibit significant
weight loss upon administration of the compound. Based on this
determination, it was suggested that shepherdin appears to be a
fairly safe reagent. However, one pitfall may  be the fact that pre-
cise pharmacokinetics were not provided. An engineered shorter
version of shepherdin showed activity against leukemia cells both
in vitro and in vivo [98]. Later on, it was  demonstrated that shep-
herdin also inhibited the mitochondrial hsp90 chaperone network
by interacting directly with TRAP1 and mhsp90. Consistent with
its pharmacodynamics, shepherdin induces a MPT-dependent cell
death specifically in tumor cells, which akin to Ant-GA requires
the functional presence of Cyclophilin-D. Along those lines, pre-
treatment with cyclosporine-A, an inhibitor of the MPT, attenuated
shepherdin-mediated cell death. In contrast, adenoviral-mediated
over-expression of Bcl-2, that at physiological levels inhibits theng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
translocation of intermembranous cytochrome c into the cytosol,
did not significantly suppress cell death mediated by shepherdin,
suggesting that this reagent acts independent of the Bcl-2 family
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yclophilin-D. All in all, shepherdin represents a prototype of a
double hit” hsp90 inhibitor with tumor specific pharmacological
ffects both in the cytosol and within mitochondria newer class
f sophisticated molecules Gamitrinibs “GA-mitochondrial matrix
nhibitors” have also been tested for their hsp90 inhibitory activity
99]. Gaminitribs are derived from 17-AAG and structurally contain
 mitochondrial linker sequence, which enables them to efficiently
ccumulate in mitochondria. Two molecules have received most
ttention: Gamitrinib-TPP and Gamitrinib-G4. They are associated
ith anti-tumor activity in a number of different disease model sys-
ems, including breast cancer, lung cancer, colon cancer, prostate
ancer lymphoma and glioblastoma (also reviewed in [100]). Col-
ectively, a comprehensive understanding of how hsp90 functions
romises not only to provide new avenues for therapeutic inter-
ention, but to shed light on fundamental biological questions of
poptosis evasion.
.  The proteasome pathway and apoptosis resistance
Eukaryotic 26S proteasome is a 2.5 MDa  large complex con-
isting of two 19S regulatory particles and one 20S catalytic
ore [101]. Each 19S regulatory particle is composed of the lid,
hich is responsible for recognition and docking of polyubiqui-
inylated proteins into the 20S catalytic core, and the base, which
s in charge of the unfolding and linearization of large proteins.
he 20S catalytic core harbors seven distinct -subunits and -
ubunits arranged in a 7777 stacked barrel, among which
ainly three sets of -subunits, 1 (caspase-like or peptidyl-
lutamyl peptide-hydrolyzing (PGPH)-like), 2 (trypsin-like), and
5 (chymotrypsin-like) are proteolytically active. Unlike common
roteolytic enzymes that contain a catalytic triad, the proteasome
atalytic subunits belong to a special group termed N-terminal
ucleophile hydrolases, which utilizes the side chain of the N-
erminal residue as the catalytic nucleophile [102–104]. All three
atalytic -subunits react with peptide bonds of substrates through
heir OH group of the N-terminal threonine (Thr1), resulting in
rotein being degraded into small fragments of less than 10 amino
cids. It has been well documented that the proteasome is required
or cell cycle progression by regulating the turnover of cyclins and
yclin-dependent kinase inhibitors, and therefore inhibition of pro-
easome function could result in cell cycle arrest. In addition, the
biquitin-proteasomal system can affect cell survival pathways by
egulating the turnover of transcriptional factors responsible for
ell survival or apoptosis such as NF-B, p53, as well as apoptotic
roteins such as the Bcl-2 family members and others [105]. There-
ore, inhibition of the proteasome is linked with the induction of
poptosis.
In tumor tissues, the proteasome activity is up-regulated by
ntracellular oncogenic factors, which render the cancer cells more
ependent on the proteasome than the normal cells. Enhanced
umor cellular proteasome activity in turn promotes the degrada-
ion of tumor suppressor proteins, resulting in cancer cell survival
nd proliferation as well as the development of resistance to apo-
tosis [106]. On the other hand, proteasome activity could be
uppressed by several endogenous inhibitors as well as various
xogenous inhibitors, including some synthetic compounds such
s bortezomib and many natural products such as plant polyphenol
pigallocatechin-3-gallate (EGCG) [107]. Although the mechanism
hat is involved is not clear, proteasome inhibition in cancer cells
s prone to accumulate pro-apoptotic target proteins and inducePlease cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
ell death. The clinical efficacy of bortezomib in multiple myeloma
nd other hematologic malignancies lends credence to the concept
hat targeting the proteasome, making it a promising strategy for
ancer treatment. PRESS
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The proteasome also degrades IB, an important inhibitor of
the tumor survival factor NF-B. Many physical (i.e., radiation),
chemical (cancer chemotherapeutic agents), viral and biological
(cytokines, growth factors) agents induce phosphorylation, ubi-
quitination and subsequent degradation of IB by the proteasome,
freeing up NF-B to translocate to the nucleus and modulate genes
involved in proliferation, invasion and tumor survival [108,109].
For example, NFB upregulates the anti-apoptotic protein Bcl-2 and
downregulates the pro-apoptotic protease caspase 8. Therefore, by
inhibiting the proteasome, IB will accumulate which will inhibit
NF-B from promoting tumor survival. The proteasome is also
responsible for degrading the tumor suppressor p53. Many tumor
cells inactivate p53 by over expressing p53 master regulator MDM2
[110]. In human tumors that over express MDM2,  the inhibition of
proteasome pathway is predicted to induce tumor cell apoptosis by
accumulating p53. It has been observed that CEP1612, a dipeptidyl
proteasome inhibitor, was able to rapidly induce apoptosis in differ-
ent human cancer cell lines, including breast, prostate, leukemia,
lung, bone, brain, and head and neck, but not in human normal
fibroblasts and normal breast cells [111].
Proteasome inhibition was also sufficient to overcome apop-
totic protection by Bcl-2 or Bcr-Abl oncoprotein. Proteasome
inhibition accumulates Bax (but not Bcl-2) protein in mitochon-
dria, resulting in increased ratio of Bax/Bcl-2, associated with
cytochrome c release and apoptosis induction [112]. It has also
been shown that during TNF--induced apoptosis, Bcl-2, but not
Bax, protein is degraded through ubiquitin/proteasome-dependent
pathway  [113] which also increased the Bax/Bcl-2 ratio. Therefore,
selectively degrading one or more Bcl-2 family proteins by the pro-
teasome should change the ratio of pro- to anti-apoptotic proteins,
which might contribute to the apoptotic commitment and result in
overcoming resistance.
7.  Epigenetics as a mechanism underlying drug resistance
There  is uniform recognition of the importance of epigenetics
(heritable non-structural changes in gene expression), as a major
mechanism that can drive acquired resistance to chemotherapy
[114]. For example, epigenetic mechanisms such as non-coding
RNA (microRNAs) and DNA methylation are important drivers
that influence the chemo-responsiveness of tumors and acquired
drug resistance. Although drug resistance can be overcome using
epigenetic therapies in experimental models, clinical studies of epi-
genetic therapies have highlighted challenges for different cancers,
and there is a need to identify more targeted approaches. Here we
highlight a few epigenetic mediated drug resistance mechanisms
and identify strategies to overcome this challenge.
The breast and ovarian cancer cell line models have provided
some of the earlier insights into the different epigenetic mecha-
nisms underlying drug resistance. Studies have shown that taxane
resistance in breast cancer may  be associated with profound
changes in the expression of apoptotic factors such as caspases.
The gradual development of taxane resistance over a relatively
small number of cell culture passages was shown to correlate with
marked downregulation of caspase 9, 7 and Bcl-2 [115]. Such a
shutdown of the intrinsic pathway was shown to be associated
with a concomitant up regulation of autophagy. Further, low Bcl-2
expression was  seen when cells develop a high level of background
autophagy and this can be associated with collateral sensitivity
to platinum agents, as seen for taxane resistant breast cancer.ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
Moreover, a high level of background autophagy has also been
demonstrated in breast cancer cell lines with acquired resistance to
anti-endocrine agents such as tamoxifen and also faslodex (fulves-
trant). Resistance to agents such as tamoxifen is a major concern
 ING ModelY
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hen one considers their widespread use in the management of
reast cancer, both in the prophylactic and adjuvant settings.
Drug  resistance in cancer in terms of changes in the entire
pigenome has also been studied. Using the cDNA microarrays
f several cancer cell line models made relatively resistant to
ytotoxic drugs in vitro, candidate genes have been identified. By
ncorporating the use of agents that can reverse epigenetic methyl-
tion a number of drug resistant cancer cell line models have been
creened and compared with their wild-type drug sensitive coun-
erparts. In this way the major genes that we believe are subjected
o silencing – generally via methylation of the CpG islands in the
romoter region of the gene – and these changes may  often be asso-
iated with the evolution of drug resistance. For example a series of
pithelial ovarian cancer (EOC) cell lines with acquired resistance to
aclitaxel and carboplatin and showed that resistance to paclitaxel,
ften with cross-resistance to carboplatin, occurred with loss of
he G2 checkpoint and apoptosis [116]. Among the featured genes
ncluded the Polo Like Kinase-2 (PLK2) that was down-regulated
ue to acquired methylation in the CpG-island at the 5′ end of
he gene. These studies demonstrated that by increasing levels of
esistance to paclitaxel there was correlation with incrementally
ecreased expression of PLK2 and increasing CpG island methyl-
tion. Based on these studies it was proposed that exposure to
hemotherapeutic stress induces methylation in the CpG island of
pecific “resistance” genes and this seeding effect leads to increas-
ng methylation as the level of resistance increases, a phenomenon
reviously described in cells exposed to 6-mercaptopurine [117]. A
tudy by Matthew et al. [118] looked at the influence of hypoxia on
hemosensitivity in PLK2-deficient tumors. Here, complete resis-
ance to camptothecin pointed to interplay between the tumor
icroenvironment and PLK2 expression, whereas in the same
xperiments normoxic cells showed increased drug sensitivity. The
ame study also showed that PLK2 can inhibit mTOR signaling
nder the influence of wild-type p53 control. Furthermore, it was
ound that the cyclin-dependent kinase inhibitor p57kip2 appears
o be down-regulated in drug resistant ovarian cancers [119].
t has also been shown that carboplatin-resistant ovarian can-
er cells show promoter methylation in the CpG island of the
romoter. By silencing otherwise carboplatin-sensitive cells using
iRNA directed against p57kip2, carboplatin resistance was  recapit-
lated which was shown by a reduced apoptotic response in those
ells when challenged with a sub-lethal dose of platinum agents
119]. However, these cell lines studies need validation from ovar-
an cancer patient tissue based expression studies to strengthen the
ole of low p57kip2 and promoter methylation and its association
ith a poor prognosis and evidence of platinum-refractory disease.
An increasing number of genes involved in cell signaling, migra-
ion and adhesion are known to be alternatively spliced and this
rocess appears to be altered during tumor development and pro-
ression. Different spliced forms of genes arise as a consequence
f alternative pre-mRNA processing and are seen in a number of
uman malignancies [120,121]. Splicing processes must recognize
ntron and exon boundaries with accuracy – otherwise there will
e changes in nucleotide sequence at the site of exon joining which
hifts the reading frame with adverse consequences to the pro-
ein coding potential. Splicing is carried out by the “spliceosome”
hich comprises 5 small nuclear RNAs complexed with several
dditional proteins. Alternative splicing is one of the many cell pro-
esses that are commonly changed in the presence of cancer. These
isturbances can result in the production of splice variants with
eoplastic potential and could cause transformation of tumors.
lternative splicing contributes to the large number of proteinsPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
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hat can be produced from a much smaller number of genes in the
uman genome. Aberrations in alternative splicing may also affect
ell proliferation, motility and susceptibility to apoptosis, which
ay be the result of variant mRNA that is tumor-suppressive or PRESS
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oncogenic and can contribute to carcinogenesis [122]. In particu-
lar, the family of splicing factors – including SC-35 (a member of
the serine rich splicing factors: srsf2) – is recognized to be crucial
in controlling the extent of mRNA splicing into active forms of var-
ious pro-apoptotic genes such as Bax. Head and neck cancer and
ovarian cancer cell lines with acquired resistance to cisplatin have
been shown to under express SC-35. Demethylation analyses have
revealed that the splicing factor, arginine/serine-rich 2 (SRSF2)
gene is silenced via methylation of CpG islands in the promoter
region. Other work looking at epigenetic silencing has highlighted
a number of genes that when silenced can reduce the apoptotic
response of cancer cells to various anticancer agents. These studies
can be used to look for biomarkers of chemo-response by detection
of methylated DNA in cancer patients.
More recently, it has emerged that splicing efficiency can be
affected by splicing enhancers which, in turn, interact with regula-
tors that increase exon inclusion such as the SR family of proteins.
SR proteins contain an RNA-binding domain and a characteristic
SRSF2 – otherwise referred to as SC-35 – is located on chromosome
17 and contains a large CpG island. SR proteins control alternative
splicing events in proto-oncogenes and tumor suppressor genes
which leads to profound changes in their cellular activity. Factors
such as SF2/ASF and SC35 are associated with transformation may
be upregulated in some tumors [123]. In a report by Merdzhanova
et al. [124] SC-35 working in conjunction with E2F1 was shown
to be upregulated and required for apoptosis using a panel of
lung cancer cell lines. E2F1, which is an established transcription
factor, is recognized to be stabilized following treatment of cells
with DNA-damaging agents such as cyclophosphamide. The up-
regulation accompanies SC-35 induction and there is evidence that
SC-35 is a direct target of E2F1. Further, SC-35 inhibition was  then
shown to repress apoptosis induced by DNA damaging agents. SC-
35 in its phosphorylated form is necessary for apoptosis following
chemotherapy treatment with cisplatin and is up-regulated follow-
ing this treatment [125,126]. These reported observations have led
to the consideration that down-regulation of SC-35 – and other
splicing factors – as a putative mediator of anticancer drug resis-
tance.
More recently it has been shown that miRNA can have a sig-
nificant effect on the expression of splicing factors such as SC-35.
In drug resistant cell line models that carry significant upregula-
tion of miR-221 and miR222 demonstrate marked downregulation
of SC-35, a target gene for both these miRs. Further work should
be focused on the influence of miR, splicing events and epigenet-
ics on the modification of the apoptotic response in drug resistant
cancers.
8. Nuclear transport in apoptosis resistance
Compartmentalization of proteins inside the eukaryotic cell is
an evolutionarily conserved mechanism [127]. Each protein (espe-
cially apoptosis inducers) requires proper sub-cellular localization
to mediate its specified function [128]. This is especially true for
tumor suppressor proteins (TSPs) that usually reside in cell nucleus
where they exert their function through sequence specific bind-
ing to DNA, modulation of gene expression, and assessment of the
integrity of the genome [129]. Mislocalization of proteins has been
long recognized to disrupt their function resulting in pathological
conditions including cancer [130]. In eukaryotic cells, the cyto-
sol and the nucleus intercommunicate via nuclear pore complexes
(NPCs) present in the nuclear membrane [131]. NPCs consist ofng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
more than two  dozen different proteins [132]. These nucleoporins
form a channel and regulate the nucleocytoplasmic transport of
various types of RNAs [133], and proteins [134]. The nuclear import
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roteins, occurs through the participation of an evolutionarily con-
erved family of transport proteins belonging to the karyopherin-
amily [135]. Karyopherins- accomplish either nuclear import and
re called importins [136] or nuclear export and are called exportins
137]. Generally, karyopherin-mediated transport occurs through
he NPC, which acts as a gateway into and out of the nucleus [138].
ost of karyopherins- interact directly with their cargoes, but
ay also be aided by adapter proteins [139]. Karyopherin-, known
lso as importin-, is the most-studied adapter protein [140]. All
roteins are synthesized on ribosomes found in the cytoplasm.
uclear proteins must traverse the NPC following their cytoplasmic
ynthesis. While nucleocytoplasmic transport is normally a highly
egulated process, the aberrant expression of karyopherins has
een consistently observed in different cancers and has been linked
o apoptosis resistance [141]. Chromosome maintenance region 1
CRM1) is a karyopherin exports different protein targets from the
ucleus of the cell [142]. CRM1 is the major exporter of tumor sup-
ressor proteins (TSPs) and functions by recognizing a leucine rich
uclear exclusion signal sequences (NESs) in cargo proteins and
ransports them to the cytoplasm in an energy consuming process
hat involves RanGTP binding and hydrolysis to RanGDP [143].
It  is well recognized that nuclear localization of TSPs and
heir DNA binding is essential for their regulatory function [144].
ere activation of apoptosis promoting TSPs (such as FOXO3a,
27, Ik and prostate apoptosis response 4/Par-4) is not suffi-
ient for their proper apoptosis induction as over-expression of
RM1 in cancer cells results in TSPs efflux and their functional
nactivation. Supporting this, over-expression of CRM1 has been
ssociated with therapy resistance, particularly resistance to apo-
tosis and poor survival in solid tumors [145]. The prognostic
ignificance of CRM1 in multiple cancers has been established
146]. Its expression is increased in pancreatic ductal adenocar-
inoma, renal carcinoma, non-Hodgkin’s lymphomas, mantle cell
ymphomas, prostate, breast, colon and other cancers. Unlike K-ras
hat is found mutated in >65% of cancers, these TSPs to a large extent
emain wild type [147]. However, till date, there are no clinically
pproved drugs that broadly target the activation of TSPs. These
ultiple lines of evidences support the need for the development
f CRM1 targeted drug for cancer treatment.
Inhibition of XPO1 is one approach to restore nuclear localiza-
ion and activation of multiple TSPs, allowing them to function
roperly [148]. Therefore, targeted inhibition of CRM1 using spe-
ific small molecule inhibitors has been suggested to be a feasible
trategy [149]. Leptomycin B (LMB) was the first natural agent
dentified to irreversibly inhibit XPO1 [150]. LMB  is a secondary
etabolite produced by Streptomyces spp and was originally dis-
overed as a potent anti-fungal antibiotic [151]. LMB has been
hown to be a potent and specific nuclear export inhibits XPO1
nd works by alkylating and inhibiting XPO1 through glycosyla-
ion of a cysteine residue (cysteine 529) [152]. Nevertheless, LMB
emonstrated marked toxicity in both preclinical studies and in a
ingle clinical trial and its clinical development discontinued [153].
nother agent, Leptomycin A (LMA) was discovered together with
MB  and showed potency twice as that of LMB  [150]. However,
ts clinical utility has not been evaluated. A novel, small molecule,
eversible inhibitor, CBS9106, with XPO1 degrading activity, was
hown to have antitumor effects against multiple myeloma cells,
oth in vitro and in vivo [154]. The development status of this agent
s not known. Recently, novel, orally bioavailable, small molecule,
rug-like, selective inhibitors of XPO1 mediated nuclear (SINE)
ave been described [155]. SINE compounds bind irreversibly to the
ys528 NES recognizing residue in XPO1 and block its ability to bindPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
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o cargo proteins [156]. SINE have been shown to potently inhibit
he growth of multiple cancer cell lines and animal tumor models
uch as acute myeloid leukemia [157], mantle cell lymphoma [158],
nd other hematological malignancies [159]. The anti-proliferative PRESS
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activity  of SINE against pancreatic ductal adenocarcinoma and Non-
Hodgkin’s Lymphoma has been demonstrated [160]. Based on these
multiple lines of pre-clinical evidence, the orally bioavailable SINE
KPT-330 have rapidly accelerated toward clinical evaluation in solid
tumors and hematological malignancies.
CRM1 carries essential roles for the normal function of non-
cancerous cells as well. Therefore, the clinical feasibility of any
XPO1 targeted strategy has a number of hurdles. While molecu-
lar mechanism(s) of action of the first generation XPO1 inhibitor
LMB were well defined, the drug proved highly toxic in preclinical
models [161] and was  discontinued in the clinic, the primary reason
being the incomplete understanding and validation of entire sets
of pathways modulated by this master exporter. This is coupled
with a lack of complete evaluation of the effects of XPO1 inhibi-
tion. As recently demonstrated by ours and independent groups,
XPO1 interferes with important and complex processes such
as miRNA processing [162], epithelial-to-mesenchymal transition
[163]. These findings indicate that more advanced pre-clinical work
in the right models is required to optimize novel XPO1 inhibitors
for applications in cancer and other diseases. Systems biology, par-
ticularly mathematical modeling and network analysis, are new
approaches that can be used to optimize results in areas where
traditional reductionist molecular biology has failed. Mathemati-
cal modeling approaches have been utilized to individually assess
the consequence of XPO1 inhibition on single pathways. Such
approaches have been able to shed light on MAPK/ERK and NF-B
signaling when their nuclear export is blocked, highlighting that the
technology, if used correctly, can be applied successfully in XPO1
related research. However, there are no studies to date that have
evaluated the differences in the effect of XPO1 inhibition on re-
alignment of proteins in cancer versus normal cell nuclei in any
kind of global context. Major unanswered questions remain as to
whether there are differences in cellular responses between cell
types (cancer with aberrant genome versus normal cells with nor-
mal  genome versus precancerous lesions). Performing such studies
at the systems level will undoubtedly lead to the optimization of
XPO1 inhibitor therapies in the clinic, as well as in the design of
novel strategies targeting nuclear transport.
9. Apoptosis resistance in different cancers
9.1. Apoptosis resistance in glioblastoma
Among all brain tumors, glioblastoma multiforme (GBM) is the
most prevalent brain tumor in humans [164]. It is classified as grade
IV astrocytoma by the World Health Organization (WHO) [165].
Various molecular alterations are responsible for development of
GBM. Apoptosis resistance plays one of the key roles in tumorigen-
esis and sustains malignant progression in GBM. GBM patients have
a poor prognosis with a median survival of 14.6 months. Surgery,
radiotherapy, and the alkylating chemotherapy with TMZ are the
standard first line treatment for GBM patients [166,167]. Combina-
tion therapeutic strategy with radiotherapy and TMZ  significantly
improves the median survival, 2 to 5 years, compared to radio-
therapy alone in patients with newly diagnosed GBM [168,169].
Therapeutic effect of TMZ  on GBM cells depends on the epige-
netic silencing of the O6-methylguanine-DNA-methyltransferase
(MGMT) gene by promoter methylation [170]. MGMT  counteracts
chemotherapy-induced DNA damage by restoring the structural
integrity of O6-alkylated bases. Unmethylated MGMT promoter is
frequently observed in glioblastoma patients and these seem to
respond poorly to TMZ  treatment [171]. Until now there has beenng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
no alternative drug treatment for GBM. Thus, understanding the
molecular mechanisms that mediate cellular survival and apopto-
sis resistance will enable us to exploit the key players to design
better drug combinations for targeted therapies for GBM patients.
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Erlotinib and gefitinib, which are two epidermal growth fac-
or receptor (EGFR) tyrosine kinase inhibitors, have been evaluated
or GBM treatment. The low molecular weights of these inhibitors
nable them to cross the blood–brain barrier (BBB). Recent stud-
es show that GBM patients with amplified or overexpressed EGFR
esponded better to erlotinib than patients with normal EGFR levels
172] and the response depended on low levels of Akt activation.
o, Akt phosphorylation may  be a direct result of increased EGFR
ctivity. Thus, treatment with EGFR inhibitors can show better clin-
cal responses. Clinical studies indicated that treatment with single
yrosine kinase inhibitor like erlotinib could not effectively inhibit
urvival signaling because many other RTK were co-activated in
BM cells [173,174]. Two other receptors, platelet-derived growth
actor receptor (PDGFR) and c-Met or hepatocyte growth factor
eceptor (HGFR), are also involved in EGFR function and in main-
aining downstream pathway activation [175]. This suggests that
arefully designed combination of inhibitors with limited toxicity
rofiles and maximal additive or synergistic effects may  provide
ore beneficial therapeutic effects [176]. TMZ  causes cell cycle
rrest at G2/M phase and EGFR inhibitors prevent cells from pro-
ressing beyond G1 and may  therefore compromise the activity of
ther cell cycle-specific agents [177]. As the EGFR tyrosine kinase
nhibitors show low toxicity, higher dose can be applied, but it may
e difficult to predict the functionally active drug in GBM patients.
owever, the lack of availability of post-treatment tumor tissue for
alidation of target inhibition results in uncertainties regarding the
ufficient inhibition of the EGFR signaling.
Many inhibitors of the anti-apoptotic members of the Bcl-2 fam-
ly have been developed and several of them are under preclinical
r clinical trials [178]. Although some of the inhibitors have been
ested, only one compound has reached the clinical trial in GBM
atients. Brain tumors that overexpress anti-apoptotic Bcl-2 and
cl-xL proteins can be treated with their inhibitors. ABT-737, a
ecently developed Bcl-2 inhibitor, is known to induce apopto-
is in glioblastoma cells both in vitro and in vivo by releasing the
ro-apoptotic Bax protein from its binding partner Bcl-2 [179]. ABT-
73 can sensitize tumor cells to the tumor necrosis factor-related
poptosis-inducing ligand (TRAIL) as well as to other anti-cancer
rugs. But, cells with higher expression of Mcl-1, which is an anti-
poptotic protein of the Bcl-2 family, are found to be less responsive
o ABT-737 treatment. So, combination therapy with inhibitors of
cl-1 and Bcl-2 can be a novel strategy to treat GBM. Recent inves-
igations indicated that the BH3-binding compound HA14-1 can
nhance the sensitivity of human glioblastoma cells to both radio-
herapy and chemotherapy [180]. Gossypol (AT-101), which is a
ulti-targeting polyphenol derived from cotton plant, is so far the
nly Bcl-2 targeting compound tested in clinical trials for treatment
f GBMs [181]. Gossypol binds to the BH3 pocket of anti-apoptotic
cl-2 proteins [182] as well as to other target proteins [183]. Studies
uggest that administration of gossypol (20 mg/day) is well toler-
ted in patients and it has a low but measurable response rate. A
hase II trial of gossypol in recurrent GBM is underway to detect its
fficacy against tumor progression and also its toxicity.
The  inhibitors of apoptosis (IAP) family proteins like XIAP, cIAP1,
IAP2, ILP2, ML-IAP, and surviving are well known for inhibition of
poptosis in GMB  [184,185]. The IAP family proteins are currently
nown as the baculoviral inhibitors of apoptosis repeat containing
BIRC) proteins. These BIRC proteins can inhibit apoptosis by mod-
lating the activity of different caspases like caspase-9, caspase-7,
nd caspase-3, which are actively involved in intrinsic pathway of
poptosis in human glioblastoma [186]. In most GBM patients, high
evels of BIRC proteins have been detected. Therefore, targetingPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
IRC proteins to make active caspases available for induction of
poptosis is now an established approach in developing strategy
or controlling growth of human glioblastoma cells [187]. Many
reclinical trials have been carried out with several small molecule PRESS
ncer Biology xxx (2015) xxx–xxx
inhibitors  directed to BIRC proteins to identify a potential agent
capable of inducing apoptosis in different cancers [188]. However,
very little research has been performed with BIRC inhibitors in
GBM. A recent report showed that BIRC-4 (XIAP) inhibitors syn-
ergize with radiation to increase glioblastoma cell apoptosis [189]
and targeting BIRC proteins can sensitize cells to TRAIL for induc-
tion of apoptosis [190]. Recent investigations also indicated that the
endogenous BIRC inhibitor Smac can significantly increase the anti-
cancer efficacy of TRAIL in an intracranial glioblastoma xenograft
model [191]. Also the use of inhibitors of histone deacetylase and
of the proteasome in clinical trials (targeting specific, but poorly
characterized aspects of apoptosis) are ongoing at the moment. The
versatility and applicability of these preclinical studies will even-
tually contribute to elucidation of the molecular mechanisms of
chemoresistance, which should ultimately result in the identifica-
tion of more effective therapeutic strategies for avoiding apoptosis
resistance in GBM.
9.2.  Resistance to apoptosis in melanoma
Melanoma is considered the most aggressive form of skin
cancer, derived from activated or genetically altered epidermal
melanocytes. Human malignant melanoma is a highly metastatic
cancer that is markedly resistant to conventional therapy such
as dacarbazine or TMZ. The RAF/MAP kinase pathway has
attracted attention because activating mutations of the BRAF ser-
ine/threonine kinase has been detected in more than 50% of
melanomas. Other mutations occur in NRAS, MEK1, MEK2 as well
as c-Kit. Activation of c-Kit results in the stimulation of MAPK
and PI3K/AKT pathways resulting in both proliferative and survival
advantage. Several other signal transduction pathways have been
found to be constitutively active or mutated in other subsets of
melanoma tumors including NF-B. Raf inhibitors in general and
specific BRAF inhibitors, including vemurafenib, frequently elicit
therapeutic response. However, durable effects are often limited
by ERK1/2 pathway reactivation via poorly defined mechanism.
Resistance to apoptosis using BRAF specific inhibitors is mediated,
in part, by the presence of NRAS mutation and required switch in
activation of RAF isoform, CRAF. Furthermore, rebound melanoma
growth after initial treatment with BRAF specific inhibitors is asso-
ciated with elevated activation of PI3K/Akt pathway.
It has been shown that the Bcl-2 positive regulator NF-B is a key
player in human melanoma tumorigenesis. Canonical NF-B acti-
vation in melanoma cells is associated with increased survival and
proliferation. In human melanoma, a number of NF-B-dependent
chemokines are constitutively expressed at high levels including
CXC ligand 8 (CXCL8 or IL8), interleukin-8 [192], CXCL1, melanoma
growth stimulatory activity or MGSA [193], CCL5 (regulated on acti-
vation), normal T expressed and secreted, or RANTES [194] and
CCL2 (monocyte chemotactic protein-1), or MCP1 [195]. In late
stages of metastatic melanoma, hyperactivated NF-B inhibits pro-
apoptotic pathways through the upregulation of (i) tumor necrosis
factor receptor-associated factor-1 (TRAF-1) and TRAF-2 [196]
to inhibit the TNF-R1/caspase-8-mediated pro-apoptotic pathway
TRAIL decoy receptor, inhibiting the TRAIL-mediated cell-death
pathway [197,198], and (iii) Fas-associated phosphatase-1 (FAP-1)
[199], which down-regulates FAS-R trafficking from cytoplasm to
membrane [200]. Furthermore, in late stage metastatic melanoma,
activation of NF-B also enhances several anti-apoptotic molecules
such as inhibitor of apoptosis (IAP) [201], caspase-8 (FLICE) and
inhibitory protein (FLIP) [202]. NF-B also promotes Myc  activ-
ity [203] and the cell cycle regulatory proteins, cyclin D1 andng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
cyclin dependent kinase 2 (CDK2) [204], which further contribute
to melanoma tumor growth.
More  than 50% of melanoma cells harbor mutations in BRAF
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erine/threonine kinases, which are effectors of the small GTPase
AS in the ERK/MAPK pathway. This pathway is activated by sev-
ral membrane-bound receptors such as receptor tyrosine kinases
nd G-protein-coupled receptors. BRAF transduces signals through
itogen activated protein kinase (MAPK) [206,207]. MAPK pro-
otes regulation of cell growth, survival and differentiation [208].
anonical activation of the MAPK pathway occurs when growth
actor-growth factor receptors bind which leads to the activation
f a RAS family member, any of the three isoforms H, N, and
-RAS. Activated RAS then binds and activates multiple effector
roteins, including the three Raf members (ARAF, BRAF and CRAF),
eading to subsequent activation of a cascade of kinases including
EK1/2 and ERK1/2. Activated ERK in turn specifically phospho-
ylates a number of nuclear and cytoplasmic substrates including
he ETS transcription factor, which has the net effect of provid-
ng a pro-growth and pro-survival signal [209]. Concurring with
hese assumptions, Erk1/2 signaling has been shown to protect
elanoma cells against TRAIL-induced apoptosis by inhibiting the
elocation of Bax from the cytosol to mitochondria and that this
ay reduce TRAIL-mediated release of Smac/DIABLO and induction
f apoptosis.
.3. Apoptosis resistance in pancreatic ductal adenocarcinoma
With mortality rates almost mirroring incidence rates, pancre-
tic ductal adenocarcinoma (PDAC) is among the most lethal of all
ancers. It causes more than 170,000 deaths worldwide and is the
ourth leading cause of cancer related deaths in the United States
aking it a deadly disease in urgent need for newer treatment
pproaches [210]. PDAC tumors are very heterogeneous and carry
lterations in many critical pathways (harbor a robust biological
etwork) rendering the design of therapy against a single path-
ay unrealistic [211]. The major reasons for this dismal outcome
nclude, lack of early detection markers [212], invasive behav-
or [213] and intrinsic resistance to therapeutic treatments [214].
ecently, several studies have identified a highly resistant sub-
et of PDAC cancer stem cells (CSCs) with self-renewal capacity
nd propensity to undergo epithelial to mesenchymal transition
215]. Additionally, the low clinical efficacy of different regimens in
DAC has been attributed to the lack of drug penetrance due to the
resence of high desmoplastic stroma that supports a low tumor
asculature [216]. Thus, holistic studies are needed that identify
ffective regimen against PDAC CSCs, and key molecules that pro-
ote desmoplastic stroma in PDAC will provide biomarkers and
otential targets to overcome chemo resistance and disease recur-
ence.
De-regulated apoptosis signaling mechanisms have been
ttributed as one of the major causes for the drug resistance. Pan-
reatic cancer has been shown to over-express Bcl-2 and its family
embers. Therefore, blockade of Bcl-2 activity should become a
ovel therapeutic strategy for pancreatic cancer. Many groups have
een working to develop anticancer drugs that block the function
f Bcl-2 members. Earlier Wang and colleagues have successfully
emonstrated that targeted inhibition of Bcl-2 can suppress PDAC
rowth in vitro and in vivo [217]. Very recently, Abulwerdi et al., [32]
xploited Mcl-1 as a therapeutic target using small molecule drugs
n PDAC. Both these studies collectively prove that targeted inhibi-
ion of BH3 family proteins could be a viable therapeutic strategy
gainst PDAC.
.4.  Apoptosis resistance in colon cancerPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
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Colorectal cancer is among the common forms of cancer world-
ide and ranks third among the cancer-related deaths in the US and
ther Western countries. It is common to both men  and women,
onstituting 10% of new cancer cases in men  and 11% in women. PRESS
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Despite  recent advancement in therapeutics, the survival rates
from metastatic are less than 5%. Growing evidence supports the
contention that epithelial cancers including colorectal cancer, the
incidence of which increases with aging, are diseases driven by the
pluripotent, self-renewing cancer stem cells (CSCs). Dysregulation
of Wnt, Notch, Hedgehog and/or TGF- signaling pathways that
are involved in proliferation and maintenance of CSCs leads to the
development therapy resistance.
The loss of heterozygosity (LOH) at the bcl-2 gene locus and
the expression of the bcl-2 gene has been examined in colorec-
tal carcinoma cell lines and carcinoma tissues. LOH at the bcl-2
locus was detected in 60% (6/10) of colonic carcinomas, all of
which were well differentiated adenocarcinomas, whereas LOH
was not seen in poorly differentiated ones. Further, tree colorectal
carcinoma cell lines, all of which were derived from poorly differ-
entiated adenocarcinomas, expressed considerable levels of bcl-2
mRNA and protein. These results suggest that LOH at the bcl-2
locus is frequently associated with well differentiated adenocar-
cinomas of colon, and bcl-2 overexpression has implications for
the development of poorly differentiated adenocarcinomas of the
gastrointestinal tract.
Colon  tumors have been shown to exploit the lymphocyte
death program by expressing FasL [218]. This may  enable colon
tumors to mount a “Fas counterattack” against antitumor lym-
phocytes, impairing antitumor immune responses. FasL-expressing
colon tumor-derived cell lines can trigger Fas-mediated apoptosis
of co-cultured T cells in vitro. FasL expressed in esophageal cancer
has been significantly associated with apoptosis and depletion of
tumor-infiltrating lymphocytes (TIL) in vivo. FasL may  also facilitate
metastatic colonization of Fas-sensitive organs such as the liver,
by inducing apoptosis of target organ cells. Normal colonic epithe-
lial cells express Fas and are relatively sensitive to Fas-mediated
apoptosis. By contrast, colon tumor-derived cell lines are usually
resistant to induction of Fas-mediated apoptosis, and colon cancer
cells frequently coexpress Fas and FasL. The mechanisms allow-
ing resistance to Fas-mediated apoptosis are complex, and defects
have been identified at several levels of Fas signal transduction. The
“Bcl-2 rheostat” may  be pitched against apoptosis in colon cancer,
in as much as over-expression of Bcl-2, downregulation of Bak, and
mutation of Bax are common defects in colon tumors. Caspase-1
is also downregulated in colon cancer. The high frequency of p53
mutations in late-stage cancers may  also inhibit Fas signaling. Fun-
damental defects in apoptosis signaling may  contribute to both
immuno- and chemoresistance in colon cancer and allow expres-
sion of FasL to counterattack antitumor lymphocytes.
9.5. Apoptosis resistance in prostate cancer
With an estimated 233,000 new cases diagnosed and 29,480
deaths, prostate cancer is considered as the top major cause for can-
cer related deaths in the United States. Hormone ablation therapy
is used to manage early stage disease, however, in majority of cases,
prostate cancer becomes castrate resistant [219]. The disturb-
ance in apoptosis pathway activation in prostate cancer therapy
resistance has been clearly defined [220]. More specifically, Bcl-
2 over-expression has been shown to promote androgen ablation
resistance [221]. Aside from disturbed apoptotic machinery, a num-
ber of studies have demonstrated that lack of autophagy activation
may also contribute to chemo- and hormone therapy resistance in
prostate tumors [222,223]. Nevertheless, there are reports showing
that autophagy pathway activation may  even promote apopto-
sis resistance and this has been linked to therapy resistance ofng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
prostate cancer [224,225]. Therefore, it is needless to say that
autophagy modulators have been shown to resensitize prostate
cancer cells to radiation or chemotherapy [226,227]. Similarly, a
number of Bcl-2 inhibitors have shown to reverse prostate cancer
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hemoresistance [228,229]. Mcl-1 inhibition has also been shown
o re-sensitize prostate cancer cells to different chemotherapeutics
nd targeted therapies [230–232]. Besides Bcl-2 and Mcl-1 over-
xpression, TRAIL induced apoptosis resistance in prostate cancer
as also been reported [233]. The development of TRAIL resistance
s both genetic and epigenetic [234] that manifests in apoptosis
esistance. Collectively, these studies clearly prove that sensitivity
o therapeutics (chemo-, hormone, radio- or targeted) is directly
orrelated to the presence of functional apoptotic machinery.
.6.  Apoptosis resistance in breast cancer
Breast cancer is the major cause for female cancer mortality
n the western world (GLOBACON). Despite the advances in early
etection and the greater understanding of the molecular path-
ays underlying breast cancer biology, a major fraction of patients
ave recurrent disease that becomes refractory to most of the
vailable therapies [235]. Systemic therapies include the use of
ytotoxic, hormonal, and immunotherapy is usually used in the
djuvant, neoadjuvant, and metastatic settings. While these sys-
emic agents are active in the majority of primary breast cancers
nd also to a great extent in metastatic cases, nevertheless, after
 variable period of time, progression occurs. Resistance to thera-
eutics in breast cancer is multi-factorial. It involves disturbances
n the apoptotic machinery, p-glycoprotein and the multidrug
esistance protein family, HER-2/neu gene amplification and pro-
ein expression, along with the expression of additional members
f the epithelial growth factor receptor family, DNA ploidy, p53
ene mutations, cyclin E and p27 dysregulation that cumulatively
rive the development of cancer stem cells [236]. A number of
tudies have linked breast cancer drug resistance to disturbed
r over-expression of pro-survival factors including Bcl-1, Mcl-1
nd other BH3 family members [237]. This is confirmed from the
bservation that BH3 mimetic ABT-737 can sensitize BH3 protein
ver-expressing breast cancer cells [238]. Studies have also linked
isturbed proteasome signaling to breast cancer chemo and radio
esistance [239]. These findings become particularly relevant as
roteasome inhibitor bortezomib treatment causes suppression of
DRs leading to induction of apoptosis in breast tumor models
240]. In summary these studies prove that the inherent resistant
raits of breast cancer are associated with malfunctioning of the
poptosis signaling. Targeting the different pathways that either
nduce apoptosis or suppress the pro-survival signaling is expected
o resulting in overcoming drug resistance to various therapies.
.7.  Apoptosis resistance in leukemia’s (focus on chronic
ymphocytic leukemia and acute promyelocytic leukemia)
Chronic lymphocytic leukemia (CLL) is the most common B-
ell malignancy in the Western world and is characterized by the
ccumulation of mature CD5 positive B lymphocytes in peripheral
lood, bone marrow, and lymphoid organs [241]. CLL disease is
enerally associated to apoptosis resistance. A combination of alter-
tions in the apoptotic machinery as well as micro-environmental
urvival signals within the CLL cells cause a cell death resistance.
ecent studies suggest that most CLL clones include activated cells
hat proliferate at appreciable rates [242,243]. Thus, the balance
etween proliferation and cell death is extremely within patients
nd reflects the different disease progression [244].
In  CLL, defects in the intrinsic and extrinsic apoptotic path-
ays have been described. B-cells can be resistant to both CD95/Fas
245] and TRAIL death receptors induction [246]. The intrinsic, orPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
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itochondrial, pathway is regulated by the Bcl-2 family proteins,
lassified into anti-apoptotic (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1) and
ro-apoptotic (Bax, Bak, Bim, Bad, Bid, Hrk, Noxa, Puma) mem-
ers [247]. In CLL the overexpression of anti-apoptotic proteins PRESS
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has  implicated in resistance to apoptosis [248]. Aberrant expres-
sion of Bcl-2 is common in CLL patients and is associated with poor
response to chemotherapy and decreased overall survival [249].
Moreover, Mcl-1 protein expression was correlated with adverse
prognostic factors, such as disease stage, IgVH mutation status,
ZAP-70 positivity and CD38 expression [250] and, was found to
be predictive of the clinical outcomes of CLL patients [251,252]. In
B-cells, several signals are involved in regulation of Bcl-2 family
proteins, including BCR, cytokine signaling and microRNA. CD40
signaling has been suggested to trigger up-regulation of the anti-
apoptotic proteins Mcl-1, A1 and Bcl-xL [253,254]. BCR signaling
has been reported to be able to regulate Mcl-1, through hyper-
activation of Akt [255] which also contributes to maintain cell
survival by phosphorylating and inactivating the pro-apoptotic
factor proteins Bad and Bim [256,257]. Given the key role that
anti-apoptotic proteins play in CLL, they became an attractive
target for the creation of novel therapeutic agents, such as anti-
sense methodology [258], small molecules mimicking the action
of BH3 domain [259], and microRNAs (mainly miRNA-15a and
miRNA-16-1) [260]. For several decades, front-line therapy for CLL
has been represented by treatment with alkylating agents and
purine analogs [261]. Recently, significant clinical outcomes have
been achieved using chemo-immunotherapy, such as rituximab, a
chimeric monoclonal antibody against CD20, administrated in com-
bination with fludarabine or fludarabine plus cyclophosphamide
[262,263]. Nevertheless, the relapse remains problematic, partic-
ularly in older patients, thus the identification of innovative and
specific agents against CLL remains of high interest [264].
Very  interesting is the use of a cottonseed extract derivative,
gossypol, which acts as a BH3-mimetic, interfering with the func-
tions of Mcl-1, Bcl-2 and Bcl-xL proteins (from highest to lowest
affinity) and displacing pro-death partners to induce apoptosis
[265–267]. However, despite this encouraging data and the abun-
dant literature describing the molecular mechanisms triggered by
phytochemicals to inhibit cell growth and induce apoptosis in can-
cer cells, only few of them entered clinical trials [268].
Acute promyelocytic leukemia (APML or APL for short) is a sub-
type of acute myelogenous leukemia (AML). APL is characterized
by an abnormal accumulation of immature granulocytes. The dis-
ease harbors chromosomal translocation involving the retinoic acid
receptor alpha (RAR  ˛ or RARA) gene and is distinguished from
other forms of AML  by its responsiveness to all-trans retinoic
acid therapy. The role of Bcl-2 proteins in apoptosis resistance
to retinoic acid therapy has been intensively investigated. It has
been shown that the ability of retinoid-induced cells to undergo
apoptosis depends on the level of expression and the functional
interaction between Bcl-2 and Bax [269]. Highlighting its signifi-
cance, autophagy and Beclin 1, an autophagic protein, were shown
to be upregulated during the course of all trans retinoic acid
(ATRA)-induced neutrophil/granulocyte differentiation of an APL-
derived cell line. This induction of autophagy is associated with
downregulation of Bcl-2 and inhibition of mTOR activity. Further,
other studies have shown that a BH3 domain mimetic, JY-1-106,
which antagonizes the anti-apoptotic BCL-2 family members B-
cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1
(MCL-1) alone and in combination with retinoids reduced cell via-
bility in HL-60 APL cells alone and in combination with retinoids.
The combination had the greatest impact on cell viability by stim-
ulating apoptosis. These studies indicate that dual BCL-xL/MCL-1
inhibitors and retinoids could work cooperatively in APL.
10.  Role of different natural compounds (phytochemicals)ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
against apoptosis resistance
Since  the early eighties, when apoptotic cell death appeared
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ypassing apoptotic resistance resulted in novel therapeutic solu-
ions against cancer. These efforts successfully involved novel and
anonical anticancer drugs, but also stimulated the interest to
xplore the possibility that natural compounds may  re-sensitize
umor cells to pro-apoptotic drugs. However, many of the studies
hat followed have been limited to preclinical laboratory exper-
ments (largely confined to cell lines). More importantly, it is
ifficult to figure out how molecules that are structurally and func-
ionally different (i.e., stability, bioavailability, biotransformation
tc.) can behave similarly, and remove the resistance occurring in
ancer cells to apoptotic induction.
It must be imagined that a unique mechanism, common to many
hytochemicals, is responsible for their ability to re-establish the
ost sensitivity to apoptosis. The well-known antioxidant capacity
hared by the large majority of these compounds has been evoked
o explain the experimental evidence. However, the “antioxidant
ypothesis” is weakened by paradoxes and contradictions. In fact,
he scavenging activity of the phytochemicals against ROS chem-
cally converts them into oxidative products which display a high
eactivity toward thiols and can lead to the loss of protein function.
herefore, paradoxically, the net result between protection offered
y many phytochemicals and damage caused by its toxic prod-
cts may  weigh in favor of the latter. As an example, in lung cells,
uercetin efficiently protects against H2O2-induced DNA damage,
ut this positive effect is counteracted by the reduction in GSH
evel, an increase in LDH leakage and cytosolic-free calcium con-
entration [270]. Quercetin may  also form quercetin–quinone (QQ)
pecies when the molecule is employed as an antioxidant. QQ, like
ther semiquinone radicals and quinones, is toxic because of its
bility to arylate protein thiols. Protection against QQ may  arise
rom GSH which, when present at the right concentration, quickly
raps QQ [271]. Accordingly with this example, a pivotal review
rom Ursini’s group explains how the major mechanism of action
or nutritional antioxidants is the paradoxical oxidative activa-
ion of the Nrf2-Keap1 (nuclear factor erythroid 2-related factor
-Kelch-like ECH associated protein 1) signaling pathway, since
inetic constraints indicate that in vivo scavenging of radicals by
hese compounds is ineffective in antioxidant defense [272].
Nonetheless, although this preamble illustrate a critical chal-
enge in this area of research, recent studies have demonstrated
hat treatment with phytochemicals may  represent an applicable
herapeutic strategy to bypass apoptotic resistance in specific types
f cancers [273,274].
Pleiotropy”’ and “synergism” are two terms often associated to
he effects of natural compounds to explain their multiple bio-
ogical activities. The former refers to their ability to bind and
nterfere with the activity of several effectors that insist on one
r more pathways, converging on the same cellular process, for
xample apoptosis, cell cycle arrest, autophagy. The latter indi-
ates the property to enhance the efficacy of chemotherapeutic
rugs in co-treatment protocols with the advantage to limit toxicity
or patients. Both features, pleiotropy and synergism, find ratio-
ale applications in the physiopathology of cancer and is highly
elevant to some specific diseases such as CLL, a form leukemia
hich remains indolent for decades. In fact, patients with CLL
ay survive for many years without any treatment because of
he relatively slow progression rate of the disease. This feature
akes CLL patients ideal models to test the pleiotropic properties
f natural chemo-preventers possessing limited toxicity. In fact,
n the temporal window during which patient’s remains asymp-
omatic, chronic administration of a specific phytochemical may
etard disease onset. Moreover, when the disease progresses toPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
linically relevant forms and requires pharmacological interven-
ions, the same compound can be introduced in the therapeutic
rotocol as adjuvant to synergistically improve the efficacy of the
herapy. Supplementation with biologically active phytochemicals PRESS
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or  phytochemicals-enriched food may  represent an important
approach to modify the clinical progression of cancers. However, to
move from speculation to clinical application, further fundamen-
tal steps are required, such as well designed, randomized, control
clinical trials.
10.1.  EGCG
Mechanistic studies suggest that polyphenols have multiple
intracellular targets, one of which is the proteasome complex
[275,276]. Several botanically derived agents such as green tea cat-
echins, isoflavones, anthocyanins, anthocyanidins, quercetin (3,3′,4
5,7-pentahydroxyflavone), apigenin and curcumin have been iden-
tified as potent proteasome inhibitors, with a more favorable
toxicity profile compared to velcade and bortezomib and may  be
ideal candidates for therapeutic applicability in cancer chemo-
prevention and treatment. The goal of this section is to focus on
providing a model of a botanically derived agent green tea polyphe-
nol that has been demonstrated to induce apoptosis through
targeting of the ubiquitin/proteasome pathway.
Among the constituents of green tea extracts (GTE), laboratory
studies have identified EGCG as the most potent chemopreventive
agent which appears to affect a number of molecular processes
including induction of apoptosis and inhibition of tumor growth
and angiogenesis [277–280]. More recently EGCG has been found
to affect several cancer-related proteins including p27, Bcl-2 or
Bcr-Abl oncoproteins, Bax, matrix metalloproteinases (MMP-2 and
MMP-9) [281], the androgen receptor, EGF receptor, activator pro-
teins 1(AP1), and some cell cycle regulators [282–284]. Based on
their studies of GTE in cell culture systems, Adhami et al. [285]
were able to demonstrate that EGCG (in GTE) induces apoptosis,
cell growth inhibition and cyclin kinase inhibitor WAF-1/p21-
mediated cell cycle-dysregulation. Using cDNA microarrays, they
also observed the EGCG treatment of prostate cancer cells results
in induction of genes that functionally exhibit growth-inhibitory
effects and repression of genes that belong to the G-protein
signaling network. These data confirm that GTEs exert potent and
selective in vitro and in vivo pro-apoptotic activity on prostate can-
cer cells. Although there are several mechanisms by which EGCG
may operate in prostate carcinogenesis, EGCG has been demon-
strated to potently and selectively inhibit the proteasome activity
in intact human cells leading to the accumulation of IkB- and p27
proteins, and growth arrest [286]. This inhibition of proteasome
activity by EGCG occurred at or near physiological concentrations
similar to that found in the body fluids of green tea drinkers.
Other studies have shown that a mixture of green tea polyphe-
nols (polyphenon E) is equally potent inhibiting the proteasome
activity as purified EGCG [287]. Polyphenon E preferentially inhibits
the proteasomal chymotrypsin-like activities over other activi-
ties; b. Polyphenon E inhibits proteasome activity in intact cells
in a concentration-dependent manner. Treatment of polyphenon
E, at all used concentrations in both cell lines, increased accumula-
tion of the proteasome target protein p27Kip1 in human multiple
myeloma and prostate cancer cells. Similar to purified EGCG, using
a cell-free proteasome assay it has been shown that Polyphenon
E significantly inhibits the chymotrypsin-like activity of the puri-
fied rabbit 20S proteasome with an IC50 value of 0.88 M. To
investigate whether polyphenon E specifically inhibits the pro-
teasomal chymotrypsin-like activity, its effects on the PGPH-like
and trypsin-like activities of the purified 20S proteasome were
determined. Polyphenon E inhibited PGPH-like activity of the puri-
fied rabbit 20S proteasome with an IC50 value of 7 M.  The IC50ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
value for trypsin-like activity was  above 100 M,  thus demon-
strating that polyphenon E preferentially inhibits the proteasomal
chymotrypsin-like activities over other activities. The most sig-
nificant study analyzed the effect of 2 mg/diet of Polyphenon E
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n a phase I/II clinical trial on asymptomatic CLL patients (Rai
tage 0 to II). The results of the study indicated that in 69% of
atients a substantial decline in absolute lymphocyte count (>20%)
nd/or reduction of lymphadenopathy (>30%) during the 6 months
f active treatment [288,289]. Also flavopiridol, a semisynthetic
avonoidal alkaloid, originated from an Indian plant and known for
ts ability to inhibit cyclin-dependent kinases, achieved significant
linical activity in patients with relapsed CLL, including those with
igh-risk genomic features and bulky lymphadenopathy [290,291].
These data strongly suggest that the proteasome, an important
arge multi subunit protease complex in the cell, is a cancer-related
olecular target of green tea catechins and that inhibition of the
roteasome activity by EGCG may  be the primary pathway by
hich tea catechins, specifically EGCG, induce prostate epithelial
ell apoptosis. This appears to be accomplished via the proteasome
nhibition pathway i.e., IB- protein expression, accumulation
f p27 proteins and decreasing NFB DNA-binding activity, and
esulting in the inhibition of prostate cell survival and the induc-
ion of apoptosis, thereby decreasing progression from HGPIN to
rostate [292,293] – similar to the effects of bortezomib and vel-
ade (PS-341) [294–296].
The  proteasome has been proven to be an excellent target for
eveloping anticancer drugs, but several side effects (including
ausea, fatigue, diarrhea, peripheral neuropathy, rapidly reversible
eduction in platelets, and reversible thrombocytopenia) have
een observed with bortezomib. Therefore, it is necessary to
dentify less toxic proteasome inhibitors with similar potency to
ortezomib or different novel proteasome inhibitors, as we  have
roposed in this study. Additionally, although it is clear that the
ster carbon of EGCG is important for mediating the proteasome-
nhibitory activity, EGCG is very unstable under physiological
onditions. Therefore, a series of EGCG analogs are evolving that
re aimed at improving stability and bioavailability of EGCG. Among
hem, peracetate-protected or the pro-drug of EGCG was  found to
ave increased bioavailability, stability, and proteasome-inhibitory
ctivities against various human cancer cells and tumors com-
ared to EGCG, suggesting its potential use for cancer prevention
nd treatment [297]. The early laboratory and Phase I trials have
emonstrated GTPs, specifically EGCG, have a completely different
hemical structure from bortezomib. Most importantly, (−)-EGCG
nd other catechin mixtures at varying doses has been found to
e relatively better tolerated in clinical trials, in contrast to the
bserved AEs seen in the bortezomib trials, and thus appear to have
ignificant potential to be tested in clinical trials.
In green tea, the catechin EGCG has been extensively studied
or the biological activities and cellular targets, among which the
roteasome attracts more attention [277]. Both naturally-occurring
−)-EGCG and synthetic enantiomer (+)-EGCG are able to potently
nd specifically inhibit the chymotrypsin-like activity of protea-
ome 5 subunit in an irreversible way with IC50 range 86–194 nM
n vitro and 1–10 M in vivo [280]. Of note, EGCG is able to inter-
ct with not only the 5 subunit in constitutive proteasome but
lso the 5i subunit in interferon- inducible immunoproteasome
referring to as BrAAP activity) with even higher affinity [298]. Pre-
linical studies have demonstrated the chemosensitizing effect of
GCG and other catechins in vitro and in vivo. It has also been shown
hat EGCG reversed drug resistance by inhibiting the drug efflux
ransporter P-gp. For example, Kitagawa et al. [299] reported that
atechins increased the cellular accumulation of P-gp substrates
n human cervical epidermal carcinoma cells. The chemosensiti-
ation by EGCG through the inhibition of P-gp expression/activity
as also been validated in Caco-2 human intestinal adenocarci-Please cite this article in press as: Mohammad RM,  et al. Broad targeti
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oma cells (which are often used as a model for intestinal transport
tudies mediated by P-gp) [300] and tamoxifen-resistant MCF-
 human breast cancer cells [301], as well as in the xenograft
ouse models using doxorubicin-resistant KB-A1 cells [302] or PRESS
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doxorubicin-resistant BEL-7404/DOX hepatocarcinoma cells [303].
The study with tamoxifen-resistant MCF-7 cells also found that
EGCG was  able to inhibit the activity of the BCRP transporter [304].
EGCG was  also reported to enhance the sensitivity of glioblas-
toma to temozolomide, and of prostate carcinoma to doxorubicin
[305], and of breast carcinoma to paclitaxel [306] in corresponding
ectopic or orthotopic xenograft mouse models. Furthermore, the
peracetate-protected prodrug of EGCG also exhibited a chemosen-
sitizing effect in the treatment of leukemia cells by augmenting the
efficacy of conventional chemotherapy daunorubicin and cytosine
arabinoside [307]. A very recent study reported that polymer-
based nanoparticle of polyphenols EGCG and theaflavin retained
biological effectiveness with over 20-fold dose advantage than
EGCG/theaflavin in exerting anti-cancer effects and also enhanced
the potential of cisplatin in several different tumor cell types [308].
Encouraged by the preclinical results, a few studies were
conducted using green tea extract (GTE) as monotherapy or a
complementary/alternative medicine (CAM) in cancer patients.
Although its anticancer activity was  unsatisfactory, the oral con-
sumption of GTE was  well tolerated in these studies [309–311].
After a temporary suspension of EGCG in clinical trials by the US
Food and Drug Administration (FDA) for additional review of toxic-
ity, a tea extract named polyphenon E further proved the safety
of tea polyphenols. In a polyphenon E phase I clinical trial in
patients with asymptomatic Rai stage 0 to II chronic lymphocytic
leukemia, most patients showed declines in absolute lymphocyte
count and/or lymphadenopathy after daily oral consumption of
Polyphenon E. A phase II trial using 2 g polyphenon E twice a
day to evaluate its efficacy showed that it was well tolerated by
patients with CLL and durable declines in the absolute lymphocyte
count and/or lymphadenopathy were observed in the majority of
patients [288]. Furthermore, two  clinical studies using polyphenon
E in combination with erlotinib are currently ongoing in patients
with advanced non-small cell lung cancer and premalignant lesions
of the head and neck, respectively. The chemosensitizing effect of
polyphenon E in clinical settings remains to be determined. The
in vitro and in vivo studies suggest that tea polyphenols (espe-
cially EGCG) may  serve as powerful agents for reversing tumor drug
resistance and enhancing the efficacy of chemotherapy.
10.2. Resveratrol
Isolated from the skin of red grapes, resveratrol received much
attention due to its association with the French Paradox (i.e., the
observation of low coronary disease incidence in high fat diet con-
suming French population who consume Red Wine-a supposedly
major source of resveratrol). Later on a number of laboratories
have demonstrated the anti-cancer activity of resveratrol in mul-
tiple tumor models. Studies have since shown that resveratrol can
reverse apoptosis resistance and also sensitize cancer cells to differ-
ent apoptosis inducing agents (chemotherapeutics). For example,
Sprouse and Herbert [312] very recently demonstrated that resver-
atrol can augment paclitaxel treatment in paclitaxel resistant breast
cancer cell line models. In another study Huq and colleagues [313]
showed that resveratrol can overcome chemoresistance in ovarian
cancer. In nasophyrangeal carcinoma, resveratrol has been shown
to cause expansion of ER, and ER caspase mediated apoptosis [314].
Similarly, it was demonstrated that resveratrol sensitizes tamox-
ifen in estrogen receptor resistance breast cancer models that show
epithelial-to-mesenchymal transition [315]. In a glioma model,
resveratrol was  shown to suppress X linked inhibitor of apop-ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
totic proteins [316]. While Díaz-Chávez [317] utilized a proteomic
approach to investigate the mechanism of resveratrol mediated
chemosensitization and highlighted the role of hsp27 (at least in




























































tARTICLESCBI-1176; No. of Pages 26
R.M. Mohammad et al. / Seminar
Other studies support the apoptosis and necrosis inducing
ffects of resveratrol in different cancer models. Aside from resver-
trol, studies have also focused on its biological analog piceatannol
s well. For example, Farrand and colleagues [318] demonstrated
hat piceatannol enhances cisplatin sensitivity in ovarian cancer via
odulation of p53, X-linked inhibitor of apoptosis protein (XIAP),
nd mitochondrial fission. Several natural compounds have been
mployed to assess their anti-apoptotic effects in in vitro mod-
ls of CLL. For example, resveratrol (3,4′,5-trihydroxystilbene), a
hytoalexin well known for its healthy properties, induced apo-
tosis in WSU-CLL cells (derived from a CLL patient resistant to
udarabine) and in B cells isolated from CLL patients; instead, nor-
al  peripheral blood mononuclear cells were slightly affected. The
ffect of this compound, used at 10–50 M concentration, was
orrelated to a down-regulation of two anti-apoptotic proteins,
nducible nitric oxide synthase and Bcl-2 [319,320]. Recently, it has
een reported that oral administration of resveratrol (5 g/day) for 4
eeks, to three CLL patients, decreased circulating white blood cell
ounts and directly lowered O-linked -N-acetylglucosamine (O-
lcNAc) levels in leukemic cells through proteasomal activation;
his is an interesting result considering that CLL cells are char-
cterized by high levels of proteins that are post-translationally
odified by O-GlcNAc moieties [321]. Resveratrol, in combination
ith quercetin, induced apoptosis and cell cycle arrest in G0/G1 in
uman 232B4 cell line derived from CLL [322]. Collectively, these
tudies very clearly demonstrate that grape derivative resveratrol
nd its analogs can either induce apoptosis by themselves or can
ensitize resistant cells to apoptosis inducers.
0.3. Curcumin
Curcumin, which is the major component of turmeric has been
sed in folklore medicine for centuries. The first reports on anti-
ancer activity of curcumin were reported in 1985 [323]. Since
hen more than 3000 studies have been reported on the different
nti-cancer mechanisms of curcumin and related analogs (numbers
rom PubMed search). Numerous studies have shown the apoptotis
nducing effects of curcumin and analogs in cancer cell lines (the
eaders are referred to several outstanding reviews in the literature
324]).
In primary B-CLL cells curcumin induced apoptosis with a mean
C50 of 5.5 M,  fourfold lower than the EC50 observed in normal
ononuclear cells (21.8 M).  The molecule blocks NF-B signaling,
robably through inhibition of IB [325]. Some authors observed an
nduction of apoptosis in primary B-cells using curcumin in associa-
ion with other natural compounds, such as rapamycin and EGCG. In
he former case, the effect was associated with a decreased expres-
ion of Bcl-2 and an increased level of the pro-apoptotic factor Bax
326]. Sequential administration of curcumin and EGCG led to a sub-
tantial increase in B-cells death, overcoming stromal protection
327,328]. These are some examples showing the potency of cur-
umin in overcoming resistance to apoptosis. The synergism shown
y curcumin with other natural compounds need to be examined
n greater details in order to move these combinations in clinical
tudies.
0.4. Quercetin
Quercetin a phytochemical found in a broad range of fruits,
egetables and beverage, is widely known for its antioxidant,
nti-inflammatory, anti-proliferative and apoptotic effects both
n cell culture and animal models [329,330]. Quercetin at rela-Please cite this article in press as: Mohammad RM,  et al. Broad targeti
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ively low concentrations (10–20 M)  is able to down-regulate
cl-1 and thus sensitize to apoptosis the B-cells isolated from CLL
atients [331,332], with the maximal effect observed in combined
reatments with apoptotic inducers (see below). Moreover, recent PRESS
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studies  have reported that quercetin affects Hh, Wnt, as well as
Notch signaling, emphasizing the potential efficacy of the molecule
against CLL [333].
10.5.  Isothiocyanates
Several studies have documented the cancer-preventive activity
of many isothiocyanates (ITCs), occurring in cruciferous vegetables.
They produce their anticancer effects through distinct but intercon-
nected signaling pathways [334]. Sulforaphane, a well-studied ITC,
restored chemosensitivity to DOX in mouse fibroblasts with p53
mutated at codon 220 [335]. The clinical pattern observed for the
above reported mutation sustains a strong oncogenic potential and
a lack of chemotherapy response. Sulforaphane was able to increase
the efficacy of DOX, allowing its administration at levels within
the concentration range clinically achievable [336]. The mecha-
nism by which Sulforaphane reversed DOX resistance involves a
rapid depletion of glutathione that renders cells more susceptible
to DOX-induced oxidative stress, stress-induced damage, and apo-
ptosis induction. The same study has shown that, pre-treatment
with N-acetyl-cysteine, a glutathione precursor, prevented Sul-
foraphane plus DOX-induced apoptosis. Since the clinical doses
of DOX currently being used during therapy are associated with
severe cardiotoxicity [337], Gupta et al. [338] analyzed the ability
of phenylethyl ITC (PEITC) to enhance the cytotoxic effects of low
(sub-toxic) concentrations of DOX in human breast carcinoma cells
stably transfected with the oncogene HER2. PEITC increased the
cytotoxicity of DOX. Moreover, DOX treatment suppressed HER2
expression modestly, whereas the combination of PEITC with DOX
markedly decreased the expression of HER2 and the phosphoryla-
tion of STAT3, known to play a critical role in the expression of cell
proliferative pathways [339]. Consistently, combination treatment
showed increased cleavage of caspase 3 and PARP as compared to
individual treatment indicating apoptosis. In colorectal cancer cells,
co-administration of Sulforaphane potentiated the growth inhibi-
tion activity of oxaliplatin through a reduction of intracellular ATP
levels, activation of caspase-3, DNA fragmentation, and PARP cleav-
age [340]. Cisplatin was also tested in combination with PEITC in
endometrial cancer cells [341] or with BITC in leukemia cells [342].
The combination therapy induced an increase in caspase-3 activity
and increased levels of cleaved PARP. Such effects were not cell-
specific since these results could also be observed in breast cancer
cells. The sensitization induced by ITCs was partly mediated by ERK
and Noxa activation. Interestingly, no effect was found in normal
breast cells or lymphocytes.
ITCs  also enhanced the efficacy of cisplatin when used against
human non-small cell lung cancer cells [343]. Neither cellular plat-
inum accumulation nor DNA platination accounts for this effect.
Protein binding is important for the induction of apoptosis by ITCs
[344]. ITCs covalently modify cysteine residues in tubulin, resulting
in tubulin conformational changes, disruption of microtubule poly-
merization, and ultimately apoptosis. Tubulin-binding agents such
as paclitaxel are commonly used in combination with platinum
drugs to treat non-small cell lung cancer [345]. Thus, -tubulin
depletion may  correlate and be important for sensitization to plat-
inum compounds by ITCs.
Taken  together, the evidence reported above indicates that
EGCG and ITCs have an enormous potential for enhancing tumor
cell sensitivity to therapy. However, some recent results sound a
cautionary note. EGCG and ITCs are able to increase Nrf2 expres-
sion [346], a key transcription factor inducing a cytoprotective gene
array. Since many standard chemotherapeutic agents are cytotoxic,ng of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
their cytotoxic effects can be abrogated by tumor cells by upregu-
lation of Nrf2 signaling, thereby yielding a more aggressive tumor
[347]. Even if pharmacologic induction of Keap1–Nrf2-signaling
axis allows for pulsed rather than permanent induction [348],
 IN PRESSG ModelY
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urther studies are necessary before suggesting the use of EGCG
r ITCs in patients with established cancers who are undergoing
hemotherapy treatment.
0.6.  Marine derived agents with apoptosis inducing properties
Aside  from different plant derived natural products, nature
as bestowed many other types of anti-cancer compounds from
arine sources as well. A key word search on ‘Marine anticancer
gents’ reveals more than 3000 hits in PubMed. Many of these
tudies directly point to the apoptotic inducing potential of marine
erived compounds in cancer cell lines and animal xenograft mod-
ls [349–358]. For those seeking additional detail in this area, we
efer the reader to an excellent literature review on the topic [359].
In summary, there is ample laboratory and early phase clinical
vidence demonstrating that natural agents (both plant and marine
erived) can impact important signaling pathways associated with
poptosis. However, a lot remains to be learned on their exact
echanism of action especially in relation to overcoming resis-
ance to apoptosis. Further studies on these agents are anticipated
o enhance our knowledge that in turn will drive their rapid clinical
se in combination with standard chemotherapeutics or targeted
herapies against therapy resistant cancers.
1. Broad spectrum approach to obtain synergies between
arious  different approaches
Given  that the heterogeneity that is present in most cancers,
t is our assumption that the complete arrest of the various sub-
opulations of immortalized cells in any given cancer will require
imultaneous actions on mechanisms that are important for several
spects of cancer’s biology. We  therefore believe that it is impor-
ant to be able to anticipate synergies that might be achieved by
cting on specific targets and with specific approaches (i.e., when
ontemplating an approach aimed at a broad-spectrum of targets).
ccordingly, in this review, we also explored cross-hallmark rela-
ionships that have been found between the prioritized target sites
nd the approaches that we identified in this review.
Specifically, when evidence in the literature showed that the
argets and approaches that we identified as relevant for apopto-
is resistance were also therapeutically relevant for other aspects
f cancer’s biology (i.e., anti-carcinogenic) we noted them as hav-
ng “complementary” cross-hallmark effects. While those that were
ound to have pro-carcinogenic actions were noted as having “con-
rary” effects. In instances where reports on relevant actions in
ther aspects of cancer biology were mixed (i.e., reports showing
oth pro-carcinogenic potential and anti-carcinogenic potential),
he term “controversial” was used. Finally, in instances where no
iterature support was found to document the relevance of a target
ite or approach in a particular aspect of cancer’s biology, we doc-
mented this as “no known relationship”. These validation results
re shown below in tabular form in Tables 1 and 2.
It  is predicted that future cancer therapeutics will be based on
etwork pharmacology strategies that will likely involve empir-
cal testing of mixtures of constituents. Therefore, we wanted to
reate a starting point for other researchers who might be consid-
ring translational projects. We  anticipated interest in approaches
eported to exhibit a large number of anti-carcinogenic actions
cross the hallmarks and we anticipated that a lack of pro-
arcinogenic potential might be important to identify in advance
since targets or approaches that have been shown to exert pro-Please cite this article in press as: Mohammad RM,  et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol (2015),
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
arcinogenic actions would potentially represent a confounding
nd unwanted influence/factor in empirical research).
Our cross validation exercise showed that in some instances,
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Table  2
Relationships of the approaches to different cancer hallmarks.
Approaches Gossypol EGCG UMI-77 Triptolide Selinexor
Other cancer hallmarks
Genomic  instability
Sustained proliferative signaling 0 + [452,453] 0 0 0
Tumor  promoting inflammation +[454,455] + [456,457] + [32] + [458,459] 0
Evasion  of anti-growth signaling +[460,461] + [462,463] 0 + [464,465] 0
Replicative  immortality +[466,467] +[468–470] + [32] + [471] 0
Deregulated  metabolism +[472,473] + [474,475] 0 + [476] 0
Immune  system evasion + [477] + [478] 0 +[479–481] 0
Angiogenesis 0 + [482,483] 0  − [484] 0
Tissue  invasion and metastasis + [454] + [485] 0 + [486] 0
Tumor  microenvironment + [487] + [488] + [32] + [489,490] +[491,492]
+  [493] + [483,494] + [32] + [495,496] + [497]
Selected approaches were evaluated for reported actions in other cancer hallmark areas. Approaches that were found to have complementary, anti-carcinogenic actions in
a  particular hallmark area were were indicated with “+”, while approaches that were found to have pro-carcinogenic actions in a particular hallmark area were indicated
w mixed












































sith “−”. In instances where reports on relevant actions in other hallmarks were 
ymbol “+/-” was used. Finally, in instances where no literature support was found
ocumented this as “0”. These cross-hallmark relationships are reported in the upp
ross-hallmark relationship was robust, consisting of multiple
tudies involving detailed in vitro and in vivo findings. In other
nstances, however, the underlying evidence that was  used to
eport the existence of a cross-hallmark relationship was  quite
eak (e.g., consisting of only a single in vitro study involving a single
ell-type). Additionally, there are examples of approaches that are
nown to exert different effects at different dose levels and in dif-
erent tissues but dose-levels and cell/tissue types were not used
o discriminate when gathering together these reported actions.
onetheless, given that the overarching goal in this project was  to
reate a foundation that would allow researchers to look systemat-
cally across the literature in each of these areas, the tables should
erve as a useful starting point as long as they are approached with
aveats in mind and a degree of caution. Essentially, we believe that
his heuristic should be useful to consider synergies that might be
nticipated in testing that involves certain targets and/or mixtures
f chemical constituents that are being considered for therapeutic
ffects.
2. Conclusions and future directions
Resistance to apoptosis is multi-factorial involving the interac-
ion of various signaling pathways at multiple levels. Therefore,
he use of single pathway targeted agents to commit cancer cells
o undergo apoptosis is not a feasible strategy (except in iso-
ated cases). Hence, this requires a careful selection of treatment
trategies that are based on a comprehensive understanding of the
iological networks involved in resistance. This article presents
ome of the major genetic and epigenetic drivers of apopto-
is resistance and provides a list of prioritized targets and the
pproaches that can be utilized against them to overcome de novo
r acquired resistance. In this review, first we discussed how Bcl-2
amily proteins play critical role in the biology of apoptosis acti-
ation/resistance. We  presented knowledge on the development
f agents such as gossypol and synthetic compounds particularly
BT-737 that have entered clinical trials. Additionally, we also
ighlighted problems associated with Bcl-2 inhibition and the
evelopment of resistance by one of its family member Mcl-1 mak-
ng it an attractive target. In this direction, specific drugs against
cl-1 are being investigated in the pre-clinical setting and some of
hese agents are expected to enter clinical evaluation in the near
uture. Additional cell death mechanisms such as autophagy andPlease cite this article in press as: Mohammad RM,  et al. Broad targeti
http://dx.doi.org/10.1016/j.semcancer.2015.03.001
ecrosis were also discussed and strategies, particularly the use
f natural agents such EGCG were highlighted. The role of chap-
rone protein hsp70 in apoptosis resistance was evaluated and
uggestions to overcome this critical protein marker using natural (i.e., reports showing both anti-carcinogenic and pro-carcinogenic potential), the
cument the relevance of an approach in a particular aspect of cancer’s biology, we
s of the table.
products  were presented. The article also discusses the molecular
mechanisms that support the resistance to apoptosis in different
cancers such as glioblastoma, multiple myeloma, CLL, prostate can-
cer, breast cancer, colon cancer and pancreatic cancer. The role of
epigenetic players, particularly miRNAs, in the development of apo-
ptosis resistance was also highlighted. The cross-validation tables
(Tables 1 and 2) are offered here as a simple heuristic frame-
work that is intended to help researchers approach the topic of
anticipated synergies. Although, these attempts do not represent a
homogenous set of underlying data, it is hoped that it can serve as a
starting point for the translational research that will be needed for
the design of effective natural product based therapies. Rigorous
experimentation will obviously be needed to determine whether
or not actual synergies between the identified approaches emerge
that can be predicted and clinically applied. A much broader range
of targets overall may  be the only chance we will have to address
cancer associate heterogeneity. It is a promising approach, but a
considerable amount of encompassing research needs to follow
to determine methodological validity. Collectively, these unique
targets and specific strategies may  bring forward a broad form
of therapy to overcome resistance to apoptosis resulting in better
treatment outcome in patients suffering from cancer.
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a  b  s  t  r  a  c  t
Cancers  harbor  significant  genetic  heterogeneity  and  patterns  of  relapse  following  many  therapies  are
due  to evolved  resistance  to treatment.  While  efforts  have  been  made  to  combine  targeted  therapies,
significant  levels  of toxicity  have  stymied  efforts  to effectively  treat  cancer  with  multi-drug  combinations
 Part  of the special issue on: “A broad-spectrum integrative design for cancer prevention and therapy”.
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using  currently  approved  therapeutics.  We  discuss  the  relationship  between  tumor-promoting  inflam-
mation and  cancer  as part  of a larger  effort  to develop  a  broad-spectrum  therapeutic  approach  aimed
at a  wide  range  of  targets  to  address  this  heterogeneity.  Specifically,  macrophage  migration  inhibitory
factor, cyclooxygenase-2,  transcription  factor  nuclear  factor-B,  tumor  necrosis  factor  alpha,  inducible
nitric oxide  synthase,  protein  kinase  B, and  CXC  chemokines  are  reviewed  as  important  antiinflammatory
targets while  curcumin,  resveratrol,  epigallocatechin  gallate,  genistein,  lycopene,  and  anthocyanins  are
reviewed as  low-cost,  low  toxicity  means  by which  these  targets  might  all  be  reached  simultaneously.
Future translational  work  will need  to assess  the  resulting  synergies  of  rationally  designed  antiinflam-
matory mixtures  (employing  low-toxicity  constituents),  and  then  combine  this  with  similar  approaches


















































In 1863, Rudolf Virchow first proposed the role of inflam-
ation in cancer, after observing the presence of leukocytes
n neoplastic tissue [1]. Since Virchow’s initial observation that
nflammation and cancer are linked, empirical evidence has under-
cored inflammation as both a cause and consequence of cancer
2,3]. The inflammatory milieu promotes a cellular microenvi-
onment that favors the expansion of genomic aberrations and
he initiation of carcinogenesis [4]. While acute inflammation is
redominantly considered to be a self-limiting process and an
mportant component of the immune system with therapeutic sig-
ificance, inadequate or incomplete resolution of inflammatory
esponses frequently leads to various chronic diseases, including
ancer [5,6]. In fact, numerous epidemiological and clinical stud-
es have indicated that chronic unresolved inflammation promotes
nd exacerbates malignancy [7]. Several types of cancer arise in the
etting of chronic inflammation suggesting a strong link between
nflammation and cancer [3,8].
It has been estimated that about 25% of all cancers are etiologi-
ally linked to chronic inflammation and infection [9]. For example,
he risk of colorectal cancer has been found to be 10-fold higher in
nflammatory bowel disease, such as ulcerative colitis and Crohn’s
isease [10]. The risk for cancer of the respiratory system is pos-
tively associated with the severity and duration of inflammatory
iseases [11]. Possible associations have also been found between
nflammatory diseases, such as esophagitis and Barrett’s metapla-
ia, and esophageal cancer [12] and between chronic pancreatitis
nd pancreatic cancer [13]. Emerging studies have established a
rucial role of chronic, unresolved inflammation in the promotion
nd progression of breast cancer, including the most aggressive
ype known as inflammatory breast cancer [14,15]. The ovarian
pithelial inflammation is linked to ovarian cancer [16]. Likewise,
oreskin inflammation (phimosis) has been associated with penile
ancer [17]. Helicobacter pylori (H. pylori) infection and associated
nflammation in the gastrointestinal tract represent the leading
ause of adenocarcinoma [12]. Hepatic inflammation, due to expo-
ure to infectious agents including hepatitis B virus and hepatitis
 virus as well as toxic compounds, represent an early step in the
evelopment of hepatocellular carcinoma [18]. Moreover, chronic
rostatitis, due to persistent bacterial infection or noninfective
timuli, has been linked to prostate cancer [19]. All of this evidence
upports an association between chronic inflammation and cancer
evelopment.
Chronic inflammation is linked to various phases implicated
n tumorigenesis, such as cellular proliferation, transformation,
poptosis evasion, survival, invasion, angiogenesis and metasta-
is [7,8,20]. A number of proinflammatory molecules within thePlease cite this article in press as: Samadi AK, et al. A multi-targete
Cancer Biol (2015), http://dx.doi.org/10.1016/j.semcancer.2015.03.00
umor microenvironment participate in a complex signaling net-
ork that enables extravasations of tumor cells through the stroma,
esulting in promotion of tumor progression [21]. Inflammation
s known to contribute to the process of carcinogenesis medi-
ted through the generation of reactive oxygen species (ROS) and© 2015  Elsevier  Ltd.  All rights  reserved.
reactive nitrogen species (RNS) capable of damaging the DNA at the
site of the tumor [22]. Free radicals and aldehydes, produced dur-
ing chronic inflammation, can induce deleterious gene mutation
and post-translational modifications of key cancer-related proteins
[23]. Damage can also occur in tissues that are distant from the
tumor [24].
Other  procarcinogenic products of inflammation include
cytokines, such as tumor necrosis factor- (TNF-), interleukin-
1 (IL-1) and interleukin-6 (IL-6), as well as chemokines,
prostaglandins, oncogenes, inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), 5-lipoxygenase, matrix metallopro-
teinases (MMPs), vascular endothelial growth factor (VEGF),
hypoxia-inducible factor-1 (HIF-1), nuclear factor-B (NF-B),
nuclear factor of activated T-cells, signal transducers and acti-
vators of transcription 3 (STAT3), activator protein-1 (AP-1),
cAMP response binding protein/p300 (CBP/p300), and CCAAT
enhancer binding protein (C/EBP) [25–28]. Additionally, activation
of various upstream kinases, including IB kinase (IKK), protein
kinase C (PKC), mitogen-activated protein kinase (MAPK), and
phosphoinositide-3 kinase/protein kinase B (PI3K)/AKT, are known
to participate in inflammation-driven oncogenesis [28]. The pro-
cancerous outcome of chronic inflammation is increased DNA
damage, increased DNA synthesis, cellular proliferation, the dis-
ruption of DNA repair pathways and cellular milieu, the inhibition
of apoptosis, the promotion of angiogenesis and invasion.
As  well, chronic inflammation has an influence on immune sys-
tem constituents that are directly linked with cancer progression.
Under normal conditions, immune cells, including macrophages,
granulocytes, mast cells, dendritic cells (DCs), innate lymphocytes,
and natural killer (NK) cells serve as the front line of defense
against pathogens. When tissue disruption occurs, macrophages
and mast cells secrete matrix-remodeling proteins, cytokines
and chemokines, which activate local stromal cells (fibroblasts,
adipocytes, vascular cells and others) to recruit circulating leuko-
cytes into damaged tissue (acute inflammation), to eliminate the
pathogens [29]. However, when these processes are initiated in
the tumor microenvironment, they are not resolved which leads to
chronic inflammation of the “damaged” (tumor) tissue. Thus, while
acute inflammation normally supports and balances two opposing
needs for the repair of damaged tissues (apoptosis and wound heal-
ing), chronic inflammation represents a loss of this balance and the
resulting confluence of factors has deleterious implications for the
immune system [30].
For  example, chronic inflammation is directly associated with
immunosuppression mediated primarily by immature myeloid-
derived suppressor cells (MDSCs) [31]. Several factors induce MDSC
differentiation arrest thus suppressing the host’s innate and adap-
tive immune systems, which are essential for effective antitumord approach to suppress tumor-promoting inflammation. Semin
6
responses [31]. For example, chronically activated leukocytes sup-
ply mitogenic growth factors that stimulate proliferation of cancer
and stromal cells [29,32]. Similarly, cluster of differentiation (CD)4+
T helper cells (e.g., subsets TH1, 2, 9, 10, 17, and 22) are key regula-
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hich are needed in immune responses [33] and contribute to
umorigenesis in a variety of ways, depending on context [29].
ndeed, the many effects that these chronically activated immune
ystem constituents have on neoplastic progression have been the
ubject of intense interest by cancer researchers [3,34,35].
Our  intent here is not to elaborate on these details, but rather to
iscuss the relationship between tumor-promoting inflammation
nd cancer as part of a larger effort to develop a broad-spectrum
herapeutic approach aimed at a wide range of therapeutic tar-
ets relevant for cancer biology. A nonprofit organization, entitled
etting to Know Cancer launched an initiative called “The Halifax
roject” in 2011 with the aim of producing a series of overarch-
ng reviews in each of the areas that are widely considered to be
ancer hallmarks [36]. The basis of this novel approach is premised
n many of the insights of genomic sequencing in cancers. Can-
ers harbor significant genetic heterogeneity [37], and patterns of
elapse following many therapies are due to evolved resistance
o treatment. While efforts have been made to combine targeted
herapies, a lack of success, rising drug costs and significant lev-
ls of toxicity have stymied efforts to effectively treat cancer with
ulti-drug combinations using currently approved therapeutics
38]. Consequently, this approach aims to target many disease-
pecific pathways simultaneously – using low-cost chemistry with
ittle to no toxicity – to address this heterogeneity (in contrast to the
imited number of actionable targets that have become the norm
n combination chemotherapy).
To  accomplish this task, the concept of the hallmarks of can-
er [36] was used as a broad organizing framework and tumor –
romoting inflammation was one of the areas of focus. We were
pecifically tasked to assess the many target choices that exist
or inflammation related to cancer, and identify up to ten impor-
ant targets as well as prospective non-toxic approaches that could
otentially be combined to produce a low-toxicity approach to the
uppression of tumor-promoting inflammation. In theory, inclusive
nvestigation toward inflammatory associated carcinogenic path-
ays and associated therapeutics would also be combined with
imilar approaches being recommended for the other hallmark
reas under review in this special issue. To that end, a list of seven
mportant therapeutic targets was identified by this team along
ith seven corresponding approaches (i.e., approaches that have
een shown to have potential to reach those targets) to support
his objective. In addition to looking at the traditional pathways
ssociated with the chosen approaches, we also review the known
mpact of these approaches on microRNA, a relatively new area of
ntense interest in cancer research. The following is a description
f those targets and approaches.
.  Therapeutic targets
The  following therapeutic targets are reviewed in relation to
nflammation: macrophage migration inhibitory factor (MIF), COX-
, NF-B, tumor necrosis factor alpha (TNF-), iNOS, AKT and CXC
hemokines.
.1. Macrophage migration inhibitory factor (MIF)
The hypothalamic–pituitary–adrenal (HPA) axis (also known
s the stress-axis) sits at the apex of the human inflammatory
esponse. Daily fluctuations of bodily inflammation are managed
nd regulated in a diurnal pattern [39] by the release of cortisol
rom the adrenal gland. The hypothalamus is comprised of a diverse
roup of nuclei at the base of the brain which integrates infor-Please cite this article in press as: Samadi AK, et al. A multi-targete
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ation from a range of stimuli (e.g., circulating hormone levels in
he blood) and generates appropriate responses based on ambi-
nt conditions. In the HPA-axis, the secretory neurons within the
ypothalamus secrete corticotrophin-releasing hormone (CRH), PRESS
er Biology xxx (2015) xxx–xxx 3
which  in turn stimulates the secretion of adrenocorticotropic
hormone  (ACTH) from the pituitary gland, which subsequently acts
on the adrenal cortex to promote cortisol release [40]. A nega-
tive feedback loop completes the HPA circuit resulting in cortisol
suppressing the production of CRH and ACTH through feedback
to both the hypothalamus and pituitary [40]. The stress-axis is
therefore widely recognized for its role in the stress response, but
adrenal cortisol is also a vitally important steroid hormone that
plays a critical role in the ongoing modulation of the inflammatory
and immune responses. Specifically, cortisol achieves this media-
tion of the inflammatory cascade, in part, by acting on the master
immune/inflammatory cytokine MIF.
MIF is released from macrophages and T lymphocytes that have
been stimulated by glucocorticoids, and is a potent proinflam-
matory cytokine that binds to the CD74 molecule on immune
cells in an acute immune response, which provides the coupling
between the HPA-axis and inflammation [41,42]. In general, the
HPA-axis is able to regulate inflammation with low concentrations
of cortisol which induce MIF  [41], and higher levels of cortisol which
result in decreases in MIF  secretions [42]. As proinflammatory
cytokine,  MIF  overcomes the inhibitory effects of glucocorticoids
on TNF-, IL-1, IL-6, and IL-8 production [43].
In cancer, MIF  is frequently elevated [44] and it has been
widely implicated in tumor growth and progression. Specifically,
the effects of MIF  extends to multiple processes fundamental to
tumorigenesis such as proliferation, tumor suppressor downreg-
ulation, evasion of apoptosis, angiogenesis, and tissue invasion
[45,46]. MIF  signaling is involved in COX-2 and PGE2 upregula-
tion, the activation of the extracellular-signal-regulated kinases
(ERK)-1/2 and AKT pathways, and the regulation of c-Jun activation
domain-binding protein-1 (JAB1), p53, Skp1–Cul1–F-box-protein
(SCF) ubiquitin ligases and HIF-1, which are central to growth
regulation, apoptosis and cell cycle control [45,47,48]. MIF  also
upregulates TNF- [49] which is believed to occur via an ampli-
fying proinflammatory loop [50]. In chronic lymphocytic leukemia
(CLL) cells, the binding of MIF  to CD74 induces NF-B activation
[51]. MIF  contributes to the immune escape of malignant gliomas
by counteracting NK and cytotoxic T-cell-mediated tumor immune
surveillance [52].
Anti-MIF  therapeutics are therefore believed to have consid-
erable promise for many types of cancer [53–57]. Indeed several
MIF-inactivating strategies have proven successful in delaying can-
cer growth, including ISO-66, a synthetic MIF  inhibitor which
caused a significant decrease in tumor burden when administered
to mice with established syngeneic melanoma or colon cancer [58].
Recently human anti-MIF antibodies have been tested for their abil-
ity to influence growth rate and invasion of the human PC3 prostate
cancer cell line in vitro, and in a PC3-xenograft mouse model in vivo.
Treatment with human anti-MIF antibodies suppressed xenograft
tumor growth in a dose-dependent manner [53].
However, it should be noted that MIF  may also be crucial for
controlling infection. In a Ugandan cohort, genetic low expressers of
MIF  were 2.4-times more frequently identified among patients with
Mycobacterium tuberculosis (TB) bacteremia compared to those
without. MIF-deficient mice have been shown to succumb to infec-
tion more quickly (with higher organism burden and decreased
innate cytokine production) and MIF-deficient macrophages show
a decrease in cytokine production and impaired mycobacterial
killing. So MIF  is a crucial upstream mediator in the innate immune
response to mycobacteria [59], and an increased risk of infection
could be a concern in any therapeutic approach aimed at suppress-
ing MIF.d approach to suppress tumor-promoting inflammation. Semin
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2.2. COX-2
The arachidonic acid (AA) cascade (see Fig. 1) plays a vital
role in mediating either the suppression or induction of the
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nflammatory response [60]. COX-1 and COX-2 are the primary
egulatory enzymes responsible for the translation of AA into the
everal prostanoids, lipid mediators involved in many biological
unctions [61]. While COX-1 is a constitutive enzyme responsible
or several house-keeping functions, the inducible form, COX-2,
s responsible for various inflammatory events. COX-2 is readily
vailable to perform both oxygenation and reduction of AA [62].
OX-1/COX-2, also known as prostaglandin (PG) H synthase, trans-
orms AA into PGG2, which is then reduced further by PGH synthase
o form PGH2 [61]. PGH2 then further metabolizes via PG syn-
hases into PGE2, PGD2, PGI2, PGF2, and TXA2, which are then
aired with distinctive G protein-coupled receptors [61,63]. The
roinflammatory messenger prostaglandin E2 (PGE2) has further
een linked to carcinogenesis [64]. PGE2 is an agonist toward
rostaglandin E receptors, which are divided into four subtypes,
P1-4 [63,64]. The binding of PGE2 to four PGE receptors along with
eterotrimeric GTP-binding proteins, results in the activation of
denylyl cyclase, stimulated via EP2 and EP4 binding, or phospho-
ipase C, stimulated via EP1 and EP3 binding [65]. This stimulation
f the PGE receptors thus results in the formation of cyclic AMP
cAMP) or the mobilization of intracellular calcium [65]. PGE2 has
oted tumorigenic properties and contributes to carcinogenesis by
romoting insensitivity to antigrowth signals, evasion of apoptosis,
ustained angiogenesis, and tissue invasion/metastasis [61].
Elevated  levels of COX-2 have been associated with both car-
inogenesis and cancer progression [66]. Overexpression of COX-2
as been associated with carcinogenesis in animal models, and in
everal human cancers [67–71]. In human UV-induced skin car-
inogenesis, elevation of COX-2 activity is associated with thePlease cite this article in press as: Samadi AK, et al. A multi-targete
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ctivation of proinflammatory transcription factors (NF-B, AP-
, STAT3 and others) [72]. COX-2 is transcriptionally regulated
nd its promoter is activated by multiple transcription factors, acid cascade.
either  alone or in combination [73–75]. This leads to breast, gas-
trointestinal, hematological prostate and oral cancers [68–78].
COX-2 induces carcinogenesis through the aromatase pathway,
particularly in estrogen positive breast cancers, and through the
COX/lipoxygenase (LOX) pathway in estrogen-independent breast
tumors [78]. Recently, elevated activity of COX-2 has been found to
be correlated with chemoresistance through altered redox induced
EGFR-mediated activation of the cell survival cascade (AKT/c-
FLIP/COX-2), which results in diminished drug-induced apoptosis
[79].
The indirect role of the COX-2/PGE2 pathway in regulating
the tumor immune microenvironment has also been suggested
through IL-17 promoting M2 macrophage differentiation [80]. The
interplay between cancer and stroma via COX-2 and indoleamine
2,3-dioxygenase (IDO) promotes tumor progression and predicts
poor patient survival [81]. COX-2 is also known to promote the
development of MDSCs which directly suppress T cell immune
responses. Indeed MDSCs accumulate in the blood, lymphoid
organs, spleens and tumor tissues of cancer patients [82] and serve
as critical mediators of tumor-associated immune suppression [83],
but recently it was  shown that a COX-2 blockade inhibited accu-
mulation and function of MDSCs and restored T-cell response after
traumatic stress [84]. So COX-2 inhibition may  also prove to be an
attractive target for counteracting MDSC-mediated immune sup-
pression in cancer [83]. However, it should be noted that chronic
inhibition of Cox-2 activity or expression, is noted to blunt the
ability of B cells to produce antiviral antibodies, thereby possibly
increasing susceptibility to viral infection [85], which has relevance
for numerous cancers that are virus-related.d approach to suppress tumor-promoting inflammation. Semin
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COX-2 expression and its activity are inhibited by small molecu-
lar inhibitors both synthetic and natural such as NSAIDS, capsaicin
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nhance the antitumor effect of fisetin by inhibiting COX-2/iNOS
nd NF-B/p300 signaling pathways [88]. However, clinically, the
ost effective way to inhibit COX-2 is with selective pharmacolog-
cal inhibitors, notably rofecoxib, valdecoxib and celecoxib. Several
linical trials of COX-2 inhibitors, including rofecoxib and celecoxib
ere performed and their clinical usage was recommended for pre-
ention of colorectal cancers. These studies showed unequivocally
hat up to 50% reduction in colonic polyps was achieved by daily
se of 800 mg  COX-2 inhibitors in patients with familial adeno-
atous polyposis [89]. However, this is not currently practiced due
o the subsequent findings of severe cardiovascular risk associated
ith COX-2 inhibitors in a small patient subpopulation (resulting
n the withdrawal of rofecoxib and valdecoxib in 2004 and 2005,
espectively).
The search for more specific inhibitors of COX-2 for long-term
reventative use has not been very successful, other than the clas-
ic NSAID, aspirin in lower dose. Long-term use of natural COX
nhibitors, such as curcumin and capsaicin has significant poten-
ial, at least for the prevention of gastrointestinal tumors [90–93].
he low bioavailability of these natural compounds by oral admin-
stration is a challenge that has limited their use in other solid
umors.
.3. NF-B
NF-B transcription factors are evolutionarily conserved, coor-
inating regulators of immune and inflammatory responses that
lay a pivotal role in oncogenesis [94]. NF-B belongs to a class of
ranscription factor family designated as p65 (RelA), RelB, c-Rel, NF-
B1 and NF-B2. NF-B1 and NF-B2 are synthesized as pro-forms,
105 and p100, which are proteolytically processed to active p50
nd p52 respectively [95,96].
All NF-B family members form mono- or heterodimers and
hare common structural features including a Rel homology
omain, which is essential for dimerization and binding to cognate
NA elements [97]. These dimers bind to inhibitory protein IB
amily of proteins (inhibitors of NF-B) preventing their binding to
NA domains and localizing them to the cytoplasm in most quies-
ent cells [98]. Furthermore, the complexity of this transcriptional
egulation system is also amplified by the fact that different NF-B
imers have differential preferences for variations of the DNA-
inding sequence [99]. Therefore distinct NF-B dimers induce
ifferent target genes. Low frequency shuttling between nucleus
nd cytoplasm is observed which might be the basis for low basal
ranscriptional activity of NF-B and indicative of rapid NF-B/IB
ssociation and re-association events.
NF-B proteins are activated by phosphorylation and polyu-
iquitination of IB and subsequent proteasomal degradation. IB
hosphorylation is catalyzed by an enzyme complex containing IB
inases (IKK1/IKK and IKK2/IKK) and at least one non-catalytic
ccessory protein (NF-B essential modulator, NEMO, also called
KK) [100,101]. Furthermore, p105 and p100 are cleaved to active
50 and p52 forms respectively by targeted polyubiquitination and
roteasomal degradation [102]. IB and IKK complex bind to other
omponents and interact with other upstream kinases [103]. NF-B
nducing kinase (NIK) phosphorylates and activates IKK1, mitogen-
ctivated protein kinase kinase kinase 1 (MEKK1), MEKK2, MEKK3
nd transforming growth factor beta (TGF-) activating kinase 1
TAK1) [104–106].
NF-B  is activated by canonical and non-canonical activation
athways. In the canonical activation pathway, ligands interact
nd activate toll-like receptors (TLRs), the IL-1 receptor (IL-1R),Please cite this article in press as: Samadi AK, et al. A multi-targete
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umor necrosis factor receptor (TNFR) and antigen receptors. TNF-
, lipopolysaccharide (LPS) and IL-1- are typical stimulating
olecules [107,108]. Alternatively, the non-canonical pathway
riginates from different classes of receptors including B-cell PRESS
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activation  factor, lymphotoxin -receptor (LTR), CD40, receptor
activator for NF-B (RANK), TNFR2 and fn14 [109]. These receptors
stimulate NF-B by activation of the kinase NIK and phosphor-
ylation of IKK1. IKK1 subsequently results in phosphorylation,
ubiquitination and partial degradation of p100 to p50 [110]. There-
fore, the non-canonical activation of NF-B is independent of the
activity of IKK2 and NEMO [111].
Upon activation, NF-B dimers move to the nucleus and their Rel
homology domains are free to bind cognate DNA-sequences in the
enhancer elements of target gene promoters. Thousands of differ-
ent target genes can be transcriptionally activated. Recent reports
point to the role of NF-B in inflammation and induction of cancer.
Physical, physiological and/or oxidative stress results in activation
of innate immunological processes leading to inflammation which
is associated with canonical activation of the NF-B signaling path-
way [112]. NF-B has a dual effect on inflammation. On one hand,
the activation of NF-B, as part of the acute immune response,
activates cytotoxic immune cells against cancer cells [113]. How-
ever, the activation of NF-B also results in up-regulation of
antiapoptotic genes and the induced expression of other proinflam-
matory cytokines (e.g., TNF-, IL-1, IL-6, and IL-8) and adhesion
molecules which leads to the recruitment of leukocytes to the
site of inflammation [114]. Both, STAT3 and HIF1 pathways are
interconnected with NF-B signaling and interact with NF-B.
For example, the proinflammatory cytokine IL-6, encoded by NF-
B target genes, is important for STAT3 activation. STAT3 and
NF-B also co-regulate numerous oncogenic and inflammatory
genes [115]. These observations suggest that NF-B and STAT3
alone or in combination induce inflammation and an inflammatory
microenvironment.
NF-B activation is also involved in growth regulation [116],
and contributes to tumor progression by controlling vasculariza-
tion of tumors via upregulation of VEGF and its receptors [117,118].
The activation of NF-B also causes an increase in the expression
of the transcription factor Snail, which is essential in the TNF--
induction of the epithelial–mesenchymal transition (EMT) [119],
which enables cancer progression and metastasis.
NF-B-induced transcriptional regulation of HIF-1 is mediated
by the recruitment of the NF-B complex to the HIF-1 promoter
[120]. Chronic expression of the proinflammatory protein tissue
transglutaminase (TG2) reprograms the transcription regulatory
network in epithelial cells via constitutive activation of NF-B. TG2-
induced NF-B binds the functional NF-B binding site in HIF-1
promoter and results in its increased expression at transcription
and protein levels even under normoxic conditions. Like NF-B,
HIF-1 is also considered a negative prognostic factor because
of its ability to promote chemoresistance, angiogenesis, invasive-
ness, metastasis, resistance to cell death, altered metabolism, and
genomic instability [121]. So aberrant activation of NF-B and its
downstream events (HIF-1, Snail, Twist, and Zeb expression) can
induce EMT, stem cell-ness, and endow cancer cells with the abil-
ity to disseminate, survive in stressful environments, and regrow
at metastatic sites, making NF-B a very important target.
However, under normal conditions, NF-B plays an important
role in the maintenance of host defense responses so it may  not
be practical to inhibit NF-B on a sustained basis. For example, in
studies on mice, a prolonged inhibition of NF-B activity resulted
in animals that were more susceptible to bacterial infection [122].
So short-term treatment with specific bioactive inhibitors of IKK
activity might be a preferred means to reduce systemic toxic-
ity and avoid broad suppression of innate immunity. Ideally, an
IKK/NF-B molecular-targeted inhibitor would prevent NF-B acti-d approach to suppress tumor-promoting inflammation. Semin
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vation without any effects on other signaling pathways, and be
differentially active in tumor cells versus in normal cells. But one
major shortcoming that will need to be addressed before targeted
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ut pronounced ability of NF-B activation inhibitors to enhance
he production of IL-1 and related cytokines (due to excessive
nflammasome activation) during bacterial infections [123]. So any
trategy that inhibits NF-B will need to be carefully monitored for
mmune-related side-effects.
.4.  TNF-˛
TNF- is a key proinflammatory cytokine, secreted by inflam-
atory cells, which is involved in inflammation-associated
arcinogenesis. It was named TNF- because it can induce tumor
egression through the induction of cell death [124]. TNF- is
nvolved in inflammation and immunity, but also in a multitude of
iological processes including apoptosis, cell survival, angiogenesis
nd tumor cell migration and invasion [125].
TNF- acts primarily via two receptors TNFR1 and TNFR2
126]. TNF- is a 17 kDa protein consisting of 157 amino acids
hat is a homotrimer in solution, and it is primarily produced in
acrophages, T lymphocytes, and NK cells. However lower expres-
ion levels have been reported in other cells including fibroblasts,
mooth muscle cells, and tumor cells. Although TNF- binds TNFR2
ve times higher than TNFR1, TNFR1 initiates the majority of the
iological activities resulting from TNF- [127]. TNFR1 (p60) is
xpressed in all cell types whereas TNFR2 (p80) is expressed mainly
n immune cells [128]. Only TNFR1 contains the death domain
DD) (i.e., TNFR2 does not contain the DD) making it an important
ember of the death receptor family that is capable of inducing
poptotic cell death [129].
Aside from death inducing activity, TNFR1 also has the ability
o transduce cell survival signals. Binding to the homotrimer TNF-
, TNFR1 trimerizes the silencer of death domain (SODD) protein
hat is released [130]. The TNFR-associated domain (TRADD) binds
o the DD of TNFR1 and recruits other adaptor proteins includ-
ng the receptor interacting protein (RIP), TNFR-associated factor
 (TRAF-2), and Fas-associated death domain (FADD) [131]. These
daptor proteins, in turn, are responsible for downstream cellular
ignaling. Apoptotic signaling mediated by TNFR1 results in FADD
inding to caspase 8 and its activation. The chain of events leads to
roteolytic activation of caspase enzymes and involves the mito-
hondrial cytochrome c release [132], which leads to the activation
f endonucleases and DNA fragmentation.
Alternatively, TNFR1 may  signal survival processes by recruit-
ng TRAF-2 to the complex. TRAF-2 inhibits apoptosis by association
ith the cytoplasmic inhibitor of the apoptosis protein (cIAP). Once
RAF-2 associates with TNFR1, cell survival pathways are initi-
ted through a series of phosphorylation steps resulting in the
ctivation of cFOS/cJun transcription factors by MAPK and cJun
-terminal kinase (JNK) [133,134]. Activation of TRAF-2 and RIP
s associated with activation of the NF-B transcription factor
ia a complex of NF-B-inducing kinase (NIK) and an inhibitor,
B kinase (IKK) [135]. The activation of cFos/cJun and NF-B
ranscription factors mediates the transcription of anti-apoptotic,
roliferative immunoregulatory, and inflammatory genes. NF-B is
he main survival transcription factor that prevents TNF--induced
poptosis, so NF-B inhibition may  be an efficient strategy for
poptosis-inducing cancer therapy [135–137].
Inhibition of NF-B is known to sensitize cancer cells to TNF-
reatment [138,139]. Furthermore, it has been shown that NF-B-
nduced expression of iNOS increases cancer cell survival [140,141].
nhibition of NOS can potentially sensitize cancer cells to TNF-
reatment. ROS are generated by TNF--mediated apoptotic events,Please cite this article in press as: Samadi AK, et al. A multi-targete
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hile NF-B induces expression of ROS-neutralizing enzymes
ike superoxide dismutase [142]. Recent data also show that the
RNA-decay protein tristetraprolin (TTP) interacts with TNFR1
n a TRAF2-mediated fashion initiating cJun-kinase activation. PRESS
er Biology xxx (2015) xxx–xxx
Inhibition  of TTP ubiquitination results in enhanced TNF-induced
apoptosis in cervical cancer cells [143].
The role of TNF- in carcinogenesis is controversial. While high
concentrations of this cytokine display antitumoral response in
murine model of sarcoma [144], low sustained TNF- levels can
induce a tumor phenotype [145]. The TNF- tumor promoting
mechanism is based on ROS and RNS which can induce DNA damage
and facilitate tumorigenesis [146–148]. TNF--mediated inflam-
mation has been linked to cancer; for instance, a recent report
shows that H. pylori strains produce TNF--inducing protein (Tip-
), a carcinogenic factor in gastric epithelium. H. pylori isolated
from gastric cancer patients secreted large amount of Tip-, which
is incorporated into gastric cancer cells by cell surface nucleolin,
a Tip- receptor. The nucleolin-Tip- binding induces TNF- and
other cytokine genes expression and results in NF-B activation.
Similarly, TNF- through TNFR1, Noxo1, and Gna14 signaling leads
to H. pylori-mediated gastric tumorigenesis [149]. These events are
also associated with epithelial to mesenchymal transition (EMT) in
human gastric carcinogenesis [150].
Direct evidence also points to the role of TNF- in the metastatic
cascade. Administration of TNF- leads to significant increase of the
number of lung metastases [151]. Conversely, tumor cells activate
myeloid cells to generate a microenvironment favorable for metas-
tasis. In Lewis lung carcinoma (LLC) cells-conditioned-medium,
high  levels of IL-6 and TNF- were induced in bone marrow-
derived macrophages [152], and TNF-−/− but not IL-6−/− mice
injected with LLC cells showed improved survival and reduced
lung tumor multiplicity, suggesting a critical role of TNF- in
LLC metastasis [152]. Others report that TNF--deficient mice are
resistant to tetradecanoyl-phorbol-13-acetate-(TPA) induced skin
carcinogenesis [153]. The role of TNF- in angiogenesis was also
studied recently, and Fajardo et al. [154] showed that high TNF-
 doses inhibited angiogenesis in mice subcutaneously implanted
with angiogenesis disk-system, an experimental strategy used to
induce new blood vessels, while low loses promoted vasculariza-
tion of the area. The antiangiogenic action of TNF- is related to
downregulation of ˛vˇ3 and the angiotensin signaling pathway
[155], while proangiogenic responses have been associated with
increased VEGF, VEFGR, IL-8, and FGF expression [156]. Further-
more, low TNF- increases tumor growth and induces angiogenesis
of diverse tumors in mice [157,158].
The effect of TNF- in induction of carcinogenesis, angiogenesis
and metastasis and invasion has therefore been supported by sev-
eral studies, so targeting TNF- and TNFR may  be a viable option
for treatment of cancer.
Recently  several TNF- targeting drugs have also been used
mostly to treat inflammatory diseases. Examples include inflix-
imab, a recombinant IgG1 monoclonal antibody specific for TNF-
[159], Etanercept, a genetically engineered protein comprising two
molecules of the extracellular domain of TNFR2 (p75) and the Fc
portion of IgG1 [160], adalimumb, a monoclonal antibody of recom-
binant IgG1 [161], golimumab, a human anti-TNF- monoclonal
antibody [162], and certolizumab, a humanized anti-TNF- anti-
body with high affinity to TNF- [163]. However, major side effects
of these anti-TNF- agents are infection (tuberculosis, varicella, and
other opportunistic infections) and malignancies especially when
TNF- antagonists are used concurrently with other therapies
[164,165]. For example, a subset of patients with inflammatory dis-
eases may  also have an increased risk of non-Hodgkin’s lymphoma
(NHL) [166], therefore treating these patients with anti-TNF- may
increase the rate of lymphoma [167–169]. Skin cancer has also been
reported as a side effect in some studies involving TNF- blockingd approach to suppress tumor-promoting inflammation. Semin
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[170,171].
So, although TNF- is a cytokine with well-known anticancer
properties that has been utilized as an anticancer agent for the






























































mARTICLESCBI-1181; No. of Pages 34
A.K. Samadi et al. / Seminars in
172], its promise as a constituent within a multipronged approach
imed at a broad-spectrum of targets will need to be carefully
ssessed in light of these divergent outcomes.
.5. iNOS
iNOS has been of interest in cancer since the discovery of
ts metabolite, nitric oxide (NO) in the 1990s. Over the years,
xperimental data highlighted iNOS overexpression as a pivotal
vent ensuring tumor growth [173]. Indeed, more than 2000 peer-
eviewed publications support the iNOS-NO axis as a potential
arget in cancer. Under normal physiological conditions, NO is pro-
uced by the constitutive forms of NOS (cNOS and eNOS) and
odulates pivotal cellular processes, such as vasodilatation, cell
urvival and growth. However, in chronic inflammatory conditions,
he iNOS-NO axis is upregulated, and quickly yields NO-derived
pecies with strong nitrosative properties, especially when other
eactive species are also produced (such as the superoxide anion).
nce formed, NO-derived species can quickly react with all cellu-
ar components, including proteins, lipids and DNA. Therefore, the
ain carcinogenic effect of NO-derived metabolites is related to
heir capability to potentiate genomic instability, as induced by the
NS peroxynitrite [174].
Experimental  data and in vitro studies have supported iNOS
s a viable target by demonstrating its overexpression in virtu-
lly all types of cancer cells, including glioma [175], hepatoma
176], mastocytoma [177], melanoma [178], B-cell lymphoma
179], neuroblastoma [180], mammary adenocarcinoma [181], and
varian carcinoma [182], among others. In the same way, iNOS up-
egulation has been documented in human cancerous tissues such
s glioblastomas [183], brain tumors [184], prostate carcinoma
185], esophageal adenocarcinomas [186], B-cell CLL [187], pri-
ary lung cancer [188], transitional cell carcinoma of the bladder
189], pancreatic cancer [190], thyroid papillary carcinomas [191],
uccal squamous-cell carcinomas [192], melanoma [193], colon
arcinoma [194], gastric cancer [195], breast cancer [196], stom-
ch cancer [197], malignant mesotheliomas and metastatic pleural
denocarcinomas [198], hepatocellular carcinoma [199] and ovar-
an carcinoma [200]. The enhanced activity and expression of iNOS
n cancer cells seems to be a necessary mechanism for generating
igh levels of NO and its derived species, which promote genomic
nstability [201], cancer growth [202], and spreading [203]. There-
ore interfering with this enhanced NO-iNOS machinery may  rep-
esent a putative target for pharmacological intervention in cancer.
Interfering with the NO dynamic is not a simple task. In cancer,
O can be derived from both host and tumor cells [204]; therefore,
locking tumor-iNOS has potential implications for healthy cells.
he mode of therapeutic delivery therefore needs a degree of speci-
city for cancerous cells (e.g., nano-carriers targeting membrane
eceptors unique to cancerous cells). In this context, strategies may
e directed against (a) iNOS activity, (b) iNOS-derived NO and (c)
ainstream regulators of iNOS expression. Regarding the iNOS-
O axis, experimental approaches have been exploited to either
lock iNOS or to scavenge NO in cancer models, and interventions
nclude treatment with aminoguanidine [197], N(G)-nitro-l-
rginine methyl ester [205], carboxy-PTIO [206], tyrosine-kinase
nhibitors [207], TGF--like molecules [208], S-methylisothiourea
ulfate [173] and some natural compounds [209].
Interventions of the mainstream regulators of iNOS expres-
ion may  be quite difficult because there are so many molecules
nvolved in inflammation. It has been demonstrated that cancer-
elevant mediators could include IL-1 [210], TNF- [211], NF-BPlease cite this article in press as: Samadi AK, et al. A multi-targete
Cancer Biol (2015), http://dx.doi.org/10.1016/j.semcancer.2015.03.00
209] and STAT-1 [212], among others. In fact, NO blockage
as reached promising results in experimental models, inhibi-
ing tumor growth [213], prolonging survival [214], and reducing
etastasis [215]. These data indicate that the pharmacological PRESS
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impairment of iNOS functioning may  be useful in patients diag-
nosed with metastatic disease, since sustained high levels of
systemic NO are reported in such patients [216–219].
Clinical trials have tested the efficacy and safety of iNOS
inhibitors in humans, and have provided support to encourage the
use of such drugs in cancer, with no important adverse effects
[220–222]. Vital functions such as blood pressure, pulse rate, or
respiratory function – all pivotal functions physiologically con-
trolled by NO – did not change after the systemic administration
of the iNOS inhibitor l-N6-(1-iminoethyl)lysine 5-tetrazole amide
(SC-51) on healthy volunteers [220]. In the same way, the use of
nebulized aminoguanidine was tested in healthy individuals and
patients with pulmonary diseases, and no adverse effects were
reported regarding cardiovascular functioning after NO blocking
[221,222]. Although the evidence is promising, in-depth studies
still need to be conducted to confirm that iNOS blockage will stop
tumor growth without compromising normal functions that are
dependent on NO.
In  theory, interfering with the NO-axis could also affect immune
function. For example, experimental knockout of iNOS enhances
the mortality of mice in sepsis [223]. However, there is no evi-
dence of immunosuppression after iNOS blockage in cancer models
and none of the clinical trials using NO-blockers have reported on
immunosuppressive effects [220–222].
2.6. AKT
Protein kinases are an important family of regulatory enzymes
required for the growth, division, and differentiation of cells, and
they have been closely examined as possible mediators of onco-
genesis. In particular, the kinase signaling pathway known as the
phosphatidylinositol 3-kinase/protein kinase-B/mammalian target
of rapamycin (PI3K/AKT/mTOR) represents one of the intracellular
cascades of utmost importance when examining cellular prolifer-
ation, differentiation, as well as cytoskeletal reorganization. The
dysregulation of this pathway can direct the cell towards carcino-
genesis [224].
AKT  was  initially defined by three groups in 1991, Bellacosa
et al. [225], Coffer et al. [226], and Jones et al. [227]. It possesses
tumorigenic potential, which normally remains downregulated via
the phosphatase and tensin homologue (PTEN) gene [224,228,229].
However, mutations in the PTEN gene, which are found in several
human malignancies, lead toward the inhibition of AKT downregu-
lation, which would normally occur through the dephosphorylation
of PIP3, a product of PI3K activation [229,230]. The increased poten-
tial for cellular proliferation leading toward tumorigenesis initiated
through PKB activation may  also result from a response toward
various cellular stimuli, such as heat shock, osmotic, and oxida-
tive stress [229]. Mechanistic research has revealed a wide range
of influences [231], including critical roles by AKT in proliferation
[232], resistance to apoptosis [233], glucose metabolism [234], cell
migration [235], and the regulation of autophagy [236].
From  an inflammation standpoint, studies of the role of AKT
in phagocytosis, bacterial infections, LPS tolerance, production of
proinflammatory cytokines, and migration during macrophage-
mediated innate immunity strongly suggest a pivotal role in the
functional activation of macrophages [237]. Evidence suggests that
AKT promotes NF-B activation [238]. In vivo tests on rodents
(rat paw edema) also suggest that AKT inhibitors prevent AKT
phosphorylation and downregulate the expression of inflammatory
factors IL-6, MCP-1, TNF and iNOS [239]. Similarly, in research ond approach to suppress tumor-promoting inflammation. Semin
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pancreatitis, researchers have found that AKT inhibition mediates
a reduction in the activation of NF-B and p38MAPK activity in SAP
rats and a downregulation of NF-B-dependent proinflammatory
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From an immune perspective, PI3K-Akt pathway inhibitors are
lso attractive for their ability to selectively inhibit regulatory
 cells (Tregs) with minimal effect on conventional T cells. In
any cancers, an important tumor immune-evasion mechanisms
nvolves the effects of suppressive immune cells, specifically regu-
atory T cells (Treg). So the depletion of Tregs has been found to be
n effective strategy to enhance the immune response, but selec-
ive depletion of these suppressive cells (i.e., without affecting other
mmune cells) has not been very successful. Notably, however,
I3K-Akt pathway inhibitors selectively inhibit Tregs with minimal
ffect on conventional T cells (this has been shown in both human
nd murine CD4T cells) and in vivo treatment with these inhibitors
esulted in a significant and selective reduction in Tregs in both
aïve and tumor-bearing mice (combined with a significant thera-
eutic antitumor effect). So PI3K-Akt pathway inhibitors appear to
epresent a promising approach to deplete Tregs in cancer [241].
Consequently,  AKT inhibition is being aggressively pursued as a
ew therapeutic strategy for a range of cancer types, including ovar-
an [242], breast [243], lung [244], and bladder [245]. PI3K and AKT
nhibitors are still in the early stages of development, but despite
hree generations of compounds targeting PI3K already having
een developed, none have proved efficacious, mainly due to the
mergence of therapeutic resistance [246,247]. It is our opinion
hat this particular target, which appears to have strong promise,
ay still prove to be more effective when acted upon with a range
f other therapeutic constituents that can address the alternate
athways that might otherwise serve to support this resistance.
.7.  CXC chemokines
Chemokines were originally characterized by their ability to reg-
late the directional migration of leukocytes to inflammatory sites.
his observation has key implications for tumorigenesis, as inflam-
atory cell infiltration is a common feature of many cancers and
as varied functional consequences.
Chemokines  or chemotactic cytokines are a group of small
8–14 kDa) heparin-binding proteins that interact with cognate
ell-surface receptors and play important roles in a number of
hysiological processes such as development, host immunity, and
ellular trafficking [248]. These functionally related small secreted
roteins constitute the largest cytokine family in humans [249].
hemokines contain cysteine residues at their N-terminus and the
osition of these amino acids forms the basis for classification into
our major groups: CXC, CC, CX3C or C [248]. Most chemokines har-
or a four-cysteine motif internally linked by disulfide bonds at
onserved sites.
The  mechanism whereby chemokines exert biological effects
elies on their ability to bind to the extracellular domain of G
rotein-coupled chemokine receptors, which leads to production
f second messengers, cytoplasmic calcium mobilization, and the
ctivation of multiple downstream signaling cascades, including
he PI3K/AKT pathway, the Ras/MAPK axis, and the Janus kinase
JAK)/STAT cascade [250]. Chemokines are produced by leukocytes,
ndothelial cells, fibroblasts, epithelial cells, and tumor cells [251].
his section will be limited to a discussion of CXC chemokines.
Chemokines produced by neoplastic and/or stromal cells con-
rol the nature of the inflammatory infiltrate by actively recruiting
ells of the innate and adaptive immune systems [249]. The ability
o regulate cell trafficking in and out of the tumor milieu has diverse
nd complex functional consequences. Some chemokines promote
onditions favorable for tumor growth and progression, while oth-Please cite this article in press as: Samadi AK, et al. A multi-targete
Cancer Biol (2015), http://dx.doi.org/10.1016/j.semcancer.2015.03.00
rs have antitumor activity [252]. For example, IL8/CXCL8 induces
eukocyte cell migration during inflammation, and this response
an promote tumor growth and development by generating a favor-
ble microenvironment [252,253]. PRESS
er Biology xxx (2015) xxx–xxx
In  contrast, chemokines such as CXCL10 can have angiostatic
properties owing to their ability to attract antitumoral lympho-
cytes via the receptor CXCR3. The extents to which chemokines
recruit immune cells to tumor sites have dramatic, often opposite,
functional effects. Indeed, chemokines recruit tumor-associated
macrophages (TAM) that promote tumor progression, but when
TAMs are recruited massively and appropriately activated, they
can exert antitumor activity [249]. Neutrophils, lymphocytes
and dendritic cells commonly are recruited to tumors such as
bronchioloalveolar carcinomas, colon adenocarcinomas, myxofi-
brosarcomas, gastric carcinomas, and melanomas, where they can
have pro- and antitumorigenic effects [254–261]. However, the
presence of NK cells is relatively infrequent in tumors and their
presence consistently correlates with good prognosis and increased
survival [262,263].
In  addition to their role in cell migration and inflammation, the
chemokine/chemokine receptor system impacts development and
progression of malignant diseases by regulating tumor initiation,
growth, survival, migration, adhesion, invasion, angiogenesis, and
metastasis [248,253]. In summary, chemokines and their receptors
regulate tumorigenesis directly by acting on tumor cells, and indi-
rectly by regulating the composition of the inflammatory infiltrate.
The diversity of the chemokine/chemokine receptor system is such
that it can both contribute to, and inhibit, key events relevant to
the tumorigenic process.
CXC  chemokines and their receptors are often over expressed
in a variety of tumors, affecting proliferation, motility, cell survival
and resistance to chemotherapeutic drugs [264–266] Chemokine
receptors, unlike other cell surface receptors, are also promiscuous
as they bind multiple ligands (chemokines), they can function in
ligand-independent manners, and they can elicit multiple effects
following binding to a single CXC chemokine [264,267]. For exam-
ple, each of the two  cell surface receptors of IL-8, CXCR1 and CXCR2
has diverse functions. IL-8 binding to CXCR1 results in activation
of mitogenic signaling and increased ERK1/2 MAP  kinase activ-
ity. CXCR2 mediates angiogenesis, motility, invasion and activation
of NF-B mediated cell survival pathways [267,268]. Some recep-
tors, e.g., the CXCL12 co-receptor CXCR7, also binds CXCL11 and
MIF, and activates EGFRs independently of their ligands [269–272].
These complex and diverse functions of CXC chemokines and their
receptors present significant challenges for cancer therapy, but also
opportunities for investigating novel targeted approaches.
Chemokines and their receptors are regarded as promising
molecular targets for therapeutic intervention. Several antagonists
of CXCL8-CXCR1/CXCR2-mediated signaling are in development,
including neutralizing antibodies, orally active small-molecule
antagonists (e.g., SCH-527123, SCH-479833 [273]), and adenoviral-
mediated anti-sense gene transfer approaches [274,275]. Studies
have shown that chemokines and their receptors are closely linked
to emergence of drug-resistant cancer stem cells following regu-
lar chemotherapy exposure [276]. Use of small molecule inhibitors
of IL-8 binding to CXCR1, such as repertaxin, has been shown
to enhance responses to chemotherapy in breast cancer [277].
Identification of the CXCL12-CXCR4/CXCR7 axis as a novel thera-
peutic target led to development of several therapeutic approaches
[248,278]. Examples of these are the anti-CXCR4 drug AMD3100
[279], the CXCL12 analog CTCE-9908 [280–282], the anti-CXCL12
aptamer NOX-A12 [283], the inhibitor of CXCR4 expression chal-
cone 4 [284], and the CXCR7-specific inhibitors CCX2066 [278,283],
CCX733 [285] and CCX754 [286,287]. CXCR4 also has been tar-
geted using monoclonal antibodies and small molecule antagonists
[288–291]. In addition, administration of recombinant forms ofd approach to suppress tumor-promoting inflammation. Semin
6
chemokines with angiostatic and/or antitumorigenic effects such as
CXCL4, CXCL9, and CXCL10 has been proposed as a potential strat-
egy to inhibit tumor growth and limit spreading [252,292–295].
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herapy, such as CXCL-1, CXCL8 and CXCL12 and others in various
tages of development [296,297].
The intrinsic functional redundancy in the chemokine system
uggests that blocking a single receptor upregulated in a particular
umor is unlikely to significantly affect the integrity of protective
mmune mechanisms. The redundancy of this system itself presents
herapeutic challenges related to possible overlapping functions of
ultiple receptors, but this feature also offers attractive opportu-
ities from a therapeutic standpoint. It may  be possible to fine-tune
xperimental screening studies to identify agents that inhibit cer-
ain signaling pathways while sparing others. The ability to bias
ignaling responses opens the possibility of selectively targeting
vents that contribute to disease while preserving immunity. In
ddition, the receptor microenvironment can profoundly affect its
unction and downstream signaling, and there may  be serendipi-
ous and unique specificities built into target cancer cells that can
e capitalized upon to maximize beneficial therapeutic action and
inimize or block the loss of beneficial responses such as antitumor
mmunity [298].
Many  recent studies have revealed that chemokines can reg-
late the movement of a wide variety of immune cells including
ymphocytes, NK cells, and dendritic cells in both physiological
nd pathological conditions. So these features endow chemokines
ith crucial roles in immune responses [299]. But therapeutic
pproaches that focus on chemokines can produce a range of
mmune-related effects. For example, a recent study demonstrated
n several murine models of anthracycline-based chemotherapy
hat the inhibition of CCL2 or CCR2 might actually impair the
nticancer immune response [300]. On the other hand, there are
ther chemokines that appear to have the potential to enhance the
ecruitment of antigen presenting cells and effector cells to sites
here they are needed [301]. Given the range of chemokines and
he complexity of the immune system, readers who  are seeking
ore detail on this topic are encouraged to peruse several recent
eviews that cover this topic in considerable detail [299,302,303].
uffice to say that although the development of therapeutics based
n targeting chemokines and their receptors has been challenging,
ut the lessons learned are leading to advances that should allow us
o develop more refined strategies with better chances of success.
.  Low toxicity approaches
Several  synthetic antiinflammatory molecules have been tested
n cancer research with important preclinical results; however, the
ranslation to clinical practice has been hampered by the abrupt
nding of unpredictable serious side effects or by a lack of signifi-
ant anticancer activity when tested in humans. For example, the
se of nonsteroidal antiinflammatory drugs (NSAIDs), in particular
spirin, have been included as a factor in several epidemiologi-
al studies, and also clinical trials have been attempted in order
o demonstrate chemopreventive activity. While epidemiological
ata do show association between long term ‘baby aspirin’ intake
nd colon cancer risk [304], many of the clinical trials designed
o look for prevention of the onset of cancer or of pre-cancerous
esions have not reached satisfactory results for a variety of rea-
ons (such as problems with the target population, duration of
he study, and more importantly, side effects [305–308] that range
rom gastrointestinal bleeding to hemorrhagic stroke). Thus, the
se of NSAIDs in clinical practice for cancer chemoprevention has
lways been outweighed by the possibility of serious complica-
ions.Please cite this article in press as: Samadi AK, et al. A multi-targete
Cancer Biol (2015), http://dx.doi.org/10.1016/j.semcancer.2015.03.00
At the same time, a wide spectrum of phytochemicals, present in
dible, non-edible and medicinal plants, and endowed with potent
ntiinflammatory properties, have been shown to prevent tumor
ccurrence in several organs of experimental animals and inhibit PRESS
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the  growth of neoplastic cells [309–315]. Indeed, several epidemi-
ological and experimental studies provide convincing evidence
that there exists a strong relationship between increased con-
sumption of various vegetables, fruits, whole grains, legumes and
spices and a decrease in cancer risk [316–319]. A large number of
phytochemicals present in dietary sources are capable of suppress-
ing carcinogenesis through inhibition of inflammatory cascade
[320–322] as well as modulation of various signaling pathways
implicated in cancer initiation, promotion and progression. We
have therefore focused on the following chemicals from plants and
foods as promising approaches with therapeutic potential to reach
the targets that we  have identified: curcumin, resveratrol, epigal-
locatechin gallate (EGCG), lycopenes, anthocyanins, and genistein.
3.1.  Curcumin
Curcumin, (diferuloylmethane) is a component of golden spice
Curcuma longa (commonly known as turmeric) which has been
used for centuries in many Asian countries as part of diet or as a
coloring agent. The anticancer and antiinflammatory effects of cur-
cumin have been demonstrated in many cell and animal studies,
and recent research has shown that curcumin can also target cancer
stem cells [323], which makes it a dietary substance of considerable
interest.
In Nepal and India, where daily curcumin uptake in diet has been
assessed as high as 50–100 mg/day, no toxicities or adverse effects
have been reported at the population level [324,325]. The National
Toxicology Program of the National Institutes of Health evaluated
the toxicology and carcinogenic effects of turmeric in 1993 at a dose
of 0.2 g/kg/day (CAS no. 8024-37-1) for 13 weeks and 2 years on rats
and mice. No adverse toxicological effects and no histopathological
changes in treated mice were found. Similarly, in a study under-
taken by National Cancer Institute in the United States, the oral
administration of 3500 mg/kg body weight curcumin for 90 days in
rats, dogs, or monkeys did not cause any adverse effects and was
well tolerated [326]. In 1996, the Food and Drug Administration of
the United States recognized curcumin as a Generally Recognized
As Safe (GRAS) compound [327]. Up to 1000 mg/kg/body weight
oral administration of curcumin did not have any adverse effect
on reproduction of rats, when fed for two  successive generations
[328]. Finally, in humans, a dose escalation study performed in 24
adults, found that single oral doses up to 12 g were well tolerated
and the observed adverse effects were not dose-related. Curcumin
supplementation up to 8 g/day for three months was well tolerated
in the patients with precancerous conditions or non-invasive can-
cer [329], and in another clinical trial in patients with advanced
colorectal cancer, curcumin supplementation ranging from 0.45
to 3.6 g/day for four months was well tolerated by subjects
[330].
However, curcumin may have adverse effect in the following
situations: (a) curcumin increases contraction in the gallbladder
and potentially could increase the risk of symptoms in people with
gallstone [331,332]; (b) curcumin can increase the risk of bleeding
in subjects taking anticoagulant medicines because it can inhibit
platelet aggregation [333,334]; and (c) curcumin also increases
acid output in the stomach and can interfere with acid suppressing
drugs in patients with duodenal ulcers [335].
Curcumin has garnered significant interest in cancer research
because it can regulate signaling pathways that are dysregulated
during tumorigenesis, including proliferation, differentiation, inva-
sion, apoptosis, and cell cycle checkpoints [336]. In vitro studies
indicate that curcumin can target numerous kinases, phosphatases,d approach to suppress tumor-promoting inflammation. Semin
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and enzymes [337]. For example, curcumin can inactivate NF-B
[338], and reduce COX-2 expression [339] and downstream targets
as well [338]. It promotes apoptosis through interaction with p53
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ell cycle arrest [342]. In animal models curcumin prevents can-
er development through reduction of TNF-, interferon- (IFN-),
nd COX-2 [343]. So the diverse biological effects of curcumin make
his compound an attractive constituent therapeutic that has been
idely evaluated for its anticancer activity [344].
Indeed, curcumin has been shown to inhibit the development
f chemically induced tumors of the oral cavity, forestomach, duo-
enum, and colon of experimental animals [337]. For example, the
ombination of 480 mg  of curcumin and 20 mg  of quercetin (three
imes daily) for six months reduced the number of polyps in a
mall number of familial adenomatous polyposis (FAP) patients
ithout major side effects [345]. Similarly, 4 g of curcumin daily
or 1 month prevented the development of aberrant crypt foci in
umans [346]. A preclinical study also suggests that curcumin could
ork as chemotherapeutic agent, by enhancing colon cancer cells
ensitivity to oxaliplatin [347]. However, not all trials have been
uccessful [348], and the systemic bioavailability of curcumin is
xtremely poor [349]. Nonetheless, at the US National Institutes
f Health website (https://clinicaltrials.gov), there are 47 ongoing
linical  trials with curcumin registered for different types of can-
ers, but most of them appear to be preclinical or pilot studies. For
ormal validation of the efficacy of curcumin as a chemopreventive
r chemotherapeutic drug, randomized, placebo-controlled, and
ouble-blind trials are required.
Chemical and photochemical instability/degradation, absorp-
ion, metabolism, and excretion of the curcumin are considered
he reason for low systemic bioavailability in human subjects [350].
hen curcumin was administered orally at a dose of 1000 mg/kg
n rats, the majority of the curcumin was excreted in feces and
egligible amounts were detected in the urine [351]. Curcumin
s bio-transformed in the intestine, and the liver converts it into
lucuronides and curcumin sulfates [352,353]. Also, reduction
f the curcumin to tetrahydrocurcumin and hexahydrocurcumin
as been reported after oral administration in rats, mice, and
uman [353–355]. Even intravenous and intraperitoneal admin-
stration of curcumin in rats resulted in reduced curcumin and
ubsequently reduced curcumin converted to monoglucuronide
onjugates [354]. Transformation of curcumin may  result in loss of
he biological activity of curcumin [353]. In pharmacokinetic and
ynamic studies, serum curcumin concentrations peaked in 1–2 h
356]. The peak serum concentrations of curcumin were 0.5, 0.6,
nd 1.8 M/liter following an oral dose of 4, 6, and 8 g of curcumin,
espectively [356].
Although  systemic availability of curcumin is very low, it has
een shown in some studies that orally administered curcumin
ccumulates in gastrointestinal tissues [357,358]. It has been
eported that when colorectal cancer patients were administered
.6 g/d of curcumin orally for seven days, curcumin was  detected in
ormal surgical samples of colorectal tissue [357]. Recent advances
hat use implantable polymeric micelles as nano-delivery systems
r phospholipid-based delivery systems for curcumin increase its
ccumulation in organs specifically in the gastrointestinal tract,
hat can target COX-2 as well as prostaglandin synthesis pathway
ore effectively [359–362]. In vitro, curcumin shows potential as
 COX-2 inhibitor, inhibiting the expression of COX-2 mRNA and
nzymatic activities of COX-2 protein in colonic epithelial and in
acrophages [363,364]. Curcumin also inhibited the expression of
OX-2 mRNA and enzymatic activities of COX-2 protein in colonic
pithelial and in macrophages [363,364].
Because curcumin can target prostaglandin biosynthesis, it can
e used in cancers where COX-2 activation plays an important
ole. New advancements in in vivo delivery systems of curcuminPlease cite this article in press as: Samadi AK, et al. A multi-targete
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ill result in a higher levels of curcumin accumulation in organs
specifically in the gastrointestinal tract) that can target COX-2
s well as prostaglandin synthesis pathway more effectively. Cur-
umin inhibited bile acid and phorbol ester induced COX-2 mRNA PRESS
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expression  in gastrointestinal epithelial cells [365]. In mouse skin
cells, curcumin inhibits phorbol ester-induced expression of COX-2
[348]. In a human non-small cell lung cancer ectopic and orthotopic
xenograft mouse model, curcumin reduced COX-2 expression in
subcutaneous tumors in vivo and caused a 36% decrease in weight
of intralung tumors accompanied by a significant survival rate
increase [366]. Curcumin inhibition of COX-2 in NSCLC cells was
associated with decreased survival [366].
Notably, in vitro treatment of curcumin also suppressed CXCL-
8 production by human pancreatic carcinoma cell lines and
downregulated the inflammatory cytokines CXCL1 and CXCL2
in breast cancer cells via NF-B [367,368]. In a Kras-mediated
lung cancer model in mice, curcumin inhibited the expression
of neutrophil chemoattractant keratinocyte-derived chemokine
CXC-KC and subsequently inhibited progression of the cancer
[369].
From an immune perspective, curcumin suppresses the type 1
immune response, which can increase susceptibility to infection
[370]. But at the same time curcumin appears to act in a supportive
manner for tumor-related immune effects. For example, in in vitro
tests aimed at studying the role of curcumin in the prevention of
tumor-induced dysfunction of T cell-based immune response, cur-
cumin prevented the loss of T cells, expanded central memory T
cell (T(CM))/effector memory T cell (T(EM)) populations, reversed
the type 2 immune bias and attenuated the tumor-induced inhibi-
tion of T-cell proliferation in tumor-bearing hosts. Curcumin also
inhibited the suppressive activity of Treg cells (by downregulat-
ing the production of TGF- and IL-10) and enhanced the ability
of effector T cells to kill cancer cells [371]. As well, curcumin sig-
nificantly inhibited the induction of IDO expression (a key enzyme
in T-cell suppression-mediated immune tolerance to tumors) and
activity by IFN- in bone marrow-derived DCs, which appears to be
an important immunomodulatory property of curcumin that may
serve to strengthen its therapeutic potential [372].
3.2. Resveratrol
Resveratrol (3,5,4′-trihydroxystilbene), a compound found in
the skins of red grapes, red wine, berries, peanuts and many other
plants, has been shown to possess health-promoting properties. It
is a bioactive polyphenol and has antiinflammatory, antioxidant,
antimicrobial, anticancer, neuroprotective, and cardioprotective
effects. Numerous preclinical animal studies provided encourag-
ing evidence for cancer chemopreventive and chemotherapeutic
potential of this phytochemical [373]. In vitro evidence of resvera-
trol efficacy is well described; however, many concerns regarding
its effectiveness in vivo arise from its poor stability and rapid
metabolism and bioavailability following oral ingestion. Peak
plasma concentrations occur at around 1hr, and levels of the parent
compound are very low [374,375]. Adverse effects are mild, even
at high doses (up to 5 g daily) [376]. Resveratrol works in animal
models [377] and humans; although the data for humans is more
sparse and controversial [378,379].
Resveratrol has been shown to have efficacy in multiple animal
models of chronic inflammatory diseases. These diseases include
hepatitis [380], esophagitis [381], and in particular, there are many
confirmed studies that resveratrol suppresses colitis [382,383] and
pancreatitis [384–386]. Resveratrol targets many of the key play-
ers involved in inflammation, prevents DNA damage, and induces
apoptosis in a p53-dependent manner [387–389]. Interestingly,
resveratrol can induce the expression of the p53 target, NAG-1
[non-steroidal antiinflammatory (NSAID) drug-activated gene-1],d approach to suppress tumor-promoting inflammation. Semin
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a member of the transforming growth factor-beta superfamily,
that has pro-apoptotic and antitumorigenesis activities [390]. Also,
resveratrol prevents pRb hyperphosphorylation and thus the inac-
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MP-2 [391] and MMP-9 [392,393], COX-1 [394], proinflammatory
ytokines [395–397], and growth factors such as hepatocyte growth
actor [398].
Additionally, resveratrol has potent NF-B-dependent antiin-
ammatory and chemopreventive effects both in vitro and in vivo,
nd impacts multiple disease phenotypes in a favorable manner.
or example, through the inhibition of NF-B, resveratrol amelio-
ates diabetic vascular inflammation and macrophage infiltration
n diabetic mice, inhibits the epithelial–mesenchymal transition,
odulates autophagy, suppresses cell transformation, regulates
iRNA levels, and reverses resistance to chemotherapeutic agents
399–405]. Notably, resveratrol has also been shown to inhibit
ther key modulators of inflammation and cancer discussed in
his review, including COX-2 [406–408], MIF  [409], TNF- [410],
NOS [411], AKT [412], and the CXC group of cytokines [413].
or example, Cichocki et al. showed resveratrol inhibited 12-O-
etradecanoylphorbol-13-acetate activated NF-B, AP-1, COX-2,
nd iNOS in mouse epidermis [414]. Similarly, Kundu et al. showed
hat resveratrol inhibits phorbol ester-induced expression of COX-2
nd activation of NF-B in mouse skin by blocking I-B kinase activ-
ty [408]. Dietary resveratrol (50–300 mg/kg) was found to inhibit
hemically induced hepatocarcinogenesis in rats with simulta-
eous suppression of hepatic iNOS, 3-nitrotyrosine, COX-2 and
F-B [415–417].
Several recently published clinical trials on resveratrol in
umans have shown that it exhibits antioxidant and antiinflam-
atory activities. It can improve glucose and lipid metabolism,
nd favorably modify a number of important pathways involved
n carcinogenesis (e.g., the insulin-like growth factor system [418],
poptosis [419] and others [420]). However, these effects can vary
nd depend on the protocols [376]. The plasma pharmacokinetics
f resveratrol in humans are also now reasonably well defined, and
aily doses up to 1 g appear to be safe and well tolerated, although
astrointestinal toxicity is observed at higher intakes, and there is
otential for drug interactions at higher doses[420].
In some of the earliest research on resveratrol and immune
unction, Falchetti et al. [421] showed that in vitro exposure to
esveratrol produced a biphasic effect on anti-CD3/anti-CD28-
nduced development of both IFN- – IL2- and IL4-producing
D8+ and CD4+ T cells (with stimulation at low resveratrol con-
entrations and suppression at high concentrations). Similarly, it
as found to induce a significant enhancement at low concen-
rations and suppression at high concentrations of both cytotoxic
 lymphocytes and NK cell cytotoxic activity [421], and this
iphasic modulation of NK cells has been confirmed in more recent
esearch as well [422]. The administration of low doses of resver-
trol also inhibited Renca tumor growth with regulatory T cells
eing decreased, and a massive amount of activated CD8+ T cells
ccumulating in the tumor microenvironment. At the same time,
he expression of T-helper (Th)-2 cytokines (e.g., IL-6 and IL-10)
witched to Th-1 cytokines with dominance of interferon (IFN)-
, which increases the expression of Fas in Renca cells [423].
nd resveratrol has also been shown to suppress tumor-derived
D4+CD25+ regulatory T cells (which are a negative regulator of the
mmune system and main obstacles to cancer immunotherapy in
umor-bearing hosts) in mice [424]. And resveratrol at low and non-
ytotoxic doses has been shown to inactivate Stat3, preventing the
eneration and function of tumor-evoked regulatory B cells (tBreg),
ncluding expression of TGF- in mice. This frees antitumor effec-
or immune responses by disabling tBreg-induced conversion of
orkhead box protein (FOX)p3(+) Tregs (without nonspecific inac-
ivation of effector immune cells), which efficiently inhibited lungPlease cite this article in press as: Samadi AK, et al. A multi-targete
Cancer Biol (2015), http://dx.doi.org/10.1016/j.semcancer.2015.03.00
etastasis in mice [425]. So the effects of resveratrol on the antitu-
or capabilities of the immune system appear equally promising,
nd notably, this is accomplished with no apparent increase in sus-
eptibility to risks of infection. PRESS
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3.3. Epigallocatechin gallate (EGCG)
EGCG is the most abundant catechin in tea, is a potent antiox-
idant and antiinflammatory agent. It is found mainly in white tea,
green tea and, in smaller quantities, black tea. Despite the demon-
stration of cancer prevention by EGCG in many animal studies,
epidemiological studies have found mixed results concerning the
effectiveness of EGCG as a superior medicine for prevention and
therapy of cancer in humans [426]. Its limited in vivo activities
can be attributed to metabolism and bioavailability. Methylation,
glucuronidation, sulfation, and ring-fission metabolism represent
the major metabolic pathways for tea catechins [427]. It has also
been found that efflux transporters P-glycoprotein (Pgp), MRP1 and
MRP2 play roles in the absorption and excretion of green tea cat-
echins [428]. Several processes including intestinal metabolism,
microbial metabolism, hepatic metabolism and chemical degra-
dation are also involved in the fate of EGCG, resulting in its low
availability in animals, and most likely also in humans [429].
Isbrucker  et al. conducted toxicity studies on EGCG. An oral
dose delivering 2000 mg  EGCG preparation/kg was lethal to rats,
whereas a dose of 200 mg  EGCG/kg induced no toxicity. The dietary
administration of EGCG to rats for 13 weeks was  not toxic at doses
up to 500 mg/kg/day. Similarly, no adverse effects were noted when
500 mg  EGCG preparation/kg/day was administered to pre-fed dogs
in divided doses. This dose caused morbidity when administered to
fasted dogs as a single bolus dose, although this model was consid-
ered an unrealistic comparison to the human condition. From these
studies a no-observed adverse effect level of 500 mg  EGCG/kg/day
was established [430].
There  are multiple mechanisms that can explain the chemo-
preventive potentials of EGCG, among which are its ability to
affect cancer cell signaling pathways, suppress cellular prolifera-
tion and induce apoptosis [426]. The diversified effects of EGCG
may explain its broad pharmacologic activities. With regards to
chronic inflammatory diseases associated with a high cancer risk,
EGCG has been shown to suppress colitis [431], hepatitis [432] (and
may  have antiviral properties against HBV and HCV [433,434]), and
pancreatitis [435] in animal models. Excitingly, in a pilot study
involving patients with mild to moderate ulcerative colitis, EGCG
(400–800 mg  daily) showed a therapeutic benefit for patients who
were refractory to 5-aminosalicylic and/or azathioprine [436].
There  is extensive evidence that EGCG targets key players in
inflammation, providing a mechanism of its efficacy in vitro and in
vivo against chronic inflammatory diseases and associated cancers.
Noh et al. showed that EGCG improves Dermatophagoides pteroniss-
inus extract-induced atopic dermatitis-like skin lesions in a mouse
model by suppressing MIF  [437]. In addition, EGCG can inhibit TNF-
 [438], iNOS [439,440], AKT [441], the CXC group of cytokines
[442], and by reducing the transcriptional activity of NF-B, COX-
2 expression and PGE-2 synthesis [443–448]. Additionally, EGCG
activates wild-type p53 [449–451], and protects from p53 muta-
tion [452]. It promotes pRb hypophosphorylation and activation of
this tumor suppressor protein [453], and inhibits MMPs such as
MMP-9 [454].
In  animal models EGCG prevents the development of adeno-
matous polyps in ApcMin/+ mice [455,456]. Some epidemiological
studies have shown that high consumption of green tea reduces
the risk of several types of cancers, including the lung, colorec-
tum, liver, esophagus and stomach [457,458]. High urinary levels of
tea polyphenol epigallocatechin (EGC) have been associated with
reduction of colorectal cancer among a Chinese population [459]
and a randomized clinical trial has shown a significant reductiond approach to suppress tumor-promoting inflammation. Semin
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in adenoma incidence among patients taking 1.5 g/day of green
tea extract [460]. Doses of green tea polyphenols greater than
800 mg/day increase in liver enzymes, and there is possible hepatic
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vidence from in vitro and non-human in vivo research on green
nd black tea as chemopreventive agents for colorectal cancer, data
re still insufficient to conclude that either tea type is protective
464]. But EGCG does target and suppress many of the key players
nvolved in the inflammation-to-cancer sequence, and therefore
ay be quite useful as a constituent within a mixture aimed at
nflammation in cancer.
From  an immune perspective, EGCG significantly suppressed
FN- production and the proliferation of peripheral blood
ononuclear cells in vitro [465]. It was also shown to exert antitu-
or effects on colorectal cancer cells, at least in part by inhibiting
he expression and function of IDO through the suppression of
TAT1 activation [466]. In leukemic BALB/c mice that received 5,
0 and 40 mg/kg EGCG (orally) for two weeks, it increased the
ercentage of CD3, T-cell, CD19, B-cell, and Macrophage-3 antigen
Mac-3), and macrophages, but reduced the percentage of CD11b
monocyte) cell surface markers. It also promoted the phagocyto-
is of macrophages from 5 mg/kg treatment and promoted NK cell
ctivity at 40 mg/kg, increased T-cell proliferation at 40 mg/kg, but
lso promoted B-cell proliferation at all three doses [467].
At  the same time, EGCG appears to have a protective effect
gainst bacterial infection. This was shown in EGCG treatment
f nicotine-suppressed macrophages where it reconstituted the
esistance to the infection and diminished a nicotine-induced inhi-
ition of cytokine production [468]. It was also demonstrated in
esearch against Pseudomonas aeruginosa and Escherichia coli iso-
ated from skin wounds [469], and against burn wound infection
y methicillin-resistant Staphylococcus aureus [470].
.4.  Lycopene
Lycopene is a phytochemical that belongs to a group of plant pig-
ents known as carotenoids. Red colored lycopene is lipophilic and
aturally occurs in many fruits and vegetables. The richest sources
f lycopene are tomatoes and tomato products, however, apricots,
uava, watermelon, papaya, and pink grapefruit are also sources
f this phytochemical. Some studies suggest that cooking toma-
oes in oil may  increase the bioavailability of lycopene [471,472].
esearch, dating as far back as the 1920s, has shown that naturally
ccurring carotenoids, specifically beta-carotene, have anticancer
roperties. Since the late 1980s when it was recognized that the
ntioxidant activity of lycopene was twice that of beta-carotene
here has been a growing interest regarding lycopene as a possible
nticancer agent.
Only  10–30% of the lycopene in dietary sources can be absorbed
ia the human digestive system [473]. Although there is conflicting
ata, it has been suggested that lycopene is better absorbed when
aken in conjunction with fats due to its lipophilic properties [474].
nce ingested, lycopene is incorporated into lipid micelles and
bsorbed by the mucosa of the small intestine. The micelles are
hen transported to the liver as chylomicrons. Lipoproteins are the
arriers of lycopene in the blood stream and the means by which
ioactive lycopene gains access to the various organ systems. High
oncentrations of lycopene have been found in the testes, prostate,
drenal glands and liver [475].
Lycopene is a constituent of human diets that are rich in fruit and
egetables and epidemiological studies suggest that it may  have a
rotective effect against various cancers [476]. Lycopene is a pow-
rful antioxidant that blocks the action of free radicals which are
ctivated oxygen molecules that can damage cells and have been
hown to support the development of some cancers. For example,
umerous studies suggest that lycopene and lycopene rich naturalPlease cite this article in press as: Samadi AK, et al. A multi-targete
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ietary products, when taken regularly, may  decrease the incidence
f a variety of malignancies including breast [477], ovarian [478]
ladder mouth, esophagus, pancreas [479] and colorectal cancer
480]. There is also great interest regarding lycopene and prostate PRESS
er Biology xxx (2015) xxx–xxx
cancer;  about 30% of the published human studies (16/54) that have
considered lycopene concern prostate cancer. The association of a
diet rich in lycopene from tomato-based foods with a lower risk of
prostate cancer is supported by multiple studies [481–485].
Thus  far, several researchers have investigated lycopene’s mech-
anism(s) of action as regards its anticancer effects. Oxidative
stress is a major factor implicated in chronic diseases and car-
cinogenesis. Lycopene has been found to increase the effects
of deoxification proteins (such as epoxide hydrolase-1) and
protective enzymes (such as glutathione-S-transferase-omega-
1,  peroxiredoxin-1 and sulphide-quinone oxidoreductase) [486].
Other studies have shown that lycopene downregulates the genes
that regulate proteins involved in the generation of ROS, including
ERO1-like protein-a and CLIC-1 [487]. In addition, lycopene may
prevent cancers, especially prostate cancer, via other mechanisms.
In vitro studies have shown that lycopene-induced activation of the
peroxisome proliferator-activated receptors (PPAR)-gamma-LXR
alpha-ABCA1 pathway is associated with decreased proliferation
of LNCaP prostate cancer cells [488,489]. When LNCaP cells were
exposed to lycopene, a dose-dependent decrease of the G0/G1
phase-related protein, cyclin D1, and an increase in the cyclin
kinase inhibitors, p53, p21 and p27 have been noted and were asso-
ciated with cell cycle arrest [490]. Other in vitro studies suggest
that lycopene may  induce apoptosis in human prostatic epithelial
cells. A protein expression profiling study revealed that lycopene
may up-regulate pro-apoptotic proteins as well as downregulate
antiapoptotic proteins in human primary prostatic epithelial cells
in vitro [487]. Lycopene has also been shown to suppress the inva-
sion and migration of prostate cancer cells by downregulating the
expression of integrins [491].
Lycopene has also been shown to have antiinflammatory effects
in both in vitro studies that assessed macrophages as well as rodent
studies. In particular, lycopene has been associated with down-
regulation of TNF- gene expression and/or inhibition of TNF-
secretion in LPS stimulated macrophages [492–494]. Also, in a rat
model of pancreatitis, blood levels of TNF- were notably lower in
lycopene-treated versus control animals [495]. Similarly, decreased
TNF expression and secretion results have been noted in a num-
ber of endothelial cell in vitro studies [496,497]. Modulation of the
following signaling pathways have been proposed as the mecha-
nism of this antiinflammatory effects: ERK, NF-B, JNK, and HMGB1
[492–494,496,497].
It is not clear whether or not lycopene predisposes patients to
infections or immune system suppression. There is limited evi-
dence that lycopene and other carotenoids have antiinflammatory
effects that may  impact native immune function [492]. In some
of the earliest animal studies, intraperitoneally or intravenously
injected lycopene produced prolonged survival times in bacteri-
ally infected mice [498]. But according to Medfacts.com, a total of
143 lycopene drug adverse event reports were reported to the FDA
between January 2004 and October 2012, including 21 infectious
complications, but lycopene was  not thought to be the cause of the
infection in any of those cases (based on physician opinions – no
further details provided).
From  an anticancer perspective, lycopene treatment promoted
promote spleen lymphocyte proliferation, and NK activity in vivo in
mice [499]. But another study on mice showed that lycopene signif-
icantly attenuates the maturation of murine bone marrow-derived
dendritic cells, and that it downregulated the expression of costim-
ulatory molecules (CD80 and CD86) and major histocompatibility
complex type II molecules, suggesting that it has immunosuppress-
ive potential [500].d approach to suppress tumor-promoting inflammation. Semin
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Studies  in which lycopene was orally administered repeatedly,
for a period of time, did not identify any clear organ toxicity related
to the lycopene in rats or mice, however, in a dog, accumula-
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n the kidneys were noted. Skin pigmentation and colored fatty
eposits in the liver were seen in a person who ingested high
arge amounts of lycopene daily over a period of years [501]. A
tudy concerning 20 male and 20 female Wistar rats that were
iven lycopene in their diets (a range of levels were assessed, the
ighest being 1% of diet) for 90 days showed no evidence of tox-
city based on: (1) clinical and neurobehavioral observations; (2)
otor activity assessment; (3) body weight and food consumption
easurements; (4) ophthalmoscopic examinations; (5) hemato-
ogy, clinical chemistry, and urinalysis; (6) organ weights, (7) gross
athology, or (7) histopathology [502].
Dietary lycopene, from eating fruits and vegetables, has no
nown side effects and is thought to be safe for humans. The opti-
um dosage for lycopene has not been established, but the amount
ound helpful in studies generally falls in the range of 4–8 mg  daily.
atients in some studies who took a lycopene-rich tomato supple-
ent of 15 mg  twice a day had some intestinal side effects such as
ausea, vomiting, diarrhea, indigestion, gas, and bloating. Lycopene
t higher doses, especially when taken for long periods of time, has
een associated with diarrhea, fat buildup under the skin, chest
ain, heart attack, skin discoloration, stomach pain, stomach ulcer
rritation, vomiting, and worsened hot flashes [503].
Supplements containing antioxidants such as lycopene may
nterfere with radiation therapy and chemotherapy if taken during
ancer treatment [504]. Even though studies have not been done
n humans, antioxidants are known to clear free radicals, which
ould interfere with one of the methods by which chemotherapy
nd radiation destroy cancer cells. Most of the human studies, thus
ar, have been case control or other types of observational studies
hich not as useful or predictive as clinical trials. More evidence
rom clinical trials is needed to confirm that lycopene-rich foods
an help prevent or treat cancer. Further studies are needed to bet-
er document the benefits and effects of lycopene supplements and
ts mechanism of action in vivo.
.5. Anthocyanins
A  diet rich in polyphenolic anthocyanins (ACs) has been reported
s a chemoprotective agent in in vivo models by regulating
nflammatory cytokines. It inhibited the development of N-
itrosomethylbenzylamine-induced esophageal cancer in rats. The
nhibition was mediated through decreased expression of inflam-
atory biomarkers like COX-2, iNOS, p-NF-B, and soluble epoxide
ydrolase (sEH) and cytokine, pentraxin-3 (PTX3) expression [505].
C-rich black currant skin extract showed chemopreventive activ-
ty through downregulation of abnormal lipid peroxidation, protein
xidation, and expression of iNOS and 3-nitrotyrosine (3-NT) in
 dose-responsive fashion (100 and 500 mg/kg) and upregula-
ion of the gene expression of a number of hepatic antioxidant
Nrf2-regulated antioxidant pathway) and carcinogen detoxifying
nzymes, such as NAD(P)H:quinone oxidoreductase, glutathione-
-transferase, and uridine diphosphate-glucuronosyltransferase
soenzymes in diethylnitrosamine (DENA)-initiated hepatocar-
inogenesis in rats [506]. Black currant anthocyanins also abrogated
levated inflammatory markers, such as COX-2 and NF-B, during
ENA hepatocarcinogenesis in rats [507].
ACs also exerted an antiinflammatory effect in H. pylori-infected
astric epithelial cells. The inflammatory cytokine IL-8 and ROS
ncrease in the H. pylori-infected gastric mucosa. First, ACs inhibit
he phosphorylation of MAPKs, translocation of NF-B and IB
egradation. Secondly, they also inhibit H. pylori-induced iNOS and
OX-2 mRNA expression and IL-8 production [508]. Additionally,Please cite this article in press as: Samadi AK, et al. A multi-targete
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n vitro studies showed that the anthocyanins inhibit the mRNA
nd/or protein expression levels of COX-2, NF-B and various inter-
eukins and exhibit antiinflammatory effects in multiple cell types
509,510]. PRESS
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These studies suggest that anthocyanins significantly inhibit
induced proinflammatory mediators, such as nitric oxide (NO) and
prostaglandin E2, as well as proinflammatory cytokines including
TNF- and IL-1, without significant cytotoxicity. Anthocyanins
also downregulated excessive expression of inducible NO synthase,
COX-2, TNF-, and IL-1 in a dose-dependent manner in different
cancers. Moreover, anthocyanins inhibited nuclear translocation of
NF-B and IB degradation as well as phosphorylating MAPKs.
In  addition to these antiinflammatory effects, anthocyanins
have been shown to inhibit the growth and invasion of SKHep-1
cells through reduced expression of MMP-9 and urokinase plas-
minogen activator (u-PA) [511]. Similarly, a MMP-9 and u-PA
mediated reduction of migration and invasion was  observed in
highly metastatic A549 human lung carcinoma cells through cyani-
din 3-rutinoside and cyanidin 3-glucoside (anthocyanins). This
inhibition was  also through the downregulation of activation of
c-Jun and NF-B [512]. Treatment with anthocyanins (such as
delphinidin, cyanidin, and pelargonidin) in normal human epi-
dermal keratinocytes inhibited UV-B-mediated degradation and
phosphorylation of IB and activation of IKK  ˛ which further
inhibited nuclear translocation and phosphorylation of NF-B/p65
at Ser (536) [513].
Some  caution must be exercised, because anthocyanins are often
addressed as a homogenous class of agents, but they represent
a group of structurally dissimilar molecules. Some studies also
look at anthocyanidins (which are similar to anthocyanins but
without sugar moieties). Both anthocyanins and anthocyanidins
(especially cyanidin and delphinidin) have been subjected to exten-
sive mechanistic studies in relation to antiproliferation, induction
of apoptosis and inhibition of activities of oncogenic transcription
factors and protein tyrosine kinases. Water soluble anthocyanins
are mostly 3-glucosides of the anthocyanidins. The most common
anthocyanidins are pelargonidin, delphinidin, peonidin, petuni-
din, malvidin and cyanidin. Peonidin 3-glucoside and cyanidin
3-glucoside extracted from black rice (Oryza sativa ssp. indica)
inhibit the growth and invasion of SKHep-1 cells through reduced
expression of MMP-9 and urokinase plasminogen activator (u-PA)
[511]. Similarly, MMP-9 and u-PA mediated reduction of migra-
tion and invasion was observed in highly metastatic A549 human
lung carcinoma cells through cyanidin 3-rutinoside and cyanidin
3-glucoside (extracted from Morus alba). This inhibition was  also
through the downregulation of activation of c-Jun and NF-B [512].
Treatment with pomegranate-derived delphinidin, cyanidin,
and pelargonidin in normal human epidermal keratinocytes
inhibited UV-B-mediated degradation and phosphorylation of IB˛
and activation of IKK  ˛ which further inhibited nuclear translo-
cation and phosphorylation of NF-B/p65 at Ser [513]. Based
on the accumulating evidence, pure anthocyanidins as well as
berry extracts enriched with anthocyanidin showed higher chemo-
preventive activities than berry extracts with high anthocyanin.
The major points of concern are pH, temperature and light-
dependent interconversion of anthocyanins and anthocyanidins, a
greater susceptibility of anthocyanidins (in comparison to the gly-
cosides) to chemical decomposition, and shorter half-lives in the
biophase.
Notably, a number of immunosuppressive effects of berry
extract rich in anthocyanins have been reported by Hushmendy
et al. [514] who demonstrated that anthocyanidin rich fractions
inhibit T-cell proliferation and IL-2 production on anti-CD3 plus
anti-CD28-activated primary human T-lymphocytes in culture
[514]. However, very little research on anthocyanidins and the
immune system in cancer exists, suggesting that this is an area thatd approach to suppress tumor-promoting inflammation. Semin
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needs further investigation.
In  general, these findings suggest that anthocyanins offer sub-
stantial chemopreventative and therapeutic potential, although
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nly a small portion of orally ingested anthocyanins is absorbed
<1%). Maximum plasma levels are reached within 2 h of consump-
ion. About 68% of absorbed anthocyanins are metabolized, and
xcreted as monoglucuronides [515]. Low bioavailability of the
nthocyanins is due to their extensive metabolism in the tissues
nd by the colonic microflora. The gut microflora degrades antho-
yanins to release simple phenolics that conjugate in intestine and
ater in liver and hamper the absorption process. However, some
eports contradict this observation and suggest that anthocyanin
lycosides remain intact during absorption [516]. Although the
ioavailability of cyanidin-3-glucoside and anthocyanin as shown
hrough the above report is low, Mayrczylo et al. demonstrated
ystemic levels of parent cyanidin-3-glucoside and total antho-
yanins as 1.7% and 3.3% respectively in C57BL6J mice that received
yanidin-3-glucoside by oral gavage or tail vein injection [517].
Overall,  in most in vitro and in vivo assays anthocyanins are not
enotoxic. Some evidence of genotoxicity was provided by a single
n vitro study using pure anthocyanidins. However, the genotoxicity
f grape seed extract was negative in a bone marrow micronucleus
est in vivo. Moreover, in guinea pigs and dogs, no short-term or
ubchronic toxic effects were observed at 3 g/kg anthocyanins and
5% of grape-skin extract respectively. In addition, in rats fed with
 g/day unspecified anthocyanins extract or grape seed extract no
oxic effect was observed. But because of a lack of data, no firm
onclusion can be drawn with respect to long-term toxicity or car-
inogenicity of anthocyanins [515].
.6. Genistein
Genistein (GEN) is a prominent isoflavone which inhibits cell
rowth and induces apoptosis in vitro and in vivo without tox-
city [518,519]. It inhibits activated AKT, the downstream target
f many pathways such as Notch [520], and IGF-1 in pancreatic
ancer cells [521], in osteosarcoma [522] and breast cancer [523].
dditionally, GEN inhibits the activity of AKT-targets like FOXM1
n pancreatic cancer cells [520] and FOXO3 [524] in colon cancer
ells. AKT also forms a complex with human TERT, heat shock pro-
ein 90, p70S6 kinase and mTOR and GEN restrains the formation of
his complex [525]. In pancreatic cancer cells GEN inhibits growth
ia inactivation of Notch-1/AKT/FOXM1 [520]. Estrogen receptor-
/AKT mediated inhibition was also observed in DLD-1 human
olon adenocarcinoma cells [526]. GEN also targets AKT and p21
AF1/CIP1 in BRCA1-mutant human breast cancer cell lines [527].
EN induced AKT-mediated enhanced apoptosis/down-regulation
f AKT has also been reported in combination with compounds like
rsenic trioxide in human hepatocellular carcinoma [528], gefitinib
n NSCLS [529], gemcitabine in human osteosarcoma [522,530], cis-
latin in cervical cancer cells [531], cetuximab in oral squamous
ell carcinoma [532], photoactivated hypericin in breast cancer
ells [533] and indole-3-carbinol in human colon cancer HT-29
ells [534]. GEN also inhibits the carcinogenic effect of 17 beta
stradiol or bisphenol-A via ER/IGF-1/AKT pathway in BG-1 ovar-
an cancer cells [535] and also downregulates FOXO3 activity in
olon cancer cells [524]. It also modulates MAPKs/AKT in cervical
ancer cells [536]. Repression of breast cancer stem cell-induced
ammospheres by GEN was similar to the AKT inhibitor perifosine
nd was related to enhanced tumor suppressor PTEN expressions
537]. Increased ceramide and lipid raft cholesterol accompanied
ith genistein inhibited the cell viability of prostate cancer cells via
he partial contribution of EGFR-AKT/p70S6k pathway and down-
egulation of androgen receptor [538,539].
Some reports also show a distinct genistein effect wherebyPlease cite this article in press as: Samadi AK, et al. A multi-targete
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t induces PI3K/AKT nongenomic ER signaling to the histone
ethyltransferase enhancer of zeste homolog 2 (EZH2). As a result,
his phosphorylates and represses EZH2 and reduces levels of
3K27me3 repressive mark in chromatin during developmental PRESS
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reprogramming, and promotes uterine tumorigenesis [540]. In
colon cancer cells, membrane androgen receptors (mAR) activation
inhibits the prosurvival signals AKT/Bad in vitro and in vivo and
blocks migration of colon cancer cells via regulation of vinculin (a
protein controlling cell adhesion) signaling and actin reorganiza-
tion, supporting the powerful tumoristatic effect of mAR receptors.
GEN inhibited actin reorganization and restored the motility of
these cells and reversed the tumoristatic effect of mARs [541].
A  number of concerns have been raised about the estrogen-
like effects of natural isoflavones (i.e., the possible promotion of
estrogen-sensitive cancers) [542–544]. However, a recent nested
case-control study and meta-analysis of numerous epidemiological
studies show an inverse correlation between GEN intake and breast
cancer risk and a number of other clinical studies support the breast
and uterine safety of purified naturally derived GEN administered
for up to 3 years [545].
Most  phase I and phase II clinical trials of GEN have consid-
ered normal dietary dose ranges, i.e., 0.3–1 mg/kg body weight/day
[546]. In one study patients were treated with 2 mg  GEN/kg
body weight and compared against no treatment prior to under-
going radical prostatectomy for localized prostate cancer [547].
After treatment, it was  shown that GEN decreased MMP-2 gene
expression to 24% of the level seen in control subjects (blood
concentrations of free GEN were approximately 140 nM in the GEN-
treated cohorts while control group levels were below detection)
[547]. Messing et al. initiated a phase 2 randomized, placebo-
controlled trial with oral GEN (300 or 600 mg/d) as the purified soy
extract G-2535 and found that GEN was more effective at lower
dose on bladder cancer tissue through EGFR phosphorylation but
the AKT pathway was  unaltered in both in vivo conditions [548].
Another phase II clinical trial with GEN administered at a dose
of 531 mg  twice daily P.O. starting day −7 until the end of study
participation with erlotinib, and gemcitabine in advanced pancre-
atic cancer did not appear to increase the survival of patients with
advanced pancreatic cancer [549]. In another phase II trial, sub-
jects with progressive prostate cancer were treated with soy milk
three times daily for 12 months (approx. 1 mg GEN/kg/day) which
decreased the rate of increase of serum prostate-specific antigen
(PSA) when compared to that which was  seen in subjects prior to
entering the study [550]. Finally, a third phase II study of GEN in
men  with various stages of prostate cancer used soy extract (6 mg
GEN/kg/day for 6 months) [551] with 17% of the participants expe-
riencing a decrease in their PSA levels.
From an immune perspective, a range of effects have been
found. For example, Yellayi et al. reported that sub-cutaneous
GEN injections (8 mg/kg/day) in ovariectomized adult mice lead to
estrogen receptor (ER) and non-ER-mediated inhibition of thymo-
cyte and CD4(+)CD8(−) helper T cell lineage maturation as well as
systemic lymphocytopenia [514]. Additionally, GEN produced sup-
pression of humoral immunity. The significant thymic and immune
changes in mice produced by serum GEN levels at 8 mg/kg/day
was also comparable to those reported in soy-fed human infants
[514]. GEN also appears to compete with endogenous 17beta-
estradiol for estrogen receptors to suppresses Ag-specific immune
responses. Specifically 20 mg/kg GEN downregulated OVA-specific
proliferative responses, interferon-gamma production levels and
immunoglobulin (Ig)G1 without reduction in responses to anti-CD3
monoclonal (m)antibody and Ag-presenting activity of CD11c(+)
dendritic cells [552]. And GEN has also been shown to potently
induce the granzyme B inhibitor, proteinase inhibitor 9 (PI-9) in
MCF-7 human breast cancer cells inhibiting the ability of human
NK cells to lyse breast cancer cells [553].d approach to suppress tumor-promoting inflammation. Semin
6
By contrast, however, the ingestion of GEN significantly
increased  lymphocyte proliferation and LDH release, and caused
a significant increment in IFN- in a mouse model of human
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herapeutic effect (compared to a control group) [554]. GEN also
roduced a significant increase in ex vivo cytotoxic T lympho-
yte (CTL), a potentiating effect on NK cells (but a decrease in
he percentage of CD4(+)CD25(+) T cells), an increase in the pro-
uction of IFN-, and the activation of STAT1 and STAT4 in a
,12-dimethylbenz[a]anthracene (DMBA)-induced tumor model in
ice. This resulted in an antitumor effect and an enhancement
o host resistance in this study [555]. So the immunomodulatory
otential  of GEN appears to be quite nuanced and it may  require
urther investigation before we fully understand how these effects
mpact various cancers.
.  MicroRNA (MiR)
In  this section we also review the known impact of these
pproaches on microRNA (miRs), a relatively new area of intense
nterest in cancer research. miRs are small non-coding RNAs that
egulate gene expression (post-transcriptionally) and target about
0% of the protein-coding mRNAs [556,557]. They are master reg-
lators of multiple cellular pathways, and the deregulation of
iRNAs plays a fundamental role in the onset and progression of
any cancers [556].
The  miRBase database (http://www.mirbase.org) is a searchable
atabase of published miRNA sequences and annotation. miRBase
ersion 16.0 has 1048 miRNA sequences annotated in the human
enome, and miRs and a single miR  can target approximately 200
ranscripts simultaneously. Each miR  can target hundreds of mes-
enger RNAs (mRNA)s and a single mRNA is often the target of
ultiple miRs within a given cell type [557]. Many housekeeping
enes have evolved with shorter length of 3′-UTR to avoid miR  reg-
lation [558]. About 50% of annotated human miR  genes are located
n cancer associated genomic regions or fragile sites that are sus-
eptible to amplification, deletion and translocation in a variety
f tumors [23,559]. Because of this, some miRs could act as either
umor suppressors or oncogenes (oncomir) [560–564].
The posttranscriptional fine tuning of mRNA and proteins levels
y miR  also plays an important role in developmental and immune
egulatory processes [565–569]. They are involved in the regulation
f nearly all aspects of cellular function including innate and adap-
ive immune responses [570–573]. Deregulated miR  expression
as been found in several autoimmune disorders and inflamma-
ory conditions [574–576]. Importantly, miRs have been found to
e either upregulated or downregulated in tumors [577–580]. Epi-
emiological studies suggests about 25% of all cancer may  be due to
hronic inflammation [3,8], and several miRs have been implicated
n both inflammation and cancer [569,581–584].
.1. MicroRNA-155
miR-155 is found on chromosome 21 (human) and 16 (mice)
585,586], and is generally considered to be an oncomir with
ostly proinflammatory effects. This miR  is upregulated by NF-B
566,587,588], which is pivotal in inflammation and cancer [589].
iR-155 is upregulated/activated in B and T cells, macrophages
nd dendritic cells [566,585,590,591]. miR-155−/− mice are highly
esistant to experimental autoimmune encephalomyelitis (EAE)
592,593]. Mechanistically, this appears to be due to the role of
iR-155 in mediating the production of IL-17 (Th17) and IFN-
Th1) producing CD4+ T cells [592].
miR-155 has been found at high levels in human B cell
ymphomas and other tumors [585,590,594–596]. Enforced over-Please cite this article in press as: Samadi AK, et al. A multi-targete
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xpression of miR-155 in mouse B cells is sufficient to trigger
urine B cell lymphoma [597]. It has also been reported that
iR-155 acts as an oncogene by targeting tumor suppressor gene
uppressors of cytokine signaling 1 (SOCS1) in breast cancer cells PRESS
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[598].  Additionally, the upregulation of miR-155 by mutant p53
was reported to drive breast cancer invasion [599] and this miR
suppressed the expression of tumor protein p53 induced nuclear
protein 1 (TP53INP1) [600]. miR-155 may  also play a role in mul-
tiple sclerosis (MS) and rheumatoid arthritis (RA), where elevated
levels have been found in brain lesions of MS  patients [601] and in
synovial samples of RA patients [602]. Overall, miR-155 is emerg-
ing, then, as a key oncomir linking inflammation and cancer.
4.2.  MicroRNA-146
miR-146 is a miRNA family, consisting of two evolutionarily
conserved miRNA genes: miR-146a and miR-146b. miR-146 sup-
presses inflammation and cancer. The distal region of chromosome
5q, which contains miR-146a gene (5q33) in humans is reported
to harbor susceptibility loci for autoimmune diseases such as RA
[603], Crohn’s Disease [604], asthma [605] and psoriasis [606]. miR-
146a and miR-146b, when expressed in highly metastatic human
breast cancer cells, function to negatively regulate NF-B activity
[607]. miR-146a and miR-146b have also been found to be highly
expressed in RA synovial tissue [608]. Although RA is not a high
cancer risk disease, other auto-immune, chronic inflammatory dis-
eases such as inflammatory bowel disease (IBD) are treated in a
similar manner (e.g., TNF inhibitors). Therefore, it would be inter-
esting to examine the role of this miR  in such diseases. miR-146a
also directly targets PGE2 synthase and increased expression of
miR-146a in bone mesenchymal stem cells (BMSCs) is correlated
with the inhibition of PGE2 synthase-2 (Ptges-2) and the inhi-
bition of PGE2 release [609]. In contrast to miR-155, miR-146a
limits T cell activation and promotes resolution of inflammatory
responses [610]. miR-146a−/− mice develop spontaneous autoim-
munity and myeloid cancers upon aging, due to hyperactivation
of T cells via de-repression of the proinflammatory proteins, IL-1
receptor-associated kinase 1 (IRAK1) and TNF receptor associated
factor (TRAF)6 [610–612]. Finally, Xie et al. recently reported that
the inhibition of miR-146 results in increased IL-1, IL-6 and TNF-
 secretion, as well as increased expression of IRAK1 [613]. Such
studies, then, again highlight a key role of miR-146 in inflammation
and cancer.
4.3.  MicroRNA-21
miR-21 is an oncomir. Its oncogenic activity has been reported
where it targets and represses important tumor suppressor genes
such as PTEN [614], programmed cell death 4 (PDCD4) [615],
tropomyosin 1 (TMP1) [616], B-cell translocation gene 2 (BTG)
[617], components of the p53 pathway [618] and also modu-
lates growth inhibitory and pro-apoptotic cytokine TGF- signaling
[618] to further enhance its tumorigenic effects. miR-21 dere-
gulation is a very early event in the multistep progression of
pancreatic ductal adenocarcinoma (PDAC) [619]. miR-21 expres-
sion is increased in breast and colorectal cancer and in the
serum of patients with hepatocellular carcinoma (HCC) [620,621].
With regards to its role in inflammation, miR-21 expression has
been shown to be induced in macrophages and peripheral blood
mononuclear (PBM) cells upon LPS challenge [622] and in mam-
mary epithelial cells by inflammatory signals [582]. Similarly
induction of miR-21 by IL-6 is a STAT3 dependent mechanism that
is responsible for the survival of multiple myeloma cells [623]. It
appears that STAT3 together with miR-21, miR-181b-1, PTEN and
cylindromatosis (CYLD) is a part of the epigenetic switch that links
inflammation to cancer in several cancer types including breast,d approach to suppress tumor-promoting inflammation. Semin
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colon, prostrate, lung and HCC [581]. Finally, Schetter et al. have
reported a positive correlation of IL-6 with miR-21 expression in
human colon cancer tissues [624], further supporting the role of
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.4. MicroRNA-17–92 Cluster
miR-17–92  (OncomiR-1) [562] is a cluster of miRs located on
uman chromosome 13 and encodes a polycistronic miR  gene
or six mature functional miRs: miR-17, miR-18a, miR-19a, -
0, -19b and -92 [625]. Overall, this cluster of miRs has cancer
nd inflammation-promoting properties. For example, SOCS1, a
ene frequently silenced in multiple myeloma, and a strong anti-
nflammatory instigator, is targeted by miR-19, elucidating the
roinflammatory property of miR-19 and its possible link to tumor-
genesis [626,627]. miR-17–92 clusters weaken TGF- signaling by
unctioning both upstream and downstream of phospho-SMAD2 as
ell as through direct inhibition of TGF- responsive genes [628].
iR-19b positively regulates NF- signaling for proinflammatory
ytokine production, is involved in controlling several negative
egulators of NF-B signaling, and plays a crucial role in the pathol-
gy of autoimmune diseases [629]. Additionally, miR-17–92 is
 well-established player of oncogenesis and overexpression of
his cluster and in a Myc-driven mouse model of B-cell leukemia
ccelerates tumor development [562]. miR-19 can exert its onco-
enic effect through its repression of tumor suppressors PTEN and
rotein phosphatase 2 (PP2A), pro-apoptotic molecule B-cell lym-
homa 2 interacting mediator of cell death and Protein kinase,
MP-activated, alpha 1 catalytic subunit [630–632]. Overall, the
iR-17–92 cluster, based on its role in inflammation and cancer
ould also serve as a potential therapeutic target.
.5. MicroRNA-196
miR-196 is considered an oncomir, is upregulated in several
ancer types [569] and is associated with Barrett’s esophagus-
o-adenocarcinoma disease progression [633]. Luthra et al.
emonstrated miR-196a directly targets the antiinflammatory
layer, annexin 1 and has growth promoting and antiapoptotic
roperties in esophageal adenocarcinoma cell lines [634]. miR-196
s overexpressed in inflamed intestinal epithelial of Crohn’s dis-
ase patients and downregulates immunity-related GTPase family
 protein (IRGM) protective variant (c.313C) but not the risk associ-
ted allele (c.313T) [635]. Also, the Rs11614913 SNP in miR-196a-2
ay promote susceptibility to breast and lung cancer [636]. These
ncogenic and proinflammatory properties of miR-196a support its
ole in inflammation and cancer.
.6. microRNA-663
miR-663 is currently reported as an antiinflammatory and
umor suppressor miR  and impairs the upregulation of miR-
55 by inflammatory stimuli [637,638]. The overexpression of
ypomethylated miR-663 induces chemotherapy resistance in
uman breast cancer cells by targeting heparan sulfate proteogly-
an 2 (HSPG2) [639].
.7.  Other microRNAs involved in inflammation and cancer
miR-9  is canonically induced by NF- following TLR4 activa-
ion in human neutrophils and monocytes and provides feedback
o repress NF-B signaling through direct targeting of p50 mRNA
640]. Overexpression of miR-9 by MYC/MYCN is involved in can-
er metastasis [641,642]. This elucidates a possible link between
nflammation and cancer by miR-9. Several studies reported
pregulation of miR-210 in hypoxic condition [643–645] and its
mportance for cell survival [646]. miR-210 is a sensor for hypoxic
tress during tumorigenesis, where increased miR-210 expres-Please cite this article in press as: Samadi AK, et al. A multi-targete
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ion inhibits tumor growth to provide tumor cells an opportunity
o prevail in stressful hypoxic condition [647]. Thus, a possible
onnection between hypoxia and tumorigenesis is mediated by
iR-210. miRNA-16 is a putative tumor suppressor miR, and is PRESS
er Biology xxx (2015) xxx–xxx
downregulated  in a variety of human cancers [648–654]. One rec-
ognized function of miR-16 is that it controls the cell cycle primarily
through a G1 cell cycle checkpoint [649,655–662].
The finding that miR-16 is upregulated in high risk colon cancer,
and chronic inflammatory disease possibly indicates an adaptive
upregulation of this tumor suppressor miR  in response to inflam-
matory stress. Finally, inhibiting the peptidyl arginine deiminase
(PAD) enzyme, which catalyzes the post-translational conversion
of peptidyl-arginine to peptidyl-citrulline (“citrullination”) causes
an increase in miR-16 [663]. The fact that citrullination is thought to
be an inflammation-dependent process [664] supports the notion
that miR-16 is involved in the suppression of inflammation. miR-
125b expression is decreased after LPS challenge in macrophage
cells [665], and additionally in several inflammatory condition such
as psoriasis and atopic eczema [666]. Further down-regulation of
miR-125b has been reported in several tumor types such as thyroid
anaplastic carcinomas, hepatocarcinomas, oral, bladder cancer,
ovarian and breast cancer [569]. Finally, miR-663 is currently
reported as antiinflammatory and tumor suppressor microRNA
and impairs the upregulation of miR-155 by inflammatory stimuli
[637,638].
4.8. Selected approaches that modulate miR involved in
inflammation and cancer
Signaling  pathways involving inflammation and cancer are
clearly regulated by miRs so here we specifically discuss studies
that relate to the therapeutic approaches reviewed above. For ref-
erence sake, additional details on other dietary components that
regulate miRs have been reviewed in detail elsewhere [557,667].
4.9.  Resveratrol
Since both resveratrol and miR  influence cellular homeostasis
and disease conditions, resveratrol could act through miRs in mod-
ulating and targeting the factors involved in disease and cellular
homeostasis. Tili and Michaille reviewed resveratrol, miRs, inflam-
mation and cancer [668], and note that resveratrol has been shown
to induce the expression of miR-663, a tumor-suppressor and
antiinflammatory miR, while down-regulating proinflammatory
miR-155 and oncogenic miR-21.
4.10. Curcumin
Curcumin regulates the expression of genes that are involved in
the regulation of cellular inflammatory and cancer signaling path-
ways, such as NF-B, AKT, MAPK and other pathways [669,670].
These signaling pathways are in turn regulated by several miRs. In
a spontaneously arising retinal pigment epithelia cell line (ARPE-
19 cells), curcumin treatment lowers the expression of miR-17–92
cluster and its pre-treatment attenuates H2O2 induced expres-
sion of miR-15b, miR-21, miR-17, miR-196b and miR-9 [671]. The
curcumin analog CDF decreases pancreatic cancer cell survival by
increasing the expression of the tumor suppressor miRs, Let-7 and
miR-146a, which are typically lost in pancreatic cancer [672]. The
mesenchymal phenotype of gemcitabine-resistant pancreatic can-
cer cells has been shown to be reversed by simply treating the cells
with either CDF or curcumin which upregulates the expression
of miR-200b and miR-200c [673]. Curcumin also reduces miR-21
expression and activity via AP-1, suppresses tumor progression,
and stabilizes the tumor suppressor Pdcd4 in colorectal cancer cells
[674].d approach to suppress tumor-promoting inflammation. Semin
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4.11. Genistein
Genistein enhances the apoptotic effects of exogenous miR-16
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nducing expression of miR-200 and let-7 to reverse EMT  phe-
otype [676]. Isoflavones have also been shown to upregulate
iR-146a and target EGFR and IRAK-1/NF-B signaling to inhibit
ancreatic cancer cell invasion [677]. These studies provide evi-
ence that isoflavones regulate miRs involved in inflammation and
ancer which may  provide a prevention and/or treatment measure.
.12. EGCG
EGCG is a major catechin in green tea and has been implicated
n many pathways involved in inflammation and cancer. EGCG
pregulates miR-210 in human and mouse lung cancer cells in
ulture which leads to reduced cell proliferation mediated by sta-
ilization of HIF-1 [678]. EGCG antagonizes androgen action and
own-regulates miR-21 and upregulates tumor suppressor miR-
30 in prostate tumors of mice [679]. EGCG has also been shown to
ecrease expression of oncomirs (miR-92, miR-93, and miR-106b)
nd increase the expression of tumor suppressor miRs (miR-7-1,
iR-34a, and miR-99a) in neuroblastoma cells [680].
.  Cross-validation for tumor promoting inflammation
Given that the heterogeneity that is present in most cancers,
t is our assumption that the complete arrest of the various sub-
opulations of immortalized cells in any given cancer will require
imultaneous actions on mechanisms that are important for several
spects of cancer’s biology. We  therefore believe that it is impor-
ant to be able to anticipate synergies that might be achieved by
cting on specific targets and with specific approaches (i.e., when
ontemplating an approach aimed at a broad-spectrum of targets).
ccordingly, in this review the prioritized target sites and the
pproaches that have been identified (as potential ways to reach
hose targets) were all cross-validated by conducting a background
iterature research. A team of researchers consisting of specialists
n each area specifically sought to determine the relevance of thesePlease cite this article in press as: Samadi AK, et al. A multi-targete
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argets and the nominated approaches across a number of impor-
ant areas of cancer’s biology.
In  this regard, targets and approaches that were not only rel-
vant for this area of study, but also relevant for other aspects of
able 1
ross  validation of targets – prioritized targets evaluated for known effects in other cance
Potential targets for inflammationa
Other hallmarks
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cancer’s  biology (i.e., anticarcinogenic) were noted as having “com-
plementary” effects. Those that were found to have procarcinogenic
actions were noted as having “contrary” effects. In instances where
reports on relevant actions in other aspects of cancer biology
were mixed (i.e., reports showing both procarcinogenic potential
and anticarcinogenic potential), the term “controversial” was used.
Finally, in instances where no literature support was found to doc-
ument the relevance of a target site or approach in a particular
aspect of cancer’s biology, we  documented this as “no known rela-
tionship”. These validation results are shown below in tabular form
in Tables 1 and 2.
The  decision to review priority target sites and approaches for
reports of cross-hallmark effects was  driven by the fact that many
individual studies and reviews fail to account systematically for the
spectrum of incidental actions that can result from various forms
of therapeutic interventions. It is our belief that this approach con-
stitutes a better way to ensure that we had assembled a reasonably
thorough review of the literature (i.e., where any sort of evidence
of cross-hallmark activity had been reported).
Because future research on therapeutic combinations will likely
involve empirical testing of mixtures of constituents, we wanted
to create a starting point for other researchers who might be
considering translational projects. We  anticipated interest in
approaches reported to exhibit a large number of anticarcinogenic
actions across the hallmarks and we anticipated that a lack of pro-
carcinogenic potential was  important to identify (since targets or
approaches that have been shown to exert procarcinogenic actions
would potentially represent a confounding and unwanted influ-
ence/factor in empirical research). A summary of these reports is
also provided in Tables 1 and 2.
Note that, in some instances, the underlying evidence used to
support the indication of a cross-hallmark relationship was robust,
consisting of multiple studies involving detailed in vitro and in
vivo findings. In other instances, however, the underlying evi-
dence that was  used to report the existence of a cross-hallmarkd approach to suppress tumor-promoting inflammation. Semin
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relationship was quite weak (e.g., consisting of only a single in vitro
study involving a single cell-type). Additionally, there are examples
of approaches that are known to exert different effects at different
dose levels and in different tissues but dose-levels and cell/tissue
r hallmark areas.










































































in another hallmark area were indicated with “ + ”, while targets that were found
tances where reports on relevant actions in other hallmark areas were mixed (i.e.,
bol “±” was used. Finally, in instances where no literature support was found to
nted this as “0”. These cross-hallmark relationships are reported in the first eleven
hallmark relationships for each target have been summed and are reported in the
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Table  2
Cross  validation of approaches. Selected approaches evaluated for reported actions in other cancer hallmark areas.
Approacha
Other hallmarks
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found to have procarcinogenic actions in a particular hallmark area were indicated with “−”. In instances where reports on relevant actions in other hallmarks were mixed




































ahe  relevance of an approach in a particular aspect of cancer’s biology, we document
f  the table. Finally, the number of anticarcinogenic, procarcinogenic and mixed cro
hree  columns of the table.
ypes were not used to discriminate when gathering together these
eported actions.
Nonetheless, given that the overarching goal in this project was
o create a foundation that would allow researchers to look system-
tically across the literature in each of these areas, the tables should
erve as a useful starting point as long as they are approached with
aveats in mind and a degree of caution. Essentially, we  believe
hat this heuristic model should be useful to consider synergies
hat might be anticipated in testing that involves certain targets
nd/or mixtures of chemical constituents that are being considered
or therapeutic effects.
.  Summary/conclusions
In sum, it was our goal to explore a series of high priority anti-
nflammatory targets for therapeutic intervention in cancer as part
f a larger effort to develop a broad-spectrum approach aimed
t a wide range of targets that are relevant for cancer biology.
he selected targets MIF, COX-2, NF-B, TNF-, iNOS, AKT and
XC chemokines represent a promising and interrelated set of tar-
ets that are pleiotropic, with demonstrated potential not only for
nflammation, but also for a wide range of other effects that support
he various hallmark phenotypes found in a wide range of cancer
ypes.
At the same time, the approaches that we selected to act on
hose targets (curcumin, resveratrol, EGCG, genistein, lycopene,
nd anthocyanins) are all agents than have demonstrated a range
f anticancer effects. While we focused mainly on antiinflamma-
ory effects, many of these approaches have demonstrated a range
f anticarcinogenic actions as well. In addition to the most widely
eported direct effects of these agents, we have also summarized
iR regulated gene expression related to inflammation and cancer,
nd the known effects of these approaches on these MiRs.
Given  the tight coupling between inflammation and the immune
ystem, we also wanted to consider the possibility that proposedPlease cite this article in press as: Samadi AK, et al. A multi-targete
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ctions on important antiinflammatory targets, and/or the chronic
dministration of the antiinflammatory chemicals might predis-
ose individuals to infection or modulate the immune system in
 manner that might be relevant for immune-related antitumor as “0”. Threse cross-hallmark relationships are reported in the first eleven columns
llmark relationships for each target have been summed and are reported in the last
effects.  Perhaps not surprisingly, an increased risk of infection
appears to be a concern for therapeutic approaches aimed at sup-
pressing MIF, Cox-2, NF-B, and TNF-, and in the use of curcumin
(as a therapeutic approach). By contrast, EGCG appears to have a
protective effect against bacterial infection. Immunomodulation of
antitumoral effects is also a nuanced picture. COX-2 inhibition and
PI3K-AKT pathway inhibition both appear to be attractive targeting
strategies that have antitumoral effects that are immune-related.
Similarly, curcumin, resveratrol and EGCG have also been shown
to act on the immune system in a favorable manner. However,
lycopene and genistein have demonstrated a range of competing
effects on the immune system making their utility from this per-
spective more difficult to discern.
Future research should address the ambiguities posed by the
wide range of CXC Chemokines and their various effects, as precise
targets are needed to better characterize the range of effects and
synergies that might be anticipated. Similarly, within the selected
approaches, specific anthocyanins that appear to have the great-
est promise should be isolated and better characterized for effects
across the range of cancer hallmark phenotypes, and for bioavail-
ability and toxicity.
Ideally,  future translational work would utilize the agents that
we have identified in this review combined as constituents within a
multi-pronged antiinflammatory approach with very little/no tox-
icity.
However, any multipronged strategy that focuses on these tar-
gets and/or approaches will need to carefully consider the potential
for increased risks related to infection and anticipate the possibil-
ity for a range of immunomodulation that will have relevance for
antitumoral effects.
Bioavailability challenges with a number of these agents are
starting to be addressed, and foreseeably recent advances that uses
implantable polymeric micelles, liposomes, microspheres, nano-
delivery systems, phospholipid-based delivery systems and other
systems (c.f. [359–362]) will help address this issue.d approach to suppress tumor-promoting inflammation. Semin
6
The cross-validation tables (Tables 1 and 2) are offered here as
a simple heuristic framework that is intended to help researchers
approach the topic of anticipated synergies. Although these initial
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s hoped that they can serve as a starting point for the transla-
ional research that will be needed. Rigorous experimentation will
bviously be needed to determine whether or not actual synergies
merge that can be predicted using this approach. Other syner-
ies may  emerge depending on the specific constituents and model
sed.
The key is to recognize that a low-toxicity approach aimed at
any important targets to reduce tumor-promoting inflammation
s only a stepping stone. Most cancers harbor significant genetic
eterogeneity [4], and patterns of relapse following many ther-
pies are due to evolved resistance to treatment. Consequently,
n antiinflammatory approach along these lines should be devel-
ped and then combined with other similar approaches that aim
o target the many disease-specific pathways that have relevance
cross the range of hallmark phenotypes. A much broader range
f targets overall may  be the only chance we will have to address
his heterogeneity. It is a promising approach, but a considerable
mount of encompassing research needs to follow to determine
ethodological validity.
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Targeted therapies and the consequent adoption of  “personalized” oncology have achieved notable 
successes in  some cancers; however, significant problems remain with this approach. Many targeted 
therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few 
disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant 
immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not 
reliant upon the same mechanisms as those which have been targeted). To address these limitations, an 
international task force of 180 scientists was assembled to explore the concept of a low-toxicity “broad- 
spectrum” therapeutic approach that could simultaneously target many key  pathways and mechanisms. 
Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects 
of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide 
range of high-priority targets (74  in total) that could be modified to improve patient outcomes. For these 
targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were 
phytochemicals. Proposed actions on  each target and all  of the approaches were further reviewed for 
known effects on  other hallmark areas and the tumor microenvironment. Potential contrary or procar- 
cinogenic effects were found for  3.9% of  the relationships between targets and hallmarks, and mixed 
evidence of complementary and contrary relationships was found for  7.1%. Approximately 67% of the 
relationships revealed potentially complementary effects, and the remainder had no known relationship. 
Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. 
These results suggest that a broad-spectrum approach should be  feasible from a safety standpoint. This 
novel approach has potential to be  relatively inexpensive, it should help us  address stages and types of 
cancer that lack  conventional treatment, and it may reduce relapse risks. A proposed agenda for  future 
research is offered. 







1.  Introduction 
 
Cancer is a source of significant and growing mortality world- 
wide, with an  increase to  19.3  million new cancer cases per year 
projected for  2025. More than half  of cancer cases and mortality 
occur in low- and middle-income countries, and these proportions 
are expected to increase by 2025 [1]. Current treatments for cancer 
include surgery, radiotherapy and systemic treatments compris- 
ing  cytotoxic chemotherapy, hormonal therapy, immunotherapy, 
and targeted therapies [2].  Cancer continues  to  stymie  clinical 
treatment efforts, however, and the search for  effective therapies 
continues. 
This capstone paper describes the methods and results of a sub- 
stantial effort by  a large international group of biochemical and 
medical researchers, operating under the name of  “The  Halifax 
Project,” sponsored by a non-profit organization, Getting To Know 
Cancer. It summarizes and draws together material from a series of 
reviews on the hallmarks of cancer, presented in this special issue 
of Seminars in Cancer Biology, to present a conceptual framework 
for  a  new approach to  cancer prevention and therapeutics. This 
approach involves the targeting of many specific high-priority anti- 
cancer mechanisms and pathways within a more comprehensive 
model of treatment and care. We refer to this as a “broad-spectrum” 
approach (i.e.,  an  approach aimed at a broad spectrum of impor- 
tant mechanisms and pathways) [3]. The broad-spectrum approach 
involves combinations of multiple low-toxicity agents that can col- 
lectively impact many pathways that are  known to  be  important 
for  the genesis and spread of cancer. By making extensive use  of 
chemicals from plants and foods that have already been studied or 
utilized for cancer prevention and treatment, this approach offers a 
compelling rationale for addressing the underlying biology of can- 
cer  while being efficacious, non-toxic and cost-effective. We come 
together in the belief that a broad-spectrum approach of this type, 
in the context of a therapeutic environment including conventional 
treatment and attentive to optimal health, would provide genuine 
benefit in  clinical outcomes for  cancer patients. In this paper we 
describe the rationale for broad-spectrum therapeutics, detail the 
methods of the Halifax Project, summarize potential targets and 
agents related to  eleven hallmark features of  cancer, propose a 
research model for the development of broad-spectrum therapies, 
and call for action to advance this research model. 
 
1.1.  Rationale for broad-spectrum approach 
 
Primary motivations for the development of a broad-spectrum 
approach stem from the distinct limitations that are  evident in 




Fig.  1.  Diagrammatic representation of  removal of  susceptible cells by  a targeted cancer therapy resulting in disease remission, which leaves genetically heterogeneous 
resistant cells to proliferate, resulting in relapse. 
 
 
many current targeted therapies and the personalized medicine 
paradigm. Molecular target therapies represent  a  significant 
advance in  the treatment of  cancer. They  include drugs such as 
imatinib, an  inhibitor of the tyrosine kinase enzyme BCR-ABL, 
which has  made chronic myelogenous leukemia a more manage- 
able disease, and inhibitors of vascular endothelial growth factor 
receptor (VEGFR), such as  sunitinib, sorafenib and bevacizumab, 
used in  renal and colon cancers [2].  Other important treatments 
based on  tumor-specific targets are  now in  use,  including exam- 
ples such as  epidermal growth factor receptor (EGFR) inhibitors 
(gefitinib, erlotinib) used in  lung cancer, and the Her2 inhibitor 
trastuzumab used in  breast cancer. Another approach is the syn- 
thetic lethal model [4] exemplified by research on poly ADP ribose 
polymerase (PARP)  inhibition, in  which mutational loss   of  one 
or  more redundant components of a cell  survival pathway in 
tumorigenic cells  confers selective sensitivity to  drugs that target 
remaining pathway components. 
These drugs target cells  bearing one, or at most a few  mutated 
gene products or  other abnormalities not found on  normal cells. 
In the therapeutic context, the action of the targeted agents can 
efficiently address malignant cells,  without some of the effects on 
normal cells  notorious in  cytotoxic chemotherapy. This  enables 
therapeutic responses and remissions. Over  time, however, the 
genetic heterogeneity of tumors increases, engendering resistance 
to  treatment. Resistant cells  drive the emergence of increasingly 
aggressive disease, through  clonal expansion and clonal evolu- 
tion (Fig. 1).  Epigenetic modifications, heritable cellular changes 
not caused by  alterations to  DNA sequences, but by  alterations 
such as methylation of DNA or modification of the histone protein 
associated with DNA, may also   affect patterns  of  gene expres- 
sion and drive cancers [5].  Relapses often occur after only a few 
months, and tumors reappear, sometimes in exactly the same areas 
in  which they originated [6].  Moreover, targeted agents are  not 
without serious side effects, such as  treatment-related mortality 
with bevacizumab and cardiopulmonary arrest with cetuximab. 
Meta-analysis of trials of recently approved cancer drugs includ- 
ing  targeted therapies versus older drugs showed increased rates 
of grades 3 and 4 toxicity (OR = 1.52), treatment  discontinuation 
(OR = 1.33) and toxic deaths  (OR = 1.40) [7].  This  worsening  of 
adverse effects has  gone in large part unacknowledged. 
The   efficacy shown  to   date  with  targeted  therapies, aside 
from now-established treatments  such as  bevacizumab and 
trastuzumab, is nevertheless still  limited. Sunitinib, for  instance, 
extends overall survival by 4.6  months in renal cancer compared 
with the previous treatment of interferon-a [8]. While statistically 
significant, this degree of improvement is small comfort to afflicted 
patients, and challenges the extraordinary monetary investment 
in  drug development as  well as  costs to  the medical system that 
targeted therapies represent. The  MOSCATO 01  trial of molecular 
triage was able to treat 25 of 111 patients with a variety of advanced 
cancers using therapies targeted to  genomic alterations assessed 
from tumor biopsies [9].  Of these, 5  patients (20%)  experienced 
partial response and 56% had stable disease. Based on  the entire 
population of 111 patients, this is a partial response of less than 5%, 
suggesting limited efficacy to  date, an  outcome also  seen in some 
other studies [10].  On  a more hopeful note however, a combina- 
tion of pertuzumab with trastuzumab and the chemotherapy agent 
docetaxel was recently found to extend overall survival among the 
subset of breast cancer patients whose tumors express Her-2 by 
15.7  months [11]. 
Interestingly, harnessing the body’s immune response against 
the tumor can  also  result in impressive durable clinical responses, 
perhaps because the immune system is  a  paragon of  adaptabil- 
ity  and can   deal with changes in  the  mutational  landscape of 
cancer to prevent escape from the therapeutic effect. Immunomod- 
ulatory antibodies recently licensed in  the United States include 
ipilimumab as  well as  nivolumab and pembrolizumab, neutraliz- 
ing  two different inhibitory pathways that block antitumor T cell 
responses. These agents have achieved some successes in treating 
late stage cancers refractory to  essentially any  other treatments 
[12].  But  even with these agents, response rates are  still  low  and 
predicting who will  respond is an unsolved challenge [13,14]. 
Many of these therapies are  somewhat narrowly described as 
“personalized” because patients’ tumors must be  tested for  spe- 
cific  mutations to  stratify patients to  the correct therapy. Viewed 
in  the larger context of individual biological variation, of course, 
specific mutations  drive only the smallest degree of  personali- 
zation. Truly  personalized treatment  approaches can  be  seen to 
include a much more comprehensive assessment of genetic and 
even lifestyle factors, such as  nutritional, biobehavioral (stress 
management) strategies, and exercise habits, along with other 
host variables such as inflammation and immune status. Such  an 
approach to personalizing treatment can be found in the systematic 
practice of integrative medicine, which played a significant role in 
the development of this model of broad-spectrum cancer therapy. 
Some definitions of integrative medicine stress simply the inclusion 
of  complementary and alternative therapies alongside orthodox 
treatment [15].  A more relevant definition emphasizes a patient- 
centered, multi-intervention treatment paradigm that addresses 
the full  range of physical, mental, emotional and environmental 
influences, utilizing an  array of disciplines including diet, mind- 
body and physical activity therapies in  addition to  conventional 
therapies and dietary supplements to support optimal health [16], 
based on  laboratory testing that enables comprehensive persona- 
lization. 
The stratification of patients for these targeted and person- 
alized therapies poses practical challenges. As indicated earlier, 
over 50% of the increase in cancer incidence by 2025 is projected 
to  occur in  the developing world [1].  As industrialization devel- 
ops  in lower-income countries, occupational cancers are  expected 
to  increase, potentially aggravating this situation [17].  Cancer 
treatment in many of these countries is already becoming a social- 
economic challenge due to the expense and medical infrastructure 
required [18],  and the new generation of treatments may further 
strain local   resources. Currently, the platforms used for  testing 
to  personalize regimens include whole exome or  whole genome 
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sequencing, whole transcriptome  sequencing, and comparative 
genomic hybridization with still  others in development. It is likely 
that such tests, and related expense, will  proliferate in the future. 
Managing treatment toxicity is also a taxing and complex problem, 
as these toxicities necessitate additional medical interventions. 
The  expense of the new targeted therapies is also  concerning. 
Eleven of twelve drugs approved by the US Food  and Drug  Admin- 
istration (US FDA) in 2012 were priced above $100,000 US per year 
per patient – perhaps not surprisingly in view of the accelerating 
costs of drug development [19].  Clinicians have drawn attention 
to  these high costs: in  2013 more than 100  experts in  chronic 
myeloid leukemia coauthored  a  paper  calling for  lower prices 
and broader access to  these drugs [20].  The  excessive costs have 
resulted in drugs not being approved for use by national or regional 
governments where cost-benefit analyses figure in approval pro- 
cesses [21].  While costs are  expected to  decrease after expiration 
of patents on the drugs, the costs for treatment in low- or middle- 
income countries may continue to  be  problematic. The  potential 
for unsupportable financial stress on health systems challenges the 
research community to  explore other treatment models that can 
be more sustainable in the face of the worldwide increase in cancer 
incidence. 
The broad-spectrum approach that we describe here is primarily 
intended to  address the two major issues of  therapeutic resis- 
tance and cost.   It  is  based on  many of  the insights of  genomic 
sequencing in cancers. We  now know that cancers harbor signif- 
icant genetic heterogeneity, even within a single patient [6]. Based 
on this heterogeneity, cancers routinely evolve resistance to treat- 
ment through switching from one growth pathway to another [22]. 
The proposed strategy employs the basic principles of rational drug 
design, but aims to stem cancer growth by precisely targeting many 
growth pathways simultaneously. Some effort is now being made 
in combining targeted agents so that more than one pathway can 
be affected, but lack of therapeutic success, significant toxicity and 
costs make this a challenge [23–26]. 
We  see  the broad-spectrum approach as  one that is  comple- 
mentary to  existing therapies, preferably within the context of a 
genuinely integrative clinical system. Clinical situations in which 
such an  approach might prove useful include (a)  as  a follow-up 
maintenance plan to  conventional adjuvant treatment; (b)  in sit- 
uations of rare cancers and disease stages for  which no  accepted 
treatments exist; (c)  for  patients who do  not tolerate conven- 
tional chemotherapy, hormonal therapy or targeted therapies; (d) 
for  patients who experience relapse or progression after targeted 
treatment; (e) in hospice or palliative care patients where low- or 
non-invasive strategies are a legitimate and humane option; and (f) 
in situations in which high-cost agents cannot be obtained. Because 
of continuous heterogeneity among cancer cells,  and their propen- 
sity  for  genomic instability, even a  broad-spectrum  approach is 
unlikely to cause complete remission. However, the design of this 
approach posed a substantial theoretical challenge, for  which we 
chose to use  the hallmarks of cancer as a broad organizing frame- 
work. 
 
1.2.  Hallmarks of cancer as a framework for developing 
broad-spectrum therapeutics 
 
Hanahan and Weinberg first published their concept of  the 
hallmarks  of   cancer  in   2000  [27].   The   hallmarks  “constitute 
an   organizing principle that  provides a  logical framework  for 
understanding the remarkable diversity of  neoplastic diseases.” 
This   framework encompasses the  biological capabilities that 
cells   acquire  during  the  development  of   cancers  that  allow 
them to  become malignancies as  we  know them. Six  hallmarks 
were proposed in  the 2000 publication: sustained proliferative 
signaling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogen- 
esis  and resisting cell death. The concept of the hallmarks became 
widely recognized and influential. In 2011, Hanahan and Weinberg 
expanded on the initial hallmarks to include other areas of cancer 
biology that they felt were equally important [28]. They pointed out 
two enabling characteristics critical to the ability of cells to acquire 
the six hallmarks, and two new hallmark capabilities. They also sin- 
gled out the crucial nature of the complex tumor microenvironment 
in the appearance of the cancer phenotype. The enabling character- 
istics are  genomic instability and tumor-promoting inflammation; 
the new hallmarks are  deregulating cellular energetics and avoid- 
ing immune destruction. 
The hallmarks framework helps to define domains in which high 
priority targets can be identified for therapeutic targeting. Hanahan 
and Weinberg point out that agents are  in development that target 
each of the hallmarks. They also  note, however, that in response to 
targeted therapy, cancers may reduce their reliance on a particular 
hallmark capability, such as angiogenesis, and instead heighten the 
activity of another capability, such as invasion and metastasis [29]. 
This reaction has been clinically verified in the case of glioblastoma 
[30]. 
Another model, which was proposed by  Vogelstein et al.  in 
2013 [6],  also   attempts to  describe the mechanisms and path- 
ways that are  relevant to  many cancers. In  this model, “driver” 
genes that drive cancer growth are distinguished from “passenger” 
mutations found in  cancer cells   that impart no  growth advan- 
tage. Twelve major signaling pathways that drive cancer growth 
have been elucidated, including signal transducers and activators 
of transcription (STAT), Notch, DNA damage control and 9 others. 
These pathways are classified into three cellular processes underly- 
ing tumor growth: cell survival, cell fate  and genome maintenance. 
Individual patients with the same cancer can have mutations on dif- 
ferent pathways, leading to inter-patient heterogeneity. Yet within 
each patient there is also  substantial heterogeneity, both within 
each patient’s primary tumor, and among and within metastases, 
with significance for treatment strategies. For instance, the small- 
est  metastases visible through medical imaging may already have 
thousands of cells  that harbor mutations rendering them resistant 
to current drugs [31]. 
Cancer mutations, moreover, are  not simply a series of isolated 
targets. Beneath the surface of  the cancer genome is  a  notably 
complex cellular signaling network, filled with redundancies. The 
elucidation of rational therapeutic combinations requires dynamic 
mechanistic models that reach beyond simple targeting [32]. What 
propels growth, dissemination and thus ineffective treatment and 
drug resistance actually appears not to be pathways acting in iso- 
lation but interconnected, multidirectional and dynamic networks 
[33]. Even sorafenib, which inhibits multiple kinases, is susceptible 
to  the rapid development of resistance deriving from crosstalk in 
pathways such as phosphatidylinositide 3-kinase/protein kinase B 
(PI3K/Akt) and Janus kinase (JAK)-STAT, hypoxia-induced signaling 
or  the epithelial-to-mesenchymal transition (EMT) [34].  Conven- 
tional drug discovery programs are  now contemplating systems 
biology approaches aimed at furthering the network approach 
to  pharmacology. The interdependence of cytokines, chemokines, 
growth factors, transcription factors, and their resulting proteomes, 
together with their relevance to cancer prevention and treatment 
[35],  makes systems biology approaches most attractive [36].  This 
realization makes the significance of a broad-spectrum approach 
to cancer of even greater importance. 
Clinicians as  well as  researchers recognize the importance of 
heterogeneity in  cancer. A least one clinical center  recognizes 
the significance of this heterogeneity, and intervenes with broad- 
spectrum approaches to  respond to  it.  In  a 2009 book, Life Over 
Cancer,  based on  a clinic in  operation since 1980, Block  lays  out 
a  model of  nutraceutical-based targeting of  nine  “pathways  of 
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progression” and six  metabolic factors impacting the challenges 
faced by  all  cancer patients [3].  The  nine growth pathways are 
proliferation, apoptosis, treatment  resistance, immune evasion, 
angiogenesis, metastasis, cell-to-cell communication, differentia- 
tion and immortality. Multiple targeting of these pathways with 
natural products is used to simultaneously address multiple inter- 
connected growth pathways. Comprehensive molecular profiling 
maps patients’ growth pathways and provides for  relevant nat- 
ural product intervention. The  six  metabolic “terrain factors” are 
oxidation, inflammation, glycemia, blood coagulation, immunity 
and stress chemistry. Terrain-focused interventions are  tailored 
to patients’ laboratory test results, which are  monitored regularly 
to  guide therapeutic modification. Interventions include elimina- 
tion of  maladaptive lifestyle patterns, adjusting exercise habits, 
improving diet, implementing biobehavioral strategies to  dimin- 
ish  adverse consequences of  unabated stress/distress, and using 
natural products and medications that affect specific targets such 
as  C-reactive protein (CRP) [37],  interleukin-6 (IL-6),  nuclear fac- 
tor  K-beta (NF-KB)  [38],  prostaglandin E2 and leukotriene B4 [39] 
for inflammation.  Clinical observations and literature review sug- 
gest potential efficacy for this system in breast cancer (including a 
near-doubling of survival time of breast cancer patients in integra- 
tive  care) and potentially other cancers [40,41]. Essentially, Block’s 
clinical model systematically addresses multiple targets and path- 
ways through a specific and selective broad-spectrum approach to 
treatment. While this system was developed in  clinical practice, 
quite independently from the discussion of hallmarks and enabling 
characteristics by Hanahan and Weinberg, the conceptual overlap 
is obvious. That  these concepts have already been used in clinical 
treatment provides powerful support for the viability of a carefully 
designed broad-spectrum approach. 
The  model we  propose to  use  to  develop a sound framework 
for  a  broad-spectrum  approach recognizes these broad areas of 
conceptual overlap and agreement, and can  be considered to best 
align with the hallmarks of cancer framework [27]. Our framework 
encompasses the molecular and metabolic diversity of malignancy 
recognized in Hanahan and Weinberg’s hallmarks, Vogelstein’s 12 
growth pathways, Block’s pathways of progression and terrain fac- 
tors, and other emerging research. For the purposes of this project, 
we  treat the 6 hallmarks, 2 enabling characteristics, 2 emerging 
hallmarks, and the tumor microenvironment equally as hallmarks 
of malignancy. From a design standpoint, each of these individual 
areas encompasses an important aspect of cancer’s biology, so each 
was seen as important to consider for a therapeutic approach aimed 
at a wide range of high priority targets. 
In mid-2012, the framework for this project and approach were 
shared with Douglas Hanahan. He  later independently provided 
support for  this type of approach in a paper, “Rethinking the war 
on  cancer” [42].  Using a military metaphor, he  suggests a three- 
dimensional cancer “battlespace” plan that  attacks cancer in  a 
full-scale war rather than individually targeted skirmishes. The first 
dimension is disruption of cancer’s many capabilities, specifically 
those figuring in the hallmarks. Rather than just removing one capa- 
bility, as targeted therapies do, he  explains that an ideal approach 
should target all the hallmark capabilities. The second dimension is 
defense against cancer’s armed forces, implying specific targeting 
of the accessory cell  types in  the tumor microenvironment, such 
as tumor-promoting inflammatory cells.  The third dimension rep- 
resents the multiple battlefields of cancer: primary tumor, tumor 
microenvironment, lymph and blood vessels through which tumors 
disseminate, draining lymph nodes and distant organs. This dimen- 
sion suggests still  more targets. 
A rapidly developing sub-discipline in  oncology is  the appli- 
cation of  genetic and immune analysis of  tumor tissue and the 
concomitant use of personalized therapies and prescriptions. These 
analyses allow better stratification of patients to  treatments and 
clinical decision-making [43].  In the case of breast cancer alone, 
tests range from Her-2 testing, the basis of trastuzumab treatment 
to sophisticated suites of tests that analyze dozens of genes. These 
complex analyses assist in  treatment decisions based on  correla- 
tions with clinical outcomes by predicting treatment response, risk 
of recurrence and outcome. They suggest the size of the network of 
genes that affect just one cancer, and emphasize the significance of 
a broad-spectrum attack. Clinical utility of these tests is still  under 
review [44]. 
Despite impressive progress in  genomic and gene expression 
profiling, however, it is often impossible to  fully  characterize the 
range of immortalized cell  variants within any  given cancer. The 
perspectives offered by Hanahan, Vogelstein and Block, as well as by 
the recognition of the network aspects of signaling pathways, how- 
ever, suggest a larger number of targets may need to  be  reached. 
So the 138  driver genes, together with the 12  signaling pathways 
that comprise them, in addition to the molecular contributors to the 
hallmarks, and Block’s nine pathways of progression and six terrain 
factors, help us delineate some of the most significant targets that 




2.  Methods 
 
The effort to  develop the concept of broad-spectrum targeting 
of  cancer through a  complex combination of  agents, emphasiz- 
ing  naturally occurring chemicals, was developed by a non-profit 
organization, Getting To Know Cancer, and implemented within 
an  initiative called “The  Halifax Project.” The  aim  of  the project 
was to  produce a series of reviews of the cancer hallmarks that 
could collectively assess and prioritize the many target choices 
that exist, and also  identify non-toxic chemicals (primarily from 
plants or foods) that could safely be combined to produce an opti- 
mized broad-spectrum approach that has  both prophylactic and 
therapeutic potential. To that end, it  was envisioned that eleven 
teams of  researchers would produce reviews on  the ten cancer 
hallmarks plus the tumor microenvironment, which was treated 
as  a  hallmark for  the purposes of  this project. Each  review was 
to  describe the hallmark, its  systemic and cellular dysfunctions, 
and its  relationships to  other hallmarks. A priority list  of relevant 
therapeutic targets and corresponding approaches suited to those 
targets was requested, along with a discussion of research needed 
in  the context of  goals of  the project. Natural compounds were 
emphasized because of the growing body of literature that sup- 
ports the low  toxicity and interesting potential that many of these 
substances have demonstrated (i.e., as targeted therapeutics or in 
cancer prevention), while recognizing the variable effectiveness of 
these compounds in  human trials as  well as  the undocumented 
safety or frank toxicity concerns with many natural products [45]. 
In recognition of the network of signaling pathways involved not 
only in drug resistance but the interconnection and maintenance of 
all the hallmarks, the project implemented a cross-validation step 
in the evaluation of targets and approaches. Because of the diversity 
of the targets involved in the 11 hallmark areas, it is not unreason- 
able to suspect that inhibiting or stimulating a target relevant to one 
hallmark may have an  adverse growth effect or clinically adverse 
effect on a target in another hallmark. For instance, reducing DNA 
damage is  a potential target for  counteracting genomic instabil- 
ity. Activation of the immune system can  counter DNA damage by 
eliminating damaged cells. However, activation of the immune sys- 
tem, while reducing overall levels of DNA damage, can  contribute 
to chronic inflammation [46]. 
Similar considerations apply to  therapeutic  approaches. For 
instance, triptolide, a component of the Chinese herb Tripterygium 
wilfordii, is known to cause apoptosis in cancer cells  [47].  Extracts 
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of the herb have been used in clinical trials for a variety of inflam- 
matory and immune-linked conditions, and have demonstrated 
both antiinflammatory and immune suppressant activity, raising 
concern for its effect on immune evasion [48,49]. 
To address this issue, a  specially designated cross-validation 
team  was created within the  project to   evaluate all  selected 
targets and approaches, i.e.,  to  determine whether the inhibi- 
tion or  activation of  targets, and the application of  approaches, 
would have negative effects on  other hallmarks. Each  potential 
target-hallmark or  approach-hallmark interaction was assessed 
to  determine whether the pair had a complementary interaction 
(i.e.,  the interaction of the target or  approach with the hallmark 
facilitated anticancer activity), a contrary interaction (i.e., the inter- 
action of the target or approach with the hallmark had a potential 
adverse tumor-stimulating or  tumor-progression  effect), a  con- 
troversial interaction (i.e.,  mixed indications of  anticancer and 
tumor-stimulating  effects), or  no  known relationship. A sample 
cross-validation table for dysregulated metabolism approaches can 
be accessed as Supplemental Table  S1. 
It is important to  note that the cross-validation team was not 
given any  restrictions for  literature selection for  this effort, and 
contributing authors were not restricted to cancer-related research. 
This approach was taken because it was realized at the outset that 
this breadth and specificity of knowledge does not yet  exist in the 
literature. As a result, the types and sources of data gathered in this 
effort varied considerably, although original studies were consis- 
tently favored over review articles. Moreover, many studies that 
were cited in  this effort considered only a compound’s ability to 
instigate or promote an  action that mimics a hallmark phenotype 
in a manner directionally consistent with changes that have been 
associated with cancer. So while we  refer to  these as  anticancer 
or  tumor-stimulating, the specificity of these activities and their 
implications for cancer treatment cannot and should not be imme- 
diately inferred from this database. In other words, the results from 
this aspect of the project were only compiled to serve as a starting 
point for future research, rather than a conclusive guide to therapy. 
Targets or  approaches that have a substantial number of 
“contrary” assessments  are   less   attractive for  inclusion in  the 
broad-spectrum approach. On the other hand, the use of targets and 
approaches that appear to have the potential for multiple comple- 
mentary interactions is consistent with principles of rational drug 
design, and akin to efforts to design “dirty” drugs (a pharmacolog- 
ical  term for  drugs with multiple targets – as  opposed to  single 
targets – aimed at multidimensional conditions) [50]. Further eval- 
uation of such “dirty” targets and approaches could be undertaken 
through more specific application of network pharmacology, for 
which new tools are  currently becoming available [51].  The tabu- 
lated results, which appear in the individual reviews, are discussed 
in a later section of this paper. 
The review teams needed for the Halifax Project were formed by 
first circulating an  email to  a large number of cancer researchers, 
seeking expressions of their interest in participation. The email was 
circulated in July 2012 by Getting To Know Cancer, and scientists 
were encouraged to  submit their details on  a dedicated webpage 
that offered additional project detail. From the pool of 703  can- 
cer  scientists who responded to  the email, 11  team leaders were 
selected to  each lead a group in producing a review of each hall- 
mark, and an  additional leader selected for  the cross-validation 
team. Those leaders were then asked to form their own teams (by 
drawing from the pool of researchers who expressed interest in the 
project, and from their own circles of collaborators). Ultimately, 
12  teams were formed. Team members were each encouraged to 
engage a junior researcher as well. This led to fairly large teams but 
it allowed us to distribute the effort considerably. Team leaders all 
received project participation guidelines; extensive and ongoing 
communication from the project leader, Leroy  Lowe; copies of the 
relevant papers of Hanahan and Weinberg; and copies of Life Over 
Cancer  by Block [3] as an example of practical clinical implementa- 
tion of the broad-spectrum approach. In addition to the 11 teams, 
two guest editors, Anupam Bishayee and Keith Block, were selected 
for this special issue of Seminars in Cancer Biology in which the team 
reviews are  published. 
The  team leaders and other team members who were able to 
attend the project workshop met in Halifax, Nova  Scotia in August 
2013 to  discuss the project. Drafts of hallmark team papers were 
submitted in  advance, and summary presentations made at the 
meeting. Other subject matter presentations included presenta- 
tions on  research funding in the natural products area (Jeffrey D. 
White, Office  of Cancer Complementary and Alternative Medicine, 
National Cancer Institute)  and the  concept of  driver and pas- 
senger genes (Bert Vogelstein, Johns Hopkins). Presentations on 
integrative cancer therapeutics made at the meeting are  summa- 
rized below (Keith Block, Penny Block, Block Center for Integrative 
Cancer Treatment). Group discussions were held to facilitate com- 
munication among teams and project staff,  and to  assist teams in 
exploring the requirements and rationale for  selection of targets 
and approaches. 
Each  hallmark team contained the following specialists: a lead 
author with demonstrated expertise in the hallmark area; domain 
experts who produced the descriptive review; anticancer phy- 
tochemical specialists; oncologists; and support researchers. The 
cross-validation team conducted background literature searches on 
the submitted targets and compounds from each review team, veri- 
fying  their activity in relation to the other hallmarks. Results of the 
cross-validation effort were tabulated and reviewed by  the indi- 
vidual teams. Ambiguous results and areas of disagreement were 




2.1.  Selection of targets and  approaches 
 
It was assumed from the outset that, in a translational project 
aimed at the development of  a  broad-spectrum approach, there 
would be  a practical upper limit to  the number of potential tar- 
gets in any  given cancer that could be  targeted. So each hallmark 
team was asked to select and prioritize up to 10 relevant targets for 
their hallmark area, bearing in mind that each target would serve 
as a starting point for  the identification of a suitable low-toxicity 
approach that might be used to reach that target. In theory, it was 
understood that this could lead to  as many as 110  targets for  the 
entire project, and since the teams were also  asked to  select one 
therapeutic approach for each target, a maximum of 110  potential 
therapeutic approaches might be selected. 
An “approach” was defined in this project as (1) a technique that 
will cause the body to respond in a manner that will act on the target 
(e.g., fasting, exercise, etc.),  or (2)  a procedure involving an  entity 
that can act on the target (e.g., phytochemical, dietary modification, 
synthetic drug, vaccination with peptides, locally administered 
oncolytic virus, etc.).  Teams were then asked to identify “favored” 
approaches with patient safety as a top priority (i.e., least likely to 
cause harm or  side effects even in combination with many other 
approaches). In addition to  safety, other practical considerations 
for choosing favored approaches were suggested as follows: 
 
• Efficacy – greatest potential to achieve the desired action on the 
intended target across the widest possible range of cancer types. 
• Cost – less  expensive is better, and by no means cost prohibitive. 
• Intellectual property – free  of intellectual property constraints if 
at all possible. Approaches that do not have patents, that cannot 
be patented, and/or those that have patents that are  expired are 
to be given priority over those that have existing patents. 
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2.1.1.   Selection of targets 
Extensive discussion took place about the principles of target 
selection. Certainly targets that are unique to cancer cells and tumor 
microenvironments, and that are  not known to  cause side effects 
when inhibited pharmacologically, would be  a primary consider- 
ation. Targets induced by  viruses or  known carcinogens that are 
of importance in therapy would also  be  examined. Consideration 
of the nature of mutations in  the cancer genome and the role of 
epigenetic modification were also  discussed. 
It is understood that great effort has  been made to sequence the 
cancer genome to identify the most common mutations seen in dif- 
ferent cancers. It is also known that different driver mutations may 
give rise to variant tumor cells, and the number of driver mutations 
required is limited, with just 2–8  per patient, which could poten- 
tially be assessed through whole genome sequencing of individual 
cancer patients. However, questions arise about treatment, since 
most of the currently available drugs are  not potent enough to tar- 
get  all susceptible cells.  Moreover, the toxicity of existing drugs, if 
administered in combination protocols, is severely limiting, even 
at the reduced dosages that may be  possible when using multi- 
ple  agents. A strong rationale supports focusing on  low  toxicity 
chemistry (e.g., such as that which has been demonstrated by many 
anticancer and chemopreventive phytochemicals as  the founda- 
tion for a broad-spectrum approach. A number of phytochemicals 
enhance absorption of other natural products through such mech- 
anisms as  cytochrome P450 modification [52],  which could also 
enhance the possibilities for low-toxicity treatment, i.e., by reduc- 
ing dosages needed for effective treatment. 
Many driver genes are  actually tumor suppressor genes, and 
in  these cases, it  is  the loss  of  the tumor suppressor gene that 
allows development of  cancer. Drugs cannot target these miss- 
ing  genes. Rather they must target unopposed pathways, such 
as  pathways that  are   active upstream  from the  missing sup- 
pressor gene. For instance, the tumor suppressor forkhead box  0 
(FOX0)  normally causes apoptosis. If FOX0 is inactivated in  can- 
cer,  an  unopposed pathway upstream from it is the PI3K/Akt1 
signaling pathway,  which could alternatively  be  targeted [53]. 
The  mitogen-activated protein kinase/extracellular-signal regu- 
lated kinase/mitogen/extracellular signal-regulated kinase (MEK) 
pathway, however, can  act  as a substitute or compensatory path- 
way to PI3 K/Akt1. So, in order to effectively shut down replication, 
it would seem necessary to address these pathways as well. 
Cancer-related signaling pathways, including even those that 
become driver pathways, may be  epigenetically modified prior to 
their genetic modification in  cancer pathogenesis [54].  This  sug- 
gests an emphasis on chemoprevention or treatment of very early 
cancers. Targeting may be more straightforward to achieve under 
these conditions, since it is easier to modulate wild-type pathways 
pharmacologically than to  treat the consequences of the onset of 
widespread aneuploidy. In  this case,  the cancer phenotype may 
well precede the cancer genotype by  years or  more. Combining 
knowledge of genetic and epigenetic changes in a particular tumor 
may result in the targeting of key pathways with fewer agents and 
reduced cost. 
A more general consideration is that both direct and indirect tar- 
gets and approaches can be considered. Direct targets are those that 
are  familiar to us from targeted therapies – oncogenes, tumor sup- 
pressor genes, signaling pathways. Indirect approaches, however, 
are  also  potentially useful. For  instance, evasion of  the immune 
system is a hallmark of cancer [27],  and immunomodulatory tar- 
gets and approaches are   appropriate to  support the capacities 
of  immune cells   to   eliminate tumor  cells.   Immune regulators 
are,  in  a sense, inherently multi-targeted due to  the complexity 
of  the responses they induce [55].   However, immunity  is  fre- 
quently compromised in patients under treatment with cytotoxic 
chemotherapies, as  well as  in  the post-surgical period. Immune 
system approaches that also  support the capacity of  patients to 
tolerate or recover from surgery or toxic therapies indirectly sup- 
port the health of cancer patients [56]. The potency of the immune 
system is illustrated by findings that chemotherapy may enhance 
antitumor immunity if given in the correct sequence, and that can- 
cer  refractory to chemotherapy or immune modulation alone may 
become susceptible to both together [57]. 
 
2.1.2.   Selection of approaches 
The  need for  low-toxicity agents  as  constituents  suggested 
that phytochemicals – especially those “pre-screened” in humans 
owing to their presence in foods or traditional medicines – should 
be  carefully considered during approach selection. Each  hallmark 
team therefore included cancer researchers who had consider- 
able experience working with phytochemicals. In considering 
phytochemicals and other low-toxicity agents for  inclusion in  a 
broad-spectrum approach, however, several limitations in the lit- 
erature promptly become clear. 
First,  the level of evidence for the effects of natural products on 
particular hallmark targets varies widely. The status of laboratory 
studies  and clinical trials on   several well-known phytochemi- 
cals,  e.g. resveratrol, epigallocatechin gallate (EGCG), curcumin, 
lycopene and others, was recently reviewed [58].  The  pleiotropic 
nature of  the effects of  these agents on  apoptosis and arrest of 
cell  growth has  been emphasized, and their potential use  in asso- 
ciation with chemotherapy drugs has  been acknowledged. Novel 
strategies based on a strategic combination of phytochemicals with 
broad-spectrum action together with radiation or  chemotherapy 
agents aimed at overcoming resistance to apoptosis and enhancing 
sensitivity to treatment are also currently being considered [59,60]. 
Second, considerable clinical experience with combinations of 
phytochemicals and other natural agents in  treatment of cancer 
patients exists. Detailed knowledge of the pharmacological effects 
of combinations of phytochemicals, however, is limited. There is 
a large literature on  herbal combinations used in traditional  Chi- 
nese medicine in  both the laboratory and clinic [61–63], but the 
quality of older clinical trials is  generally low.  Additionally, lab- 
oratory studies of herbal medicines often use  concentrations far 
higher than are  clinically achievable. Supra-physiological concen- 
trations can produce artifactual or irrelevant mechanisms of action 
or cause toxicity. The limited bioavailability of major phytochem- 
icals   makes this especially concerning, although products with 
improved bioavailability are  in development [64].  In general, phy- 
tochemical research merits rigorous attention if we  hope to  gain 
a  more detailed understanding of  how these compounds affect 
the cancer hallmarks. Basic research needs to be followed up  with 
better-designed, statistically powered clinical trials, if we  hope to 
fully  realize the therapeutic potential of phytochemicals. 
In addition to laboratory studies and clinical trials, approaches 
may be suggested by epidemiological studies and the observations 
of  integrative medicine, which uses diet and lifestyle therapies 
to affect medical conditions including cancer. Observational stud- 
ies  of soy  consumption, along with corroborating evidence from 
clinical studies, suggest that  dietary consumption of  soy  foods 
consistent with levels in the Japanese diet (2–3 servings daily, con- 
taining 25–50 mg isoflavones) may be associated with reduced risk 
of breast cancer incidence and mortality [65].  However, findings 
from animal studies [66]  of negative effects of the soy  isoflavone 
genistein on breast cancer and its treatment suggest some caution 
and avoidance of simplistic recommendations. 
At all levels of investigation, the multi-targeted nature of phy- 
tochemicals as  well as  the integrative therapies is notable. Many 
isolated phytochemicals and herbals may alter large numbers of 
targets through multifaceted effects on physiology and metabolism 
[67–69]. A basic complication of these multi-targeted agents, 
however, is the lack  of mechanistic understanding and scientific 




Fig.  2.  Hallmarks of cancer, sequenced roughly in the order in which these capabilities are acquired by  most cancers, as portrayed in the graphical representation of tumor 
evolution. 
 
acceptance of the roles of synergistic or additive molecules in for- 
mulation. Although used by human populations for millennia, there 
remains a question of how to develop and assess multi-component 
natural product formulations that are  suitable for large-scale pro- 
duction. Genome-wide screening for assessment of targeted effects 
and experimentation with formulation of some herbs typical of tra- 
ditional Ayurvedic medicine have recently been attempted in Asian 
laboratories, and are  examples of attempts to  better understand 
effects of multi-component agents [70–72]. 
 
3.  Hallmarks of cancer 
 
In  this section we  provide brief summaries of  each hallmark 
review included in this special issue of Seminars in Cancer  Biology. 
Each summary includes the targets and approaches selected in the 
hallmark review. Tables summarizing the targets and approaches 
and discussion of the cross-validation results follow. In addition, a 
summary of the impacts of integrative therapies on cancer-related 
molecular targets follows the hallmark summary material. 
The hallmark summaries are  roughly sequenced to capture the 
acquired capabilities of most cancers (see Fig. 2). The section begins 
with genomic instability, an enabling characteristic, followed by sus- 
tained proliferative signaling and evasion of anti-growth signaling, 
two hallmarks that ensure that proliferation is unabated in cancer 
cells.  These are  followed by  resistance to apoptosis and replicative 
immortality, two layers of defense that are  believed to be bypassed 
in   all   cancers.  Then  we   discuss  dysregulated metabolism and 
tumor-promoting inflammation, which signal an important self- 
reinforcing evolution in the tumor microenvironment. Sections on 
angiogenesis and tissue invasion and metastasis speak to disease pro- 
gression. Finally the tumor microenvironment and immune system 
evasion summaries relate to the last lines of defense to be defeated 
in most cancers. 
 
3.1.  Genomic  instability 
 
Genomic instability plays a critical role in cancer initiation and 
progression. It provides the means by which a cell or subset of cells 
acquire a selective advantage over neighboring cells,  enabling out- 
growth and dominance in the tissue microenvironment. In normal 
cells, the fidelity of the genome is protected at every stage of the cell 
cycle by checkpoints. In cancer, the presence of aneuploid cells indi- 
cates the failure of one or more of these checkpoints. The resulting 
genomic heterogeneity may offer the cancer “tissue” growth advan- 
tages under selective pressures, including hypoxia, immune- and 
therapy-related challenges. Understanding these checkpoints, and 
how they are  bypassed in cancer cells,  may provide opportunities 
for the development of rational combinatorial or broad-spectrum 
treatment strategies, including nutraceuticals such as  resveratrol 
[73,74]. 
A cell, either transformed or normal, must pass through multi- 
ple  checkpoints during the process of division. These checkpoints 
are operated by functional complexes of proteins that either enable 
the cell to pass through the checkpoint (e.g. proto- or oncogenes) or 
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prevent the progression through the cell cycle  (i.e. tumor suppres- 
sors). The abundance of these proteins, and their functionality, can 
be modified by genetic changes to their encoding sequences or by 
non-genetic, or epigenetic, changes that regulate their abundance. 
Briefly, small changes to the genes that encode proto-oncogenes or 
tumor suppressors will  positively or  negatively impact the func- 
tion of the gene products. These small changes can  be induced by 
environmental and lifestyle factors, such as toxic substances, diet, 
and smoking, or they can  be encoded in the individual at concep- 
tion. In the case of DNA damage generated by the environment, it 
is important that the cell repairs the damage effectively. Dysfunc- 
tion in the molecules that come together to recognize and respond 
to  sites of damage is often associated with human cancer. Thus, 
an understanding of the genetic or epigenetic status of DNA repair 
genes, and of the nutraceuticals that may modulate them [75], pro- 
vides an opportunity to predict, detect, prevent and treat a variety 
of human cancers. 
Growing evidences show that vitamins, minerals, and other 
dietary factors have profound and protective effects against can- 
cer   cells,   whether  they are   grown  in   the lab,   in   animals, or 
studied in  human populations. We  have identified five   targets 
against genomic instability: (1)  prevention of  DNA damage; (2) 
enhancement of DNA repair; (3) targeting deficient DNA repair; (4) 
impairing centrosome clustering; and, (5) inhibition of telomerase 
activity. Vitamins D and B, selenium, carotenoids, PARP inhibitors, 
resveratrol, and isothiocyanates are  priority approaches against 
genomic instability; these approaches may dampen other enabling 
characteristics of tumor cells,  such as replicative immortality, eva- 
sion of anti-growth signaling, tumor promoting inflammation, and 
oncogenic metabolism [73,76–82]. 
 
3.2.  Sustained proliferative signaling 
 
Proliferation plays an  important role in  cancer development 
and progression, as manifested by altered expression and activity 
of  proteins related to  the cell  cycle  [83,84]. Constitutive activa- 
tion of  a  large number  of  signal transduction  pathways takes 
place in  cancer; this also  stimulates cell  growth. Early  in  tumor 
development a fibrogenic response is often seen. Along  with the 
development of  a  hypoxic environment  [85,86], this  favors the 
appearance and proliferation of cancer stem cells  (CSCs). The 
survival strategies distinguishing CSCs from normal tissue stem 
cells   involve  lack   of  cellular differentiation and  alterations  in 
cell  metabolism, such as  higher antioxidant  levels [83,84]. These 
alterations  take place as  cells   adapt to  the changing microen- 
vironment in  affected tissue, prior  even to   the  appearance  of 
tumors. A part of this adaptation embodies epigenetic and genetic 
alterations in  gene expression [6,87] that also  confer resistance 
to  many cytotoxic treatments  [88,89]. Thus,  adaptive resistance 
is   likely  acquired  early  in   the  pathogenesis of   many tumor 
types. 
Once  tumors appear, the continued selection of cells  with 
sustained proliferative signaling further promotes tumor hetero- 
geneity. This  is  accomplished by  growth and metastasis, which 
may be supported by overproduction of appropriate hormones (in 
hormonally dependent  cancers), by  promoting angiogenesis, by 
undergoing EMT, by altering the balance between apoptosis, necro- 
sis  and autophagy, and by  taking cues from surrounding stromal 
cells.  A number of natural compounds (such as  EGCG) have been 
found to  inhibit one or  more pathways that contribute to  prolif- 
eration [90–92]. Many of these compounds are  nontoxic at doses 
that inhibit tumor growth and/or prevent the appearance of tumor. 
However, one of the keys to their efficacy involves their earliest pos- 
sible therapeutic application. This is because their efficacy is likely 
to be the greatest in target tissues prior to the appearance of a tumor 
where cellular heterogeneity is the least. In addition, many of the 
steps in carcinogenesis prior to tumor appearance are epigenetic in 
nature, and are  more easily targeted by existing compounds, most 
of which target wild type molecules. This  approach limits adap- 
tive  resistance, since early intervention does not have to deal with 
the issues of aneuploidy, loss  of heterozygosity in multiple tumor 
suppressor genes, and point mutations in  oncogenes. The  contri- 
bution of bioinformatics analyses will be important for identifying 
signaling pathways and molecular targets that may provide early 
diagnostic markers and/or critical targets for  the development of 
new drugs or combinations that block tumor formation. Thus, early 
intervention in  pathways and molecules that mediate sustained 
proliferative signaling will limit adaptive resistance because it tar- 
gets cells  in  tissues that have limited genotypic and phenotypic 
heterogeneity. 
Targets selected  for  sustained proliferative signaling are 
hypoxia-inducible factor-1 (HIF-1)  signaling, NF-KB signaling, 
PI3K/Akt  signaling, wingless-type mouse mammary tumor inte- 
gration site (Wnt) (�-catenin) signaling, insulin-like growth factor 
receptor (IGF-1R)  signaling, cell  cycle  [cyclin-dependent kinases 
(CDKs)/cyclins], androgen receptor signaling, and estrogen recep- 
tor  signaling. Possible therapeutic approaches include curcumin, 
genistein and resveratrol. 
 
3.3.  Evasion  of anti-growth signaling 
 
Normal cells  must acquire the ability to  continuously prolifer- 
ate  in  order to  transform into malignant phenotypes. However, 
cells   have internal programs (anti-growth  signaling) to  oppose 
limitless growth. In order to  continue to  proliferate, cancer cells 
must somehow evade many anti-growth signals. In general, anti- 
growth signaling is mediated by the activation of tumor suppressor 
genes. The Cancer Genome Atlas  has  compiled data encompassing 
all  tumor types, which indicates that p53  is the most frequently 
mutated  tumor  suppressor  gene followed by  PTEN, APC, ATM, 
BRCA2, VHL, RB, CDKN2A, BRCA1 and WT1. 
Retinoblastoma protein 1 (RB1) was the first identified tumor 
suppressor and deletion of this gene is frequently found in cancers 
[93].  In many cases, the loss  of RB is due to  defects in  upstream 
signaling molecules such as inactivation of INK4. Loss of p16ink4a 
results in unopposed activation of CDK4/6, which phosphorylates 
the RB protein thereby activating E2F-mediated transcription of 
genes involved in entry into the cell cycle  [94]. 
Another tumor suppressor frequently deleted due to  chromo- 
somal loss  is p53 [95].  In fact,  more than 50% of all  tumors have 
loss  of p53 tumor suppressive functions. Recently, mutant p53 has 
gained renewed attention due to the fact that along with the loss of 
tumor suppressive functions, mutant p53 gains oncogenic/tumor 
promoting functions [96]. 
Epigenetic silencing of tumor suppressor proteins, which 
includes DNA methylation, histone methylation and acetylation, 
is  another mechanism through which tumor cells   evade anti- 
growth signaling. Many tumor suppressor genes have been found 
to  have promoter hypermethylation in cancers [97].  Finally, anti- 
growth signaling plays a major role in treatment response and drug 
development. For  example, the patients with human papilloma 
virus-positive oropharyngeal cancer mostly retain wild-type p53 
and have better prognosis and survival. 
Although genetic  alterations  are   mostly irreversible, epige- 
netic repressions are  potentially reversible and targets for  drug 
development. At least three histone deacetylase inhibitors, beli- 
nostat, vorinostat and romidepsin, are  currently approved by the 
US FDA for cancer treatment. Many natural compounds also  target 
the restoration of  tumor suppressors through modifying epige- 
netic changes [98–102]. Thus,  approaches to  activate anti-growth 
signaling will   open another chapter for  cancer prevention and 
therapy. 
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The  prioritized targets for  anti-growth signaling are  RB, p53, 
phosphatase and tensin homolog (PTEN), Hippo, growth differen- 
tiation factor 15 (GDF15),  AT-rich interactive domain 1A (ARID1A), 
Notch, IGF-1R and others. The  approaches are  inactivation of E2F 
by  down regulation of  pRb  using CDK inhibitors,  activation  of 
p53 through up-regulation of  wild-type p53,  activation of  PTEN 
to  inhibit PI3K-AKT, activation of  Hippo pathways by  inhibiting 
Yes-associated protein/transcriptional enhancer activator domain 
(YAP/TEAD) activity, induction of GDF15  through p53 activation, 
activation of ARID1A, blocking Notch pathway, and inhibition of 
IGF-1R  to  restore tumor suppressor pathways. Suggested phy- 
tochemicals for  these approaches are  EGCG, luteolin, curcumin, 
genistein, resveratrol, withaferin A, and deguelin. Furthermore, 
while the evasion of  anti-growth signaling is  a  critical hallmark 
of  cancer, other hallmarks are   similarly important  and a  more 
integrative approach is necessary to simultaneously target several 
hallmarks of cancer to combat this deadly disease. 
 
3.4.  Resistance to apoptosis 
 
Apoptosis naturally removes aged and unhealthy  cells   from 
the  body  [103]. However, in  cancer, cells   lose   their ability to 
undergo apoptosis leading to  uncontrolled proliferation and mul- 
tiplication. These malignant cells  are  often found to  overexpress 
many of  the proteins that play important roles in  resisting the 
activation of  the apoptotic cascade, and one of  the major hall- 
marks of  human cancers is  the intrinsic or  acquired resistance 
to  apoptosis [104]. Evasion of apoptosis may contribute to  tumor 
development, progression, and also  to treatment resistance, since 
most of  the  currently available anticancer therapies  including 
chemotherapy, radio- and immunotherapy primarily act by activat- 
ing death/apoptotic pathways in cancer cells  [105]. Hence, a better 
understanding of  the molecular mechanisms underlying tumor 
resistance to  apoptotic cell  death is expected to  provide the basis 
for a rational approach to develop molecular targeted therapies. 
Apoptosis resistance is multi-factorial and emanates from the 
interactions of various molecules and signaling pathways at mul- 
tiple levels. Several mechanisms  exist allowing cells   to  escape 
programmed cell death. Among them is the overexpression of the 
anti-apoptotic molecules. B-cell  lymphoma-2  (Bcl-2) family pro- 
teins play a  critical role in  the biology of  apoptosis resistance. 
Robust agents against the Bcl-2  homology domain 3 proteins are 
in development and accelerating toward clinical application. Other 
cell  death mechanisms such as  autophagy and necrosis can  also 
be  highlighted and strategies against them exist, including the 
use   of  natural agents such as  EGCG. The  role of  the chaperone 
protein heat shock protein 70  (Hsp70) in  apoptosis resistance 
is  important, and natural agents may also  address this. Various 
molecular mechanisms support resistance to  apoptosis in  differ- 
ent disease models such as  glioblastoma, multiple myeloma and 
chronic lymphocytic leukemia. Epigenetic players, particularly the 
non-coding RNAs/microRNAs, are also of importance. Novel targets 
can  be  pinpointed, such as  ecto-nicotinamide dinucleotide disul- 
fide  thiol exchanger protein (ENOX)  and nuclear export protein 
chromosomal regional maintenance protein 1(CRM1),  along with 
specific strategies to  overcome these important drug resistance 
promoters. Other targets include inhibition of  Mcl-1, activation 
of  tumor autophagy, activation of  tumor  necrosis, inhibition of 
Hsp90, inhibition of proteasomes, and inhibition of EGFR and Akt. 
Approaches to these targets include gossypol, UMI-77, EGCG, trip- 
tolide, PXD, selinexor, and inhibitors of EGFR and Akt. Collectively, 
the knowledge gained through greater understanding of the apo- 
ptosis resistance targets and specific strategies is  anticipated to 
bring forward a  broad form of  therapy that could result in  bet- 
ter treatment outcome in patients suffering from therapy-resistant 
cancers. 
3.5.  Replicative immortality 
 
Replicative immortality, the ability to undergo continuous self- 
renewal, is necessary for propagation of normal germ cells,  but is 
not a property of normal somatic cells.  When acquired by somatic 
cells  that have sustained genetic damage or  instability, replica- 
tive   immortality allows accumulation of  sequential aberrations 
that  confer autonomous growth, invasiveness, and therapeutic 
resistance [106]. As a result, several mechanisms have evolved to 
regulate replicative potential as a hedge against malignant progres- 
sion [107]. Senescence, a viable growth arrest characterized by the 
inability of affected cells  to resume proliferation in the presence of 
appropriate mitogenic factors, is a specific response to  the grad- 
ual  shortening of  chromosomal end structures (telomeres) with 
each round of cell replication, and a more general response to onco- 
genic and genotoxic stresses. Senescence often involves convergent 
interdependent activation of tumor suppressors p53 and p16/pRB 
[108,109], but can  still  be  induced, albeit with reduced sensitiv- 
ity, when these suppressors are  inactivated. Doses of conventional 
genotoxic drugs required to  achieve cancer cell  senescence are 
often much lower than doses required to  achieve outright  cell 
death [110]. Additional targeted therapies may induce senescence 
specifically in  cancer cells  by  blocking cyclin-dependent  kinase 
mediated inhibition of RB-family proteins  [111], or  by  exploiting 
cancer cells’ heightened requirements for maintenance of telomere 
length through the action of the enzyme telomerase [112]. Develop- 
ing  optimized and truly holistic cancer prevention and treatment 
regimens will  likely incorporate strategies that target replicative 
immortality. 
The  chief advantage to  be  gained by  the use  of  senescence- 
inducing therapeutic regimens is elimination of the tumor’s 
repopulating ability with reduced collateral damage compared to 
conventional cytotoxic regimens. There are, however, certain ques- 
tions and risks associated with this strategy that must be addressed 
before its clinical adoption. In the case of telomere and telomerase 
based strategies, replicative senescence may occur more readily 
in  rapidly dividing cancer cells  bearing short telomeres than in 
slowly dividing stem cells  with comparatively longer telomeres, 
but telomere lengths in cancer cells may still be long enough to per- 
mit sufficient population doublings for invasion and metastases to 
occur [112] Moreover, telomere dysfunction promotes the devel- 
opment of  chromosomal instability, which in  turn can  generate 
mutations that enable cells  to  become drug resistant and/or acti- 
vate mechanisms based on  alternative lengthening of telomeres 
for  telomere maintenance and/or become more malignant [113]. 
High priority should therefore be given to further research into the 
determinants of senescence stability, as the implications of delayed 
cell cycle re-entry, permanent cytostasis, or eventual clearance may 
be profoundly different. Lower doses of genotoxic drugs needed to 
induce senescence may reduce collateral damage to  critical nor- 
mal  cells,  but allow establishment of dormancy and/or adaptive 
resistance by  cancer cells.  The  microenvironmental and systemic 
effects of senescent cells  also  need further clarification, as factors 
secreted by senescent cells  may promote tumorigenic changes in 
nearby cells.  Conversely, since it  is  almost impossible to  kill  all 
the cells  in  malignant tumors even using the highest tolerated 
doses of chemotherapy, combined use  of an  agent that induces or 
enhances stable senescence in the cancer cells that manage to retain 
viability might additively or  synergistically increase therapeutic 
efficacy. 
A  number of  potential targets can   be   singled out  for   fur- 
ther research, including telomerase, human telomerase reverse 
transcriptase (hTERT),  mammalian target of  rapamycin  (mTOR), 
CDK4/6,  CDK 1/2/5/9, Akt  and PI3K. Several approaches deserve 
further research, although the activity of  the phytochemicals in 
particular is still  far from clinical utility. These include imetelstat, 
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genistein,  perillyl alcohol, palbociclib, dinaciclib, curcumin and 
EGCG. 
 
3.6.  Dysregulated metabolism 
 
Dysregulated metabolism is a hallmark of cancer in which many 
cancer cells  show increased glucose uptake and produce lactate. 
This  characteristic is often called the “Warburg effect” [114], but 
how and why cancer cells  reprogram their metabolic state is not 
well understood. Recent research has focused on understanding the 
metabolic changes accompanying oncogenesis [27].  A new model 
of  cancer metabolism positions metabolic rewiring in  cancer as 
a  coordinated process to  support rapid cellular proliferation by 
tuning cellular energy production needs toward biosynthetic pro- 
cesses. Indeed, several metabolic shifts associated with cancer can 
be  linked to  cellular growth, which serve to  support biosynthesis 
of lipids, proteins, nucleic acids required for tumor formation and 
survival [115]. 
In several cases, expression of oncogenes and/or loss  of tumor 
suppressors lead directly to changes in metabolism, by expression, 
activity, or  flux  of  key  metabolic nodes. Several components  of 
glucose and glutamine metabolism have emerged as important reg- 
ulators of metabolism in cancer. In glucose metabolism, hexokinase 
2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
(PFKFB3) and pyruvate kinase isoform M2 (PKM2) all regulate gly- 
colytic flux.  Using a “kitchen sink”  analogy for glycolysis, both HK2 
and PFKFB3 are  regulators of the faucet, and fill up  the sink.  Con- 
versely, PKM2 regulates the drain. Cancer metabolism turns on the 
faucet and plugs the drain, which over-spills the glycolytic path- 
way and provides metabolites used as building blocks for cellular 
growth. Efforts are  underway to  identify therapeutic strategies to 
“turn off the faucet” or “unplug the drain” in glycolysis, limiting cel- 
lular growth in  cancer. Recent studies have also  determined that 
glutamine is used as  a fuel  (glutaminolysis) in  proliferating can- 
cer cells.  Glutamine oxidation can  provide carbon and nitrogen for 
growth, and therefore is  an  attractive therapeutic target in  can- 
cer.  Additionally, mutations in  genes encoding enzymes directly 
involved in  metabolic pathways have been associated with sev- 
eral types of cancer. Rather than acting as a bystander or facilitator 
of oncogenesis, aberrant metabolism now has  a pro-oncogenic role 
and has led to the redefinition of some metabolites as ‘oncometabo- 
lites’ [116]. Indeed, these oncometabolites are powerful influencers 
of proliferation, and are also positioned as new therapeutic targets. 
In principle, a broad-spectrum approach to target metabolic 
shifts in  cancer is  likely to  be  a  promising therapeutic strategy. 
However, studies using this approach to  target dysregulated 
metabolism  in   cancer  are   in   their  infancy. Lessons could be 
learned from other strategies to  target mitochondria or  to  target 
metabolism in  order to  identify efficacious and  safe   therapies 
targeted at cancer metabolism; some drugs targeting metabolism 
are   being  re-purposed  for   their  antitumorigenic  effects. Sev- 
eral approaches could be  mentioned, such as  3-bromopyruvate, 
1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK-15), 6-[(3- 
aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)- 
5H-thieno[2∗,3∗:4,5]pyrrolo[2,3-d]pyridazin-5-one (TEPP-46), 
dichloroacetate,  hexachlorophene,  bis-2-(5-phenylacet-amido- 
1,2,3-thiadiazol-2-yl)ethyl  sulfide  (BPTES)  and  2,3-Dihydroxy- 
6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecar-boxylic 
acid   (FX11),  but data for  these must be  regarded as  extremely 
preliminary, and they lack  sufficient justification to be included in 
therapy without further study. Most target proteins or  pathways 
identified as  having potential to  manipulate cancer metabolism 
have not been directly tested in the context of other hallmarks. The 
emerging efficacy of physiological interventions that manipulate 
cancer outcomes, such as  fasting, calorie restriction, or  exercise, 
could influence cancer metabolism and other hallmarks of cancer 
[117]. Future studies directly testing the ability to  manipulate 
dysregulated metabolism in  cancer will   be   an   important  and 
exciting new area of cancer biology that has  potential for treating 
a variety of cancers. 
 
3.7.  Tumor-promoting inflammation 
 
Virchow first proposed the role of  inflammation in  cancer in 
1863, while observing the presence of  leukocytes in  neoplasms, 
and empirical evidence has   since underscored the importance 
of this linkage [118,119]. The  inflammatory milieu promotes a 
cellular microenvironment that favors the expansion of genomic 
aberrations and the initiation of carcinogenesis [120]. Chronic 
inflammation is linked to various phases of tumorigenesis, such as 
cellular proliferation, transformation, apoptosis evasion, survival, 
invasion, angiogenesis and metastasis [121–123]. Inflammation is 
also  known to  contribute to  carcinogenesis through the genera- 
tion of reactive oxygen species (ROS) and reactive nitrogen species 
which can  damage DNA at the site of the tumor [124]. Free  radi- 
cals and aldehydes, produced during chronic inflammation, can also 
induce deleterious gene mutation and post-translational modifica- 
tions of key cancer-related proteins [125]. 
In addition, chronic inflammation has  an influence on immune 
system constituents that  are   directly linked with cancer pro- 
gression. Under normal conditions, immune cells,  including 
macrophages, granulocytes, mast cells,  dendritic cells,  innate lym- 
phocytes, and  natural  killer (NK)  cells   serve as  the  front line 
of defense against pathogens. When tissue disruption occurs, 
macrophages and mast cells  secrete matrix-remodeling proteins, 
cytokines and chemokines, which activate local  stromal cells  (e.g., 
fibroblasts, adipocytes, vascular cells) to recruit circulating leuko- 
cytes into damaged tissue (acute inflammation), to  eliminate 
pathogens  [126]. However, when these processes are  initiated in 
the tumor microenvironment, they are not resolved, which leads to 
chronic inflammation of the “damaged” (tumor) tissue. Thus, while 
acute inflammation normally supports and balances two opposing 
needs for the repair of damaged tissues (apoptosis and wound heal- 
ing), chronic inflammation represents a loss of this balance and the 
resulting confluence of factors has  deleterious implications for the 
immune system [127]. 
Accordingly, the   relationship   between   tumor-promoting 
inflammation and cancer is  important to  consider. Macrophage 
migration inhibitory factor, cyclooxygenase-2 (COX-2),  NF-KB, 
tumor necrosis factor alpha (TNF-a),  inducible nitric oxide syn- 
thase (iNOS), Akt, and chemokines are important antiinflammatory 
targets that might be  suitable for  a  multi-pronged therapeutic 
approach to  inflammation  suppression. Additionally, curcumin, 
resveratrol, EGCG, genistein, lycopene, and anthocyanins are 
forms of low-cost chemistry with little to no toxicity that could be 
employed to reach these targets. 
Future translational work should make use  of promising agents 
such as  these (combined as  constituents within a multi-pronged 
antiinflammatory approach) bearing in  mind that some of these 
targets impact the immune system and can increase the risks asso- 
ciated with infection. Bioavailability challenges are  also  a concern 
for a number of these agents but recent advances in delivery sys- 
tems will  help address this issue. 
 
3.8.  Angiogenesis 
 
Angiogenesis, the expansion of an  existing vasculature, is the 
main mechanism of blood vessel growth, and is therefore essential 
for tumor development [128]. Tumor angiogenesis is switched on 
by changing the balance between angiogenic factors and inhibitors 
in favor of angiogenesis [129], a process induced by tumor hypoxia 
as  the tumor grows beyond a size  of approximately a few  mm3 
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[128,130]. At more advanced stages, progressive genomic insta- 
bility in  the tumor leads to  mutations in  pathways regulating 
the production of multiple  angiogenic factors [131], and stroma 
cells  also become important sources of sustained angiogenic factor 
production [29].  These collectively result in  a stronger and more 
complex angiogenic factor profile. It  is  therefore not surprising 
that targeted neutralization of  a  single angiogenic factor, which 
has  been the focus for antiangiogenic cancer therapy so far, rarely 
produces long-term antitumor effects [29]. 
Due to the multifactorial nature of tumor angiogenesis this pro- 
cess  is likely to  be  more efficiently treated by  targeting multiple 
aspects of  tumor angiogenesis and vascular dysfunction at the 
same time. Ten  of  the most important targets for  tumor angio- 
genesis and vascular dysfunction are  to  inhibit endothelial cell 
migration/tip cell  formation, reduce structural abnormalities of 
tumor vessels, reduce hypoxia, inhibit lymphangiogenesis, reduce 
elevated interstitial fluid pressure, reverse poor perfusion, nor- 
malize disrupted circadian rhythms, suppress tumor-promoting 
inflammation, deactivate tumor-promoting fibroblasts and nor- 
malize tumor cell metabolism/acidosis. 
Currently available non-specific antiangiogenic agents, able to 
perform some of these tasks, are  however quite toxic, which ren- 
ders them unsuitable for  long-term use   [131–133]. There is  an 
urgent need to identify alternative compounds that could be used 
in  combination over extended periods of  time, targeting tumor 
angiogenesis broadly and thus lowering the risk of resistance. Plant- 
derived compounds, phytochemicals, are   in  many cases better 
tolerated than the synthetic analogs used in cancer therapy today. 
Furthermore, they often exhibit broader mechanisms of action and 
sometimes even higher affinity against important cancer targets 
compared to the synthetic alternatives [134]. Ten phytochemicals 
that may be  effective as  approaches to  neutralize the 10  identi- 
fied  targets are  oleanoic acid,  tripterine, silibinin, curcumin, EGCG, 
kaempferol, melatonin, enterolactone, withaferin A and resvera- 
trol. Further study is  needed to  determine the optimal use  and 
combination of  these phytochemicals in  antiangiogenic therapy, 
focusing on  delivery, toxicity and their use  in  prophylactic regi- 
mens. 
 
3.9.  Tissue invasion and  metastasis 
 
Cancer causes substantial patient morbidity and mortality glob- 
ally,  making it a key  health issue. Metastatic dissemination of the 
disease to  distant sites impacts prognosis, with metastatic dis- 
eases accounting for a vast percentage of cancer patient mortality 
[27,135,136]. Cancer cells  must overcome particular obstacles in 
order to  successfully disseminate to  and establish at a secondary 
location, progressing through the metastatic cascade. Successful 
progression through this cascade is linked with numerous estab- 
lished changes in  cellular functions  leading to   the acquisition 
of  an  invasive phenotype. This  involves loss  of  cell-cell contact 
with the main tumor body, invasion, degradation and migration 
through  surrounding tissue and extracellular matrix, secretion 
of  angiogenic/lymphangiogenic factors and intravasation to  the 
blood/lymph vessel, transport around the body and evasion of the 
immune system, extravasation at the secondary site and establish- 
ment of a secondary tumor [137,138]. 
Hence, factors influencing these processes such as  cell  adhe- 
sion molecules, proteolytic matrix degrading enzymes, cell motility 
and factors involved in the process of EMT have all been subject to 
scientific scrutiny. Additionally, the complex heterogeneity within 
tumors, together with cellular interactions between tumor cells 
and other, non-cancerous, cell types have been established to play 
key  roles in  metastatic dissemination and add further complex- 
ity to this cascade [136,137]. While advances in the field of cancer 
research have been made, the process of cancer metastasis and the 
factors governing cancer spread and establishment at secondary 
locations are  still  poorly understood. Current treatment  regimes 
for metastatic disease pose many adverse effects, which can further 
negatively impact on a subset of patients generally presenting with 
poorer health conditions. Hence there is a great need to  develop 
new therapeutics that not only target tumor growth and inhibit 
metastasis but that also have a lower toxicity and reduced inherent 
side effects. Factors associated with metastasis such disruption of 
E-cadherin and tight junctions, key  signaling pathways, including 
urokinase-type plasminogen activator, PI3K/AKT, focal  adhesion 
kinase, �-catenin/zinc finger E-box-binding homeobox 1 and trans- 
forming growth factor (TGF)-�, together with inactivation of activa- 
tor  protein 1 (AP-1)  and suppression of matrix metalloproteinase- 
9   (MMP-9)  activity   should   be    considered  as   key    research 
priorities. 
The  need can  also  be  highlighted for  new, low  toxicity 
compounds, which interfere with  these  processes but  remain 
inexpensive alternatives that are  readily available and free  from 
intellectual property. Phytochemicals, or natural products, such as 
those from Agaricus  blazei, Albatrellus confluens, Cordyceps militaris, 
Ganoderma lucidum, Poria  cocos  and Silybum  marianum,  together 
with diet-derived fatty acids gamma-linolenic acid  and eicosapen- 
taenoic acid  and inhibitory compounds have potential to  inhibit 
these key metastatic events. These potential targets and strategies 
thus present new therapeutic opportunities to  both manage can- 
cer metastasis as well as having holistic effects against many of the 
hallmarks of cancer. 
 
3.10.   Tissue interactions in the tumor microenvironment 
 
Cancer arises in  an  in  vivo  tumor microenvironment. This 
microenvironment is a cause and consequence of tumorigenesis, 
and consists of cancer cells  and host cells  that co-evolve dynam- 
ically  through indirect and direct cellular interactions, producing 
metabolites and secreting factors that affect cancer progression 
[139,140]. In turn, this environment regulates the ability of a can- 
cer  to  grow and survive via  multiscale effects on  many biological 
programs including cellular proliferation, growth and metabolism, 
as  well as  angiogenesis and hypoxia, innate and adaptive immu- 
nity [141]. Specific biological programs  could be,  based on  our 
most recent understanding, exploited as targets for the prevention 
and therapy of cancer, including: the inhibition of cholesterol syn- 
thesis and metabolites, ROS and hypoxia, macrophage activation 
and conversion, regulation of dendritic cells,  regulation of angio- 
genesis, fibrosis inhibition, endoglin, and cytokine signaling. These 
programs emerge as  examples of important potential nexuses in 
the regulation of tumorigenesis and the tumor microenvironment 
that can  be targeted. 
Potential targets include metabolic programs that may broadly 
influence many cell   biology programs that  impact tumorigen- 
esis   and  the  tumor  microenvironment  (cholesterol  synthesis 
and  metabolites, ROS  and hypoxia), inflammation, innate and 
adaptive immunity-related programs (macrophage conversion, 
dendritic cell  activation, immune signaling), host microenviron- 
ment associated cellular programs (fibrosis, angiogenesis), and 
cytokine-mediated regulatory programs (IL-6, endoglin, and JAK). 
We  have particularly focused on identifying approaches for inhib- 
iting these targets that included natural products that have been 
suggested to  have significant anticancer activity. Some of  these 
molecules may more generally influence tumorigenesis and the 
microenvironment (berberine), others  more specifically target 
ROS (resveratrol, desoxyrhapontigenin), macrophage conversion 
(onionin A), indoleamine 2,3-dioxygenase (IDO) regulation of 
dendritic cells  (EGCG), cholesterol synthesis (genistein), fibrosis 
(naringenin), inflammation and immune signaling (piperine) and 
JAK signaling (zerumbone). This  approach will  provide a starting 
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point for examining synergies that might be anticipated in testing 
certain targets and/or mixtures of natural chemical constituents 
that may modulate the tumor microenvironment in the treatment 
and prevention of cancer. 
 
 
3.11.   Immune system evasion 
 
Tumors evade immune attack by  several mechanisms includ- 
ing  generation of regulatory cells  and their secretions, defective 
antigen presentation, induction of immune suppressive mediators 
either by cancerous cells  themselves or by those in the microenvi- 
ronment, tolerance, immune deviation and apoptosis. 
Current approaches to immune therapy include (a) cellular tar- 
gets, (b) molecular targets, (c) vaccination therapy, (d) therapy by 
phytochemicals, (e) adoptive T cell therapy and (f) immunomodu- 
latory antibodies. Of these anticancer agents, the most important 
are  those that are  targeted in  nature and to  lesser extent, those 
that are  non-specific in  nature. Targeting specific costimulatory 
molecules such as cytotoxic T-lymphocyte-associated protein-4 
(CTLA-4)  [142] or  programmed cell  death  protein  (PD1/PD-L1) 
[143] is  considered an  important anticancer strategy. Also,  anti- 
PD-1  antibodies are  showing enormous therapeutic potential in 
advanced cancers. Targets that  are   considered  appropriate  for 
broad-spectrum, low-toxicity therapeutics are   less   specific and 
include enhancing Th1 responses, enhancing 'YO T cells,  activation 
of macrophages, inhibition of Treg lymphocytes, enhancing natural 
killer cell activity and induction of IL-12. 
There are  a number of important nonspecific anticancer agents 
that have been reported, including vaccination therapy, as  well 
as nonspecific bacteria-based therapies [144], and phytochemicals 
[145–147]. Phytochemicals (the biologically active components of 
fruits and vegetables) have been shown to exert protective effects 
against cancer. Examples of potential phytochemical approaches 
include extracts of Ganoderma lucidum, Trametes versicolor, Astra- 
galus  membranaceus, and Lentinus edodes, as  well as  astaxanthin 
and the polyphenol resveratrol analog HS-1793. There is, however, 
a downside to  phytochemical therapy such as  their poor absorp- 
tion by humans and rapid metabolism and excretion. More work is 
required to assess which phytochemicals block evasion of immune 
surveillance and also to determine which phytochemicals promote 
antitumor responses in cancer patients before these can  be recog- 
nized for therapeutic value in the clinic. 
 
 
4.  Summary of findings on targets and  approaches in 
hallmark reviews 
 
As described above, a cross-validation process was employed 
to  review the proposed actions on  each target and all  of the 
approaches  for   known  effects  on   other  hallmark  areas  and 
the  tumor  microenvironment. Anticarcinogenic synergies and 
confounding/procarcinogenic effects were  then  compiled and 
summarized in Tables 1–3.  Supplemental Table  S1, a sample cross- 
validation table for dysregulated metabolism approaches, was used 
in construction of Tables 2 and 3. Supplemental Tables S2 and S3 
contain the aggregated cross-validation tables from each review 
(with references omitted). More detailed discussion of these inter- 
actions can  be found in the individual hallmark reviews. 
Table  1 shows an alphabetical listing of prioritized targets from 
each hallmark review, as  well as  the number of  contrary, con- 
troversial, none known and complementary interactions with all 
other hallmarks. Dysregulated metabolism targets do  not appear 
in the table; too  little is known about the targets in this new area 
of  research to  reliably assess their interactions with other hall- 
marks. Of these relationships, 3.98%  were contrary, 7.62%  were 
controversial, 21.74%  of interaction assessments found no  known 
relationship, and 66.71% were complementary. 
Table  2 shows the prioritized therapeutic approaches–the phy- 
tochemicals, plant extracts and drugs chosen as  modifiers of the 
priority targets. Of these, 1.08% were contrary, 7.62%  were con- 
troversial, 34.05% had no  known relationships and 62.1% were 
complementary. Both contrary and controversial interactions indi- 
cate potential conflict among the targets and approaches selected 
for  different hallmarks that could result in  a broad-spectrum 
approach with antagonistic, rather than synergistic effects. 
The small number of contrary and controversial interactions is 
encouraging, and suggests that the potential for negative interac- 
tions among the selected targets and approach may be  limited. 
However, this may also reflect the common bias  in the literature to 
publish positive antitumor effects. Nearly a third of potential inter- 
actions were listed as having no known relationship, suggesting the 
need for substantially more research in this area. The large number 
of complementary interactions is also  encouraging but may result 
from indirect or bystander effects. 
Table  3,  in  which the different types of  interactions of  both 
targets and approaches are  listed for  each hallmark, reflects dif- 
ferent levels of knowledge regarding hallmarks, as well as varying 
prevalence of complementary approaches. Genomic instability has 
the largest number of unknown relationships with the targets and 
approaches. On  the other hand, tumor microenvironment, tissue 
invasion and metastasis and resistance to apoptosis have the high- 
est  number of  complementary interactions for  both targets and 
approaches. Small numbers of  contrary interactions were found 
for  the different hallmarks for  both targets and approaches, but 
the number of targets for  replicative immortality and angiogene- 
sis, reflecting mixed positive and negative interactions, were larger 
than for other hallmarks. 
There are  a number of limitations that should be  noted in this 
delineation of cross-hallmark relationships. First,  the researchers 
who assembled these results were not asked to distinguish between 
direct effects on other hallmark areas and reported effects on other 
hallmark areas that may have resulted in an indirect or “bystander” 
effect mediated through a different mechanism. In many cases, but 
not all, this distinction was made. Therefore it is likely that some of 
the complementary interactions do not represent a fully  indepen- 
dent cross-hallmark relationship, but rather are  simply indicative 
of  some sort of  downstream  effect (e.g.,  within a  signaling cas- 
cade or via  some other signaling molecule that exerts pleiotropic 
effects). However, we did not feel that this project needed to inves- 
tigate the nature of  these complementary interactions in  detail, 
especially since the clinical impacts of these interactions would be 
similar for indirect and direct effects. Instead, our main concern was 
focused on  the possibility that a large number of cross-hallmark 
relationships might be  revealed where actions with procarcino- 
genic or tumor-promoting potential had been reported. It was more 
important to  identify contrary and controversial cross-hallmark 
interactions than complementary ones, since targets or approaches 
that exert procarcinogenic actions would normally need to be more 
carefully assessed (or  avoided altogether) in  the development of 
combination approaches or interventions. 
The  second limitation of these reports of cross-hallmark rela- 
tionships is related to data quality. In some instances, the available 
evidence used to  support the indication of a cross-hallmark rela- 
tionships was robust, consisting of multiple studies involving 
detailed in vitro and in vivo  findings. In other instances, however, 
the underlying evidence that was used to  report the existence of 
a cross-hallmark relationship was quite weak (e.g.,  consisting of 
only a single in vitro  study involving a single cell-type). Again,  the 
overarching goal  in  this project was to  create a  foundation that 
would allow us to look  systematically across the literature in each 
of these areas, to  help us  shape the selection of the targets and 
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Table 1 
Prioritized targets with summary of information from cross-validation tables. 
 
Hallmarka,b Target (action on target) Contrary Controversial Complementary None known 
AP, RI, TPI Akt (inhibit) 0 0 11 0 
SPS Androgen receptor signaling (suppress) 0 2 8 1 
TIM AP-1 (inhibit) 1 RI 0 7 3 
EAG ARID1A (activate) 1 TIM 0 5 5 
AP Bcl-2 (inhibit) 0 1 9 1 
RI CDK 1/2/5/9 (inhibit) 1 TME 0 9 1 
RI CDK 4/6  (inhibit) 1 GI 1 8 1 
SPS Cell cycle  (CDKs/cyclins) (attenuate) 2 IS, TIM 0 9 0 
GI Centrosome clustering (block) 0 0 8 3 
TME Cholesterol metabolites (inhibit) 0 0 7 4 
TME Cholesterol synthesis (inhibit) 0 1 8 2 
TPI COX-2 (inhibit) 1 AN 0 10 0 
TPI CXC chemokine (inhibit) 0 3 5 3 
AN Disturbed circadian rhythms (normalize) 0 2 9 0 
GI DNA damage (prevent) 1 TPI 3 5 2 
GI DNA repair (enhance) 1 TPI 3 5 2 
EAG, TIM E-cadherin (restore) 1 AN 4 4 2 
EAG E2F (inactivate) 1 TME 0 7 3 
AP EGFR (inhibit) 0 0 10 1 
AN Elevated interstitial fluid pressure (reduce) 0 0 9 2 
TME Endoglin (inhibit) 0 1 5 5 
AN Endothelial cell migration/tip cell formation (inhibit) 0 0 7 4 
AP ENOX (inhibit) 0 0 5 6 
SPS Estrogen receptor signaling (suppress) 1 TIM 3 7 0 
EAG Endoplasmic reticulum stress (induce) 2 AN, TIM 1 7 1 
TIM FAK signaling (inhibit) 0 0 9 2 
TME Fibrosis (inhibit) 0 0 6 5 
EAG Growth differentiation factor 15 (induce) 1 GI 0 5 5 
SPS HIF-1 signaling (inhibit) 0 0 9 2 
AP Hsp90 (inhibit) 1 TIM 0 8 2 
RI hTERT (inhibit) 0 1 8 2 
AN Hypoxia (reduce) 0 1 10 0 
TME IDO (inhibit) 0 1 7 3 
EAG, SPS IGF-1R (inhibit) 0 0 9 2 
IE IL-12 (induce) 1 AP 0 5 5 
TME IL-6 (inhibit) 0 3 7 1 
TPI iNOS (block) 1 AN 1 6 3 
TME JAK (inhibit) 0 0 10 1 
AN Lymphangiogenesis (impede) 0 1 4 6 
TME M2 macrophage conversion (inhibit) 0 0 7 4 
IE Macrophages (activate) 2 SPS, TIM 2 3 4 
AP Mcl-1 (inhibit) 0 0 10 1 
TPI MIF (block) 0 0 9 2 
TIM MMP-9 (suppress) 0 1 7 3 
RI mTOR (inhibit) 0 2 8 1 
SPS, TIM, TPI NF-KB signaling (inhibit) 0 2 8 1 
IE NK cell activity (promote) 0 0 7 4 
EAG NOTCH (block) 1 AN 0 8 2 
AP Nuclear exporter CRM1 (inhibit) 0 0 6 5 
RI PI3K (inhibit) 0 0 11 0 
EAG, SPS, TIM PI3K/Akt  signaling (inhibit) 0 0 11 0 
AN Poor  perfusion (improve) 0 1 7 3 
AP Proteasome (inhibit) 0 0 10 1 
TME ROS (inhibit) 0 2 7 2 
AN Structural abnormalities of vessel walls (inhibit) 0 0 7 4 
GI Target deficient DNA repair 1 TPI 2 5 3 
GI, RI Telomerase (inhibit) 0 0 10 1 
TIM TGF-� (inhibit) 1 RI 2 7 1 
IE Th1 response (promote) 1 TPI 0 5 5 
TIM Tight  junctions (promote) 1 AN 0 6 4 
TPI TNF-a (block) 1 IE 1 8 1 
IE Treg lymphocytes (inhibit) 0 1 6 4 
AP Tumor autophagy (activate) 1 TPI 4 4 2 
AN Tumor cell metabolism/acidosis (normalize) 0 0 9 2 
AP Tumor necrosis (activate) 2 AN, TME 3 5 1 
AN Tumor-promoting fibroblasts (deactivate) 0 0 9 2 
AN Tumor-promoting inflammation (suppress) 0 0 7 4 
TIM Urokinase plasminogen activator (suppress) 1 RI 0 7 3 
TME VEGF (inhibit) 0 3 8 0 
EAG Wildtype p53 (upregulate) 0 0 10 1 
SPS Wnt (B-catenin) (inhibit) 0 3 7 1 
EAG YAP/TEAD activity (inhibit) 0 0 6 5 
TIM �-catenin/ZEB1 (inactivate) 0 0 7 4 
IE 'YO T-cell  activity (promote) 2 TPI, AN 0 4 5 
Totals:  32 62 543 177 
Percentages: 3.93% 7.62% 66.71%  21.74% 
a   For each target, the following items are shown: the hallmark(s) for which it was selected, and the number of other hallmarks with which it has complementary relationships, contrary 
relationships, no known relationships and controversial relationships. For targets that have contrary relationships, the conflicted hallmark(s) are  shown. Totals and percentages of each 
type of relationship are  shown at the end of the table. 
b   AN, angiogenesis; AP, resistance to  apoptosis; DM, dysregulated metabolism; EAG, evasion of anti-growth signaling; GI, genomic instability; IE, immune evasion; RI, replicative 
immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TME, tumor microenvironment; TPI, tumor promoting inflammation. 
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Table 2 
Prioritized approaches with summary of information from cross-validation tables. 
 
Hallmarksa,b Approaches Contrary, conflicted hallmarks Controversial Complementary None known 
DM 3-bromopyruvatec 0 0 7 4 
TIM 5,6-dihydro-4H-pyrrolo[1,2-b]-pyrrazolesc 0 0 2 9 
TPI Anthocyanins 0 0 9 2 
IE Astaxanthin 0 0 7 4 
IE Astragalus membranaceus polysaccharide 1 AN 0 6 4 
TME Berberine 1 IE 0 9 1 
DM BPTESc 0 0 5 6 
GI Carotenoids 0 1 10 0 
TIM Cordycepin 0 0 8 3 
AN, EAG, RI, SPS, TME, TPI Curcumin 0 0 11 0 
EAG Deguelin 0 0 7 4 
TME Desoxyrhapontigenin 0 0 2 9 
DM Dichloroacetatec 0 0 7 4 
RI Dinacicilibc 0 0 6 5 
AN, AP, EAG, RI, TME, TPI EGCG 0 0 11 0 
TIM Eicosapentaenoic acid 0 0 8 3 
AN Enterolactone 0 0 7 4 
DM FX11c 1 GI 0 2 8 
TIM Gamma linolenic acid 0 0 7 4 
TIM Ganoderic acids 0 0 7 4 
IE Ganoderma lucidum polysaccharide 0 0 9 2 
EAG, RI, SPS, TME, TPI Genistein 0 5 6 0 
AP Gossypol 0 0 9 2 
TIM Grifolin 0 0 6 5 
DM GW5074c 0 1 3 7 
DM Hexachlorophenec 0 0 6 5 
IE HS-1793 (polyphenol resveratrol analog)c 0 0 5 6 
RI Imetelstatc 0 1 4 6 
GI Isothiocyanate 0 0 10 1 
AN Kaempferol 0 0 7 4 
IE Lentinus edodes polysaccharide 0 0 8 3 
EAG Luteolin 0 0 9 2 
TPI Lycopene 0 0 8 3 
AN Melatonin 0 0 10 1 
DM Metforminc 0 1 10 0 
TME Naringenin 0 2 6 3 
AN Oleanoic acid 0 0 10 1 
TME Onionin A 0 0 1 10 
TIM Pachymic acid 0 0 6 5 
RI Palbociclib c 1 TIM 0 4 6 
GI PARP inhibitorc 0 0 9 2 
RI Perillyl alcohol 0 0 10 1 
TME Piperine 1 IE 0 7 3 
DM PK15c 0 0 6 5 
TIM Polysaccharide (G. lucidum) 0 1 8 2 
AN, DM, EAG, GI, SPS, TME, TPI Resveratrol 0 2 9 0 
GI Selenium 1 TPI 2 6 2 
AP Selinexorc 0 0 3 8 
AN, TIM Silibinin 0 0 11 0 
DM TEPP-46c 0 0 3 8 
IE Trametes versicolor polysaccharide-k 0 0 3 8 
AN Tripterine 0 0 5 6 
AP Triptolide 1 IE 0 9 1 
AP UMI-77c 0 0 5 6 
GI Vitamin B 0 2 3 6 
GI Vitamin D 0 0 10 1 
AN, EAG Withaferin A 0 0 9 2 
TME Zerumbone 0 0 6 5 
TIM �-(1-6)-D-glucan (A. blazei) 0 0 6 5 
Totals:  7 18 403 221 
Percentages:  1.08% 2.77% 62.10% 34.05% 
a   For  each approach, the following items are shown: the hallmark(s) for  which it was selected, and the number of  other hallmarks with which it has complementary 
relationships, contrary relationships, no known relationships and controversial relationships. For  approaches that have contrary relationships, the conflicted hallmark(s) are 
shown. Totals and percentages of each type of relationship are shown at the end of the table. 
b   AN, angiogenesis; AP, resistance to apoptosis; DM,  dysregulated metabolism; EAG, evasion of  anti-growth signaling; GI, genomic instability; IE, immune  evasion; RI, 
replicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TME, tumor microenvironment; TPI, tumor promoting inflammation. 
c   Targeted therapy, synthetic compound or natural product analog/derivative. 
 
 
approaches in  order to  comprehensively counter tumor growth 
pathways. So  although we  realized that not all  of  these reports 
of cross-hallmark relationships represented the same level of evi- 
dence, we still wanted to examine available evidence to flag targets 
and approaches where procarcinogenic actions had been reported. 
There was also  considerable debate within the task force over 
the value of  tables containing only a  simplified indication of  a 
relationship (i.e.,  + or  −) supported by  evidence that varied con- 
siderably in quality. But since many individual studies and reviews 
that focus on  therapeutic approaches fail  to  work systematically 



























































































































































































































































































































































































































































































































































































































































































































































across the spectrum of incidental actions that might result from 
combining therapies, it was our  opinion that a tabularized frame- 
work was the only way to ensure that we had assembled a complete 
view of cross-hallmark activity. 
The  types of approaches selected differed among different 
review teams. While some review teams selected all or mostly phy- 
tochemicals or plant extracts, some teams felt that the evidence for 
these was insufficient, and emphasized other types of molecules, 
including drugs in development. These may pose more difficulties 
for  translational investigators due to  intellectual property, toxic- 
ity  or  other concerns, but may offer  advantages in  a more clear 
understanding of their mechanisms. We suggest, however, that the 
approaches as well as the targets presented in Tables 1 and 2 can 
be viewed as simply a model for broad-spectrum cancer therapies, 
rather than as  a final list.  Some of the recommended approaches 
are  clearly experimental, and further research will  likely discover 
compounds, phytochemical or  synthetic, that are  not on  this list 
that may be useful in a broad-spectrum approach. The prevalence 
of interactions where no  interactions were found – over 20% for 
targets and over 30% for  approaches – also  suggests caution and 
a need for further research investigating potential cross-hallmark 
relationships as well as other mechanisms that may lead to  toxi- 
cities. 
Bioavailability of  the phytochemicals chosen will   also   be  a 
concern for  future studies. The  need for  development of  better 
preclinical models for screening compounds and testing rationally 
designed combinatorial therapies composed of compounds from 
any  source is also  obvious, and should clearly be a first step in the 
development of the broad-spectrum approach. 
 
4.1.  Role of integrative therapies in the broad-spectrum approach 
 
Integrative medicine is  an   approach to   health  and healing 
that “makes use   of  all  appropriate therapeutic and lifestyle 
approaches, healthcare professionals and disciplines to  achieve 
optimal  health  and  healing”  [148].  A  comprehensive integra- 
tive  medicine intervention for  cancer patients typically includes 
nutrition  education, mind-body medicine and physical activity 
components, as  well as  dietary supplements including herbs, 
nutraceuticals   and  phytochemicals   [3,149].  Such   an   interven- 
tion may contribute uniquely to  a  broad-spectrum therapeutic 
approach through its impact on a wide variety of relevant molecular 
targets and hallmarks. Hallmarks that may be particularly impacted 
include genomic instability, tumor-promoting inflammation, dys- 
regulated  metabolism and immune system evasion. Because of 
their susceptibility to  manipulation by  diet, exercise and supple- 
mentation, these may be characterized as metabolic hallmarks. 
Nutrition has  long been the primary focus of research on  inte- 
grative interventions for cancer. The World Cancer Research Fund 
and the American Institute for Cancer Research find that diets high 
in fruits and vegetables substantially reduce risks of several cancers 
[150]. Cancer prevention diets are  also  suitable after a cancer diag- 
nosis [151]. For example, colon cancer patients eating a Western 
diet after diagnosis were at higher risk for recurrence and mortality 
than those with healthy diets [152]. Breast cancer patients who fol- 
lowed low-fat diets were found to have lost  weight and had lower 
recurrence risks, especially among patients with estrogen receptor- 
negative cancers [153]. Trials  of  diets enriched in  whole grains, 
low-glycemic diets, and both low-fat diets and Mediterranean diets 
enriched in  olive   oil  and almonds reduced levels of  inflamma- 
tion as  measured by  CRP [154–157]. Low  fat  diets, weight loss 
and supplements (anthocyanins and fish  oil)  have been observed 
in randomized trials to  reduce cytokines and signaling molecules 
[158–161]. Mind-body  interventions have emphasized immune 
targets, with findings of interventional trials including activation of 
T cells  and lymphokine-activated killer cells  and increased natural 
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killer cell  activity [162,163]. Exercise interventions have docu- 
mented effects on  survival, IGF-1,  natural killer cell  activity, and 
sex hormones [164–167]. While much work remains to be done on 
integrative interventions, preliminary data suggest that integrative 
medicine may significantly support a broad-spectrum approach to 
cancer therapy. 
 
5.  Proposed research model 
 
The review process for this project has  revealed many potential 
targets and approaches. The cross-validation activity suggests that 
only a small number of targets and approaches affect other hall- 
marks in contrary or controversial ways. Indeed the results suggest 
that the design of a broad-spectrum approach should in fact be fea- 
sible from a safety standpoint. Although considerable research will 
be needed, disease relapse is a substantial and longstanding prob- 
lem,  so this novel model definitely warrants further investigation. 
 
5.1.  In vitro  research 
 
An array of in  vitro models is available for  preliminary study 
of  broad-spectrum  formulas. One   question is  the  suitability of 
receptor-based assays versus cell-based assays. While receptor- 
based assays may seem more suitable for targeted therapy research, 
examining the impacts of a putative agent on  a molecule such as 
NF-KB, which is at the intersection of multiple signaling pathways 
related to inflammation, might be advised. Cultivated cell lines are 
valuable for  preliminary screening of mixtures, but are,  in  most 
respects, limited in their predictive ability. Isolated cell lines from 
clinical samples are  an  alternative, and use  of transformed cancer 
cells  versus non-transformed lines should be discussed. Tissue and 
organ explants are  another useful in vitro model. 
Basic  research on  the properties of  the natural products and 
other approaches selected in  the reviews needs to  continue. The 
pharmacology of mixtures and combinations of phytochemicals, 
bioavailability, dose optimization and synergy are among the areas 
in  which research is needed for  many phytochemicals [168,169]. 
However, multicomponent herbal therapies used in traditional and 
alternative medicine have not received detailed analysis. Network 
pharmacology could be a means of exploring these presumed syn- 
ergisms, and efforts are   being made to  apply this approach to 
the complex herbal mixtures used in traditional Chinese medicine 
[170]. Studies on the pharmacokinetics of herbal extracts and phy- 
tochemicals, which often begin at the in vitro level, are also needed 
[171]. 
In  sum, given the complexity that is  immediately suggested 
when combinations of approaches are possible, we strongly recom- 
mend that well-coordinated, multi-faceted programs be  pursued 
initially to ensure that the constituent approaches that are selected 
are   well-characterized using in  vitro models, and that delivery 
methods that are  selected for  in vivo  work receive careful evalu- 
ation before animal research is undertaken. 
 
5.2.  In vivo research 
 
Multiple in  vivo  models for  further study of  broad-spectrum 
approaches are   also   available. Two  obvious choices are   animal 
tumor models and human tumor xenografts implanted in athymic 
mice. While human tumor xenografts have the advantage in pre- 
dicting effects of  agents on  human cancer cells,  animal tumors 
offer  some interesting choices for chemoprevention studies, since 
several are  induced by exposure to  various chemicals. The rodent 
tumors are questionable, however, in their ability to predict human 
responses to  antitumor therapy. Differences in immunity are  one 
consideration, most obviously with athymic mice but also  with 
other animals. Many other differences are  known. Rodents and 
humans, for  instance, differ significantly in  their blood levels of 
soy  isoflavones after these are  administered through a variety of 
dietary and experimental routes [172]. Isoflavone levels in rodent 
blood 20–150 times those in humans after similar oral  intake have 
been observed, raising questions about the suitability of animals 
for prediction of phytochemical effects in humans. 
Additionally, as  shown in  different preclinical mouse models, 
immune and inflammatory responses to  cancer differ in  young 
and old  individuals, and many cancer treatments  are   likely to 
be  less  effective at older ages. Combination treatment  including 
immunotherapeutic  approaches may be  most suitable for  older 
animals. Therefore, there is a strong argument for testing and opti- 
mizing combination treatments in suitable model systems before 
attempting to apply them to cancer patients. The US National Can- 
cer  Institute Mouse Models of  Human Cancer Consortium [173] 
has  tried to provide the scientific community with accurate, repro- 
ducible models of human cancers that can  be used in translational 
and preclinical studies. Such  improved models could be  of great 
importance for developing combination treatment strategies. Com- 
panion animals, such as  dogs and cats, which experience several 
tumors analogous to  human cancers, can  also  act  as comparative 
models for human tumors [174]. 
 
5.3.  Clinical trials 
 
Keeping in mind that a broad-spectrum approach may be used 
not only by  itself, but  also   as  adjuvant therapy with conven- 
tional agents, there are  numerous potential settings for  clinical 
trials, either  for   proof  of  principle  or   therapeutic  goals. Pre- 
liminary studies could include metabolomic studies to  identify 
metabolites of dietary interventions, or the pharmacokinetics and 
pharmacodynamics of phytochemical agents. A variety of settings 
can  be  contemplated for  clinical trials. One  period during which 
a  broad-spectrum  approach may be  particularly appropriate  is 
the perioperative period. Murine data demonstrate that tumor 
growth accelerates after surgery; there are  also  numerous anec- 
dotal reports regarding cancer patients in whom rapid growth of 
metastatic tumors has been noted after surgery [175–180]. Further, 
there is reasonable human evidence that colon or rectal resection 
results in  significant increases in  the plasma levels of numerous 
proangiogenic proteins after surgery [181–184]. This period is not 
generally used for  chemotherapy administration because of fears 
of  impaired wound healing, but the above findings provide the 
rationale and motivation for  systemically administering selected 
anticancer agents perioperatively. 
Several non-standard chemotherapy agents, including phyto- 
chemicals, have been administered perioperatively in small studies 
[185–187]. These agents upregulate immune function via nonspe- 
cific mechanisms. A Phase I trial assessing the combination of EGCG 
and silibinin in  colorectal cancer is  underway, with both agents 
given orally before and after surgery [188–190]. Such  trials rep- 
resent an  innovative approach to  clinical assessment  of  natural 
products that can  be carried out within a restricted time. 
Although clinical trials of  phytochemicals and plant extracts 
in cancer are  limited compared to  those with conventional 
chemotherapy, they are   by  no  means lacking. Russo et al.  [58] 
review nearly 50  ongoing and completed trials of  phytochemi- 
cals  and extracts in  cancer prevention and therapy, noting that 
even though clinical research is still limited, preliminary results are 
promising. Most of the 50 studies took place in the United States, 
and most included a single phytochemical or  single-herb extract. 
Nearly 3000 controlled trials of Chinese traditional medicine, 90% 
concerning herbals, were reviewed by  Li et al.  [191]. Only  16% 
of traditional medicine trials in  this review reported use  of ade- 
quate methods of randomization, and only a very small percentage 
reported  study blinding, although quality of  studies improved 
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through time. Most Chinese herbal formulas contain multiple herbs 
and are  aimed at many targets. 
The design and execution of clinical trials of natural chemicals 
from plants and foods, however, has  been challenging worldwide. 
An  herbal products extension of  the Consolidated Standards of 
Reporting Trials  (CONSORT) randomized trial reporting guideline 
has  been published to  help improve herbal trial reporting [192]. 
A review of published studies of Panax ginseng, which is common 
in Chinese formulas but has  been studied globally for  many con- 
ditions, found that only 48% of them reported CONSORT-suggested 
items, and only 39% reported items from the herbal products exten- 
sion [193], although these study designs also  improved over time. 
 
5.4.  Translational considerations 
 
Assuming that translational research work will  involve a sub- 
stantial combination of therapeutic agents such as those proposed 
in Table  2 as a starting point, a first step would be the selection of 
specific targets and approaches for preliminary study. To achieve a 
truly broad-spectrum effect, one strategy might be  to  use  small 
doses of  every approach that lacks significant contrary interfer- 
ences. While such a  mixture might be  made up  and applied to 
cell  lines, it could be  questioned whether the concentrations that 
could be  achieved in  the cells  would be  physiologically relevant, 
especially given the low  bioavailability of many phytochemicals. 
Most in vitro work on single phytochemicals, however, has actually 
been conducted at high concentrations that are  not achievable in 
humans. The pharmacokinetics and pharmacodynamics of phyto- 
chemicals are complex and many are not yet well known, although 
progress is  being made on  some agents  [194]. Another method 
to  narrow the number of  phytochemicals that need to  be  in  an 
agent might be to select the phytochemicals that are  most widely 
represented across hallmarks, such as  curcumin and resveratrol, 
and analyze combinations of these agents. Some of the selected 
approaches, e.g. silibinin, appear to have favorable pharmacokine- 
tics  [195]. Other phytochemicals with favorable pharmacokinetics 
could also  be  considered for inclusion in a broad-spectrum agent, 
such as phenethyl  isothiocyanate [196]. Research is also  urgently 
needed on  the question of the stability of phytochemicals as well 
as synthetic compounds in mixtures. 
Alternative approaches to  the question of  bioavailability are 
being explored, especially with the polyphenols. One  of the main 
issues with these compounds, which include quercetin, green tea 
catechins, curcumin and others, is ensuring that circulating doses of 
aglycones (one of the active forms of these molecules) are sufficient 
for activity. After oral  supplementation of food-grade molecules at 
doses safe  for  humans (200–500 mg/day), only conjugated forms 
are   found in  the bloodstream. As  an  example, quercetin is  not 
found in  the plasma as  aglycone or  as  the parent glycosides: at 
the doses usually employed in  intervention studies, it  would be 
found exclusively as methyl, sulfate or glucuronic acid  conjugates 
[197]. This observation discloses a paradox common to many bio- 
logically active phytochemicals: if free  aglycones are absent in vivo 
after a dietary intake or supplementation with high doses, how can 
we  explain the high biological activity of these molecules, largely 
described in vitro? 
Two main hypotheses can be considered. First, conjugated forms 
of some flavonoids (e.g. quercetin) may be biologically active. Sec- 
ond, after cellular uptake, these metabolites may be de-conjugated, 
regenerating the free  aglycones. To sustain these hypotheses, key 
issues need to  be  addressed, such as  the efficacy of mechanisms 
of uptake of polyphenol metabolites and the substrate specificity 
of  each metabolite, which is  largely unknown. The  use  of  pure 
compounds tested in vitro may shed light on these questions. Alter- 
natively, pharmacological doses (2–4 g/day) administered  orally 
[198] may saturate the metabolic pathways of conjugation [199]. 
Efforts are being made, however, to improve bioavailability of these 
agents, such as microspheres [200], liposomes [201] and nanopar- 
ticles [202]. An  additional complication is  that individuals may 
vary in their absorption, distribution, metabolism and elimination 
of phytochemicals, based in some instances on  genetic variability 
[203], dietary habits [204] and potentially on intestinal microbiota 
[205]. 
Considerations of quality control are  essential along the spec- 
trum of research from in vitro studies to  clinical trials. Good 
agricultural practice, correct botanical identification and good 
manufacturing practice are  mandatory to prevent adulteration, 
contamination and toxicity [206]. The  example of PC-SPES, a 
botanical cancer remedy that was found to contain indomethacin, 
warfarin and synthetic estrogens, leading to  its  withdrawal from 
the market in 2002 resulted in greater awareness of the need for a 
strict approach to quality control [207]. 
 
 
6.  Implementation of broad-spectrum research agenda 
 
A variety of practical considerations come into play in  trans- 
lating the proposed research model into a developmental program. 
These include regulatory considerations, intellectual property, clin- 
ical considerations and funding. 
 
 
6.1.  Regulatory considerations 
 
Research on  the broad-spectrum model must be  undertaken 
with regulatory constraints in  mind. Laws  controlling herbal 
medicines, which would likely apply to  the broad-spectrum 
approach, typically have regulatory paths for herbal or traditional 
medicine products that differ from those for  prescription drugs. 
Regulations relevant to traditional Chinese herbal medicines, per- 
haps the closest model for the proposed broad-spectrum approach, 
are reviewed by Fan et al. [208]. A few examples of national regula- 
tions regarding herbal medicines, traditional medicines and natural 
product drugs follow. 
The United States has  perhaps the most challenging regulations 
for  drug approval, and regulations for  mixtures are  particularly 
complex. Some multicomponent formulas have nevertheless been 
tested in clinical trials in the US [209,210], but are  still  being sold 
only as  dietary supplements, without labeling for  use  in  malig- 
nancy. The  designation of the Botanical Drugs category may offer 
opportunities to  broad-spectrum agents. A recent court decision 
declaring natural products unpatentable under US law   adds an 
interesting wrinkle to the regulatory framework [211]. In Canada, 
development as a high-risk Natural Health Product could be  con- 
sidered  [212]. China has   a  variety of  regulatory categories that 
could be  used for  multicomponent natural product therapeutics 
[213]. The relevance of Chinese regulations for multi-targeted drugs 
has  been explored [214]. In  the European Union, the Marketing 
Authorization scheme for  conventional drugs would need to  be 
used, rather than the Traditional Herbal Regulation Scheme [215], 
increasing the challenge for developmental research. In India it is 
likely that New Chemical Entity approval would be required [216], 
since use  in cancer would likely be considered beyond traditional 
herbal medicine usage. Japan allows herbal medicines to be regis- 
tered as prescription or over-the-counter drugs [208]; prescription 
licensing appears likely for an  anticancer therapeutic. A variety of 
regulations exist in other countries, which are  beyond the scope of 
this paper, and which would need to be explored individually. We 
expect that working under these strict regulations will be difficult, 
but we  do not see  it as impossible. 
An additional regulatory consideration is the acceptability of the 
broad-spectrum approach to  institutionally-based ethical review 
boards needed  for   clinical research.  In  institutions  located in 
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countries in  which multi-component herbal formulas are  typical 
of traditional medicine, ethical approval of such formulas is com- 
mon, as  suggested by  the large numbers of  clinical studies on 
traditional  Chinese herbal medicine [191] and Japanese Kampo 
medicine [217]. Trials  with multi-component formulas and natu- 
ral products have been conducted under other regulatory schemes 
as  well. For  instance, Phase I and Phase Ib studies of BZL101, an 
extract of Scutellaria barbata in metastatic breast cancer have been 
conducted in  the United States [218,219]. A 4-herb combination 
originating in traditional Chinese medicine, PHY906,  has  been the 
subject of a Phase I trial as an adjunct to capecitabine in advanced 
pancreatic cancer, also  in the United States [220]. In general, pro- 
vision of sufficient preclinical and drug formulation information, 
review of  prior clinical studies, and  possession of  appropriate 
approvals from national-level agencies will  facilitate approval of 
study protocols. 
 
6.2.  Intellectual property 
 
Herbs and natural products in  their native forms do  not have 
intellectual property protection, which should help in developing a 
low-cost, broad-spectrum formulation. Specified extracts and indi- 
vidual phytochemicals may have intellectual property of various 
types. Researchers could pursue intellectual property protection 
for  specific broad-spectrum therapeutics they develop, as well as 
licensing to  a pharmaceutical company with sufficient resources 
to  support development and testing of the agent. Herbal extracts 
of  some complexity have received patent  or  trademark status, 
and have been granted drug approval even in  the United States, 
Examples include a mixture of green tea  polyphenols known as 
Polyphenon E and sold   as  the patented  drug sinecatechins for 
genital  warts  [221], and  crofelemer,  an  extract from the South 
American plant Croton   lechleri,   approved for  HIV-induced diar- 
rhea [222]. The  complexities of natural product patenting are 
beyond the scope of this paper but are  covered in depth elsewhere 
[223]. 
 
6.3.  Clinical considerations for a multi-component natural 
product therapeutic 
 
Based on   current  clinical experience with natural  products 
administered together with conventional drugs, one may anticipate 
potential concerns with broad-spectrum therapeutics that would 
be  administered jointly with conventional therapies. A primary 
concern is  the interactions between drugs and herbs or  phyto- 
chemicals, including both pharmacokinetic and pharmacodynamic 
interactions  [224]. This  has  been of  special concern in  oncology 
due to  the life-threatening consequences of lowered blood levels 
of drugs, and the potential for severe side effects when blood lev- 
els  of a drug are  increased or actions of herbal products reinforce 
those of conventional agents. Antiplatelet activity is  common in 
natural  products  [225], and may aggravate clinical consequences 
in patients with thrombocytopenia due to chemotherapy or other 
drugs [226]. Several other examples of negative interactions are 
known or  suspected. St  John’s  wort (used for  depression) con- 
tains the strong cytochrome P450 3A4  inducer hyperforin, which 
is known to  reduce blood levels of many drugs, including irinote- 
can   [227].  Green  tea,   which is  often taken  in   high  doses  by 
cancer patients, has   potential interactions with sunitinib [228], 
with hepatotoxic  drugs [229], and with bortezomib. On the other 
hand, positive interactions have been observed with green tea  and 
erlotinib, a combination now in  clinical trials [230]. Curcumin is 
one of several natural products that act  as  chemosensitizers and 
radiosensitizers for  several tumors, while protecting normal tis- 
sues [231]. The ability of herbs and other natural products to relieve 
treatment-related side effects should not be overlooked [232,233]. 
Furthermore, many natural products possess antioxidant activ- 
ity.  The  role of oxidation in  cancer progression and treatment  is 
controversial [234]. Oxidative stress is increased in late-stage dis- 
ease [235], which suggests that suppression  would be  beneficial. 
Antioxidants may relieve some adverse treatment  effects caused 
by the reactive oxygen species generated by many chemotherapy 
drugs, but data on this point are not conclusive [236,237]. Random- 
ized trials of antioxidant supplements given with chemotherapy 
do  not find evidence of reduced efficacy, but research with bet- 
ter study design and larger sample size  should be conducted [238]. 
Additionally, some natural antioxidants, including the polyphenols, 
manifest pro-oxidant properties in cancer cells, due to interactions 
with metal ions, which contribute to anticancer effects [239]. This 
pro-oxidant effect has  been hypothesized to  underlie the broadly 
multi-targeted actions of polyphenols such as curcumin and EGCG 
[240]. However, activity of most chemotherapy drugs depends on 
generation of  ROS which should not be  abrogated. Additionally, 
some oxidative metabolites may act  as  signaling molecules with 
anticancer  activity [241]. Further, intracellular antioxidants may 
contribute to drug resistance [242]. Our understanding of the inter- 
actions of antioxidants and cancer thus continues to develop [243]. 




6.4.  Funding 
 
Development of new clinical agents that could be approved by 
regulatory agencies is an  expensive endeavor. A recent economic 
model of  drug discovery and development in  the United States 
used industry-appropriate assumptions to  estimate that the fully 
capitalized cost of a typical new single-molecule drug developed 
is  now approximately $1.8  billion, 63% of  which is  attributable 
to  clinical development  (Phase I–III  studies)  [244]. The  details 
of  such estimates are   beyond the scope of  this paper, but the 
financial challenges are  clear. It  is  our  contention that a  multi- 
component broad-spectrum therapeutic approach is  needed to 
complement and balance the current drug discovery paradigm, 
which focuses on narrowly scoped approaches and singular molec- 
ular targets, including targeted therapies, immunotherapy, “one 
mouse-one patient” avatars that identify personalized therapeu- 
tic  regimens by  implanting patients’ tumors into mice [245,246] 
and a  variety of  other approaches. Such   an  approach could be 
expensive  to   develop, and  could  face   similar  costs  for   trials 
and approval. However, a  broad-spectrum approach could be 
aimed at wide applicability among many cancer types and sub- 
types. Thus,   initial investment  could be  more easily recovered 
than is  the case with narrowly-focused target therapies, since 
it  would have utility across a  large group of  patients. Whether 
the development of  the broad-spectrum approach should be 
carried forward by  governments, for-profit pharmaceutical com- 




6.5.  Importance for low-  and  middle-income countries 
 
The possibility that a broad-spectrum approach could be devel- 
oped that is  both effective and inexpensive is  an  important 
consideration, especially in low- and middle-income countries. One 
of the cost components of drug development is the cost of target 
identification and validation. However, in  the Halifax Project the 
strategic list  of targets that has  been developed has  been drawn 
from the open literature, so  individual laboratories  or  nations 
that are  interested in  developing a multi-component therapeutic 
approach can use  this information as a starting point (i.e., as a basis 
for rationally selecting an array of targets). 
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7.  Summary and  conclusions 
 
In  spite of the importance of targeted therapies now used in 
treatment  and currently in  development, it  is  clear that  most 
cancers  cannot  be   successfully addressed  solely  with  single- 
target therapies. The  history of  cancer treatment has  taught us 
the importance of drug resistance, stemming ultimately from 
genetic heterogeneity in cancers. Our  therapeutic tool kit  now 
includes a large array of cytotoxic chemotherapies, molecular tar- 
get  drugs, immunotherapies and hormonal therapies. A major 
paradigm in cancer research, in response to the advances in anal- 
ysis  of  the cancer genome, is  the development of  increasingly 
targeted  therapies. Examples illustrating the  vigor of  research 
and development in  this area are  several targeted therapies that 
have received approval in  2013–2014 by  the US FDA, including 
ceritinib (anaplastic lymphoma kinase inhibitor), ramucirumab 
(VEGFR2  blocker), ibrutinib (Bruton’s tyrosine kinase inhibitor), 
trametinib  (MEK   inhibitor)  and  dabrafenib  (B-Raf   inhibitor) 
[244]. 
At the same time there is an  increasing awareness of a need to 
develop a therapeutic approach to address the genetic heterogene- 
ity within tumors. Even within this group of newly approved agents, 
the combination of trametinib and dabrafenib was approved for 
joint use  in 2014, due to  the rapid (6–7 months) development of 
resistance to the sole  use  of B-Raf inhibitors. The emergence of the 
concept of multiple hallmarks of cancer [27],  the nine pathways of 
progression [3]  the listing of 138  driver genes [6]  and the recog- 
nition of the importance of network pharmacology [51]  all attest 
to the importance of this issue. A recent review similarly suggests 
combining antiinflammatory and antioxidant treatment in  long- 
term maintenance therapy of cancer [247]. It is the contention of the 
Halifax Project that a broad-spectrum approach to cancer prophy- 
laxis and treatment (i.e., simultaneously attacking many targets) is 
a strategic and promising response to our increasing understanding 
of the significance of genetic heterogeneity. 
Although current drugs have notably increased initial respon- 
siveness to  treatment in comparison to  traditional approaches to 
chemotherapy, there remain situations in which a broad-spectrum 
approach could make real contributions. Some examples include 
use  as  follow-up to  conventional treatment; for  rare cancers; for 
patients who do  not tolerate conventional treatment; for  early- 
stage disease, when aggressive treatment should be  avoided; and 
in hospice and palliative care. If significant interactions with treat- 
ments can   be  avoided, it  might even be  possible to  use   such 
approaches in conjunction with targeted therapies and other treat- 
ments. 
What are   the  implications of  this broad-spectrum strategy 
for  current clinical practice? First,  clinicians should realize that 
this paper presents a developmental research program, not clin- 
ical  guidelines. Use  of uninformed selections of phytochemical or 
botanical extracts in  poorly-defined clinical situations is unlikely 
to  deliver positive results. Further, as noted above, concerns with 
interactions of  natural products with conventional treatments 
should be  kept in  mind. That  said,  lifestyle therapies appear to 
affect multiple molecular targets and to  improve the health of 
cancer patients in a variety of ways, and integrative lifestyle mod- 
ifications should be  assessed as  a  health-promoting foundation 
for  use  of broad-spectrum therapeutics [3,149]. Clinical trials are 
now defining beneficial impacts of  natural  products  [248]. The 
positive implications of dietary therapies for  improvement of the 
metabolic hallmarks of  inflammation, dysregulated metabolism, 
genomic instability and immune system evasion should be  kept 
in mind [249,250]. Clinicians choosing to use  natural product sup- 
plements should attend to  product quality and be  familiar with 
advances in  the formulation of poorly absorbed polyphenols and 
other phytochemicals [200–202]. 
The development of the broad-spectrum approach is not with- 
out cost.   A primary need is  further development of  preclinical 
models for  testing of combinatorial therapies, including study of 
the stability, pharmacodynamics and pharmacokinetics of agents 
comprising multiple phytochemicals and other molecules. While 
some of the targets and approaches recommended in these reviews 
are  well-known and have been the subject of  multiple reviews, 
others are   still   only promising leads and may need much bet- 
ter characterization before being adopted as constituents in such 
an  approach. For  example, among approaches, curcumin, genis- 
tein, resveratrol and EGCG boast a wealth of fundamental research, 
whereas other approaches such as  tripterine, oleanoic acid  and 
withaferin A will require additional basic research. Targets are  also 
in need of more basic research, especially in replicative immortality 
and in  dysregulated metabolism, a field in  which studies of rele- 
vant targets are  just beginning. The approaches analyzed in these 
areas are  similarly only in the most preliminary stages of research. 
All the hallmarks, however, include targets and approaches that 
need substantial basic research. Determining how many of the sug- 
gested targets should be  included in  a broad-spectrum approach 
is  also   a  question that  needs substantial research. Supporting 
these areas of basic research should be  an  initial goal  of funding 
efforts. 
The  pharmacology of mixtures of natural products is another 
area in  which basic research is most relevant to  the goals of this 
project. There is  certainly a  body of  research on  complex mix- 
tures of  natural  products  [210,214,217,218,220]. A recent study 
suggested that EGCG lowers the concentration of curcumin needed 
to reduce proliferation and induce apoptosis in uterine leiomyosar- 
coma cells  [251]. Traditional Chinese medicine formulas have also 
been subjected to  extensive pharmacological testing [252,253]. 
However, much remains to  be  done in  quantitative optimization 
of  formulas as  well as  in  selection of  optimal natural product 
extracts or  phytochemicals. And  although this effort emphasized 
phytochemicals, it is also  important and relevant to study defined 
botanical and food  extracts. Standardized black raspberry extract, 
for  instance, has  produced positive results in  human trials on 
apoptosis, angiogenesis and several specific targets selected in 
the project [254]. Aged  garlic extract [255] increased immunity 
in  advanced cancer patients, and lyophilized strawberries [256] 
improved premalignant esophageal lesions. Defined herbal extracts 
such as  PHY  906   and BZL101  mentioned above have demon- 
strated preliminary clinical antitumor activity [219,220]. Stability 
and pharmacokinetic properties of complex mixtures are  another 
critical research need, as  are  proper methods of  quality control 
[257]. 
The  development of complex natural product agents appears 
ripe for  cross-disciplinary approaches as  well as  attention to  the 
process of translational research. Natural products research, in fact, 
has  long been nurtured most successfully in multidisciplinary and 
collaborative working groups [258], and the teams that authored 
the reviews in  this special issue were notably interdisciplinary 
themselves. In view of the challenges as well as the unique oppor- 
tunities this new concept entails, scientists wishing to take part in 
the development of broad-spectrum approaches to  cancer would 
do   well to   commit themselves to   a  set   of  new attitudes  and 
skills. Laboratories and grant proposals have achieved success typ- 
ically  based on  highly focused exploration of a small intellectual 
niche. The broad-spectrum approach upends this paradigm. Build- 
ing  linkages with laboratories across campus, or  even with the 
department down the hall,  is not always encouraged in academic 
institutions. But  this challenge is  not insurmountable, and insti- 
tutions and granting agencies have successfully mounted efforts 
that embrace, for instance, natural product development “from the 
field to  the clinic” [259,260]. At the same time, integrative oncol- 
ogy  centers globally employ broad-spectrum clinical approaches 
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involving therapies ranging from natural products to meditation in 
the service of patient  needs [261]. There is thus no  need to  start 
from absolute zero in building the cross-disciplinary alliances we 
project will  be needed for this effort. 
What will  be  needed is  a  core group of  scientists willing to 
become advocates for  this approach. Advocacy must take place 
within academic institutions, as institutional silos,  perhaps reluc- 
tantly, open  their  doors to   collaboration. Institutional  review 
boards and grant offices may need education in the concept of the 
broad-spectrum approach. Advocacy must take place at higher lev- 
els  as well. National funding agencies and charitable foundations 
that currently support cancer research need to  heed these rec- 
ommendations and shift quickly to  embrace the rationale for this 
interdisciplinary team-based approach. Grant review committees 
may need to  confront established interests promoting competing 
studies with more familiar narrow aims. Creativity in funding initial 
research efforts will be needed. International agencies interested in 
addressing the growth of cancer in low to middle income countries 
might be convinced that broad-spectrum approaches could result 
in  lower-cost and often more culturally acceptable therapeutic 
tools for these areas. 
Now  is  the time to  begin the work of  advocating for  broad- 
spectrum therapeutic approaches in cancer. Scientists need to seize 
the opportunities provided by the unique information provided in 
this special issue to  expand their acquaintance with this model 
–  and perhaps with the scientists themselves who are   already 
involved in this effort. Scientists and clinicians alike should become 
advocates to their institutions, to funding sources and to the wider 
public. This dimension of cancer biology and therapy has  too  much 
potential to  allow it  to  languish. At the same time, clinical chal- 
lenges mount, despite the emergence of new targeted therapies. We 
look  forward to  seeing concentrated energy and intellect focused 
on this new approach, and to seeing it yield significant therapeutic 
benefits in the future. 
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